<SEC-DOCUMENT>0000950170-25-066387.txt : 20250508
<SEC-HEADER>0000950170-25-066387.hdr.sgml : 20250508
<ACCEPTANCE-DATETIME>20250508072520
ACCESSION NUMBER:		0000950170-25-066387
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		75
CONFORMED PERIOD OF REPORT:	20250331
FILED AS OF DATE:		20250508
DATE AS OF CHANGE:		20250508

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Mind Medicine (MindMed) Inc.
		CENTRAL INDEX KEY:			0001813814
		STANDARD INDUSTRIAL CLASSIFICATION:	MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			A1
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40360
		FILM NUMBER:		25923866

	BUSINESS ADDRESS:	
		STREET 1:		ONE WORLD TRADE CENTER
		STREET 2:		SUITE 8500
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10007
		BUSINESS PHONE:		212-220-6633

	MAIL ADDRESS:	
		STREET 1:		ONE WORLD TRADE CENTER
		STREET 2:		SUITE 8500
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10007
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>mnmd-20250331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-05-07T16:04:56.3490+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:mnmd="http://www.mindmed.co/20250331" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16">
 <head>
  <title>10-Q</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;position:relative;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_15ebbc75-b668-4995-8617-7d98e6a460e7" name="dei:CurrentFiscalYearEndDate" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387">--12-31</ix:nonNumeric><ix:nonNumeric id="F_ead768be-ec5e-4935-a087-1de2d31e7076" name="dei:AmendmentFlag" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387">false</ix:nonNumeric><ix:nonNumeric id="F_b837dc70-6f2d-4b50-8836-87bf24950a1f" name="dei:DocumentFiscalPeriodFocus" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387">Q1</ix:nonNumeric><ix:nonNumeric id="F_32a24a42-a095-46f6-8846-c2313fc501f0" name="dei:EntityCentralIndexKey" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387">0001813814</ix:nonNumeric><ix:nonFraction id="F_88461b8f-b10d-4348-8f11-5a095afbfb82" name="us-gaap:CommitmentsAndContingencies" contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_a5f6e01e-d45d-48c2-a8b5-6ec8ed432e26" name="us-gaap:CommitmentsAndContingencies" contextRef="C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_bdc0d770-37db-4b91-b201-46ab50f8b510" name="us-gaap:CommonStockSharesAuthorizedUnlimited" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387">Unlimited</ix:nonNumeric><ix:nonNumeric id="F_8aef1a60-8a65-43d5-88a7-a12bf6efa231" name="us-gaap:CommonStockSharesAuthorizedUnlimited" contextRef="C_62a1dfe7-53cc-4860-88cd-5195a323ecfb">Unlimited</ix:nonNumeric><ix:nonFraction id="F_48b94f86-01e6-4c6b-ba2f-884f3c981c63" name="us-gaap:CommonStockValue" contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_f4dfe000-183d-4ac2-8317-e5d26a5c8b53" name="us-gaap:CommonStockValue" contextRef="C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_878b4f9e-49e3-4bfc-bf0e-3f4c1e867bf8" name="us-gaap:DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" contextRef="C_0c871994-f7b4-4304-86d5-391aaec3c1e0">http://fasb.org/us-gaap/2024#PrimeRateMember</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="mnmd-20250331.xsd"/></ix:references><ix:resources><xbrli:context id="C_8105c1cf-df27-4598-b667-6e48ef3b3337"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mnmd:TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_81f4f1da-ef96-4aad-9e47-23f8b90a22b7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mnmd:UnderwrittenOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_83fc4e0e-c83d-497b-af6e-c962abe5d2fd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8951a923-02f7-4d9d-aa15-eece5d45babf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8ddb2856-0c3b-4cce-9cc5-aab5dca27c39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mnmd:DirectorsDeferredShareUnitPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8e014f8c-ec6c-4965-ad7a-4716062b7c4d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8e1a6127-7406-40c2-a294-e96d17a71e6c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mnmd:UsdFinancingWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8eca3c03-2aed-492a-b29b-dd10aed0202f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">mnmd:DirectorsDeferredShareUnitsLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_90573d83-d120-4c4b-9277-fd2e39b59277"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnmd:TwoThousandTwentyFourAtTheMarketOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-28</xbrli:startDate><xbrli:endDate>2024-06-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_910d296e-b905-4051-81fa-bd26919dc2be"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">mnmd:TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_925b985b-901b-4479-a40b-d64febbd22cf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_92619440-2ce2-4466-9498-1c8dd0f4bb1c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_939e4af1-6bdb-4858-a841-8acd4d2a47f4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9530e32c-7cf2-41f3-bd67-a92ee6762331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_97bfc649-2b8e-41f0-8976-f5330877ad56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">mnmd:TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_98c96557-3887-4999-b5e8-247c1ed96005"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9b3887ab-9632-4cdf-8108-dd0d06f5614f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9e259264-1dab-4ca4-a6a1-b8eba8c5e07f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mnmd:UsdFinancingWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a39c400a-978e-47bc-a958-d2b3c57c3ab7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a5257296-f7b1-43a0-9556-3801f55d61c2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">mnmd:TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a76dd043-ee75-4b71-a525-e4107e5d3732"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a897d154-518a-4ffc-a776-063ea244783d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a8edddb6-a7d1-4462-a57e-b8c66cc64c46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a991fead-ed19-4c7e-a11e-4d30d6b8613d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ade2e71f-765e-4fb6-86cf-647ae7dd133c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_afb02b48-cbcb-40bd-950a-da13b4f46b8a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">mnmd:LongTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_aff55750-479b-4423-af77-60c8f43e209e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mnmd:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b180f4c3-0072-43ff-9725-7c3a3e4ad1f1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mnmd:UsdFinancingWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b2ef454a-9f53-4e0f-adeb-d446b560c825"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mnmd:UnderwrittenOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-08-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b58805d9-68aa-4a81-99f4-2a397090939f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mnmd:TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b72d06dd-d6d5-41b9-91f8-bad834196904"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">mnmd:TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bc56a365-8e98-4a9c-b1c1-8e03984015fd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">mnmd:TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bd03d603-030d-4d7d-8bdb-3dd6759f747f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c223fe50-1eba-4855-9ab8-186a0c6e6c18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mnmd:UnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c2fa1d86-6d26-4f04-8543-c015b28e335a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c9514733-173b-4015-8d17-721fcab04ad2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">mnmd:TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c9d7271c-3855-4150-a286-178b67eef766"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mnmd:SubsequentTrancheTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnmd:AmendmentTermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mnmd:K2HealthventuresLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cb6db0ce-574c-45c7-a69a-4330f84bb3c7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cb762e0c-1384-4979-be76-95297f6af7c8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cf111989-4654-4f24-8b88-1ac2ede3bffd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">mnmd:TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cf474416-20d3-4fb7-a080-b12775ae6c42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mnmd:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-08-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cf6044bc-91e6-4b8c-82c8-fab4740fed04"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d0dd088c-1d9e-451f-88b7-d6ec7c48a41b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mnmd:UnderwrittenOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-09</xbrli:startDate><xbrli:endDate>2024-08-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d169998a-953e-4d00-b8cc-a69fa0e9660b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnmd:AmendmentTermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mnmd:K2HealthventuresLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mnmd:FirstTrancheTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d2978ec1-8cd7-4990-abd7-153da97219c6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">mnmd:DirectorsDeferredShareUnitsLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d320d06d-9c2c-4fb0-9558-f2351f1dc8ad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnmd:AmendmentTermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mnmd:K2HealthventuresLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d6c40bae-8846-460f-9af3-802080fee535"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnmd:TwoThousandTwentyTwoAtTheMarketOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d74b207d-4c84-4383-8d90-5ecc70a0eeb9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_db671577-db0a-4a9e-b198-84650c9bc0dd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dd654da2-3037-41d6-b072-b777c8f63fe4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">mnmd:TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dff63d85-7ca9-411d-a4f5-a8cf59bcaded"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mnmd:TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e2246019-6180-4085-ac79-bbe6f51150c7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mnmd:K2HealthventuresLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnmd:LoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">mnmd:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-11</xbrli:startDate><xbrli:endDate>2024-11-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e34dffa8-783f-47f9-b3eb-1d1ea40a50f2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">mnmd:LongTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e36f91bd-0fb2-41fd-b1b0-74152cad4505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnmd:TwoThousandTwentyTwoAtTheMarketOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-07</xbrli:startDate><xbrli:endDate>2024-03-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e3b59676-7289-49e6-94f9-2ea1da43b0c3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mnmd:TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e6549b22-6f92-4409-ac7d-193000c6fe21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e69e4c45-b9fa-4c14-a874-f74d991218c1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnmd:TwoThousandTwentyTwoAtTheMarketOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-04</xbrli:startDate><xbrli:endDate>2022-05-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ea9d77da-eba9-4810-91d9-0f141316dc18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mnmd:SubsequentTrancheTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mnmd:K2HealthventuresLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnmd:LoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">mnmd:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_eb1ae7bc-3517-4ce3-9504-2825a5456a78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mnmd:K2HealthventuresLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnmd:LoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">mnmd:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mnmd:AdditionalTrancheTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_eb56ad75-806f-4117-8a10-7450fb345387"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ebfcf44a-8b21-4107-a576-08b906d78af5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ec162c56-805d-451c-8646-927ea169440e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-08-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f83f983a-590e-4074-8513-66e59d9de42c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mnmd:K2HealthventuresLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnmd:LoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">mnmd:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fc88df44-67ae-47e8-a51a-83bbbe2805d6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-30</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fd8b6f33-1ed4-4940-897a-df0a934092d1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mnmd:UsdFinancingWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fe5a097f-3c97-4699-94f4-51951985f607"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mnmd:K2HealthventuresLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mnmd:FirstTrancheTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnmd:LoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">mnmd:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0054b3c6-4d0e-43c8-b522-a912b7fc8728"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_01a2dc55-35b5-4300-97d4-8821ba88df11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0229cf68-edf9-4c29-9a29-b011952417f5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_02d3e741-f89c-4731-a810-9c92f1a21ee4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_05d13ef9-8e4a-4163-9c2d-b90faeb5d396"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">mnmd:DirectorsDeferredShareUnitsLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_06e3dec8-4efa-4049-969d-372ad64052f3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_074eb5b5-3385-4cab-a533-970336354d46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_093e9bfe-6581-4ff9-8a14-13447fd595d8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mnmd:ConversionSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_095bf73d-2ada-4710-8b73-6c8b87d5dc15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0c871994-f7b4-4304-86d5-391aaec3c1e0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mnmd:K2HealthventuresLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnmd:LoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">mnmd:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-11</xbrli:startDate><xbrli:endDate>2023-08-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_11c49272-f55d-49f3-b7a7-0fefff64a7f1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mnmd:UnderwrittenOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-07</xbrli:startDate><xbrli:endDate>2024-03-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_122040ac-3410-4ee2-92d7-5ca02f09a42e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mnmd:TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_12ece47b-93f1-4de7-b519-aa935811a9f5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_13b67830-d4f4-404f-a407-d676bfd7b796"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_16552037-eed1-494f-9bc7-fe5f2b5e07a7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_21366178-d703-4ba8-b838-8bd6400186cc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnmd:AmendmentTermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mnmd:K2HealthventuresLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_214de9bb-0f67-49d7-91e6-f326f72e5fda"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_21b8ddb5-b023-4fb7-95ad-c159194b8c6f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mnmd:K2HealthventuresLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mnmd:SecondMilestoneBasedTrancheTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnmd:LoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">mnmd:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_239ca22a-8f41-45e3-9088-34e3006f84b0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mnmd:K2HealthventuresLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnmd:LoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">mnmd:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-11</xbrli:startDate><xbrli:endDate>2023-08-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_24991487-9f41-4eb3-b745-b05e5c54af14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mnmd:UsdFinancingWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_26a40041-e25c-4e75-bf9d-fa804e8cd077"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">mnmd:DirectorsDeferredShareUnitsLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2711bf7d-51fa-4c13-8e64-2c94219ab80a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mnmd:UsdFinancingWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2995588c-67ea-4d43-b4bf-a6059a698028"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mnmd:CommonShareAndWarrantPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2bdf42cd-b1cd-4bff-9840-27592a404165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-08-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2e215081-711a-47c3-8879-d448652f7b35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-07</xbrli:startDate><xbrli:endDate>2024-03-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2e42dac1-0eaa-4f5d-b79b-b48d8486374e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_307c81b2-2ca0-4668-bba0-7a7b5291fc9f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mnmd:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-08-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_30b95ea8-0cae-41e0-b81a-309b08ca75f2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">mnmd:TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_36b4af29-5d76-4291-b73b-cd8c72915e01"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3719fe9d-d9b5-450f-af3d-bfac82d59821"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_37fa8a98-03fc-4f71-9bce-63073a3d3907"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_385312b0-168e-450a-8069-c73e69ed32d7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_39a7f94d-b020-4c68-859b-28f61826d359"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3c75786f-e793-48f9-af75-c6a4be9a5a7f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3eda8f94-de7e-4394-a39c-79afdb6058ce"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mnmd:UsdFinancingWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4094340a-fb0c-443d-8f83-3a756fca8506"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnmd:AmendmentTermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mnmd:K2HealthventuresLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mnmd:AdditionalTrancheTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4167881d-1e68-4b3c-b401-a89cc1d4f259"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mnmd:ConversionSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_42ce987a-6c17-43ee-b6d2-679c22b90e37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mnmd:K2HealthventuresLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnmd:LoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">mnmd:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_430d76fe-9c73-4a88-a973-58ab8a42cea6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4350eef0-c7b4-4a27-8d23-cb926ba2db8d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">mnmd:TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_47ed8762-d376-4fac-a861-d53fdd21f2ce"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4abdbb57-7e44-40e1-a361-dedbe9966b38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4b6d6580-13c5-46e6-baba-77d54955725a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mnmd:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4ea41252-c084-4a13-8fad-6ff6f7cfeccf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mnmd:TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4f9c94fe-d4da-4fdb-80c6-934c635c61cf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_528dd0c0-1ac6-48fd-ba94-56b201899f5f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mnmd:UnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-08-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_53549879-ba1d-4877-b935-3c96fc46f9bb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_54995453-beb7-498a-8683-7850a8191dba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_54d8dbd9-a485-4061-8471-60237a056875"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mnmd:K2HealthventuresLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnmd:LoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">mnmd:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_57494605-d58d-4ef0-b4ff-8e96f7bcf04c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_592df924-3dca-44fb-a185-3cc0e5436ffc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5a13acac-19e1-4c71-912c-83e07c93e680"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-04-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5d84c0a3-45aa-4e65-83e3-9a191c580b57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">mnmd:TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5e3a61c1-28b2-4c74-befa-0a83e0e3f355"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6011eb25-af6f-4f60-b18a-f48be80a2b48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_62a1dfe7-53cc-4860-88cd-5195a323ecfb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_634127f7-e2ca-4f43-b3c1-b5a15d394d01"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6451cf6d-c95a-4e4b-8351-0fe9c5190c13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mnmd:K2HealthventuresLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnmd:LoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">mnmd:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6a7256ae-8741-49e1-a84a-94da6e3a03ec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6ad17a66-7ef6-4b6b-947f-8a82218b53f9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnmd:AmendmentTermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mnmd:K2HealthventuresLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-18</xbrli:startDate><xbrli:endDate>2025-04-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6e0c796f-cafa-42be-9627-7b5c560ee658"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mnmd:K2HealthventuresLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnmd:LoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">mnmd:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6e886f9e-717a-465f-9fee-5b794de40e69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6f79a0fa-c5d0-4e2a-bc5d-e6aec1b53c1e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mnmd:DirectorsDeferredShareUnitPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6f8c2f52-b2c4-47bf-b3a7-5478bee3c660"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mnmd:K2HealthventuresLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnmd:LoanAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">mnmd:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6feaeecd-fd52-496a-87c2-1985d67f38f0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mnmd:UsdFinancingWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7141ebf5-28cf-4a53-aafe-4ebd1582b154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnmd:AmendmentTermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mnmd:K2HealthventuresLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-18</xbrli:startDate><xbrli:endDate>2025-04-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_71fc6e95-5099-42fb-ad90-d49887a3de3c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mnmd:TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_71fe533e-e23e-4d50-b70c-175f681b0e12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">mnmd:TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_73ffda6d-742d-40f9-a06d-603da3eab457"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_74cedffa-5bb3-47b3-afc1-6024110f7963"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mnmd:DirectorsDeferredShareUnitPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_75bc9303-a477-4604-852c-7370782dc59b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_795cce7f-e02c-4025-a046-7502e810b283"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mnmd:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-17</xbrli:startDate><xbrli:endDate>2024-10-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7cf3b999-3819-4049-8c52-90a0e922de85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7f0ccbf3-018b-4d47-8587-c44623598ad3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001813814</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="U_UsdShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="U_Segment"><xbrli:measure>mnmd:Segment</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNITED STATES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Washington, D.C. 20549</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d1574bf2-ba7d-498c-9bd7-14e86380c5f1" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10-Q</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (Mark One)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:4%;box-sizing:content-box;"/>
     <td style="width:96%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_dc9df8a8-cdf0-419d-8f50-2ccf9743a967" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the quarterly period ended </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d1256b95-a82f-40d1-9d11-5b58cfc2836b" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c5c20c05-61a6-4ee1-a7f1-bfbc600d453d" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="dei:DocumentFiscalYearFocus"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2025</span></ix:nonNumeric></span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OR</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:4%;box-sizing:content-box;"/>
     <td style="width:96%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_2e2ca219-7c4f-43ac-8ee4-dc96bac046a1" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="dei:DocumentTransitionReport" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from                      to</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commission File Number </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3d104c0e-a9ff-4120-83ee-a01364128fd7" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">001-40360</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:20pt;font-family:Times New Roman;"><ix:nonNumeric id="F_da37d61f-f72b-4ff8-affe-48527386f0cc" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:20pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Mind Medicine (MindMed) Inc.</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Exact name of Registrant as specified in its Charter)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:50%;box-sizing:content-box;"/>
     <td style="width:50%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_3de2490e-596a-4e8c-aeef-94e7e29d9aac" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:edgarprovcountryen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">British Columbia</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">, Canada</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_12baf33f-9559-44e5-83c5-0ab2ba3e6e10" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">98-1582438</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:10.8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(State or other jurisdiction of</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">incorporation or organization)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(I.R.S. Employer</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Identification No.)</span></p></td>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_cc1046d3-cdd3-4cc2-90a3-4d3319a84f6c" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">One World Trade Center</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:8pt;"><ix:nonNumeric id="F_7184db5f-67f9-4139-bf04-1017f497279d" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Suite 8500</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_b135f0a4-11d2-43c0-af2d-879f993a25cb" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">New York</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-kerning:none;min-width:fit-content;">,</span><span style="font-size:8pt;"><ix:nonNumeric id="F_fff73cef-b021-448e-8818-cc40c6cf5295" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> New York</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_1c952431-2b49-44cc-a274-fd99ab9ee000" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">10007</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Zip Code)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registrant&#8217;s telephone number, including area code: </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_aec1bcc5-f763-43e4-892d-bb32b53406d8" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">212</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_25e70a73-47a7-4e35-96e0-a6d3224ba8dd" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">220-6633</span></ix:nonNumeric></span></p><p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:38%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:15%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:45%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title of each class</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trading</span></p><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Symbol(s)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
    </tr>
    <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_73b840cf-0cba-4bfb-b118-808f9a68fe08" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Common Shares, no par value per share</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_a0db2fa6-d7bb-4032-8be1-2b93c403d11e" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">MNMD</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_61b3d218-84e1-49da-8a3d-bc8b789d717b" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">The Nasdaq Stock Market LLC</span></ix:nonNumeric></span></p><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(The Nasdaq Global Select Market)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c53c55ce-0d83-46e8-ac11-4c5435966767" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="dei:EntityCurrentReportingStatus"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#9746; </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   No  </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#9744;</span></p><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).     </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1c427a37-eb11-4dca-8a62-ebe58b057545" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="dei:EntityInteractiveDataCurrent"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#9746; </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   No  </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#9744;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:4pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:19.116%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:55.649%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:20.316%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.92%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10.8pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Large accelerated filer</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accelerated filer</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></p></td>
    </tr>
    <tr style="height:2.15pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_5ca4a22b-c9d9-4409-85f1-4a661657a172" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-accelerated filer</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9746;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Smaller reporting company</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_4c10ceb9-c19f-4965-83a7-7489069eec7f" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:2.15pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Emerging growth company</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_0f4e73fe-8347-4804-a4f5-d6b9c078c551" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:9pt;font-family:Arial;"><ix:nonNumeric id="F_5b25eb79-03a8-42a7-8457-9d144b1f5c96" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#9744; </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   No  </span><span style="font-size:9pt;font-family:Arial;"><ix:nonNumeric id="F_1fd3ce79-1850-492f-86e5-15134404d463" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="dei:EntityShellCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of April 23, 2025, t</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">he registrant had </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3df0fa59-788c-405e-8f3d-1979037aa4fc" contextRef="C_5a13acac-19e1-4c71-912c-83e07c93e680" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">75,553,266</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Common Shares outstanding.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="border-top:2.25pt double;padding-top:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:10%;box-sizing:content-box;"/>
     <td style="width:82.92%;box-sizing:content-box;"/>
     <td style="width:7.08%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Page</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">PART I</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_1_financial_information"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">FINANCIAL INFORMATION</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1_financial_statements"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Financial Statements</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_balance_sheets"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Condensed Consolidated Balance Sheets</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#operations_and_comprehensive_loss"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Condensed Consolidated Statements of Operations and Comprehensive Loss</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#shareholders_equity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Condensed Consolidated Statements of Shareholders' Equity</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_of_cash_flows"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Condensed Consolidated Statements of Cash Flows</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#notes_to_consolidated_financial"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Notes to Condensed Consolidated Financial Statements</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 2.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_2_mda"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 3.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_3_quantitative_and_qualitative"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 4.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_4_controls_and_procedures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Controls and Procedures</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">PART II</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_ii"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">OTHER INFORMATION</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28</span></p></td>
    </tr>
    <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1.</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc_page"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Legal Proceedings</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1A.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item1a_risk_factors"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Risk Factors</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 2.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item2_unregistered_sales"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 3.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item3_defaults_upon_senior"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Defaults Upon Senior Securities</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 4.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item4_mine_safety_disclosure"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 5.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item5_other_information"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Other Information</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 6.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_6_exhibits"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Exhibits</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#signatures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Signatures</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Quarterly Report on Form 10-Q ("Quarterly Report") contains forward-looking statements about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this Quarterly Report, including statements regarding our future results of operations or financial condition, business strategy and plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will&#8221; or &#8220;would&#8221; or the negative of these words or other similar terms or expressions. These forward-looking statements include, but are not limited to, statements concerning the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing, progress and results of our investigational programs for MM120, a proprietary, pharmaceutically optimized form of lysergide D-tartrate (LSD), MM402, also referred to as R(-)-MDMA (together, our &#8220;lead product candidates&#8221;) and any other product candidates (together with our lead product candidates, our &#8220;product candidates&#8221;);</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our reliance on the success of our investigational MM120 product candidate;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our expectations regarding our cash runway;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the protocols and timing of availability of data from our ongoing Phase 3 clinical program for MM120 orally disintegrating tablet (&#8220;ODT&#8221;) in generalized anxiety disorder (&#8220;GAD&#8221;);</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the protocol and timing of availability of data from our ongoing Phase 3 clinical program for MM120 in major depressive disorder (&#8220;MDD&#8221;);</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing, scope or likelihood of regulatory filings and approvals and our ability to obtain and maintain regulatory approvals for product candidates for any indication;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our expectations regarding the size of the eligible patient populations for our lead product candidates, if approved and commercialized;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to identify third-party treatment sites to conduct our trials and our ability to identify and train appropriate qualified healthcare practitioners (&#8220;HCPs&#8221;) to administer our treatments;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to implement our business model and our strategic plans for our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to identify new indications for our lead product candidates beyond our current primary focuses;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to achieve profitability and then sustain such profitability;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our commercialization, marketing and manufacturing capabilities and strategy;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the pricing, coverage and reimbursement of our lead product candidates, if approved and commercialized;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the rate and degree of market acceptance and clinical utility of our lead product candidates, in particular, and controlled substances, in general;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">future investments in our business, our anticipated capital expenditures and our estimates regarding our capital requirements;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to establish or maintain collaborations or strategic relationships or to obtain additional funding;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our expectations regarding potential benefits of our lead product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to maintain effective patent rights and other intellectual property protection for our product candidates, and to prevent competitors from using technologies we consider important in our successful development and commercialization of our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">infringement or alleged infringement on the intellectual property rights of third parties;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">legislative and regulatory developments in the United States, including individual states, the UK, the European Union and other jurisdictions, including decisions by the U.S. Drug Enforcement Administration (&#8220;DEA&#8221;) and states to reschedule any of our product candidates, if approved, containing Schedule I controlled substances, before they may be legally marketed in the U.S.;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the effectiveness of our internal control over financial reporting;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">actions of activist shareholders against us that have previously been and could be disruptive and costly and may result in litigation and have an adverse effect on our business and stock price;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the impact of adverse global economic conditions, including public health crises, geopolitical conflicts, fluctuations in interest rates, supply-chain disruptions and inflation, on our financial condition and operations;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our Amended Loan Agreement (as defined herein) contains certain covenants that could adversely affect our operations and, if an event of default were to occur, we could be forced to repay any outstanding indebtedness sooner than planned and possibly at a time when we do not have sufficient capital to meet this obligation;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our expectations regarding our revenue, expenses and other operating results;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs and success of our marketing efforts, and our ability to promote our brand;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our reliance on key personnel and our ability to identify, recruit and retain skilled personnel;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to effectively manage our growth; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to compete effectively with existing competitors and new market entrants.</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You should not rely on forward-looking statements as predictions of future events. We have based the forward-looking statements contained in this Quarterly Report primarily on our current expectations and projections about future events and trends that we believe may affect our business, financial condition and operating results. The outcome of the events described in these forward-looking statements is subject to risks, uncertainties and other factors described in the section titled &#8220;Risk Factors&#8221; previously disclosed in Part I, Item 1A. in our Annual Report on Form 10-K, as filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) on March 6, 2025 (the &#8220;2024 Annual Report&#8221;) and in Part II, Item 1A in this Quarterly Report and the section titled &#8220;Management's Discussion and Analysis of Financial Condition and Results of Operations&#8221; in Part I, Item 2 of this Quarterly Report. Moreover, we operate in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this Quarterly Report. The results, events and circumstances reflected in the forward-looking statements may not be achieved or occur, and actual results, events or circumstances could differ materially from those described in the forward-looking statements.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based on information available to us as of the date of this Quarterly Report. And while we believe that information provides a reasonable basis for these statements, that information may be limited or incomplete. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely on these statements.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The forward-looking statements made in this Quarterly Report relate only to events as of the date on which the statements are made. We undertake no obligation to update any forward-looking statements made in this Quarterly Report to reflect events or circumstances after the date of this Quarterly Report or to reflect new information or the occurrence of unanticipated events, except as required by law. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may announce material business and financial information to our investors using our investor relations website  (https://ir.mindmed.co/). We therefore encourage investors and others interested in our company to review the information that we make available on our website, in addition to following our filings with the SEC, webcasts, press releases and conference calls. Our website and information included in or linked to our website are not part of this Quarterly Report. Unless otherwise noted or the context indicates otherwise, references in this Quarterly Report to the &#8220;Company,&#8221; &#8220;MindMed,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to Mind Medicine (MindMed) Inc. and its consolidated subsidiaries.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_1_financial_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I&#8212;FINANCIAL INFORMATION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1_financial_statements"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1. Fin</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ancial Statements.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="balance_sheet">&#160;</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Mind Medicine (MindMed) Inc.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_balance_sheets"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Condensed </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated Balance Sheets</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(In thousands, except share amounts)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:67.152%;box-sizing:content-box;"/>
     <td style="width:1.758%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:13.313%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.758%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.02%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31, 2025<br/>(unaudited)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Assets</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current assets:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e49b335c-d0f2-4c33-b593-c4ddeb462449" contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">82,854</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_01ab89eb-4ad8-4b51-b175-06a25074d0de" contextRef="C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">273,741</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term investments</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d96ea098-e7c6-4764-a944-d9e116f2c415" contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">129,587</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid and other current assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_78e1b3f7-b203-40b3-ba87-72ba3646bf51" contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,259</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_229ec2f8-b56f-4b50-9aa7-ebc3b5c0d0aa" contextRef="C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,879</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2e92063c-4a8e-4334-8df1-9cf209b061b5" contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">221,700</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1a93fb51-84cc-4e74-8bcb-4701f4ef4f0e" contextRef="C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">281,620</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Long-term investments</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_69fbe64c-8593-4fd2-96d2-9c17dd77b915" contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256" name="us-gaap:LongTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,099</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Goodwill</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8ad3dfd9-41c6-40d5-990b-ce6377c40fd8" contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256" name="us-gaap:Goodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,918</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_914f7113-f097-489a-ad6a-f8f6140992e0" contextRef="C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc" name="us-gaap:Goodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,918</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other non-current assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e1729d32-ecbf-4c82-b90a-54d4402df0b7" contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">606</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8c3e5ac2-27f8-4785-a975-69b65af231fe" contextRef="C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">613</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5860ab78-00c7-4ede-9bbd-8337f589e471" contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">275,323</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_18183e36-d99c-4f33-94e3-df56e6e22b05" contextRef="C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">302,151</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Liabilities and Shareholders&#8217; Equity</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current liabilities:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fdf1d289-5ca3-4e8a-8135-ba2ef8d69317" contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,268</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3fde0b74-f4f3-49d8-9efb-b58d07ca22dc" contextRef="C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,010</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_47000f97-cc65-4681-8957-99476cddee5b" contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,497</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5679a879-34f8-4a7e-9573-9ba6fd13856f" contextRef="C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,829</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2022 USD Financing Warrants</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_feedee3b-065a-432b-8ab2-8bb3bf0d5fd8" contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256" name="mnmd:FinancingWarrantsLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,716</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_afc04f00-70a4-4a76-ad33-f2f34d6079ea" contextRef="C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc" name="mnmd:FinancingWarrantsLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,010</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0d1c74df-daaf-42bb-aeb5-6d9363966de5" contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,481</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cb837a3f-01b3-414a-aae0-f7b71c9cb43a" contextRef="C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,849</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Credit facility, long-term</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_776a9324-0ee4-477c-97d6-b60c62ffb0cc" contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256" name="us-gaap:LongTermLineOfCredit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,036</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5e6d6d7f-371a-45d6-813e-d5bbdb705c43" contextRef="C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc" name="us-gaap:LongTermLineOfCredit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,854</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_07dc4012-4f12-44ba-bab3-6ecd119bcac5" contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">52,517</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0322ecab-004d-4e39-9255-ac47da48ac0c" contextRef="C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">60,703</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_88461b8f-b10d-4348-8f11-5a095afbfb82;"><span style="-sec-ix-hidden:F_a5f6e01e-d45d-48c2-a8b5-6ec8ed432e26;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commitments and contingencies (Note 10)</span></span></span></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shareholders' equity:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common shares, </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5c8067cc-6993-4fe3-a253-fb858fe7cd1f" contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UsdShare" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_0a0c4241-4e1b-4f84-80b2-7d7177715100" contextRef="C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UsdShare" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;par value, </span><span><span style="-sec-ix-hidden:F_bdc0d770-37db-4b91-b201-46ab50f8b510;"><span style="-sec-ix-hidden:F_8aef1a60-8a65-43d5-88a7-a12bf6efa231;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">unlimited</span></span></span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;authorized as of March 31, 2025 and December 31, 2024; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_404bd8c7-01c0-4cdc-abc2-ae6ef42f0b13" contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_bc958c2f-f2e2-458b-b471-810c29a73037" contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">75,511,375</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;and </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_788add1e-0804-483b-b377-8ccea53f1061" contextRef="C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_9b322a3d-fb0e-40b6-8278-05d85db318f7" contextRef="C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">75,100,763</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;issued and outstanding as of March 31, 2025 and December 31, 2024, respectively</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_48b94f86-01e6-4c6b-ba2f-884f3c981c63;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></span></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_f4dfe000-183d-4ac2-8317-e5d26a5c8b53;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></span></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additional paid-in capital</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_89310f74-3231-4e3a-999f-153060f997fb" contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">644,231</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_44ef3deb-a600-433f-ab56-9653cc16b35a" contextRef="C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">639,508</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated other comprehensive income</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c96ebbdb-ab62-4e53-9fbf-4ec4e2e0a67c" contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">802</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d0df376d-6b84-4b8f-a48d-8105661420a3" contextRef="C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">819</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated deficit</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_43702ee0-c5be-4f39-9a7f-398a12902491" contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">422,227</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2b81b864-98b4-4279-9d18-4a8513e7eced" contextRef="C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">398,879</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total shareholders' equity</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_60742cfa-fb5e-4442-8ad9-3d9da72a276e" contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">222,806</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a85b6ba0-030e-46d0-b5ac-f2628d50a300" contextRef="C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">241,448</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities and shareholders' equity</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c225a96c-6241-4a8e-91e1-9402b4e22216" contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">275,323</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7d9eff17-1310-4550-9d9a-8ed8b1b26f1a" contextRef="C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">302,151</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">See accompanying notes to unaudited condensed consolidated financial statements.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Mind Medicine (MindMed) Inc.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="operations_and_comprehensive_loss"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Condensed Consolidated Statements of Operations and Co</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">mprehensive Loss</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Unaudited)</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(In thousands, except share and per share amounts)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:97.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:66.907%;box-sizing:content-box;"/>
     <td style="width:1.753%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.866000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.753%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.722000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_93bb77a6-a126-4cc4-ba41-5531d8b638cb" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,357</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_95332ca9-d96c-40cb-b302-a0ebcc314c17" contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,705</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1314d69d-a5b7-4f8a-9e37-3314f5d9456e" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,802</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b1a74b65-9637-4472-ba28-ce5b7306a52b" contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,499</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_23ebb5fe-2d36-43f3-adb3-0f0415c4ff4f" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,159</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_06b00695-e2a5-4bed-83fa-f1d4d9bccd95" contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,204</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_84606b17-2bb8-41b3-afc6-d81d82b1a778" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">32,159</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9da70c3e-d52f-4b98-a773-1a77fa47be97" contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">22,204</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income/(expense):</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest income</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aa40f28f-4ee7-4a09-97c0-470b422d4295" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:InvestmentIncomeInterestAndDividend" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,433</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7a86f410-7fc2-43c1-95a8-36c619f235e9" contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb" name="us-gaap:InvestmentIncomeInterestAndDividend" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,656</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest expense</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a6290542-699d-41da-8ced-6927396d5530" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">602</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b2687579-4de1-441a-b9de-b23325241372" contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">434</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign exchange loss, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7d283256-c8e6-4524-8851-657683b46dd0" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">19</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_620c1258-16be-44f0-a1e9-9c5c925e3943" contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">525</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value of 2022 USD Financing Warrants</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ea3b3ac8-1207-4b00-9038-37f80695acdf" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">6,999</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e957c067-5031-4c6c-8898-ac39b1cb34f1" contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,893</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total income/(expense), net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_616e13df-ec18-484a-a46e-9d4b0bf6bdd7" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,811</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a683b086-319d-4a7e-8132-da21e839b724" contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">32,196</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_93702d9a-53c4-43a8-8478-7d73143ba34c" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">23,348</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_13ade13d-0c3c-42fa-a37c-c9ad59327443" contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">54,400</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other comprehensive loss</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrealized gain on investments</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_00561164-01a9-4568-aacc-e1b8deb2d2bb" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:UnrealizedGainLossOnInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Loss)/gain on foreign currency translation</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_53863f66-a6a1-4894-aed3-ac17bd9a84e6" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">27</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a6b38bf5-35fc-4335-8480-0dcc578e9e10" contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">493</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Comprehensive loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e5113b84-b996-4f43-810c-ac57a5c1dc11" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">23,365</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_492b73c3-dc05-4336-a99f-82e6d38d2345" contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">53,907</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per common share, basic</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0160c27f-e942-4a00-aa71-cbbfeb28c631" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:EarningsPerShareBasic" unitRef="U_UsdShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.27</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5c799877-e248-4b01-a966-5d0e31d66647" contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb" name="us-gaap:EarningsPerShareBasic" unitRef="U_UsdShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.14</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per common share, diluted</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ebab1cc7-4c9d-42e9-9daf-90409c3abd4d" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UsdShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.35</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8b357347-2224-4461-943f-157658a10473" contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UsdShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.14</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average common shares, basic</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ce1dcb81-c32c-45c8-9421-60f38d1b6aa3" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">85,067,855</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c72931fe-8fb1-4605-aa68-7eab3fe897aa" contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">47,860,757</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average common shares, diluted</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_45329e87-849f-4667-806c-506fd4f6bc36" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">87,091,461</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_723f1f9d-dfa6-4edc-859f-1166aba7806f" contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">47,860,757</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">See accompanying notes to unaudited condensed consolidated financial statements.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="equity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Mind Medicine (MindMed) Inc.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="shareholders_equity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Condensed Consolidated Statements of </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Shareholders&#8217; Equity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Unaudited)</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(In thousands, except share amounts)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:32.027%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:8.796%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.06%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:8.177%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:8.177%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:8.177%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:8.177%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:8.417%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Common Shares</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Additional Paid-In Capital</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated OCI</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated Deficit</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance, December 31, 2024</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_de7a1b3c-7f19-4cd8-ba3d-4e1ac24187a2" contextRef="C_a8edddb6-a7d1-4462-a57e-b8c66cc64c46" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">75,100,763</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d87a7b96-3e78-4955-8f42-5699123fa60e" contextRef="C_a991fead-ed19-4c7e-a11e-4d30d6b8613d" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">639,508</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2e67503c-a26e-4778-9d69-23e1d2bcacc7" contextRef="C_385312b0-168e-450a-8069-c73e69ed32d7" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">819</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_07ad578f-76fd-4b8c-a22d-6887d88b8894" contextRef="C_6e886f9e-717a-465f-9fee-5b794de40e69" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">398,879</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4df2da8f-e2de-4d15-a40d-9fda5a1b96d6" contextRef="C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">241,448</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common shares under employee share purchase plan ("ESPP")</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7a323798-2d90-4b1d-967b-c97d970cff3f" contextRef="C_cb6db0ce-574c-45c7-a69a-4330f84bb3c7" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">34,017</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_57a7e6ae-95fd-4869-a7f2-2de49b5e599d" contextRef="C_cf6044bc-91e6-4b8c-82c8-fab4740fed04" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">186</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9a827b54-c458-414c-990a-4fb129524ea5" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">186</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common shares upon settlement of restricted share unit ("RSU") awards, net of shares withheld for tax</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6ad861fe-d154-4983-8900-4b6d657e6859" contextRef="C_cb6db0ce-574c-45c7-a69a-4330f84bb3c7" name="mnmd:StockIssuedDuringPeriodSharesUponSettlementOfRestrictedStockUnitAwardsNetOfSharesWithheldForTax" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">186,708</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercise of 2022 USD Financing Warrants</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_21414216-831e-4d02-8568-6df38fe8a3c1" contextRef="C_2711bf7d-51fa-4c13-8e64-2c94219ab80a" name="mnmd:StockIssuedDuringPeriodSharesWarrantsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">136,346</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_da69e159-9da8-47f9-bb7c-6ebd26acb336" contextRef="C_6feaeecd-fd52-496a-87c2-1985d67f38f0" name="mnmd:StockIssuedDuringPeriodValueWarrantsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">874</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_69519416-2fbb-48bb-ab1c-069490a05475" contextRef="C_b180f4c3-0072-43ff-9725-7c3a3e4ad1f1" name="mnmd:StockIssuedDuringPeriodValueWarrantsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">874</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation expense</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1a905233-2840-423f-b534-76538864042f" contextRef="C_cf6044bc-91e6-4b8c-82c8-fab4740fed04" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,426</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_555c6fb8-2017-44c1-aadd-c799a0fec8b2" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,426</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercise of stock options</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5ad89844-1047-437a-9759-1b59c66d1ead" contextRef="C_cb6db0ce-574c-45c7-a69a-4330f84bb3c7" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">53,541</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4230cb0e-a4d7-4940-a358-5463ce2974ea" contextRef="C_cf6044bc-91e6-4b8c-82c8-fab4740fed04" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">237</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c779ba4c-c3a7-4586-83f1-d9645c020072" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">237</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss and comprehensive loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dbc62f05-59a2-4171-acf1-14b51068bad5" contextRef="C_4abdbb57-7e44-40e1-a361-dedbe9966b38" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">17</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b3dfc902-15e2-480b-b241-39fabb3fccea" contextRef="C_39a7f94d-b020-4c68-859b-28f61826d359" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">23,348</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_45f81ea0-6cc0-4ca4-841c-df94dab6b339" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">23,365</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance, March 31, 2025</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_70dc6267-c2aa-4050-adf7-f07b4ea7fca6" contextRef="C_98c96557-3887-4999-b5e8-247c1ed96005" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">75,511,375</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b56c4304-03f3-4866-a719-72724ac5a294" contextRef="C_83fc4e0e-c83d-497b-af6e-c962abe5d2fd" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">644,231</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5447cb05-dd39-49c4-b4ea-e04d5b272ab1" contextRef="C_cb762e0c-1384-4979-be76-95297f6af7c8" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">802</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a1090ea5-7851-460f-9c99-ad065c789b3a" contextRef="C_939e4af1-6bdb-4858-a841-8acd4d2a47f4" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">422,227</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_79072a10-fecd-4155-a12e-a4116446fef4" contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">222,806</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance, December 31, 2023</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d3332014-cd2a-4dc0-af74-509bb3a69adb" contextRef="C_57494605-d58d-4ef0-b4ff-8e96f7bcf04c" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">41,101,303</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_df3929db-867c-4f4f-89f0-59601617ee1d" contextRef="C_54995453-beb7-498a-8683-7850a8191dba" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">367,991</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae6d0c66-aeaa-44db-bd60-1ad4044b5e5f" contextRef="C_a39c400a-978e-47bc-a958-d2b3c57c3ab7" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">343</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_245c1c4d-3690-40cc-a044-8ea050f7a3ca" contextRef="C_37fa8a98-03fc-4f71-9bce-63073a3d3907" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">290,200</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_be5cb3dc-ecc9-4eb2-86f1-d856bebf65b0" contextRef="C_ebfcf44a-8b21-4107-a576-08b906d78af5" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">78,134</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common shares, net of share issuance costs</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8678f894-375a-422f-a71c-f5da2233db56" contextRef="C_a76dd043-ee75-4b71-a525-e4107e5d3732" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">29,338,553</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_17683d08-1404-4398-aad6-a86a22a38d85" contextRef="C_925b985b-901b-4479-a40b-d64febbd22cf" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">164,298</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5d9294ce-c2d1-4cfa-a00c-c3b8bc0abbba" contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">164,298</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common shares upon settlement of RSU awards, net of shares withheld for tax</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c7c69cd6-cbab-4d05-b347-2d7cc9478d37" contextRef="C_a76dd043-ee75-4b71-a525-e4107e5d3732" name="mnmd:StockIssuedDuringPeriodSharesUponSettlementOfRestrictedStockUnitAwardsNetOfSharesWithheldForTax" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">204,968</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_92247aa7-f82b-4da8-8a73-823a987b114c" contextRef="C_925b985b-901b-4479-a40b-d64febbd22cf" name="mnmd:StockIssuedDuringPeriodValueUponSettlementOfRestrictedStockUnitAwardsNetOfSharesWithheldForTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">54</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7e49f9eb-f630-438f-9437-7fa4c5ee2468" contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb" name="mnmd:StockIssuedDuringPeriodValueUponSettlementOfRestrictedStockUnitAwardsNetOfSharesWithheldForTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">54</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercise of 2022 USD Financing Warrants</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2b9b200f-a13f-4b4f-b591-a93232cd217f" contextRef="C_8e1a6127-7406-40c2-a294-e96d17a71e6c" name="mnmd:StockIssuedDuringPeriodSharesWarrantsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">400,000</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_37dc5674-963c-4a9f-9b0f-e005d3668d72" contextRef="C_24991487-9f41-4eb3-b745-b05e5c54af14" name="mnmd:StockIssuedDuringPeriodValueWarrantsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,369</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_73704735-4ed7-4bfd-be14-72c71b7b4bb6" contextRef="C_9e259264-1dab-4ca4-a6a1-b8eba8c5e07f" name="mnmd:StockIssuedDuringPeriodValueWarrantsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,369</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation expense</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6fa5c2de-5013-475c-a591-2f8fb95e657a" contextRef="C_925b985b-901b-4479-a40b-d64febbd22cf" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,689</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c460ca0c-30f8-40e2-ae93-23c2ccf38ac1" contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,689</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercise of stock options</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3bfb4ae9-f030-4e92-81c5-1233abcf6c91" contextRef="C_a76dd043-ee75-4b71-a525-e4107e5d3732" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">118,896</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1f788144-715a-4c69-a7e8-87b61611d930" contextRef="C_925b985b-901b-4479-a40b-d64febbd22cf" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">530</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e2925748-10b5-4395-b4b1-bc25ec5a3890" contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">530</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss and comprehensive loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b167cd98-8234-461d-ae22-fce9431c0292" contextRef="C_75bc9303-a477-4604-852c-7370782dc59b" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">493</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_30930b7e-cc6b-4194-9ccf-17741fb14766" contextRef="C_01a2dc55-35b5-4300-97d4-8821ba88df11" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">54,400</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1fbd5933-e1f2-474d-8431-9a84bea3106b" contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">53,907</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance, March 31, 2024</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_66963c86-bf8f-4621-9d49-2c9329476389" contextRef="C_095bf73d-2ada-4710-8b73-6c8b87d5dc15" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">71,163,720</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7a0f254d-1aa7-436d-a548-fde333f4b752" contextRef="C_e6549b22-6f92-4409-ac7d-193000c6fe21" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">539,823</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_764070d0-2797-4255-b781-72aacdc94370" contextRef="C_13b67830-d4f4-404f-a407-d676bfd7b796" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">836</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6adbc681-e903-4ed7-818b-1aec56edf750" contextRef="C_bd03d603-030d-4d7d-8bdb-3dd6759f747f" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">344,600</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_30c98250-2f2a-4b73-aca6-0e69e693fa67" contextRef="C_06e3dec8-4efa-4049-969d-372ad64052f3" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">196,059</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">See accompanying notes to unaudited condensed consolidated financial statements.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="cash_flows"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Mind Medicine (MindMed) Inc.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statements_of_cash_flows"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Condensed </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated Statements of Cash Flows</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Unaudited)</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(In thousands)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:97.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:70.33%;box-sizing:content-box;"/>
     <td style="width:1.835%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:11.464%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.031%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:11.34%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash flows from operating activities</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c8bad7b0-d86c-4e66-ae5c-7c557f9e242c" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">23,348</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_10a45c67-09ff-4d30-896a-d32cfc3d07b5" contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">54,400</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adjustments to reconcile net loss to net cash used in operating activities:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fe342b06-e385-400a-90f7-cafe2708aa1b" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,426</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_62d766a5-2bab-4749-8f56-9d31cb1c0b03" contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,689</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value on directors' deferred share units ("DDSU")</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0e897274-6d06-45ca-bc09-e93b5c892cfe" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="mnmd:ChangeInFairValueOnDirectorsDeferredShareUnits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9f67234e-c641-464d-a55b-c77d9d5466e0" contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb" name="mnmd:ChangeInFairValueOnDirectorsDeferredShareUnits" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">781</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amortization of intangible assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ca1ab64e-b623-4be0-afb3-6870c497838c" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b3efe1c0-a04e-4a6a-9e72-b12621f1311f" contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">527</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value of the 2022 USD Financing Warrants</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cf898555-3ad8-44e3-8a10-41459dde0c1f" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">6,999</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_19e1b528-850a-4728-9c85-e33f4e530b08" contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,893</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrealized foreign exchange</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2402945e-2653-47b3-a89b-e4d199ede957" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3ca463c5-0c0c-4801-bf52-d73b137473d5" contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">514</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other non-cash adjustments</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_326ee79f-0909-4a79-9c86-4a9122e2365e" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="mnmd:OtherNonCashAdjustments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">19</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_84272f74-58ff-45fb-948d-f22194dec162" contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb" name="mnmd:OtherNonCashAdjustments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">75</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in operating assets and liabilities:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid and other current assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e9ffc9d1-297b-4508-bc82-80882082d596" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,380</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_93098d1c-f52e-4458-8f75-c6f884653286" contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">468</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other noncurrent assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0632fe4b-4d47-401c-8b62-f5ee1f2524a5" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c744ddfb-6bb0-417d-89de-bebdc54d46b8" contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">66</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_57ebd9c9-6196-4648-b259-0b2349cf057f" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">258</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_87158d5d-84de-4997-b510-de17f8bb4853" contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,509</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0e47e25d-ad9c-4bc0-ae75-590bc81c56b3" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,329</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_774ba73f-3789-4994-a74c-4af92a05c76f" contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,703</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other liabilities, long-term</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_87b86468-3cf6-44e4-825b-a6df240a6044" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="mnmd:OtherLiabilitiesLongTerm" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_082d6792-fecb-4452-b1eb-9f37510c05f6" contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb" name="mnmd:OtherLiabilitiesLongTerm" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5.56%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash used in operating activities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_860687b8-092b-4634-ab27-98a9ae40da4e" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">29,419</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bbe5c696-85c3-4b1f-a367-e0d3ec088817" contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">16,598</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash flows from investing activities</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchases of investments</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_578e3791-d1ff-4487-9c61-1b27286190c2" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:PaymentsToAcquireInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">162,458</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_047900d2-eae1-4713-9e26-84fd8abb359f" contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb" name="us-gaap:PaymentsToAcquireInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5.56%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash used in investing activities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c3f3450d-d935-4b0f-99dd-49c8c51e651f" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">162,458</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_432ac63c-fa70-48ab-8056-6d466362d425" contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash flows from financing activities</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from the Offering and Private Placement</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_44ab149d-97c8-4047-a548-099e633e6f7f" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="mnmd:ProceedsFromOfferingAndPrivatePlacement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5cac1732-efea-4a8f-851e-f5971f2c88ca" contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb" name="mnmd:ProceedsFromOfferingAndPrivatePlacement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">175,000</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Payment of issuance costs from the Offering and Private Placement</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ec37bf7a-8b5c-407d-8a74-74213d2cda03" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_38d14adb-2ac9-4200-b727-065c9faf09a2" contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,720</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Payment of credit facility issuance costs</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_597e4570-08d3-4024-a2df-309d72308d9d" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:PaymentsOfFinancingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_57b4e01e-c0cc-4b4d-acfd-26a2aeaf5d2a" contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb" name="us-gaap:PaymentsOfFinancingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">128</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from the at-the-market offering program, net of issuance costs</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d887e9d-0058-491c-b4d8-158bfceaa47c" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="mnmd:ProceedsFromAtTheMarketOfferingProgramNetOfIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7f3da661-3851-4476-8e3d-ffff156fd678" contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb" name="mnmd:ProceedsFromAtTheMarketOfferingProgramNetOfIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">984</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from exercise of warrants</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_476b7a77-c848-4ed8-a656-3dec3fd507eb" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:ProceedsFromWarrantExercises" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">579</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ce2f122b-ce7e-4d06-ac17-8c9614d657ae" contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb" name="us-gaap:ProceedsFromWarrantExercises" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,700</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from exercise of options</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6ddd3af6-0da8-4428-a601-078a0db9d8e6" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">237</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_349f0d70-bb21-4b8e-bcaa-7e88076d0938" contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">465</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from issuance of common shares under ESPP</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4999393a-846a-432e-9430-a8582e5a690b" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">186</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_723d9e9b-c03e-45d4-97d6-4dcc568e5d92" contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Withholding taxes paid on vested RSUs</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f1920035-f711-4e71-bd18-5a0dfbe9d4a3" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3f2ea04c-1157-4266-9da6-69d3576a50fb" contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">54</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5.56%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b72a2688-53a2-4264-9593-00cdfa90789b" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,002</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_382a40f9-87f1-4275-b65e-a3eb01c7daba" contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">169,247</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Effect of exchange rate changes on cash</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b29808d8-c6fe-47a9-a1d4-e8b2afcba0b1" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">12</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_761bc4ce-ed6f-4571-bf57-5ed2106ac4c6" contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">21</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net (decrease)/increase in cash and cash equivalents</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6fa63cf5-0ddb-41b8-ae42-c8b2aa2bf46b" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">190,887</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d5069f48-320e-442a-8a21-b2ab1f23e669" contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">152,628</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents, beginning of period</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_35853e7b-aea9-49d3-933e-5f57968eeaa4" contextRef="C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">273,741</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cd0c1698-86da-4e7e-bb50-2b0875fa58f3" contextRef="C_ebfcf44a-8b21-4107-a576-08b906d78af5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">99,704</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents, end of period</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2868d349-319c-4b84-9b60-3f8eb7ba2f36" contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">82,854</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e97942fd-0a04-4337-a9c1-375e5573aa44" contextRef="C_06e3dec8-4efa-4049-969d-372ad64052f3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">252,332</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Supplemental Cash Flow Information</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash paid for interest</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c98c0437-e364-4947-bfcd-cff6d826692d" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">602</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_873252c1-66e8-42df-b160-79ce5f8a08cb" contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">434</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Supplemental Noncash Disclosures</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Conversion of 2022 USD Financing Warrants to common shares upon exercise of warrants</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_26a33404-82cc-4fac-a2a5-0eb135fabc15" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:StockIssued1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">295</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6e388cca-cef7-4f3f-a76f-7ab2f2c9fcc9" contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb" name="us-gaap:StockIssued1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,669</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unpaid issuance costs for the Offering and Private Placement</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a5b54769-6c2d-4aff-9735-d1b22354e475" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="mnmd:UnpaidIssuanceCostsForOfferingAndPrivatePlacement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bf45a1d2-0e61-4657-a79a-35c7a3272913" contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb" name="mnmd:UnpaidIssuanceCostsForOfferingAndPrivatePlacement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,340</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from exercise of options in prepaid and other current assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_521a9ddb-a807-4509-8a81-a139d9000eac" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="mnmd:ProceedsFromExerciseOfOptionsInPrepaidAndOtherCurrentAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_18a945af-bbf3-4555-9be8-d4b237a95bc4" contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb" name="mnmd:ProceedsFromExerciseOfOptionsInPrepaidAndOtherCurrentAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">65</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Reclass of deferred financing fees to additional paid-in capital</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_14641fa9-e1d3-4382-a203-788c8a13ecd5" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="mnmd:ReclassOfDeferredFinancingFeesToAdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9dfccbd8-0015-48d9-bd26-04aacae529f1" contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb" name="mnmd:ReclassOfDeferredFinancingFeesToAdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">332</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">See accompanying notes to unaudited condensed consolidated financial statements.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Mind Medicine (MindMed) Inc.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="notes_to_consolidated_financial"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to Unaudited Condensed Consolidated Financial Statements</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c56a2f01-a753-48be-af3e-04598df8c1bf" contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb" name="us-gaap:NatureOfOperations" escape="true"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DESCRIPTION OF THE BUSINESS</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Mind Medicine (MindMed) Inc. (the &#8220;Company&#8221; or &#8220;MindMed&#8221;) is incorporated under the laws of the Province of British Columbia. Its wholly owned subsidiaries, Mind Medicine, Inc. (&#8220;MindMed US&#8221;), HealthMode, Inc., MindMed Pty Ltd., and MindMed GmbH are incorporated in Delaware, Delaware, Australia and Switzerland respectively. MindMed US was incorporated on May 30, 2019.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">MindMed is a late-stage clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders. The Company&#8217;s mission is to be the global leader in the development and delivery of treatments for brain health disorders that unlock new opportunities to improve patient outcomes. The Company is developing a pipeline of innovative product candidates targeting neurotransmitter pathways that play key roles in brain health. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, the Company&#8217;s lead product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Liquidity</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of March 31, 2025, the Company had an accumulated deficit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_35c02392-1070-4376-964a-756a1ec0cbef" contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">422.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. Through March 31, 2025, the Company&#8217;s financial support has primarily been provided by proceeds from the issuance of its common shares, no par value per share (&#8220;Common Shares&#8221;) and warrants to purchase Common Shares, and the Company&#8217;s credit facility.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As the Company continues its expansion, it may seek additional financing and/or strategic investments; however, there can be no assurance that any additional financing or strategic investments will be available to the Company on acceptable terms, if at all. If events or circumstances occur such that the Company does not obtain additional funding, it will most likely be required to reduce its plans and/or certain discretionary spending, which could have a material adverse effect on the Company&#8217;s ability to achieve its intended business objectives. The accompanying unaudited condensed consolidated financial statements do not include any adjustments that might be necessary if it were unable to continue as a going concern. Management believes that it has sufficient working capital on hand to fund operations through at least the next twelve months from the date of the issuance of these unaudited condensed consolidated financial statements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Emerging Growth Company Status</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use the extended transition period for complying with new or revised accounting standards, and as a result of this election, the unaudited condensed consolidated financial statements may not be comparable to companies that comply with public company Financial Accounting Standards Board (&#8220;FASB&#8221;) standards&#8217; effective dates. The Company may take advantage of these exemptions up until the last day of the fiscal year following the fifth anniversary of the first sale of its common equity securities under an effective Securities Act of 1933 (the "Securities Act") registration statement or such earlier time that it is no longer an emerging growth company.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the opinion of management, these unaudited condensed consolidated financial statements reflect all adjustments necessary for a fair presentation of the Company's financial position and results of operations and cash flows for the periods presented.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_806caf41-aa05-4d5f-9fef-ffa4e2408309" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" escape="true" continuedAt="F_806caf41-aa05-4d5f-9fef-ffa4e2408309_1"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">BASIS OF pRESENTATION AND Summary of Significant Accounting Policies</span></div></div><div><ix:nonNumeric id="F_3f60e965-3732-4faa-a4af-15b74ed14535" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" escape="true" continuedAt="F_3f60e965-3732-4faa-a4af-15b74ed14535_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basis of Presentation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification and as amended by Accounting Standards Updates of FASB. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the related notes thereto for the year ended December 31, 2024, which are included in the Company&#8217;s 2024 Annual Report on Form 10-K filed with the SEC on March 6, 2025 (the &#8220;2024 Annual Report&#8221;). The Company&#8217;s significant accounting policies are disclosed in the audited consolidated financial statements for the periods ended December 31, 2024 and 2023, included in the 2024 Annual Report. Since the date of those financial statements, there have been no changes to the Company's significant accounting policies.</span></p></ix:nonNumeric></div></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_806caf41-aa05-4d5f-9fef-ffa4e2408309_1" continuedAt="F_806caf41-aa05-4d5f-9fef-ffa4e2408309_2"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_3f60e965-3732-4faa-a4af-15b74ed14535_1" continuedAt="F_3f60e965-3732-4faa-a4af-15b74ed14535_2"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make a number of estimates and assumptions relating to the reporting of assets and liabilities and the disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates under different assumptions or conditions.</span></p></ix:continuation></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_3f60e965-3732-4faa-a4af-15b74ed14535_2"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intercompany balances and transactions, and any unrealized income and expenses arising from intercompany transactions, are eli</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">minated in preparing the unaudited condensed consolidated financial statements.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c577902d-2e4f-4113-ad2f-63c18af90ccb" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Foreign Currency</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to April 1, 2024, the Company&#8217;s functional currency was the Canadian dollar (&#8220;CAD&#8221;). Translation gains and losses from the application of the U.S. dollar (&#8220;USD&#8221;) as the reporting currency during the period that the Canadian dollar was the functional currency were included as part of cumulative currency translation adjustment, which is reported as a component of shareholders&#8217; equity as accumulated other comprehensive income.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following the Company&#8217;s voluntary delisting from Cboe Canada in April 2024, the Company reassessed its functional currency and determined that, as of April 1, 2024, its functional currency had changed from the CAD to the USD.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For periods commencing April 1, 2024, monetary assets and liabilities denominated in currencies other than USD are remeasured at period-end using the period-end exchange rate. Opening balances related to non-monetary assets and liabilities are based on prior period translated amounts, and non-monetary assets acquired, and non-monetary liabilities incurred after April 1, 2024, are translated at the approximate exchange rate prevailing at the date of the transaction. Income and expense accounts are translated at the average rates in effect during the fiscal year. Foreign exchange gains and losses are included in the unaudited condensed cons</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">olidated statements of operations and comprehensive loss.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7038a90e-2d4b-4a99-a16c-f9231dc51695" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash Equivalents</span></p><p style="text-indent:4.535%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.037%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company considers all investments with an original maturity date at the time of purchase of three months or less to be cash equivalents. As of March 31, 2025, the Company&#8217;s cash equivalents consisted of U.S. government money market funds at a high-credit quality and federally insured financial institution. The Company&#8217;s accounts may, at times, exceed federally insured limits. The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company had cash equivalents of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a933acaf-b691-4d6a-b5fd-f046149c7387" contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">80.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of March 31, 2025, and $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_751ec4db-c570-4196-952f-e2422b86eaa1" contextRef="C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">271.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of December 31, 2024.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5a9700df-dbee-4b5b-958e-a400f202b714" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:AvailableForSaleSecuritiesPurchasedOptionsPricePolicy" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investments</span></p><p style="text-indent:4.535%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.037%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All investments have been classified as &#8220;available-for-sale&#8221; and are carried at fair value as determined based upon quoted market prices or pricing models for similar securities at period end. Investments with contractual maturities within 12 months at the balance sheet date are considered short-term investments. Those investments with contractual maturities greater than 12 months at the balance sheet date are considered long-term investments. Dividend and interest income are recognized when earned. Realized gains and losses are included in earnings and are derived using the specific identification method for determining the cost of securities sold. Unrealized gains and losses are reported as a component of accumulated other comprehensive income (loss). The Company reviews its portfolio of available-for-sale debt securities, using both quantitative and qualitative factors, to determine if declines in fair value below cost have resulted from a credit-related loss or other factors. If the decline in fair value is due to credit-related factors, a loss is recognized in statements of operations, whereas if the decline in fair value is not due to credit-related factors, the loss is recorded in other co</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">mprehensive income (loss).</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_9d9e2b06-4656-4e21-a722-268ac3bb676e" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true" continuedAt="F_9d9e2b06-4656-4e21-a722-268ac3bb676e_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net Loss per Share</span></p><p style="text-indent:4.535%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.037%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the three-month period ended March 31, 2025, the Company determined that the 2022 USD Financing Warrants had a dilutive impact to the calculation of net loss per share. As a result, the Company calculated the diluted net loss per Common Share for the three months ended March 31, 2025.</span></p></ix:nonNumeric></div></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_806caf41-aa05-4d5f-9fef-ffa4e2408309_2"><div><ix:continuation id="F_9d9e2b06-4656-4e21-a722-268ac3bb676e_1" continuedAt="F_9d9e2b06-4656-4e21-a722-268ac3bb676e_2"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_38310de2-f545-4825-88fb-ecd08a1a73fb" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth the computation of basic and diluted net loss per share attributable to common shareholders (in thousands, except sh</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">are and per share amounts). As the exercise price of the Company&#8217;s pre-funded warrants is $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0ebc797c-63ed-480c-b6f7-6cb01f046151" contextRef="C_aff55750-479b-4423-af77-60c8f43e209e" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UsdShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, it was determined to be non-substantive for accounting purposes and the pre-funded warrants were included in the denominator of both basic and diluted loss per share:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
         <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
          <tr style="visibility:collapse;">
           <td style="width:66.673%;box-sizing:content-box;"/>
           <td style="width:1.64%;box-sizing:content-box;"/>
           <td style="width:1%;box-sizing:content-box;"/>
           <td style="width:13.023%;box-sizing:content-box;"/>
           <td style="width:1%;box-sizing:content-box;"/>
           <td style="width:1.64%;box-sizing:content-box;"/>
           <td style="width:1%;box-sizing:content-box;"/>
           <td style="width:13.023%;box-sizing:content-box;"/>
           <td style="width:1%;box-sizing:content-box;"/>
          </tr>
          <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Numerator:</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
           <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss attributable to common shareholders, basic</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b4db1957-0d10-41e3-9c75-d2c2f81c4910" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">23,348</ix:nonFraction></span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_388520b1-3212-4744-b1a0-af57e3099dd0" contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">54,400</ix:nonFraction></span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
           <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value of the 2022 USD Financing Warrants</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c9551053-2dd8-466b-9913-b76f53685b8d" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">6,999</ix:nonFraction></span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
           <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss attributable to common shareholders, diluted</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9af5800b-1d0b-4575-a966-27d532904582" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">30,347</ix:nonFraction></span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0f5ef660-b4fb-4726-87e2-05219a72d896" contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">54,400</ix:nonFraction></span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Denominator:</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
           <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average pre-funded warrants used in computing net loss<br/>per share attributable to common shareholders, basic</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_38eff021-6ccb-4dec-b16b-f7ca14230e70" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="mnmd:WeightedAverageNumberOfPreFundedWarrantsOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">9,753,775</ix:nonFraction></span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
           <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average shares used in computing net loss per share<br/>attributable to common shareholders, basic</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_31eec6aa-2a84-4e50-8bfb-e982c0a5dcea" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="mnmd:WeightedAverageNumberOfCommonSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">75,314,080</ix:nonFraction></span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_df5d9900-0da0-4e5b-b084-636b8ab3438c" contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb" name="mnmd:WeightedAverageNumberOfCommonSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">47,860,757</ix:nonFraction></span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
           <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total weighted-average shares used in computing net loss per<br/>share attributable to common shareholders, basic</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3fe522a7-11b4-45bf-8ac7-455a954fe3e2" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">85,067,855</ix:nonFraction></span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_77f27da7-da1f-41e7-9393-95262baf480e" contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">47,860,757</ix:nonFraction></span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
           <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Incremental shares from 2022 USD Financing Warrants</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_94a50a80-3f17-42d8-92eb-a4e13f17cf22" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,023,606</ix:nonFraction></span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
           <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total weighted-average shares used in computing net loss per<br/>share attributable to common shareholders, diluted</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_66c1f9a2-d3a9-4c84-a7e5-df824a62160c" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">87,091,461</ix:nonFraction></span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c5079fa6-8c21-467e-8b17-95743a68d195" contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">47,860,757</ix:nonFraction></span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Net loss per share:</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
           <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Basic</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_18e74aca-ad74-4ca5-9faf-cfc09f1d9188" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:EarningsPerShareBasic" unitRef="U_UsdShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.27</ix:nonFraction></span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_22449ade-f464-48af-8a42-d2d1ff9da220" contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb" name="us-gaap:EarningsPerShareBasic" unitRef="U_UsdShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.14</ix:nonFraction></span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
           <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Diluted</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0dc2a204-cafc-44b6-9c8d-72d17fdf1ed0" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UsdShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.35</ix:nonFraction></span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4a1347c7-247c-4e1f-8934-c79b10128ab5" contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UsdShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.14</ix:nonFraction></span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          </tr>
         </table></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9f73c574-481f-482f-93ee-da1babfb1670" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true" continuedAt="F_9f73c574-481f-482f-93ee-da1babfb1670_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following potentially dilutive securities have been excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
         <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
          <tr style="visibility:collapse;">
           <td style="width:66.967%;box-sizing:content-box;"/>
           <td style="width:1.16%;box-sizing:content-box;"/>
           <td style="width:1%;box-sizing:content-box;"/>
           <td style="width:13.357%;box-sizing:content-box;"/>
           <td style="width:1%;box-sizing:content-box;"/>
           <td style="width:1.16%;box-sizing:content-box;"/>
           <td style="width:1%;box-sizing:content-box;"/>
           <td style="width:13.357%;box-sizing:content-box;"/>
           <td style="width:1%;box-sizing:content-box;"/>
          </tr>
          <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2022 USD Financing Warrants</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_700f9d7f-e338-485e-a711-64cc48855722" contextRef="C_fd8b6f33-1ed4-4940-897a-df0a934092d1" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">4,949,954</ix:nonFraction></span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_63862701-f34b-48bb-914e-8abed8613e7b" contextRef="C_3eda8f94-de7e-4394-a39c-79afdb6058ce" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">6,631,823</ix:nonFraction></span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5bb634fa-e89e-45a2-b118-0b206ac55f44" contextRef="C_6011eb25-af6f-4f60-b18a-f48be80a2b48" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">4,465,831</ix:nonFraction></span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_12cfb136-c3e9-47c8-801d-debbbb94755e" contextRef="C_d74b207d-4c84-4383-8d90-5ecc70a0eeb9" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">3,696,128</ix:nonFraction></span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">RSUs</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_81928284-cbaf-428f-a605-dfb7a48f24ec" contextRef="C_db671577-db0a-4a9e-b198-84650c9bc0dd" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">5,948,852</ix:nonFraction></span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2526006b-9d33-42a4-a2f0-529043bccece" contextRef="C_7cf3b999-3819-4049-8c52-90a0e922de85" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,112,546</ix:nonFraction></span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Conversion Shares</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_280a9f35-e7fe-44dd-a2af-35ef37f039bf" contextRef="C_093e9bfe-6581-4ff9-8a14-13447fd595d8" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">249,377</ix:nonFraction></span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2d592266-b6e6-4771-8f3b-38a643f63052" contextRef="C_4167881d-1e68-4b3c-b401-a89cc1d4f259" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">997,506</ix:nonFraction></span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Estimated ESPP awards</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b2300244-379f-4aca-aed6-99c67dd6fbba" contextRef="C_3c75786f-e793-48f9-af75-c6a4be9a5a7f" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">27,939</ix:nonFraction></span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
           <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
           <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_25c3af2f-2fc1-4786-a46d-a0cdc69f41e6" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">15,641,953</ix:nonFraction></span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0560b09f-81c0-4c74-a60e-f6fe9a9f5c65" contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">13,438,003</ix:nonFraction></span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
         </table></ix:nonNumeric></div></ix:continuation></div></ix:continuation></div><div><ix:continuation id="F_9d9e2b06-4656-4e21-a722-268ac3bb676e_2"><div><ix:continuation id="F_9f73c574-481f-482f-93ee-da1babfb1670_1"></ix:continuation></div></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dad2b098-0ff5-463e-940c-54f8cbb4c91e" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" escape="true"><div class="item-list-element-wrapper" style="display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INVESTMENTS</span></div></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9dc64658-9a1f-4207-a84b-f3b11399661a" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company's available-for-sale investments consisted of the following (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50.4%;box-sizing:content-box;"/>
         <td style="width:1.22%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.18%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.22%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.18%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.22%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.18%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.22%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.18%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized Cost</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Gain</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Losses</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated Fair Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Short-term:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e8fcf2cc-2b25-4bc9-af9c-0506f72088af" contextRef="C_0229cf68-edf9-4c29-9a29-b011952417f5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,725</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ebb39847-d3ab-48a2-a1bb-0af3a02818e1" contextRef="C_0229cf68-edf9-4c29-9a29-b011952417f5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e8ab12c2-b901-49f2-98f2-990f56d6c14b" contextRef="C_0229cf68-edf9-4c29-9a29-b011952417f5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,722</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. agency bonds</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e1aa825b-d3cf-4242-9811-4a88fd35f101" contextRef="C_592df924-3dca-44fb-a185-3cc0e5436ffc" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">96,868</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_31ef0644-8775-447d-9933-df6eb46bd4ee" contextRef="C_592df924-3dca-44fb-a185-3cc0e5436ffc" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ce614dd5-3ffc-4633-97bf-1f4f4b7a65ea" contextRef="C_592df924-3dca-44fb-a185-3cc0e5436ffc" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1197bc3e-4756-42fd-b6f5-1b13b18608c8" contextRef="C_592df924-3dca-44fb-a185-3cc0e5436ffc" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">96,865</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_485f4d3b-fbf8-4b92-823d-9f59a2ba77d7" contextRef="C_9530e32c-7cf2-41f3-bd67-a92ee6762331" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">129,593</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0c1dbff7-fdee-4a58-8492-c15aa636558e" contextRef="C_9530e32c-7cf2-41f3-bd67-a92ee6762331" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_06150f8e-ce8b-41ea-a490-f7ed8ee8ee7d" contextRef="C_9530e32c-7cf2-41f3-bd67-a92ee6762331" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_66cac4d6-8897-47ea-a2f8-2e77a2d5f9ca" contextRef="C_9530e32c-7cf2-41f3-bd67-a92ee6762331" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">129,587</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Long-term:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. agency bonds</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3bdd9bc9-34a6-460d-9b90-bbab1981e3a3" contextRef="C_afb02b48-cbcb-40bd-950a-da13b4f46b8a" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,083</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1d2a98be-744c-49d1-9a95-fdc2811b13d6" contextRef="C_afb02b48-cbcb-40bd-950a-da13b4f46b8a" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6b5ca835-fdd9-4e58-bd10-c10a0adf39da" contextRef="C_afb02b48-cbcb-40bd-950a-da13b4f46b8a" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fd8a0932-a7a0-438d-9156-6207bcc8ffc8" contextRef="C_afb02b48-cbcb-40bd-950a-da13b4f46b8a" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,099</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dca33761-6c90-4ed4-9c84-000584c02b86" contextRef="C_e34dffa8-783f-47f9-b3eb-1d1ea40a50f2" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,083</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba954ef0-e464-4b4b-b506-58285ed17cd0" contextRef="C_e34dffa8-783f-47f9-b3eb-1d1ea40a50f2" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_61a19fa9-e1cd-4191-9be3-f89064a9f7da" contextRef="C_e34dffa8-783f-47f9-b3eb-1d1ea40a50f2" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_df9e87cb-687b-4e91-a31a-2b934a6da1f2" contextRef="C_e34dffa8-783f-47f9-b3eb-1d1ea40a50f2" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,099</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has determined that there were no material declines in the fair value of its investments due to credit-related factors as of March 31, 2025. The Company held </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_27efdac6-da73-4957-84c8-43e5d791e134" contextRef="C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> available-for-sale investments as of December 31, 2024.</span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4e43f441-4924-4015-99bc-f8299808d4de" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:FairValueDisclosuresTextBlock" escape="true"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FAIR VALUE OF FINANCIAL INSTRUMENTS</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a5f8a319-5a68-4a15-8582-8bc165c98c0b" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" escape="true" continuedAt="F_a5f8a319-5a68-4a15-8582-8bc165c98c0b_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents information about the Company&#8217;s assets and liabilities measured at the fair value on a recurring basis as of March 31, 2025 and December 31, 2024 (in thousands), and the fair value hierarchy of the valuation techniques utilized.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company classifies its assets and liabilities as either short-term or long-term based on maturity and anticipated realization dates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_a5f8a319-5a68-4a15-8582-8bc165c98c0b_1">
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50.4%;box-sizing:content-box;"/>
         <td style="width:1.22%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.18%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.22%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.18%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.22%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.18%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.22%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.18%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial assets:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_72d65443-bbf8-4a8a-9d8a-47fed1c2890b" contextRef="C_8e014f8c-ec6c-4965-ad7a-4716062b7c4d" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">80,444</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_48e708e5-ad40-4df4-a9f9-957bfe4faba6" contextRef="C_36b4af29-5d76-4291-b73b-cd8c72915e01" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">80,444</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a715a5e3-bf9f-4e1c-a5af-a4b3ff260106" contextRef="C_634127f7-e2ca-4f43-b3c1-b5a15d394d01" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,722</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_20d96744-c359-4c0d-9b95-d059284d7187" contextRef="C_4f9c94fe-d4da-4fdb-80c6-934c635c61cf" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,722</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. agency bonds</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0a850b7e-21b4-4d42-adc7-d845b930b9da" contextRef="C_5e3a61c1-28b2-4c74-befa-0a83e0e3f355" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">129,964</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_24150ff2-9482-4bfe-92a8-5acd2d6610e0" contextRef="C_02d3e741-f89c-4731-a810-9c92f1a21ee4" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">129,964</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_adfeb40f-20dc-4709-8a9d-57f9b8c6c24a" contextRef="C_8e014f8c-ec6c-4965-ad7a-4716062b7c4d" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">113,166</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_39de1689-f511-4427-a33d-9f8d22c7658b" contextRef="C_ade2e71f-765e-4fb6-86cf-647ae7dd133c" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">129,964</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6388d9c0-091b-46cf-be10-4929244df589" contextRef="C_36b4af29-5d76-4291-b73b-cd8c72915e01" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">243,130</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial liabilities:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">DDSU Liability</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_40d0fbb1-8554-4c35-9f96-ce878b8446c8" contextRef="C_05d13ef9-8e4a-4163-9c2d-b90faeb5d396" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,129</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_47e33917-00f6-4459-b8f3-d95644c4e487" contextRef="C_26a40041-e25c-4e75-bf9d-fa804e8cd077" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,129</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2022 USD Financing Warrant Liability</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d331c7af-b70a-4c3d-83e2-196eb5121e6e" contextRef="C_910d296e-b905-4051-81fa-bd26919dc2be" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,716</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5394d51a-6958-43d9-9db6-3bd1aecba1f1" contextRef="C_dd654da2-3037-41d6-b072-b777c8f63fe4" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,716</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4e9cb890-cf6e-48d9-aac1-9e46c63920fc" contextRef="C_8e014f8c-ec6c-4965-ad7a-4716062b7c4d" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,129</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1e43fb8f-0760-49d8-89f2-6818286fcf9d" contextRef="C_73ffda6d-742d-40f9-a06d-603da3eab457" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,716</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_546168a6-4b91-4b53-b305-e3ef1069fee2" contextRef="C_36b4af29-5d76-4291-b73b-cd8c72915e01" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,845</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial assets:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_48551829-4186-4c9e-abd6-be866c9e7f43" contextRef="C_3719fe9d-d9b5-450f-af3d-bfac82d59821" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">271,537</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_29dd9796-2d9a-4438-bb6a-b19ffb516741" contextRef="C_2e42dac1-0eaa-4f5d-b79b-b48d8486374e" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">271,537</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b3963f28-7184-4658-9b5f-5f4133b8198c" contextRef="C_3719fe9d-d9b5-450f-af3d-bfac82d59821" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">271,537</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a3097839-2bcf-4260-a856-02e62cb79aa4" contextRef="C_2e42dac1-0eaa-4f5d-b79b-b48d8486374e" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">271,537</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial liabilities:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">DDSU Liability</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_84557089-1249-431b-ac84-4274e679abcc" contextRef="C_8eca3c03-2aed-492a-b29b-dd10aed0202f" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,148</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e7de39a7-bc69-4e2f-84dc-1ad549e2cc12" contextRef="C_d2978ec1-8cd7-4990-abd7-153da97219c6" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,148</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2022 USD Financing Warrant Liability</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9fc852ed-0c65-402c-a938-ea8cda8da9ab" contextRef="C_b72d06dd-d6d5-41b9-91f8-bad834196904" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,010</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7f158224-4c8d-454f-866f-10e199fc8ed7" contextRef="C_4350eef0-c7b4-4a27-8d23-cb926ba2db8d" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,010</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_09d4623c-b6b3-4215-9239-a2f7795d16e0" contextRef="C_3719fe9d-d9b5-450f-af3d-bfac82d59821" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,148</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e3818ad6-984b-4ad6-9130-6c8f21a49e4e" contextRef="C_12ece47b-93f1-4de7-b519-aa935811a9f5" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,010</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_67af5662-5f33-4d65-b9a4-275944e1b168" contextRef="C_2e42dac1-0eaa-4f5d-b79b-b48d8486374e" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,158</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d917a83-8c96-40b8-ad98-749b2ce8762a" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_f51ec0b7-52c6-42fb-9c31-fd050057e214" contextRef="C_62a1dfe7-53cc-4860-88cd-5195a323ecfb" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_837b2834-dc76-4534-89c0-7d4f12716fd8" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_f6223532-be0f-4478-a26d-7f183044cef3" contextRef="C_62a1dfe7-53cc-4860-88cd-5195a323ecfb" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> transfers into or out of Level 1, Level 2, or Level 3 during the three months ended March 31, 2</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5c8abac6-a3f4-44a6-a89b-d392e4466657" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" unitRef="U_USD" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_de936f17-57bd-47dc-ab11-0f380f161f9b" contextRef="C_62a1dfe7-53cc-4860-88cd-5195a323ecfb" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" unitRef="U_USD" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_12d9193c-b41d-49eb-9ad0-b0517dab7671" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" unitRef="U_USD" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_d203d8f1-27ae-4b62-8979-4e6c71c883e3" contextRef="C_62a1dfe7-53cc-4860-88cd-5195a323ecfb" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" unitRef="U_USD" decimals="INF" format="ixt:num-dot-decimal">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">25 and the year ended December 31, 2024.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a39ced36-31a7-4dc4-89a8-a9fe960f0d48" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company issued liability-classified warrants to purchase Common Shares in our underwritten public offering that closed on September 30, 2022 (the &#8220;2022 USD Financing Warrants&#8221;). The warrant liability is measured at fair value on a recurring basis and is classified as Level 3 in the fair value hierarchy. Its fair value is determined using the Black-Scholes option pricing model using the following assumptions:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:35.24%;box-sizing:content-box;"/>
         <td style="width:2.86%;box-sizing:content-box;"/>
         <td style="width:29.52%;box-sizing:content-box;"/>
         <td style="width:2.86%;box-sizing:content-box;"/>
         <td style="width:29.52%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Share price</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2bf69522-2802-475c-a635-d4b2111ab9a7" contextRef="C_97bfc649-2b8e-41f0-8976-f5330877ad56" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" unitRef="U_UsdShare" scale="0" decimals="2" format="ixt:num-dot-decimal">5.85</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_84d2c804-6ac4-4f1d-b982-7499d74e0015" contextRef="C_cf111989-4654-4f24-8b88-1ac2ede3bffd" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" unitRef="U_UsdShare" scale="0" decimals="2" format="ixt:num-dot-decimal">6.96</ix:nonFraction></span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_69a26bb1-cfc7-4cc7-ac35-5792179e5a55" contextRef="C_a5257296-f7b1-43a0-9556-3801f55d61c2" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">79.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9d5f7baf-1781-402f-be22-162f88d757e4" contextRef="C_c9514733-173b-4015-8d17-721fcab04ad2" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">90.70</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free rate</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_10c37ae5-199f-4762-ac81-c9fb3cbbde6f" contextRef="C_5d84c0a3-45aa-4e65-83e3-9a191c580b57" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">3.85</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c094441e-229e-44c8-954a-8cbcc61004b6" contextRef="C_71fe533e-e23e-4d50-b70c-175f681b0e12" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.18</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected life</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_c3877cfd-cc94-4fa4-ad1c-825b60db715d" contextRef="C_30b95ea8-0cae-41e0-b81a-309b08ca75f2" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.5 </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">years</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_abde0ef5-72f9-4663-baca-2a4e716103a8" contextRef="C_bc56a365-8e98-4a9c-b1c1-8e03984015fd" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.75 </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">years</span></p></td>
        </tr>
       </table></ix:nonNumeric></div></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_16490e19-a99a-49e1-b881-b656fbb1440b" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" escape="true"><div class="item-list-element-wrapper" style="display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GOODWILL</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the three months ended March 31, 2025, the Company has made </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_17f3e916-1dc9-4c89-91b2-c6df3b23db04" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:GoodwillAcquiredDuringPeriod" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> additions to its outstanding goodwill. There were no triggering events identified, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0c3759f5-4e62-49dd-8372-65913e9b0e6a" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="mnmd:IndicationOfImpairmentOfGoodwillAndLongLivedAssets" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_aa8d9631-ecc0-40f1-91cc-1ef96ee8cc1b" contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb" name="mnmd:IndicationOfImpairmentOfGoodwillAndLongLivedAssets" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> indication of impairment of the Company&#8217;s goodwill, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5bfd7d3a-f8c9-4542-9459-c6265a82f35c" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:GoodwillImpairmentLoss" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_28727d97-69f1-4ba9-88e4-50b8bc0c5d1c" contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb" name="us-gaap:GoodwillImpairmentLoss" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> impairment charges recorded during the three months ended March 31, 2025 and 2024, respectively.</span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d421ad91-4b95-440c-9a60-8c08c05855ee" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" escape="true"><div class="item-list-element-wrapper" style="display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ACCRUED EXPENSES</span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e908c9bc-d6fc-45ab-8fe1-d82a1971803d" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At March 31, 2025 and December 31, 2024, accrued expenses consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:64.167%;box-sizing:content-box;"/>
         <td style="width:1.76%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:14.157%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.76%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:14.157%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee2a0774-fa3f-4adc-953c-1edb5fbede77" contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256" name="us-gaap:WorkersCompensationLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,361</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dc92f530-0b1e-4328-b410-bd30388d34b3" contextRef="C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc" name="us-gaap:WorkersCompensationLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,405</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued clinical trial costs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c5947fdf-4b6f-48fc-9ab8-3297ec8d3a28" contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256" name="mnmd:AccruedClinicalAndManufacturingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,537</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_75323b55-91a3-4f77-b426-600997c28074" contextRef="C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc" name="mnmd:AccruedClinicalAndManufacturingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,332</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued other research and development costs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6f4b0c90-d7d7-4d47-bdae-3066c35d93bf" contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256" name="mnmd:AccruedOtherResearchAndDevelopmentCostsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">901</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dcb3c05a-1a62-49e9-b8d1-fb868be8cb39" contextRef="C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc" name="mnmd:AccruedOtherResearchAndDevelopmentCostsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">841</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Professional services</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_26e02522-3174-4af1-b0de-03370cefca5d" contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,437</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f20e7d1b-1dc2-4613-a072-04d0bbcdad6b" contextRef="C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">973</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other accruals</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d230770f-242a-49c3-b25c-629350ef0803" contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">261</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6bf5ba19-74bb-40f3-a260-d002c9e2e76c" contextRef="C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">278</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0619732c-de9d-431b-ad93-fac8cd10e793" contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,497</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b8cc9eeb-913e-4e0e-bbb8-a80b43f2de0f" contextRef="C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,829</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><ix:nonNumeric id="F_5767ccfd-6237-43ca-b2a7-9341eff798e2" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true" continuedAt="F_5767ccfd-6237-43ca-b2a7-9341eff798e2_1"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">7.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SHAREHOLDERS' EQUITY</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Common Shares</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is authorized to issue an unlimited number of Common Shares, which have </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c3dd4293-4fa1-4599-9946-42716f946089" contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256" name="us-gaap:CommonStockNoParValue" unitRef="U_UsdShare" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> par value. As of March 31, 2025, the Company ha</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">d </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_124fd2db-0d6f-4fb2-9e1e-d1ed95bcc451" contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256" name="mnmd:CommonStockSharesIssuedAndOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">75,511,375</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Common Shares issued and outstanding.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">At-The-Market Facilities</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 4, 2022, the Company filed a shelf registration statement on Form S-3 (the &#8220;2022 Registration Statement&#8221;), as well as an accompanying prospectus supplement (the &#8220;Prior ATM Prospectus&#8221;). </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the filing of the 2022 Registration Statement and Prior ATM Prospectus, the Company also entered into a sales agreement (the &#8220;Prior Sales Agreement&#8221;) with Cantor Fitzgerald &amp; Co. and Oppenheimer &amp; Co. Inc. as sales agents (together, the &#8220;Prior Sales Agents&#8221;), pursuant to which the Company was able to issue and sell Common Shares for an aggregate offering price of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_56257f19-9a73-44db-9e33-aaf74b78d8a3" contextRef="C_e69e4c45-b9fa-4c14-a874-f74d991218c1" name="mnmd:SaleOfEquityAggregatePublicOfferingAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">100.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million under an at-the-market offering program (the &#8220;Prior ATM&#8221;). During the three months ended March 31, 2024, the Company sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4441c8bf-c8b3-477f-92d1-a0ac73e1fa12" contextRef="C_d6c40bae-8846-460f-9af3-802080fee535" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">171,886</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Common Shares for net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7d5fd069-c6c3-4af3-9316-5752260ba78b" contextRef="C_d6c40bae-8846-460f-9af3-802080fee535" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million under the Prior ATM. As of March 7, 2024, the Company had raised an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_495bc5df-7f84-44bc-8222-0b31401087c1" contextRef="C_e36f91bd-0fb2-41fd-b1b0-74152cad4505" name="mnmd:SaleOfEquityAggregatePublicOfferingAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">40.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million under the ATM and had the remaining availability of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9c2f009c-99c0-476d-8af2-0202e5d73fbe" contextRef="C_e36f91bd-0fb2-41fd-b1b0-74152cad4505" name="mnmd:SaleOfEquityRemainingOfferingAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">59.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. On March 7, 2024, the Company announced that it had delivered written notice to the Sales Agents that it was suspending and terminating the Prior ATM Prospectus. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 28, 2024, the Company delivered written notice to the Prior Sales Agents that it was terminating the Prior Sales Agreement.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On June 28, 2024, the Company filed a shelf registration statement on Form S-3 (the &#8220;2024 Registration Statement&#8221;), as well as an accompanying prospectus supplement (&#8220;New ATM Prospectus&#8221;). In connection with the filing of the 2024 Registration Statement and the New ATM Prospectus, the Company entered into a sales agreement (the "Sales Agreement") with Leerink Partners LLC (the &#8220;Sales Agent&#8221;) pursuant to which the Company may issue and sell from time to time Common Shares for an aggregate offering price of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a051f9a4-8e1b-4b8f-b1cd-dc8abf98a443" contextRef="C_90573d83-d120-4c4b-9277-fd2e39b59277" name="mnmd:SaleOfEquityAggregatePublicOfferingAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">150.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in accordance with the New ATM Prospectus under an at-the-market offering program (the "2024 ATM"). Pursuant to the 2024 ATM, the Company will pay the Sales Agent a commission rate of up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1d17eb8f-f21b-4343-9a6f-e2b3b500bc35" contextRef="C_90573d83-d120-4c4b-9277-fd2e39b59277" name="mnmd:PercentageOfGrossProceedsSaleOfCommonSharesPayableAsSalesAgentsCommissionRate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">3.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the gross proceeds from the sale of any Common Shares. The Company is not obligated to make any sales of its Common Shares under the 2024 ATM. The Company has not sold any Common Shares under the 2024 ATM as of March 31, 2025.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The March 2024 Offering and Private Placement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 7, 2024, the Company entered into an underwriting agreement with Leerink Partners LLC and Cantor Fitzgerald &amp; Co., as representatives of the underwriters named therein, in connection with the issuance and sale by the Company in an underwritten offering (the &#8220;March 2024 Offering&#8221;) of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ed4df974-6f78-4152-a286-34000de5c3a8" contextRef="C_81f4f1da-ef96-4aad-9e47-23f8b90a22b7" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">16,666,667</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Common Shares, at an offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_27a9565d-8b02-43c8-90fe-04309e222a72" contextRef="C_81f4f1da-ef96-4aad-9e47-23f8b90a22b7" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UsdShare" decimals="INF" format="ixt:num-dot-decimal">6.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, less underwriting discounts and commissions.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The net proceeds to the Company from the March 2024 Offering were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_853a0e05-e663-4f40-bee2-1cf535247d77" contextRef="C_11c49272-f55d-49f3-b7a7-0fefff64a7f1" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">93.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Also on March 7, 2024, the Company entered into a securities purchase agreement with certain investors, pursuant to which the investors agreed to purchase, and the Company agreed to sell </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d45b2e7a-88c7-4833-b7e1-9e4e6f4fc9f1" contextRef="C_2e215081-711a-47c3-8879-d448652f7b35" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">12,500,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Common Shares (the &#8220;Private Placement Shares&#8221;), at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_438d7c7e-ba1f-4d0b-96ac-ca9b76c98d9a" contextRef="C_430d76fe-9c73-4a88-a973-58ab8a42cea6" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UsdShare" decimals="INF" format="ixt:num-dot-decimal">6.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per Private Placement Share, in a private placement transaction (the &#8220;March 2024 Private Placement&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The net proceeds to the Company from the March 2024 Private Placement were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a6b6af0f-80fc-4336-9486-5d9d8b1a75a0" contextRef="C_2e215081-711a-47c3-8879-d448652f7b35" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">70.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, after deducting fees and expenses payable by the Company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_5767ccfd-6237-43ca-b2a7-9341eff798e2_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company intends to use the net proceeds from the March 2024 Offering and the March 2024 Private Placement for (i) the research and development of the Company&#8217;s product candidates and (ii) working capital and general corporate purposes.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The March 2024 Offering and the March 2024 Private Placement closed on March 11, 2024.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The August 2024 Offering</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On August 9, 2024, the Company entered into an underwriting agreement with Leerink Partners LLC and Evercore Group L.L.C., as representatives of the several underwriters named therein, in connection with an underwritten public offering (the &#8220;August 2024 Offering&#8221;) of (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_80ccd0bf-1e36-4316-bdae-64618646e858" contextRef="C_528dd0c0-1ac6-48fd-ba94-56b201899f5f" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">9,285,511</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Common Shares (the &#8220;Shares&#8221;), and (ii) to certain investors, pre-funded warrants (the &#8220;Pre-Funded Warrants&#8221;) to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_48116889-394d-4ce5-b9ef-fbabb3459da9" contextRef="C_307c81b2-2ca0-4668-bba0-7a7b5291fc9f" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,428,775</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Common Shares (the "Pre-Funded Warrant Shares"). The offering price for the Shares was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_601bdb64-2025-4913-8e62-80aac9ec7f97" contextRef="C_b2ef454a-9f53-4e0f-adeb-d446b560c825" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UsdShare" scale="0" decimals="2" format="ixt:num-dot-decimal">7.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, less underwriting discounts and commissions. The offering price for the Pre-Funded Warrants was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6b6d46fd-6590-4750-a8e9-5c8d088dd6c5" contextRef="C_307c81b2-2ca0-4668-bba0-7a7b5291fc9f" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UsdShare" scale="0" decimals="3" format="ixt:num-dot-decimal">6.999</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per Pre-Funded Warrant, which represents the per share public offering price for the Shares less a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5c601759-08f4-4736-96d8-8f0450cc2c36" contextRef="C_cf474416-20d3-4fb7-a080-b12775ae6c42" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UsdShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share exercise price for each such Pre-Funded Warrant.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The net proceeds to the Company from the August 2024 Offering were approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_21ce7817-ebd6-45a5-9ba2-9099cf1cb601" contextRef="C_d0dd088c-1d9e-451f-88b7-d6ec7c48a41b" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">70.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, after deducting underwriting discounts and commissions and other offering expenses payable by the Company. The August 2024 Offering closed on August 12, 2024.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company intends to use the net proceeds from the August 2024 Offering to fund the research and development of its product candidates and for working capital and general corporate purposes.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Pre-Funded Warrants are exercisable at any time after the date of issuance. The exercise price and the number of Pre-Funded Warrant Shares are subject to appropriate adjustment in the event of certain share dividends and distributions, share splits, share combinations, reclassifications or similar events affecting the Common Shares as well as upon any distribution of assets, including cash, securities or other property, to the Company&#8217;s shareholders. The Pre-Funded Warrants will not expire and are exercisable in cash or by means of a cashless exercise. A holder of Pre-Funded Warrants may not exercise such Pre-Funded Warrants if the aggregate number of Common Shares beneficially owned by such holder, together with its affiliates, would exceed more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0ccbfbd9-2323-4035-abdc-c0bb5800357d" contextRef="C_2bdf42cd-b1cd-4bff-9840-27592a404165" name="mnmd:AggregateNumberOfCommonSharesOwnedByHolderPercentage" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.99</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% or </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2206d91a-a30f-4ec5-ae62-db8d2c69383c" contextRef="C_ec162c56-805d-451c-8646-927ea169440e" name="mnmd:AggregateNumberOfCommonSharesOwnedByHolderPercentage" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">9.99</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% (at the initial election of the holder) of the number of Common Shares outstanding following such exercise, as such percentage ownership is determined in accordance with the terms of the Pre-Funded Warrants. A holder of Pre-Funded Warrants may increase or decrease this percentage not in excess of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fbc41c8f-6260-48c0-aa61-850678374c75" contextRef="C_ec162c56-805d-451c-8646-927ea169440e" name="mnmd:PercentageOfIncreaseOrDecreaseOfOwnershipByPreFundedWarrantsHolder" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">19.99</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% by providing at least 61 days&#8217; prior notice to the Company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">October 2024 Exchange Agreements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 17, 2024, the Company entered into exchange agreements (the &#8220;Exchange Agreements&#8221;) with Commodore Capital Master LP, Deep Track Biotechnology Master Fund, LTD and certain other investors (collectively, the &#8220;Holders&#8221;) pursuant to which the Holders exchanged an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b7362358-fb8f-471d-944c-2d36ebaadd7b" contextRef="C_795cce7f-e02c-4025-a046-7502e810b283" name="us-gaap:StockIssuedDuringPeriodSharesOther" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,325,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Common Shares for pre-funded warrants to purchase an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fa7fd6dc-e03e-48f9-b0a2-0a3a3266c996" contextRef="C_4b6d6580-13c5-46e6-baba-77d54955725a" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,325,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Common Shares with an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0cafbd4a-7812-4843-9221-197e8f6e1af4" contextRef="C_4b6d6580-13c5-46e6-baba-77d54955725a" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UsdShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. Such Common Shares were retired upon exchange. The exchange transactions represented offsetting increases and decreases with additional paid-in capital that had no overall impact to the Company&#8217;s financial statements.</span></p></ix:continuation></div><div><ix:nonNumeric id="F_c28bd0c3-3728-4305-bf11-1114a14a0d63" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="mnmd:WarrantsDisclosureTextBlock" escape="true" continuedAt="F_c28bd0c3-3728-4305-bf11-1114a14a0d63_1"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">8.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WARRANTS</span></div></div><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2022 USD Financing Warrants</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On September 30, 2022, the Company closed an underwritten public offering of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c290faad-ad4f-4635-a260-5b4e4b233ea6" contextRef="C_c223fe50-1eba-4855-9ab8-186a0c6e6c18" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">7,058,823</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Common Shares and accompanying 2022 USD Financing Warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0f227aae-5b88-446d-9ab5-f0843b1f0559" contextRef="C_8105c1cf-df27-4598-b667-6e48ef3b3337" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">7,058,823</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Common Shares. Each 2022 USD Financing Warrant is immediately exercis</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">able for one Common Share at an initial exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9ef03d7f-5959-4919-aae2-d49e08c1d08f" contextRef="C_2995588c-67ea-4d43-b4bf-a6059a698028" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UsdShare" decimals="INF" format="ixt:num-dot-decimal">4.25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per Common Share, subject to certain adjustments, and will expire on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_68783136-3504-4389-ae36-d821d4f09bd6" contextRef="C_fc88df44-67ae-47e8-a51a-83bbbe2805d6" name="mnmd:CommonShareAndWarrantPublicOfferingExpireDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">September 30, 2027</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_c28bd0c3-3728-4305-bf11-1114a14a0d63_1"><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:nonNumeric id="F_781bd0a2-92bb-48ba-a65e-629c3165d3c8" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The table below represents the activity </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">associated with the Company's outstanding liability-classified 2022 USD Financing Warrants for the three months ended March 31, 2025.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.02%;box-sizing:content-box;"/>
         <td style="width:2.88%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:29.1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022 USD Financing Warrants</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_afa81824-2e72-4cb3-9e77-6adfd059fd4d" contextRef="C_4ea41252-c084-4a13-8fad-6ff6f7cfeccf" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,086,300</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issued</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2d4a12f9-539c-45e0-b580-12b3ebf0e86e" contextRef="C_dff63d85-7ca9-411d-a4f5-a8cf59bcaded" name="mnmd:WarrantsIssued" unitRef="U_shares" decimals="INF" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_175789b4-c475-4b55-a7f0-6b1a2b7c2b74" contextRef="C_dff63d85-7ca9-411d-a4f5-a8cf59bcaded" name="mnmd:WarrantsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">136,346</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expired</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e65f9179-050b-40cd-8eb8-c09880578fd5" contextRef="C_dff63d85-7ca9-411d-a4f5-a8cf59bcaded" name="mnmd:WarrantsExpired" unitRef="U_shares" decimals="INF" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_074de9ed-ac23-44c2-aedc-0cf69450d9ef" contextRef="C_71fc6e95-5099-42fb-ad90-d49887a3de3c" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,949,954</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The 2022 USD Financing Warrants are liability-classified. Accordingly, the 2022 USD Financing Warrants are recognized at fair value upon issuance and are adjusted to fair value at the end of each reporting period. Any change in fair value is recognized on the condensed consolidated statements of operations and comprehensive loss.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9b3674d2-14cd-4aee-8600-ba7b1f76370a" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="mnmd:ScheduleOfWarrantLiabilityTableTextBlock" escape="true" continuedAt="F_9b3674d2-14cd-4aee-8600-ba7b1f76370a_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The below table summarizes the activity of the outstanding liability for the 2022 USD Financing Warrants for the three months ended March 31, 2025 (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:67.725%;box-sizing:content-box;"/>
         <td style="width:2.5%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:27.775000000000002%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f52d9ffb-a303-4f4b-8e05-73f97576718c" contextRef="C_b58805d9-68aa-4a81-99f4-2a397090939f" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,010</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrant exercise</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6b92c3c8-904f-43d2-af44-4b4e685a03fe" contextRef="C_e3b59676-7289-49e6-94f9-2ea1da43b0c3" name="mnmd:WarrantExercise" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">295</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value of the warrant liability</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_114def8d-0f36-415d-a7d4-5140a85b05b0" contextRef="C_e3b59676-7289-49e6-94f9-2ea1da43b0c3" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">6,999</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c7bcd366-0104-4f7b-a58a-ae48b259b2e8" contextRef="C_122040ac-3410-4ee2-92d7-5ca02f09a42e" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,716</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div></ix:continuation></div><div><ix:continuation id="F_9b3674d2-14cd-4aee-8600-ba7b1f76370a_1"></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><ix:nonNumeric id="F_a97ecfdd-f77b-43ed-aaca-9e0674133b69" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true" continuedAt="F_a97ecfdd-f77b-43ed-aaca-9e0674133b69_1"><div class="item-list-element-wrapper" style="display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">9.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">STOCK-BASED COMPENSATION</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is authorized to issue such number of equity awards equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fb0f367f-cf54-4d1e-84e1-db45eff66174" contextRef="C_8951a923-02f7-4d9d-aa15-eece5d45babf" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">15</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the Company&#8217;s issued and outstanding Common Shares under the terms of the MindMed Stock Option Plan (the &#8220;Stock Option Plan&#8221;), together with Common Shares that are issuable pursuant to outstanding awards or grants under any other compensation or incentive mechanism involving the issuance or potential issuance of Common Shares, including the Performance and Restricted Share Unit Plan (the &#8220;PRSU Plan&#8221;) and ESPP. The Option Plan and the PRSU Plan were retired effective March 14, 2025, and no further grants will be made under the Option Plan or the PRSU Plan. With the retirement of the Option Plan and the PRSU Plan, the ESPP and any other compensation or incentive mechanism involving the issuance or potential issuance of Common Shares (including inducement grants made outside a plan) are no longer subject to the </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_299be47e-812b-4639-8b5c-d02feb32e318" contextRef="C_8951a923-02f7-4d9d-aa15-eece5d45babf" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">15</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% cap from the Option Plan and PRSU Plan.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock Options</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b70cc795-916d-4eda-92c1-0845fcf91e32" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the Company&#8217;s stock option activity for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three months ended March 31, 2025:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:37.305%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.695%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.399%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.235%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.695%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.399%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.275%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of Options</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted Average Exercise Price</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted Average Remaining Contractual Life (Years)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate Intrinsic <br/>Value (USD$)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options outstanding at December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dc82ce29-2c25-485c-b1d8-ec59e5c5a519" contextRef="C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,225,032</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_999115c8-7c0c-404d-9728-2a462b727a94" contextRef="C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UsdShare" scale="0" decimals="2" format="ixt:num-dot-decimal">12.35</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;"><ix:nonNumeric id="F_20dca849-27d6-431a-9f07-b86f61178355" contextRef="C_62a1dfe7-53cc-4860-88cd-5195a323ecfb" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.6</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e956c060-2594-4d6e-a194-2822f6f712c6" contextRef="C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,147,893</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2ac1ffc8-c15f-4b4c-8354-e5900f89857e" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">755,500</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_989ae172-4be8-4ad3-b208-2861c1bf8428" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UsdShare" scale="0" decimals="2" format="ixt:num-dot-decimal">6.65</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ca7acf04-b27c-4527-9216-d57929880ece" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">53,541</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4706b9f9-5148-48d6-9767-803741e7682a" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UsdShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4.42</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d9fd97c5-d1bd-4fde-b9a4-895cc0d22d64" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">385,629</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7753a2da-e318-4587-8571-ad5e17f1d667" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UsdShare" scale="0" decimals="2" format="ixt:num-dot-decimal">6.75</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expired</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cb3bb8ef-66ca-493d-9e44-9083446f066a" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">75,531</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d64fe77-3eea-442b-814e-671b196e0bab" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" unitRef="U_UsdShare" scale="0" decimals="2" format="ixt:num-dot-decimal">17.39</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options outstanding at March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_887ee81e-1c61-4f6c-a1f0-bea3a25a489d" contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,465,831</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_94b399e6-ecc2-4a26-9ce2-a56fa28d1127" contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UsdShare" scale="0" decimals="2" format="ixt:num-dot-decimal">11.88</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;"><ix:nonNumeric id="F_4b7ad1f3-753c-4cdd-8714-193185b56c56" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.9</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f26bfaa4-fa61-4251-b633-8530d0e7d4da" contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,681,194</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options vested and exercisable at March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_56c2c4b7-97f6-4ad0-9697-8df83f5985a0" contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,879,772</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9b31f86f-bb8d-40fe-a434-02f2e06a1765" contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" unitRef="U_UsdShare" scale="0" decimals="2" format="ixt:num-dot-decimal">18.52</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;"><ix:nonNumeric id="F_f88a8184-65d6-43b1-a834-63a7b9aa0643" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.0</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ea3007f1-505a-47db-9363-ab2b332f6062" contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">805,673</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The expense recognized related to options during the three months ended March 31, 2025 and 2024 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8c070a78-221f-4e6a-b3da-da87ff4e8150" contextRef="C_8951a923-02f7-4d9d-aa15-eece5d45babf" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8e6ff065-91d2-4b16-b69a-5c99acc0f2c3" contextRef="C_c2fa1d86-6d26-4f04-8543-c015b28e335a" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_a97ecfdd-f77b-43ed-aaca-9e0674133b69_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Share Units</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2a45eae2-413c-4c2f-a655-85badecc9cbe" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the Company's restricted share activity for the three months ended March 31, 2025:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:63.593%;box-sizing:content-box;"/>
         <td style="width:1.26%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:14.943%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.74%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:14.463%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of RSUs</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted Average Grant Date Fair Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dfdea9cf-e85b-4325-9e81-74272b5f4fd2" contextRef="C_16552037-eed1-494f-9bc7-fe5f2b5e07a7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,371,266</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_24c0dcc3-20d2-47cf-9b2a-44f88c4ae92f" contextRef="C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UsdShare" scale="0" decimals="2" format="ixt:num-dot-decimal">6.35</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_af17ea4f-4eec-4af9-bbd8-97972c14db7e" contextRef="C_074eb5b5-3385-4cab-a533-970336354d46" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">5,024,500</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b9410b7c-668f-493a-af2d-9f86e8367011" contextRef="C_074eb5b5-3385-4cab-a533-970336354d46" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UsdShare" scale="0" decimals="2" format="ixt:num-dot-decimal">6.34</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested and issued</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d706285d-368c-4636-98e5-c70b2d66fae7" contextRef="C_074eb5b5-3385-4cab-a533-970336354d46" name="mnmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">186,708</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_13bf2ecd-3f48-445c-b8c4-09a826af576a" contextRef="C_074eb5b5-3385-4cab-a533-970336354d46" name="mnmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UsdShare" scale="0" decimals="2" format="ixt:num-dot-decimal">10.76</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cancelled</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3cd256be-ff17-421b-a997-d466d765c600" contextRef="C_074eb5b5-3385-4cab-a533-970336354d46" name="mnmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">260,206</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8cae6a8e-a524-4056-8c16-6c6c5f814fac" contextRef="C_074eb5b5-3385-4cab-a533-970336354d46" name="mnmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UsdShare" scale="0" decimals="2" format="ixt:num-dot-decimal">5.74</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1e20ff5e-c2b5-4007-b3f2-a78141cee11f" contextRef="C_0054b3c6-4d0e-43c8-b522-a912b7fc8728" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,948,852</ix:nonFraction></span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c8ce68ac-0c6b-41b5-bd76-091f164b6c5b" contextRef="C_0054b3c6-4d0e-43c8-b522-a912b7fc8728" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UsdShare" scale="0" decimals="2" format="ixt:num-dot-decimal">6.23</ix:nonFraction></span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the three months ended March 31, 2025, RSUs granted include </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_355d095f-5065-4645-8255-e7612b467119" contextRef="C_92619440-2ce2-4466-9498-1c8dd0f4bb1c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">3,696,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> performance share units that vest based on the achievement of certain clinical milestones and require service for </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a8d50a92-f384-41c1-bed1-676d0d6d6826" contextRef="C_92619440-2ce2-4466-9498-1c8dd0f4bb1c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">36</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> months after grant. As of March 31, 2025, the Company has determined that all of these milestones are probable of achievement. The Company will recognize the related compensation expense for awards that are probable of vesting over the </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a0c45b2b-6219-46c0-a2cb-137bf2482d42" contextRef="C_92619440-2ce2-4466-9498-1c8dd0f4bb1c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">36</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> month requisite service period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The expense recognized related to RSUs during the three months ended March 31, 2025 and 2024 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_881839cc-2793-4070-b200-d7a1b4d71335" contextRef="C_074eb5b5-3385-4cab-a533-970336354d46" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c887855d-1a77-4d98-8177-e643e7fe2f9b" contextRef="C_9b3887ab-9632-4cdf-8108-dd0d06f5614f" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Employee Share Purchase Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In August 2024, the Company commenced the first offering under the ESPP. Subsequent to this offering, new offerings under the ESPP will commence every six months. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the three months ended March 31, 2025, the Company recognized a nominal amount of expense in relation to its ESPP and issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eb7f80a0-b017-477e-a90c-2849a02a3d55" contextRef="C_214de9bb-0f67-49d7-91e6-f326f72e5fda" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">34,017</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares under the ESPP.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-based Compensation Expense</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_30ba998a-427c-4d1f-9624-a3d136e9e62d" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation expense for all equity arrangements for the three months ended March 31, 2025 and 2024 was as follows (in thousands):</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:67.033%;box-sizing:content-box;"/>
         <td style="width:1.62%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.863000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.62%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.863000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4e4f9f5b-8989-4333-b20c-a950262f7edc" contextRef="C_7f0ccbf3-018b-4d47-8587-c44623598ad3" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,053</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7787ca5d-9931-4822-935d-abd8d9b8f2f2" contextRef="C_47ed8762-d376-4fac-a861-d53fdd21f2ce" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,455</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_035ac182-222b-4e2d-9518-ffce838b26b9" contextRef="C_a897d154-518a-4ffc-a776-063ea244783d" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,373</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3ed168c4-1ea7-497b-aa41-b73f2fc35a20" contextRef="C_6a7256ae-8741-49e1-a84a-94da6e3a03ec" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,234</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_33592675-32fc-4461-beb0-12f2ff07a421" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,426</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_66ed097f-b037-4f18-8fad-23a0cf7b201e" contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,689</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of March</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> 31, 2025, there was approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_29f9dec8-7157-454a-89cf-1ea871b9240c" contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">12.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of total unrecognized stock-based compensation expense, related to unvested options granted to employees under the Option Plan that is expected to be recognized over a weighted average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1bfed3f0-2283-481a-8d60-5be21c3f5060" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.1</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years. As of March 31, 2025, there was approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a083140b-79c6-436c-ad8f-8a8469a9e3e7" contextRef="C_0054b3c6-4d0e-43c8-b522-a912b7fc8728" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">35.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of total unrecognized stock-based compensation expense, related to restricted share units granted to employees under the PRSU Plan that is expected to be recognized over a </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">weighted average period of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_421cb478-21af-4edf-bd9f-df2671078e47" contextRef="C_214de9bb-0f67-49d7-91e6-f326f72e5fda" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.0</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Directors' Deferred Share Unit Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 16, 2021, the Company adopted the MindMed Director&#8217;s Deferred Share Unit Plan (the &#8220;DDSU Plan&#8221;). The DDSU Plan sets out a framework to grant non-employee directors DDSUs, which are cash settled awards. The DDSUs generally vest ratably over twelve months after grant and are settled within 90 days of the date the director ceases service to the Company. For the three months ended March 31, 2025 and 2024, compensation expense of a nominal amount and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7c677d2c-1c26-4652-80a8-71b50e0d296b" contextRef="C_6f79a0fa-c5d0-4e2a-bc5d-e6aec1b53c1e" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_420b614b-ad9d-475a-84fb-c002888bea5c" contextRef="C_74cedffa-5bb3-47b3-afc1-6024110f7963" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.8</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, was recognized relating to the revaluation of the vested DDSUs, recorded in general and administrative expense in the accompanying condensed consolidated statements of operations and comprehensive loss. During the three months ended March 31, 2025, the Company did not issue any additional DDSUs. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_871d542c-050a-47d4-91df-93097ee9ad99" contextRef="C_6f79a0fa-c5d0-4e2a-bc5d-e6aec1b53c1e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">178,697</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> DDSUs vested as of March 31, 2025. The liability associated with the outstanding vested DDSU&#8217;s was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cef37743-77ee-4a44-b7a0-4ac5b8bbd361" contextRef="C_8ddb2856-0c3b-4cce-9cc5-aab5dca27c39" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of March 31, 2025, and was recorded to accrued expenses in the accompanying condensed consolidated balance sheets.</span></p><p style="text-indent:4.535%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.037%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To conform with the current year presentation, certain prior year amounts related to DDSUs expense have been reclassified and separately presented from stock-based compensation on the statement of cash flows.</span></p></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3969b4b0-608b-4722-b9e9-fa84d3c2611c" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">10.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">COMMITMENTS AND CONTINGENCIES</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of March 31, 2025, the Company had obligations to make future payments, representing significant research and development contracts and other commitments that are known and committed in the amount of approxima</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">tely $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_af1a97b0-1edd-4dfa-81c5-850e22bc3e1c" contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256" name="us-gaap:OtherCommitment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">114.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> mi</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">llion. Most of these agreements are cancelable by the Company with notice. These commitments include agreements related to the conduct of the clinical trials, sponsored research, manufacturing and preclinical studies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company enters into research, development and license agreements in the ordinary course of business where the Company receives research services and rights to proprietary technologies. Milestone and royalty payments that may become due under various agreements are dependent on, among other factors, clinical trials, regulatory approvals and ultimately the successful development of a new drug, the outcome and timing of which are uncertain.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company periodically enters into research and license agreements with third parties that include indemnification provisions customary in the industry. These guarantees generally require the Company to compensate the other party for certain damages and costs incurred as a result of claims arising from research and development activities undertaken by or on behalf of the Company. In some cases, the maximum potential amount of future payments that could be required under these indemnification provisions could be unlimited. These indemnification provisions generally survive termination of the underlying agreement. The nature of the indemnification obligations prevents the Company from making a reasonable estimate of the maximum potential amount it could be required to pay. Historically, the Company has not made any indemnification payments under such agreements and no amount has been accrued in the unaudited condensed consolidated financial statements with respect to these indemnification obligations.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_ce89e396-f264-4f28-bfea-0fa0f5493ffb" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:DebtDisclosureTextBlock" escape="true" continuedAt="F_ce89e396-f264-4f28-bfea-0fa0f5493ffb_1"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">11.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CREDIT FACILITY</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On August 11, 2023 (the &#8220;Closing Date&#8221;), the Company and certain of its subsidiaries party thereto, as co-borrowers (together wi</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th the Company, the &#8220;Borrowers&#8221;) entered into a Loan and Security Agreement (the &#8220;Loan Agreement&#8221;) with K2 HealthVentures LLC (&#8220;K2HV&#8221;), as administrative agent and Canadian collateral agent for lenders thereunder (K2HV, together with any other lender from time to time, the "Lenders"), and Ankura Trust Company, LLC, as collateral trustee for the Lenders. The Loan Agreement provides for up to an aggregate principal amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_446f688f-d890-4dcd-be1e-ab09e6f27045" contextRef="C_6451cf6d-c95a-4e4b-8351-0fe9c5190c13" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">50.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in term loans (the &#8220;Term Loan&#8221;) consisting of a first tranche term loan of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7f87b77d-db29-433a-b1d0-e958a4ac01c2" contextRef="C_fe5a097f-3c97-4699-94f4-51951985f607" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">15.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million funded on the Closing Date, subsequent tranches of term loans totaling $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fe75fb54-378a-42d7-805e-273998d001c6" contextRef="C_ea9d77da-eba9-4810-91d9-0f141316dc18" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">20.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to be funded upon the achievement of certain time-based, clinical and regulatory milestones, and an additional tranche term loan of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b952bb17-2cd1-4b32-9692-50e7a712ad36" contextRef="C_eb1ae7bc-3517-4ce3-9504-2825a5456a78" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">15.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upon the Company&#8217;s request, subject to the Lenders' review of certain information from the Company and discretionary approval by the Lenders. On the Closing Date, the Company paid a facility fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e6ce557f-2986-460e-930e-6a575fc7ba58" contextRef="C_0c871994-f7b4-4304-86d5-391aaec3c1e0" name="us-gaap:PaymentsOfFinancingCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to K2HV. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The second milestone-based tranche of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_367d900c-de9d-4cb5-bb54-d23e0f09817c" contextRef="C_21b8ddb5-b023-4fb7-95ad-c159194b8c6f" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was funded in the second quarter of 2024.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Term Loan matures on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ee6c2793-56bc-4b87-a234-2b0b0223bc69" contextRef="C_0c871994-f7b4-4304-86d5-391aaec3c1e0" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">August 1, 2027</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and the Company's obligations under the Loan Agreement are secured by substantially all of the assets of the Company, excluding intellectual property.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_98623321-316d-4077-9d55-401c6dfb77ca" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:DebtInstrumentInterestRateTerms"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Term Loan bears a variable interest rate equal to the greater of (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f9c74a38-4a83-4ee9-9544-9a6526bdf7ef" contextRef="C_42ce987a-6c17-43ee-b6d2-679c22b90e37" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">10.95</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% and (ii) the sum of (a) the </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_878b4f9e-49e3-4bfc-bf0e-3f4c1e867bf8;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">prime rate</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> as reported in The Wall Street Journal plus (b) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7deaad58-6571-4bf1-b6b1-bf0145706c01" contextRef="C_0c871994-f7b4-4304-86d5-391aaec3c1e0" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">2.95</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company may prepay, at its option, all, but not less than all, of the outstanding principal balance and all accrued and unpaid interest with respect to the principal balance being prepaid of the Term Loan, subject to certain prepayment notice requirements; provided that such prepayment notice may be conditioned upon the effectiveness of a refinancing or any other transaction, in which case such prepayment notice may be revoked by the Company. Principal payments were postponed from March 2025 to March 2026 as the interest-only extension event per the Loan Agreement was met. Additionally, the Term Loan contains a final payment fee of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e07b60bc-1588-4d12-8f4e-4e6c076d4fdd" contextRef="C_0c871994-f7b4-4304-86d5-391aaec3c1e0" name="mnmd:PercentageOfFinalPaymentFee" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">6.95</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the original principal amount borrowed due upon the final maturity date or upon prepayment of the Term Loan. As of March 31, 2025, the Company has accrued $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ed7d23c7-c4ef-434c-b968-1c7de989bc63" contextRef="C_6e0c796f-cafa-42be-9627-7b5c560ee658" name="us-gaap:DebtInstrumentFeeAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in relation to this final payment fee.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Lenders may elect at any time following the Closing Date and prior to the full repayment of the Term Loan to convert any portion of the principal amount of the term loans then outstanding, up to an aggregate principal amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c12b689c-715b-4996-ba48-ddf1b7eb538e" contextRef="C_239ca22a-8f41-45e3-9088-34e3006f84b0" name="us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">4.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, into the Company&#8217;s Common Shares (the &#8220;Conversion Shares&#8221;), at a conversion price equal to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5dff88a9-542c-420e-a536-3f7afedf0a71" contextRef="C_6451cf6d-c95a-4e4b-8351-0fe9c5190c13" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" unitRef="U_UsdShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4.01</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per Conversion Share, subject to certain limitations. The embedded conversion option qualifies for a scope exception from derivative accounting because it is both indexed to the Company&#8217;s shares and meets the conditions for equity classification. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 11, 2024, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_41f6cb75-6bf1-4aaf-a246-3e1c438604ae" contextRef="C_e2246019-6180-4085-ac79-bbe6f51150c7" name="us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of principal was converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a8429ac0-3cc5-4d78-9f0b-5b50d66e4be5" contextRef="C_6f8c2f52-b2c4-47bf-b3a7-5478bee3c660" name="mnmd:DebtInstrumentConvertibleConvertedIntoCommonShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">748,129</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Company's Common Shares. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of March 31, 2025, the Company estimated the fair value of the Conversion Shares to be $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8c0a77de-30eb-4e88-84f4-c04cc85629bf" contextRef="C_54d8dbd9-a485-4061-8471-60237a056875" name="us-gaap:DebtConversionConvertedInstrumentAmount1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million using the Black-Scholes option pricing model.</span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_ce89e396-f264-4f28-bfea-0fa0f5493ffb_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Loan Agreement contains customary representations and warranties and affirmative and negative covenants, including covenants that limit or restrict the Company's ability to, among other things, dispose of assets; make changes to the Company's business, management, ownership, or business locations; merge or consolidate; incur additional indebtedness, encumbrances, or liens; pay dividends or other distributions or repurchase equity; make investments; and enter into certain transactions with affiliates, in each case subject to certain exceptions. The Company was in compliance with the Loan Agreement as of March 31, 2025. On April 18, 2025, the Company entered into an amendment to the Loan Agreement. See Note 13 for additional information.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4b375418-86b2-449a-bf03-a41aa91a71c0" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:InterestExpenseDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in interest expense for the three months ended March 31, 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_626217ba-7dc6-4ca0-9e49-990e03134e7a" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Future expected repayments of principal amount due on the credit facility as of March 31, 2025 were as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:76.08%;box-sizing:content-box;"/>
         <td style="width:2.36%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:19.56%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Remainder of 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4621b250-a1f6-41d1-9684-5b15b42002ab" contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256" name="mnmd:DebtRepaymentsOfPrincipalInNextTwelveMonthsBeforeUnamortizedDebtIssuanceCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,999</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e93ea6af-b35c-4053-82af-ee5b552b48ad" contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256" name="mnmd:DebtRepaymentsOfPrincipalInYearTwoBeforeUnamortizedDebtIssuanceCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,001</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total principal repayments</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cb4b3026-d998-47c8-b619-1ea3ebfec6b0" contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256" name="us-gaap:DebtInstrumentCarryingAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,000</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unamortized debt issuance costs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_81c9f98b-2776-42cc-a129-b51f1741848d" contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">567</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued final payment fee</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b1a83803-e2c8-4810-916e-13a9e8947a73" contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256" name="us-gaap:DebtInstrumentFeeAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">603</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total credit facility, non-current, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7cc766ee-f7b0-480e-9a81-25da4335ac13" contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256" name="us-gaap:LongTermDebtNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,036</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of March 31, 2025, the Company estimated the fair value of the credit facility to be </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_26cd60e0-8f7e-4d04-b4ff-3a70e48944a1" contextRef="C_6e0c796f-cafa-42be-9627-7b5c560ee658" name="us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">21.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million, assuming the full $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_28c64274-01a4-4035-910c-fd176f845049" contextRef="C_f83f983a-590e-4074-8513-66e59d9de42c" name="us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of principal is converted into Conversion Shares.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div><div><ix:nonNumeric id="F_beb52212-ed78-42a4-ace4-d477c723a3ef" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:SegmentReportingDisclosureTextBlock" escape="true"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">12.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SEGMENT REPORTING</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9cd7d630-f007-430b-9871-09cf4828e950" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:NumberOfReportableSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reportable segment related to the research and development of the Company&#8217;s product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s Chief Operating Decision Maker (the &#8220;CODM&#8221;), its Chief Executive Officer, reviews the Company&#8217;s operations, including reviewing budgets and trial-related data, and decides how to allocate resources and assess performance. When evaluating the Company&#8217;s financial performance, the CODM regularly reviews total expenses and total assets and the CODM makes decisions using this information on a consolidated basis. The CODM uses consolidated net income or loss as a measure of profit or loss in allocating resources </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and assessing segment performance. </span><span><ix:nonNumeric id="F_2f4dcc0b-bd22-4a18-a219-41634c989c0e" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" escape="true" continuedAt="F_2f4dcc0b-bd22-4a18-a219-41634c989c0e_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to the expense categories included within net income presented on the Company's Consolidated Statements of Operations and Comprehensive Loss, see below for additional expense details that are routinely reviewed by the CODM: </span></ix:nonNumeric></span><span style=""></span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:continuation id="F_2f4dcc0b-bd22-4a18-a219-41634c989c0e_1" continuedAt="F_2f4dcc0b-bd22-4a18-a219-41634c989c0e_2"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50.89%;box-sizing:content-box;"/>
         <td style="width:2.42%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:20.136%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:2.42%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:20.136%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Internal expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ac74684a-decc-4d61-b23c-d58032ff77ef" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="mnmd:ResearchAndDevelopmentInternalExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,846</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d8084499-8100-41f4-8494-bda7046ccf9b" contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb" name="mnmd:ResearchAndDevelopmentInternalExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,452</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">External expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ffddcee4-eee5-4eda-b122-cd724efce1ec" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="mnmd:ResearchAndDevelopmentExternalExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,511</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ad5d404a-f045-40d2-a32c-ba3305577e63" contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb" name="mnmd:ResearchAndDevelopmentExternalExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,253</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2cb2f6b5-8a8e-4bda-a253-e82e7be65866" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,357</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cbbfb22a-fee3-433d-99f7-12ee0c262ee7" contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,705</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Internal expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_196613d6-7a90-4b29-9995-761b43a4a2f4" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="mnmd:GeneralAndAdministrativeInternalExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,822</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ceb82065-0003-4922-9a3e-93b649b5bb54" contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb" name="mnmd:GeneralAndAdministrativeInternalExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,163</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">External expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b96f31c1-0bec-426f-b3b6-e220e816f5ce" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="mnmd:GeneralAndAdministrativeExternalExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,980</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ea9d78e4-4553-4d26-aa86-a84f509e171d" contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb" name="mnmd:GeneralAndAdministrativeExternalExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,336</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6cf1ad67-917d-401b-9e32-285d38ef9b40" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,802</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_33b1720b-f874-4d3c-9d53-19eceb7ba101" contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,499</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6a6194d4-c9f8-4cf3-8a7f-ddaf761b2f65" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">32,159</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_51e09576-a9ff-4dc6-8509-84db0be4aac8" contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">22,204</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total other income/(loss), net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f6ebc799-0102-41ab-b09d-4570713d2f75" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,811</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4a27a766-8897-4cd9-bcbc-152c50a5f300" contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">32,196</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a083bc25-6c90-4b0e-a2b4-733a44d7512a" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">23,348</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0c3707bf-17f5-49de-a96f-270855be2243" contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">54,400</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
       </table></ix:continuation></div></ix:nonNumeric></div><div><ix:continuation id="F_2f4dcc0b-bd22-4a18-a219-41634c989c0e_2"></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><ix:nonNumeric id="F_b438a5f0-e3f6-462e-9c68-4b2b9eebb42f" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="us-gaap:SubsequentEventsTextBlock" escape="true" continuedAt="F_b438a5f0-e3f6-462e-9c68-4b2b9eebb42f_1"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">13.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SUBSEQUENT EVENTS</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 18, 2025 (the &#8220;Effective Date&#8221;), the Borrowers, entered into the First Amendment to the Loan Agreement with K2HV (as amended by the First Amendment, the &#8220;Amended Loan Agreement&#8221;).</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Amended Loan Agreement provide for, among other things: (i) an aggregate principal amount of term loans (the &#8220;Amendment Term Loans&#8221;) of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e53e70ad-d721-41a1-9e55-7f4e5c7b1ece" contextRef="C_21366178-d703-4ba8-b838-8bd6400186cc" name="us-gaap:LineOfCredit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">120.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">consisting of (A) a new Restatement First Tranche Term Loan (as defined in the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_b438a5f0-e3f6-462e-9c68-4b2b9eebb42f_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Loan Agreement) of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0cdf5f78-981a-4afe-a89d-9856fdab4b3e" contextRef="C_d169998a-953e-4d00-b8cc-a69fa0e9660b" name="us-gaap:LineOfCredit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">42.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which was funded on the Effective Date, a portion of the proceeds of which was used on the Effective Date to refinance in full all Term Loans outstanding under the Loan Agreement, and to pay fees and expenses in connection with the Amended Loan Agreement and the refinancing of the existing term loans, (B) subsequent tranches of Amendment Term Loans totaling up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0c9901b7-0625-4847-874f-1b9e0cb0022b" contextRef="C_c9d7271c-3855-4150-a286-178b67eef766" name="us-gaap:LineOfCredit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">28.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, subject to the occurrence of certain time-based clinical and regulatory milestones and (C) an additional tranche of Amendment Term Loans of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dd21dd7c-d507-46ae-8e24-e4223fd745e7" contextRef="C_4094340a-fb0c-443d-8f83-3a756fca8506" name="us-gaap:LineOfCredit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">50.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upon the Company&#8217;s request, subject to review by the Lenders of certain information from the Company and discretionary approval by the Lenders, (ii) to the extent any Amendment Term Loans other than the Restatement First Tranche Term Loans are made during the term of the Amended Loan Agreement, a minimum liquidity covenant, beginning on the earlier to occur of (x) July 1, 2026 (which may be extended to July 1, 2027 to the extent the Company has achieved certain fundraising milestones) and (y) the date on which certain clinical and regulatory milestones are not achieved, which covenant shall be waived in any period where the Company&#8217;s market capitalization exceeds $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_593764e2-30f7-4e7f-9666-e9da43824b93" contextRef="C_6ad17a66-7ef6-4b6b-947f-8a82218b53f9" name="mnmd:CovenantShallBeWaivedDuringMarketCapitalizationExceeds" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">500.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, (iii) a decrease in the interest rate applicable to all Amendment Term Loans under the Amended Loan Agreement to the greater of (x) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b5b2c2db-2352-4a4a-a0ce-ca38fd24d0d6" contextRef="C_d320d06d-9c2c-4fb0-9558-f2351f1dc8ad" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">10.25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% and (y) the sum of (a) the Prime Rate as reported in The Wall Street Journal plus (b) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a6d08c09-44e8-44e4-81b9-9e09b524d2c9" contextRef="C_6ad17a66-7ef6-4b6b-947f-8a82218b53f9" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">2.75</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% per annum, and (iv) a conversion right at the election of the Lenders at any time following the Effective Date and prior to the full repayment of the Amendment Term Loans to convert up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_109e40a6-4774-43a2-acb2-a43e55217359" contextRef="C_7141ebf5-28cf-4a53-aafe-4ebd1582b154" name="us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of the outstanding Amendment Term Loans into the Company&#8217;s common shares (the &#8220;Amendment Conversion Shares&#8221;), at conversion prices ranging from $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_22fae705-f83b-46a0-bda7-e2fa78b53bba" contextRef="C_d320d06d-9c2c-4fb0-9558-f2351f1dc8ad" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" unitRef="U_UsdShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4.01</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per Amendment Conversion Share to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_80ca251d-ae7c-4a47-9756-3fa3401c1857" contextRef="C_21366178-d703-4ba8-b838-8bd6400186cc" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" unitRef="U_UsdShare" scale="0" decimals="2" format="ixt:num-dot-decimal">9.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per Amendment Conversion Share. The Amendment Term Loans mature on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_58f69050-d3d0-4946-9192-fa957d871a55" contextRef="C_6ad17a66-7ef6-4b6b-947f-8a82218b53f9" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">April 1, 2029</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, provided that upon the occurrence of certain events the maturity date may be extended to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6496631b-51f5-4d22-9da6-a575d0b10987" contextRef="C_6ad17a66-7ef6-4b6b-947f-8a82218b53f9" name="mnmd:DebtInstrumentExtendedMaturityDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 1, 2029</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The obligations of the Borrowers under the Amended Loan Agreement are secured by substantially all of the assets of the Borrowers, excluding intellectual property. Other than as described above, the proceeds of borrowings under the Amended Loan Agreement are expected to be used for working capital and other general corporate purposes and/or to further support commercial activities and/or business development opportunities. Once repaid, the Amendment Term Loans may not be reborrowed.</span></p></ix:continuation></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_2_mda"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 2. Manage</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ment&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The following discussion should be read in conjunction with the unaudited condensed consolidated financial statements and notes thereto included elsewhere in this Quarterly Report. This Quarterly Report, including the following sections, contains forward-looking statements. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those expressed or implied by such forward-looking statements. For a detailed discussion of these risks and uncertainties, see Item 1A &#8220;Risk Factors&#8221; in our 2024 Annual Report and this Quarterly Report. See also &#8220;Special Note Regarding Forward-Looking Statements.&#8221; We caution the reader not to place undue reliance on these forward-looking statements, which reflect management&#8217;s analysis only as of the date of this Quarterly Report. We undertake no obligation to update forward-looking statements, which reflect events or circumstances occurring after the date of this Quarterly Report.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our U.S. GAAP accounting policies are referred to in Note 2 of the Condensed Consolidated Financial Statements in this Quarterly Report as well as the Consolidated Financial Statements included in our 2024 Annual Report. All amounts are in United States dollars, unless otherwise indicated.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Overview</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments for brain health disorders that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes including MM120 and MM402, our lead product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our lead product candidate, MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that we are developing for the treatment of generalized anxiety disorder and major depressive disorder (&#8220;MDD&#8221;). In December 2023, we announced positive topline results from our Phase 2b clinical trial of MM120 for the treatment of GAD. The trial met its primary endpoint, with MM120 demonstrating statistically significant and clinically meaningful dose-dependent improvements on the Hamilton Anxiety Rating Scale (&#8220;HAM-A&#8221;) compared to placebo at Week 4. In March 2024, we announced that the U.S. Food and Drug Administration (&#8220;FDA&#8221;) granted breakthrough designation to our MM120 program for the treatment of GAD. We also announced in March 2024 that our Phase 2b clinical trial of MM120 in GAD met its key secondary endpoint, and 12-week topline data demonstrated clinically and statistically significant durability of activity observed through Week 12.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On June 20, 2024, we announced the completion of our End-of-Phase 2 meeting with the FDA, supporting the advancement of MM120 into pivotal trials for the treatment of adults with GAD. Our Phase 3 clinical program for MM120 orally disintegrating tablet (&#8220;ODT&#8221;) is expected to consist of two clinical trials: the Voyage study (MM120-300) and the Panorama study (MM120-301). Both trials are comprised of two parts: Part A, which is a 12-week, randomized, double-blind, placebo-controlled, parallel-group trial assessing the efficacy and safety of MM120 ODT versus placebo; and Part B, which is a 40-week extension period during which participants will be eligible for open-label treatment with MM120 ODT, subject to certain conditions for treatment eligibility. Voyage is anticipated to enroll approximately 200 participants (randomized 1:1 to receive MM120 ODT 100 &#181;g or placebo) and Panorama is anticipated to enroll approximately 250 participants (randomized 2:1:2 to receive MM120 ODT 100 &#181;g, MM120 ODT 50 &#181;g or placebo). We expect both trials will utilize an adaptive trial design with a blinded interim sample size re-estimation, allowing for an increase in sample size by up to 50% in each trial in the case of certain parameters. The primary endpoint for each trial is the change from baseline in HAM-A score at Week 12 between MM120 ODT 100 &#181;g and placebo. On December 16, 2024, we announced the initiation of Voyage, with an anticipated topline readout (Part A results) in the first half of 2026. On January 30, 2025, we announced the initiation of Panorama, with an anticipated topline readout (Part A results) in the second half of 2026. Both trials are subject to ongoing regulatory review and discussions, which could result in changes to trial design, including of the Phase 3 clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to our Phase 3 clinical program for GAD, we are developing MM120 ODT for the treatment of MDD. In the first quarter of 2024, we held a pre-IND meeting with FDA to discuss the initiation of our Phase 3 clinical program for MM120 ODT in MDD and the trial design for our planned Emerge study (MM120-310), which like our pivotal trials in GAD, we anticipate will be comprised of two parts: Part A, which is a 12-week, randomized, double-blind, placebo-controlled, parallel group trial assessing the efficacy and safety of MM120 ODT versus placebo; and Part B, which is a 40-week extension period during which participants will be eligible for open-label treatment with MM120 ODT, subject to certain conditions for treatment eligibility. Emerge is anticipated to enroll at least 140 participants (randomized 1:1 to receive MM120 ODT 100 &#181;g or placebo). The primary endpoint is the change from baseline in Montgomery &#197;sberg Depression Rating Scale (&#8220;MADRS&#8221;) score at Week 6 between MM120 ODT 100 &#181;g and placebo. On April 15, 2025, we announced the initiation of Emerge, with an anticipated topline readout (Part A results) in the second half of 2026. We expect to conduct a second Phase 3 pivotal trial in MDD, with the trial design and timing to be informed by the progress from Emerge and additional regulatory discussions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our second lead product candidate, MM402, also referred to as R(-)-MDMA, is our proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (&#8220;MDMA&#8221;), which we are developing for the treatment of autism spectrum disorder (&#8220;ASD&#8221;). MDMA is a synthetic molecule that is often referred to as an empathogen because it is reported to increase feelings of connectedness and compassion. Preclinical studies of R(-)-MDMA demonstrated its acute pro-social and empathogenic effects, while its diminished dopaminergic activity suggests that it has the potential to exhibit less stimulant activity, neurotoxicity, hyperthermia and abuse liability compared to racemic MDMA or the S(+)-enantiomer. In October 2024, we completed our first clinical trial of MM402, a single-ascending dose trial in adult healthy volunteers. The data from this Phase 1 clinical trial helped to characterize the tolerability, pharmacokinetics and pharmacodynamics of MM402. We expect to initiate further trials of MM402 for the treatment of ASD, with the exact timing and scope of such trials to be determined.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Beyond our clinical stage product candidates, we are exploring additional programs, including through external collaborations, which we seek to expand our drug development pipeline and broaden the potential applications of our lead product candidates. These research and development programs include non-clinical, pre-clinical and human clinical trials of current and new product candidates and research compounds with our collaborators.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our business is premised on a growing body of research supporting the use of novel psychoactive compounds to treat a myriad of brain health disorders. For all product candidates, we intend to proceed through research and development, and with marketing of the product candidates that may ultimately be approved pursuant to the regulations of the FDA and the regulations in other jurisdictions. This entails, among other things, conducting clinical trials with research scientists, using internal and external clinical drug development teams, producing and supplying product candidates according to current Good Manufacturing Practices (&#8220;cGMP&#8221;), and conducting all trials and development in accordance with the regulations of the FDA, and other regulations in other jurisdictions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We were incorporated under the laws of the Province of British Columbia. Our wholly owned subsidiary, Mind Medicine, Inc. (&#8220;MindMed US&#8221;) was incorporated in Delaware. Prior to February 27, 2020, our operations were conducted through MindMed US.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since inception, we have incurred losses while advancing the research and development of our products and processes. Our net losses were $23.3 million for the three months ended March 31, 2025, and $54.4 million for the three months ended March 31, 2024. As of March 31, 2025, we had an accumulated deficit of $422.2 million and an aggregate of $245.5 million of cash, cash equivalents, and investments.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Product Candidate Pipeline</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the status of our portfolio of product candidates:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img196101975_0.jpg" alt="img196101975_0.jpg" style="width:720px;height:254px;"/></p><p style="margin-left:6.667%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#404040;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1. Full trial details and clinicaltrials.gov links available at mindmed.co/clinical-digital-trials/</span><span style="color:#404040;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#404040;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2. Studies in exploration and/or planning stage.</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#404040;white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">R(-)-MDMA: rectus-3,4-methylenedioxymethamphetamine</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recent Developments</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 18, 2025 (the &#8220;Effective Date&#8221;), we and certain of our subsidiaries party thereto, as co-borrowers (together with us, the &#8220;Borrowers&#8221;), entered into the First Amendment to that certain Loan and Security Agreement, dated as of August 11, 2023, by and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">among the Borrowers, the lenders referred to therein (the &#8220;Lenders&#8221;), K2 HealthVentures LLC, as administrative agent and Canadian collateral agent for the Lenders, and Ankura Trust Company, LLC, as collateral trustee for the Lenders (as amended by the First Amendment, the &#8220;Amended Loan Agreement&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Amended Loan Agreement provide for, among other things: (i) an aggregate principal amount of term loans (the &#8220;Term Loans&#8221;) of up to $120.0 million, consisting of (A) a new Restatement First Tranche Term Loan (as defined in the Amended Loan Agreement) of $42.0 million, which was funded on the Effective Date, a portion of the proceeds of which was used on the Effective Date to refinance in full all term loans outstanding under the original Loan Agreement, and to pay fees and expenses in connection with the Amended Loan Agreement and the refinancing of the existing term loans, (B) subsequent tranches of Term Loans totaling up to $28.0 million, subject to the occurrence of certain time-based clinical and regulatory milestones and (C) an additional tranche of Term Loans of up to $50.0 million upon our request, subject to review by the Lenders of certain information from us and discretionary approval by the Lenders, (ii) to the extent any Term Loans other than the Restatement First Tranche Term Loans are made during the term of the Amended Loan Agreement, a minimum liquidity covenant, beginning on the earlier to occur of (x) July 1, 2026 (which may be extended to July 1, 2027 to the extent we have achieved certain fundraising milestones) and (y) the date on which certain clinical and regulatory milestones are not achieved, which covenant shall be waived in any period where our market capitalization exceeds $500.0 million, (iii) a decrease in the interest rate applicable to all Term Loans under the Amended Loan Agreement to the greater of (x) 10.25% and (y) the sum of (a) the Prime Rate as reported in The Wall Street Journal plus (b) 2.75% per annum, and (iv) a conversion right at the election of the Lenders at any time following the Effective Date and prior to the full repayment of the Term Loans to convert up to $7.0 million of the outstanding Term Loans into our common shares (the &#8220;Conversion Shares&#8221;), at conversion prices ranging from $4.01 per Conversion Share to $9.00 per Conversion Share. The Term Loans mature on April 1, 2029, provided that upon the occurrence of certain events the maturity date may be extended to October 1, 2029. The obligations of the Borrowers under the Amended Loan Agreement are secured by substantially all of the assets of the Borrowers, excluding intellectual property.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other than as described above, the proceeds of borrowings under the Amended Loan Agreement are expected to be used for working capital and other general corporate purposes and/or to further support commercial activities and/or business development opportunities. Once repaid, the Term Loans may not be reborrowed. For additional information, please refer to our Current Report on Form 8-K filed with the SEC on April 21, 2025.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Components of Operating Results</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operating Expenses</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses account for a significant portion of our operating expenses. Research and development expenses consist primarily of direct and indirect costs incurred for the development of our product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">External expenses include:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">payments to third parties in connection with the clinical development of our product candidates, including licensing fees and fees to contract research organizations and consultants;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of manufacturing products for use in our preclinical studies and clinical trials, including payments to contract manufacturing organizations and consultants;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">payments to third parties in connection with the preclinical development of our product candidates, including outsourced professional scientific development services, consulting research fees and sponsored research arrangements with third parties; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">allocated operational expenses, which include direct or allocated expenses for information technologies and human resources.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may also incur in-process research and development expenses as we acquire or in-license assets from other parties. Technology acquisitions are expensed or capitalized based upon the asset achieving technological feasibility in accordance with management&#8217;s assessment regarding the ultimate recoverability of the amounts paid and the potential for alternative future use. Acquired in-process research and development costs that have no alternative future use are immediately expensed.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Internal expenses include employee-related costs such as salaries, related benefits and non-cash stock-based compensation expense for employees engaged in research and development functions.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">21</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect our research and development expenses to increase for the foreseeable future as we continue the clinical development of our product candidates and other preclinical programs in GAD, MDD, ASD and other potential or future indications, including initiating additional and larger clinical trials.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General and Administrative</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and administrative expenses consist primarily of compensation costs, including stock-based compensation, for executive management and administrative employees, including finance and accounting, legal, human resources and other administrative functions, professional services fees, advisory and professional service fees in connection with financing transactions, insurance expenses and allocated expenses.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect our general and administrative expenses to continue to increase for the foreseeable future as we continue to advance our research and development programs, grow our business and, if any of our product candidates receive marketing approval, commence commercialization activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Results of Operations</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Comparison of the Three Months Ended March 31, 2025 and 2024</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables summarize our results of operations for the periods presented (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:41.92%;box-sizing:content-box;"/>
     <td style="width:1.4%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.88%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.4%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.88%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.4%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.82%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:11.3%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">$<br/>Change</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">% <br/>Change</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,357</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,705</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,652</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,802</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,499</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1,697</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(16</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,159</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,204</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,955</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(32,159</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(22,204</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(9,955</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income/(expense):</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest income</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,433</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,656</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">777</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest expense</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(602</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(434</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(168</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign exchange loss, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(19</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(525</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">506</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(96</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value of 2022 USD Financing Warrants</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,999</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(32,893</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,892</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(121</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total other expense, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,811</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(32,196</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41,007</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(127</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(23,348</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(54,400</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,052</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(57</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operating Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:37.12%;box-sizing:content-box;"/>
     <td style="width:1.54%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.18%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.54%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.18%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.54%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.18%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.08%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.64%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">$<br/>Change</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">% <br/>Change</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">External costs</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">MM120 program</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">MM120 GAD</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,911</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,687</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,224</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">196</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">MM120 MDD</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,758</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,757</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">MM120 other</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,469</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,075</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">394</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total MM120 program</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,138</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,763</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,375</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">197</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">MM402 program</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">162</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">383</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(221</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(58</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Preclinical and other programs</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,211</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,107</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total external costs</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,511</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,253</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,258</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">148</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Internal costs</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,846</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,452</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,394</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total research and development expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,357</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,705</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,652</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
   </table><p style="text-indent:6.667%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">       * </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Represents a change greater than 300%</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">22</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses increased by $11.7 million for the three months ended March 31, 2025, compared to the three months ended March 31, 2024. The increase was primarily due to increases of $9.4 million in expenses related to our MM120 program, an increase of $2.4 million in internal personnel costs as a result of increasing research and development capacities, an increase of $0.1 million in preclinical and other program expenses, partially offset by a decrease of $0.2 million in MM402 program expenses.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General and Administrative</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and administrative expenses decreased by $1.7 million for the three months ended March 31, 2025, compared to the three months ended March 31, 2024. The decrease was primarily attributable to a decrease in stock-based compensation expense.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Income (Expense)</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other income/(expense) increased by $41.0 million for the three months ended March 31, 2025, compared to the three months ended March 31, 2024. The increase was primarily driven by a change in fair value on the 2022 USD Financing Warrants.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Liquidity and Capital Resources</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sources of Liquidity</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since inception, we have financed our operations primarily from the issuance of equity and debt under our Amended Loan Agreement. Our primary capital needs are for funds to support our scientific research and development activities including staffing, manufacturing, preclinical studies, clinical trials, administrative costs and for working capital.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have experienced operating losses and cash outflows from operations since inception and will require ongoing financing in order to continue our research and development activities. We have not earned any revenue or reached successful commercialization of our product candidates. Our future operations are dependent upon our ability to finance our cash requirements which will allow us to continue our research and development activities and the commercialization of our product candidates, if approved. There can be no assurance that we will be successful in continuing to finance our operations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cash, cash equivalents, and investments and our working capital at March 31, 2025, were $245.5 million and $191.2 million, respectively. We believe that our cash, cash equivalents, and investments as of March 31, 2025, will be sufficient to fund our operations into 2027 based on our current operating plan. Based on our current operating plan and anticipated R&amp;D milestones, we expect our cash runway to extend at least 12 months beyond the first Phase 3 topline data readout for MM120 in GAD.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 7, 2024, we entered into an underwriting agreement with Leerink Partners LLC and Cantor Fitzgerald &amp; Co., as representatives of the underwriters named therein, in connection with the offering of 16,666,667 of our common shares, no par value per share ("Common Shares), at an offering price of $6.00 per share, less underwriting discounts and commissions (the "March 2024 Offering").</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The net proceeds from the March 2024 Offering were approximately $93.5 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Also on March 7, 2024, we entered into a purchase agreement with certain investors, pursuant to which such investors agreed to purchase, and we agreed to sell 12,500,000 Common Shares at a price of $6.00 per share, in a private placement (the "March 2024 Private Placement").</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The net proceeds from the March 2024 Private Placement were $70.1 million, after deducting fees and expenses payable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We intend to use the net proceeds from the March 2024 Offering and the March 2024 Private Placement for (i) the research and development of our product candidates and (ii) working capital and general corporate purposes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On June 28, 2024, we entered into a sales agreement with Leerink Partners LLC (the "Sales Agreement") to create an at-the-market equity program under which we from time to time may offer and sell the ATM Shares (as defined below), through or to the Agent. We also filed a prospectus supplement on June 28, 2024 allowing for up to $150.0 million of Common Shares (the &#8220;ATM Shares&#8221;) to be sold under the Sales Agreement.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">23</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subject to the terms and conditions of the Sales Agreement, the Agent will use its commercially reasonable efforts to sell the ATM Shares from time to time, based upon our instructions. The Agent will be entitled to a commission of up to 3.0% of the aggregate gross proceeds from each sale of the ATM Shares effectuated through or to the Agent.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have no obligation to sell any of the ATM Shares and may, at any time suspend offers under the Sales Agreement or terminate the Sales Agreement.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On August 9, 2024, we entered into an underwriting agreement with Leerink Partners LLC and Evercore Group L.L.C., as representatives of the several underwriters named therein, in connection with an offering of (i) Common Shares, and (ii) to certain investors, pre-funded warrants to purchase Common Shares (the "August 2024 Offering"). The offering price for the common shares was $7.00 per share, less underwriting discounts and commissions. The offering price for the pre-funded warrants was $6.999 per pre-funded warrant, which represents the per share public offering price for the Common Shares less a $0.001 per share exercise price for each such pre-funded warrant.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The net proceeds from the August 2024 Offering were approximately $70.0 million, after deducting underwriting discounts and commissions and other offering expenses payable by us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We intend to use the net proceeds from the August 2024 Offering to fund the research and development of its product candidates and for working capital and general corporate purposes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On August 11, 2023, we entered into the Loan Agreement. On April 18, 2025, we entered into the Amended Loan Agreement. The Amended Loan Agreement provide for, among other things, an aggregate principal amount of Term Loans of up to $120.0 million, consisting of (A) a new Restatement First Tranche Term Loan (as defined in the Amended Loan Agreement) of $42.0 million, which was funded on the Effective Date, a portion of the proceeds of which was used on the Effective Date to refinance in full all term loans outstanding under the original Loan Agreement, and to pay fees and expenses in connection with the Amended Loan Agreement and the refinancing of the existing term loans, (B) subsequent tranches of Term Loans totaling up to $28.0 million, subject to the occurrence of certain time-based clinical and regulatory milestones and (C) an additional tranche of Term Loans of up to $50.0 million upon our request, subject to review by the Lenders of certain information from us and discretionary approval by the Lenders.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.037%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Future Funding Requirements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To date, we have not generated any revenue. We do not expect to generate any meaningful revenue unless and until we obtain regulatory approval of and commercialize any of our product candidates, and we do not know when, or if at all, that will occur. We will continue to require substantial additional capital to develop our product candidates and to fund operations for the foreseeable future. Moreover, we expect our expenses to increase in connection with our ongoing activities, particularly as we continue the development of and seek regulatory approvals for our product candidates. Further, we are subject to all the risks incident in the development of new pharmaceutical products, and we may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may harm our business. Our expenses will increase if, and as, we:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">advance our product candidates through preclinical and clinical development;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seek regulatory approvals for any product candidates that successfully complete clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seek to discover and develop additional product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establish a sales, marketing, medical affairs, and distribution infrastructure to commercialize any product candidates for which we may obtain marketing approval and intend to commercialize on our own or jointly; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expand our operational, financial and management systems and increase personnel, including personnel to support our development, manufacturing, and commercialization efforts and our operations as a public company.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect our cash and cash equivalents will be sufficient to fund our current operating plans into 2027. Based on our current operating plan and anticipated R&amp;D milestones, we expect our cash runway to extend at least 12 months beyond the first Phase 3 topline data readout for MM120 in GAD. However, our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement that involves risks and uncertainties, and actual results could vary materially. In order to complete the development of our product candidates and to build the sales, marketing and distribution infrastructure that we believe will be necessary to commercialize our product candidates, if approved, we will require substantial additional funding. Until we can generate a sufficient amount of revenue from the commercialization of our product candidates, we may seek to raise any necessary additional capital through the sale of equity, debt financings or other capital sources, which could include income from collaborations, strategic partnerships or marketing, distribution or licensing arrangements with third parties or from grants. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our shareholders will be or could be diluted, and the terms of these securities may include liquidation or other preferences</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that adversely affect the rights of our common shareholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, including restricting our operations and limiting our ability to incur liens, issue additional debt, pay dividends, repurchase our Common Shares, make certain investments or engage in merger, consolidation, licensing or asset sale transactions. If we raise funds through collaborations, strategic partnerships and other similar arrangements with third parties, we may be required to grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. We may be unable to raise additional funds or enter into such agreements or arrangements on favorable terms, or at all. If we are unable to raise additional funds when needed, we may be required to delay, reduce or eliminate our product development or future commercialization efforts. We have based our projections of operating capital requirements on our current operating plan, which is based on several assumptions that may prove to be incorrect and we may use all of our available capital resources sooner than we expect. Because of the numerous risks and uncertainties associated with research, development and commercialization of product candidates, we are unable to estimate the exact amount and timing of our working capital requirements. Our future funding requirements will depend on many factors, including:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope, progress, results and costs of researching and developing our product candidates, and conducting preclinical studies and clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs, timing and outcome of regulatory review of our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of future activities, including building a commercial organization, product sales, medical affairs, marketing, manufacturing and distribution, for any of our product candidates for which we receive marketing approval;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of manufacturing commercial-grade products and sufficient inventory to support commercial launch;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the revenue, if any, received from commercial sale of our products, should any of our product candidates receive marketing approval;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost and timing of hiring new employees to support our continued growth;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ability to establish and maintain collaborations on favorable terms, if at all;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the extent to which we acquire or in-license other product candidates and technologies; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing, receipt and amount of sales of, or milestone payments related to or royalties on, our product candidates.</span></div></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.037%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash Flows (in thousands)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.037%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:67.033%;box-sizing:content-box;"/>
     <td style="width:1.62%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.863000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.62%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.863000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash used in operating activities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(29,419</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(16,598</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash used in investing activities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(162,458</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,002</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">169,247</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign exchange impact on cash</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(12</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(21</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net (decrease)/increase in cash and cash equivalents</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(190,887</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">152,628</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.037%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.037%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash flows from operating activities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash used in operating activities for the three months ended March 31, 2025 was $29.4 million, which consisted of a net loss of $23.3 million, a net change of $2.5 million in our net operating assets and liabilities, and $3.6 million in non-cash charges. The non-cash charges primarily consisted of a change in fair value on the 2022 USD Financing Warrants liability of $7.0 million, offset by share-based compensation expense of $3.4 million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash used in operating activities for the three months ended March 31, 2024 was $16.6 million, which consisted of a net loss of $54.4 million and a net change of $0.7 million in our net operating assets and liabilities, partially offset by $38.5 million in non-cash charges. The non-cash charges primarily consisted of a change in fair value on the 2022 USD Financing Warrants liability of $32.9 million, share-based compensation of $4.5 million, unrealized foreign exchange of $0.5 million, and amortization of intangible assets of $0.5 million.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">25</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash flows from investing activities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash used in investing activities for the three months ended March 31, 2025 consisted of purchases of investments of $162.5 million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash flows from financing activities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash provided by financing activities for the three months ended March 31, 2025, was $1.0 million, which consisted of $0.6 million of proceeds from the exercise of the 2022 USD Financing Warrants, $0.2 million in proceeds from the exercise of options, and $0.2 million in proceeds from the issuance of Common Shares under the ESPP.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash provided by financing activities for the three months ended March 31, 2024, was $169.2 million, which consisted of $175.0 million of gross proceeds from the March 2024 Offering and March 2024 Private Placement, $1.7 million of proceeds from the exercise of the 2022 USD Financing Warrants, $1.0 million net proceeds from the Prior ATM (as defined in Note 7 to our unaudited condensed consolidated financial statements), net of issuance costs, $0.5 million in proceeds from the exercise of options, partially offset by $8.7 million of issuance costs related to the March 2024 Offering and March 2024 Private Placement, $0.1 million of our credit facility issuance costs and $0.1 million of withholding taxes paid on vested RSUs.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Contractual Obligations and Contingencies</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See Note 10 to our unaudited condensed consolidated financial statements located in &#8220;Part I &#8211; Financial Information, Item 1. Notes to Condensed Consolidated Financial Statements&#8221; in this Quarterly Report for a description of our contractual obligations and contingencies.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Critical Accounting Policies and Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our unaudited interim condensed consolidated financial statements as of March 31, 2025, which have been prepared in accordance with U.S. GAAP, and on a basis consistent with those accounting principles followed by us and disclosed in Note 2 to our most recent annual audited consolidated financial statements in the 2024 Annual Report. The preparation of these unaudited condensed consolidated financial statements requires our management to make judgments and estimates that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenue generated and expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these judgments and estimates under different assumptions or conditions and any such differences may be material.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other than as described under Note 2 of our unaudited interim condensed consolidated financial statements, there have been no material changes to our critical accounting policies from those described in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; included in our 2024 Annual Report.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recent Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See Note 2 to our unaudited condensed consolidated financial statements located in &#8220;Part I &#8211; Financial Information, Item 1. Notes to Condensed Consolidated Financial Statements&#8221; in this Quarterly Report for a description of recent accounting pronouncements applicable to our financial statements.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Emerging Growth Company Status</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are an &#8220;emerging growth company,&#8221; as defined in the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have elected to use this extended transition period to enable us to comply with new or revised accounting standards that have different effective dates for public and private companies until the last day of the fiscal year following the fifth anniversary of our first sale of common equity securities under an effective Securities Act of 1933 registration statement or such earlier time that we no longer are an emerging growth company. As a result, our financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">26</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_3_quantitative_and_qualitative"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 3. Quantita</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">tive and Qualitative Disclosures About Market Risk.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a "smaller reporting company" as defined by Item 10 of Regulation S-K, we are not required to provide the information required by this item.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_4_controls_and_procedures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 4. Cont</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">rols and Procedures.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#212529;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Evaluation of Disclosure Controls and Procedures</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time period specified in the SEC's rules and forms, and that such information is accumulated and communicated to management including our Chief Executive Officer and Principal Financial Officer as appropriate, to allow timely decisions regarding required disclosure. As of March 31, 2025, our Chief Executive Officer and Principal Financial Officer carried out an evaluation with the participation of management of the effectiveness of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934. Based upon that evaluation, our Chief Executive Officer and Principal Financial Officer concluded that our disclosure controls and procedures were effective at a reasonable assurance level as of March 31, 2025.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#212529;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in Internal Control over Financial Reporting</span><span style="color:#212529;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There was no change in our internal control over financial reporting identified in connection with the evaluation required by Rules 13a-15(d) and 15d-15(d) of the Securities Exchange Act of 1934 that occurred during the quarter ended March 31, 2025 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Inherent Limitations on Effectiveness of Controls</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A control system, no matter how well designed and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives. In reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs. In addition, the design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">27</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><h1 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_ii"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Part Ii</span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> - OTHER INFORMATION</span></h1><h2 style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="toc_page"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> 1.  Legal Proceedings</span></h2><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we may become involved in litigation or other legal proceedings arising in the ordinary course of our business. We are not currently a party to any material litigation or legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business.</span></p><h2 style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item1a_risk_factors"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ite</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">m 1A. Risk Factors.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></h2><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the three months ended March 31, 2025, there were no material changes to the "Risk Factors" included in our Annual Report on Form 10-K for the year ended December 31, 2024. You should carefully consider the information described therein and in this Quarterly Report on Form 10-Q, which could materially affect our business condition, results of operations and cash flows.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">28</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item2_unregistered_sales"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ite</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">m 2. Unregistered Sales of Equity Securities and Use of Proceeds.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For a description of certain working capital restrictions, including limitations upon the payment of dividends, see the description of our Loan and Security Agreement in Note 10 to our unaudited interim condensed consolidated financial statements located in &#8220;Part I &#8211; Financial Information, Item 1. Notes to Condensed Consolidated Financial Statements&#8221; in this Quarterly Report.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item3_defaults_upon_senior"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ite</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">m 3. Defaults upon Senior Securities</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item4_mine_safety_disclosure"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ite</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">m 4. Mine Safety Disclosures.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item5_other_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ite</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">m 5. Other Information.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rule 10b5-1 Trading Arrangements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the fiscal quarter ended March 31, 2025, no director or officer of the Company </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_39b5d04b-fabb-4eaa-8fc1-88db62f0cf04" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_f1907158-8f89-4f10-9e4b-4a3a942e34bd" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adopted</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1f07950d-c32c-4a59-aa74-691aca48ae66" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_4961a9ce-3172-4bc4-8f64-d1084ecec3b4" contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">terminated</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> a &#8220;Rule 10b5-1 trading arrangement&#8221; or a &#8220;non-Rule 10b5-1 trading arrangement&#8221; (in each case, as defined in Item 408 of Regulation S-K).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">29</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_6_exhibits"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 6. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibits.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:8%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:41%;box-sizing:content-box;"/>
     <td style="width:10.92%;box-sizing:content-box;"/>
     <td style="width:11%;box-sizing:content-box;"/>
     <td style="width:15%;box-sizing:content-box;"/>
     <td style="width:13.08%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description</span></p></td>
     <td colspan="4" style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Incorporated by Reference</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Form</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit No.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Filing Date</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">File No.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1813814/000095017022004724/mnmd-ex3_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Articles of Mind Medicine (MindMed) Inc., effective as of June 30, 2022.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;3.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 9, 2023</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-40360</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.2</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1813814/000095017024095753/mnmd-ex3_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Notice of Articles, Incorporated on July 26, 2010, effective as of July 30, 2024.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.2</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">August 13, 2024</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-40360</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1*#</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="mnmd-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Performance Share Unit Grant Agreement to Performance and Restricted Share Unit Plan.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2*#</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="mnmd-ex10_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Performance Share Unit Grant Agreement granted as an Inducement Award.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.3*#</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="mnmd-ex10_3.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Restricted Share Unit Grant Agreement granted as an Inducement Award.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.4*#</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="mnmd-ex10_4.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Option Agreement granted as an Inducement Award.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.5*#</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="mnmd-ex10_5.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Executive Employment Agreement, dated as of March 17, 2025, between Mind Medicine (MindMed) Inc. and Matthew T. Wiley.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.6&#134;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1813814/000110465925036841/tm2512703d1_ex10-1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">First Amendment to Loan and Security Agreement, dated April 18, 2025, by and among Mind Medicine (MindMed) Inc., certain of its subsidiaries party thereto, K2 HealthVentures LLC and Ankura Trust Company, LLC.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1*</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">April 21, 2025</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-40360</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.1*</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="mnmd-ex31_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.2*</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="mnmd-ex31_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.1*+</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="mnmd-ex32_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;32.2*+</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="mnmd-ex32_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section  1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.INS</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.SCH</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema with Embedded Linkbase Documents</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#ff0000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:86.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">* Filed or furnished herewith.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"># Indicates management contract or compensatory plan.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#134; Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">+ These certifications are being furnished herewith solely to accompany this Quarterly Report pursuant to 18 U.S.C. Section 1350, and are not</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and are not to be incorporated by</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reference into any filing of the registrant, whether made before or after the date hereof, regardless of any general incorporation</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">language in such filing.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="signatures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIGN</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ATURES</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:42%;box-sizing:content-box;"/>
     <td style="width:5%;box-sizing:content-box;"/>
     <td style="width:3%;box-sizing:content-box;"/>
     <td style="width:50%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Mind Medicine (Mindmed) Inc,</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: May 8, 2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Robert Barrow</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Robert Barrow</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Executive Officer</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: May 8, 2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Carrie F. Liao</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Carrie F. Liao, CPA</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Principal Financial Officer and Chief Accounting Officer</span></p></td>
    </tr>
    <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">31</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>mnmd-ex10_1.htm
<DESCRIPTION>EX-10.1
<TEXT>
<html>
 <head>
  <title>EX-10.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:12.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.1</font></p><h1 style="font-size:10pt;margin-top:4.7pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.204%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">MIND MEDICINE (MINDMED) INC.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></h1><h1 style="font-size:10pt;margin-top:4.7pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.204%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PERFORMANCE AND RESTRICTED SHARE UNIT PLAN</font></h1><h1 style="font-size:10pt;margin-top:4.7pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PERFORMANCE SHARE UNIT AWARD AGREEMENT</font></h1><p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:11.65pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This PSU Award Agreement (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PSU Award Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) is entered into between Mind Medicine (MindMed) Inc. (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Corporation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) and the Participant named below pursuant to the Performance and Restricted Share Unit Plan of the Corporation (the &#34;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#34;) effective March 7, 2023, as amended, and confirms that:</font></p><div class="item-list-element-wrapper" style="font-size:0;margin-top:11.65pt;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">A.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On [DATE] (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Grant Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) [[FIRSTNAME]] [[LASTNAME]] (the </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Participant&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) was issued an award for a target number of [NUMBER] non-assignable performance share units (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PSUs</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;, and such award,</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Award</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). Each PSU represents the right to receive one common share of the Corporation (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PSU Share</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), subject to the terms and conditions set forth in this PSU Award Agreement and the Plan. Vesting of the Award, or portions thereof, will be subject to the attainment of one or more Performance Criteria during the Performance Period as set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> attached hereto. </font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">B.</font><div style="width:100%;display:inline;"><font style="color:#1c1c1c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By signing </font><font style="color:#0c0c0c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">this </font><font style="color:#1c1c1c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PSU Award Agreement, the Participant:</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.983857620229827%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#1c1c1c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">acknowledges that </font><font style="color:#0c0c0c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">he </font><font style="color:#1c1c1c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or she </font><font style="color:#0c0c0c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">has received </font><font style="color:#1c1c1c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a copy of the Plan, has read and </font><font style="color:#0c0c0c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">understands </font><font style="color:#1c1c1c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Plan and that he or she will abide </font><font style="color:#0c0c0c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">by </font><font style="color:#1c1c1c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">its terms and conditions, which </font><font style="color:#0c0c0c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">terms </font><font style="color:#1c1c1c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and conditions </font><font style="color:#0c0c0c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">include </font><font style="color:#1c1c1c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the </font><font style="color:#0c0c0c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">right </font><font style="color:#1c1c1c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of </font><font style="color:#0c0c0c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the </font><font style="color:#1c1c1c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Corporation </font><font style="color:#0c0c0c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to </font><font style="color:#1c1c1c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">amend or terminate </font><font style="color:#0c0c0c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Plan </font><font style="color:#1c1c1c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or any of its terms and </font><font style="color:#0c0c0c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to </font><font style="color:#1c1c1c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">determine vesting and other </font><font style="color:#0c0c0c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">matters in </font><font style="color:#1c1c1c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">respect of an Award;</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:4.407%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;min-width:6.796%;text-align:justify;"><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.109307166842761%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#1c1c1c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">agrees </font><font style="color:#0c0c0c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that </font><font style="color:#1c1c1c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">other </font><font style="color:#0c0c0c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">than pursuant to </font><font style="color:#1c1c1c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.2 of </font><font style="color:#0c0c0c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the </font><font style="color:#1c1c1c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Plan, a P</font><font style="color:#0c0c0c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SU does not </font><font style="color:#1c1c1c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">carry any voting </font><font style="color:#0c0c0c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">rights </font><font style="color:#1c1c1c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or </font><font style="color:#0c0c0c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the right </font><font style="color:#1c1c1c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to receive </font><font style="color:#0c0c0c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">dividends </font><font style="color:#1c1c1c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or distributions of the Corporation</font><font style="color:#484848;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#0c0c0c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">if </font><font style="color:#1c1c1c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and when declared;</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.983857620229827%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="width:100%;display:inline;"><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">recognizes that (A) during the period between </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">granting </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an Award and </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the end of the Performance Period (and the settlement thereof), the </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">value </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an Award </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and the PSU Shares may be </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">subject </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">number of </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">factors; and </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(B) the </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Corporation accepts </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">no responsibility </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for any </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fluctuations in the value of the Award or the </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PSU </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Shares</font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">;</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.983857620229827%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(iv)</font><div style="width:100%;display:inline;"><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">acknowledges that neither the </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Corporation </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nor its affiliates or </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">associates, </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nor </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">their </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">respective </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">advisors, </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">assume </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">responsibility as regards </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the tax consequences that participation in </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Plan will have </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Participant </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or as </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regard to </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any changes to, or interpretations of, </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">applicable </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">tax laws </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulations made by </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">applicable governmental authorities and </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Participant is urged to consult his </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">her </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">own </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">tax advisor in </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">such </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regard;</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:4.398%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.973703479006714%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(v)</font><div style="width:100%;display:inline;"><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">acknowledges </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that he or </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">she </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">is solely liable for </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">taxes or penalties </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">which </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">may be payable pursuant to the </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Internal Revenue Code of 1986, as amended (the &#x201c;</font><font style="color:#212121;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Code</font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.398%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.973703479006714%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to the </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Canada </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agency </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">under the </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Tax Act </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Canada) or </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">other taxing </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">authority </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in respect of the </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">grant, vesting </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">settlement </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Award (including any taxes or penalties that may arise under Section 409A of the </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Code) and agrees </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to make arrangements </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">satisfactory </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to the </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Corporation </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">payment of </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cash </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Corporation sufficient </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">satisfy any </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">income </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or employment </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">taxes in respect of the grant</font><font style="color:#505050;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">vesting or </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delivery of the Award or the PSU Share</font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">under this PSU Award Agreement, </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided further that the delivery </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PSU Shares</font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">pursuant </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to an Award </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">is contingent upon satisfaction of </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">applicable withholding </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">requirements, and </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">applicable taxes </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">may be </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">withheld </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">from </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">payments due to him or her, including </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">such </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">payment in </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">settlement of </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Award;</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.983857620229827%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(vi)</font><div style="width:100%;display:inline;"><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">agrees </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that he </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or she will, </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">at </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">all </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">times, </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">act </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">strict </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">compliance with </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">applicable </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">laws </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">all polices of the </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Corporation applicable </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to the Participant in connection </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">with </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Plan and the Award</font><font style="color:#505050;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">which applicable </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">laws </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">policies shall include</font><font style="color:#505050;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">without limitation, those governing &#x201c;</font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">insiders&#x201d; </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and &#x201c;</font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reporting </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">issuers&#x201d; </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(as </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">those </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">terms are </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">defined in </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">applicable securities </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">laws) </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Corporation's </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Insider Trading Policy, </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">copy </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">which has been provided </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">made </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">available </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to the Participant</font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">;</font></div></div><p style="margin-left:0.987%;text-indent:6.827%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.361%;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.983857620229827%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(vii)</font><div style="width:100%;display:inline;"><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">acknowledges that he or she has not been induced to enter into this PSU Award Agreement or acquire the Award or any subsequent awards under the Plan by expectation of employment or continued employment with the Corporation or any of its Subsidiaries;</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.983857620229827%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(viii)</font><div style="width:100%;display:inline;"><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">acknowledges </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that: (i) the Award </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shall </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">not be </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">effective </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">until the date the </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Corporation </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">has confirmed the </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">grant of </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Award </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">by countersigning this PSU </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Award Agreement; </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and (ii) the Participant has no right or </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">entitlement </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to be issued any underlying PSU Shares</font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">prior to </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">such </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">date; </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.983857620229827%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(ix)</font><div style="width:100%;display:inline;"><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">acknowledges </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that, unless </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Award and the PSU Shares are registered or qualified under applicable securities laws, the PSU Shares issued upon redemption of the Awards hereunder may be subject to statutory restrictions upon resale including </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">hold periods </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the certificates representing such PSU </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Shares will </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">bear </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">legend to that </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">effect.</font></div></div><p style="font-size:10pt;margin-top:3.25pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.093%;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.74%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.093%;text-align:justify;"><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The grant of the Award and the issuance and delivery of the PSU Shares is subject to the terms and conditions of the Plan (as modified or varied by this PSU Award Agreement), all of which are incorporated into and form </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">integral part of this PSU Award Agreement.</font></p><p style="text-indent:6.74%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.093%;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.737%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.037%;text-align:justify;"><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nothing in </font><font style="color:#050505;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Plan or in this PSU Award Agreement will affect the right of the Corporation or any of its Subsidiaries to terminate the employment of, term of office of, or consulting agreement with, the Participant at any time for any reason whatsoever. Upon </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">such </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">termination, the Participant's rights to the Award and the PSU Shares will be </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">subject </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to </font><font style="color:#050505;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and time </font><font style="color:#050505;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">limits as set forth in this PSU Award Agreement</font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.739%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.074%;text-align:justify;"><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This PSU Award Agreement shall be binding upon and inure to the benefit of the Corporation, its </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">successors </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and assigns and the Participant </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the </font><font style="color:#050505;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">legal </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">representative of the</font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.074%;text-align:justify;"><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Participant's estate any other person who acquires the Award or PSU Shares by bequest or inheritance</font><font style="color:#5d5d5d;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Participant shall not be entitled to assign this PSU Award Agreement nor the Award granted hereby except in accordance with the Plan.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.738%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.065%;text-align:justify;"><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This PSU Award Agreement may be executed in counterparts </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">by facsimile or other electronic means, each of which shall constitute an original and all of which taken together shall constitute one </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the same instrument.</font></p><p style="margin-left:24.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.738%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.056%;text-align:justify;"><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PSU Award Agreement, the grant </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Award hereunder and under the Plan, and the </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">settlement </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of the Award </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shall </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">be, as applicable, governed by and construed in </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">accordance </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">with the laws of the Province of Ontario and the </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">federal </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">laws of Canada </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">applicable </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">therein </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">without regard </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to principles of conflicts of </font><font style="color:#050505;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">laws </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that would impose the laws of another jurisdiction. The </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Courts </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of the Province of Ontario </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shall </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">have the </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">exclusive </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">jurisdiction to hear and decide any disputes or other matters arising herefrom.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.736%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.028%;text-align:justify;"><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the extent applicable, with respect to U.S. Participants</font><font style="color:#494949;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Award is intended to be exempt from the requirements of Section 409A of the </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Code and </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">applicable regulations and </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">guidance </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">under the statute and </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shall </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">be construed and interpreted accordingly</font><font style="color:#494949;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In no </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">event </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">whatsoever </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shall </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Corporation or any Subsidiary or affiliate of the </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Corporation </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">be liable for any additional </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">tax, </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">interest or penalties that may be imposed on the Participant or the Participant's beneficiary or estate </font><font style="color:#050505;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">under </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 409A of the Code or </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">damages for </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failing </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to comply with Section 409A of the Code or otherwise</font><font style="color:#494949;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p><p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All capitalized terms used in this PSU Award Agreement, including Exhibit A, unless expressly defined </font><font style="color:#050505;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a different manner, have the meanings ascribed thereto in the Plan.</font></p><p style="font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><h1 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.88%;text-align:center;"><font style="color:#050505;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[REMAINDER </font><font style="color:#161616;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OF PAGE INTENTIONALLY LEFT BLANK]</font></h1><p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0.4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#151515;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Should </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">you </font><font style="color:#151515;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">wish to </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">accept </font><font style="color:#151515;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the grant of the Award as described in this PSU Award Agreement, please sign where indicated below </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and </font><font style="color:#151515;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">return one copy of this PSU Award Agreement to the </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Corporation.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ACCEPTED AND AGREED </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">by the Participant as at [[RESADDR1]] [[RESADDR2]] [[RESCITY]] [[RESSTATEORPROV]] [[RESPOSTALCODE]] [[RESCOUNTRY]] and intending to be legally bound:</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0.25pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="border-spacing:0;table-layout:auto;width:94.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:25.2pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0.25pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[[FIRSTNAME]] [[LASTNAME]]</font></p></td>
    </tr>
    <tr style="height:23.75pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0.25pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Name of Participant</font></p></td>
    </tr>
    <tr style="height:25.2pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:25.2pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[[SIGNATURE]]</font></p></td>
    </tr>
    <tr style="height:23.75pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Signature of Participant</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0.25pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:11.65pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.352%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Corporation hereby confirms the grant of the Award described in this PSU Award Agreement effective as of the Grant Date</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.352%;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.352%;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="border-spacing:0;table-layout:auto;width:67.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:10.448%;box-sizing:content-box;"></td>
     <td style="width:89.552%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:16.55pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">MIND MEDICINE (MINDMED) INC</font></p></td>
    </tr>
    <tr style="height:15.85pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:15.85pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:15.85pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Signature of MindMed Officer</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A-</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>mnmd-ex10_2.htm
<DESCRIPTION>EX-10.2
<TEXT>
<html>
 <head>
  <title>EX-10.2</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:12.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.2</font></p><h1 style="font-size:10pt;margin-top:4.7pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.204%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">MIND MEDICINE (MINDMED) INC.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></h1><h1 style="font-size:10pt;margin-top:4.7pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INDUCEMENT GRANT</font></h1><h1 style="font-size:10pt;margin-top:4.7pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PERFORMANCE SHARE UNIT AWARD AGREEMENT</font></h1><p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:11.65pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This PSU Award Agreement (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PSU Award Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) is entered into between Mind Medicine (MindMed) Inc. (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Corporation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) and the Participant named below. The PSUs (as defined below) have been granted to the Participant as an inducement that is material to the Participant&#x2019;s employment with the Corporation pursuant to the inducement grant exception under Nasdaq Stock Market Rule 5635(c)(4), and not pursuant to the Corporation&#x2019;s Performance and Restricted Share Unit Plan effective March 7, 2023, as amended, (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) or any other equity incentive plan of the Corporation. Accordingly, the PSUs have been granted outside of the Plan, however, the PSUs will be governed in all aspects as if issued under the Plan, as well as this PSU Award Agreement.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p><p style="margin-left:0.987%;text-indent:7.332%;font-size:10pt;margin-top:11.65pt;font-family:Times New Roman;margin-bottom:0;margin-right:8.093%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unless otherwise defined herein, the terms defined in the Plan will have the same defined meanings in this PSU Award Agreement.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:11.65pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This PSU Award Agreement confirms that:</font></p><div class="item-list-element-wrapper" style="font-size:0;margin-top:11.65pt;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">A.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On [DATE] (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Grant Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) [[FIRSTNAME]] [[LASTNAME]] (the </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Participant&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) was issued an award for a target number of [NUMBER] non-assignable performance share units (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PSUs</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;, and such award,</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Award</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). Each PSU represents the right to receive one common share of the Corporation (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PSU Share</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), subject to the terms and conditions set forth in this PSU Award Agreement and the Plan. Vesting of the Award, or portions thereof, will be subject to the attainment of one or more Performance Criteria during the Performance Period as set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> attached hereto. </font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">B.</font><div style="width:100%;display:inline;"><font style="color:#1c1c1c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By signing </font><font style="color:#0c0c0c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">this </font><font style="color:#1c1c1c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PSU Award Agreement, the Participant:</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.983857620229827%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#1c1c1c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">acknowledges that </font><font style="color:#0c0c0c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">he </font><font style="color:#1c1c1c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or she </font><font style="color:#0c0c0c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">has received </font><font style="color:#1c1c1c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a copy of the Plan, has read and </font><font style="color:#0c0c0c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">understands </font><font style="color:#1c1c1c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Plan and that he or she will abide </font><font style="color:#0c0c0c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">by </font><font style="color:#1c1c1c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">its terms and conditions, which </font><font style="color:#0c0c0c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">terms </font><font style="color:#1c1c1c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and conditions </font><font style="color:#0c0c0c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">include </font><font style="color:#1c1c1c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the </font><font style="color:#0c0c0c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">right </font><font style="color:#1c1c1c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of </font><font style="color:#0c0c0c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the </font><font style="color:#1c1c1c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Corporation </font><font style="color:#0c0c0c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to </font><font style="color:#1c1c1c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">amend or terminate </font><font style="color:#0c0c0c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Plan </font><font style="color:#1c1c1c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or any of its terms and </font><font style="color:#0c0c0c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to </font><font style="color:#1c1c1c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">determine vesting and other </font><font style="color:#0c0c0c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">matters in </font><font style="color:#1c1c1c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">respect of an Award;</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:4.407%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;min-width:6.796%;text-align:justify;"><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.109307166842761%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#1c1c1c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">agrees </font><font style="color:#0c0c0c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that </font><font style="color:#1c1c1c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">other </font><font style="color:#0c0c0c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">than pursuant to </font><font style="color:#1c1c1c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.2 of </font><font style="color:#0c0c0c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the </font><font style="color:#1c1c1c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Plan, a P</font><font style="color:#0c0c0c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SU does not </font><font style="color:#1c1c1c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">carry any voting </font><font style="color:#0c0c0c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">rights </font><font style="color:#1c1c1c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or </font><font style="color:#0c0c0c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the right </font><font style="color:#1c1c1c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to receive </font><font style="color:#0c0c0c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">dividends </font><font style="color:#1c1c1c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or distributions of the Corporation</font><font style="color:#484848;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#0c0c0c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">if </font><font style="color:#1c1c1c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and when declared;</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.983857620229827%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="width:100%;display:inline;"><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">recognizes that (A) during the period between </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">granting </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an Award and </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the end of the Performance Period (and the settlement thereof), the </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">value </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an Award </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and the PSU Shares may be </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">subject </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">number of </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">factors; and </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(B) the </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Corporation accepts </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">no responsibility </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for any </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fluctuations in the value of the Award or the </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PSU </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Shares</font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">;</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.983857620229827%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(iv)</font><div style="width:100%;display:inline;"><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">acknowledges that neither the </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Corporation </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nor its affiliates or </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">associates, </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nor </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">their </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">respective </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">advisors, </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">assume </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">responsibility as regards </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the tax consequences that participation in </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Plan will have </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Participant </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or as </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regard to </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any changes to, or interpretations of, </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">applicable </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">tax laws </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulations made by </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">applicable governmental authorities and </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Participant is urged to consult his </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">her </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">own </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">tax advisor in </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">such </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regard;</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:4.398%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.973703479006714%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(v)</font><div style="width:100%;display:inline;"><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">acknowledges </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that he or </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">she </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">is solely liable for </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">taxes or penalties </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">which </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">may be payable pursuant to the </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Internal Revenue Code of 1986, as amended (the &#x201c;</font><font style="color:#212121;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Code</font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or to the </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Canada </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agency </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">under the </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Tax Act </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Canada) or </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">other taxing </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">authority </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in respect of the </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">grant, vesting </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">settlement </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Award (including any taxes or penalties that may arise under Section 409A of the </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Code) and agrees </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to make arrangements </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">satisfactory </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to the </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Corporation </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">payment of </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cash </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Corporation sufficient </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">satisfy any </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">income </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or employment </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">taxes in respect of the grant</font><font style="color:#505050;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">vesting or </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delivery of the Award or the PSU Share</font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">under this PSU Award Agreement, </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided further that the delivery </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PSU Shares</font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">pursuant </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to an Award </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">is contingent upon satisfaction of </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">applicable withholding </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">requirements, and </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">applicable taxes </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">may be </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">withheld </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">from </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">payments due to him or her, including </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">such </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">payment in </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">settlement of </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Award;</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.983857620229827%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(vi)</font><div style="width:100%;display:inline;"><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">agrees </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that he </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or she will, </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">at </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">all </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">times, </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">act </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">strict </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">compliance with </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">applicable </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">laws </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">all polices of the </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Corporation applicable </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to the Participant in connection </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">with </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Plan and the Award</font><font style="color:#505050;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">which applicable </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">laws </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">policies shall include</font><font style="color:#505050;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">without limitation, those governing &#x201c;</font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">insiders&#x201d; </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and &#x201c;</font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reporting </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">issuers&#x201d; </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(as </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">those </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">terms are </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">defined in </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">applicable securities </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">laws) </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Corporation's </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Insider Trading Policy, </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">copy </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">which has been provided </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">made </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">available </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to the Participant</font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">;</font></div></div><p style="margin-left:0.987%;text-indent:6.827%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.361%;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.983857620229827%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(vii)</font><div style="width:100%;display:inline;"><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">acknowledges </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that: (i) the Award </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shall </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">not be </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">effective </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">until the date the </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Corporation </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">has confirmed the </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">grant of </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Award </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">by countersigning this PSU </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Award Agreement; </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and (ii) the Participant has no right or </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">entitlement </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to be issued any underlying PSU Shares</font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">prior to </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">such </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">date; </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.983857620229827%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(viii)</font><div style="width:100%;display:inline;"><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">acknowledges </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that, unless </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Award and the PSU Shares are registered or qualified under applicable securities laws, the PSU Shares issued upon redemption of the Awards hereunder may be subject to statutory restrictions upon resale including </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">hold periods </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the certificates representing such PSU </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Shares will </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">bear </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">legend to that </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">effect.</font></div></div><p style="font-size:10pt;margin-top:3.25pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.093%;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.74%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.093%;text-align:justify;"><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The grant of the Award and the issuance and delivery of the PSU Shares is subject to the terms and conditions of the Plan (as modified or varied by this PSU Award Agreement), all of which are incorporated into and form </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">integral part of this PSU Award Agreement.</font></p><p style="text-indent:6.74%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.093%;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.737%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.037%;text-align:justify;"><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nothing in </font><font style="color:#050505;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Plan or in this PSU Award Agreement will affect the right of the Corporation or any of its Subsidiaries to terminate the employment of, term of office of, or consulting agreement with, the Participant at any time for any reason whatsoever. Upon </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">such</font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.037%;text-align:justify;"><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">termination, the Participant's rights to the Award and the PSU Shares will be </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">subject </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to </font><font style="color:#050505;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and time </font><font style="color:#050505;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">limits as set forth in this PSU Award Agreement</font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.739%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.074%;text-align:justify;"><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This PSU Award Agreement shall be binding upon and inure to the benefit of the Corporation, its </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">successors </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and assigns and the Participant </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the </font><font style="color:#050505;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">legal </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">representative of the Participant's estate any other person who acquires the Award or PSU Shares by bequest or inheritance</font><font style="color:#5d5d5d;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Participant shall not be entitled to assign this PSU Award Agreement nor the Award granted hereby except in accordance with the Plan.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.738%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.065%;text-align:justify;"><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This PSU Award Agreement may be executed in counterparts </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">by facsimile or other electronic means, each of which shall constitute an original and all of which taken together shall constitute one </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the same instrument.</font></p><p style="margin-left:24.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.738%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.056%;text-align:justify;"><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PSU Award Agreement, the grant </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Award hereunder and under the Plan, and the </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">settlement </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of the Award </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shall </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">be, as applicable, governed by and construed in </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">accordance </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">with the laws of the Province of Ontario and the </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">federal </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">laws of Canada </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">applicable </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">therein </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">without regard </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to principles of conflicts of </font><font style="color:#050505;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">laws </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that would impose the laws of another jurisdiction. The </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Courts </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of the Province of Ontario </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shall </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">have the </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">exclusive </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">jurisdiction to hear and decide any disputes or other matters arising herefrom.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.736%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.028%;text-align:justify;"><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the extent applicable, with respect to U.S. Participants</font><font style="color:#494949;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Award is intended to be exempt from the requirements of Section 409A of the </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Code and </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">applicable regulations and </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">guidance </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">under the statute and </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shall </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">be construed and interpreted accordingly</font><font style="color:#494949;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In no </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">event </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">whatsoever </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shall </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Corporation or any Subsidiary or affiliate of the </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Corporation </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">be liable for any additional </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">tax, </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">interest or penalties that may be imposed on the Participant or the Participant's beneficiary or estate </font><font style="color:#050505;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">under </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 409A of the Code or </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">damages for </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failing </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to comply with Section 409A of the Code or otherwise</font><font style="color:#494949;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p><p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All capitalized terms used in this PSU Award Agreement, including Exhibit A, unless expressly defined </font><font style="color:#050505;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a different manner, have the meanings ascribed thereto in the Plan.</font></p><p style="font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><h1 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.88%;text-align:center;"><font style="color:#050505;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[REMAINDER </font><font style="color:#161616;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OF PAGE INTENTIONALLY LEFT BLANK]</font></h1><p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0.4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#151515;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Should </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">you </font><font style="color:#151515;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">wish to </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">accept </font><font style="color:#151515;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the grant of the Award as described in this PSU Award Agreement, please sign where indicated below </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and </font><font style="color:#151515;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">return one copy of this PSU Award Agreement to the </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Corporation.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ACCEPTED AND AGREED </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">by the Participant as at [[RESADDR1]] [[RESADDR2]] [[RESCITY]] [[RESSTATEORPROV]] [[RESPOSTALCODE]] [[RESCOUNTRY]] and intending to be legally bound:</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0.25pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="border-spacing:0;table-layout:auto;width:94.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:25.2pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0.25pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[[FIRSTNAME]] [[LASTNAME]]</font></p></td>
    </tr>
    <tr style="height:23.75pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0.25pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Name of Participant</font></p></td>
    </tr>
    <tr style="height:25.2pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:25.2pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[[SIGNATURE]]</font></p></td>
    </tr>
    <tr style="height:23.75pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Signature of Participant</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0.25pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:11.65pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.352%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Corporation hereby confirms the grant of the Award described in this PSU Award Agreement effective as of the Grant Date</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.352%;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.352%;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="border-spacing:0;table-layout:auto;width:67.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:8.96%;box-sizing:content-box;"></td>
     <td style="width:91.04%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:16.55pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">MIND MEDICINE (MINDMED) INC</font></p></td>
    </tr>
    <tr style="height:15.85pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:15.85pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A-</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>mnmd-ex10_3.htm
<DESCRIPTION>EX-10.3
<TEXT>
<html>
 <head>
  <title>EX-10.3</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;position:relative;">
  <div style="padding-top:0.19in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:12.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.3</font></p><h1 style="font-size:10pt;margin-top:4.7pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.204%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">MIND MEDICINE (MINDMED) INC.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></h1><h1 style="font-size:10pt;margin-top:4.7pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.204%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INDUCEMENT GRANT</font></h1><h1 style="margin-left:27.333%;text-indent:-1.213%;padding-left:0.533%;font-size:10pt;margin-top:4.7pt;font-family:Times New Roman;margin-bottom:0;margin-right:28.148%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RSU AWARD AGREEMENT</font></h1><p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:11.65pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This RSU Award Agreement is entered into between Mind Medicine (MindMed) Inc. (the &#34;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Corporation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#34;) and the RSU Holder named below. Your Award has </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">been granted as an inducement that is material to your employment with the Corporation pursuant to the inducement grant exception under Nasdaq Stock Market Rule 5635(c)(4) and not pursuant to the</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Corporation&#x2019;s Performance and Restricted Share Unit Plan of the Corporation (the &#34;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#34;) effective March 7, 2023, as amended, </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">however, the Award will be governed in all respects as if issued under the Plan, as well this RSU Award Agreement.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:11.65pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unless otherwise defined herein, the terms defined in the Plan will have the same defined meanings in this RSU Award Agreement. This RSU Award Agreement confirms that:</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:11.65pt;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">on [[GRANTDATE]]</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[[FIRSTNAME]] [[LASTNAME]] (the </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;RSU Holder&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">)</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;margin-right:1.333%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">was granted [[SHARESGRANTED]] non-assignable restricted share units (the </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#34;Award&#34;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">), such Award to be effective on the date the Corporation confirms the grant of the Award by countersigning this RSU Award Agreement;</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;margin-right:1.333%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">vesting of the Award will not be subject to the attainment of performance objectives;</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;margin-right:1.333%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Award, or portions thereof, as applicable, shall vest at 5:00 p.m. (Toronto time) as to the number of Shares (the </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#34;RSU Shares&#34;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) and on the dates listed in the following table (each, a </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#34;Vesting Date&#34;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) provided, however, that if the RSU Holder experiences a Period of Absence (as defined in the Plan) for any period between the Award Date (as hereinafter defined) and an applicable Vesting Date, the portion of the Award that vests shall be subject to adjustment in accordance with the terms set out in the Plan:</font></div></div>
   <table style="margin-left:4.167%;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:50%;box-sizing:content-box;"></td>
     <td style="width:50%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:18.7pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="text-indent:12.104%;font-size:12pt;margin-top:11.65pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.611%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Vesting Date</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:11.65pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.565%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Portion of Award Vested</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  [[ALLVESTSEGS]]	</font></p>
   <table style="margin-left:5.556%;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:50%;box-sizing:content-box;"></td>
     <td style="width:50%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:12.95pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:11.65pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.611%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="text-indent:10.057%;font-size:12pt;margin-top:11.65pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.565%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[[SHARESGRANTED]]  RSU Shares</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:11.65pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:1.053%;text-indent:0.014%;font-size:10pt;margin-top:4.65pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.472%;text-align:left;"><font style="color:#1c1c1c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">all on </font><font style="color:#0c0c0c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the terms </font><font style="color:#1c1c1c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and subject to </font><font style="color:#0c0c0c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the </font><font style="color:#1c1c1c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">conditions set out in the Plan.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.187%;font-size:10pt;margin-top:0.85pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.19in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="margin-left:1.053%;text-indent:0.014%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.472%;text-align:left;"><font style="color:#1c1c1c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By signing </font><font style="color:#0c0c0c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">this </font><font style="color:#1c1c1c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RSU Award Agreement, the RSU Holder:</font></p><p style="margin-left:1.053%;text-indent:0.014%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.472%;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:left;"><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.983857620229827%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#1c1c1c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">acknowledges that </font><font style="color:#0c0c0c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">he </font><font style="color:#1c1c1c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or she </font><font style="color:#0c0c0c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">has received </font><font style="color:#1c1c1c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a copy of the Plan, has read and </font><font style="color:#0c0c0c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">understands </font><font style="color:#1c1c1c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Plan and that he or she will abide </font><font style="color:#0c0c0c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">by </font><font style="color:#1c1c1c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">its terms and conditions, which </font><font style="color:#0c0c0c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">terms </font><font style="color:#1c1c1c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and conditions </font><font style="color:#0c0c0c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">include </font><font style="color:#1c1c1c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the </font><font style="color:#0c0c0c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">right </font><font style="color:#1c1c1c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of </font><font style="color:#0c0c0c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the </font><font style="color:#1c1c1c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Corporation </font><font style="color:#0c0c0c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to </font><font style="color:#1c1c1c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">amend or terminate </font><font style="color:#0c0c0c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Plan </font><font style="color:#1c1c1c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or any of its terms and </font><font style="color:#0c0c0c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to </font><font style="color:#1c1c1c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">determine vesting and other </font><font style="color:#0c0c0c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">matters in </font><font style="color:#1c1c1c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">respect of an Award;</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:4.407%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;min-width:6.796%;text-align:left;"><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.109307166842761%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#1c1c1c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">agrees </font><font style="color:#0c0c0c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that </font><font style="color:#1c1c1c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">other </font><font style="color:#0c0c0c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">than pursuant to </font><font style="color:#1c1c1c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.2 of </font><font style="color:#0c0c0c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the </font><font style="color:#1c1c1c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Plan, an </font><font style="color:#0c0c0c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RSU does not </font><font style="color:#1c1c1c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">carry any voting </font><font style="color:#0c0c0c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">rights </font><font style="color:#1c1c1c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or </font><font style="color:#0c0c0c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the right </font><font style="color:#1c1c1c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to receive </font><font style="color:#0c0c0c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">dividends </font><font style="color:#1c1c1c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or distributions of the Corporation</font><font style="color:#484848;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#0c0c0c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">if </font><font style="color:#1c1c1c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and when declared;</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:left;"><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.983857620229827%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="width:100%;display:inline;"><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">recognizes that (A) during the period between </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">granting </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an Award and </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Vesting Date of </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">all or a </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">portion of </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Award (or </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">settlement </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">thereof), the </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">value </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an Award </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and RSU Shares may be </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">subject </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">number of </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">factors; and </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(B) the </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Corporation accepts </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">no responsibility </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for any </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fluctuations in the value of the Award or the RSU </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Shares;</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:left;"><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.983857620229827%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(iv)</font><div style="width:100%;display:inline;"><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">acknowledges that neither the </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Corporation </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nor its affiliates or </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">associates, </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nor </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">their </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">respective </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">advisors, </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">assume </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">responsibility as regards </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the tax consequences that participation in </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Plan will have </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RSU Holder </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or as </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regard to </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any changes to, or interpretations of, </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">applicable </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">tax laws </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulations made by </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">applicable governmental authorities and </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the RSU Holder is urged to consult his </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">her </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">own </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">tax advisor in </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">such </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regard;</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:left;"><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.983857620229827%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(v)</font><div style="width:100%;display:inline;"><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">acknowledges </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that he or </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">she </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">is solely liable for </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">taxes or penalties </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">which </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">may be payable pursuant to the </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Code </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or to </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Canada </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agency </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">under the </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Tax Act </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Canada) or </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">other taxing </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">authority </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in respect of the </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">grant, vesting </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">settlement </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Award (including any taxes or penalties that may arise under Section 409A of the </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Code) and agrees </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to make arrangements </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">satisfactory </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to the </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Corporation </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">payment of </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cash </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Corporation sufficient </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">satisfy any </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">income </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or employment </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">taxes in respect of the grant</font><font style="color:#505050;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">vesting or </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delivery of the Award or the RSU </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Shares </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">under this RSU Award Agreement, </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided further that the delivery </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RSU </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Shares </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">pursuant </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to an Award </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">is contingent upon satisfaction of </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">applicable withholding </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">requirements and </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">applicable taxes </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">may be </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">withheld </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">from </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">payments due to him or her, including </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">such </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">payment in </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">settlement of </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Award;</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:left;"><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.983857620229827%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(vi)</font><div style="width:100%;display:inline;"><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">agrees </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that he </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or she will, </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">at </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">all </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">times, </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">act </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">strict </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">compliance with </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">applicable </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">laws </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">all polices of the </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Corporation applicable </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to the RSU Holder in connection </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">with </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Plan and the Award</font><font style="color:#505050;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">which applicable </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">laws </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">policies shall include</font><font style="color:#505050;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">without limitation, those governing </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#34;insiders&#34; </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#34;reporting </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">issuers&#34; </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(as </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">those </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">terms are </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">defined in </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">applicable securities </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">laws) </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Corporation's </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">insider trading policy, </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">copy </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">which has been provided </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">made </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">available </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to the RSU </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Holder;</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:left;"><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.983857620229827%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(vii)</font><div style="width:100%;display:inline;"><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">acknowledges </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that: (i) the Award </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shall </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">not be </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">effective </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">until the date the </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.187%;font-size:10pt;margin-top:0.85pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.19in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:left;"><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.983857620229827%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Corporation </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">has confirmed the </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">grant of </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Award </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">by countersigning this RSU </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Award Agreement; </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and (ii) the RSU Holder has no right or </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">entitlement </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to be issued any underlying RSU </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Shares </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">prior to </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">such </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">date; </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:left;"><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.983857620229827%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(viii)</font><div style="width:100%;display:inline;"><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">acknowledges </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that, unless the </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Award and </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the RSU Shares are </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">registered </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or qualified under </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">applicable </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">securities laws, the RSU </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Shares </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">issued upon redemption of the Awards hereunder may be </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">subject </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">statutory </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions upon resale </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">including </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">hold periods </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the certificates representing such RSU </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Shares will </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">bear </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a </font><font style="color:#111111;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">legend to that </font><font style="color:#212121;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">effect.</font></div></div><p style="font-size:10pt;margin-top:3.25pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.093%;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.74%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.093%;text-align:left;"><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The grant of the Award and the issuance and delivery of the underlying RSU Shares or the payment of the Market Value in respect of </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RSU Share are subject to the terms and conditions of the Plan (as modified or varied by this RSU Award Agreement), all of which are incorporated into and form </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">integral part of this RSU Award Agreement.</font></p><p style="text-indent:6.74%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.093%;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.737%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.037%;text-align:left;"><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nothing in </font><font style="color:#050505;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Plan or in this RSU Award Agreement will affect the right of the Corporation or any of its Subsidiaries to terminate the employment of, term of office of, or consulting agreement with, the RSU Holder at any time for any reason whatsoever. Upon </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">such </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">termination, the RSU Holder's rights to the Award and the RSU Shares will be </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">subject </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to </font><font style="color:#050505;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and time </font><font style="color:#050505;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">limits, </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the complete details of which are </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">set </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">out in the Plan.</font></p><p style="text-indent:6.739%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.074%;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.739%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.074%;text-align:left;"><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This RSU Award Agreement shall be binding upon and inure to the benefit of the Corporation, its </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">successors </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and assigns and the RSU Holder </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the </font><font style="color:#050505;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">legal </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">representative of the RSU Holder's estate any other person who acquires the Award or RSU Shares by bequest or inheritance</font><font style="color:#5d5d5d;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The RSU Holder shall not be entitled to assign this RSU Award Agreement nor the Award granted hereby except in accordance with the Plan.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.738%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.065%;text-align:left;"><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This RSU Award Agreement may be executed in counterparts </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">by facsimile or other electronic means, each of which shall constitute an original and all of which taken together shall constitute one </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the same instrument.</font></p><p style="margin-left:24.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.738%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.056%;text-align:left;"><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RSU Award Agreement, the grant </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Award hereunder and under the Plan, and the </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">settlement </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of the Award </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shall </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">be, as applicable, governed by and construed in </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">accordance </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">with the laws of the Province of Ontario and the </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">federal </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">laws of Canada </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">applicable </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">therein </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">without regard </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to principles of conflicts of </font><font style="color:#050505;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">laws </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that would impose the laws of another jurisdiction. The </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Courts </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of the Province of Ontario </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shall </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">have the </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">exclusive </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">jurisdiction to hear and decide any disputes or other matters arising herefrom.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.736%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.028%;text-align:left;"><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the extent applicable, with respect to U.S. RSU Holders</font><font style="color:#494949;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Award is intended to be exempt from the requirements of Section 409A of the </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Code and </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">applicable regulations and </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">guidance </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">under the statute and </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shall </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">be construed and interpreted accordingly</font><font style="color:#494949;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In no </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">event </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">whatsoever </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shall </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Corporation or any Subsidiary or affiliate of the </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Corporation </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">be liable for any additional </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">tax, </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">interest or penalties that may be imposed on the RSU Holder or the RSU Holder's beneficiary or estate </font><font style="color:#050505;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">under </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 409A of the Code or </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">damages for </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failing </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to comply with Section 409A of the Code or otherwise</font><font style="color:#494949;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p><p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.187%;font-size:10pt;margin-top:0.85pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.19in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All capitalized terms used herein, unless expressly defined </font><font style="color:#050505;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in </font><font style="color:#161616;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a different manner, have the meanings ascribed thereto in the Plan.</font></p><p style="font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><h1 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.88%;text-align:center;"><font style="color:#050505;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[REMAINDER </font><font style="color:#161616;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OF PAGE INTENTIONALLY LEFT BLANK]</font></h1><p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0.4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.187%;font-size:10pt;margin-top:0.85pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.19in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#151515;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Should </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">you </font><font style="color:#151515;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">wish to </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">accept </font><font style="color:#151515;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the grant of the Award as described in this RSU Award Agreement, please sign where indicated below </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and </font><font style="color:#151515;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">return one copy of this RSU Award Agreement to the </font><font style="color:#262626;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Corporation.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ACCEPTED AND AGREED </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">by the RSU Holder as at [[RESADDR1]] [[RESADDR2]] [[RESCITY]] [[RESSTATEORPROV]] [[RESPOSTALCODE]] [[RESCOUNTRY]] and intending to be legally bound:</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0.25pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="border-spacing:0;table-layout:auto;width:94.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:25.2pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0.25pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[[FIRSTNAME]] [[LASTNAME]]</font></p></td>
    </tr>
    <tr style="height:23.75pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0.25pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Name of RSU Holder</font></p></td>
    </tr>
    <tr style="height:25.2pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:25.2pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[[SIGNATURE]]</font></p></td>
    </tr>
    <tr style="height:23.75pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Signature of RSU Holder</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0.25pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:11.65pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.352%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Corporation hereby confirms the grant of the Award described in this RSU Award Agreement effective as of this [[GRANTDATE]] (the </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Award Date&#x201d;).</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.352%;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.352%;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="border-spacing:0;table-layout:auto;width:67.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:8.96%;box-sizing:content-box;"></td>
     <td style="width:91.04%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:16.55pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">MIND MEDICINE (MINDMED) INC</font></p></td>
    </tr>
    <tr style="height:15.85pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:15.85pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.187%;font-size:10pt;margin-top:0.85pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>5
<FILENAME>mnmd-ex10_4.htm
<DESCRIPTION>EX-10.4
<TEXT>
<html>
 <head>
  <title>EX-10.4</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;position:relative;">
  <div style="padding-top:0.19in;z-index:2;min-height:1.08in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:5.472%;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:12.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.4</font></p><h1 style="margin-left:1.32%;font-size:10pt;margin-top:4.7pt;font-family:Times New Roman;margin-bottom:0;margin-right:5.472%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">MIND MEDICINE (MINDMED) INC.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></h1><h1 style="margin-left:1.32%;font-size:10pt;margin-top:4.7pt;font-family:Times New Roman;margin-bottom:0;margin-right:5.472%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> INDUCEMENT GRANT</font></h1><h1 style="margin-left:1.32%;font-size:10pt;margin-top:4.7pt;font-family:Times New Roman;margin-bottom:0;margin-right:5.472%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NONSTATUTORY STOCK OPTION AGREEMENT</font></h1><h1 style="margin-left:27.333%;text-indent:-1.213%;padding-left:0.533%;font-size:10pt;margin-top:4.7pt;font-family:Times New Roman;margin-bottom:0;margin-right:28.148%;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"></font>&#160;</h1><p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.987%;text-indent:7.332%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:8.093%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Your Option has been granted as an &#x201c;inducement&#x201d; award pursuant to the inducement grant exception under Nasdaq Stock Market Rule 5635(c)(4) and not pursuant to the Mind Medicine (MindMed) Inc. Stock Option Plan (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) or any equity incentive plan of the Corporation, as an inducement that is material to the Participant&#x2019;s employment with the Corporation. However, the Option will be governed in all respects as if issued under the Plan, as well this Stock Option Agreement.</font></p><p style="margin-left:0.987%;text-indent:7.332%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:8.093%;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.987%;text-indent:7.332%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:8.093%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It is intended that the option evidenced by this Stock Option Agreement shall not be an incentive stock option as defined in Section 422 of the Internal Revenue Code of 1986, as amended, and any regulations promulgated thereunder (the &#x201c;Code&#x201d;).  Unless otherwise defined herein, the terms defined in the Plan will have the same defined meanings in this Stock Option Agreement, which includes this Notice of Stock Option Grant (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notice of Grant</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:11.65pt;font-family:Times New Roman;margin-bottom:0;margin-right:8.093%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTICE GRANT</font></p><p style="font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:8.093%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Participant:  [[FIRSTNAME]] [[LASTNAME]]	</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:8.093%;text-align:left;"><font style="white-space:pre-wrap;font-size:13pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:11pt;font-family:Times New Roman;margin-bottom:0;margin-right:8.093%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Address:  [[RESADDR1]] [[RESADDR2]] [[RESCITY]] [[RESSTATEORPROV]] [[RESPOSTALCODE]] [[RESCOUNTRY]]	</font></p><p style="font-size:10pt;margin-top:0.4pt;font-family:Times New Roman;margin-bottom:0;margin-right:8.093%;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.987%;text-indent:7.332%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:8.093%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The undersigned Participant has been granted an Option to purchase Shares of the Corporation, subject to the terms and conditions of the Plan are as follows:</font></p><p style="font-size:10pt;margin-top:0.2pt;font-family:Times New Roman;margin-bottom:0;margin-right:8.093%;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:2.507%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:8.093%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Grant Number:  [[GRANTNUMBER]]	</font></p><p style="margin-left:2.507%;font-size:10pt;margin-top:0.2pt;font-family:Times New Roman;margin-bottom:0;margin-right:8.093%;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:2.507%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:8.093%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Date of Grant:  [[GRANTDATE]]	</font></p><p style="margin-left:2.52%;font-size:10pt;margin-top:11.7pt;font-family:Times New Roman;margin-bottom:0;margin-right:8.083%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Vesting Commencement Date: [[VESTINGSTARTDATE]]	</font></p><p style="margin-left:2.52%;font-size:10pt;margin-top:11.7pt;font-family:Times New Roman;margin-bottom:0;margin-right:8.083%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Number of Shares Subject to the Option:  [[SHARESGRANTED]]</font></p><p style="margin-left:2.507%;font-size:10pt;margin-top:11.7pt;font-family:Times New Roman;margin-bottom:0;margin-right:8.093%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Type of Grant: Option</font></p><p style="margin-left:2.507%;font-size:10pt;margin-top:0.65pt;font-family:Times New Roman;margin-bottom:0;margin-right:8.093%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Option:</font></p><p style="margin-left:2.507%;font-size:10pt;margin-top:0.65pt;font-family:Times New Roman;margin-bottom:0;margin-right:8.093%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exercise Price per Share (USD): $ [[GRANTCODE1]]</font></p><p style="margin-left:2.507%;font-size:10pt;margin-top:11.7pt;font-family:Times New Roman;margin-bottom:0;margin-right:8.093%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Total Exercise Price (USD): $[[GRANTCODE2]]</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="margin-left:2.507%;font-size:10pt;margin-top:0.2pt;font-family:Times New Roman;margin-bottom:0;margin-right:8.093%;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:1.03in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.187%;font-size:10pt;margin-top:0.85pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.19in;z-index:2;min-height:1.08in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="margin-left:2.507%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:8.093%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Type of Option: [[GRANTTYPE]]	</font></p><p style="margin-left:2.507%;font-size:10pt;margin-top:0.2pt;font-family:Times New Roman;margin-bottom:0;margin-right:8.093%;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:2.507%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:8.093%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Term/Expiration Date: [[GRANTEXPIRATIONDATE]]	</font></p><p style="font-size:10pt;margin-top:0.4pt;font-family:Times New Roman;margin-bottom:0;margin-right:8.093%;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.987%;text-indent:7.332%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:8.093%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These Options will be exercisable, in whole or in part, in accordance with the following schedule:</font></p><p style="margin-left:0.987%;text-indent:7.332%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:8.093%;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.987%;text-indent:6.826%;font-size:10pt;margin-top:6.7pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.352%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[[VESTINGTEMPLATEDESC]]</font></p><p style="margin-left:7.653%;font-size:10pt;margin-top:11.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:7.653%;font-size:10pt;margin-top:11.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:7.653%;font-size:10pt;margin-top:11.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:7.653%;font-size:10pt;margin-top:11.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:7.653%;font-size:10pt;margin-top:11.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Termination of Employment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0.4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.987%;text-indent:6.828%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.37%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 15 of the Plan sets out the early termination provisions if the Participant has an Event of Termination.  In no event may this Option be exercised after the Term/Expiration Date as provided above.</font></p><p style="font-size:10pt;margin-top:0.4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.987%;text-indent:6.826%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.352%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By Participant's signature and the signature of the representative of the Corporation below, Participant and the Corporation agree that this Agreement is granted under and governed by the terms and conditions of the Plan. Participant acknowledges receipt of a copy of the Plan. Participant has reviewed the Plan in its entirety, has had an opportunity to obtain the advice of counsel prior to executing this Agreement, and fully understands all provisions of the Plan and this Agreement.   Participant hereby agrees to accept as binding, conclusive, and final all decisions or interpretations of the Administrators upon any questions relating to the Plan and the Agreement. Participant further agrees to notify the Corporation upon any change in the residence address indicated below.</font></p><p style="margin-left:0.987%;text-indent:6.826%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.352%;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:13pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[[SIGNATURE]]</font></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:40.372%;box-sizing:content-box;"></td>
     <td style="width:3.499%;box-sizing:content-box;"></td>
     <td style="width:56.129%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:16.55pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">PARTICIPANT</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">MIND MEDICINE (MINDMED) INC</font></p></td>
    </tr>
    <tr style="height:15.85pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:15.85pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:15.85pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:16.55pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[[FIRSTNAME]] [[LASTNAME]]</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#181818;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[Name]</font></p></td>
    </tr>
    <tr style="height:34.55pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[Title]</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.2in;min-height:1.03in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.187%;font-size:10pt;margin-top:0.85pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>6
<FILENAME>mnmd-ex10_5.htm
<DESCRIPTION>EX-10.5
<TEXT>
<html>
 <head>
  <title>EX-10.5</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;position:relative;">
  <div style="padding-top:0.49in;z-index:2;min-height:1.18in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:12.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.5</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXECUTIVE EMPLOYMENT AGREEMENT</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This </font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Executive Employment Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) is entered into effective March 17, 2025 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), by and between Matthew Wiley (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Executive</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) and Mind Medicine (MindMed), Inc. (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company desires to employ Executive and, in connection therewith, to compensate the Executive for Executive&#x2019;s personal services to the Company.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Executive wishes to be employed by the Company and provide personal services and certain covenants to the Company in return for certain compensation and benefits.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accordingly, in consideration of the mutual promises and covenants contained herein, the parties agree to the following:</font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.57143775513484%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employment by the Company.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">1.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Position; Duties</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Subject to the terms set forth herein, the Company agrees to employ Executive in the position of Chief Commercial Officer, and Executive hereby accepts such employment. During the term of Executive&#x2019;s employment with the Company, Executive will devote Executive&#x2019;s best efforts, business time and attention to the business of the Company. Executive&#x2019;s  principal workplace shall be his home office in Berwyn, Pennsylvania, or such other location within the United States as requested by Executive and agreed upon Company. Executive will report to the Company&#x2019;s Chief Executive Officer (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">CEO</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) or CEO&#x2019;s designee. Executive will perform such duties as are normally associated with Executive&#x2019;s position, as assigned from time to time, subject to the oversight and direction of the CEO or the CEO&#x2019;s designee. The Executive shall make such business trips to such places as may be reasonably necessary or advisable for the Company. Executive&#x2019;s start date will be March 17, 2025.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">1.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company Policies</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The employment relationship between the parties shall be subject to the Company&#x2019;s personnel policies and procedures as they may be interpreted, adopted, revised or deleted from time to time in the Company&#x2019;s sole discretion.  Notwithstanding the foregoing, in the event that the terms of this Agreement differ from, or are in conflict with, the Company&#x2019;s employment policies or practices, this Agreement shall control.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">1.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Expense Reimbursement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company will reimburse Executive for reasonable business expenses in accordance with the Company&#x2019;s standard expense reimbursement policy, as the same may be modified by the Company&#x2019;s Board of Directors (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Board</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) from time to time.  The Company shall reimburse Executive for all customary and appropriate business-related expenses actually incurred and documented in accordance with Company policy, as in effect from time to time.  For the avoidance of doubt, to the extent that any reimbursements payable to Executive are subject to the provisions of Section 409A of the Internal Revenue Code of 1986, as amended (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Code</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;):</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a) any such reimbursements will be paid no later than December 31 of the year following the year in which the expense was incurred, (b) the amount of expenses reimbursed in one year will not affect the amount eligible for reimbursement in any subsequent year, and (c) the right to reimbursement under this Agreement will not be subject to liquidation or exchange for another benefit.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.49in;min-height:1.18in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.49in;z-index:2;min-height:1.18in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.57143775513484%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compensation and Benefits.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">2.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Salary</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Executive shall receive for Executive&#x2019;s services to be rendered hereunder a base salary of $475,000 on an annualized basis, subject to review and adjustment by the Company in its sole discretion, and payable subject to standard federal and state payroll withholding requirements in accordance with the Company&#x2019;s standard payroll practices (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Base Salary</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">2.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Annual Discretionary Bonus</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Executive will be eligible for a discretionary annual (fiscal year) cash bonus with a target of forty percent (40%) of Executive&#x2019;s then current Base Salary, subject to review and adjustment from time to time by the Company in its sole discretion, payable subject to standard payroll withholding requirements (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Target Bonus</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).  Whether or not Executive receives any bonus will be dependent upon (a) the actual achievement by Executive and the Company of the applicable individual and corporate performance goals, as determined by the Board in its sole discretion, and (b) Executive&#x2019;s continuous performance of services to the Company through the date any such bonus is paid.  The bonus may be greater or lesser than the Target Bonus and may be zero.  The annual period over which performance is measured for purposes of this bonus is the Company&#x2019;s fiscal year, January 1 through December 31 and the Company shall pay the bonus, if any, no later than March 15</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> immediately following the end of the applicable fiscal year.  The Board will determine in its sole discretion the extent to which each of Executive and the Company has achieved the performance goals upon which the bonus is based and the amount of the bonus, if any.  In the event the Executive leaves the employ of the Company for any reason prior to payment of any bonus, Executive is not eligible for such bonus, prorated or otherwise, except as provided in Section 6 below. Executive will be eligible for a pro-rated bonus for 2025 based on the percentage of 2025 that Executive is a full time employee.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">2.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  </font></div></div><div class="item-list-element-wrapper" style="margin-left:1.731%;text-indent:20.352%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:0.9514699447435102%;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock Option</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Subject to approval by the Compensation Committee of the Board, the Company anticipates granting Executive an option to purchase 350,000 shares of the Company&#x2019;s Common Shares (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Option</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).  The Option will vest over four years, with 25% of the shares vesting on the first anniversary of the Vesting Commencement Date (as defined in the award agreement), and 1/36th of the remaining shares vesting per month thereafter over 36 months, subject to Executive&#x2019;s continuous service with the Company on each such vesting date.  </font></div></div><div class="item-list-element-wrapper" style="margin-left:1.731%;text-indent:20.352%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:0.9514699447435102%;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Performance Stock Units</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Subject to approval by the Board, the Company anticipates granting Executive 125,000 performance stock units (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">PSUs</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), pursuant to the terms and conditions of the PSU award agreement entered into between Executive and the Company. The PSUs will vest based on the achievement of performance criteria set forth in the PSU award agreement over a three-year performance measurement period and threshold, target and stretch performance multipliers of 0.5x, 1.0x and 2.0x, respectively.</font></div></div><div class="item-list-element-wrapper" style="margin-left:1.731%;text-indent:20.352%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:0.9514699447435102%;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Inducement Grants</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Option and PSUs are being granted to Executive pursuant to the inducement grant exception under Nasdaq Rule 5635(c)(4) and not pursuant to any of the Company&#x2019;s equity incentive plans, as an inducement that is material to Executive&#x2019;s employment with the Company.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">2.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Benefits</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Executive will be eligible to participate on the same basis as similarly situated employees in the Company&#x2019;s benefit plans in effect from time to time during Executive&#x2019;s employment.  All matters of eligibility for coverage or benefits under any benefit plan </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.49in;min-height:1.18in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.49in;z-index:2;min-height:1.18in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shall be determined in accordance with the provisions of such plan.  The Company reserves the right to change, alter, or terminate any benefit plan in its sole discretion.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">3.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Confidential Information and Restrictive Covenants</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. As a condition of employment, Executive agrees to execute and abide by the Employee Confidential Information and  Inventions Assignment Agreement attached as Exhibit A (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Confidential Information Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), which may be amended by the parties from time to time without regard to this Agreement.  The Confidential Information</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agreement contains provisions that are intended by the parties to survive and do survive termination of this Agreement. </font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">4.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Outside Activities</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Except with the prior written consent of the CEO, Executive will not, while employed by the Company, undertake or engage in any other employment, occupation or business enterprise that would interfere with Executive&#x2019;s responsibilities and the performance of Executive&#x2019;s duties hereunder except for (i) reasonable time devoted to volunteer services for or on behalf of such religious, educational, non-profit and/or other charitable organization as Executive may wish to serve, (ii) reasonable time devoted to activities in the non-profit and business communities consistent with Executive&#x2019;s duties, (iii) Executive&#x2019;s existing advisory board role as of the Effective Date, provided it requires no more than 10 hours per quarter and the entity neither develops nor markets psychedelic-based therapeutics nor targets disease states in the Company&#x2019;s pipeline, and (iv) such other activities as may be specifically approved in writing by the CEO or the Board (including those activities approved by the Board on or around the Effective Date).  This restriction shall not, however, preclude the Executive (x) from owning less than one percent (1%) of the total outstanding shares of a publicly traded company, or (y) from employment or service in any capacity with Affiliates of the Company. As used in this Agreement, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Affiliates</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means an entity under common management or control with the Company.  </font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">5.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Conflict with Existing Obligations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Executive represents that Executive&#x2019;s performance of all the terms of this Agreement and service as an Executive of the Company do not and will not breach any agreement or obligation of any kind made prior to Executive&#x2019;s employment by the Company, including agreements or obligations Executive may have with prior employers or entities for which Executive has provided services. Executive has not entered into, and Executive agrees that Executive will not enter into, any agreement or obligation, either written or oral, in conflict herewith.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">6.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Termination of Employment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The parties acknowledge that Executive&#x2019;s employment relationship with the Company is at-will.  Either Executive or the Company may terminate the employment relationship at any time, with or without Cause, subject to the notice requirements set forth in Section 6.5. The provisions in this Section 6 govern the amount of compensation, if any, to be provided to Executive upon termination of employment and do not alter this at-will status.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">6.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Termination by the Company without Cause; Resignation for Good Reason</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="margin-left:1.731%;text-indent:20.352%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:0.9514699447435102%;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company shall have the right to terminate Executive&#x2019;s employment with the Company pursuant to this Section 6.1 at any time without &#x201c;Cause&#x201d; (as defined in Section 6.2(b) below) by giving notice as described in Sections 6.5 and 7.1 of this Agreement.  A termination pursuant to Sections 6.2, 6.3, or 6.4 below is not a termination without Cause for purposes of receiving the benefits described in this Section 6.1.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.49in;min-height:1.18in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">3</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.49in;z-index:2;min-height:1.18in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:1.731%;text-indent:20.352%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:0.9514699447435102%;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Executive shall have the right to resign from Executive&#x2019;s employment for Good Reason (as defined in this Section 6.1) by following the notice and cure process outlined in this Section 6.1, provided that the circumstance creating Good Reason is not cured by the Company pursuant to this Section 6.1. </font></div></div><div class="item-list-element-wrapper" style="margin-left:1.731%;text-indent:20.352%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:0.9514699447435102%;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the Company terminates Executive&#x2019;s employment without Cause or Executive resigns from Executive&#x2019;s employment with the Company for Good Reason, and provided that such termination constitutes a &#x201c;separation from service&#x201d; (as defined under Treasury Regulation Section l.409A-l(h), without regard to any alternative definition thereunder, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Separation from Service</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), then Executive shall be entitled to receive the Accrued Obligations (defined in Section 6.1(f) below). If Executive complies with the obligations in Section 6.1(e) below, Executive shall be eligible to receive the following &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Severance Benefits</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;:</font></div></div><div class="item-list-element-wrapper" style="text-indent:26.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:26.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.067%;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Salary</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="text-indent:33.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:33.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.933%;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the termination without Cause or resignation for Good Reason occurs at any time except during the Change in Control Measurement Period (as defined in Section 6.1(d) below), the Company will pay Executive an amount equal to Executive&#x2019;s then current Base Salary for nine (9) months, less all applicable withholdings and deductions, and paid in equal installments beginning on the Company&#x2019;s first regularly scheduled payroll date following the Release Effective Date (as defined below in Section 6.1(e) below), with the remaining installments occurring on the Company&#x2019;s regularly scheduled payroll dates thereafter.  </font></div></div><div class="item-list-element-wrapper" style="text-indent:33.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:33.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.933%;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the termination without Cause or resignation for Good Reason occurs during the Change in Control Measurement Period, the Company will pay Executive an amount equal to Executive&#x2019;s then current Base Salary for twelve (12) months, less all applicable withholdings and deductions, in a lump sum on the Company&#x2019;s first regularly scheduled payroll date following the Release Effective Date.  </font></div></div><div class="item-list-element-wrapper" style="text-indent:26.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:26.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.067%;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Benefits</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="text-indent:33.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:33.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.933%;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the termination without Cause or resignation for Good Reason occurs at any time except during the Change in Control Measurement Period, then if Executive timely elects continued coverage under COBRA for Executive and Executive&#x2019;s covered dependents under the Company&#x2019;s group health plans following such termination, then the Company shall reimburse Executive for that portion of Executive&#x2019;s COBRA premiums it was paying prior to the Separation Date necessary to continue Executive and Executive&#x2019;s covered dependents&#x2019; health insurance coverage in effect for Executive (and Executive&#x2019;s covered dependents) on the termination date until the earliest of: (i) nine (9) months from the separation date; (ii) the date when Executive becomes eligible for substantially equivalent health insurance coverage in connection with new employment or self-employment; or (iii) the date Executive ceases to be eligible for COBRA continuation coverage for any reason, including plan termination (such period from the termination date through the earlier of (i)-(iii), the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Non-CIC COBRA Payment Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).  Notwithstanding the foregoing, if at any time the Company determines that its payment of COBRA premiums on Executive&#x2019;s behalf would result in a violation of applicable law (including, but not limited to, the 2010 Patient Protection and Affordable Care Act, as amended by the 2010 Health Care and Education Reconciliation Act), then in lieu of paying COBRA premiums pursuant to this Section, the Company shall pay Executive on the last day of each remaining month of the Non-CIC COBRA Payment Period, a fully taxable cash payment equal to the COBRA premium for such month, subject to </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.49in;min-height:1.18in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">4</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.49in;z-index:2;min-height:1.18in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:33.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">applicable tax withholding for the remainder of the Non-CIC COBRA Payment Period. Nothing in this Agreement shall deprive Executive of Executive&#x2019;s rights under COBRA or ERISA for benefits under plans and policies arising under Executive&#x2019;s employment by the Company.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></div></div><div class="item-list-element-wrapper" style="text-indent:33.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:33.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.933%;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the termination without Cause or resignation for Good Reason occurs during the Change in Control Measurement Period, then the COBRA Payment Period shall be modified with respect to prong (i) above to twelve (12) months, but prongs (ii) and (iii) above shall remain the same (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">CIC COBRA Payment Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).</font></div></div><div class="item-list-element-wrapper" style="text-indent:26.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:26.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.067%;">(iii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Bonus</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </font></div></div><div class="item-list-element-wrapper" style="text-indent:33.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:33.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.933%;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the termination without Cause or resignation for Good Reason occurs outside of the Change in Control Measurement Period and after the completion of the Company&#x2019;s fiscal year, but before any bonuses are paid for such fiscal year, Executive will be eligible for a bonus for the completed fiscal year pursuant to the terms and process set forth in Section 2.2 above, dependent upon the actual achievement by Executive and the Company of the applicable individual and corporate performance goals, as determined by the Board in its sole discretion. The Company will pay Executive any bonus awarded for the completed fiscal year, less applicable withholdings and deductions, payable in a lump sum on the later of (x) the date that annual performance bonuses are normally paid to other Executives at the Company for that fiscal year or (y) the Release Effective Date, but in no event later than March 15 the year immediately following the year in which the termination or resignation occurs.  </font></div></div><div class="item-list-element-wrapper" style="text-indent:33.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:33.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.933%;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the termination without Cause or resignation for Good Reason occurs </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">during the Change in Control Measurement Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, a</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nd after the completion of the Company&#x2019;s fiscal year, but before any bonuses are paid, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Company will make a lump sum cash payment to Executive in an amount equal to 50% of the Target Bonus for the fiscal year in which the termination occurs, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">subject to standard deductions and withholdings</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which will be paid in a lump sum on </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> sixtieth (</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">60th) day following Executive&#x2019;s date of Separation from Service, provided the Release Effective Date has occurred on or before that date.</font></div></div><div class="item-list-element-wrapper" style="text-indent:26.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:26.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.067%;">(iv)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </font></div></div><div class="item-list-element-wrapper" style="text-indent:33.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:33.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.933%;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">termination without Cause or resignation for Good Reason occurs outside of the Change in Control Measurement Period, then the vesting of all </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">outstanding equity awards subject only to a time-based vesting schedule that are held by Executive immediately prior to the termination date (if any) shall cease vesting upon Executive&#x2019;s Separation from Service. </font></div></div><div class="item-list-element-wrapper" style="text-indent:33.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:33.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.933%;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">termination without Cause or resignation for Good Reason occurs during the Change in Control Measurement Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the vesting and exercisability of all outstanding equity awards subject only to a time-based vesting schedule that are held by Executive immediately prior to the termination date (if any) shall be accelerated in full.</font></div></div><div class="item-list-element-wrapper" style="margin-left:1.731%;text-indent:20.352%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:0.9514699447435102%;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A termination without Cause or resignation for Good Reason in either case on or within twelve (12) months following the effective date of a Change in Control of the Company (as defined in the Mind Medicine (MindMed) Inc. Stock Option Plan), but provided that an event will not constitute a &#x201c;Change in Control&#x201d; under this Agreement unless it also qualifies as </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.49in;min-height:1.18in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">5</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.49in;z-index:2;min-height:1.18in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:1.731%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a &#x201c;change in control event&#x201d; under Treasury Regulations Section 1.409A-3(i)(5)) is a termination or resignation during the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Change in Control Measurement Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.&#x201d;</font></div></div><div class="item-list-element-wrapper" style="margin-left:1.731%;text-indent:20.352%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:0.9514699447435102%;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Executive will be paid all of the Accrued Obligations on the Company&#x2019;s first payroll date after Executive&#x2019;s date of termination from employment or earlier if required by law.  Executive shall only receive the Severance Benefits if: (i) by the 60th day following the date of Executive&#x2019;s Separation from Service, Executive has signed and delivered to the Company a separation agreement containing an effective, general release of claims in favor of the Company and its affiliates and representatives, in a form presented by the Company that includes, among other terms, a general release of claims and non-disparagement in favor of the Company and its affiliates and representatives (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Release</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), and which cannot be revoked in whole or part by such date (the date that the Release can no longer be revoked is referred to as the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Release Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;); (ii) Executive returns all Company property; (iii) Executive is in compliance with Executive&#x2019;s post-termination obligations under this Agreement and the Confidential Information Agreement when any such Severance Benefits are due and payable; and (iv) Executive complies with the terms of the Release, including without limitation any non-disparagement and confidentiality provisions contained in the Release. To the extent that any of the Severance Benefits are deferred compensation under Section 409A of the Code, and are not otherwise exempt from the application of Section 409A, then, if the period during which Executive may consider and sign the Release spans two calendar years, the payment of the Severance Benefits will not be made or begin until the later calendar year.</font></div></div><div class="item-list-element-wrapper" style="margin-left:1.731%;text-indent:20.352%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:0.9514699447435102%;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For purposes of this Agreement, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accrued Obligations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; are (i) Executive&#x2019;s accrued but unpaid salary through the date of termination, (ii) any unreimbursed business expenses incurred by Executive payable in accordance with the Company&#x2019;s standard expense reimbursement policies, and (iii) benefits owed to Executive under any qualified retirement plan or health and welfare benefit plan in which Executive was a participant in accordance with applicable law and the provisions of such plan.</font></div></div><div class="item-list-element-wrapper" style="margin-left:1.731%;text-indent:20.352%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:0.9514699447435102%;">(g)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Severance Benefits provided to Executive pursuant to Section 6.1(c) are in lieu of, and not in addition to, any benefits to which Executive may otherwise be entitled under any Company severance plan, policy or program. </font></div></div><div class="item-list-element-wrapper" style="margin-left:1.731%;text-indent:20.352%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:0.9514699447435102%;">(h)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any damages caused by the termination of Executive&#x2019;s employment without Cause would be difficult to ascertain; therefore, the Severance Benefits for which Executive is eligible pursuant to this Section 6.l in exchange for the Release is agreed to by the parties as liquidated damages, to serve as full compensation, and not a penalty.</font></div></div><div class="item-list-element-wrapper" style="margin-left:1.731%;text-indent:20.352%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:0.9514699447435102%;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For purposes of this Agreement, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Good Reason</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall mean the occurrence of any of the following conditions without Executive&#x2019;s consent, after Executive&#x2019;s provision of written notice to the Company of the existence of such condition (which notice must be provided as described in Section 7.1 within thirty (30) days of the initial existence of the condition and must specify the particular condition in reasonable detail), provided that the Company has not first provided notice to Executive of its intent to terminate Executive&#x2019;s employment:  (i) a material (greater than 10%) reduction by the Company of Executive&#x2019;s Base Salary (except in the case of either (x) an across the board reduction in salaries, but only to the same proportional extent impacting </font><font><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">substantially all</font></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> other employees of the Company, or (y) a temporary reduction due to financial exigency); (ii) the relocation of Executive&#x2019;s principal place of employment by fifty (50) or more miles from Executive&#x2019;s then-current principal place of employment; or (iii) a material </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.49in;min-height:1.18in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">6</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.49in;z-index:2;min-height:1.18in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:1.731%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reduction in Executive&#x2019;s duties, responsibilities or authorities relative to Executive&#x2019;s title, duties, authority, or responsibilities in effect immediately prior to such reduction , provided, however, that neither the conversion of the Company to a subsidiary, division or unit of an acquiring entity, nor an action taken by the Company for the purposes of either accommodating a disability of the Executive or pursuant to the Family and Medical Leave Act (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">FMLA</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;),</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">will be deemed a &#x201c;material reduction&#x201d; in and of itself; further provided, a suspension in connection with an internal investigation by the Company shall not be a &#x201c;material reduction&#x201d;.  Notwithstanding the foregoing, Good Reason shall only exist if the Company is provided a thirty (30) day period to cure the event or condition giving rise to Good Reason, and it fails to do so within that cure period (and, additionally, Executive must resign for such Good Reason condition by giving notice as described in Section 7.1 within thirty (30) days after the period for curing the violation or condition has ended).</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">6.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Termination by the Company for Cause</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="margin-left:1.731%;text-indent:20.352%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:0.9514699447435102%;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company shall have the right to terminate Executive&#x2019;s employment with the Company at any time for Cause by giving notice as described in Section 6.5(b) of this Agreement.</font></div></div><div class="item-list-element-wrapper" style="margin-left:1.731%;text-indent:20.352%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:0.9514699447435102%;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For purposes of this Agreement, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cause</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall mean that the Company determined that Executive has engaged in any of the following: (i) a material breach of any covenant or condition under this Agreement or any other agreement between the Company and Executive, including but not limited to the Confidential Information</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agreement; (ii) any act constituting theft, dishonesty, fraud, immoral or disreputable conduct, that is deemed by the Board in its reasonable discretion to be harmful to the Company or its reputation; (iii) any conduct which constitutes a felony under applicable law; (iv) a material violation of any Company policy or any material act of misconduct, in either case that causes, or is likely to cause, harm to the Company or its reputation; (v) refusal to follow or implement a clear, reasonable, and lawful directive of the Board; (vi) breach of fiduciary duty; or (vii) gross negligence or gross incompetence in the performance of Executive&#x2019;s duties.</font></div></div><div class="item-list-element-wrapper" style="margin-left:1.731%;text-indent:20.352%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:0.9514699447435102%;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event Executive&#x2019;s employment is terminated at any time for Cause, Executive will not receive the Severance Benefits as described in Section 6.1(c) or any other severance compensation or benefit, except that, consistent with the Company&#x2019;s standard payroll policies, the Company shall provide to Executive the Accrued Obligations.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">6.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Resignation by the Executive without Good Reason</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="margin-left:1.731%;text-indent:20.352%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:0.9514699447435102%;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Executive may resign from Executive&#x2019;s employment with the Company at any time without Good Reason by giving notice as described in Section 6.5(f).</font></div></div><div class="item-list-element-wrapper" style="margin-left:1.731%;text-indent:20.352%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:0.9514699447435102%;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event Executive resigns from Executive&#x2019;s employment with the Company without Good Reason, Executive will not receive any Severance Benefits as described in Section 6.1(c) or any other severance compensation or benefit, except that, pursuant to the Company&#x2019;s standard payroll policies, the Company shall provide to Executive the Accrued Obligations.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.49in;min-height:1.18in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">7</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.49in;z-index:2;min-height:1.18in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">6.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Termination by Virtue of Death or Disability of the Executive</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="margin-left:1.731%;text-indent:20.352%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:0.9514699447435102%;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event of Executive&#x2019;s death while employed pursuant to this Agreement, all obligations of the parties hereunder shall terminate immediately, and the Company shall, pursuant to the Company&#x2019;s standard payroll practices, provide to the Executive&#x2019;s legal representative(s) Executive&#x2019;s Accrued Obligations.</font></div></div><div class="item-list-element-wrapper" style="margin-left:1.731%;text-indent:20.352%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:0.9514699447435102%;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subject to applicable state and federal law, the Company shall at all times have the right, upon written notice to Executive, to terminate this Agreement based on Executive&#x2019;s Disability (as defined below).  Termination by the Company of Executive&#x2019;s employment based on &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Disability</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall mean termination because the Executive is unable due to a physical or mental condition to perform the essential functions of Executive&#x2019;s position with or without reasonable accommodation for six (6) months in the aggregate during any twelve (12) month period or based on the written certification by two licensed physicians of the likely continuation of such condition for such period.  This definition shall be interpreted and applied consistent with the Americans with Disabilities Act, the FMLA, and other applicable law.  In the event Executive&#x2019;s employment is terminated based on the Executive&#x2019;s Disability, Executive will not receive any Severance Benefits as described in Section 6.1(c) or any other severance compensation or benefit, except that, pursuant to the Company&#x2019;s standard payroll policies, the Company shall provide to Executive the Accrued Obligations.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">6.5</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notice; Effective Date of Termination</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Termination of Executive&#x2019;s employment pursuant to this Agreement shall be effective on the earliest of (each, the applicable &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Separation Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;):</font></div></div><div class="item-list-element-wrapper" style="margin-left:1.731%;text-indent:20.352%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:0.9514699447435102%;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">thirty (30) days after the Company gives written notice to Executive of Executive&#x2019;s termination without Cause (&#x201c;Without Cause Notice Period&#x201d;); </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company may, at any time during the Without Cause Notice Period, relieve Executive from all or any of Executive&#x2019;s duties for all or part of the remainder of the Without Cause Notice Period and/or consider Executive&#x2019;s termination  effective as of any date within the Without Cause Notice Period, without any requirement to provide Executive with salary and benefits for the remainder of the Without Cause Notice Period beyond the Accrued Obligations as of the date of termination.  </font></div></div><div class="item-list-element-wrapper" style="margin-left:1.731%;text-indent:20.352%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:0.9514699447435102%;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">immediately after the Company gives written notice to Executive of a termination with Cause pursuant to Section 6.2(b)(i)-(vii). In the event of a termination for Cause, such notice shall specify the subsection(s) of the definition of Cause relied on to support the decision to terminate;</font></div></div><div class="item-list-element-wrapper" style="margin-left:1.731%;text-indent:20.352%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:0.9514699447435102%;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">immediately upon the Executive&#x2019;s death;</font></div></div><div class="item-list-element-wrapper" style="margin-left:1.731%;text-indent:20.352%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:0.9514699447435102%;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ten (10) days after the Company gives written notice to Executive of Executive&#x2019;s termination on account of Executive&#x2019;s Disability, unless the Company specifies a later date, in which case, termination shall be effective as of such later date, provided that Executive has not returned to the full time performance of Executive&#x2019;s duties prior to such date;</font></div></div><div class="item-list-element-wrapper" style="margin-left:1.731%;text-indent:20.352%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:0.9514699447435102%;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">immediately upon Executive&#x2019;s full satisfaction of the requirements of Section 6.1(i) for a resignation for Good Reason; and</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.49in;min-height:1.18in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">8</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.49in;z-index:2;min-height:1.18in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:1.731%;text-indent:20.352%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:0.9514699447435102%;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">thirty (30) days after Executive gives written notice to the Company of Executive&#x2019;s resignation without Good Reason (&#x201c;Resignation Notice Period&#x201d;); </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company may, at any time during the Resignation Notice Period, relieve Executive from all or any of Executive&#x2019;s duties for all or part of the remainder of the Resignation Notice Period and/or consider Executive&#x2019;s resignation effective as of any date within the Resignation Notice Period, without any requirement to provide Executive with salary and benefits for the remainder of the Resignation Notice Period beyond the Accrued Obligations as of the date of termination.  Any acceleration by the Company of the termination date pursuant to this Section 6.5(f) shall not result in a termination by the Company for purposes of this Agreement.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">6.6</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Resignation of All Other Positions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. To the extent applicable, Executive shall be deemed to have resigned from all officer and board member positions that Executive holds with the Company and any of its subsidiaries and affiliates upon the termination of Executive&#x2019;s employment for any reason.  Executive shall execute any documents in reasonable form as may be requested to confirm or effectuate any such resignations.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">6.7</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Litigation and Regulatory Cooperation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  During Executive&#x2019;s employment, Executive shall cooperate fully with the Company in (i) the defense or prosecution of any claims or actions now in existence or which may be brought in the future against or on behalf of the Company, and (ii) the investigation, whether internal or external, of any matters about which the Company believes Executive may have knowledge or information.  Executive&#x2019;s full cooperation in connection with such claims, actions or investigations shall include, but not be limited to, being available to meet with counsel upon reasonable notice to answer questions or to prepare for discovery or trial and to act as a witness on behalf of the Company at mutually convenient times.  During Executive&#x2019;s employment, Executive also shall cooperate fully with the Company in connection with any investigation or review of any federal, state or local regulatory authority as any such investigation or review relates to events or occurrences that transpired while Executive was employed by the Company.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">6.8</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cooperation After Termination of Employment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Following termination of Executive&#x2019;s employment for any reason, Executive shall cooperate with the Company and its parent companies or affiliates in all matters relating to the winding up of Executive&#x2019;s pending work including, but not limited to, any litigation in which the Company (or its parent companies or affiliates) is involved, and the orderly transfer of any such pending work to such other employees as may be designated by the Company. The Company will reimburse Executive for all reasonable expenses  incurred in complying with this Section 6.6, in accordance with Company expense reimbursement policies. </font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">6.9</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Application of Section 409A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  It is intended that all of the severance payments payable under this Agreement satisfy, to the greatest extent possible, the exemptions from the application of Section 409A of the Code and the regulations and other guidance thereunder and any state law of similar effect (collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Section 409A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) provided under Treasury Regulations Sections 1.409A-1(b)(4) and 1.409A-1(b)(9), and this Agreement will be construed in a manner that complies with Section 409A.  If not so exempt, this Agreement (and any definitions hereunder) will be construed in a manner that complies with Section 409A and incorporates by reference all required definitions and payment terms.  No severance payments will be made under this Agreement unless Executive&#x2019;s termination of employment constitutes a &#x201c;separation from service&#x201d; (as defined under Treasury Regulation Section 1.409A-1(h)).  For purposes of Section 409A (including, without limitation, for purposes of Treasury Regulations Section 1.409A-2(b)(2)(iii)), Executive&#x2019;s right to </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.49in;min-height:1.18in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">9</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.49in;z-index:2;min-height:1.18in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">receive any installment payments under this Agreement (whether severance payments or otherwise) shall be treated as a right to receive a series of separate payments and, accordingly, each installment payment hereunder shall at all times be considered a separate and distinct payment.  To the extent that any severance payments are deferred compensation under Section 409A, and are not otherwise exempt from the application of Section 409A, then, if the period during which Executive may consider and sign the Release spans two calendar years, the severance payments will not begin until the second calendar year. If the Company determines that the severance benefits provided under this Agreement constitutes &#x201c;deferred compensation&#x201d; under Section 409A and if Executive is a &#x201c;specified employee&#x201d; of the Company, as such term is defined in Section 409A(a)(2)(B)(i) of the Code at the time of Executive&#x2019;s Separation from Service, then, solely to the extent necessary to avoid the incurrence of the adverse personal tax consequences under Section 409A, the timing of the Severance will be delayed as follows: on the earlier to occur of (a) the date that is six months and one day after Executive&#x2019;s Separation from Service, and (b) the date of Executive&#x2019;s death (such earlier date, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Delayed Initial Payment Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), the Company will (i) pay to Executive a lump sum amount equal to the sum of the severance benefits that Executive would otherwise have received through the Delayed Initial Payment Date if the commencement of the payment of the severance benefits had not been delayed pursuant to this Section 6.7 and (ii) commence paying the balance of the severance benefits in accordance with the applicable payment schedule set forth in Section 6.1. No interest shall be due on any amounts deferred pursuant to this Section 6.7.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">6.10</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Parachute Payments</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Notwithstanding any provision of this Agreement to the contrary, if any payment or benefit that Executive would receive from the Company pursuant to this Agreement or otherwise (each a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) would: (i) constitute a &#x201c;parachute payment&#x201d; within the meaning of Section 280G of the Code; and (ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Excise Tax</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), then such Payment will be equal to the Reduced Amount (defined below). The &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Reduced Amount</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; will be either: (l) the largest portion of the Payment that would result in no portion of the Payment (after reduction) being subject to the Excise Tax; or (2) the entire Payment, whichever amount after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate, net of the maximum reduction in federal income taxes which could be obtained from a deduction of such state and local taxes), results in Executive&#x2019;s receipt, on an after-tax basis, of the greatest amount of the Payment. If a reduction in the Payment is to be made so that the Payment equals the Reduced Amount, (x) the Payment will be paid only to the extent permitted under the Reduced Amount alternative, and Executive will have no rights to any additional payments and/or benefits constituting the Payment, and (y) reduction in payments and/or benefits will occur in the following order: (A) reduction of cash payments; (B) cancellation of accelerated vesting of equity awards other than stock options; (C) cancellation of accelerated vesting of stock options; and (D) reduction of other benefits paid to Executive. In the event that acceleration of vesting of equity award compensation is to be reduced, such acceleration of vesting will be cancelled in the reverse order of the date of grant of the Executive&#x2019;s equity awards. In no event will the Company or any stockholder be liable to Executive for any amounts not paid as a result of the operation of this Section 6.8. The professional firm engaged by the Company to make the foregoing calculations as of the day prior to the closing will perform the foregoing calculations. The Company will bear all expenses with respect to the determinations by such firm required to be made hereunder. Any good faith determinations of the firm made hereunder will be final, binding and conclusive upon the Company and Executive. </font></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.57143775513484%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">7.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General Provisions.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.49in;min-height:1.18in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">10</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.49in;z-index:2;min-height:1.18in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">7.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recoupment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Executive shall be required to repay any incentive pay received if, and to the extent that, the Compensation Committee of the Board or the Board determines, in its sole discretion, that repayment is due on account of a restatement of the Company&#x2019;s financial statements or otherwise pursuant to any clawback or compensation recoupment policy as may be in effect or amended from time to time) (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recoupment Policy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).  If the Committee or the Board seeks to recover payment of incentive pay as a result of a restatement of the Company&#x2019;s financial statements or otherwise under the Recoupment Policy, Executive shall pay to the Company, as applicable, (A) all or a portion (as determined by the Committee or the Board in its sole discretion) of the amount by which the payment received by Executive exceeds the amount that would have been paid to Executive based on the restated financial statements, or (B) the amount (as determined by the Committee or the Board in its sole discretion) to be repaid pursuant to the Recoupment Policy.  Nothing in this Section 7.1 shall preclude the Company (or any other person) from taking any other action.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">7.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notices</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Any notices required hereunder to be in writing shall be deemed effectively given: (a) upon personal delivery to the party to be notified; (b) when sent, if sent by electronic mail, telex or confirmed facsimile during normal business hours of the recipient, and if not, then on the next business day; (c) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one (1) day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt.  All communications shall be sent to the Company at its primary office location, ATTN: CEO, and to Executive at Executive&#x2019;s address as listed on the Company payroll or Executive&#x2019;s company-provided email address, or at such other address as the Company or the Executive may designate by ten (10) days&#x2019; advance written notice to the other.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">7.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Severability</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability will not affect any other provision or any other jurisdiction, but this Agreement will be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provisions had never been contained herein.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">7.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Waiver</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  If either party should waive any breach of any provisions of this Agreement, Executive or it shall not thereby be deemed to have waived any preceding or succeeding breach of the same or any other provision of this Agreement.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">7.5</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Complete Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This Agreement, along with the Confidential Information  Agreement, constitutes the entire agreement between Executive and the Company with regard to the subject matter hereof.  This Agreement is the complete, final, and exclusive embodiment of their agreement with regard to this subject matter and supersedes any prior oral discussions or written communications and agreements.  This Agreement is entered into without reliance on any promise or representation other than those expressly contained herein, and it cannot be modified or amended except in writing signed by Executive and an authorized officer of the Company.  The parties have entered into a separate Confidential Information Agreement and have entered or may enter into other agreements governing Executive&#x2019;s equity grant(s).  Any such separate agreements govern other aspects of the relationship between the parties, have or may have provisions that survive termination of the Executive&#x2019;s employment under this Agreement, may be amended or superseded </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.49in;min-height:1.18in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">11</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.49in;z-index:2;min-height:1.18in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">by the parties without regard to this Agreement and are enforceable according to their terms without regard to the enforcement provision of this Agreement.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">7.6</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Counterparts</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This Agreement may be executed in separate counterparts, any one of which need not contain signatures of more than one party, but all of which taken together will constitute one and the same Agreement.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">7.7</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Headings</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The headings of the sections hereof are inserted for convenience only and shall not be deemed to constitute a part hereof nor to affect the meaning thereof.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">7.8</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Successors and Assigns</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company shall assign this Agreement and its rights and obligations hereunder in whole, but not in part, to any company or other entity with or into which the Company may hereafter merge or consolidate or to which the Company may transfer all or substantially all of its assets, if in any such case said company or other entity shall by operation of law or expressly in writing assume all obligations of the Company hereunder as fully as if it had been originally made a party hereto, but may not otherwise assign this Agreement or its rights and obligations hereunder. The Executive may not assign or transfer this Agreement or any rights or obligations hereunder, other than to Executive&#x2019;s estate upon Executive&#x2019;s death.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">7.9</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Choice of Law</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. All questions concerning the construction, validity and interpretation of this Agreement will be governed by the laws of the State of New York.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">7.10</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Resolution of Disputes</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. To ensure the rapid and economical resolution of disputes that may arise in connection with Executive&#x2019;s employment with the Company, Executive and the Company agree that any and all disputes, claims, or causes of action, in law or equity, including but not limited to statutory claims, arising from or relating to the enforcement, breach, performance, or interpretation of this Agreement, Executive&#x2019;s employment with the Company, or the termination of Executive&#x2019;s employment, shall be resolved pursuant to the Federal Arbitration Act, 9 U.S.C. &#167;1-16 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">FAA</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), to the fullest extent permitted by law, by final, binding and confidential arbitration conducted by Judicial Arbitration and Mediation Services, Inc. or its successor (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">JAMS</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), in the State of New York or as otherwise mutually agreed upon, under JAMS&#x2019; then-applicable rules and procedures for employment disputes before a single arbitrator (available upon request and also currently available at: </font><font><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">https://www.jamsadr.com/rules-employment-arbitration/</font></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">). </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Executive acknowledges that by agreeing to this arbitration procedure, both Executive and the Company waive the right to resolve any such dispute through a trial by jury or judge or administrative proceeding.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, all claims, disputes, or causes of action under this Section, whether by Executive or the Company, must be brought in an individual capacity, and shall not be brought as a plaintiff (or claimant) or class member in any purported class or representative proceeding, nor joined or consolidated with the claims of any other person or entity.  The arbitrator may not consolidate the claims of more than one person or entity, and may not preside over any form of representative or class proceeding.  To the extent that the preceding sentences regarding class claims or proceedings are found to violate applicable law or are otherwise found unenforceable, any claim(s) alleged or brought on behalf of a class shall proceed in a court of law rather than by arbitration.  This paragraph shall not apply to sexual assault disputes and sexual harassment disputes as defined in the FAA, or any action or claim that cannot be subject to mandatory arbitration as a matter of law, to the extent such claims are not permitted by applicable law(s) to be submitted to mandatory arbitration and the applicable law(s) are not preempted by the Federal Arbitration Act or otherwise invalid (collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Excluded Claims</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).  In the event Executive intends to bring multiple claims, including one of the Excluded Claims listed above, the Excluded Claims may be filed with a court, while any other </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.49in;min-height:1.18in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">12</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.49in;z-index:2;min-height:1.18in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">claims will remain subject to mandatory arbitration.  Executive will have the right to be represented by legal counsel at any arbitration proceeding.  Questions of whether a claim is subject to arbitration under this Agreement shall be decided by the arbitrator.  Likewise, procedural questions which grow out of the dispute and bear on the final disposition are also matters for the arbitrator.  The arbitrator shall:  (a) have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be permitted by law; and (b) issue a written statement signed by the arbitrator regarding the disposition of each claim and the relief, if any, awarded to each claim, the reasons for the award, and the arbitrator&#x2019;s essential findings and conclusions on which the award is based.  The arbitrator shall be authorized to award all relief that Executive or the Company would be entitled to seek in a court of law and any such awards may be entered into and enforced as judgments in federal and state courts of any competent jurisdiction.  The Company shall pay all JAMS arbitration fees in excess of the administrative fees that Executive would be required to pay if the dispute were decided in a court of law.  Except as modified in the Confidential Information Agreement, each party is responsible for its own attorneys&#x2019; fees.  Nothing in this Agreement is intended to prevent either Executive or the Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration.  Any awards or orders in such arbitrations may be entered and enforced as judgments in the federal and state courts of any competent jurisdiction.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">7.11</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In Witness Whereof</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the parties have executed this Executive Employment Agreement on the day and year first written above.</font></div></div><p style="text-indent:36.8%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:50.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:10%;box-sizing:content-box;"></td>
     <td style="width:14%;box-sizing:content-box;"></td>
     <td style="width:76%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
     <td colspan="3" style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Mind Medicine (MindMed), Inc.</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Robert Barrow</font></p></td>
    </tr>
    <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Name:</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:right;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Robert Barrow</font></p></td>
    </tr>
    <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Title:</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:right;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Executive Officer</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:right;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
     <td colspan="3" style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Executive</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:right;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;text-align:right;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Matthew Wiley</font></p></td>
    </tr>
    <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
     <td colspan="3" style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Matthew Wiley</font></p></td>
    </tr>
   </table><p style="text-indent:36.8%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.49in;min-height:1.18in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">13</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.49in;z-index:2;min-height:1.18in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employee Confidential Information and  Inventions Assignment Agreement</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.49in;min-height:1.18in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">14</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> MACROBUTTON DocID \\4135-8644-9233  v2</font><font style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="margin-left:0.933%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">MIND MEDICINE, INC.</font></p><p style="margin-left:0.933%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EMPLOYEE CONFIDENTIAL INFORMATION AND INVENTIONS ASSIGNMENT AGREEMENT</font></p><p style="margin-left:0.933%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In consideration of my employment or continued employment by </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Mind Medicine, Inc.</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (&#x201c;</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">E</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">mployer</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;)</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and its subsidiaries, parents, affiliates, successors and assigns (together with Employer, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), the compensation paid to me now and during my employment with Company, and Company&#x2019;s agreement to provide me with access to its Confidential Information (as defined below), I enter into this Employee Confidential Information and Inventions Assignment Agreement with Employer (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). Accordingly, in consideration of the mutual promises and covenants contained herein, Employer (on behalf of itself and Company) and I agree as follows:</font></p><p style="margin-left:0.933%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.933%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.4in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Employee Confidential Information and Inventions Assignment Agreement</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Page </font><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">1</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:0.935%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.6319588149194972%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Confidential Information Protections</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recognition of Company&#x2019;s Rights; Nondisclosure</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  My employment by Company creates a relationship of confidence and trust with respect to Confidential Information (as defined below) and Company has a protectable interest in the Confidential Information. At all times during and after my employment, I will hold in confidence and will not disclose, use, lecture upon, or publish any Confidential Information, except as required in connection with my work for Company, or as approved by an officer of Company.  I will obtain written approval by an officer of Company before I lecture on or submit for publication any material (written, oral, or otherwise) that discloses and/or incorporates any Confidential Information.  I will take all reasonable precautions to prevent the disclosure of Confidential Information.  Notwithstanding the foregoing, pursuant to 18 U.S.C. Section 1833(b), I will not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that: (1) is made in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney, and solely for the purpose of reporting or investigating a suspected violation of law; or (2) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.  I agree that Company information or documentation to which I have access during my employment, regardless of whether it contains Confidential Information, is the property of Company and cannot be downloaded or retained for my personal use or for any use that is outside the scope of my duties for Company. </font></div></div><div class="item-list-element-wrapper" style="text-indent:4%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:5.067%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Confidential Information</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Confidential Information</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any and all confidential knowledge or data of Company, and includes any confidential knowledge or data that Company has received, or receives in the future, from third parties that Company has agreed to treat as confidential and to use for only certain limited purposes. By way of illustration but not limitation, Confidential Information includes (a) trade secrets, inventions, ideas, processes, formulas, software in source or object code, data, technology, know-how, designs and techniques, and any other work product of any nature, and all Intellectual Property Rights (defined below) in all of the foregoing (collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Inventions</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), including all Company Inventions (defined in Section 2.1); (b) information regarding research, development, new products, business and operational plans, budgets, unpublished financial statements and projections, costs, margins, discounts, credit terms, pricing, quoting procedures, future plans and strategies, capital-raising plans, internal services, suppliers and supplier information; (c) information about customers and potential customers of Company, including customer lists, names, representatives, their needs or desires with respect to the types of products or services offered by Company, and other non-public information; (d) information about Company&#x2019;s business partners and their services, including names, representatives, proposals, bids, contracts, and the products and services they provide; (e) information regarding personnel, employee lists, compensation, and employee skills; and (f) any other non-public information that a competitor of Company could use to Company&#x2019;s competitive disadvantage. However, Company agrees that I am free to use information that I knew prior to my employment with Company or that is, at the time of use, generally known in the trade or industry through no breach of this Agreement by me.  Company further agrees that this Agreement does not limit my right to discuss my employment or discuss or disclose information about unlawful acts in the workplace, such as harassment or discrimination or any other conduct that I have reason to believe is unlawful, or report possible violations of law or regulation with any federal, state or local government agency, or to discuss the terms and conditions of my employment with others to the extent expressly permitted by Section 7 of the National Labor Relations Act, or to the extent that such disclosure is protected under the applicable provisions of law or regulation, including but not limited to &#x201c;whistleblower&#x201d; statutes or other similar provisions that protect such disclosure, to the extent any such rights are not permitted by applicable law to be the subject of nondisclosure obligations.</font></div></div><div class="item-list-element-wrapper" style="text-indent:4%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:5.067%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Term of Nondisclosure Restrictions</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  I will only use or disclose Confidential Information as provided in this Section 1 and I agree that the restrictions in Section 1.1 are intended to continue indefinitely, even after my employment by Company ends. However, if a time limitation on my obligation not to use or disclose Confidential Information is required under applicable law, and the Agreement or its restriction(s) cannot otherwise be enforced, Company and I agree that the two year period after the date my employment ends will be the time limitation relevant to the contested restriction; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided, however</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that my obligation not to disclose or use trade secrets that are protected without time limitation under applicable law shall continue indefinitely.</font></div></div><div class="item-list-element-wrapper" style="text-indent:4%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:4%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:5.067%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Improper Use of Information of Prior Employers and Others</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  During my employment by Company, I will not improperly use or disclose confidential information or trade secrets, if any, of any former employer or any other person to whom I have an obligation of confidentiality, and I will not bring onto Company&#x2019;s premises any unpublished </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Employee Confidential Information and Inventions Assignment Agreement</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Page </font><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">2</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:4%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">documents or property belonging to a former employer or any other person to whom I have an obligation of confidentiality unless that former employer or person has consented in writing.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Assignments of Inventions</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="text-indent:4%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:5.067%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">2.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Definitions</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The term (a) </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Intellectual Property Rights</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> means all past, present and future rights of the following types, which may exist or be created under the laws of any jurisdiction in the world: trade secrets, Copyrights, trademark and trade name rights, mask work rights, patents and industrial property, and all proprietary rights in technology or works of authorship (including, in each case, any application for any such rights, all rights to priority, and any rights to apply for any such rights, as well as all rights to pursue remedies for infringement or violation of any such rights); (b) &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Copyright</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the exclusive legal right to reproduce, perform, display, distribute and make derivative works of a work of authorship (for example, a literary, musical, or artistic work) recognized by the laws of any jurisdiction in the world; (c) &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Moral Rights</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means all paternity, integrity, disclosure, withdrawal, special and similar rights recognized by the laws of any jurisdiction in the world; and (d) &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Company Inventions</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any and all Inventions (and all Intellectual Property Rights related to Inventions) that are made, conceived, developed, prepared, produced, authored, edited, amended, reduced to practice, or learned or set out in any tangible medium of expression or otherwise created, in whole or in part, by me, either alone or with others, during my employment by Company, and all printed, physical, and electronic copies, and other tangible embodiments of Inventions.</font></div></div><div class="item-list-element-wrapper" style="text-indent:4%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:5.067%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">2.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Non-Assignable Inventions</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. I recognize that this Agreement will not be deemed to require assignment of any Invention that I develop entirely on my own time without using Company&#x2019;s equipment, supplies, facilities or trade secrets, or Confidential Information, except for Inventions that either (i) relate to Company&#x2019;s actual or anticipated business, research or development, or (ii) result from or are connected with any work performed by me for Company (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Nonassignable Inventions</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).</font></div></div><div class="item-list-element-wrapper" style="text-indent:4%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:5.067%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">2.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior Inventions</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On the signature page to this Agreement is a</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">list describing any Inventions that (i) are owned by me or in which I have an interest and that were made or acquired by me prior to my date of first employment by Company, and (ii) may relate to Company&#x2019;s business or actual or demonstrably anticipated research or development, and (iii) are not to be assigned to Company (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Prior Inventions</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).  If no such list is attached, I represent and warrant that no Inventions that would be classified as Prior Inventions exist as of the date of this Agreement.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I agree that if I use any Prior Inventions and/or Nonassignable Inventions in the scope of my employment, or if I include any Prior Inventions and/or Nonassignable Inventions in any product or service of Company, or if my rights in any Prior Inventions and/or any Nonassignable Inventions may block or interfere with, or may otherwise be required for, the exercise by Company of any rights assigned to Company under this Agreement (each, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License Event</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), (i) I will immediately notify Company in writing, and (ii) unless Company and I agree otherwise in writing, I hereby grant to Company a non-exclusive, perpetual, transferable, fully-paid, royalty-free, irrevocable, worldwide license, with rights to sublicense through multiple levels of sublicensees, to reproduce, make derivative works of, distribute, publicly perform, and publicly display in any form or medium (whether now known or later developed), make, have made, use, sell, import, offer for sale, and exercise any and all present or future rights in, such Prior Inventions and/or Nonassignable Inventions.  To the extent that any third parties have any rights in or to any Prior Inventions or any Nonassignable Inventions, I represent and warrant that such third party or parties have validly and irrevocably granted to me the right to grant the license stated above.  For purposes of this paragraph, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Prior Inventions</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; includes any Inventions that would be classified as Prior Inventions, whether or not they are listed on the signature page to this Agreement.</font></div></div><div class="item-list-element-wrapper" style="text-indent:4%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:5.067%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">2.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Assignment of Company Inventions</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  I hereby assign to Employer all my right, title, and interest in and to any and all Company Inventions other than Nonassignable Inventions and agree that such assignment includes an assignment of all Moral Rights.  To the extent such Moral Rights cannot be assigned to Employer and to the extent the following is allowed by the laws in any country where Moral Rights exist, I hereby unconditionally and irrevocably waive the enforcement of such Moral Rights, and all claims and causes of action of any kind against Employer or related to Employer&#x2019;s customers, with respect to such rights.  I further agree that neither my successors-in-interest nor legal heirs retain any Moral Rights in any Company Inventions.  Nothing contained in this Agreement may be construed to reduce or </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Employee Confidential Information and Inventions Assignment Agreement</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Page </font><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">3</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">limit Company&#x2019;s rights, title, or interest in any Company Inventions so as to be less in any respect than that Company would have had in the absence of this Agreement.</font></div></div><div class="item-list-element-wrapper" style="text-indent:4%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:5.067%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">2.5</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Obligation to Keep Company Informed</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  During my employment by Company, I will promptly and fully disclose to Company in writing all Inventions that I author, conceive, or reduce to practice, either alone or jointly with others.  At the time of each disclosure, I will advise Company in writing of any Inventions that I believe constitute Nonassignable Inventions; and I will at that time provide to Company in writing all evidence necessary to substantiate my belief. Subject to Section 2.3(b), Company agrees to keep in confidence, not use for any purpose, and not disclose to third parties without my consent, any confidential information relating to Nonassignable Inventions that I disclose in writing to Company.</font></div></div><div class="item-list-element-wrapper" style="text-indent:4%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:5.067%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">2.6</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Government or Third Party</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  I agree that, as directed by Company, I will assign to a third party, including without limitation the United States, all my right, title, and interest in and to any particular Company Invention.</font></div></div><div class="item-list-element-wrapper" style="text-indent:4%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:5.067%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">2.7</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ownership of Work Product</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. I acknowledge that all original works of authorship that are made by me (solely or jointly with others) within the scope of my employment and that are protectable by Copyright are &#x201c;works made for hire,&#x201d; pursuant to United States Copyright Act (17 U.S.C., Section 101).</font></div></div><div class="item-list-element-wrapper" style="text-indent:4%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:5.067%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">2.8</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Enforcement of Intellectual Property Rights and Assistance</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  I will assist Company, in every way Company requests, including signing, verifying and delivering any documents and performing any other acts, to obtain and enforce United States and foreign Intellectual Property Rights and Moral Rights relating to Company Inventions in any jurisdictions in the world.  My obligation to assist Company with respect to Intellectual Property Rights relating to Company Inventions will continue beyond the termination of my employment, but Company will compensate me at a reasonable rate after such termination for the time I actually spend on such assistance.  If Company is unable for any reason, after reasonable effort, to secure my signature on any document needed in connection with the actions specified in this paragraph, I hereby irrevocably designate and appoint Employer and its duly authorized officers and agents as my agent and attorney in fact, which appointment is coupled with an interest, to act for and on my behalf to execute, verify and file any such documents and to do all other lawfully permitted acts to further the purposes of this Agreement with the same legal force and effect as if executed by me.  I hereby waive and quitclaim to Company any and all claims, of any nature whatsoever, which I now or may hereafter have for infringement of any Intellectual Property Rights assigned to Employer under this Agreement.</font></div></div><div class="item-list-element-wrapper" style="text-indent:4%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:4%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:5.067%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">2.9</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Incorporation of Software Code</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  I agree not to incorporate into any Inventions, including any Company software, or otherwise deliver to Company, any software code licensed under the GNU General Public License, Lesser General Public License, or any other license that, by its terms, requires or conditions the use or distribution of such code on the disclosure, licensing, or distribution of any source code owned or licensed by Company, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">except</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in strict compliance with Company&#x2019;s policies regarding the use of such software or as directed by Company.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Records</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  I agree to keep and maintain adequate and current records (in the form of notes, sketches, drawings and in any other form that is required by Company) of all Confidential Information developed by me and all Company Inventions made by me during the period of my employment at Company, which records will be available to and remain the sole property of Employer at all times.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Duty of Loyalty During Employment</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  During my employment by Company, I will not, without Company&#x2019;s written consent, directly or indirectly engage in any employment or business activity that is directly or indirectly competitive with, or would otherwise conflict with, my employment by Company.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Solicitation of Employees, Consultants, Contractors, or Customers.  </font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">agree that during the period of my employment and for the one year period after the date my employment ends for any reason, including but not limited to voluntary termination by me or involuntary termination by Company, I will not, as an officer, director, employee, consultant, owner, partner, or in any other capacity, either directly or through others, except on behalf of Company:</font></div></div><div class="item-list-element-wrapper" style="text-indent:4%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:5.067%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">5.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">solicit, induce, encourage, or participate in soliciting, inducing or encouraging any person known to me to be an employee, consultant, or independent contractor of Company to terminate his, her or its relationship with Company, even if I did not initiate the discussion or seek out the contact;</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Employee Confidential Information and Inventions Assignment Agreement</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Page </font><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">4</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="text-indent:4%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:5.067%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">5.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">solicit, induce, encourage, or participate in soliciting, inducing, or encouraging any person known to me to be an employee, consultant, or independent contractor of Company to terminate his, her or its relationship with Company to render services to me or any other person or entity that researches, develops, markets, sells, performs or provides or is preparing to develop, market, sell, perform or provide Conflicting Services (as defined below);</font></div></div><div class="item-list-element-wrapper" style="text-indent:4%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:5.067%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">5.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">hire, employ, or engage in a business venture to research, develop, market, sell, perform or provide Conflicting Services (as defined below) as partners or owners or other joint capacity any person then employed by Company or who has left the employment of Company within the preceding three months, or attempt to hire, employ, or engage in a business venture to research, develop, market, sell, perform or provide Conflicting Services as partners or owners or other joint capacity any person then employed by Company or who has left the employment of Company within the preceding three months;</font></div></div><div class="item-list-element-wrapper" style="text-indent:4%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:5.067%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">5.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">solicit, induce or attempt to induce any Customer (as defined below), to terminate, diminish, or materially alter in a manner harmful to Company its relationship with Company; </font></div></div><div class="item-list-element-wrapper" style="text-indent:4%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:5.067%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">5.5</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">solicit or assist in the solicitation of any Customer to induce or attempt to induce such Customer to purchase or contract for any Conflicting Services; or</font></div></div><div class="item-list-element-wrapper" style="text-indent:4%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:5.067%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">5.6</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">perform, provide or attempt to perform or provide any Conflicting Services for a Customer.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The parties agree that for purposes of this Agreement, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Customer</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is any person or entity who or which, at any time during the one year period prior to my contact with such person or entity as described in Sections 5.4, 5.5 or 5.6 above if such contact occurs during my employment or, if such contact occurs following the termination of my employment, during the one year period prior to the date my employment with Company ends: (i) contracted for, was billed for, or received from Company any product, service or process with which I worked directly or indirectly during my employment by Company or about which I acquired Confidential Information; or (ii) was in contact with me or in contact with any other employee, owner, or agent of Company, of which contact I was or should have been aware, concerning the sale or purchase of, or contract for, any product, service or process with which I worked directly or indirectly during my employment with Company or about which I acquired Confidential Information; or (iii) was solicited by Company in an effort in which I was involved or of which I was aware.</font></p><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Non-Compete Provision</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="text-indent:4%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:5.067%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">6.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I agree that for the one year period after the date my employment ends for any reason, including but not limited to voluntary termination by me or involuntary termination by Company, I will not, directly or indirectly, as an officer, director, employee, consultant, owner, partner, or in any other capacity solicit, perform, or provide, or attempt to perform or provide Conflicting Services (defined below) anywhere in the Restricted Territory (defined below), nor will I assist another person to solicit, perform or provide or attempt to perform or provide Conflicting Services anywhere in the Restricted Territory.</font></div></div><div class="item-list-element-wrapper" style="text-indent:4%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:5.067%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">6.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The parties agree that, for purposes of this Agreement, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Conflicting Service</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any product, service, or process or the research and development thereof, of any person or organization other than Company that directly competes with a product, service, or process, including the research and development thereof, of Company with which I worked directly or indirectly during my employment by Company or about which I acquired Confidential Information during my employment by Company.</font></div></div><div class="item-list-element-wrapper" style="text-indent:4%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:5.067%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">6.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The parties agree that, for purposes of this Agreement, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Territory</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means (i) all counties in the state in which I primarily perform services for Company; (ii) all other states of the United States of America in which Company, with my involvement in some capacity, including, without limitation, my having knowledge of Confidential Information related thereto, provided goods or services, had customers, or otherwise conducted business at any time during the two-year period prior to the date of the termination of my relationship with Company; and (iii) any other countries from which Company provided goods or services, had customers, or otherwise conducted business, with my involvement in some capacity, including, without limitation, my having knowledge of Confidential Information related thereto, at any time during the two-year period prior to the date of the termination of my relationship with Company.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">7.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reasonableness of Restrictions</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  I have read this entire Agreement and understand it. I acknowledge that Section 6 protects Company&#x2019;s legitimate business interests, including its interests in Company&#x2019;s trade secrets and </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Employee Confidential Information and Inventions Assignment Agreement</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Page </font><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">5</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Confidential Information, relationships with customers or recent past customers, and its customer goodwill. I acknowledge that Section 6 is reasonably necessary to protect these legitimate business interests as defined by Wis. Stat. &#167; 103.465. I acknowledge that (a) I have the right to consult with counsel prior to signing this Agreement, (b) I will derive significant value from Company&#x2019;s agreement to provide me with Company Confidential Information to enable me to optimize the performance of my duties to Company, and (c) that my fulfillment of the obligations contained in this Agreement, including, but not limited to, my obligation neither to disclose nor to use Company Confidential Information other than for Company&#x2019;s exclusive benefit and my obligations not to compete and not to solicit are necessary to protect Company Confidential Information and, consequently, to preserve the value and goodwill of Company.  I agree that (i) this Agreement does not prevent me from earning a living or pursuing my career, and (ii) the restrictions contained in this Agreement are reasonable, proper, and necessitated by Company&#x2019;s legitimate business interests.  I represent and agree that I am entering into this Agreement freely, with knowledge of its contents and the intent to be bound by its terms.  If a court finds this Agreement, or any of its restrictions, are ambiguous, unenforceable, or invalid, Company and I agree that the court will read the Agreement as a whole and interpret such restriction(s) to be enforceable and valid to the maximum extent allowed by law.  If the court declines to enforce this Agreement in the manner provided in this Section and/or Section 13.2, Company and I agree that this Agreement will be automatically modified to provide Company with the maximum protection of its business interests allowed by law, and I agree to be bound by this Agreement as modified.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">8.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Conflicting Agreement or Obligation</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  I represent that my performance of all the terms of this Agreement and as an employee of Company does not and will not breach any agreement to keep in confidence information acquired by me in confidence or in trust prior to my employment by Company.  I have not entered into, and I agree I will not enter into, any written or oral agreement in conflict with this Agreement.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">9.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Return of Company Property</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  When I cease to be employed by Company, I will deliver to Company any and all materials, together with all copies thereof, containing or disclosing any Company Inventions, or Confidential Information.  I will not copy, delete, or alter any information contained upon my Company computer or Company equipment before I return it to Company.  In addition, if I have used any personal computer, server, or e-mail system to receive, store, review, prepare or transmit any Company information, including but not limited to, Confidential Information, I agree to provide Company with a computer-useable copy of all such information and then permanently delete such information from those systems; and I agree to provide Company access to my system as reasonably requested to verify that the necessary copying and/or deletion is completed.  I further agree that any property situated on Company&#x2019;s premises and owned by Company, including disks and other storage media, filing cabinets or other work areas, is subject to inspection by Company&#x2019;s personnel at any time during my employment, with or without notice.  Prior to leaving, I hereby agree to: provide Company any and all information needed to access any Company property or information returned or required to be returned pursuant to this paragraph, including without limitation any login, password, and account information; cooperate with Company in attending an exit interview; and complete and sign Company&#x2019;s termination statement if required to do so by Company.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">10.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Legal and Equitable Remedies</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  I agree that (a) it may be impossible to assess the damages caused by my violation of this Agreement or any of its terms, (b) any threatened or actual violation of this Agreement or any of its terms will constitute immediate and irreparable injury to Company, and (c) Company will have the right to enforce this Agreement by injunction, specific performance or other equitable relief, without bond and without prejudice to any other rights and remedies that Company may have for a breach or threatened breach of this Agreement.  I agree that if Company is successful in whole or in part in any legal or equitable action against me under this Agreement, Company will be entitled to payment of all costs, including reasonable attorney&#x2019;s fees, from me.  If Company enforces this Agreement through a court order, I agree that the restrictions of Sections 5 and 6 will remain in effect for a period of 12 months from the effective date of the order enforcing the Agreement.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">11.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notices</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any notices required or permitted under this Agreement will be given to Company at its headquarters location at the time notice is given, labeled &#x201c;Attention Chief Executive Officer,&#x201d; and to me at my address as listed on Company payroll, or at such other address as Company or I may designate by written notice to the other.  Notice will be effective upon receipt or refusal of delivery.  If delivered by certified or registered mail, notice will be considered to have been given five business days after it was mailed, as evidenced by the postmark.  If delivered by courier or express </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Employee Confidential Information and Inventions Assignment Agreement</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Page </font><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">6</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">mail service, notice will be considered to have been given on the delivery date reflected by the courier or express mail service receipt.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">12.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Publication of This Agreement to Subsequent Employer or Business Associates of Employee</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  If I am offered employment, or the opportunity to enter into any business venture as owner, partner, consultant or other capacity, while the restrictions in Sections 5 and/or 6 of this Agreement are in effect, I agree to inform my potential employer, partner, co-owner and/or others involved in managing the business I have an opportunity to be associated with, of my obligations under this Agreement and to provide such person or persons with a copy of this Agreement. I agree to inform Company of all employment and business ventures which I enter into while the restrictions described in Sections 5 and/or 6 of this Agreement are in effect and I authorize Company to provide copies of this Agreement to my employer, partner, co-owner and/or others involved in managing the business I have an opportunity to be associated with and to make such persons aware of my obligations under this Agreement.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">13.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General Provisions</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="text-indent:4%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:5.067%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">13.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Governing Law; Consent to Personal Jurisdiction</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  This Agreement will be governed by and construed according to the laws of the State of New York without regard to any conflict of laws principles that would require the application of the laws of a different jurisdiction.  I expressly consent to the personal jurisdiction and venue of the state and federal courts located in </font><font style="color:#222222;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NY</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for any lawsuit filed there against me by Company arising from or related to this Agreement.</font></div></div><div class="item-list-element-wrapper" style="text-indent:4%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:5.067%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">13.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Severability</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  If any portion of this Agreement is, for any reason, held to be invalid, illegal or unenforceable, such invalidity, illegality or unenforceability will not affect the other provisions of this Agreement, and this Agreement will be construed as if such provision had never been contained in this Agreement.  If any portion of this Agreement is, for any reason, held to be excessively broad as to duration, geographical scope, activity or subject, it will be construed by limiting and reducing it, so as to be enforceable to the extent allowed by the then applicable law.</font></div></div><div class="item-list-element-wrapper" style="text-indent:4%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:5.067%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">13.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Successors and Assigns</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  This Agreement is for my benefit and the benefit of Company and its and their successors, assigns, parent corporations, subsidiaries, affiliates, and purchasers, and will be binding upon my heirs, executors, administrators and other legal representatives.</font></div></div><div class="item-list-element-wrapper" style="text-indent:4%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:5.067%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">13.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Survival</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  This Agreement will survive the termination of my employment, regardless of the reason, and the assignment of this Agreement by Company to any successor in interest or other assignee.</font></div></div><div class="item-list-element-wrapper" style="text-indent:4%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:5.067%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">13.5</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employment At-Will</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  I understand and agree that nothing in this Agreement will change my at-will employment status or confer any right with respect to continuation of employment by Company, nor will it interfere in any way with my right or Company&#x2019;s right to terminate my employment at any time, with or without cause or advance notice.</font></div></div><div class="item-list-element-wrapper" style="text-indent:4%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:5.067%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">13.6</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Waiver</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  No waiver by Company of any breach of this Agreement will be a waiver of any preceding or succeeding breach.  No waiver by Company of any right under this Agreement will be construed as a waiver of any other right.  Company will not be required to give notice to enforce strict adherence to all terms of this Agreement.</font></div></div><div class="item-list-element-wrapper" style="text-indent:4%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:5.067%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">13.7</font><div style="width:100%;display:inline;" id="ole_link1"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Export</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  I agree not to export, reexport, or transfer, directly or indirectly, any U.S. technical data acquired from Company or any products utilizing such data, in violation of the United States export laws or regulations.</font></div></div><div class="item-list-element-wrapper" style="text-indent:4%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:5.067%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">13.8</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Counterparts</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  This Agreement may be executed in two or more counterparts, each of which will be deemed an original, but all of which together will constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or other applicable law) or other transmission method and any counterpart so delivered will be deemed to have been duly and validly delivered and be valid and effective for all purposes.</font></div></div><div class="item-list-element-wrapper" style="text-indent:4%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:5.067%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">13.9</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Advice of Counsel</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I ACKNOWLEDGE THAT, IN EXECUTING THIS AGREEMENT, I HAVE HAD THE OPPORTUNITY TO SEEK THE ADVICE OF INDEPENDENT LEGAL COUNSEL, AND I HAVE READ AND UNDERSTOOD ALL OF THE TERMS AND PROVISIONS OF THIS AGREEMENT.  THIS AGREEMENT WILL NOT BE CONSTRUED AGAINST ANY PARTY BY REASON OF THE DRAFTING OR PREPARATION OF THIS AGREEMENT.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Employee Confidential Information and Inventions Assignment Agreement</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Page </font><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">7</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="text-indent:4%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:4%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:5.067%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">13.10</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Entire Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The obligations in Sections 1 and 2 (except Section 2.2 with respect to a consulting relationship) of this Agreement will apply to any time during which I was previously engaged, or am in the future engaged, by Company as a consultant, employee or other service provider if no other agreement governs nondisclosure and assignment of inventions during such period.  This Agreement is the final, complete and exclusive agreement of the parties with respect to the subject matter of this Agreement and supersedes and merges all prior discussions between us, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, if, prior to execution of this Agreement, Company and I were parties to any agreement regarding the subject matter hereof, that agreement will be superseded by this Agreement prospectively only.  No modification of or amendment to this Agreement will be effective unless in writing and signed by the party to be charged.  Any subsequent change or changes in my duties, salary or compensation will not affect the validity or scope of this Agreement.</font></div></div><p style="margin-left:0.933%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Employee Confidential Information and Inventions Assignment Agreement</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Page </font><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">8</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="margin-left:0.933%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.933%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[Signatures to follow on next page]</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Employee Confidential Information and Inventions Assignment Agreement</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Page </font><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">9</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="margin-left:0.933%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Agreement will be effective as of the date signed by the Employee below.</font></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:47.86%;box-sizing:content-box;"></td>
     <td style="width:4.28%;box-sizing:content-box;"></td>
     <td style="width:47.86%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">EMPLOYER: Mind Medicine, Inc.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;text-indent:5.05pt;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="margin-left:0.933%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;text-indent:5.05pt;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="margin-left:0.933%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">EMPLOYEE:</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;text-indent:5.05pt;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="margin-left:0.933%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;text-indent:5.05pt;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="margin-left:0.933%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;text-indent:5.05pt;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="margin-left:0.933%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;text-indent:5.05pt;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="margin-left:0.933%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;text-indent:5.05pt;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="margin-left:0.933%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;text-indent:5.05pt;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="margin-left:0.933%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;text-indent:5.05pt;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="margin-left:0.933%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#222222;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">{{COMPANY_SIGNATURE}}</font></p></td>
     <td style="padding-top:0in;text-indent:5.05pt;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;"><p style="margin-left:0.933%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;text-indent:5.05pt;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="margin-left:0.933%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#222222;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">{{CANDIDATE_SIGNATURE}}</font></p></td>
    </tr>
    <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;text-indent:5.05pt;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="margin-left:0.933%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Signature)</font></p></td>
     <td style="padding-top:0in;text-indent:5.05pt;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="margin-left:0.933%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;text-indent:5.05pt;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="margin-left:0.933%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Signature)</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;text-indent:5.05pt;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="margin-left:0.933%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;text-indent:5.05pt;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="margin-left:0.933%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;text-indent:5.05pt;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="margin-left:0.933%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;text-indent:5.05pt;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="margin-left:0.933%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#222222;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Robert Barrow</font></p></td>
     <td style="padding-top:0in;text-indent:5.05pt;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;"><p style="margin-left:0.933%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;text-indent:5.05pt;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="margin-left:0.933%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#222222;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Mathew Wiley</font></p></td>
    </tr>
    <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;text-indent:5.05pt;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="margin-left:0.933%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Printed Name)</font></p></td>
     <td style="padding-top:0in;text-indent:5.05pt;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="margin-left:0.933%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;text-indent:5.05pt;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="margin-left:0.933%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Printed Name)</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;text-indent:5.05pt;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="margin-left:0.933%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;text-indent:5.05pt;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="margin-left:0.933%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;text-indent:5.05pt;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="margin-left:0.933%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;text-indent:5.05pt;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="margin-left:0.933%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#222222;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Chief Executive Officer</font></p></td>
     <td style="padding-top:0in;text-indent:5.05pt;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;"><p style="margin-left:0.933%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;text-indent:5.05pt;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="margin-left:0.933%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#222222;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">{{CANDIDATE_SIGNATURE_DATE}}</font></p></td>
    </tr>
    <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;text-indent:5.05pt;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="margin-left:0.933%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Title)</font></p></td>
     <td style="padding-top:0in;text-indent:5.05pt;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="margin-left:0.933%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;text-indent:5.05pt;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="margin-left:0.933%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Date Signed)</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;text-indent:5.05pt;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="margin-left:0.933%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;text-indent:5.05pt;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="margin-left:0.933%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;text-indent:5.05pt;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:left;"><p style="margin-left:0.933%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
   </table><p style="margin-left:6.667%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:6.667%;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:24%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:24%;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.933%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior Inventions</font></p><p style="margin-left:0.933%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior Inventions Disclosure</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Except as listed in Section 2 below, the following is a complete list of all Prior Inventions:</font></p>
   <table style="margin-left:9.333%;border-spacing:0;table-layout:auto;width:54.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:37.037%;box-sizing:content-box;"></td>
     <td style="width:11.111%;box-sizing:content-box;"></td>
     <td style="width:51.852%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">FORMCHECKBOX</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No Prior Inventions.</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">FORMCHECKBOX</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">See below:</font></p></td>
    </tr>
   </table><p style="margin-left:0.92%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:14.398%;border-spacing:0;table-layout:auto;width:77.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;text-indent:5.05pt;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="margin-left:0.933%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;text-indent:5.05pt;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="margin-left:0.933%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;text-indent:5.05pt;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="margin-left:0.933%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
   </table><p style="margin-left:0.933%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:9.333%;border-spacing:0;table-layout:auto;width:54.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:37.037%;box-sizing:content-box;"></td>
     <td style="width:11.111%;box-sizing:content-box;"></td>
     <td style="width:51.852%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">FORMCHECKBOX</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additional sheets attached.</font></p></td>
    </tr>
   </table><p style="margin-left:0.92%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.933%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.	</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Due to a prior confidentiality agreement, I cannot complete the disclosure under Section 1 above with respect to the Prior Inventions generally listed below, the intellectual property rights and duty of confidentiality with respect to which I owe to the following party(ies):</font></p>
   <table style="border-spacing:0;table-layout:auto;width:92.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:8.522%;box-sizing:content-box;"></td>
     <td style="width:26.165%;box-sizing:content-box;"></td>
     <td style="width:2.801%;box-sizing:content-box;"></td>
     <td style="width:35.467%;box-sizing:content-box;"></td>
     <td style="width:2.801%;box-sizing:content-box;"></td>
     <td style="width:24.245%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Excluded Invention</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Party(ies)</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Relationship</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;text-indent:5.75pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:right;"><div class="item-list-element-wrapper" style="margin-left:1.065%;text-indent:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.5063425481376655%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"></font></div></div></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;text-indent:5.75pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:right;"><div class="item-list-element-wrapper" style="margin-left:1.065%;text-indent:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.5063425481376655%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"></font></div></div></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;text-indent:5.75pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:right;"><div class="item-list-element-wrapper" style="margin-left:1.065%;text-indent:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.5063425481376655%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"></font></div></div></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
   </table><p style="margin-left:0.933%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="border-spacing:0;table-layout:auto;width:52.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:32.692%;box-sizing:content-box;"></td>
     <td style="width:17.308%;box-sizing:content-box;"></td>
     <td style="width:50%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;text-indent:9.35pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.733%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">FORMCHECKBOX</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;text-indent:5.05pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:0.933%;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Additional sheets attached.</font></p></td>
    </tr>
   </table><p style="margin-left:0.933%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.4in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>7
<FILENAME>mnmd-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;position:relative;">
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 31.1</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Robert Barrow, certify that:</font></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I have reviewed this Quarterly Report on Form 10-Q of Mind Medicine (Mindmed) Inc., (the &#x201c;Company&#x201d;) for the period ending March 31, 2025;</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</font></div></div><div class="item-list-element-wrapper" style="margin-left:8.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.9599877558159875%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div><div class="item-list-element-wrapper" style="margin-left:8.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.9599877558159875%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div><div class="item-list-element-wrapper" style="margin-left:8.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.9599877558159875%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:8.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.9599877558159875%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></div><div class="item-list-element-wrapper" style="margin-left:8.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.9599877558159875%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:8.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.9599877558159875%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:45.46%;box-sizing:content-box;"></td>
     <td style="width:5.04%;box-sizing:content-box;"></td>
     <td style="width:3.04%;box-sizing:content-box;"></td>
     <td style="width:46.46%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: May 8, 2025</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Robert Barrow</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Robert Barrow</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Chief Executive Officer</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>8
<FILENAME>mnmd-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;position:relative;">
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 31.2</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Carrie F. Liao, certify that:</font></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I have reviewed this Quarterly Report on Form 10-Q of Mind Medicine (Mindmed) Inc., (the &#x201c;Company&#x201d;) for the period ending March 31, 2025;</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</font></div></div><div class="item-list-element-wrapper" style="margin-left:8.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.9599877558159875%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div><div class="item-list-element-wrapper" style="margin-left:8.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.9599877558159875%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div><div class="item-list-element-wrapper" style="margin-left:8.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.9599877558159875%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:8.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.9599877558159875%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></div><div class="item-list-element-wrapper" style="margin-left:8.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.9599877558159875%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:8.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.9599877558159875%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:45.46%;box-sizing:content-box;"></td>
     <td style="width:5.04%;box-sizing:content-box;"></td>
     <td style="width:9%;box-sizing:content-box;"></td>
     <td style="width:40.5%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date:  May 8, 2025</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Carrie F. Liao</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Carrie F. Liao</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Principal Financial Officer and Chief Accounting Officer</font></p></td>
    </tr>
    <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>9
<FILENAME>mnmd-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;position:relative;">
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 32.1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the Quarterly Report of Mind Medicine (Mindmed) Inc., (the &#x201c;Company&#x201d;) on Form 10-Q for the period ending March 31, 2025 as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</font></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:45.46%;box-sizing:content-box;"></td>
     <td style="width:5.04%;box-sizing:content-box;"></td>
     <td style="width:3.04%;box-sizing:content-box;"></td>
     <td style="width:46.46%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: May 8, 2025</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Robert Barrow</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Robert Barrow</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Chief Executive Officer</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>10
<FILENAME>mnmd-ex32_2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html>
 <head>
  <title>EX-32.2</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;position:relative;">
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 32.2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the Quarterly Report of Mind Medicine (Mindmed) Inc., (the &#x201c;Company&#x201d;) on Form 10-Q for the period ending March 31, 2025 as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</font></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. </font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:45.46%;box-sizing:content-box;"></td>
     <td style="width:5.04%;box-sizing:content-box;"></td>
     <td style="width:3.04%;box-sizing:content-box;"></td>
     <td style="width:46.46%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: May 8, 2025</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Carrie F. Liao</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Carrie F. Liao</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Principal Financial Officer and Chief Accounting Officer</font></p></td>
    </tr>
    <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img196101975_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img196101975_0.jpg
M_]C_X  02D9)1@ ! @$!2@%*  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" 6I$ D# 2(  A$! Q$!_\0
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M?^@QK?\ X,KK_P"2*/\ A,=9_P"@QK?_ (,KK_Y(KD**/[=S#^:C_P""*?\
M\B']GX?M4_\ !DOZ_P"'?E;K_P#A,=9_Z#&M_P#@RNO_ )(H_P"$QUG_ *#&
MM_\ @RNO_DBN0HH_MW,/YJ/_ ((I_P#R(?V?A^U3_P &2_K_ (=^5NO_ .$Q
MUG_H,:W_ .#*Z_\ DBC_ (3'6?\ H,:W_P"#*Z_^2*Y"BC^W<P_FH_\ @BG_
M /(A_9^'[5/_  9+^O\ AWY6Z_\ X3'6?^@QK?\ X,KK_P"2*/\ A,=9_P"@
MQK?_ (,KK_Y(KD**/[=S#^:C_P""*?\ \B']GX?M4_\ !DOZ_P"'?E;K_P#A
M,=9_Z#&M_P#@RNO_ )(H_P"$QUG_ *#&M_\ @RNO_DBN0HH_MW,/YJ/_ ((I
M_P#R(?V?A^U3_P &2_K_ (=^5NO_ .$QUG_H,:W_ .#*Z_\ DBC_ (3'6?\
MH,:W_P"#*Z_^2*Y"BC^W<P_FH_\ @BG_ /(A_9^'[5/_  9+^O\ AWY6Z_\
MX3'6?^@QK?\ X,KK_P"2*/\ A,=9_P"@QK?_ (,KK_Y(KD**/[=S#^:C_P""
M*?\ \B']GX?M4_\ !DOZ_P"'?E;K_P#A,=9_Z#&M_P#@RNO_ )(H_P"$QUG_
M *#&M_\ @RNO_DBN0HH_MW,/YJ/_ ((I_P#R(?V?A^U3_P &2_K_ (=^5NO_
M .$QUG_H,:W_ .#*Z_\ DBC_ (3'6?\ H,:W_P"#*Z_^2*Y"BC^W<P_FH_\
M@BG_ /(A_9^'[5/_  9+^O\ AWY6Z_\ X3'6?^@QK?\ X,KK_P"2*/\ A,=9
M_P"@QK?_ (,KK_Y(KD**/[=S#^:C_P""*?\ \B']GX?M4_\ !DOZ_P"'?E;K
M_P#A,=9_Z#&M_P#@RNO_ )(H_P"$QUG_ *#&M_\ @RNO_DBN0HH_MW,/YJ/_
M ((I_P#R(?V?A^U3_P &2_K_ (=^5NO_ .$QUG_H,:W_ .#*Z_\ DBC_ (3'
M6?\ H,:W_P"#*Z_^2*Y"BC^W<P_FH_\ @BG_ /(A_9^'[5/_  9+^O\ AWY6
MZ_\ X3'6?^@QK?\ X,KK_P"2*/\ A,=9_P"@QK?_ (,KK_Y(KD**/[=S#^:C
M_P""*?\ \B']GX?M4_\ !DOZ_P"'?E;K_P#A,=9_Z#&M_P#@RNO_ )(H_P"$
MQUG_ *#&M_\ @RNO_DBN0HH_MW,/YJ/_ ((I_P#R(?V?A^U3_P &2_K_ (=^
M5NO_ .$QUG_H,:W_ .#*Z_\ DBC_ (3'6?\ H,:W_P"#*Z_^2*Y"BC^W<P_F
MH_\ @BG_ /(A_9^'[5/_  9+^O\ AWY6Z_\ X3'6?^@QK?\ X,KK_P"2*/\
MA,=9_P"@QK?_ (,KK_Y(KD**/[=S#^:C_P""*?\ \B']GX?M4_\ !DOZ_P"'
M?E;K_P#A,=9_Z#&M_P#@RNO_ )(H_P"$QUG_ *#&M_\ @RNO_DBN0HH_MW,/
MYJ/_ ((I_P#R(?V?A^U3_P &2_K_ (=^5NO_ .$QUG_H,:W_ .#*Z_\ DBC_
M (3'6?\ H,:W_P"#*Z_^2*Y"BC^W<P_FH_\ @BG_ /(A_9^'[5/_  9+^O\
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MMW,/YJ/_ ((I_P#R(?V?A^U3_P &2_K_ (=^5NO_ .$QUG_H,:W_ .#*Z_\
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M_P"2*/\ A,=9_P"@QK?_ (,KK_Y(KD**/[=S#^:C_P""*?\ \B']GX?M4_\
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M2*Y"BC^W<P_FH_\ @BG_ /(A_9^'[5/_  9+^O\ AWY6Z_\ X3'6?^@QK?\
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MGX?M4_\ !DOZ_P"'?E;K_P#A,=9_Z#&M_P#@RNO_ )(H_P"$QUG_ *#&M_\
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M?^@QK?\ X,KK_P"2*/\ A,=9_P"@QK?_ (,KK_Y(KD**/[=S#^:C_P""*?\
M\B']GX?M4_\ !DOZ_P"'?E;K_P#A,=9_Z#&M_P#@RNO_ )(H_P"$QUG_ *#&
MM_\ @RNO_DBN0HH_MW,/YJ/_ ((I_P#R(?V?A^U3_P &2_K_ (=^5NO_ .$Q
MUG_H,:W_ .#*Z_\ DBC_ (3'6?\ H,:W_P"#*Z_^2*Y"BC^W<P_FH_\ @BG_
M /(A_9^'[5/_  9+^O\ AWY6Z_\ X3'6?^@QK?\ X,KK_P"2*/\ A,=9_P"@
MQK?_ (,KK_Y(KD**/[=S#^:C_P""*?\ \B']GX?M4_\ !DOZ_P"'?E;K_P#A
M,=9_Z#&M_P#@RNO_ )(H_P"$QUG_ *#&M_\ @RNO_DBN0HH_MW,/YJ/_ ((I
M_P#R(?V?A^U3_P &2_K_ (=^5NO_ .$QUG_H,:W_ .#*Z_\ DBC_ (3'6?\
MH,:W_P"#*Z_^2*Y"BC^W<P_FH_\ @BG_ /(A_9^'[5/_  9+^O\ AWY6Z_\
MX3'6?^@QK?\ X,KK_P"2*/\ A,=9_P"@QK?_ (,KK_Y(KD**/[=S#^:C_P""
M*?\ \B']GX?M4_\ !DOZ_P"'?E;K_P#A,=9_Z#&M_P#@RNO_ )(H_P"$QUG_
M *#&M_\ @RNO_DBN0HH_MW,/YJ/_ ((I_P#R(?V?A^U3_P &2_K_ (=^5NO_
M .$QUG_H,:W_ .#*Z_\ DBC_ (3'6?\ H,:W_P"#*Z_^2*Y"BC^W<P_FH_\
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MH_\ @BG_ /(A_9^'[5/_  9+^O\ AWY6Z_\ X3'6?^@QK?\ X,KK_P"2*/\
MA,=9_P"@QK?_ (,KK_Y(KD**/[=S#^:C_P""*?\ \B']GX?M4_\ !DOZ_P"'
M?E;K_P#A,=9_Z#&M_P#@RNO_ )(H_P"$QUG_ *#&M_\ @RNO_DBN0HH_MW,/
MYJ/_ ((I_P#R(?V?A^U3_P &2_K_ (=^5NO_ .$QUG_H,:W_ .#*Z_\ DBC_
M (3'6?\ H,:W_P"#*Z_^2*Y"BC^W<P_FH_\ @BG_ /(A_9^'[5/_  9+^O\
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MMW,/YJ/_ ((I_P#R(?V?A^U3_P &2_K_ (=^5NO_ .$QUG_H,:W_ .#*Z_\
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M_P"2*/\ A,=9_P"@QK?_ (,KK_Y(KD**/[=S#^:C_P""*?\ \B']GX?M4_\
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M2*Y"BC^W<P_FH_\ @BG_ /(A_9^'[5/_  9+^O\ AWY6Z_\ X3'6?^@QK?\
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MGX?M4_\ !DOZ_P"'?E;K_P#A,=9_Z#&M_P#@RNO_ )(H_P"$QUG_ *#&M_\
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M?^@QK?\ X,KK_P"2*/\ A,=9_P"@QK?_ (,KK_Y(KD**/[=S#^:C_P""*?\
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M_P#R(?V?A^U3_P &2_K_ (=^5NO_ .$QUG_H,:W_ .#*Z_\ DBC_ (3'6?\
MH,:W_P"#*Z_^2*Y"BC^W<P_FH_\ @BG_ /(A_9^'[5/_  9+^O\ AWY6Z_\
MX3'6?^@QK?\ X,KK_P"2*/\ A,=9_P"@QK?_ (,KK_Y(KD**/[=S#^:C_P""
M*?\ \B']GX?M4_\ !DOZ_P"'?E;K_P#A,=9_Z#&M_P#@RNO_ )(H_P"$QUG_
M *#&M_\ @RNO_DBN0HH_MW,/YJ/_ ((I_P#R(?V?A^U3_P &2_K_ (=^5NO_
M .$QUG_H,:W_ .#*Z_\ DBC_ (3'6?\ H,:W_P"#*Z_^2*Y"BC^W<P_FH_\
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MH_\ @BG_ /(A_9^'[5/_  9+^O\ AWY6Z_\ X3'6?^@QK?\ X,KK_P"2*/\
MA,=9_P"@QK?_ (,KK_Y(KD**/[=S#^:C_P""*?\ \B']GX?M4_\ !DOZ_P"'
M?E;K_P#A,=9_Z#&M_P#@RNO_ )(H_P"$QUG_ *#&M_\ @RNO_DBN0HH_MW,/
MYJ/_ ((I_P#R(?V?A^U3_P &2_K_ (=^5NO_ .$QUG_H,:W_ .#*Z_\ DBC_
M (3'6?\ H,:W_P"#*Z_^2*Y"BC^W<P_FH_\ @BG_ /(A_9^'[5/_  9+^O\
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MMW,/YJ/_ ((I_P#R(?V?A^U3_P &2_K_ (=^5NO_ .$QUG_H,:W_ .#*Z_\
MDBC_ (3'6?\ H,:W_P"#*Z_^2*Y"BC^W<P_FH_\ @BG_ /(A_9^'[5/_  9+
M^O\ AWY6Z_\ X3'6?^@QK?\ X,KK_P"2*/\ A,=9_P"@QK?_ (,KK_Y(KD**
M/[=S#^:C_P""*?\ \B']GX?M4_\ !DOZ_P"'?E;K_P#A,=9_Z#&M_P#@RNO_
M )(H_P"$QUG_ *#&M_\ @RNO_DBN0HH_MW,/YJ/_ ((I_P#R(?V?A^U3_P &
M2_K_ (=^5NO_ .$QUG_H,:W_ .#*Z_\ DBC_ (3'6?\ H,:W_P"#*Z_^2*Y"
MBC^W<P_FH_\ @BG_ /(A_9^'[5/_  9+^O\ AWY6Z_\ X3'6?^@QK?\ X,KK
M_P"2*/\ A,=9_P"@QK?_ (,KK_Y(KD**/[=S#^:C_P""*?\ \B']GX?M4_\
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M2*Y"BC^W<P_FH_\ @BG_ /(A_9^'[5/_  9+^O\ AWY6Z_\ X3'6?^@QK?\
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MGX?M4_\ !DOZ_P"'?E;K_P#A,=9_Z#&M_P#@RNO_ )(H_P"$QUG_ *#&M_\
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M?^@QK?\ X,KK_P"2*/\ A,=9_P"@QK?_ (,KK_Y(KD**/[=S#^:C_P""*?\
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M_P#R(?V?A^U3_P &2_K_ (=^5NO_ .$QUG_H,:W_ .#*Z_\ DBC_ (3'6?\
MH,:W_P"#*Z_^2*Y"BC^W<P_FH_\ @BG_ /(A_9^'[5/_  9+^O\ AWY6Z_\
MX3'6?^@QK?\ X,KK_P"2*/\ A,=9_P"@QK?_ (,KK_Y(KD**/[=S#^:C_P""
M*?\ \B']GX?M4_\ !DOZ_P"'?E;K_P#A,=9_Z#&M_P#@RNO_ )(H_P"$QUG_
M *#&M_\ @RNO_DBN0HH_MW,/YJ/_ ((I_P#R(?V?A^U3_P &2_K_ (=^5NO_
M .$QUG_H,:W_ .#*Z_\ DBC_ (3'6?\ H,:W_P"#*Z_^2*Y"BC^W<P_FH_\
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MH_\ @BG_ /(A_9^'[5/_  9+^O\ AWY6Z_\ X3'6?^@QK?\ X,KK_P"2*/\
MA,=9_P"@QK?_ (,KK_Y(KD**/[=S#^:C_P""*?\ \B']GX?M4_\ !DOZ_P"'
M?E;K_P#A,=9_Z#&M_P#@RNO_ )(H_P"$QUG_ *#&M_\ @RNO_DBN0HH_MW,/
MYJ/_ ((I_P#R(?V?A^U3_P &2_K_ (=^5NO_ .$QUG_H,:W_ .#*Z_\ DBC_
M (3'6?\ H,:W_P"#*Z_^2*Y"BC^W<P_FH_\ @BG_ /(A_9^'[5/_  9+^O\
MAWY6Z_\ X3'6?^@QK?\ X,KK_P"2*/\ A,=9_P"@QK?_ (,KK_Y(KD**/[=S
M#^:C_P""*?\ \B']GX?M4_\ !DOZ_P"'?E;K_P#A,=9_Z#&M_P#@RNO_ )(H
M_P"$QUG_ *#&M_\ @RNO_DBN0HH_MW,/YJ/_ ((I_P#R(?V?A^U3_P &2_K_
M (=^5NO_ .$QUG_H,:W_ .#*Z_\ DBC_ (3'6?\ H,:W_P"#*Z_^2*Y"BC^W
M<P_FH_\ @BG_ /(A_9^'[5/_  9+^O\ AWY6Z_\ X3'6?^@QK?\ X,KK_P"2
M*/\ A,=9_P"@QK?_ (,KK_Y(KD**/[=S#^:C_P""*?\ \B']GX?M4_\ !DOZ
M_P"'?E;K_P#A,=9_Z#&M_P#@RNO_ )(H_P"$QUG_ *#&M_\ @RNO_DBN0HH_
MMW,/YJ/_ ((I_P#R(?V?A^U3_P &2_K_ (=^5NO_ .$QUG_H,:W_ .#*Z_\
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M_P"2*/\ A,=9_P"@QK?_ (,KK_Y(KD**/[=S#^:C_P""*?\ \B']GX?M4_\
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M2*Y"BC^W<P_FH_\ @BG_ /(A_9^'[5/_  9+^O\ AWY6Z_\ X3'6?^@QK?\
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MGX?M4_\ !DOZ_P"'?E;K_P#A,=9_Z#&M_P#@RNO_ )(H_P"$QUG_ *#&M_\
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M?^@QK?\ X,KK_P"2*/\ A,=9_P"@QK?_ (,KK_Y(KD**/[=S#^:C_P""*?\
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M_P#R(?V?A^U3_P &2_K_ (=^5NO_ .$QUG_H,:W_ .#*Z_\ DBC_ (3'6?\
MH,:W_P"#*Z_^2*Y"BC^W<P_FH_\ @BG_ /(A_9^'[5/_  9+^O\ AWY6Z_\
MX3'6?^@QK?\ X,KK_P"2*/\ A,=9_P"@QK?_ (,KK_Y(KD**/[=S#^:C_P""
M*?\ \B']GX?M4_\ !DOZ_P"'?E;K_P#A,=9_Z#&M_P#@RNO_ )(H_P"$QUG_
M *#&M_\ @RNO_DBN0HH_MW,/YJ/_ ((I_P#R(?V?A^U3_P &2_K_ (=^5NO_
M .$QUG_H,:W_ .#*Z_\ DBC_ (3'6?\ H,:W_P"#*Z_^2*Y"BC^W<P_FH_\
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MH_\ @BG_ /(A_9^'[5/_  9+^O\ AWY6Z_\ X3'6?^@QK?\ X,KK_P"2*/\
MA,=9_P"@QK?_ (,KK_Y(KD**/[=S#^:C_P""*?\ \B']GX?M4_\ !DOZ_P"'
M?E;K_P#A,=9_Z#&M_P#@RNO_ )(H_P"$QUG_ *#&M_\ @RNO_DBN0HH_MW,/
MYJ/_ ((I_P#R(?V?A^U3_P &2_K_ (=^5NO_ .$QUG_H,:W_ .#*Z_\ DBC_
M (3'6?\ H,:W_P"#*Z_^2*Y"BC^W<P_FH_\ @BG_ /(A_9^'[5/_  9+^O\
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MMW,/YJ/_ ((I_P#R(?V?A^U3_P &2_K_ (=^5NO_ .$QUG_H,:W_ .#*Z_\
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M_P"2*/\ A,=9_P"@QK?_ (,KK_Y(KD**/[=S#^:C_P""*?\ \B']GX?M4_\
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M2*Y"BC^W<P_FH_\ @BG_ /(A_9^'[5/_  9+^O\ AWY6Z_\ X3'6?^@QK?\
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MGX?M4_\ !DOZ_P"'?E;K_P#A,=9_Z#&M_P#@RNO_ )(H_P"$QUG_ *#&M_\
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M?^@QK?\ X,KK_P"2*/\ A,=9_P"@QK?_ (,KK_Y(KD**/[=S#^:C_P""*?\
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M_P#R(?V?A^U3_P &2_K_ (=^5NO_ .$QUG_H,:W_ .#*Z_\ DBC_ (3'6?\
MH,:W_P"#*Z_^2*Y"BC^W<P_FH_\ @BG_ /(A_9^'[5/_  9+^O\ AWY6Z_\
MX3'6?^@QK?\ X,KK_P"2*/\ A,=9_P"@QK?_ (,KK_Y(KD**/[=S#^:C_P""
M*?\ \B']GX?M4_\ !DOZ_P"'?E;K_P#A,=9_Z#&M_P#@RNO_ )(H_P"$QUG_
M *#&M_\ @RNO_DBN0HH_MW,/YJ/_ ((I_P#R(?V?A^U3_P &2_K_ (=^5NO_
M .$QUG_H,:W_ .#*Z_\ DBC_ (3'6?\ H,:W_P"#*Z_^2*Y"BC^W<P_FH_\
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MH_\ @BG_ /(A_9^'[5/_  9+^O\ AWY6Z_\ X3'6?^@QK?\ X,KK_P"2*/\
MA,=9_P"@QK?_ (,KK_Y(KD**/[=S#^:C_P""*?\ \B']GX?M4_\ !DOZ_P"'
M?E;K_P#A,=9_Z#&M_P#@RNO_ )(H_P"$QUG_ *#&M_\ @RNO_DBN0HH_MW,/
MYJ/_ ((I_P#R(?V?A^U3_P &2_K_ (=^5NO_ .$QUG_H,:W_ .#*Z_\ DBC_
M (3'6?\ H,:W_P"#*Z_^2*Y"BC^W<P_FH_\ @BG_ /(A_9^'[5/_  9+^O\
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MMW,/YJ/_ ((I_P#R(?V?A^U3_P &2_K_ (=^5NO_ .$QUG_H,:W_ .#*Z_\
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M_P"2*/\ A,=9_P"@QK?_ (,KK_Y(KD**/[=S#^:C_P""*?\ \B']GX?M4_\
M!DOZ_P"'?E;^@3_@VN2[U7_@LG^RM?-=2-]CTC]H'4KKSY)9);I)OV<OBOIX
M1F+-OD\_4(9V,A((B8YW[:_U+*_RW?\ @V5_Y3!?LT_]BC\>?_5$?$&O]2*O
MY^\<YRJ<697.5KOAC+F[*RO+&YI-Z?XI/TV/TKP]BHY-BTMO[6Q/X8;!Q7X)
M'^(M\4O^1X\:?]CGXE_].]_7G%>C_%+_ )'CQI_V.?B7_P!.]_7G%?O^=?[[
M_P!R^&_]-1/S; ?P'_U]J?\ I04445Y)VA1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 ?T'?\&RO_*8+]FG_ +%'X\_^J(^(-?ZD5?Y;O_!LK_RF"_9I_P"Q
M1^//_JB/B#7^I%7XGXW_ /)4Y5_V2^6?^I>9'WWA]_R)L7_V-L5_Z8PA_B+?
M%+_D>/&G_8Y^)?\ T[W]><5Z/\4O^1X\:?\ 8Y^)?_3O?UYQ7]!9U_OO_<OA
MO_343\TP'\!_]?:G_I04445Y)VA1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH _H._X-E?^4P7[-/_ &*/QY_]41\0:_U(J_RW?^#97_E,
M%^S3_P!BC\>?_5$?$&O]2*OQ/QO_ .2IRK_LE\L_]2\R/OO#[_D38O\ [&V*
M_P#3&$/\1;XI?\CQXT_['/Q+_P"G>_KSBO1_BE_R/'C3_L<_$O\ Z=[^O.*_
MH+.O]]_[E\-_Z:B?FF _@/\ Z^U/_2@HHHKR3M"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'PSXBT_Q##\'_A[J^ESI!XHUS4=:T336^)/B2RN[KPII6@1W/P_@'B/6=?\
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MJ.+_ );'A9GBWCL?BL5KRU:LG3ONJ4;0I)^:IQBGYA1117L'"%%%% !1110
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M .AFH_X@_?\ @I;_ -%P_89_\.7\??\ Z&:OFO\ 7/A;_H=X+_P*?_R!ZO\
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MXTXN32;UG.,5INT:T*%7$U84*%.56K4;4(1MS2:3D[7:6D4WOLC\P**_:/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;44V?HA_P>;Z'K#:A_P3W\2+IMX^@16?[3&ASZPD$CZ?;:Q<3_ V_M=-NKI
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M$FU!-)R=VM$Y13]4?@I17]67_$'[_P %+?\ HN'[#/\ X<OX^_\ T,U5[O\
MX- _^"F-O;R30_&7]B&_D39MM+3XF_')+B7<ZH?+:^_9OL[4;%8R/YMS'E$8
M)OD*1OXW^N?"W_0[P7_@<U^<#N_L'./^A?B/_ 8__)>?]69_*K17ZF?MR?\
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M-XMKFC?FBG%M)25RBBBO7.(**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#^@[_@V5_Y3!?LT_P#8H_'G_P!41\0:_P!2*O\ +=_X-E?^4P7[-/\
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M\):)J6A:_P")-2T^"RO=6.NZ+I&@ZO;R_P!M76F=D^(,'AN'\/Q!CD\-AZV
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M_L[S'XAXW,,5B:'#G#F*S:CA7>IB?:3CS0]Y1E[&GAY^R55PDZ*G5=6I%/\
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MJI)72DJ:25FU*::9^3O_  9T_P#)EW[4_P#V=!;_ /JJ/ ]?'W_!YS_R-?\
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MFBZY%;3Z)K&G>((_#K:3>Z7K$%[9S:7J%M=RVFH17=M):33)/$7\"K_6QO\
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M/@S_ ,% /V3OB5XG;PEI.D_M+?!WP5XK\?\ P>^)VF6S:=KMWJ?A_0O[0N_
MOBV[TK1=8U/Q1X2\4:?HL&F)I4UA?7VF:E#I=[H,UC+'=1WG^417V7"O%&&X
MHP57$4J$L+B,-4C2Q6&E-55"4TY4YTZJC#VE.I&,K-PA)2C.+C9*4O"SC**N
M45X4IU(UJ=6+G1JJ+@Y*+2G&4&Y<LHMJZ4I)Q<7>[<44445]0>0%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !7U!^Q#_ ,GH_LA_]G0? '_U:_A.
MOE^OJ#]B'_D]']D/_LZ#X _^K7\)US8W_<\7_P!@U?\ ]-3-:'\>C_U]I_\
MI<3_ &D*_B9^(O\ P>*_\(#\0?'7@3_AW5_:W_"%>,O$_A+^U?\ AKG[!_:?
M_".:W?:/_:'V'_AF*\^Q_;/L?VG[)]LN_L_F>3]IGV>:_P#;-7^)E^T3_P G
M _'7_LL?Q._]3;6Z_ O#K(,HSZMFL,UPGUJ.&I825!>WQ-#D=6>(51WPU:BY
M<RA'2;DE;2UW?](XHS+&Y=#!/!UO8NK*NJC]G1J<R@J3C_%ISM;FE\-KWUO9
M'^I;_P $N?\ @N/^R=_P5*UCQ3\/OAUI/C3X2?&OP=H<7B:_^%7Q+_L)KWQ#
MX:62UM=4\0^ ]=T'4[^R\2Z7H&I7MI8ZS#=VVA:[9B]LKXZ(VG3274'RO_P<
ME_\ !,[X3_M7_L6_$[]JW2= T;0?VFOV3_A]J/C[0_'Z2'29_%_PA\(SR>(/
MB'\-?&=Q;6-\_B#3['PT_B3Q5\.X;NW^V:)XZMH].TS6- T'QEXU.I?RY?\
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MR47JFK/_ $H_^#;'_E"M^QA_W<5_ZUA\=:_C*_X.F_\ E+I\1O\ LCGP0_\
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M@YX5M/#7@GPKXM_:!/AY+GXL?M)>+O#^BW'Q"US7+^/3]1\2:;X>UJY6^G\
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MW5MHVI:QXI\-:+IGA_PEH'AC3%_I$_X,_?\ E&E\</\ L^;XE_\ J@OV9J^
M/^#SOQ#HMSXA_P""=WA2#4;>7Q%HNC?M3>(=5TE2_P!JLM%\3WW[/FFZ!J,P
M*A!;ZI?>$?$EM;%79S)I%WO5 (R_W_\ \&?O_*-+XX?]GS?$O_U07[,U;9OB
M\3CO"[+L3BYSJXB6(HTY5*C;G.&'QV*P]*<Y2]Z<I4:5-N;;<V^=MN5W&!H4
ML/Q?BJ5",84U2G*,(V48NIAZ-6:BEHDISDE%:1V25K'X9_\ !X%_RDM^!_\
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M$_@;X3^/?%OAZYNK&4P7MM!K6@:!J&FS7%G.K0W4,=RTEO*#'*J."M?Z2?\
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MK09M4TN\%QIU]<KKNEI:7,%M;0?L=^V+_P '9WQE_:2_9C^)'P#^%_[*6A?
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MQ;X.\5?$#2=%\0^'M:T^0Q7>G:IIE])#<VMQ$V& =-DL3QSPM)!+'(W^5?\
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M:?\ L4?CS_ZHCX@U_J15_EN_\&RO_*8+]FG_ +%'X\_^J(^(-?ZD5?B?C?\
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M?\I4[_\ [-?^+W_J0_#BOZU_^#FC_E#1^U#_ -C#^S]_ZT+\,*_DH_X--/\
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ML^.O$"69BCEG>8Z187EEHWVV>=Y;X:>+L16,,T.G6?\ "-_P<G?\IJ?VS_\
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M/BC\5;N2:*YGA2V^'G@?7?%T[S0V=I?WDT2Q:.[216MC>W,B I!:7,I2%_\
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MM[5_"%MKGB"[M+NST>#2-&FUCQ(#9Z';W^F?UL_'C_@E9_P7M_X*O?"7X?\
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M3 5<+BY8#!U<)24U&?M:LZOM9*F]4YRDERII2C%V]Y7Z'^(K7^P)_P $;O\
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MOA<(GAGAJM2M1G%04&J45'GE6UIMJ+DKJ*UTO;\@****_8CX<**** "BBB@
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M0-J?BF"Q^(*^-M<CTRWU*#PYX?TRQ'B)M)F\8>$3JW]I_P#P79_Y1%_MU?\
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MZED/'XI1GS\-RFI>P^IXB*:VYT\*ZJ7:7(Z>^^EMF;\'N/+FBC;VGMZ;:?\
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MCU/#2[X1S=;_ /"CCTE_W3,!HCDXK_Y'6"_[!<-?_P *\2?[._B[_D5/$_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MF);WEK*R3I\D_P#!T]X^_P""A7[+O[2?P5^./P(_:?\ VIOA)^S;\5/A;8^
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MLF[+HF]DSZ#.T_\ 5;*]-H9:WY+ZG)7?S:7JSVO_ (,_?^4EOQP_[,9^)?\
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M2(7US%#??%/Q(\-I<SR6ED\\\UE%#-J%^\_R?_P><_\ (U_\$]/^Q>_:=_\
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M/1S)9CF^*='G4JN)J1C&$IN+<7&<%'GG"7+3CSM**YY7:E+_ %7?V$OV6_\
MABG]D7X%?LK_ /"<_P#"R_\ A2O@T^$O^$[_ .$9_P"$-_X27.KZIJO]H?\
M"+_\)#XK_L;_ )"7D?9/^$BU7_4^;]I_>>7'_FE_\'),,4'_  6G_;02&*.%
M&D_9ZF9(D6-3+<?LJ? VXN)2J  R3SRR33.1NEED>1RSNS'_ $9?^"5&E_&[
M1_\ @G1^R!:?M'WWC[4/C;-\&?#VJ>/[CXJ7_B;4OB/'J>N2WFMV=CXVN/&9
M/BF/Q)IFCZAINFZK8:Y_I^E75I)I<H LU _SGO\ @Y._Y34_MG_]VZ_^LG_
MJN+PY]I_KEG?MJT<35^HYE[7$4U&,,14_M7 \]:$8)04:LKSBHI12DE%)61M
MQ1R?V%E_)3=*'UC"<E*3;E2A]3Q'+3DY7DW!6BVVVVKO4_M2_P"#7K_E#Y\$
M?^RC?'?_ -6KXCK^7+_@[H_Y2??#W_LSKX5_^K1^.=?U&_\ !KU_RA\^"/\
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MIZAI5_#<6-Y<P2?T-_\ !X]_R=7^R#_V;YXJ_P#5CZA7\Z'_  3 _P"4EO\
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MW^S[\/?"/[!OQ%_:'AT31KOXK?%WXY^,O"^I>,&T>WB\0:9\/? FC^#K+1/
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MX1U7^Z__ (*)?\%J/@[_ ,$S?B'HO@3XR_LV?MB?$3PQ)X-\/>*=<^-OPO\
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M+K2]<T+4XW1RCRVTE_I=S:7MU_CQ?LL?LW^//VO/VA/A7^S5\,-0\):5X_\
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MPPQ1"29A'&B;5'^O)_P1N_Y16?L"?]FO_"O_ -1ZVK_,5_X*Z_!CX>_L^?\
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M;XOT;SK8ZOX6\4:/<76E:M;07=AJEHDT6K>'M6T/Q)INCZWIW^C#_P $_?\
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M\'^,8["]\*Z1HVLWNG>+;GP7X<\)66KWW]>_Q)U7_@F=^UY\/_#?C7XMZO\
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M7X<^%6UK4-=\ S6&CKXA\8:KHVD-JE]%9WDMGIXO#=W,=K<O#"ZP2E/Z??\
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MAC48]1MO&X\>/8SW<?B;P]J6DQ7,'BX:DNMZ3<:9&8]3MS9J(_S<_P""C?\
MP<G?L+_L?^!=2TS]G7QYX'_;+_:"U&WMT\+>#_A7XK76OA3H27T]]:GQ1X]^
M,/ANTUKPA)I^D'3[JX;P7X/U76?&VM7+:/8W=OX1T#Q!'XXTS_+_ **^4PGA
MA@E7I5<TS;'9I1H<JI8:<70I\D7_  IS]M7J>R:23C1E0=EI)'LUN+L0Z4X8
M3!8?!U*E^>M%^TES/[<8^SA'GWLZBJ+75.UWZ3\8OC#\3?V@/BCXY^-/QE\9
MZQ\0?BC\2?$-]XI\:^,-=DA?4-9UG4'!DD$%K#;:?INGVD"0:?HVB:19V&AZ
M!H]I8:)H>G:=I&GV5E;_ -M'_!J9^UW^R?\ L[?LD?M)>&_V@?VG_P!GCX%^
M(M=_:,@US1- ^,?QJ^&WPQUK6=%'PS\'6!UC2M*\:^)=$OM0TL7UK<V1U"T@
MFM!=V\]L9O.AD1?X3J*^SSW(</GF4RRB526#H.6'<)8>G#]W'#SC*%.%-I0C
M!**BHI)1C9):6/!R[,:F7XR.-4%7J)5$U4E+WG534I2DKR<M6[O=ZNY_81_P
M=I?M-?LW?M'^)OV%KC]GC]H+X(?'F#PCH7[1,/BR;X,?%?P'\48O#$NMZA\%
MGT6+Q#)X'U_7$T635TTK5'TM-2:V:_73;]K02BSN#'_*=\!]1T_1_CC\&=6U
M:_L]+TK2_BO\.]1U/4]1NH+'3].T^Q\7Z/<WM_?WMR\5M9V=I;12W%U=7$L<
M%O!&\LKI&C,/***UR;)Z>39/A\HI5IUJ>'A7A&M4C&,Y*O6K5FW&/NKE=9Q5
MMU%-ZLG'8Z>.QU3'3IQISJ2I2<(MN*]G3A323>NJ@F^S;/\ 9*_X>?\ _!-+
M_I(?^PS_ .):_ +_ .>!7^-K117E<+<)8;A;Z_\ 5\77Q7U[ZKS^VA3A[/ZK
M]8Y>7DWYOK$KWVY5;=G9G&=5<X^K^UH4Z/U?VW+R2E+F]M[*]^;:WLE:W=WV
M"BBBOK3Q0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^C/V/=<T7
MPQ^UO^RUXD\2:QI?A[P[X>_:,^".N:_K^N:A::3HNAZ+I/Q,\,7^JZQK&JW\
MUO8Z9I>F6-O/>ZAJ%[/!:6=I!-<W,T<,;NOSG16=6FJM*K2;:56G.FVMTIQ<
M6U?2ZO=%0ER3A-*_)*,K=^5IV^=C_9*_X>?_ /!-+_I(?^PS_P"):_ +_P">
M!7^09\>-1T_6/CC\9M6TF_L]4TK5/BO\1-1TS4].NH+[3]1T^^\7ZQ<V5_87
MML\MM>6=W;2Q7%K=6\LD%Q!(DL3O&ZL?***^3X6X/PW"\\9/#XROBGC(4(25
M:G3@H*@ZK3CR;\WM7>^UE8]G-\\JYO&A&I0IT?8.HTX2E+F]HH)WYMK<FEN_
MD%%%%?8'B']+G_!J[\>/@=^SS_P4'^,7C3X_?&7X4_ [P=J?[&WQ!\+Z;XL^
M,'Q$\(?#/PSJ/B:]^-O[/.K6?AVQU[QIK&B:7=Z[=Z7HFLZE;:1;W4FH3Z?I
M&IWD5N]O874D7[T_\'+W[;/[&?QX_P""9.K> O@=^UQ^S'\9O'4GQS^$VKQ^
M"_A1\>_A5\1/%DFE:;)X@.HZFGASPAXKUC6'T^P$T)O;U;,VUJ)8C/+'YB9_
MSNJ*^/QW!^&QW$>%XBGC*].MA9X6<<-&G3=*;PKO%2F_?7/]JVW0]O#YW5P^
M5ULKC0IRIUE53JN4E./M;7M%>[I;2^X5^MO_  1W_P""K'CK_@E-^TA?_$>S
M\-2?$3X+_%#2M-\'?';X:P7@T[5=8\/:;J$M]H7B[P=?RNEA;>/? MU>:G<:
M%#K*2Z+K>D:SXE\+WDNB3:_:>+/#GY)45]-CL%A<QPE? XRE&OA<33=.M2DV
ME*+:::E%J491DE.$XM2A.,91:DDSRL/B*N%K4\10FZ=6E)3A)6=FM+-.Z<6F
MXRBTU*+:::;1_K;?"O\ X*;_ /!(+_@IG\-3\-[OXU_LY_$K0_'>H6VCZI^S
MM^TS9>&?"_B;6=?T6'1O%EM8CX3?&6VL#XQN-"N9=/U/2_$?@^S\4: FN:/?
M3>'?$-QJ?AC4WTWNO _PE_X([_L*:Q)\8/!V@?L"_LP:^+.;3H_BE<:K\$OA
MWK%AI]Y)%I5[8:;XWUS4K"]TBSU276+/3=4M=,U.S@U:2\TVSU%+IC81K_D'
MT5^:S\+Z,74HX/B#,\-@*K;JX-QC44[V34I4ZM"E*\5&-YX>;LE?F/JH\75'
MRSKY;A*N)@DH5TW%QMLTI0J3CK=^[52N]+=?[S/^"Z7_  <;_!;6?@S\1_V-
MOV O&NK>.O&GQ&TNU\,_$?\ :6\(S16/@'PIX(U5DE\4^%/A?KCRG4_%7BWQ
M+I$<WA;7O$EEI=EX=\.>']>OY?"WB/4_%H6X\*_PCZ'KFM>&-:T?Q)X;UC5/
M#WB+P]JFGZYH&OZ'J%WI.M:'K6DW<-_I6L:/JMA-;WVF:IIE];P7NGZA93P7
M=G=P0W-M-'-&CKET5]QD/#^7\/8%X+ PDXU)>TQ%:LXSK8FHXJ#E4:C&/*HJ
MT*<8QIP3=H\TIRE\_F.9XK,\1]8Q$DG%<M*G33C"E!-RM!7;NV[RG)N4G:[M
M&*7^D%_P2Z_X.>?V3_CQ\//!?PP_;D\7V?[.'[1VE66E^'M4\>>(=-OH?@;\
M4[V-)K:+Q-9>,K)M5M_AMJMQ;62W_BVR^(X\,^$;+4+R%O#GBS5%O7T?1?VU
MN/!/_!+G]H+Q9HW[0UWX1_8%^-WCJ.?0-7\/_'&XT#]GCXE>+$N=(^R:[X6U
M/1OB9)::UK"SZ6+FQUG0+VRUL267GVFHZ=+%YL,S?XY%%?'8_P ,<OJXFIB<
MKS+&91[9R<Z-**K48J;O*%&U3#U84GO[.=6K%;1Y8J,5[F'XMQ,*,*6,PE#&
M^SMRU)OV<WR[2G>%2$II:<T80?5W=V_]5/\ ;G_X.%?^"<7[&?PSN=1^'?QD
M^'W[5OQ0OM&U:/X=_"O]G'QQX5\?:-=:OIUG:KID7CGXA>$K[6_"'PY\+"[O
MM/BO+NXGU/Q&VG1ZG-X7\'^)KK2+S3XO\R/]I[]H[XG_ +77Q_\ BM^TI\9=
M1L]3^)/Q@\6WOBSQ(^EV\]GHNG&:.&RTCP[X?LKN[U"\LO#7A70K+2_#/ANR
MO=1U*]M-"TG3[:\U&_N8I;R;PBBOH^&N$<LX9C5EA75Q&+Q$>2MC,0X^T=-2
MYE2IP@E"E3YDI22YI3FDYS:C",/+S7.\7FS@JRA2HTGS4Z%)/E4VK.<I2;E.
M5KJ-[*,6U%)N3E_99_P;L_\ !>#]GG]D/X.?\,0?MBWEQ\,_!&G>,M:\2_!W
MXX6&A:KKOABQ_P"$VOKG5?$?@_XHVFA0ZEKVC!?$LRWOAKQA8:+J>BBUUO4+
M3Q?-X5TSPY;:UJG]9WCS_@HG_P $G_B?X'U)M?\ VV?V _%L-QX:\01:7I_C
M#]H'X W5_$NJ:<\%S:IHGB?Q4NI6,NH&"WBN+.:QMYKGRH%EA<+$!_D"T5X^
M<>'.59IF-7,Z6+QF KXBHZU>-'V<Z4ZTM9U8*:4Z<JCO*HE4<')MQC&[3[L#
MQ1C,'A882=&AB:=.*A3=3FC.,%\,).+Y9*"TC>*DDE=NR/Z7/^#5WX\? []G
MG_@H/\8O&GQ^^,OPI^!W@[4_V-OB#X7TWQ9\8/B)X0^&?AG4?$U[\;?V>=6L
M_#MCKWC36-$TN[UV[TO1-9U*VTBWNI-0GT_2-3O(K=[>PNI(OWI_X.7OVV?V
M,_CQ_P $R=6\!? []KC]F/XS>.I/CG\)M7C\%_"CX]_"KXB>+)-*TV3Q =1U
M-/#GA#Q7K&L/I]@)H3>WJV9MK42Q&>6/S$S_ )W5%>ECN#\-CN(\+Q%/&5Z=
M;"SPLXX:-.FZ4WA7>*E-^^N?[5MNAR8?.ZN'RNME<:%.5.LJJ=5RDIQ]K:]H
MKW=+:7W/U5_X(A_$3X?_  G_ ."J?['/Q#^*?CGP=\-/ 'ACQ[XDO/$OCGQ_
MXFT7P;X/\/6D_P -?&]A!=:YXF\17VFZ+I-M-?7=K9Q3W][;Q27=S;VZ,9IH
MT;_0/_X*<_\ !1'_ ()^^/O^"='[<O@CP+^W1^QUXU\:>+?V4_CMX=\*>$/"
M7[3?P4\1^*/$WB#5_AQXAL=)T+P]H&C^-KS5M:UG5+V>&ST[3--M+F]O;J:*
MWMH)9I$0_P"4W11GO!^&SW-<!FM;&5Z%3 0H0A2ITZ<H5%0Q,\2G*4O>3E*;
MB[;))K4>79Y6R[!XC!PH4ZD<1*I)SG*2E%U*4:3LEHTE&ZOU?8*_T1?^#:']
MMG]C/X#_ /!,G2? 7QQ_:X_9C^#/CJ/XY_%G5Y/!?Q7^/?PJ^'?BR/2M2D\/
MG3M3?PYXO\5Z/K":??B&8V5ZUF+:Z$4I@ED\M\?YW5%>CQ'D%'B/+EEU?$5,
M-!8BEB/:4HQG+FI1J14;3TL_:.[WT1RY5F4\JQ3Q5.E"K)TITN2;<5:;BV[Q
MUNN56Z:G]+G_  =1?'CX'?M#?\%!_@[XT^ /QE^%/QQ\':9^QM\/O"^I>+/@
M_P#$3PA\3/#.G>)K+XV_M#:M>>';[7O!>L:WI=IKMII>MZ-J5SI%Q=1ZA!I^
MKZ9>2VZ6]_:R2_JK_P &IG[7?[)_[.W[)'[27AO]H']I_P#9X^!?B+7?VC(-
M<T30/C'\:OAM\,=:UG11\,_!U@=8TK2O&OB71+[4-+%]:W-D=0M()K07=O/;
M&;SH9$7^$ZBN+%<)X?%<-4.&I8NM"A0C0BL2H4W5E["K[5-P?N+F>CMLMC>C
MG-6EFM3-51IRJ5'-NDY24%[2'([2^+1:KS/["/\ @[2_::_9N_:/\3?L+7'[
M/'[07P0^/,'A'0OVB8?%DWP8^*_@/XHQ>&)=;U#X+/HL7B&3P/K^N)HLFKII
M6J/I::DULU^NFW[6@E%G<&/^>'_@G)^WW\6O^";'[4_@S]ISX36EGX@ETNSU
M#PG\0OA]JU_>:9H?Q/\ AAXAFL9?$_@?5=1L$EN=-DFN=,TGQ#X<UD6FIP>'
M_&?A[PUK][H?B"RTNXT+4OA6BO0RS(<)EV1TL@J-XW!PI8BC4]O%1=:GB:U:
MM.,XP:4;>V<8N+4E9234M5S8O,JV*S">912P]=SI5(^S;:A.E3A"+BY;WY$V
MFFG=IIH_UG?V4O\ @NW_ ,$M?VT?#45IIG[1G@7X5^*=6MM%TG7/@_\ M,7F
MC_"/Q)]O\7IJ5G;>%[*?QC>Q> ?B-<74EA=Z?>VOP\\5^,H+9[S2;35ULI_$
M.BVVH?2/AO0/^"5W[%\&I_%+PAHG_!/W]DZVF^Q:5K/Q%\-Z;^SG\"8)?M3S
MVFG:;J?B[3(?"T;_ &B2]N;:RL[K4#YSW<\,$;-<2*_^.C17PU;PKP?M*BP6
M=9AA,)6:]KA90A6YXK50=2-2A&48WER>UHU7%-7<FFY?0T^,*_+%XC 8:O6@
MO<K*4J?*]+RY7&HTW9.7).";5TDK)?WN_P#!;[_@Y&^"4_PB^)G['W[ _B*7
MXG^,?B5X:OO!/Q&_:,T5Y;3X<>#_  9XJTJZL/$>C_"K6K;4+/6?%7CZ\TVX
M?3I_$]K8VOA+PQ;:@;G1-8\1>($F@\/?Q]_\$Z?VS_%7_!/W]LKX(?M5^%[&
M77(/ASXFDA\:^$TN)+<>,_AIXHT^[\+_ !#\+H1<V]J-4O\ PIJVIS^%KS4E
MN]-T3QC:>'?$5SI]]_9"6TGQ-17V>4\+Y3D^5U\IH495:&,A.&-G7ES5<7[2
MFZ4_:2BHJ,>1N,(4XQC!-N*YG*4O"QN;XW'8RGC*LU"I0E&6'C35H4.2:G'D
M3NV^9)RE)R<FDF^5)+_8,_9Y_P""C_\ P3?_ ."B?PAU2/P+\:_@O\0O"7C/
M2M1\)^/O@G\7Y_#.B>*FT[5M,O(]9\+>/_@]\0WAO=3T+5-,BU6UEG?2=9\&
M>)K*RU==+U76;&SOGC^&_B!=_P#!O3_P2J\2:E\>G\/?L=?#7XT^$+=/$N@:
M#\.G\-?$3X]6DVNO=:/9W'PV^&^GZOK_ (E\-'5EU>]T^/5M$TOPYH=KI!OI
M=0U:PT#2KVXL?\M>BOD*7ACAZ%:M"AGV:T<MKR_?8&DU3E6I[.G6KPFJ55.-
MXWEA'H]GK?VI\6U:D(.IEV#GBJ:_=XB:<E"724*<HN<'>SM&LM>Q_K-?L0?\
M%N/V(_VF_P!F?P)\</C'^TQ^R=^S/X\\;Z[\5#<_!'XD?M+_  D\,^/? _AG
MPY\7O'GA+X?)XMT7Q3XNTC6;77?$'P]T'POXJOY9--L]/OIM=;4-$A&B76G,
MW^?O_P ' GQ0^&GQF_X*Z?M:_$KX/_$3P+\5_AUXD_X4-_PCOC_X:^+= \=>
M"M>_L?\ 9E^#&@:O_8OBKPOJ&J:%JG]EZ[I>IZ+J/V&_G^PZMIU_IUSY5Y9W
M$,?XVT5[N0<%8'A[-<7F>#Q-:4<31Q&'AA)QC[/#T:V)HXB,(5+NI/V2H1I1
M<VW*-Y2;D>?F6?XC,\'0PE>E33HU*=65:+?/5G3I3I.4HV4(\[J2FU%))V22
M1_5M_P &YG_!;GX$_P#!/#PY\3_V5_VLTU7PG\$_B5\1I?B]X/\ C%X9\*:W
MXM?P)X[O?!>D^%_%]A\1M%\/2ZMXJU/PEXAT?P#X$L_"-QX'\':WK&@^)QJO
M]O65]X?U]M8\&?VRW7_!2G_@E%\0M-M)==_;F_8,UZQAD\^SM?&?[0OP(CEM
M9IH(V,L>E>*_%5O>6DK0RK'(_P!DB=6$EM(1+#+&G^/)17'GOAYE>=9A4S..
M*Q>!Q-=J6(5#V<Z52:C&"JQA.*E3G**M4Y:G)-VER1DYRGOEW$^,P&&AA'1H
MXBE3TINIS1G&+;?(Y1=I13?N7CS1VYFE%1]*^,__  C_ /PN'XK_ /")?V-_
MPBO_  LKQU_PC/\ PCOV+_A'_P#A'_\ A*-5_L;^PO[,_P");_8W]F_9O[,_
ML_\ T+[%Y'V3]QY=>:T45]]"/)"$+N7)&,;O=\J2N_-VN_,^;D[MNR5VW9;*
M[O9>044450@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH _KH_X--OVD_V=/V<OBA^VAJ'[0OQ]^"OP'L/%/@+
MX.6?AB^^,WQ4\"_"^T\1W>E^(?'D^IVN@W/C?7=#AU>YTZ&\M)KZ#3WN);2*
MZMI+A8TGB+?J[_P<O?ML_L9_'C_@F3JW@+X'?M<?LQ_&;QU)\<_A-J\?@OX4
M?'OX5?$3Q9)I6FR>(#J.IIX<\(>*]8UA]/L!-";V]6S-M:B6(SRQ^8F?\[JB
MOB\7P7A<7Q+2XEEC<1"O2KX2NL-&G3=)O"4Z=.,7-^_::I)RZIMV/=HY[5HY
M5/*E0IRISA6@ZKE)32K3E-M17N^[S-+OH%%%%?:'A!7]]W_!J[^V/^R'^SS_
M ,$^/C%X+^/W[5/[-_P.\8ZG^V3\0?%&F^$_C!\<?AC\,_$VH^&;WX)?L\Z3
M9^(K'0?&GBC1-4N]"N]4T36=-MM7M[633Y]0TC4[.*X>XL+J.+^!&BO#XBR.
MEQ%ELLMK5ZF'A*M2K>UI1C.:=)MI6GI9WUZGHY7F,\KQ2Q5.G&K)0G3Y)MQ5
MIVN[QUNK:']67_!UU^T3^S]^T5^TM^RSKW[/OQT^#GQUT/P]\#/$FD:_K/P;
M^)W@KXG:5H>JS^/KZ\@TS6-1\$ZWKEGIFH36;I=165[-!<R6S+.D1B8.?P6_
MX)T>*/#/@C_@H/\ L)>-/&GB+0O"'@[PA^V3^S#XH\6>+/%&KZ?H'AGPOX9T
M#XV^!]6U[Q%XBU[5KBTTO1-"T32[2ZU+5]7U*ZMM/TW3[:XO+RXAMX9)%^-J
M*O+LFI9=DE+)(5JE2E2PU;#*O*,54<:SJMR<5[MX^U=EMHKDXK'SQ682S"5.
M,9RJTZKIQ;<4Z:@DKO6SY%?U9_L&_%7_ (*9_P#!-[4?A?\ $C3]/_X*"?L1
M7U_?> O&%G96-G^U=\![J\O+NZ\/:C!;6MK;0>/7FN+FXF=(8((4>665UCC5
MG8 _Y)GP%^-?CO\ 9O\ C9\)_C]\,;VWL/B!\&_B#X3^)'A*:]6[ETR;6O"&
MM6>M6FGZW:V-YI]SJ/A_5FM#I?B'24O;5-7T2\O],FF6"[DKR6BO*X:X0PG#
M=',*%/$U<;3S%48UHXBG3C%0I1KP<+0NI1J1KR4E+HK=6=F:YW7S6>&J2I0P
M\L*YN#I2DVY3=.7->6SBZ:<;=_(_UROV%_\ @L_^P!^W]X"L=0\%_&CP3\/_
M (C/I6D)XW^ _P 7O$.C^#/'F@:KJ\%K;WVEZ5:^)9=*L?B3H5OJ=['HX\3^
M"#K&D337>G6VIII&IZG!I-> _%KX+_\ !O)^Q-XH'[0GQ+\"?L"?"7QOHJWG
MQ"\,647_  @MWX@FO?"<MOK":K\*O@CH][J/V_6])U'3K)M$@^'O@.2_M=9>
MTM=*CBO[Z..?_*SHKYV/AEAZ&)K3P.>YI@<%7=JN$H/EJ3IZ_NI8F-2"G"+<
ME'VN'J-1=I.4KR?IOBVK4I4UB,NP>(KTM85JEW&,]/?5)QDXR=ES<E6";LUR
MI)+_ %;/V&?^"\W[#G[6_A3XW>/O'WQZ_9\_9@T+PE^T'XG^&OP?\*_'GXY_
M#3X8_$OQ[\*- \ _#36-,^+&L^$_&GBO2+VQM_%GB[Q'XSLM-BTZ"XTZPLM"
MBT:>^O-=TO6IC_'?_P '47QX^!W[0W_!0?X.^-/@#\9?A3\<?!VF?L;?#[PO
MJ7BSX/\ Q$\(?$SPSIWB:R^-O[0VK7GAV^U[P7K&MZ7::[::7K>C:E<Z1<74
M>H0:?J^F7DMNEO?VLDO\T=%>QDO N79%G#S7!8G$<JI5*-/"3C"4(1J0C!MU
M6_:3E[KDV]Y2>RT.+'\18K,,#]3KTJ5W.,Y5HN2E)QDY+W/A2UM9;)+KJ_Z:
M/^#?'_@MWX1_X)LZKXP_9S_:.TZX'[+'Q:\8W?Q$G\>^'M)U/6O%'PH^)<_A
MS0_#=UKUUH.E1W=_XH\'>(]%\*>'M*UK3]*L)]?T>ZTVQU?2H=0B.HZ9<_V?
M^/+W_@BG_P %CO .C#QQXP_96_:ET[1=#T_5])=_B'#X+^-/P[T/Q#>:5K<<
M$LNE^(/ GQX^$T6M7NDV$6N:%?/X5FOYK&[T#Q!I\ICU+3J_R6**G.^!,%FF
M8/-\%C\;D^9R<93Q&$E>,JD5R^VY5*E5A6<$HRE2KTXR24G!R<I2,!Q%B,)A
ME@J^'H8[")-1I5UJHMWY.9J<)03NTITY--V4E%)+_6<^$FE?\$0?^"1FD>(V
M^&?CC]D+]F"_U[3Y(M?N]5^-6E^*/B_XJTJRN[76'T>&_P#&WC?QG\8/%FGV
M-QK>G:BOAW3)]3MK2*ZTNXCTZ*VBL&B_C'_X.$/^"VO@_P#X*3ZWX,_9Z_9R
MT^]/[+?PA\6Q>/K;QWK^GZSH?B+XL?$D>'M6\/0:_!X9U/['/X<\)>&M&\1Z
M]I.@6NM:7'XEU"XU35=3OETJWN+?2H_YFZ*,EX%PF69BLWQN88W.<RA=T\1C
M).T)N+A[7EE.K5G44&XP=6O.,$VU'F491,?Q#7Q>%>!H8;#X'".W-2H+644U
M+DNE"$8.2YI*%.+ELY6YD_N;_@G1^WK\5/\ @FY^U3X'_:?^%6GZ=XDN-#M]
M1\,>._ .LW=UIVC?$CX;>(S:KXH\&7^IV4<UUI%Q<-9:?K7AW7([74HM \7:
M)X>UN]T7Q!I^GW>@:G_I-?LV?\%NO^"3?_!0#X;WG@[Q!\;/A1X,O/&VA:9X
M5^(/[//[62^'? K:M_PGMIJ>F7/@&2W^(WE?#7XO66I_8]0T?5-.\%ZWXPLI
M(;W2K/7K+3Y?$NCV-]_D_P!%=G$G!N6<1U*6)K5*^#Q]""A3QF&<>9PC+FA&
MM3FFJBIMR=.494JD7+^(XI1,<JSW%Y5&=*$:=?#5).4J%9.RDU:4J<HM.+DD
ME)-3@TOA4GS'^O'X<_9=_P""-/[+OB2U^.VA_"?]@#X)^(?"-Q<:SI?Q.N[/
MX)^$CX,O;6.;5YM:T+7]8N+:R\(ZAIUI87=U%JVD3:9>:9ID%^MO<VVGF\1O
MRE_X*Z_\')W[,'[/_P */'7P9_8B^)&F?'S]I7QQX1UW0?#WQ4^%VIZ)XC^$
M'P3N-4CN-$_X32?QU%=7NC>,?&VCK+-K?@CP_P"%[+Q/X<EU&QMK_P 8:I8Z
M8++2/$G^;M17A8+PUP<,71Q>;YMC<Z=!Q<*.(BX4I<KYHPJN=;$5)TE+5TXU
M(1EM*\7*+]"OQ77="I1P6#P^ ]HFI5*3YIIM6E*'+"G&,VM%)QDX[III-7-1
MU'4-8U"_U;5K^\U35=4O+K4=3U/4;J>^U#4=0OIWN;V_O[VY>6YO+R[N99;B
MZNKB62>XGD>65WD=F-.BBOTM))62LEHDMDNQ\H%%%% '^L#_ ,$Z/^"B_P#P
M3X\$?\$^/V$O!?C3]NW]C;PAXQ\(?L;?LP^%_%GA/Q1^T]\$M \3>%_$V@?!
M+P/I.O>'?$6@ZMXXM-4T37=$U2TNM-U?2-2M;;4--U"VN+.\MX;B&2-?\_3_
M (+Q?$KX<_&#_@K)^U[\1_A+X_\ !7Q1^'GB;7?A=-X<\>?#KQ5H7C;P9X@B
MT_X%_"_2+^71/%'AJ_U/0]5CL=6T^_TN\>POKA;;4;*[LIBES;31)^1-%?&Y
M!P;ALAS7&YK1QM?$5,;2KTITJE.G&$%7Q-+$MQE%\S<94E%7W3;>I[N8Y[5S
M'!8?!3H4Z4,/.G.,XRE*4O9TITDFGHKJ;D[=4D%%%%?9'A!1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %?ZP/\ P3H_X*+_ /!/CP1_P3X_82\%^-/V[?V-O"'C
M'PA^QM^S#X7\6>$_%'[3WP2T#Q-X7\3:!\$O ^DZ]X=\1:#JWCBTU31-=T35
M+2ZTW5](U*UMM0TW4+:XL[RWAN(9(U_R?J*^7XHX7H<44,+0KXJMA8X6M.M&
M5&$)N;G#D::GHDEKIK<]?*,WJ915K5:=&%9UH1IM3E**BHRYKKEW;V/UV_X+
MQ?$KX<_&#_@K)^U[\1_A+X_\%?%'X>>)M=^%TWASQY\.O%6A>-O!GB"+3_@7
M\+](OY=$\4>&K_4]#U6.QU;3[_2[Q["^N%MM1LKNRF*7-M-$GY$T45[V PD<
M!@<'@83E4A@\)A\)&I))2G'#T848SDEHI24$VEHF]-#SL36>)Q%?$2BHRKUJ
MM9Q3;475G*;BF]6DY63>M@K[)_X)T>*/#/@C_@H/^PEXT\:>(M"\(>#O"'[9
M/[,/BCQ9XL\4:OI^@>&?"_AG0/C;X'U;7O$7B+7M6N+32]$T+1-+M+K4M7U?
M4KJVT_3=/MKB\O+B&WADD7XVHK3$45B*%>A)N,:]&K1<E9N*JPE!M)Z72E=7
MTN12J.E5IU4DW3J0J)/9N$E))^3M8_UU_P!I_P#X*4?\$Z/$'[-/[0^@Z#^W
MW^Q3K>N:W\#/BUI&C:-I'[5'P+U+5=7U74O /B"ST[3-,TZS\=S7E_J%_>30
MVME96L,MS=7,L4$$4DLB(?\ (HHHKYOA?A7#\+TL92P^+K8I8RI1J2=:$(.#
MHQG%*/)NGSMN_96/5S?.*N;RH2JT:='V$9Q2A*4N;G<6V^;:W+I;N?WW?\&K
MO[8_[(?[//\ P3X^,7@OX_?M4_LW_ [QCJ?[9/Q!\4:;X3^,'QQ^&/PS\3:C
MX9O?@E^SSI-GXBL=!\:>*-$U2[T*[U31-9TVVU>WM9-/GU#2-3LXKA[BPNHX
MOSY_X.R?VD_V=/VC?BA^Q?J'[/7Q]^"OQXL/"W@+XQV?B>^^#/Q4\"_%"T\.
M7>J>(? <^F6NO7/@C7=<ATBYU&&SNYK&#4'MY;N*UN9+=9$@E*_R+T5AA^#L
M-A^)JG$T<97E7J5*]1X5TZ:I)U\/+#R2FO?M%2<EW:L]#6KGM:KE,<I="FJ<
M84X>V4I<[5*I&HGR_#=N-GY/0_K7_P"#;K_@M=\'/V&=%^(G[(O[7GB>]\'?
M!3QSXUM?B+\)OB;_ &5K>OZ7\/\ QWKEIIGAOQGX:\7Q:6-5U#3/!7B:UTGP
MUKFCZCIFD1:5X5UZQ\7ZEXA:6W\62:EHW]I'QX\"_P#!+G]O7P/X>USX[R?L
M@?M)>"?"UO=ZMX2\<:MXU^''B>+PSIVJ6>F:SJD_AGXB:-KXU'0]&UO3[71-
M4UJ'2/$%II>MV-II%YJD5Y;VMC)'_CP45Y^=^'^%S/-)9O@LRQ>48VK)3K3P
M\5.,JB@H.K2Y:E"I1J3BG[5QJ2C.3<N52<W/HP'$M;"8-8&OA*.-P\%RPC5?
M*U#FYE"=X5(5(Q?P)P3C9*[2BE_IA>)/^"NO_!'S_@G!XG^!7[)W[!A_9HNS
M\;?V@/@IH7Q0\2?!K6?#%C\!?A;\.O%_CS1/!'Q$^,WQ9^-VDWDGA;7_ !'X
M4\#:?J$UI#?^+-3OM-@@TSQ#XPO]-\+0Q#5_K_\ X*+_ /!1?_@GQXW_ ."?
M'[=O@OP7^W;^QMXO\8^+_P!C;]I[POX3\)^%_P!I[X):_P")O%'B;7_@EXXT
MG0?#OAW0=)\<7>J:WKNMZI=VNFZ1I&FVMSJ&I:A<V]G9V\UQ-'&W^3]17-+P
MSRUUL'B?[2S">)P]6-?$8BNX5ZN,JQJ0G%U)3MR1BH*$5&[46W*4I:FRXLQ2
MA6I?5,-&E4@Z=*E34J<*$'%Q:@H_$W=R;=E>R225CT+X2?$_Q9\$OBM\,OC/
MX"NK>Q\=?"/XA>"_B?X+O;RW%W:6?BSP#XDTWQ7X<NKJT+QBZM[?6-)LY9[<
MR1B:-&CWINW#_37_ &#?^#C#_@G;^V'\,?#.B_'WXK?#W]F#XZ:AX6N(_B;\
M,_C/>3^%OA=+=P2V^CZS-X8^*_B^UM/AMJOAW7S?17NE^&M?\3VGC"/2[F^M
MKW1[^UT74M7?_+FHKZ/B3A3+>)J=%8N5:AB,-S?5\5AY152$9V<J<XSC*%2D
MY*,N5J,XR5X3AS34O*RK.<7E,YN@J=2E5M[6C53<)..THN+C*,TFU=-Q:?O1
ME:-O]536/^"1O_! :;QH?CWJGP(_95L+J>73=9$\/QIUG0_@VR3Z?::/ILT7
MPIL/BE8? ]-+OK=[5X[2'P4NEZEJEP-8>WN-9NWOI>-_;P_X.$O^"=G[$?P9
MU+2/V>?BE\)?VE?C!I_A:+1OA!\(_@-KNF>+/AEILMI9V.GZ&/%/CSP ;[P'
MX4\&^&[2>VDE\/Z3K7_"0W=GITNA:'IEK)'/>Z7_ );M%?-T_#>G7K4)YUG^
M:YS1PS7L<-7G.%-05OW7-5KXF<*<N5*:HNBW%6C*+LUZLN*9TX5(X#+<'@:E
M5/VE6G&,I.3^W:%.E&4TVVG4]HDWJGK?O?BK\2?%7QE^*'Q(^,'CJ[CU#QO\
M5O'OC#XD^,;^)9EBO?%7CKQ#J/BCQ#=QK<3W,ZQW.KZI>3(L]S<3!7 DGE<-
M(W]D/_!#3_@Y%^$O[/WP-\)?L=?M_7FL>%?"/PDT9=!^"_[0FA>'?$WC6"'P
M-9NQTCX=?$KPGX5T[7O%27'A&W<:1X,\4^$]%U.TN_"UOI7A[7-"TJ]\/-XF
M\4_Q0T5]CG.09;GN 678ZE)4:;A*A.A)4ZV&G"+A&="3C.,6H-P<9PG3E%VE
M!V37AX#,L5EV)>*P\TYR352-1.<*L9/F<:B3C)WDE*\91DFM)*[O_KV>+/"_
M_!'7_@HC=1_%#Q5#^P1^UGK'AFWMO",GQ!DU?X+_ !'\2Z)8V<E]J-AX2U/Q
M597][K]CIUM+JNH:KIWAO4[Z.RA?5;G5;*Q4Z@]S-#X@_;6_X)'_ /!-GX6:
MCX*TCXU?LA_ +PCX.M=1UY?@I\&M;^',?B^_O1'=VU[?:=\(?AM-<^+=>\0Z
MS>>'[C3+W6I-!N+O4];L_L^KZHU\K,/\AFBOA%X74I<E"OQ#F5; 4Y)T\'R1
MBH)=(RE6J48NS:4HX96OMW^B_P!;YJ]2GEF$AB9)J5?F;<KVW2A&;6BNG5=[
M(_:__@MK_P %>?$'_!5?X^>']5\(Z3XN^'O[,OPFTJ;1_A!\,_%-UIPUJ]U;
M4IY9_$OQ/\<:?HE[JNCVWC;Q)"=.T1-+L-<U[2?#7AW0=/L=*U">^U#Q'JFM
M?BA117Z3E^ PN5X.A@,%25'#8:')3@FV]W*4I2=W.<Y.4YSDVY3DY/5GRN)Q
M-;%UZF)Q$W4JU9<TY/3HDDDM%&,4HQBM%%)+8]X_98_X0O\ X:=_9R_X63_P
MB_\ PKO_ (7Q\(?^$^_X3C^R?^$+_P"$+_X6#X>_X2G_ (2_^WO^)'_PB_\
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M@S#+*]3,\=1R_!U9T:-9P4:-*<J=-<L7RN232>MTG*[O<_G3HKZX_:\_8/\
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MU[0/BU!H$4=RT%T-<T#PA?7WC/3;>PB,%_?:Q/X9'AZWT^X-PVL'[#JJ:?\
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M_!J[^RUX-_:#_P""D]Q\0?B%X7T[Q/X=_9>^$NK_ !F\,1:O!8ZAIUE\8/\
MA+O!_A;X;:E)I=U<K)+J/AY-:\3^-O#>K)87T7A[Q5X1T/58I-/UF'1+V/\
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MMQ:LXMIKLT[-::;]@HHHJA!1110 4444 %%%% !1110 4444 %%%% !1110
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MU7RU.6-E%3DXU(SY4K*3ASO>4I,_UO?VE_\ @KQ_P2V_X)U_#2;PK?\ QO\
M@Z+KX8:-;>$/!W[,O[-\_A7Q=XSTM]%T&:?PW\/M)^'?P]F;0OA?IRZ7IT&G
MZ3/XWF\">"='BETFSGU6P&H:5#=?YL/_  5#_P""EOQB_P""HG[2NI?'7XD6
MMQX,\&Z3IUOX:^#WP5M/$3^(_#7PB\(Q6]H;_3].U7^QO#O]O^(/$^L03^(O
M%_B^\T2QU/6]0N+73HX=/\,>'O"OA_0_S@HKU>&^"LLX<JSQ<*E;'9A4BX/&
M8E13IQG9U%0I1NJ;J->_.4JE5J\%44)3C+DS7/\ %YI"-"488?#1:DJ%*_O.
M/P^TF]9*'V8Q4()VDXN48M?TN?\ !J[\>/@=^SS_ ,%!_C%XT^/WQE^%/P.\
M':G^QM\0?"^F^+/C!\1/"'PS\,ZCXFO?C;^SSJUGX=L=>\::QHFEW>NW>EZ)
MK.I6VD6]U)J$^GZ1J=Y%;O;V%U)%^]/_  <O?ML_L9_'C_@F3JW@+X'?M<?L
MQ_&;QU)\<_A-J\?@OX4?'OX5?$3Q9)I6FR>(#J.IIX<\(>*]8UA]/L!-";V]
M6S-M:B6(SRQ^8F?\[JBGCN#\-CN(\+Q%/&5Z=;"SPLXX:-.FZ4WA7>*E-^^N
M?[5MNA.'SNKA\KK97&A3E3K*JG5<I*<?:VO:*]W2VE]PK_5D_P""8W_!1'_@
MG[X!_P""='[#7@CQU^W1^QUX*\:>$OV4_@3X=\5^$/%O[3?P4\.>*/#/B#2/
MAQX>L=6T+Q#H&L>-K/5M%UG2[V":SU'3-2M+:]LKJ&6WN8(IHW0?Y3=%=/$_
M#%#B?#8;#5\56PL<-7E7C*C"$W)RINGRM3T22=]-;F649M4RBK5JTZ,*SJTU
M3:G*44DI*5UR]=+'ZJ_\%O/B)\/_ (L?\%4_VQOB'\+/'/@[XE^ /$_CWPW>
M>&O'/@#Q-HOC+P?XAM(/AKX(L)[K0_$WAV^U+1=6MH;ZTNK.6>PO;B*.[MKB
MW=A-#(B_E5117NX+"QP6"PF"A)SCA,+A\+&<DE*<</2A24I):)R4$VEHF]#S
MJ]5UZ]:NTHNM5J57%:J+J3E-I-ZM)NRN%%%%=1D%%%% !1110 4444 ?T'?\
M&RO_ "F"_9I_[%'X\_\ JB/B#7^I%7^6[_P;*_\ *8+]FG_L4?CS_P"J(^(-
M?ZD5?B?C?_R5.5?]DOEG_J7F1]]X??\ (FQ?_8VQ7_IC"'^(M\4O^1X\:?\
M8Y^)?_3O?UYQ7H_Q2_Y'CQI_V.?B7_T[W]><5_06=?[[_P!R^&_]-1/S3 ?P
M'_U]J?\ I04445Y)VA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MK&DVOA+Q)_1A_P %:O\ @F/\(?\ @J'^RSXD\":SHFA+\<O!_AKQ-XE_9?\
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MPV?AG1-::5DA_F/^ '_!XI^TOI_CK3E_:F_9<^!?B[X9W>HZ3;:O+\ &\?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M6]T[1W\'_%^S%Z\TWA^1M)T;2OAEJFEZ7%!INO36H\5:@SZ[IFFN/#?Z:?\
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MO6JUIV4JU2=626W-4DYNU[NUV[!111709A1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?T'?
M\&RO_*8+]FG_ +%'X\_^J(^(-?ZD5?Y;O_!LK_RF"_9I_P"Q1^//_JB/B#7^
MI%7XGXW_ /)4Y5_V2^6?^I>9'WWA]_R)L7_V-L5_Z8PA_B+?%+_D>/&G_8Y^
M)?\ T[W]><5Z/\4O^1X\:?\ 8Y^)?_3O?UYQ7]!9U_OO_<OAO_343\TP'\!_
M]?:G_I04445Y)VA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?T'?\&RO_*8
M+]FG_L4?CS_ZHCX@U_J15_EN_P#!LK_RF"_9I_[%'X\_^J(^(-?ZD5?B?C?_
M ,E3E7_9+Y9_ZEYD??>'W_(FQ?\ V-L5_P"F,(?XBWQ2_P"1X\:?]CGXE_\
M3O?UYQ70?$CQKX0OO&?C">R\3:'=V\WB[Q#/!<6VIVD]O<02ZK?/%/;SQRM#
M<02HRO%-"[Q2(RNCLK*3P7_"3^'/^@YI7_@=;_\ QROW'.,WRF>,YH9IETE[
M##J\<;AI*ZI135U5:NFFFNCT9^?8' XV-%J6#Q47[6H[/#U4[.2L[.&SNK=[
MHW:*PO\ A)_#G_0<TK_P.M__ (Y1_P )/X<_Z#FE?^!UO_\ '*\O^U<K_P"A
ME@/_  LP_P#\L.OZGB_^@7$_^"*O_P CYK[S=HK"_P"$G\.?]!S2O_ ZW_\
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M*/[5RO\ Z&6 _P#"S#__ "P/J>+_ .@7$_\ @BK_ /(^:^\W:*PO^$G\.?\
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MG\.?]!S2O_ ZW_\ CE'_  D_AS_H.:5_X'6__P <H_M7*_\ H98#_P +,/\
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MPO\ A)_#G_0<TK_P.M__ (Y1_P )/X<_Z#FE?^!UO_\ '*/[5RO_ *&6 _\
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M_P""*O\ \CYK[S=HK"_X2?PY_P!!S2O_  .M_P#XY1_PD_AS_H.:5_X'6_\
M\<H_M7*_^AE@/_"S#_\ RP/J>+_Z!<3_ ."*O_R/FOO-VBL+_A)_#G_0<TK_
M ,#K?_XY1_PD_AS_ *#FE?\ @=;_ /QRC^U<K_Z&6 _\+,/_ /+ ^IXO_H%Q
M/_@BK_\ (^:^\W:*PO\ A)_#G_0<TK_P.M__ (Y1_P )/X<_Z#FE?^!UO_\
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M$G\.?]!S2O\ P.M__CE'_"3^'/\ H.:5_P"!UO\ _'*/[5RO_H98#_PLP_\
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MK[S=HK"_X2?PY_T'-*_\#K?_ ..4?\)/X<_Z#FE?^!UO_P#'*/[5RO\ Z&6
M_P#"S#__ "P/J>+_ .@7$_\ @BK_ /(^:^\W:*PO^$G\.?\ 0<TK_P #K?\
M^.4?\)/X<_Z#FE?^!UO_ /'*/[5RO_H98#_PLP__ ,L#ZGB_^@7$_P#@BK_\
MCYK[S=HK"_X2?PY_T'-*_P# ZW_^.4?\)/X<_P"@YI7_ ('6_P#\<H_M7*_^
MAE@/_"S#_P#RP/J>+_Z!<3_X(J__ "/FOO-VBL+_ (2?PY_T'-*_\#K?_P".
M4?\ "3^'/^@YI7_@=;__ !RC^U<K_P"AE@/_  LP_P#\L#ZGB_\ H%Q/_@BK
M_P#(^:^\W:*PO^$G\.?]!S2O_ ZW_P#CE'_"3^'/^@YI7_@=;_\ QRC^U<K_
M .AE@/\ PLP__P L#ZGB_P#H%Q/_ ((J_P#R/FOO-VBL+_A)_#G_ $'-*_\
M ZW_ /CE'_"3^'/^@YI7_@=;_P#QRC^U<K_Z&6 _\+,/_P#+ ^IXO_H%Q/\
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M+_A)_#G_ $'-*_\  ZW_ /CE)_PE'AP?\QS2O_ VW/<#L_O^63T!H_M7*_\
MH98#_P +,/\ _+!_4\7_ - N)_\ !%7_ .1\T;U%87_"3^'/^@YI7_@=;_\
MQRC_ (2?PY_T'-*_\#K?_P".4?VKE?\ T,L!_P"%F'_^6"^IXO\ Z!<3_P""
M*O\ \CYK[S=HK"_X2?PY_P!!S2O_  .M_P#XY1_PD_AS_H.:5_X'6_\ \<H_
MM7*_^AE@/_"S#_\ RP/J>+_Z!<3_ ."*O_R/FOO-VBL+_A)_#G_0<TK_ ,#K
M?_XY1_PD_AS_ *#FE?\ @=;_ /QRC^U<K_Z&6 _\+,/_ /+ ^IXO_H%Q/_@B
MK_\ (^:^\W:*PO\ A)_#G_0<TK_P.M__ (Y1_P )/X<_Z#FE?^!UO_\ '*/[
M5RO_ *&6 _\ "S#_ /RP/J>+_P"@7$_^"*O_ ,CYK[S=HK"_X2?PY_T'-*_\
M#K?_ ..4?\)/X<_Z#FE?^!UO_P#'*/[5RO\ Z&6 _P#"S#__ "P/J>+_ .@7
M$_\ @BK_ /(^:^\W:*PO^$G\.?\ 0<TK_P #K?\ ^.4?\)/X<_Z#FE?^!UO_
M /'*/[5RO_H98#_PLP__ ,L#ZGB_^@7$_P#@BK_\CYK[S=HK"_X2?PY_T'-*
M_P# ZW_^.4?\)/X<_P"@YI7_ ('6_P#\<H_M7*_^AE@/_"S#_P#RP/J>+_Z!
M<3_X(J__ "/FOO-VBL+_ (2?PY_T'-*_\#K?_P".4?\ "3^'/^@YI7_@=;__
M !RC^U<K_P"AE@/_  LP_P#\L#ZGB_\ H%Q/_@BK_P#(^:^\W:*PO^$G\.?]
M!S2O_ ZW_P#CE'_"3^'/^@YI7_@=;_\ QRC^U<K_ .AE@/\ PLP__P L#ZGB
M_P#H%Q/_ ((J_P#R/FOO-VBL+_A)_#G_ $'-*_\  ZW_ /CE'_"3^'/^@YI7
M_@=;_P#QRC^U<K_Z&6 _\+,/_P#+ ^IXO_H%Q/\ X(J__(^:^\W:*PO^$G\.
M?]!S2O\ P.M__CE'_"3^'/\ H.:5_P"!UO\ _'*/[5RO_H98#_PLP_\ \L#Z
MGB_^@7$_^"*O_P CYK[S=HK"_P"$G\.?]!S2O_ ZW_\ CE'_  D_AS_H.:5_
MX'6__P <H_M7*_\ H98#_P +,/\ _+ ^IXO_ *!<3_X(J_\ R/FOO-VBL+_A
M)_#G_0<TK_P.M_\ XY1_PD_AS_H.:5_X'6__ ,<H_M7*_P#H98#_ ,+,/_\
M+ ^IXO\ Z!<3_P""*O\ \CYK[S=HK"_X2?PY_P!!S2O_  .M_P#XY1_PD_AS
M_H.:5_X'6_\ \<H_M7*_^AE@/_"S#_\ RP/J>+_Z!<3_ ."*O_R/FOO-VBL+
M_A)_#G_0<TK_ ,#K?_XY1_PD_AS_ *#FE?\ @=;_ /QRC^U<K_Z&6 _\+,/_
M /+ ^IXO_H%Q/_@BK_\ (^:^\W:*PO\ A)_#G_0<TK_P.M__ (Y1_P )/X<_
MZ#FE?^!UO_\ '*/[5RO_ *&6 _\ "S#_ /RP/J>+_P"@7$_^"*O_ ,CYK[S=
MHK"_X2?PY_T'-*_\#K?_ ..4?\)/X<_Z#FE?^!UO_P#'*/[5RO\ Z&6 _P#"
MS#__ "P/J>+_ .@7$_\ @BK_ /(^:^\W:*PO^$G\.?\ 0<TK_P #K?\ ^.4?
M\)/X<_Z#FE?^!UO_ /'*/[5RO_H98#_PLP__ ,L#ZGB_^@7$_P#@BK_\CYK[
MS=HK"_X2?PY_T'-*_P# ZW_^.4?\)/X<_P"@YI7_ ('6_P#\<H_M7*_^AE@/
M_"S#_P#RP/J>+_Z!<3_X(J__ "/FOO-VBL+_ (2?PY_T'-*_\#K?_P".4?\
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M_H98#_PLP_\ \L#ZGB_^@7$_^"*O_P CYK[S=HK"_P"$G\.?]!S2O_ ZW_\
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M*/[5RO\ Z&6 _P#"S#__ "P/J>+_ .@7$_\ @BK_ /(^:^\W:*PO^$G\.?\
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MG\.?]!S2O_ ZW_\ CE'_  D_AS_H.:5_X'6__P <H_M7*_\ H98#_P +,/\
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MPO\ A)_#G_0<TK_P.M__ (Y1_P )/X<_Z#FE?^!UO_\ '*/[5RO_ *&6 _\
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M_P""*O\ \CYK[S=HK"_X2?PY_P!!S2O_  .M_P#XY1_PD_AS_H.:5_X'6_\
M\<H_M7*_^AE@/_"S#_\ RP/J>+_Z!<3_ ."*O_R/FOO-VBL+_A)_#G_0<TK_
M ,#K?_XY1_PD_AS_ *#FE?\ @=;_ /QRC^U<K_Z&6 _\+,/_ /+ ^IXO_H%Q
M/_@BK_\ (^:^\W:*PO\ A)_#G_0<TK_P.M__ (Y1_P )/X<_Z#FE?^!UO_\
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M$G\.?]!S2O\ P.M__CE'_"3^'/\ H.:5_P"!UO\ _'*/[5RO_H98#_PLP_\
M\L#ZGB_^@7$_^"*O_P CYK[S=HK"_P"$G\.?]!S2O_ ZW_\ CE'_  D_AS_H
M.:5_X'6__P <H_M7*_\ H98#_P +,/\ _+ ^IXO_ *!<3_X(J_\ R/FOO-VB
ML+_A)_#G_0<TK_P.M_\ XY1_PD_AS_H.:5_X'6__ ,<H_M7*_P#H98#_ ,+,
M/_\ + ^IXO\ Z!<3_P""*O\ \CYK[S=HK"_X2?PY_P!!S2O_  .M_P#XY1_P
MD_AS_H.:5_X'6_\ \<H_M7*_^AE@/_"S#_\ RP/J>+_Z!<3_ ."*O_R/FOO-
MVBL+_A)_#G_0<TK_ ,#K?_XY1_PD_AS_ *#FE?\ @=;_ /QRC^U<K_Z&6 _\
M+,/_ /+ ^IXO_H%Q/_@BK_\ (^:^\W:*PO\ A)_#G_0<TK_P.M__ (Y1_P )
M/X<_Z#FE?^!UO_\ '*/[5RO_ *&6 _\ "S#_ /RP/J>+_P"@7$_^"*O_ ,CY
MK[S=HK"_X2?PY_T'-*_\#K?_ ..4?\)/X<_Z#FE?^!UO_P#'*/[5RO\ Z&6
M_P#"S#__ "P/J>+_ .@7$_\ @BK_ /(^:^\W:*PO^$G\.?\ 0<TK_P #K?\
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M .AE@/\ PLP__P L#ZGB_P#H%Q/_ ((J_P#R/FOO-VBL+_A)_#G_ $'-*_\
M ZW_ /CE'_"3^'/^@YI7_@=;_P#QRC^U<K_Z&6 _\+,/_P#+ ^IXO_H%Q/\
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M_P#+ ^IXO_H%Q/\ X(J__(^:^\W:*PO^$G\.?]!S2O\ P.M__CE'_"3^'/\
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MRC^U<K_Z&6 _\+,/_P#+ ^IXO_H%Q/\ X(J__(^:^\W:*PO^$G\.?]!S2O\
MP.M__CE'_"3^'/\ H.:5_P"!UO\ _'*/[5RO_H98#_PLP_\ \L#ZGB_^@7$_
M^"*O_P CYK[S=HK"_P"$G\.?]!S2O_ ZW_\ CE'_  D_AS_H.:5_X'6__P <
MH_M7*_\ H98#_P +,/\ _+ ^IXO_ *!<3_X(J_\ R/FOO-VBL+_A)_#G_0<T
MK_P.M_\ XY1_PD_AS_H.:5_X'6__ ,<H_M7*_P#H98#_ ,+,/_\ + ^IXO\
MZ!<3_P""*O\ \CYK[S=HK"_X2?PY_P!!S2O_  .M_P#XY1_PD_AS_H.:5_X'
M6_\ \<H_M7*_^AE@/_"S#_\ RP/J>+_Z!<3_ ."*O_R/FOO-VBL+_A)_#G_0
M<TK_ ,#K?_XY1_PD_AS_ *#FE?\ @=;_ /QRC^U<K_Z&6 _\+,/_ /+ ^IXO
M_H%Q/_@BK_\ (^:^\W:*PO\ A)_#G_0<TK_P.M__ (Y1_P )/X<_Z#FE?^!U
MO_\ '*/[5RO_ *&6 _\ "S#_ /RP/J>+_P"@7$_^"*O_ ,CYK[S=HK"_X2?P
MY_T'-*_\#K?_ ..4?\)/X<_Z#FE?^!UO_P#'*/[5RO\ Z&6 _P#"S#__ "P/
MJ>+_ .@7$_\ @BK_ /(^:^\W:*PO^$G\.?\ 0<TK_P #K?\ ^.4?\)/X<_Z#
MFE?^!UO_ /'*/[5RO_H98#_PLP__ ,L#ZGB_^@7$_P#@BK_\CYK[S=HK"_X2
M?PY_T'-*_P# ZW_^.4?\)/X<_P"@YI7_ ('6_P#\<H_M7*_^AE@/_"S#_P#R
MP/J>+_Z!<3_X(J__ "/FOO-VBL+_ (2?PY_T'-*_\#K?_P".4?\ "3^'/^@Y
MI7_@=;__ !RC^U<K_P"AE@/_  LP_P#\L#ZGB_\ H%Q/_@BK_P#(^:^\W:*P
MO^$G\.?]!S2O_ ZW_P#CE'_"3^'/^@YI7_@=;_\ QRC^U<K_ .AE@/\ PLP_
M_P L#ZGB_P#H%Q/_ ((J_P#R/FOO-VBL+_A)_#G_ $'-*_\  ZW_ /CE'_"3
M^'/^@YI7_@=;_P#QRC^U<K_Z&6 _\+,/_P#+ ^IXO_H%Q/\ X(J__(^:^\W:
M*PO^$G\.?]!S2O\ P.M__CE'_"3^'/\ H.:5_P"!UO\ _'*/[5RO_H98#_PL
MP_\ \L#ZGB_^@7$_^"*O_P CYK[S=HK"_P"$G\.?]!S2O_ ZW_\ CE'_  D_
MAS_H.:5_X'6__P <H_M7*_\ H98#_P +,/\ _+ ^IXO_ *!<3_X(J_\ R/FO
MO-VBL+_A)_#G_0<TK_P.M_\ XY1_PD_AS_H.:5_X'6__ ,<H_M7*_P#H98#_
M ,+,/_\ + ^IXO\ Z!<3_P""*O\ \CYK[S=HK"_X2?PY_P!!S2O_  .M_P#X
MY1_PD_AS_H.:5_X'6_\ \<H_M7*_^AE@/_"S#_\ RP/J>+_Z!<3_ ."*O_R/
MFOO-VBL+_A)_#G_0<TK_ ,#K?_XY1_PD_AS_ *#FE?\ @=;_ /QRC^U<K_Z&
M6 _\+,/_ /+ ^IXO_H%Q/_@BK_\ (^:^\W:*PO\ A)_#G_0<TK_P.M__ (Y1
M_P )/X<_Z#FE?^!UO_\ '*/[5RO_ *&6 _\ "S#_ /RP/J>+_P"@7$_^"*O_
M ,CYK[S=HK"_X2?PY_T'-*_\#K?_ ..4?\)/X<_Z#FE?^!UO_P#'*/[5RO\
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MQ/\ X(J__(^:^\W:*PO^$G\.?]!S2O\ P.M__CE'_"3^'/\ H.:5_P"!UO\
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M>+_Z!<3_ ."*O_R/FOO-VBL+_A)_#G_0<TK_ ,#K?_XY1_PD_AS_ *#FE?\
M@=;_ /QRC^U<K_Z&6 _\+,/_ /+ ^IXO_H%Q/_@BK_\ (^:^\W:*PO\ A)_#
MG_0<TK_P.M__ (Y1_P )/X<_Z#FE?^!UO_\ '*/[5RO_ *&6 _\ "S#_ /RP
M/J>+_P"@7$_^"*O_ ,CYK[S=HK"_X2?PY_T'-*_\#K?_ ..4?\)/X<_Z#FE?
M^!UO_P#'*/[5RO\ Z&6 _P#"S#__ "P/J>+_ .@7$_\ @BK_ /(^:^\W:*PO
M^$G\.?\ 0<TK_P #K?\ ^.4?\)/X<_Z#FE?^!UO_ /'*/[5RO_H98#_PLP__
M ,L#ZGB_^@7$_P#@BK_\CYK[S=HK"_X2?PY_T'-*_P# ZW_^.4?\)/X<_P"@
MYI7_ ('6_P#\<H_M7*_^AE@/_"S#_P#RP/J>+_Z!<3_X(J__ "/FOO-VBL+_
M (2?PY_T'-*_\#K?_P".4?\ "3^'/^@YI7_@=;__ !RC^U<K_P"AE@/_  LP
M_P#\L#ZGB_\ H%Q/_@BK_P#(^:^\W:*PO^$G\.?]!S2O_ ZW_P#CE'_"3^'/
M^@YI7_@=;_\ QRC^U<K_ .AE@/\ PLP__P L#ZGB_P#H%Q/_ ((J_P#R/FOO
M-VBL+_A)_#G_ $'-*_\  ZW_ /CE'_"3^'/^@YI7_@=;_P#QRC^U<K_Z&6 _
M\+,/_P#+ ^IXO_H%Q/\ X(J__(^:^\W:*PO^$G\.?]!S2O\ P.M__CE'_"3^
M'/\ H.:5_P"!UO\ _'*/[5RO_H98#_PLP_\ \L#ZGB_^@7$_^"*O_P CYK[S
M=HK"_P"$G\.?]!S2O_ ZW_\ CE'_  D_AS_H.:5_X'6__P <H_M7*_\ H98#
M_P +,/\ _+ ^IXO_ *!<3_X(J_\ R/FOO-VBL+_A)_#G_0<TK_P.M_\ XY1_
MPD_AS_H.:5_X'6__ ,<H_M7*_P#H98#_ ,+,/_\ + ^IXO\ Z!<3_P""*O\
M\CYK[S=HK"_X2?PY_P!!S2O_  .M_P#XY1_PD_AS_H.:5_X'6_\ \<H_M7*_
M^AE@/_"S#_\ RP/J>+_Z!<3_ ."*O_R/FOO-VBL+_A)_#G_0<TK_ ,#K?_XY
M1_PD_AS_ *#FE?\ @=;_ /QRC^U<K_Z&6 _\+,/_ /+ ^IXO_H%Q/_@BK_\
M(^:^\W:*PO\ A)_#G_0<TK_P.M__ (Y1_P )/X<_Z#FE?^!UO_\ '*/[5RO_
M *&6 _\ "S#_ /RP/J>+_P"@7$_^"*O_ ,CYK[S=HK"_X2?PY_T'-*_\#K?_
M ..4?\)/X<_Z#FE?^!UO_P#'*/[5RO\ Z&6 _P#"S#__ "P/J>+_ .@7$_\
M@BK_ /(^:^\W:*PO^$G\.?\ 0<TK_P #K?\ ^.4?\)/X<_Z#FE?^!UO_ /'*
M/[5RO_H98#_PLP__ ,L#ZGB_^@7$_P#@BK_\CYK[S=HK"_X2?PY_T'-*_P#
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M#G_0<TK_ ,#K?_XY1_PD_AS_ *#FE?\ @=;_ /QRC^U<K_Z&6 _\+,/_ /+
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MW:*PO^$G\.?]!S2O_ ZW_P#CE'_"3^'/^@YI7_@=;_\ QRC^U<K_ .AE@/\
MPLP__P L#ZGB_P#H%Q/_ ((J_P#R/FOO-VBL+_A)_#G_ $'-*_\  ZW_ /CE
M'_"3^'/^@YI7_@=;_P#QRC^U<K_Z&6 _\+,/_P#+ ^IXO_H%Q/\ X(J__(^:
M^\W:*PO^$G\.?]!S2O\ P.M__CE'_"3^'/\ H.:5_P"!UO\ _'*/[5RO_H98
M#_PLP_\ \L#ZGB_^@7$_^"*O_P CYK[S=HK"_P"$G\.?]!S2O_ ZW_\ CE'_
M  D_AS_H.:5_X'6__P <H_M7*_\ H98#_P +,/\ _+ ^IXO_ *!<3_X(J_\
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M\#K?_P".4?\ "3^'/^@YI7_@=;__ !RC^U<K_P"AE@/_  LP_P#\L#ZGB_\
MH%Q/_@BK_P#(^:^\W:*PO^$G\.?]!S2O_ ZW_P#CE'_"3^'/^@YI7_@=;_\
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M2?PY_P!!S2O_  .M_P#XY1_PD_AS_H.:5_X'6_\ \<H_M7*_^AE@/_"S#_\
MRP/J>+_Z!<3_ ."*O_R/FOO-VBL+_A)_#G_0<TK_ ,#K?_XY1_PD_AS_ *#F
ME?\ @=;_ /QRC^U<K_Z&6 _\+,/_ /+ ^IXO_H%Q/_@BK_\ (^:^\W:*PO\
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MYK[S=HK"_P"$G\.?]!S2O_ ZW_\ CE'_  D_AS_H.:5_X'6__P <H_M7*_\
MH98#_P +,/\ _+ ^IXO_ *!<3_X(J_\ R/FOO-VBL+_A)_#G_0<TK_P.M_\
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M)_#G_0<TK_P.M_\ XY1_PD_AS_H.:5_X'6__ ,<H_M7*_P#H98#_ ,+,/_\
M+ ^IXO\ Z!<3_P""*O\ \CYK[S=HK"_X2?PY_P!!S2O_  .M_P#XY1_PD_AS
M_H.:5_X'6_\ \<H_M7*_^AE@/_"S#_\ RP/J>+_Z!<3_ ."*O_R/FOO-VBL+
M_A)_#G_0<TK_ ,#K?_XY1_PD_AS_ *#FE?\ @=;_ /QRC^U<K_Z&6 _\+,/_
M /+ ^IXO_H%Q/_@BK_\ (^:^\_HK_P"#97_E,%^S3_V*/QY_]41\0:_U(J_R
MOO\ @V.\5>&KG_@L?^S#IMOKVDRW]YX5^/L-G9I?VQN+N>']G_XD7DL%I%Y@
M:YFBL[6ZNY(8!)(EM;7-PRB*"9T_U0:_&_&?%87%\3994PF)H8JG'AK+J<JF
M'K4ZT(U(XO,7*G*5.4HJ<5*+E!M22:NE='W7 =&M0RC%0K4JE&3S3$S4:M.5
M.3A*AA;22FDW%V=I)6=G9Z'^,_\ \$CO^"0'B7_@J[^T_P#&S]FSPW\:-#^$
M%Y\&_AWK_P 0KGQ3K?A:_P#$UMK<&A_$+PSX".FP:=8:EITMI+<2^)$U$7$E
MS(D<=HT!C=I1(G]$/_$#_P#%C_H_7X>?^&=\2?\ S65Y=_P9R_\ *4_]N7_L
MVOQ__P"M%_"VO])"OR^CC948<GU;!U=7+GK8:G4F[N]G)ZV71;):+0^OGAU.
M7-[6O#1+EIU90BK*VB7X]V?YX'_$#_\ %C_H_7X>?^&=\2?_ #64?\0/_P 6
M/^C]?AY_X9WQ)_\ -97^A_16O]I2_P"@++?_  BI?UT_/NR/JJ_Y_P"*_P#!
M\S_/ _X@?_BQ_P!'Z_#S_P ,[XD_^:RC_B!_^+'_ $?K\//_  SOB3_YK*_T
M/Z*/[2E_T!9;_P"$5+^NGY]V'U5?\_\ %?\ @^9_G@?\0/\ \6/^C]?AY_X9
MWQ)_\UE'_$#_ /%C_H_7X>?^&=\2?_-97^A_11_:4O\ H"RW_P (J7]=/S[L
M/JJ_Y_XK_P 'S/\ / _X@?\ XL?]'Z_#S_PSOB3_ .:RC_B!_P#BQ_T?K\//
M_#.^)/\ YK*_T/Z*/[2E_P! 66_^$5+^NGY]V'U5?\_\5_X/F?YX'_$#_P#%
MC_H_7X>?^&=\2?\ S64?\0/_ ,6/^C]?AY_X9WQ)_P#-97^A_11_:4O^@++?
M_"*E_73\^[#ZJO\ G_BO_!\S_/ _X@?_ (L?]'Z_#S_PSOB3_P":RC_B!_\
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M (14OZZ?GW8?55_S_P 5_P"#YG^>!_Q _P#Q8_Z/U^'G_AG?$G_S64?\0/\
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M_M*7_0%EO_A%2_KI^?=A]57_ #_Q7_@^9_G@?\0/_P 6/^C]?AY_X9WQ)_\
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M\5_X/F?YX'_$#_\ %C_H_7X>?^&=\2?_ #64?\0/_P 6/^C]?AY_X9WQ)_\
M-97^A_11_:4O^@++?_"*E_73\^[#ZJO^?^*_\'S/\\#_ (@?_BQ_T?K\//\
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MP^JK_G_BO_!\S_/ _P"('_XL?]'Z_#S_ ,,[XD_^:RC_ (@?_BQ_T?K\//\
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M\_\ #.^)/_FLK_0_HH_M*7_0%EO_ (14OZZ?GW8?55_S_P 5_P"#YG^>!_Q
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MT?K\//\ PSOB3_YK*/\ B!_^+'_1^OP\_P##.^)/_FLK_0_HH_M*7_0%EO\
MX14OZZ?GW8?55_S_ ,5_X/F?YX'_ ! __%C_ */U^'G_ (9WQ)_\UE'_ ! _
M_%C_ */U^'G_ (9WQ)_\UE?Z']%']I2_Z LM_P#"*E_73\^[#ZJO^?\ BO\
MP?,_SP/^('_XL?\ 1^OP\_\ #.^)/_FLH_X@?_BQ_P!'Z_#S_P ,[XD_^:RO
M]#^BC^TI?] 66_\ A%2_KI^?=A]57_/_ !7_ (/F?YX'_$#_ /%C_H_7X>?^
M&=\2?_-91_Q _P#Q8_Z/U^'G_AG?$G_S65_H?T4?VE+_ * LM_\ "*E_73\^
M[#ZJO^?^*_\ !\S_ #P/^('_ .+'_1^OP\_\,[XD_P#FLH_X@?\ XL?]'Z_#
MS_PSOB3_ .:RO]#^BC^TI?\ 0%EO_A%2_KI^?=A]57_/_%?^#YG^>!_Q _\
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M_/\ Q7_@^9_G@?\ $#_\6/\ H_7X>?\ AG?$G_S64?\ $#_\6/\ H_7X>?\
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M;_X14OZZ?GW8?55_S_Q7_@^9_G@?\0/_ ,6/^C]?AY_X9WQ)_P#-91_Q _\
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MP^JK_G_BO_!\S_/ _P"('_XL?]'Z_#S_ ,,[XD_^:RC_ (@?_BQ_T?K\//\
MPSOB3_YK*_T/Z*/[2E_T!9;_ .$5+^NGY]V'U5?\_P#%?^#YG^>!_P 0/_Q8
M_P"C]?AY_P"&=\2?_-91_P 0/_Q8_P"C]?AY_P"&=\2?_-97^A_11_:4O^@+
M+?\ PBI?UT_/NP^JK_G_ (K_ ,'S/\\#_B!_^+'_ $?K\//_  SOB3_YK*/^
M('_XL?\ 1^OP\_\ #.^)/_FLK_0_HH_M*7_0%EO_ (14OZZ?GW8?55_S_P 5
M_P"#YG^>!_Q _P#Q8_Z/U^'G_AG?$G_S64?\0/\ \6/^C]?AY_X9WQ)_\UE?
MZ']%']I2_P"@++?_  BI?UT_/NP^JK_G_BO_  ?,_P \#_B!_P#BQ_T?K\//
M_#.^)/\ YK*/^('_ .+'_1^OP\_\,[XD_P#FLK_0_HH_M*7_ $!9;_X14OZZ
M?GW8?55_S_Q7_@^9_G@?\0/_ ,6/^C]?AY_X9WQ)_P#-91_Q _\ Q8_Z/U^'
MG_AG?$G_ ,UE?Z']%']I2_Z LM_\(J7]=/S[L/JJ_P"?^*_\'S/\\#_B!_\
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M_"*E_73\^[#ZJO\ G_BO_!\S_/ _X@?_ (L?]'Z_#S_PSOB3_P":RC_B!_\
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MXI_[.4_;-_\ 6.OCI7^DA1_:4O\ H"RW_P (J7]=/S[L/JJ_Y_XK_P 'S/\
M/ _X@?\ XL?]'Z_#S_PSOB3_ .:RC_B!_P#BQ_T?K\//_#.^)/\ YK*_T/Z*
M/[2E_P! 66_^$5+^NGY]V'U5?\_\5_X/F?YX'_$#_P#%C_H_7X>?^&=\2?\
MS64?\0/_ ,6/^C]?AY_X9WQ)_P#-97^A_11_:4O^@++?_"*E_73\^[#ZJO\
MG_BO_!\S_/ _X@?_ (L?]'Z_#S_PSOB3_P":RC_B!_\ BQ_T?K\//_#.^)/_
M )K*_P!#^BC^TI?] 66_^$5+^NGY]V'U5?\ /_%?^#YG^>!_Q __ !8_Z/U^
M'G_AG?$G_P UE'_$#_\ %C_H_7X>?^&=\2?_ #65_H?T4?VE+_H"RW_PBI?U
MT_/NP^JK_G_BO_!\S_/ _P"('_XL?]'Z_#S_ ,,[XD_^:RC_ (@?_BQ_T?K\
M//\ PSOB3_YK*_T/Z*/[2E_T!9;_ .$5+^NGY]V'U5?\_P#%?^#YG^>!_P 0
M/_Q8_P"C]?AY_P"&=\2?_-91_P 0/_Q8_P"C]?AY_P"&=\2?_-97^A_11_:4
MO^@++?\ PBI?UT_/NP^JK_G_ (K_ ,'S/\\#_B!_^+'_ $?K\//_  SOB3_Y
MK*/^('_XL?\ 1^OP\_\ #.^)/_FLK_0_HH_M*7_0%EO_ (14OZZ?GW8?55_S
M_P 5_P"#YG^>!_Q _P#Q8_Z/U^'G_AG?$G_S64?\0/\ \6/^C]?AY_X9WQ)_
M\UE?Z']%']I2_P"@++?_  BI?UT_/NP^JK_G_BO_  ?,_P \#_B!_P#BQ_T?
MK\//_#.^)/\ YK*/^('_ .+'_1^OP\_\,[XD_P#FLK_0_HH_M*7_ $!9;_X1
M4OZZ?GW8?55_S_Q7_@^9_G@?\0/_ ,6/^C]?AY_X9WQ)_P#-91_Q _\ Q8_Z
M/U^'G_AG?$G_ ,UE?Z']%']I2_Z LM_\(J7]=/S[L/JJ_P"?^*_\'S/\\#_B
M!_\ BQ_T?K\//_#.^)/_ )K*/^('_P"+'_1^OP\_\,[XD_\ FLK_ $/Z*/[2
ME_T!9;_X14OZZ?GW8?55_P _\5_X/F?YX'_$#_\ %C_H_7X>?^&=\2?_ #64
M?\0/_P 6/^C]?AY_X9WQ)_\ -97^A_11_:4O^@++?_"*E_73\^[#ZJO^?^*_
M\'S/\\#_ (@?_BQ_T?K\//\ PSOB3_YK*/\ B!_^+'_1^OP\_P##.^)/_FLK
M_0_HH_M*7_0%EO\ X14OZZ?GW8?55_S_ ,5_X/F?YX'_ ! __%C_ */U^'G_
M (9WQ)_\UE'_ ! __%C_ */U^'G_ (9WQ)_\UE?Z']%']I2_Z LM_P#"*E_7
M3\^[#ZJO^?\ BO\ P?,_SP/^('_XL?\ 1^OP\_\ #.^)/_FLH_X@?_BQ_P!'
MZ_#S_P ,[XD_^:RO]#^BC^TI?] 66_\ A%2_KI^?=A]57_/_ !7_ (/F?YX'
M_$#_ /%C_H_7X>?^&=\2?_-91_Q _P#Q8_Z/U^'G_AG?$G_S65_H?T4?VE+_
M * LM_\ "*E_73\^[#ZJO^?^*_\ !\S_ #P/^('_ .+'_1^OP\_\,[XD_P#F
MLH_X@?\ XL?]'Z_#S_PSOB3_ .:RO]#^BC^TI?\ 0%EO_A%2_KI^?=A]57_/
M_%?^#YG^>!_Q _\ Q8_Z/U^'G_AG?$G_ ,UE'_$#_P#%C_H_7X>?^&=\2?\
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M_P#A%2_KI^?=A]57_/\ Q7_@^9_G@?\ $#_\6/\ H_7X>?\ AG?$G_S64?\
M$#_\6/\ H_7X>?\ AG?$G_S65_H?T4?VE+_H"RW_ ,(J7]=/S[L/JJ_Y_P"*
M_P#!\S_/ _X@?_BQ_P!'Z_#S_P ,[XD_^:RC_B!_^+'_ $?K\//_  SOB3_Y
MK*_T/Z*/[2E_T!9;_P"$5+^NGY]V'U5?\_\ %?\ @^9_G@?\0/\ \6/^C]?A
MY_X9WQ)_\UE'_$#_ /%C_H_7X>?^&=\2?_-97^A_11_:4O\ H"RW_P (J7]=
M/S[L/JJ_Y_XK_P 'S/\ / _X@?\ XL?]'Z_#S_PSOB3_ .:RC_B!_P#BQ_T?
MK\//_#.^)/\ YK*_T/Z*/[2E_P! 66_^$5+^NGY]V'U5?\_\5_X/F?YX'_$#
M_P#%C_H_7X>?^&=\2?\ S64?\0/_ ,6/^C]?AY_X9WQ)_P#-97^A_11_:4O^
M@++?_"*E_73\^[#ZJO\ G_BO_!\S_/ _X@?_ (L?]'Z_#S_PSOB3_P":RC_B
M!_\ BQ_T?K\//_#.^)/_ )K*_P!#^BC^TI?] 66_^$5+^NGY]V'U5?\ /_%?
M^#YG^>!_Q __ !8_Z/U^'G_AG?$G_P UE'_$#_\ %C_H_7X>?^&=\2?_ #65
M_H?T4?VE+_H"RW_PBI?UT_/NP^JK_G_BO_!\S_/ _P"('_XL?]'Z_#S_ ,,[
MXD_^:RC_ (@?_BQ_T?K\//\ PSOB3_YK*_T/Z*/[2E_T!9;_ .$5+^NGY]V'
MU5?\_P#%?^#YG^>!_P 0/_Q8_P"C]?AY_P"&=\2?_-91_P 0/_Q8_P"C]?AY
M_P"&=\2?_-97^A_11_:4O^@++?\ PBI?UT_/NP^JK_G_ (K_ ,'S/\\#_B!_
M^+'_ $?K\//_  SOB3_YK*_,_P#X*P_\&TOB_P#X)4?LHR?M4^,/VH_#?Q?T
MA/B3X-^'/_"(>&_A_J?A?4C=>,(=:F@U3^U-4UO5+46]D-%D66W^R^9,9T*2
M)L;/^K?7\L/_  >%_P#*'ZX_[.@^"7_I#XZH_M*7_0%EO_A%2_KI^?=A]57_
M #_Q7_@^9_+Y_P $W?\ @U:\<_\ !1K]BSX*_MF^&/VN/"?PQT/XSP^/I;'P
M-KWPVUCQ#JVA#P'\4?&_PPN5N]8T_7]/L[PZC=^"I]6@,-G#Y%O?PVTF^6%Y
M7^XO^('_ .+'_1^OP\_\,[XD_P#FLK^DW_@U_P#^4%W["W_7G^T3_P"M:?'F
MOWRH_M*7_0%EO_A%2_KI^?=A]57_ #_Q7_@^9_G@?\0/_P 6/^C]?AY_X9WQ
M)_\ -91_Q __ !8_Z/U^'G_AG?$G_P UE?Z']%']I2_Z LM_\(J7]=/S[L/J
MJ_Y_XK_P?,_SP/\ B!_^+'_1^OP\_P##.^)/_FLH_P"('_XL?]'Z_#S_ ,,[
MXD_^:RO]#^BC^TI?] 66_P#A%2_KI^?=A]57_/\ Q7_@^9_G@?\ $#_\6/\
MH_7X>?\ AG?$G_S64?\ $#_\6/\ H_7X>?\ AG?$G_S65_H?T4?VE+_H"RW_
M ,(J7]=/S[L/JJ_Y_P"*_P#!\S_/ _X@?_BQ_P!'Z_#S_P ,[XD_^:RC_B!_
M^+'_ $?K\//_  SOB3_YK*_T/Z*/[2E_T!9;_P"$5+^NGY]V'U5?\_\ %?\
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M^$5+^NGY]V'U5?\ /_%?^#YG^>!_Q __ !8_Z/U^'G_AG?$G_P UE'_$#_\
M%C_H_7X>?^&=\2?_ #65_H?T4?VE+_H"RW_PBI?UT_/NP^JK_G_BO_!\S_/
M_P"('_XL?]'Z_#S_ ,,[XD_^:RC_ (@?_BQ_T?K\//\ PSOB3_YK*_T/Z*/[
M2E_T!9;_ .$5+^NGY]V'U5?\_P#%?^#YG^>!_P 0/_Q8_P"C]?AY_P"&=\2?
M_-91_P 0/_Q8_P"C]?AY_P"&=\2?_-97^A_11_:4O^@++?\ PBI?UT_/NP^J
MK_G_ (K_ ,'S/\\#_B!_^+'_ $?K\//_  SOB3_YK*/^('_XL?\ 1^OP\_\
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M_P"('_XL?]'Z_#S_ ,,[XD_^:RO]#^BC^TI?] 66_P#A%2_KI^?=A]57_/\
MQ7_@^9_G@?\ $#_\6/\ H_7X>?\ AG?$G_S64?\ $#_\6/\ H_7X>?\ AG?$
MG_S65_H?T4?VE+_H"RW_ ,(J7]=/S[L/JJ_Y_P"*_P#!\S_/ _X@?_BQ_P!'
MZ_#S_P ,[XD_^:RC_B!_^+'_ $?K\//_  SOB3_YK*_T/Z*/[2E_T!9;_P"$
M5+^NGY]V'U5?\_\ %?\ @^9_G@?\0/\ \6/^C]?AY_X9WQ)_\UE'_$#_ /%C
M_H_7X>?^&=\2?_-97^A_11_:4O\ H"RW_P (J7]=/S[L/JJ_Y_XK_P 'S/\
M/ _X@?\ XL?]'Z_#S_PSOB3_ .:RC_B!_P#BQ_T?K\//_#.^)/\ YK*_T/Z*
M/[2E_P! 66_^$5+^NGY]V'U5?\_\5_X/F?YX'_$#_P#%C_H_7X>?^&=\2?\
MS64?\0/_ ,6/^C]?AY_X9WQ)_P#-97^A_11_:4O^@++?_"*E_73\^[#ZJO\
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M\5_X/F?YX'_$#_\ %C_H_7X>?^&=\2?_ #64?\0/_P 6/^C]?AY_X9WQ)_\
M-97^A_11_:4O^@++?_"*E_73\^[#ZJO^?^*_\'S/\\#_ (@?_BQ_T?K\//\
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MP^JK_G_BO_!\S_/ _P"('_XL?]'Z_#S_ ,,[XD_^:RC_ (@?_BQ_T?K\//\
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MXD_^:RO]#^BC^TI?] 66_P#A%2_KI^?=A]57_/\ Q7_@^9_G@?\ $#_\6/\
MH_7X>?\ AG?$G_S64?\ $#_\6/\ H_7X>?\ AG?$G_S65_H?T4?VE+_H"RW_
M ,(J7]=/S[L/JJ_Y_P"*_P#!\S_/ _X@?_BQ_P!'Z_#S_P ,[XD_^:RC_B!_
M^+'_ $?K\//_  SOB3_YK*_T/Z*/[2E_T!9;_P"$5+^NGY]V'U5?\_\ %?\
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M^$5+^NGY]V'U5?\ /_%?^#YG^>!_Q __ !8_Z/U^'G_AG?$G_P UE'_$#_\
M%C_H_7X>?^&=\2?_ #65_H?T4?VE+_H"RW_PBI?UT_/NP^JK_G_BO_!\S_/
M_P"('_XL?]'Z_#S_ ,,[XD_^:RC_ (@?_BQ_T?K\//\ PSOB3_YK*_T/Z*/[
M2E_T!9;_ .$5+^NGY]V'U5?\_P#%?^#YG^>!_P 0/_Q8_P"C]?AY_P"&=\2?
M_-91_P 0/_Q8_P"C]?AY_P"&=\2?_-97^A_11_:4O^@++?\ PBI?UT_/NP^J
MK_G_ (K_ ,'S/\\#_B!_^+'_ $?K\//_  SOB3_YK*/^('_XL?\ 1^OP\_\
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M_P"('_XL?]'Z_#S_ ,,[XD_^:RO]#^BC^TI?] 66_P#A%2_KI^?=A]57_/\
MQ7_@^9_G@?\ $#_\6/\ H_7X>?\ AG?$G_S64?\ $#_\6/\ H_7X>?\ AG?$
MG_S65_H?T4?VE+_H"RW_ ,(J7]=/S[L/JJ_Y_P"*_P#!\S_/ _X@?_BQ_P!'
MZ_#S_P ,[XD_^:RC_B!_^+'_ $?K\//_  SOB3_YK*_T/Z*/[2E_T!9;_P"$
M5+^NGY]V'U5?\_\ %?\ @^9_G@?\0/\ \6/^C]?AY_X9WQ)_\UE'_$#_ /%C
M_H_7X>?^&=\2?_-97^A_11_:4O\ H"RW_P (J7]=/S[L/JJ_Y_XK_P 'S/\
M/ _X@?\ XL?]'Z_#S_PSOB3_ .:RC_B!_P#BQ_T?K\//_#.^)/\ YK*_T/Z*
M/[2E_P! 66_^$5+^NGY]V'U5?\_\5_X/F?YX'_$#_P#%C_H_7X>?^&=\2?\
MS64?\0/_ ,6/^C]?AY_X9WQ)_P#-97^A_11_:4O^@++?_"*E_73\^[#ZJO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "O\V[_ (/.?^4CW[$7_9M6B?\ J]_'
MU?Z2-?YMW_!YS_RD>_8B_P"S:M$_]7OX^H _TD:*** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _EY_X.^?\
ME#CXI_[.(^!?_IRUZO?/^#6C_E!=^Q5_U^?M+?\ K6GQTKP/_@[Y_P"4./BG
M_LXCX%_^G+7J]\_X-:/^4%W[%7_7Y^TM_P"M:?'2@#^@JBBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@#_-O_91_P"5U[Q3_P!G*?MF_P#K'7QT
MK_20K_-O_91_Y77O%/\ V<I^V;_ZQU\=*_TD* "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=JBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5_I(U_FW?\'G/_*1[]B+_LVK1/\ U>_CZ@#_ $D:*** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _EY_X.^?^
M4./BG_LXCX%_^G+7J]\_X-:/^4%W[%7_ %^?M+?^M:?'2O _^#OG_E#CXI_[
M.(^!?_IRUZO?/^#6C_E!=^Q5_P!?G[2W_K6GQTH _H*HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH _P V_P#91_Y77O%/_9RG[9O_ *QU\=*_
MTD*_S;_V4?\ E=>\4_\ 9RG[9O\ ZQU\=*_TD* "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "OY8?^#PO_E#]<?\ 9T'P2_\ 2'QU7]3U?RP_\'A?
M_*'ZX_[.@^"7_I#XZH ^K/\ @U__ .4%W["W_7G^T3_ZUI\>:_?*OP-_X-?_
M /E!=^PM_P!>?[1/_K6GQYK]\J "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ K_-M\)?\KKMW_V<MXU_]8\UZO\ 22K_ #;?"7_*Z[=_]G+>
M-?\ UCS7J /])*BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MMK_20H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ K_ #;O^#SG_E(]^Q%_V;5HG_J]_'U?Z2-?YMW_
M  ><_P#*1[]B+_LVK1/_ %>_CZ@#_21HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#^7G_@[Y_Y0X^*?^SB
M/@7_ .G+7J]\_P"#6C_E!=^Q5_U^?M+?^M:?'2O _P#@[Y_Y0X^*?^SB/@7_
M .G+7J]\_P"#6C_E!=^Q5_U^?M+?^M:?'2@#^@JBBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@#_-O_ &4?^5U[Q3_V<I^V;_ZQU\=*_P!)"O\
M-O\ V4?^5U[Q3_V<I^V;_P"L=?'2O])"@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ K_ #;?"7_*Z[=_]G+>-?\ UCS7J_TDJ_S;?"7_ "NNW?\ V<MXU_\
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MR_\ 9M?C_P#]:+^%M?Z2%?YM_P#P9R_\I3_VY?\ LVOQ_P#^M%_"VO\ 20H
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "O\VWPE_P KKMW_ -G+>-?_ %CS7J_TDJ_S;?"7_*Z[=_\ 9RWC7_UCS7J
M/])*BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /Y2?^#Q[_ )1%Z+_V
M=Q\&/_42^*]?;G_!LY_R@[_8/_[%OXS_ /K2GQFKXC_X/'O^41>B_P#9W'P8
M_P#42^*]?;G_  ;.?\H._P!@_P#[%OXS_P#K2GQFH _=JBBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *_S;O\ @\Y_Y2/?L1?]FU:)_P"KW\?5_I(U_FW?\'G/
M_*1[]B+_ +-JT3_U>_CZ@#_21HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@#^7G_@[Y_P"4./BG_LXCX%_^
MG+7J]\_X-:/^4%W[%7_7Y^TM_P"M:?'2O _^#OG_ )0X^*?^SB/@7_Z<M>KW
MS_@UH_Y07?L5?]?G[2W_ *UI\=* /Z"J*** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** /\V_]E'_ )77O%/_ &<I^V;_ .L=?'2O])"O\V_]E'_E
M=>\4_P#9RG[9O_K'7QTK_20H **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *_EA_X/"_\ E#]<?]G0?!+_ -(?'5?U/5_+#_P>%_\ *'ZX_P"SH/@E
M_P"D/CJ@#ZL_X-?_ /E!=^PM_P!>?[1/_K6GQYK]\J_ W_@U_P#^4%W["W_7
MG^T3_P"M:?'FOWRH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "O\VWPE_RNNW?_ &<MXU_]8\UZO])*O\VWPE_RNNW?_9RWC7_UCS7J /\
M22HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#^4G_@\>_Y1%Z+_ -G<
M?!C_ -1+XKU]N?\ !LY_R@[_ &#_ /L6_C/_ .M*?&:OB/\ X/'O^41>B_\
M9W'P8_\ 42^*]?;G_!LY_P H._V#_P#L6_C/_P"M*?&:@#]VJ*** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** /\ -O\ ^">?_*Y5\>?^SE/^"@?_
M *K?XQ5_I(5_FW_\$\_^5RKX\_\ 9RG_  4#_P#5;_&*O])"@#_-O_X,Y?\
ME*?^W+_V;7X__P#6B_A;7^DA7^;?_P &<O\ RE/_ &Y?^S:_'_\ ZT7\+:_T
MD* "BBB@ HHHH ^-OVR?^"@7[(O_  3^\->#/&'[7/Q;_P"%2^'?B#KM_P"&
MO"&H_P#"!?$WQY_:^M:78+JE]9?9/AEX,\9WUAY%BZS_ &G4[6RM)<^5#/),
M#&/B[X=_\'!__!'SXJ^//!WPT\%_MD:3=>+_ ![XDT?PEX8M-=^#G[1/@O2+
MO7M>OH=-TJTO_%?C7X1>'O">@075[<0VYU/Q#KFEZ7;M(K75[!'EQ^.?_!Y%
M_P FU?L:?]ER\??^H#;U_GZU^N<*< 91G^14,RQ.*S&CBJT\5"U"KAE0BZ-:
MI2IR]G4PDZC5HIS7MES.ZBX75OB<XXEQN79C5PE*CA9T::HRO4A5]HU.G"<E
MS1K1BG>347[-V5KJ5M?]S"BOP6_X-Z_^"F4W_!1#]BNVT7XB:U?ZM^TE^S"?
M#'PP^-%]J]U>:EJ_C72K_2KMOAI\7K_5)[<1W5[X_P!-T#Q!I>O&XO[O6;CQ
MIX*\5ZQJ$5O8:SHTUY^\-W=VFGVEU?W]U;V5C96\UW>WMW-';6EI:6T;37%U
M=7$S)#;V]O"CRS32ND<4:-)(RJI(_,<RR[$Y5C\5EV+ARXC"UG2FE>TUI*G4
MA?5TZU.4*M-VO*$XNRN?787%4L9AJ.*HRO2K04XOJMU*,NTH24H27246CY,_
M;%_;Q_9-_8#\#^&/B-^UO\7[#X2>$O&GBM?!/A:\D\+>.O&^IZUXB_LC4M=E
MMK3PS\-_"_C#Q.;"STS2KF74==ET>/0=,N)M+T_4-3M=0UO1;6_^*/A?_P '
M G_!(OXS?$OX=_!_X:_M:_\ "2?$7XK^.O"7PU\ >'?^%#?M-:/_ &]XU\=:
M_I_A?PKHO]KZ_P#!C2]"TO\ M37=4L+'^T=:U/3M)L?/^TZC?V=G%-<1_P "
MO_!>[_@H[;?\%%?VZ_%6N^ M7FU']GOX%0W_ ,'_ (&2+-$^F^(]+TC5)V\7
M_%&P2"22-K?XF>)(I-4T.[E\J_N/ FG>"8=4M+'4;2YLK?XQ_P""8'_*2W_@
MGA_V?-^R5_ZOWX?U^L8'PSP+R&./S/$9C2S%X*KBYX>C4PU.C1?LY5:5&<*N
M%JU7.,5%5_WD??YHQ4>5-_&8CBS$?VD\-A*>%GA?K$*$:M2-652:<XPG.,HU
MH0Y7)R=/W'[O*W>]C_9*K\4/%'_!Q3_P1P\&>)?$7@_Q+^V%_9OB+PIKNK>&
MM?T[_AGW]J6\^P:UH6H7&EZK9?:[#X(W5C=?9;ZUG@^TV5U<VD_E^;;3S0LD
MC?M?7^*#^T]_R<K^T-_V7+XM?^I]X@KY;@7A;+^)ZV8T\?6QE&.#IX:=)X.I
M0IN3K2K1E[3VV'Q":2IQY>51:;=V]+>OQ%G&)RF&$EAJ=";KRK*?MXU))*FJ
M;CR^SJTK7YW>]^EK:W_V"OV0/VZ?V4?V]O >N_$O]DOXPZ3\7?"'A?Q))X2\
M1W=KH/C'PAJ^A:\EC:ZE'::MX4^('AWPIXLL(+RRNX[C3-3N=#CTO5ECO%TR
M]NY+"^2V^M*_R?O^"$'_  4RF_X)L_MJ:%K7C76K^T_9M^.IT/X8?M!6*W5Y
M_9&B:5-JK+X2^+UWI=I;WLFH7OPCU+5-3U20VEA=ZR_@O6O'6CZ'$]_KJPR_
MZP->?QCPS+AG,HT*<JM7 8FG[7!5ZW*ZDE#EC7HU90A3@ZM&<DY<L(ITZE*5
MDY-+JR/-EFV$=2:A#$TI<F(IPNHIN[IS@I.4E"I%.UY-J49QN[797XO>//\
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M\':[<?9]"\8^'+[^T;33)])F_M'[-!?RWEG?V]K]65_*;_P9^_\ *-+XX?\
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M^&>A2^)?&_BG^Q?$/B+^Q-%AG@MI;W^Q/">DZ[XCU+;-<PI]FTC2+^[;?N6
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M 4444 %?YMW_  ><_P#*1[]B+_LVK1/_ %>_CZO])&O\V[_@\Y_Y2/?L1?\
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M4^)<EJ34%C.5MV4JE&M3@_6<J:45YSY5W9_9/17E'P1^.GP>_:2^&7A?XR?
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M $<#\$?_  ZW@/\ ^7U'_#3/[-__ $<#\$?_  ZW@/\ ^7U?Q^T4?\0]P?\
MT,<5_P""J7^?K_2U/^(X9K_T(\O_ /"C$_Y']@7_  TS^S?_ -' _!'_ ,.M
MX#_^7U'_  TS^S?_ -' _!'_ ,.MX#_^7U?Q^T4?\0]P?_0QQ7_@JE_GZ_TM
M3_B.&:_]"/+_ /PHQ/\ D?V!?\-,_LW_ /1P/P1_\.MX#_\ E]1_PTS^S?\
M]' _!'_PZW@/_P"7U?Q^T4?\0]P?_0QQ7_@JE_GZ_P!+4_XCAFO_ $(\O_\
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M_P#0QQ7_ (*I?Y^O]+4_XCAFO_0CR_\ \*,3_D?V!?\ #3/[-_\ T<#\$?\
MPZW@/_Y?4?\ #3/[-_\ T<#\$?\ PZW@/_Y?5_'[11_Q#W!_]#'%?^"J7^?K
M_2U/^(X9K_T(\O\ _"C$_P"1_8%_PTS^S?\ ]' _!'_PZW@/_P"7U'_#3/[-
M_P#T<#\$?_#K> __ )?5_'[11_Q#W!_]#'%?^"J7^?K_ $M3_B.&:_\ 0CR_
M_P *,3_D?V!?\-,_LW_]' _!'_PZW@/_ .7U'_#3/[-__1P/P1_\.MX#_P#E
M]7\?M%'_ !#W!_\ 0QQ7_@JE_GZ_TM3_ (CAFO\ T(\O_P#"C$_Y']@7_#3/
M[-__ $<#\$?_  ZW@/\ ^7U'_#3/[-__ $<#\$?_  ZW@/\ ^7U?Q^T4?\0]
MP?\ T,<5_P""J7^?K_2U/^(X9K_T(\O_ /"C$_Y']@7_  TS^S?_ -' _!'_
M ,.MX#_^7U'_  TS^S?_ -' _!'_ ,.MX#_^7U?Q^T4?\0]P?_0QQ7_@JE_G
MZ_TM3_B.&:_]"/+_ /PHQ/\ D?V!?\-,_LW_ /1P/P1_\.MX#_\ E]1_PTS^
MS?\ ]' _!'_PZW@/_P"7U?Q^T4?\0]P?_0QQ7_@JE_GZ_P!+4_XCAFO_ $(\
MO_\ "C$_Y']@7_#3/[-__1P/P1_\.MX#_P#E]1_PTS^S?_T<#\$?_#K> _\
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M3/[-_P#T<#\$?_#K> __ )?5_'[11_Q#W!_]#'%?^"J7^?K_ $M3_B.&:_\
M0CR__P *,3_D?V!?\-,_LW_]' _!'_PZW@/_ .7U'_#3/[-__1P/P1_\.MX#
M_P#E]7\?M%'_ !#W!_\ 0QQ7_@JE_GZ_TM3_ (CAFO\ T(\O_P#"C$_Y']@7
M_#3/[-__ $<#\$?_  ZW@/\ ^7U'_#3/[-__ $<#\$?_  ZW@/\ ^7U?Q^T4
M?\0]P?\ T,<5_P""J7^?K_2U/^(X9K_T(\O_ /"C$_Y']@7_  TS^S?_ -'
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MZ$>7_P#A1B?\C^P+_AIG]F__ *.!^"/_ (=;P'_\OJ/^&F?V;_\ HX'X(_\
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MZ$>7_P#A1B?\C^P+_AIG]F__ *.!^"/_ (=;P'_\OJ/^&F?V;_\ HX'X(_\
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MZ$>7_P#A1B?\C^P+_AIG]F__ *.!^"/_ (=;P'_\OJ/^&F?V;_\ HX'X(_\
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MZ$>7_P#A1B?\C^P+_AIG]F__ *.!^"/_ (=;P'_\OJ/^&F?V;_\ HX'X(_\
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MZ$>7_P#A1B?\C^P+_AIG]F__ *.!^"/_ (=;P'_\OJ/^&F?V;_\ HX'X(_\
MAUO ?_R^K^/VBC_B'N#_ .ACBO\ P52_S]?Z6I_Q'#-?^A'E_P#X48G_ "/[
M O\ AIG]F_\ Z.!^"/\ X=;P'_\ +ZC_ (:9_9O_ .C@?@C_ .'6\!__ "^K
M^/VBC_B'N#_Z&.*_\%4O\_7^EJ?\1PS7_H1Y?_X48G_(_L"_X:9_9O\ ^C@?
M@C_X=;P'_P#+ZC_AIG]F_P#Z.!^"/_AUO ?_ ,OJ_C]HH_XA[@_^ACBO_!5+
M_/U_I:G_ !'#-?\ H1Y?_P"%&)_R/[ O^&F?V;_^C@?@C_X=;P'_ /+ZC_AI
MG]F__HX'X(_^'6\!_P#R^K^/VBC_ (A[@_\ H8XK_P %4O\ /U_I:G_$<,U_
MZ$>7_P#A1B?\C^P+_AIG]F__ *.!^"/_ (=;P'_\OJ/^&F?V;_\ HX'X(_\
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MZ$>7_P#A1B?\C^P+_AIG]F__ *.!^"/_ (=;P'_\OJ/^&F?V;_\ HX'X(_\
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MZ$>7_P#A1B?\C^P+_AIG]F__ *.!^"/_ (=;P'_\OJ/^&F?V;_\ HX'X(_\
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M5_'[11_Q#W!_]#'%?^"J7^?K_2U/^(X9K_T(\O\ _"C$_P"1_8%_PTS^S?\
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M<5_X*I?Y^O\ 2U/^(X9K_P!"/+__  HQ/^1_8%_PTS^S?_T<#\$?_#K> _\
MY?4?\-,_LW_]' _!'_PZW@/_ .7U?Q^T4?\ $/<'_P!#'%?^"J7^?K_2U/\
MB.&:_P#0CR__ ,*,3_D?V!?\-,_LW_\ 1P/P1_\ #K> _P#Y?4?\-,_LW_\
M1P/P1_\ #K> _P#Y?5_'[11_Q#W!_P#0QQ7_ (*I?Y^O]+4_XCAFO_0CR_\
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MR_\ \*,3_D?V!?\ #3/[-_\ T<#\$?\ PZW@/_Y?4?\ #3/[-_\ T<#\$?\
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M_P"ACBO_  52_P _7^EJ?\1PS7_H1Y?_ .%&)_R/[ O^&F?V;_\ HX'X(_\
MAUO ?_R^H_X:9_9O_P"C@?@C_P"'6\!__+ZOX_:*/^(>X/\ Z&.*_P#!5+_/
MU_I:G_$<,U_Z$>7_ /A1B?\ (_L"_P"&F?V;_P#HX'X(_P#AUO ?_P OJ/\
MAIG]F_\ Z.!^"/\ X=;P'_\ +ZOX_:*/^(>X/_H8XK_P52_S]?Z6I_Q'#-?^
MA'E__A1B?\C^P+_AIG]F_P#Z.!^"/_AUO ?_ ,OJ/^&F?V;_ /HX'X(_^'6\
M!_\ R^K^/VBC_B'N#_Z&.*_\%4O\_7^EJ?\ $<,U_P"A'E__ (48G_(_L"_X
M:9_9O_Z.!^"/_AUO ?\ \OJ/^&F?V;_^C@?@C_X=;P'_ /+ZOX_:*/\ B'N#
M_P"ACBO_  52_P _7^EJ?\1PS7_H1Y?_ .%&)_R/[ O^&F?V;_\ HX'X(_\
MAUO ?_R^H_X:9_9O_P"C@?@C_P"'6\!__+ZOX_:*/^(>X/\ Z&.*_P#!5+_/
MU_I:G_$<,U_Z$>7_ /A1B?\ (_L"_P"&F?V;_P#HX'X(_P#AUO ?_P OJ/\
MAIG]F_\ Z.!^"/\ X=;P'_\ +ZOX_:*/^(>X/_H8XK_P52_S]?Z6I_Q'#-?^
MA'E__A1B?\C^P+_AIG]F_P#Z.!^"/_AUO ?_ ,OJ/^&F?V;_ /HX'X(_^'6\
M!_\ R^K^/VBC_B'N#_Z&.*_\%4O\_7^EJ?\ $<,U_P"A'E__ (48G_(_L"_X
M:9_9O_Z.!^"/_AUO ?\ \OJ/^&F?V;_^C@?@C_X=;P'_ /+ZOX_:*/\ B'N#
M_P"ACBO_  52_P _7^EJ?\1PS7_H1Y?_ .%&)_R/[ O^&F?V;_\ HX'X(_\
MAUO ?_R^H_X:9_9O_P"C@?@C_P"'6\!__+ZOX_:*/^(>X/\ Z&.*_P#!5+_/
MU_I:G_$<,U_Z$>7_ /A1B?\ (_L"_P"&F?V;_P#HX'X(_P#AUO ?_P OJ/\
MAIG]F_\ Z.!^"/\ X=;P'_\ +ZOX_:*/^(>X/_H8XK_P52_S]?Z6I_Q'#-?^
MA'E__A1B?\C^P+_AIG]F_P#Z.!^"/_AUO ?_ ,OJ/^&F?V;_ /HX'X(_^'6\
M!_\ R^K^/VBC_B'N#_Z&.*_\%4O\_7^EJ?\ $<,U_P"A'E__ (48G_(_L"_X
M:9_9O_Z.!^"/_AUO ?\ \OJ/^&F?V;_^C@?@C_X=;P'_ /+ZOX_:*/\ B'N#
M_P"ACBO_  52_P _7^EJ?\1PS7_H1Y?_ .%&)_R/[ O^&F?V;_\ HX'X(_\
MAUO ?_R^H_X:9_9O_P"C@?@C_P"'6\!__+ZOX_:*/^(>X/\ Z&.*_P#!5+_/
MU_I:G_$<,U_Z$>7_ /A1B?\ (_L"_P"&F?V;_P#HX'X(_P#AUO ?_P OJ/\
MAIG]F_\ Z.!^"/\ X=;P'_\ +ZOX_:*/^(>X/_H8XK_P52_S]?Z6I_Q'#-?^
MA'E__A1B?\C^P+_AIG]F_P#Z.!^"/_AUO ?_ ,OJ/^&F?V;_ /HX'X(_^'6\
M!_\ R^K^/VBC_B'N#_Z&.*_\%4O\_7^EJ?\ $<,U_P"A'E__ (48G_(_L$3]
MI;]G*1UCC^/_ ,$W=R%1$^*O@5G9B<!55=>)8D\  $D]*](\/>,_!_BU))/"
MGBOPUXFCA19)7\/:[I>M)$CDJCR-IMU<JB.P(5F(#$$ D@U_%G6GI&M:QX?U
M"WU;0-6U/1-4M6WVNI:1?W6F:A;-_>@O+.6"YA;@<QR*>*SJ>'E!Q?L<SK1G
M;3VF'A.+?FHU(-)]TW;L[:[X?QQQBJ1^M9!AITKKF^KXVK2J)=7%U*-6,FMU
M%J*>W,KW7]KM%?SQ?LS?\%.?B-X"OM)\*_'*>Y^(G@5I8K27Q5*IF\>^'[=B
MRB\EO-R#Q9;0NRO=1:INUMX@[P:M.\45A/\ O]X5\5>'?&_AW1_%OA+6+'7_
M  WK]C#J.CZQITPFM+VTF!VR1M@/')&ZO#<6\R1W-I<QS6MU##<0RQ)\-G&1
M8_):L88N$94JC:HXFDW*C4M]GF:3A42U=.:C*UW'FC[Q^O\ "_&.3<68>=7+
M:LH8BC&+Q6 Q"C#%X?FLN=Q4I1JT7)\L:U*4H7M&?)-\BWZ***\8^J"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /Y
M2?\ @\>_Y1%Z+_V=Q\&/_42^*]?;G_!LY_R@[_8/_P"Q;^,__K2GQFKXC_X/
M'O\ E$7HO_9W'P8_]1+XKU]N?\&SG_*#O]@__L6_C/\ ^M*?&:@#]VJ*** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** /\V__ ()Y_P#*Y5\>?^SE
M/^"@?_JM_C%7^DA7^;?_ ,$\_P#E<J^//_9RG_!0/_U6_P 8J_TD* /\V_\
MX,Y?^4I_[<O_ &;7X_\ _6B_A;7^DA7^;?\ \&<O_*4_]N7_ +-K\?\ _K1?
MPMK_ $D* "BBB@ HHHH _C9_X/(O^3:OV-/^RY>/O_4!MZ_DX_X):_L!7/\
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MPM+XY_9_^/K]Q_R+'_".?\@[_0O^>G_$P^WU^KW_  9J_P!L_P#"COVX?/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M,XM-I_45\)AL12E0K4*52E*+CR2@K)-6]VRO!K1QE%J46DXM-)G^:-_P0/\
MVLOCS_P34_X*HM^P;\9-0O\ 1/AY\7_C'KW[-'QD^&%UJ$>LZ'X9_:!M-2N/
M!GP^\<^#VM]3@T?^W+SX@:7H7@&_\1Z9=7>D^*OA[XEFO19^(;S1_ UQI?\
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M([^[$IL=,CU77[ZPM+G5]1:&2+2](MI)M3U.X7[-I]K<SE8S\(:9_P %I_\
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M_$+4K2?RKJ.T^R6-CY=NDWVB27\Q_%/_  :)?L#^"?#'B/QGXM_:Z_:8\/\
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MQ'_P>/?\HB]%_P"SN/@Q_P"HE\5Z^W/^#9S_ )0=_L'_ /8M_&?_ -:4^,U
M'[M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'1IR^:RNA.>7\23PTZU7#U(5L/@I592G.I"C2KW:VNZD*E-*T5KH]FE_%O\
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M@_ ?_P!6WX6KY:_X,_?^4:7QP_[/F^)?_J@OV9J6'_Y-ECO^RDA_Z8P85/\
MDK*'_8JE_P"G:Q_5E7\*O_!S=_P5EU_XA>-!_P $J_V2-;U_7+QM=TG0?VG+
MSP!$=9O?'7C+5[C2Y/"G[.'AL:1:7NJZM>Z?J<]A-\0M-\/3M<7_ (IN-/\
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MEX[_ /$1?VV?_DBON3_@U/\ VN?"WQH_X)T0?LV7&MV'_"SOV2O'/BWP_?\
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MQ'\2+[3Y9/\ A)]5TNWS>W7@7X:V3CQ9XQEW:=8WYAT/P.=?T/7?'/AVY?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!_FW_ /!//_E<J^//_9RG_!0/_P!5O\8J_P!)"O\ -O\
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MED-#BL[$^,+S4_'WQ83P[JFK: 9_#/BC5]9\26'!_P#!%O\ X(Y?MZ?L8_\
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M+?\ B30KRQT7Q%;,;>\1;WPWK4FGZ]8M+9WL*WFG0&>RNX@]M+_(G_P;N?\
M!-3_ (*L_P#!.G]M#Q1K'[0O[,M[X&_9T^-/PIUWP5\0/$$'QB_9P\7V?AWQ
M7X;GA\7_  X\3WVB^"_B[K_C2ZV7EAKW@>V70=%U>.&7X@->ZOI\6G6<NN:)
M_;?17N9?Q!C,NRO-,GITL+7P>:QBJ\<3"K.=&<(M1K89TZU*,*J?LYWJ0JQY
MZ-)\ME)2\_$Y;0Q6,PF.E.M3KX-OV;I2A&-2,FFX55*G-RA;FC:$H/EG-7U3
M7\.W_!<#_@CY_P %%_VO_P#@J58?M&_LZ_L[_P#"P_@S!X6^!FFR^,O^%M_
MOPEMO?!TF[Q'#_PCWCGXF^&?%3?V<.?,70S%>?\ +A)=&O[B:**C,\]Q>:X+
M*<#B*>&A2R;#3PN%E1A5C4J4YQHQ;Q#G6J1E.U"%G3A2C=RO%W5JPF7T<'7Q
MN(I2JRGCJL:U95)0<8RBYM*FHPBU']Y*ZE*;T6N]_B+_ (*4_"#XB?'_ /8#
M_:]^"?PD\/?\);\3OBC\ _B)X*\"^&?[6T/0?[<\3:[H-S9:5IG]L^)M3T;P
M_IGVJYD2+[9K&JZ?I\&=]S=PQ@N/PJ_X-CO^";'[:O\ P3T_X;<_X;!^"_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?YMW_!YS_P I'OV(
MO^S:M$_]7OX^K_21K_-N_P"#SG_E(]^Q%_V;5HG_ *O?Q]0!_I(T444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MR_\ 9M?C_P#]:+^%M?Z2%?YM_P#P9R_\I3_VY?\ LVOQ_P#^M%_"VO\ 20H
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MA(MM)JFJ_&768K:3SDMM,GO/#_P<U:P;4KRWOHX[:ZN+6SAMM6N].U33Y_\
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M>(_$-U<^(?%7B?Q -"O=9U#4]7N[O7_$>MWTDUW-=:I?.9/X2=,_:Z_X+/\
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MPI<WNN7^L7_@S[;8ZMJO]AG_  0V_P""QG@S_@L#^S9XB\<77AS1_AQ^T/\
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M:H^$7Q;\:>$O!'PS^*?C7Q5KWC7Q/X7U_P"*FC6O_"C_ !;X!\<>.3)XXO\
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M,-4C5I3VDKIIK>,HNTHSCUC))K1[--E%?PU_M-?\$6/^"NGQ$_X+>:S^U_\
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M_#CQ!7KKVF#R;'XFAK:LTJ:FDTN:FN6:FM]I7TUMKR_Z'M%?YQOPL_X+;_\
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MV3FN:PRN.'E*A5Q$L15=*$*32ES))I)/=RO9):MZ'^IC17^=Y_P["_X.MO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ']@7[,W_)M
M_P"S]_V1'X4?^H'H->W5XC^S-_R;?^S]_P!D1^%'_J!Z#7MU?SAC?]\Q?_83
M7_\ 3LS^\,I_Y%66?]B_!?\ J-2"BBBN8] **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@#^4G_@\>_Y1%Z+_ -G<?!C_ -1+
MXKU]N?\ !LY_R@[_ &#_ /L6_C/_ .M*?&:OB/\ X/'O^41>B_\ 9W'P8_\
M42^*]?;G_!LY_P H._V#_P#L6_C/_P"M*?&:@#]VJ*** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/A/3]?\ #?A[3?&6H7ESXINO /C/PUK.M^&==\8'6O$'PZ\)^)?$&LZ?J?\
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M1IKC5;B1(-0MQXL^)'Q M[2TL;-K?39+>\>35;R[U"YT[1 #A?\ @]F_:/\
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M_P"VO#&K:ZL"77]@?#*\LS\/O#WA^V:#2K"#PS)JDMK<>)-8\0ZWJX!\0/\
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M34;V_M[;2X-. /[CZ_SC_P#@@G9Z9_P4%_X.5?VUOVWTC74_A_\ #B^_:?\
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M5]/=MXD^&T]C?1ZM>:HDPUO^TK.SBO+"YU+]Z_\ @YW\>^*OA]_P1&_;0O\
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M;FRU'2_#/BN'0?%&L?$W5;6XL98+B]T#1]+\"&WOK#5-!\=^)VBOM)A^P?\
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M+M(LM=\.>(-(NP!/8:II6H0SVEU"65)8_,C+P7$4-S \=Q#%(G^<!9>&)_\
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MC-6\3G.2X!O]W&I5QU6+UC)T(RE1<ELTG3J15[WYVGI>_P#<'7^51/KOCO\
MX+Z_\%L/#=GKESK=KX*^-7Q6.C:78QW%M)<?#;]EGX76VK^)+S3-/NGM/#]I
M;7MG\.="UN_2>XM;2ZU/QQKLLC07^MZLMO>?Z77[;6I7NC_L8_M<ZOILWV;4
M=*_9B^/FI6%QY<4WD7MC\*O%EU:S>5/'+!+Y4\4;^7-%)$^W;)&Z%E/\%O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/9:I;M:>.?AS/JER-:D\*WUUIM]INJ+<WGA3Q'X8GUGQ#)J_X,Z)_P &WO\
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MZW7A&:'P5X=\&?"#X7P^)]*L#I_C#QA\+XO&/Q \2:);Z-%=^.[;Q!%'JV@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'/IPIYSD$ZDXTX1JU'*<Y*,(I5*-W*4FDDN[:1_JFT5^-W_$01_P1V_Z/?\
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M73:<G446TKO_ #3OVPO^5K+PC_VDG_8:_P#4A_9]K_2_K_- _;"_Y6LO"/\
MVDG_ &&O_4A_9]K^Z7_@KAX,_:!\>?\ !.+]J[1?V6/'?Q ^&_Q[TWX?V'CG
MX?\ BGX5>(M>\)_$,7'PR\8^&?B1K_AOPIK_ (8UKP_KMAJGCGPIX4UWP.HT
M[5(I+N#Q%-8R6NIV]S+IEY?&%".*AP)AI588>.(R/+:$J]2[IT8U5AJ;JU$M
M7"FI.<K:\L7;4G(ZCHOB&JH2J.EF.*J*G&W-4</:R4(WTYI6Y5?2[5S\;/\
M@HK_ ,&K?[+W[4/BOQ!\7OV3O'<W[)?Q.\3:M/K?B7P/_P (^OB_X!^(;Z^G
MU.]U2ZT7PI:WFC>(?AAJNIZCJ%M/*WAK6-7\":?8:7'I>A_#+29;VXU:/\(_
M$?\ P2(_X.%?^"75W;^+OV5_'WQ#^(7@[PS!K,T)_9#^+?B3Q;I":<6NM6;3
M]8_9X\7V?AS6?%\NIW&H:EJ*Z!I7PQ\=Z<OB6*>YCFEU:;1;W4?T$_X-RO\
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M8FC[22A[:G4<Y)Q<K)R4)0E9.[4FTFHRM^U5?YH'_!IA_P I4-6_[-:^+O\
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M2PL88/ZWB,1B*=.E0I8[%2G[U[5;>WFN6+Y5JO><E;1.W]Q7_!3_ /Y1I?\
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M;XXN/"%I:6GBB]TV_P!:DO([.PGFO[BZFT?351YYS';QVH%O%&TUP\WXH_\
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MH2TJ^;JK16L?YY7_  \]_P"#K;_HV[]JO_Q6AK7_ ,Y"OR:_X)[_ !V^-_\
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M .":WP$^)_B:^L;WXG> ;&\^!/Q<>RN8+B27QS\*8[+1[76]42#RULM;\<>
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P &SG_*#O\ 8/\ ^Q;^,_\ ZTI\9J /W:HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MDW8L4445\0?0!1110 4444 %%%% !1110 4444 ?R\_\'?/_ "AQ\4_]G$?
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M89SZ1I.I4DU&#/?Z*/\ /^?\_6BOU\_EX**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** /\V_\ X)Y_\KE7QY_[.4_X*!_^JW^,5?Z2%?YM_P#P3S_Y7*OC
MS_V<I_P4#_\ 5;_&*O\ 20H _P V_P#X,Y?^4I_[<O\ V;7X_P#_ %HOX6U_
MI(5_FW_\&<O_ "E/_;E_[-K\?_\ K1?PMK_20H **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K_ #;O
M^#SG_E(]^Q%_V;5HG_J]_'U?Z2-?YMW_  ><_P#*1[]B+_LVK1/_ %>_CZ@#
M_21HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'_#N7]C3_HCG_F0OBI_\W%'_ !$#)O\ H&S/_P $X7_YM#_B"G%7_0PX?_\
M"K,?_G4?RUT5_4I_P[E_8T_Z(Y_YD+XJ?_-Q1_P[E_8T_P"B.?\ F0OBI_\
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M *(Y_P"9"^*G_P W%'_$0,F_Z!LS_P#!.%_^;0_X@IQ5_P!##A__ ,*LQ_\
MG4?RUT5_4I_P[E_8T_Z(Y_YD+XJ?_-Q1_P .Y?V-/^B.?^9"^*G_ ,W%'_$0
M,F_Z!LS_ /!.%_\ FT/^(*<5?]##A_\ \*LQ_P#G4?RUT5_4I_P[E_8T_P"B
M.?\ F0OBI_\ -Q1_P[E_8T_Z(Y_YD+XJ?_-Q1_Q$#)O^@;,__!.%_P#FT/\
MB"G%7_0PX?\ _"K,?_G4?RUT5_4I_P .Y?V-/^B.?^9"^*G_ ,W%'_#N7]C3
M_HCG_F0OBI_\W%'_ !$#)O\ H&S/_P $X7_YM#_B"G%7_0PX?_\ "K,?_G4?
MRUT5_4I_P[E_8T_Z(Y_YD+XJ?_-Q1_P[E_8T_P"B.?\ F0OBI_\ -Q1_Q$#)
MO^@;,_\ P3A?_FT/^(*<5?\ 0PX?_P#"K,?_ )U'\M=%?U*?\.Y?V-/^B.?^
M9"^*G_S<4?\ #N7]C3_HCG_F0OBI_P#-Q1_Q$#)O^@;,_P#P3A?_ )M#_B"G
M%7_0PX?_ /"K,?\ YU'\M=%?U*?\.Y?V-/\ HCG_ )D+XJ?_ #<4?\.Y?V-/
M^B.?^9"^*G_S<4?\1 R;_H&S/_P3A?\ YM#_ (@IQ5_T,.'_ /PJS'_YU'\M
M=%?U*?\ #N7]C3_HCG_F0OBI_P#-Q1_P[E_8T_Z(Y_YD+XJ?_-Q1_P 1 R;_
M *!LS_\ !.%_^;0_X@IQ5_T,.'__  JS'_YU'\M=%?U*?\.Y?V-/^B.?^9"^
M*G_S<4?\.Y?V-/\ HCG_ )D+XJ?_ #<4?\1 R;_H&S/_ ,$X7_YM#_B"G%7_
M $,.'_\ PJS'_P"=1_+717]2G_#N7]C3_HCG_F0OBI_\W%'_  [E_8T_Z(Y_
MYD+XJ?\ S<4?\1 R;_H&S/\ \$X7_P";0_X@IQ5_T,.'_P#PJS'_ .=1_+71
M7]2G_#N7]C3_ *(Y_P"9"^*G_P W%'_#N7]C3_HCG_F0OBI_\W%'_$0,F_Z!
MLS_\$X7_ .;0_P"(*<5?]##A_P#\*LQ_^=1_+717]2G_  [E_8T_Z(Y_YD+X
MJ?\ S<4?\.Y?V-/^B.?^9"^*G_S<4?\ $0,F_P"@;,__  3A?_FT/^(*<5?]
M##A__P *LQ_^=1_+717]2G_#N7]C3_HCG_F0OBI_\W%'_#N7]C3_ *(Y_P"9
M"^*G_P W%'_$0,F_Z!LS_P#!.%_^;0_X@IQ5_P!##A__ ,*LQ_\ G4?RUT5_
M4I_P[E_8T_Z(Y_YD+XJ?_-Q1_P .Y?V-/^B.?^9"^*G_ ,W%'_$0,F_Z!LS_
M /!.%_\ FT/^(*<5?]##A_\ \*LQ_P#G4?RUT5_4I_P[E_8T_P"B.?\ F0OB
MI_\ -Q1_P[E_8T_Z(Y_YD+XJ?_-Q1_Q$#)O^@;,__!.%_P#FT/\ B"G%7_0P
MX?\ _"K,?_G4?RUT5_4I_P .Y?V-/^B.?^9"^*G_ ,W%'_#N7]C3_HCG_F0O
MBI_\W%'_ !$#)O\ H&S/_P $X7_YM#_B"G%7_0PX?_\ "K,?_G4?RUT5\3_L
M^?%SXA^./^#H?7_^"=?BCQ!_:G['%E\;_P!IKPA;?![^R=#LO*\._#W]FOXK
M^/\ PAIW_"P=.TVT^*;_ -D>+O#6B:M]KD\;O?7_ -B^P:I<WNF7-W93_P!M
MG_#N7]C3_HCG_F0OBI_\W%'_ !$#)O\ H&S/_P $X7_YM#_B"G%7_0PX?_\
M"K,?_G4?RUT5_4I_P[E_8T_Z(Y_YD+XJ?_-Q1_P[E_8T_P"B.?\ F0OBI_\
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M *(Y_P"9"^*G_P W%'_$0,F_Z!LS_P#!.%_^;0_X@IQ5_P!##A__ ,*LQ_\
MG4?RUT5_4I_P[E_8T_Z(Y_YD+XJ?_-Q1_P .Y?V-/^B.?^9"^*G_ ,W%'_$0
M,F_Z!LS_ /!.%_\ FT/^(*<5?]##A_\ \*LQ_P#G4?RUT5_4I_P[E_8T_P"B
M.?\ F0OBI_\ -Q1_P[E_8T_Z(Y_YD+XJ?_-Q1_Q$#)O^@;,__!.%_P#FT/\
MB"G%7_0PX?\ _"K,?_G4?RUT5_4I_P .Y?V-/^B.?^9"^*G_ ,W%'_#N7]C3
M_HCG_F0OBI_\W%'_ !$#)O\ H&S/_P $X7_YM#_B"G%7_0PX?_\ "K,?_G4?
MRUT5_4I_P[E_8T_Z(Y_YD+XJ?_-Q1_P[E_8T_P"B.?\ F0OBI_\ -Q1_Q$#)
MO^@;,_\ P3A?_FT/^(*<5?\ 0PX?_P#"K,?_ )U'\M=%?U*?\.Y?V-/^B.?^
M9"^*G_S<4?\ #N7]C3_HCG_F0OBI_P#-Q1_Q$#)O^@;,_P#P3A?_ )M#_B"G
M%7_0PX?_ /"K,?\ YU'\M=%?U*?\.Y?V-/\ HCG_ )D+XJ?_ #<4?\.Y?V-/
M^B.?^9"^*G_S<4?\1 R;_H&S/_P3A?\ YM#_ (@IQ5_T,.'_ /PJS'_YU'\M
M=%?U*?\ #N7]C3_HCG_F0OBI_P#-Q1_P[E_8T_Z(Y_YD+XJ?_-Q1_P 1 R;_
M *!LS_\ !.%_^;0_X@IQ5_T,.'__  JS'_YU'\M=%?U*?\.Y?V-/^B.?^9"^
M*G_S<4?\.Y?V-/\ HCG_ )D+XJ?_ #<4?\1 R;_H&S/_ ,$X7_YM#_B"G%7_
M $,.'_\ PJS'_P"=1_+717]2G_#N7]C3_HCG_F0OBI_\W%'_  [E_8T_Z(Y_
MYD+XJ?\ S<4?\1 R;_H&S/\ \$X7_P";0_X@IQ5_T,.'_P#PJS'_ .=1_+71
M7]2G_#N7]C3_ *(Y_P"9"^*G_P W%'_#N7]C3_HCG_F0OBI_\W%'_$0,F_Z!
MLS_\$X7_ .;0_P"(*<5?]##A_P#\*LQ_^=1_+717]2G_  [E_8T_Z(Y_YD+X
MJ?\ S<4?\.Y?V-/^B.?^9"^*G_S<4?\ $0,F_P"@;,__  3A?_FT/^(*<5?]
M##A__P *LQ_^=1_+717]2G_#N7]C3_HCG_F0OBI_\W%'_#N7]C3_ *(Y_P"9
M"^*G_P W%'_$0,F_Z!LS_P#!.%_^;0_X@IQ5_P!##A__ ,*LQ_\ G4?RUT5_
M4I_P[E_8T_Z(Y_YD+XJ?_-Q1_P .Y?V-/^B.?^9"^*G_ ,W%'_$0,F_Z!LS_
M /!.%_\ FT/^(*<5?]##A_\ \*LQ_P#G4?RUT5_4I_P[E_8T_P"B.?\ F0OB
MI_\ -Q1_P[E_8T_Z(Y_YD+XJ?_-Q1_Q$#)O^@;,__!.%_P#FT/\ B"G%7_0P
MX?\ _"K,?_G4?RUT5_4I_P .Y?V-/^B.?^9"^*G_ ,W%'_#N7]C3_HCG_F0O
MBI_\W%'_ !$#)O\ H&S/_P $X7_YM#_B"G%7_0PX?_\ "K,?_G4?RUT5_4I_
MP[E_8T_Z(Y_YD+XJ?_-Q1_P[E_8T_P"B.?\ F0OBI_\ -Q1_Q$#)O^@;,_\
MP3A?_FT/^(*<5?\ 0PX?_P#"K,?_ )U'\M=%?U*?\.Y?V-/^B.?^9"^*G_S<
M4?\ #N7]C3_HCG_F0OBI_P#-Q1_Q$#)O^@;,_P#P3A?_ )M#_B"G%7_0PX?_
M /"K,?\ YU'\M=%?U*?\.Y?V-/\ HCG_ )D+XJ?_ #<4?\.Y?V-/^B.?^9"^
M*G_S<4?\1 R;_H&S/_P3A?\ YM#_ (@IQ5_T,.'_ /PJS'_YU'\M=%?U*?\
M#N7]C3_HCG_F0OBI_P#-Q1_P[E_8T_Z(Y_YD+XJ?_-Q1_P 1 R;_ *!LS_\
M!.%_^;0_X@IQ5_T,.'__  JS'_YU'\M=%?U*?\.Y?V-/^B.?^9"^*G_S<4?\
M.Y?V-/\ HCG_ )D+XJ?_ #<4?\1 R;_H&S/_ ,$X7_YM#_B"G%7_ $,.'_\
MPJS'_P"=1_+717]2G_#N7]C3_HCG_F0OBI_\W%'_  [E_8T_Z(Y_YD+XJ?\
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M/\6O OA\_P#".> M8\+>$M-^P>%?#&AZ7C2=!L!=?8?MUZ+G4;F\O+C]=?\
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M8_\ SJ/Y:Z*_J4_X=R_L:?\ 1'/_ #(7Q4_^;BC_ (=R_L:?]$<_\R%\5/\
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M<O[&G_1'/_,A?%3_ .;BC_AW+^QI_P!$<_\ ,A?%3_YN*/\ B(&3?] V9_\
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M/^'<O[&G_1'/_,A?%3_YN*/^'<O[&G_1'/\ S(7Q4_\ FXH_XB!DW_0-F?\
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MK^I3_AW+^QI_T1S_ ,R%\5/_ )N*/^'<O[&G_1'/_,A?%3_YN*/^(@9-_P!
MV9_^"<+_ /-H?\04XJ_Z&'#_ /X59C_\ZC^6NBOZE/\ AW+^QI_T1S_S(7Q4
M_P#FXH_X=R_L:?\ 1'/_ #(7Q4_^;BC_ (B!DW_0-F?_ ()PO_S:'_$%.*O^
MAAP__P"%68__ #J/Y:Z*_J4_X=R_L:?]$<_\R%\5/_FXH_X=R_L:?]$<_P#,
MA?%3_P";BC_B(&3?] V9_P#@G"__ #:'_$%.*O\ H8</_P#A5F/_ ,ZC^6NB
MOZE/^'<O[&G_ $1S_P R%\5/_FXK^)'P[\7?B'??\'0UQ_P3KNO$/F_L<)\<
M?%'@]?@]_9.AICPYIW[-NK>/K/3O^%@QZ8GQ2/D^+;6#5OM9\;F^DV?8);I]
M,9[-C_B(&3?] V9_^"<+_P#-H?\ $%.*O^AAP_\ ^%68_P#SJ/MJBOZE/^'<
MO[&G_1'/_,A?%3_YN*/^'<O[&G_1'/\ S(7Q4_\ FXH_XB!DW_0-F?\ X)PO
M_P VA_Q!3BK_ *&'#_\ X59C_P#.H_EKHK^I3_AW+^QI_P!$<_\ ,A?%3_YN
M*/\ AW+^QI_T1S_S(7Q4_P#FXH_XB!DW_0-F?_@G"_\ S:'_ !!3BK_H8</_
M /A5F/\ \ZC^6NBOZE/^'<O[&G_1'/\ S(7Q4_\ FXH_X=R_L:?]$<_\R%\5
M/_FXH_XB!DW_ $#9G_X)PO\ \VA_Q!3BK_H8</\ _A5F/_SJ/Y:Z*_J4_P"'
M<O[&G_1'/_,A?%3_ .;BC_AW+^QI_P!$<_\ ,A?%3_YN*/\ B(&3?] V9_\
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M/^'<O[&G_1'/_,A?%3_YN*/^'<O[&G_1'/\ S(7Q4_\ FXH_XB!DW_0-F?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_
MFW_\$\_^5RKX\_\ 9RG_  4#_P#5;_&*O])"O\V__@GG_P KE7QY_P"SE/\
M@H'_ .JW^,5?Z2% '^;?_P &<O\ RE/_ &Y?^S:_'_\ ZT7\+:_TD*_S;_\
M@SE_Y2G_ +<O_9M?C_\ ]:+^%M?Z2% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?YMW_  ><_P#*
M1[]B+_LVK1/_ %>_CZO])&O\V[_@\Y_Y2/?L1?\ 9M6B?^KW\?4 ?Z2-%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 ?R\_\'?/_ "AQ\4_]G$? O_TY:]7OG_!K1_R@N_8J_P"OS]I;_P!:
MT^.E>!_\'?/_ "AQ\4_]G$? O_TY:]7OG_!K1_R@N_8J_P"OS]I;_P!:T^.E
M ']!5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '^;?^RC_P K
MKWBG_LY3]LW_ -8Z^.E?Z2%?YM_[*/\ RNO>*?\ LY3]LW_UCKXZ5_I(4 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %?RP_\'A?_ "A^N/\ LZ#X
M)?\ I#XZK^IZOY8?^#PO_E#]<?\ 9T'P2_\ 2'QU0!]6?\&O_P#R@N_86_Z\
M_P!HG_UK3X\U^^5?@;_P:_\ _*"[]A;_ *\_VB?_ %K3X\U^^5 !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 5_FV^$O^5UV[_[.6\:_^L>:
M]7^DE7^;;X2_Y77;O_LY;QK_ .L>:]0!_I)4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P"4I_[<O_9M?C__ -:+^%M?Z2% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?YMW_!YS_P I'OV(
MO^S:M$_]7OX^K_21K_-N_P"#SG_E(]^Q%_V;5HG_ *O?Q]0!_I(T444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10!_+S_P=\_\H<?%/_9Q'P+_ /3EKU>^?\&M'_*"[]BK_K\_:6_]:T^.E>!_
M\'?/_*''Q3_V<1\"_P#TY:]7OG_!K1_R@N_8J_Z_/VEO_6M/CI0!_051110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110!_FW_ +*/_*Z]XI_[.4_;
M-_\ 6.OCI7^DA7^;?^RC_P KKWBG_LY3]LW_ -8Z^.E?Z2% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !7\L/_!X7_RA^N/^SH/@E_Z0^.J_J>K^
M6'_@\+_Y0_7'_9T'P2_](?'5 'U9_P &O_\ R@N_86_Z\_VB?_6M/CS7[Y5^
M!O\ P:__ /*"[]A;_KS_ &B?_6M/CS7[Y4 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !7^;;X2_Y77;O_LY;QK_ .L>:]7^DE7^;;X2_P"5
MUV[_ .SEO&O_ *QYKU '^DE1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 5_FW?\'G/_*1[]B+_ +-JT3_U>_CZ
MO])&O\V[_@\Y_P"4CW[$7_9M6B?^KW\?4 ?Z2-%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?R\_P#!WS_R
MAQ\4_P#9Q'P+_P#3EKU>^?\ !K1_R@N_8J_Z_/VEO_6M/CI7@?\ P=\_\H<?
M%/\ V<1\"_\ TY:]7OG_  :T?\H+OV*O^OS]I;_UK3XZ4 ?T%4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 ?YM_[*/_*Z]XI_[.4_;-_]8Z^.
ME?Z2%?YM_P"RC_RNO>*?^SE/VS?_ %CKXZ5_I(4 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %?RP_P#!X7_RA^N/^SH/@E_Z0^.J_J>K^6'_ (/"
M_P#E#]<?]G0?!+_TA\=4 ?5G_!K_ /\ *"[]A;_KS_:)_P#6M/CS7[Y5^!O_
M  :__P#*"[]A;_KS_:)_]:T^/-?OE0 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %?YMOA+_ )77;O\ [.6\:_\ K'FO5_I)5_FV^$O^5UV[
M_P"SEO&O_K'FO4 ?Z25%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?R
MD_\ !X]_RB+T7_L[CX,?^HE\5Z^W/^#9S_E!W^P?_P!BW\9__6E/C-7Q'_P>
M/?\ *(O1?^SN/@Q_ZB7Q7K[<_P"#9S_E!W^P?_V+?QG_ /6E/C-0!^[5%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% '^;?_P $\_\ E<J^//\
MV<I_P4#_ /5;_&*O])"O\V__ ()Y_P#*Y5\>?^SE/^"@?_JM_C%7^DA0!_FW
M_P#!G+_RE/\ VY?^S:_'_P#ZT7\+:_TD*_S;_P#@SE_Y2G_MR_\ 9M?C_P#]
M:+^%M?Z2% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MW_"'_P .5X,_^75'_#07P$_Z+?\ "'_PY7@S_P"75?P5?\0.7Q(_Z2,^"/\
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M7Q(_Z2,^"/\ Q&?7O_GV4?\ $#E\2/\ I(SX(_\ $9]>_P#GV4 ?WJ_\-!?
M3_HM_P (?_#E>#/_ )=4?\-!? 3_ *+?\(?_  Y7@S_Y=5_!5_Q Y?$C_I(S
MX(_\1GU[_P"?91_Q Y?$C_I(SX(_\1GU[_Y]E ']ZO\ PT%\!/\ HM_PA_\
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M^DC/@C_Q&?7O_GV4 ?WJ_P##07P$_P"BW_"'_P .5X,_^75'_#07P$_Z+?\
M"'_PY7@S_P"75?P5?\0.7Q(_Z2,^"/\ Q&?7O_GV4?\ $#E\2/\ I(SX(_\
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M^?91_P 0.7Q(_P"DC/@C_P 1GU[_ .?90!_>K_PT%\!/^BW_  A_\.5X,_\
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MP$_Z+?\ "'_PY7@S_P"75?P5?\0.7Q(_Z2,^"/\ Q&?7O_GV4?\ $#E\2/\
MI(SX(_\ $9]>_P#GV4 ?WJ_\-!? 3_HM_P (?_#E>#/_ )=4?\-!? 3_ *+?
M\(?_  Y7@S_Y=5_!5_Q Y?$C_I(SX(_\1GU[_P"?91_Q Y?$C_I(SX(_\1GU
M[_Y]E ']ZO\ PT%\!/\ HM_PA_\ #E>#/_EU1_PT%\!/^BW_  A_\.5X,_\
MEU7\%7_$#E\2/^DC/@C_ ,1GU[_Y]E'_ ! Y?$C_ *2,^"/_ !&?7O\ Y]E
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M,_\ EU7\%7_$#E\2/^DC/@C_ ,1GU[_Y]E'_ ! Y?$C_ *2,^"/_ !&?7O\
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M^75'_#07P$_Z+?\ "'_PY7@S_P"75?P5?\0.7Q(_Z2,^"/\ Q&?7O_GV4?\
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M?!'_ (C/KW_S[* /[U?^&@O@)_T6_P"$/_ARO!G_ ,NJ/^&@O@)_T6_X0_\
MARO!G_RZK^"K_B!R^)'_ $D9\$?^(SZ]_P#/LH_X@<OB1_TD9\$?^(SZ]_\
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M?!'_ (C/KW_S[* /[U?^&@O@)_T6_P"$/_ARO!G_ ,NJ/^&@O@)_T6_X0_\
MARO!G_RZK^"K_B!R^)'_ $D9\$?^(SZ]_P#/LH_X@<OB1_TD9\$?^(SZ]_\
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M?!'_ (C/KW_S[* /[U?^&@O@)_T6_P"$/_ARO!G_ ,NJ/^&@O@)_T6_X0_\
MARO!G_RZK^"K_B!R^)'_ $D9\$?^(SZ]_P#/LH_X@<OB1_TD9\$?^(SZ]_\
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MU&ZNO(A,D8EF\KRXRZ!V&Y<_E3_Q Y?$C_I(SX(_\1GU[_Y]E?F%_P %<?\
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MRO!G_P NJ/\ AH+X"?\ 1;_A#_X<KP9_\NJ_@J_X@<OB1_TD9\$?^(SZ]_\
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MO^$/_ARO!G_RZH_X:"^ G_1;_A#_ .'*\&?_ "ZK^"K_ (@<OB1_TD9\$?\
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MH_X@<OB1_P!)&?!'_B,^O?\ S[* /[U?^&@O@)_T6_X0_P#ARO!G_P NJ/\
MAH+X"?\ 1;_A#_X<KP9_\NJ_@J_X@<OB1_TD9\$?^(SZ]_\ /LH_X@<OB1_T
MD9\$?^(SZ]_\^R@#^]7_ (:"^ G_ $6_X0_^'*\&?_+JC_AH+X"?]%O^$/\
MX<KP9_\ +JOX*O\ B!R^)'_21GP1_P"(SZ]_\^RC_B!R^)'_ $D9\$?^(SZ]
M_P#/LH _O5_X:"^ G_1;_A#_ .'*\&?_ "ZH_P"&@O@)_P!%O^$/_ARO!G_R
MZK^"K_B!R^)'_21GP1_XC/KW_P ^RC_B!R^)'_21GP1_XC/KW_S[* /[U?\
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M?!'_ (C/KW_S[*/^('+XD?\ 21GP1_XC/KW_ ,^R@#^]7_AH+X"?]%O^$/\
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MU7\%7_$#E\2/^DC/@C_Q&?7O_GV4?\0.7Q(_Z2,^"/\ Q&?7O_GV4 ?WJ_\
M#07P$_Z+?\(?_#E>#/\ Y=4?\-!? 3_HM_PA_P##E>#/_EU7\%7_ ! Y?$C_
M *2,^"/_ !&?7O\ Y]E'_$#E\2/^DC/@C_Q&?7O_ )]E ']ZO_#07P$_Z+?\
M(?\ PY7@S_Y=4?\ #07P$_Z+?\(?_#E>#/\ Y=5_!5_Q Y?$C_I(SX(_\1GU
M[_Y]E'_$#E\2/^DC/@C_ ,1GU[_Y]E ']ZO_  T%\!/^BW_"'_PY7@S_ .75
M'_#07P$_Z+?\(?\ PY7@S_Y=5_!5_P 0.7Q(_P"DC/@C_P 1GU[_ .?91_Q
MY?$C_I(SX(_\1GU[_P"?90!_>K_PT%\!/^BW_"'_ ,.5X,_^75'_  T%\!/^
MBW_"'_PY7@S_ .75?P5?\0.7Q(_Z2,^"/_$9]>_^?91_Q Y?$C_I(SX(_P#$
M9]>_^?90!_>K_P -!? 3_HM_PA_\.5X,_P#EU1_PT%\!/^BW_"'_ ,.5X,_^
M75?P5?\ $#E\2/\ I(SX(_\ $9]>_P#GV4?\0.7Q(_Z2,^"/_$9]>_\ GV4
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M!_>K_P -!? 3_HM_PA_\.5X,_P#EU1_PT%\!/^BW_"'_ ,.5X,_^75?P5?\
M$#E\2/\ I(SX(_\ $9]>_P#GV4?\0.7Q(_Z2,^"/_$9]>_\ GV4 ?WJ_\-!?
M 3_HM_PA_P##E>#/_EU1_P -!? 3_HM_PA_\.5X,_P#EU7\%7_$#E\2/^DC/
M@C_Q&?7O_GV4?\0.7Q(_Z2,^"/\ Q&?7O_GV4 ?WJ_\ #07P$_Z+?\(?_#E>
M#/\ Y=4?\-!? 3_HM_PA_P##E>#/_EU7\%7_ ! Y?$C_ *2,^"/_ !&?7O\
MY]E'_$#E\2/^DC/@C_Q&?7O_ )]E ']ZO_#07P$_Z+?\(?\ PY7@S_Y=4?\
M#07P$_Z+?\(?_#E>#/\ Y=5_!5_Q Y?$C_I(SX(_\1GU[_Y]E'_$#E\2/^DC
M/@C_ ,1GU[_Y]E ']ZO_  T%\!/^BW_"'_PY7@S_ .75'_#07P$_Z+?\(?\
MPY7@S_Y=5_!5_P 0.7Q(_P"DC/@C_P 1GU[_ .?91_Q Y?$C_I(SX(_\1GU[
M_P"?90!_>K_PT%\!/^BW_"'_ ,.5X,_^75'_  T%\!/^BW_"'_PY7@S_ .75
M?P5?\0.7Q(_Z2,^"/_$9]>_^?91_Q Y?$C_I(SX(_P#$9]>_^?90!_>K_P -
M!? 3_HM_PA_\.5X,_P#EU1_PT%\!/^BW_"'_ ,.5X,_^75?P5?\ $#E\2/\
MI(SX(_\ $9]>_P#GV4?\0.7Q(_Z2,^"/_$9]>_\ GV4 ?WJ_\-!? 3_HM_PA
M_P##E>#/_EU1_P -!? 3_HM_PA_\.5X,_P#EU7\%7_$#E\2/^DC/@C_Q&?7O
M_GV4?\0.7Q(_Z2,^"/\ Q&?7O_GV4 ?WJ_\ #07P$_Z+?\(?_#E>#/\ Y=4?
M\-!? 3_HM_PA_P##E>#/_EU7\%7_ ! Y?$C_ *2,^"/_ !&?7O\ Y]E'_$#E
M\2/^DC/@C_Q&?7O_ )]E ']ZO_#07P$_Z+?\(?\ PY7@S_Y=4?\ #07P$_Z+
M?\(?_#E>#/\ Y=5_!5_Q Y?$C_I(SX(_\1GU[_Y]E'_$#E\2/^DC/@C_ ,1G
MU[_Y]E ']ZO_  T%\!/^BW_"'_PY7@S_ .75'_#07P$_Z+?\(?\ PY7@S_Y=
M5_!5_P 0.7Q(_P"DC/@C_P 1GU[_ .?91_Q Y?$C_I(SX(_\1GU[_P"?90!_
M>K_PT%\!/^BW_"'_ ,.5X,_^75'_  T%\!/^BW_"'_PY7@S_ .75?P5?\0.7
MQ(_Z2,^"/_$9]>_^?91_Q Y?$C_I(SX(_P#$9]>_^?90!^G_ /P=]?%;X7>,
M_P#@D[HVC^#_ (D^ ?%>K+^UA\';QM+\->,?#NNZB+2#PI\4TFNC9:7J-U<B
MVA>:))9S%Y4;2QJ[ NH/VE_P;<?&3X0^&/\ @BA^PUH7B7XJ_#?P]K=AX=^,
M:WVC:YXY\,:3JMDT_P"T;\8;J%;O3[_5+>[MFFMIX;B(30H9()HI4!CD1C_%
M-_P5Z_X-I_%__!)O]D^S_:FUS]KKPW\;K*\^*_@[X6CP9I/P:U3P'=1S^+M*
M\4ZI'K)UR\^(_BJ)HK%?##PO8_V6'N#>*ZW40A*R^T?\$WO^#47QO_P40_8I
M^!W[9.D_ML>%?A7I_P :].\8ZA;> =1^!6K^+KSP\/"/Q&\8?#V2*?Q%;?%/
MP_!J1OI?"4FJH\>CV0MX[Y+1EF:W:XE /]+7_AH+X"?]%O\ A#_X<KP9_P#+
MJC_AH+X"?]%O^$/_ (<KP9_\NJ_@J_X@<OB1_P!)&?!'_B,^O?\ S[*/^('+
MXD?])&?!'_B,^O?_ #[* /[U?^&@O@)_T6_X0_\ ARO!G_RZH_X:"^ G_1;_
M (0_^'*\&?\ RZK^"K_B!R^)'_21GP1_XC/KW_S[*/\ B!R^)'_21GP1_P"(
MSZ]_\^R@#^]7_AH+X"?]%O\ A#_X<KP9_P#+JC_AH+X"?]%O^$/_ (<KP9_\
MNJ_@J_X@<OB1_P!)&?!'_B,^O?\ S[*/^('+XD?])&?!'_B,^O?_ #[* /[U
M?^&@O@)_T6_X0_\ ARO!G_RZH_X:"^ G_1;_ (0_^'*\&?\ RZK^"K_B!R^)
M'_21GP1_XC/KW_S[*/\ B!R^)'_21GP1_P"(SZ]_\^R@#^]7_AH+X"?]%O\
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M^O?_ #[* /[U?^&@O@)_T6_X0_\ ARO!G_RZH_X:"^ G_1;_ (0_^'*\&?\
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M'_21GP1_XC/KW_S[*/\ B!R^)'_21GP1_P"(SZ]_\^R@#^]7_AH+X"?]%O\
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M^O?_ #[* /[U?^&@O@)_T6_X0_\ ARO!G_RZH_X:"^ G_1;_ (0_^'*\&?\
MRZK^"K_B!R^)'_21GP1_XC/KW_S[*/\ B!R^)'_21GP1_P"(SZ]_\^R@#^]7
M_AH+X"?]%O\ A#_X<KP9_P#+JC_AH+X"?]%O^$/_ (<KP9_\NJ_@J_X@<OB1
M_P!)&?!'_B,^O?\ S[*/^('+XD?])&?!'_B,^O?_ #[* /[U?^&@O@)_T6_X
M0_\ ARO!G_RZH_X:"^ G_1;_ (0_^'*\&?\ RZK^"K_B!R^)'_21GP1_XC/K
MW_S[*/\ B!R^)'_21GP1_P"(SZ]_\^R@#^]7_AH+X"?]%O\ A#_X<KP9_P#+
MJC_AH+X"?]%O^$/_ (<KP9_\NJ_@J_X@<OB1_P!)&?!'_B,^O?\ S[*/^('+
MXD?])&?!'_B,^O?_ #[* /[U?^&@O@)_T6_X0_\ ARO!G_RZH_X:"^ G_1;_
M (0_^'*\&?\ RZK^"K_B!R^)'_21GP1_XC/KW_S[*/\ B!R^)'_21GP1_P"(
MSZ]_\^R@#^]7_AH+X"?]%O\ A#_X<KP9_P#+JC_AH+X"?]%O^$/_ (<KP9_\
MNJ_@J_X@<OB1_P!)&?!'_B,^O?\ S[*/^('+XD?])&?!'_B,^O?_ #[* /[U
M?^&@O@)_T6_X0_\ ARO!G_RZH_X:"^ G_1;_ (0_^'*\&?\ RZK^"K_B!R^)
M'_21GP1_XC/KW_S[*/\ B!R^)'_21GP1_P"(SZ]_\^R@#^]7_AH+X"?]%O\
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M^O?_ #[* /[U?^&@O@)_T6_X0_\ ARO!G_RZH_X:"^ G_1;_ (0_^'*\&?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 5_FW?\'G/_*1[]B+_ +-JT3_U>_CZO])&O\V[_@\Y
M_P"4CW[$7_9M6B?^KW\?4 ?Z2-%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 ?R\_P#!WS_RAQ\4_P#9Q'P+
M_P#3EKU>^?\ !K1_R@N_8J_Z_/VEO_6M/CI7@?\ P=\_\H<?%/\ V<1\"_\
MTY:]7OG_  :T?\H+OV*O^OS]I;_UK3XZ4 ?T%4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 ?YM_[*/_*Z]XI_[.4_;-_]8Z^.E?Z2%?YM_P"R
MC_RNO>*?^SE/VS?_ %CKXZ5_I(4 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %?RP_P#!X7_RA^N/^SH/@E_Z0^.J_J>K^6'_ (/"_P#E#]<?]G0?
M!+_TA\=4 ?5G_!K_ /\ *"[]A;_KS_:)_P#6M/CS7[Y5^!O_  :__P#*"[]A
M;_KS_:)_]:T^/-?OE0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %?YMOA+_ )77;O\ [.6\:_\ K'FO5_I)5_FV^$O^5UV[_P"SEO&O_K'F
MO4 ?Z25%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?RD_\ !X]_RB+T
M7_L[CX,?^HE\5Z^W/^#9S_E!W^P?_P!BW\9__6E/C-7Q'_P>/?\ *(O1?^SN
M/@Q_ZB7Q7K[<_P"#9S_E!W^P?_V+?QG_ /6E/C-0!^[5%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% '^;?_P $\_\ E<J^//\ V<I_P4#_ /5;
M_&*O])"O\V__ ()Y_P#*Y5\>?^SE/^"@?_JM_C%7^DA0!_FW_P#!G+_RE/\
MVY?^S:_'_P#ZT7\+:_TD*_S;_P#@SE_Y2G_MR_\ 9M?C_P#]:+^%M?Z2% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %?YMW_!YS_RD>_8B_[-JT3_ -7OX^K_ $D:_P V[_@\Y_Y2
M/?L1?]FU:)_ZO?Q]0!_I(T444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110!_+S_P '?/\ RAQ\4_\ 9Q'P+_\
M3EKU>^?\&M'_ "@N_8J_Z_/VEO\ UK3XZ5X'_P '?/\ RAQ\4_\ 9Q'P+_\
M3EKU>^?\&M'_ "@N_8J_Z_/VEO\ UK3XZ4 ?T%4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 ?YM_[*/\ RNO>*?\ LY3]LW_UCKXZ5_I(5_FW
M_LH_\KKWBG_LY3]LW_UCKXZ5_I(4 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %?RP_\ !X7_ ,H?KC_LZ#X)?^D/CJOZGJ_EA_X/"_\ E#]<?]G0
M?!+_ -(?'5 'U9_P:_\ _*"[]A;_ *\_VB?_ %K3X\U^^5?@;_P:_P#_ "@N
M_86_Z\_VB?\ UK3X\U^^5 !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 ?YM__!//_E<J^//_ &<I_P % _\
MU6_QBK_20K_-O_X)Y_\ *Y5\>?\ LY3_ (*!_P#JM_C%7^DA0!_FW_\ !G+_
M ,I3_P!N7_LVOQ__ .M%_"VO])"O\V__ (,Y?^4I_P"W+_V;7X__ /6B_A;7
M^DA0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !7^;=_P 'G/\ RD>_8B_[-JT3_P!7OX^K_21K_-N_
MX/.?^4CW[$7_ &;5HG_J]_'U '^DC1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?RD_\'CW_*(O
M1?\ L[CX,?\ J)?%>OMS_@V<_P"4'?[!_P#V+?QG_P#6E/C-7Q'_ ,'CW_*(
MO1?^SN/@Q_ZB7Q7K[<_X-G/^4'?[!_\ V+?QG_\ 6E/C-0!^[5%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% '^;?\ \$\_^5RKX\_]G*?\% __
M %6_QBK_ $D*_P V_P#X)Y_\KE7QY_[.4_X*!_\ JM_C%7^DA0!_FW_\&<O_
M "E/_;E_[-K\?_\ K1?PMK_20K_-O_X,Y?\ E*?^W+_V;7X__P#6B_A;7^DA
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !7^;=_P><_\ *1[]B+_LVK1/_5[^/J_TD:_S;O\ @\Y_
MY2/?L1?]FU:)_P"KW\?4 ?Z2-%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 ?R\_\'?/_*''Q3_V<1\"_P#T
MY:]7OG_!K1_R@N_8J_Z_/VEO_6M/CI7@?_!WS_RAQ\4_]G$? O\ ].6O5[Y_
MP:T?\H+OV*O^OS]I;_UK3XZ4 ?T%4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 ?YM_P"RC_RNO>*?^SE/VS?_ %CKXZ5_I(5_FW_LH_\ *Z]X
MI_[.4_;-_P#6.OCI7^DA0 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 5_+#_P>%_\H?KC_LZ#X)?^D/CJOZGJ_EA_X/"_^4/UQ_V=!\$O_2'QU0!]
M6?\ !K__ ,H+OV%O^O/]HG_UK3X\U^^5?@;_ ,&O_P#R@N_86_Z\_P!HG_UK
M3X\U^^5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5_FV^$
MO^5UV[_[.6\:_P#K'FO5_I)5_FV^$O\ E==N_P#LY;QK_P"L>:]0!_I)4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!_*3_ ,'CW_*(O1?^SN/@Q_ZB
M7Q7K[<_X-G/^4'?[!_\ V+?QG_\ 6E/C-7Q'_P 'CW_*(O1?^SN/@Q_ZB7Q7
MK[<_X-G/^4'?[!__ &+?QG_]:4^,U '[M4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 ?YM_\ P3S_ .5RKX\_]G*?\% __5;_ !BK_20K_-O_
M .">?_*Y5\>?^SE/^"@?_JM_C%7^DA0!_FW_ /!G+_RE/_;E_P"S:_'_ /ZT
M7\+:_P!)"O\ -O\ ^#.7_E*?^W+_ -FU^/\ _P!:+^%M?Z2% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %?YMW_!YS_RD>_8B_P"S:M$_]7OX^K_21K_-N_X/.?\ E(]^Q%_V;5HG
M_J]_'U '^DC1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% '\O/\ P=\_\H<?%/\ V<1\"_\ TY:]7OG_  :T
M?\H+OV*O^OS]I;_UK3XZ5X'_ ,'?/_*''Q3_ -G$? O_ -.6O5[Y_P &M'_*
M"[]BK_K\_:6_]:T^.E ']!5<5XV^)'P_^&^GG5?'_C7POX-L-K-'<>)-;T_2
M1<;3@I:1WEQ%->3%L*D%I'--(Y")&S$ _DK^V3_P4HN/#NJ:E\,?V<[^RFU+
M3I[K3O$_Q->V@U"TM;N'S+>XTWP7!<K+97LMM.&6?Q)=0W5@SQLFCV]U&T.K
M+^)7B3Q/XB\8ZU?>(_%>NZMXDU_4YFN-0UC6[^YU+4KR5CDM-=W<LLSA<[44
MOLC3:D:J@51]SDW!&+Q]*&)QU5X&A42E"DH<^)G!V:E*,G&-%23O'FYY]Z:3
M3?X_Q3XNY9D^(JX#)\,LXQ=&4J=;$NM[++Z51:.,*D(SJ8N4)7C-4_94D_AK
MS::7]1>I_P#!0/\ 8^TF7R;KXT:9*^2,Z9X8\=ZU%D?]-]&\+7\./0^9@]B:
MS/\ AXU^QI_T6/\ \Q[\5/\ YAZ_EKHKZ5>'^3V5\5F3?5JKA4ODG@W;[V?
M2\;.*&WR9=D$8]%+#9C)KUDLS@G_ . H_J4_X>-?L:?]%C_\Q[\5/_F'H_X>
M-?L:?]%C_P#,>_%3_P"8>OY:Z*?_ !#_ ";_ *"<S_\ !V%_^8A?\1KXJ_Z%
M_#__ (2YC_\ /4_J4_X>-?L:?]%C_P#,>_%3_P"8>C_AXU^QI_T6/_S'OQ4_
M^8>OY:Z*/^(?Y-_T$YG_ .#L+_\ ,0?\1KXJ_P"A?P__ .$N8_\ SU/ZE/\
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M5/\ YAZ/^'C7[&G_ $6/_P Q[\5/_F'K^6NBC_B'^3?]!.9_^#L+_P#,0?\
M$:^*O^A?P_\ ^$N8_P#SU/ZE/^'C7[&G_18__,>_%3_YAZ/^'C7[&G_18_\
MS'OQ4_\ F'K^6NBC_B'^3?\ 03F?_@["_P#S$'_$:^*O^A?P_P#^$N8__/4_
MJ4_X>-?L:?\ 18__ #'OQ4_^8>C_ (>-?L:?]%C_ /,>_%3_ .8>OY:Z*/\
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M .#L+_\ ,0?\1KXJ_P"A?P__ .$N8_\ SU/ZE/\ AXU^QI_T6/\ \Q[\5/\
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MC_\ ,>_%3_YAZ_EKHH_XA_DW_03F?_@["_\ S$'_ !&OBK_H7\/_ /A+F/\
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M/_S'OQ4_^8>C_AXU^QI_T6/_ ,Q[\5/_ )AZ_EKHH_XA_DW_ $$YG_X.PO\
M\Q!_Q&OBK_H7\/\ _A+F/_SU/ZE/^'C7[&G_ $6/_P Q[\5/_F'H_P"'C7[&
MG_18_P#S'OQ4_P#F'K^6NBC_ (A_DW_03F?_ (.PO_S$'_$:^*O^A?P__P"$
MN8__ #U/ZE/^'C7[&G_18_\ S'OQ4_\ F'H_X>-?L:?]%C_\Q[\5/_F'K^6N
MBC_B'^3?]!.9_P#@["__ #$'_$:^*O\ H7\/_P#A+F/_ ,]3^I3_ (>-?L:?
M]%C_ /,>_%3_ .8>C_AXU^QI_P!%C_\ ,>_%3_YAZ_EKHH_XA_DW_03F?_@[
M"_\ S$'_ !&OBK_H7\/_ /A+F/\ \]3^I3_AXU^QI_T6/_S'OQ4_^8>C_AXU
M^QI_T6/_ ,Q[\5/_ )AZ_EKHH_XA_DW_ $$YG_X.PO\ \Q!_Q&OBK_H7\/\
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M3F?_ (.PO_S$'_$:^*O^A?P__P"$N8__ #U/ZE/^'C7[&G_18_\ S'OQ4_\
MF'H_X>-?L:?]%C_\Q[\5/_F'K^6NBC_B'^3?]!.9_P#@["__ #$'_$:^*O\
MH7\/_P#A+F/_ ,]3^I3_ (>-?L:?]%C_ /,>_%3_ .8>C_AXU^QI_P!%C_\
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M /,>_%3_ .8>C_AXU^QI_P!%C_\ ,>_%3_YAZ_EKHH_XA_DW_03F?_@["_\
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M_P#F/?BI_P#,/1_P\:_8T_Z+'_YCWXJ?_,/7\M=%'_$/\F_Z"<S_ /!V%_\
MF(/^(U\5?]"_A_\ \)<Q_P#GJ?U*?\/&OV-/^BQ_^8]^*G_S#T?\/&OV-/\
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M-/\ HL?_ )CWXJ?_ ##U_+711_Q#_)O^@G,__!V%_P#F(/\ B-?%7_0OX?\
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MX?\ _"7,?_GJ?U*?\/&OV-/^BQ_^8]^*G_S#T?\ #QK]C3_HL?\ YCWXJ?\
MS#U_+711_P 0_P F_P"@G,__  =A?_F(/^(U\5?]"_A__P )<Q_^>I_4I_P\
M:_8T_P"BQ_\ F/?BI_\ ,/1_P\:_8T_Z+'_YCWXJ?_,/7\M=%'_$/\F_Z"<S
M_P#!V%_^8@_XC7Q5_P!"_A__ ,)<Q_\ GJ?U*?\ #QK]C3_HL?\ YCWXJ?\
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M-/\ HL?_ )CWXJ?_ ##U_+711_Q#_)O^@G,__!V%_P#F(/\ B-?%7_0OX?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBB@ HHHH **** "BBB@ HHHH _EY_P"#OG_E#CXI_P"SB/@7_P"G+7J^/O\
M@DW^TK>_";_@WH_8:^%G@W5I=-\=?$Z;]IXZE>6,OE7^B> X?VMOCO:ZC/%*
M%+VUQXCNP^C6=Q&R2K9V^N/!)#<PP2K]@_\ !WS_ ,H<?%/_ &<1\"__ $Y:
M]7X8_P#!,RPU;0_^"?\ ^RKX<U.[:[BTCP#XBO\ 2 T?E?9=)\??%+X@?%2.
MT"[W#+%>>/+UED&WS0_F%%+$5]7P=EU/,,X@ZT5.C@Z4L7*$DG&<X3A"C&2>
MZ52:J-/22IN,M'9_F_BGGU?).%ZL<)4E2Q6:UX9=3JP;4Z5&I3J5<54A)-<L
MG1I2HJ2?-%UE.%I14E]R?Y_S_G^E% _G^/Y45^VG\CA1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MVJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /\V_\ X)Y_\KE7
MQY_[.4_X*!_^JW^,5?Z2%?YM_P#P3S_Y7*OCS_V<I_P4#_\ 5;_&*O\ 20H
M_P V_P#X,Y?^4I_[<O\ V;7X_P#_ %HOX6U_I(5_FW_\&<O_ "E/_;E_[-K\
M?_\ K1?PMK_20H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU/\ @Y$_8C^)?_!)S_@HU\&/^"NW[%]O-X \%_%3XM:+XVNKC1HX+'PM\/\
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MAI+'PQ?^)Y_"-S?3:5K7PJ\<W5E8:/X4UG2]1 /VW_X._/\ @IB='\!>!O\
M@D_\!M0U+Q!\7OCAJ/@OQS\?]+\'J^KZG8^ 6UIY_A=\'VM-'EN=1;QC\2_&
MFGZ1XMN?# MH]8_X131?"KR65UH_Q&TUKG\=_P#@M#_P2ZT+_@E?_P $8O\
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MYU?X\>+=.U/1="\5SV7B\1>&O!&D:GXFU%+?7[[1O'/B/2[35&T_7?$]I?\
M]OG_ !$=?\$3O^C^?AQ_X1'QF_\ G:T ?@!_P2]_X.</VI?A[^UGI_\ P3X_
MX+5>"-/\ >/IO&-M\+V^/6I^#-/^$WBKP'\2];O--A\+V/QZ\'Z3#H_P^M/
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M %;PO\1K[Q!KL%U>Z'H7B35?AVVJ07D']5O_ !$=?\$3O^C^?AQ_X1'QF_\
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M?VWAGQAHMOX<NE?4+V3P-J&LV^O7D6M:?J]O8:[$=&O=%O\ 3(+F*[6S /U
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MNMIM]X*EMVN-.UQ1)_:/7^7/^R"C_P#!;[_@Z,U7XW7D<WBOX(>#?CIX@_:
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M!X9T< _UGJ*** "BBB@ HHHH _EY_P"#OG_E#CXI_P"SB/@7_P"G+7J_'_\
M8P@BM_V/_P!E:.&-8T;]G/X*3LJ\ RW/PW\-W,\A_P!J6>625_5G)XZ5^P'_
M  =\_P#*''Q3_P!G$? O_P!.6O5^0G[&W_)H/[*G_9MWP-_]5AX7K]"\/?\
M?<P_[!:?_IX_#_'#_D59'_V,,1_ZC+_-_>?2-%%%?JQ_-X4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?V#?LURR3?LZ? *:5
MVDEE^"GPKEED8Y9Y)/ NA.[L>[,Q))[DFO:J\1_9F_Y-O_9^_P"R(_"C_P!0
M/0:]NK^<,9_OF*_[":__ *=F?WAE.N598WO_ &?@_P#U&IA1117,>@%%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_*3_P '
MCW_*(O1?^SN/@Q_ZB7Q7K[<_X-G/^4'?[!__ &+?QG_]:4^,U?$?_!X]_P H
MB]%_[.X^#'_J)?%>OMS_ (-G/^4'?[!__8M_&?\ ]:4^,U '[M4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 ?YM__  3S_P"5RKX\_P#9RG_!
M0/\ ]5O\8J_TD*_S;_\ @GG_ ,KE7QY_[.4_X*!_^JW^,5?Z2% '^;?_ ,&<
MO_*4_P#;E_[-K\?_ /K1?PMK_20K_-O_ .#.7_E*?^W+_P!FU^/_ /UHOX6U
M_I(4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[$W_ &<3XX_]5K-7]N=?Q&?\'N__ ":9^Q-_V<3XX_\ 5:S4 ?KK_P &N/\
MR@H_89_[N9_];#_:"K\7O^#L?_@M+^T=^R]\0?A__P $_?V1/B3K/P@U/Q7\
M)[GXC?M(?$KPDFGP>-;O0/'E_JWASP-\+_"'BN1)-=^'MU!I_AW7?&'C#7O"
MXTOQ/?V?B'P%9Z#XKTJP@\7:5KG[0_\ !KC_ ,H*/V&?^[F?_6P_V@J_FH_X
M/&OV$OC=X._:9^#O_!3;X;>']0UCX0ZA\/\ P-\+?B;XFTFVFUE_A1\7? 'B
MS6KKP-K_ (OL[BTEL=(\(?$#1?$'ASP_X6U!TO='/C+PCJ^C^(I=-U'Q9X.L
M?$0!]@?L&?\ !G+\(-9\%>%OC/\ \%+OCA\8/B/\;O'UE<^./'/P@^'.N6GA
M3PWX;U[Q?9/>3Z'X^^(VLZ?XD\?_ !$\8:5?7\VL^)-?T.]\!VDGB_?I?_%3
MZ)IESK'B[[^_:L_X-H?^"+7P>_8]_:<^(7@[]D._7Q_\-/V=?CCX[\(^+M3_
M &A_VGKZ^L/%?A3X=>*O$GAO59])'QEA\+7W]D:I96+Q6-YX?FTV\AM(X=4L
M[]9;K[1XS^RY_P 'D7_!.[QU\'_"FH?M3^%?C)\#?CI::186GQ$\.>$_AY+X
M_P#AMJ/B6.-TU'5_AMX@TGQ'J&O'PM?-''>P:9XSTO2-=T.6\?0S<^)X--7Q
M3JWPG^UI_P %A/VZ/^"]_@CXH_LI_P#!*_\ 9\^)'P!_8R_X5SX^NOVP_P!J
MWXSZ0NGZM_P@.B^';_6_$7PJG\0^"M7\5>!/!D/CCPDHTJ\^'6B>(?%_Q(^*
MBZV-'%YX-^%VF?$'5=: /G;_ (,@_P#DYK]NC_LA/PQ_]6!JE?VY_P#!6+_E
M%E_P4L_[, _;(_\ 6=?B-7\1G_!D'_R<U^W1_P!D)^&/_JP-4K^W/_@K%_RB
MR_X*6?\ 9@'[9'_K.OQ&H _C&_X,<_\ DI__  45_P"Q#_9L_P#4A^,M?H#_
M ,'L/P_U76/V!/V6_B59N9=,\#?M:0>&-8M(K2YGEC7X@?"3XAWEAJ\]S$K6
M]EI]G=>!O[*F>Z*";4->TJ"%_,?8_P"?W_!CG_R4_P#X**_]B'^S9_ZD/QEK
M^TS_ (*6_L*^!_\ @I'^Q1\<OV0/'&JGPROQ.\.VL_@SQQ%IUKJ=W\/_ (F>
M$]5L?%7P\\8Q6DZK/<Z?IOBG2-.M_%6EZ=>Z1J7B/P5>^)O"MMKFCC79-0@
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MQ+U9]#T=IHH[:[U#3/#OBC5+=KF&6W\/WT2W#0@'Y'_\'P/C#P_>_M _L$>
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M_P %?_\ E;6_[O#_ ."9G_JI?V1Z_P!3>@ HHHH _D"_X/5O^467P#_[/_\
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M  $\3ZYJFM:SJMN]E9ZW!H.H^%+F[B>TMM2CM%,$4R?FC_P;5?\ !/+XE?\
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M7\-:-:V&J>*M0T^T>:/^W_&.LQZAXK\37TUS>W^K>(]9U35=3U#4-2O;J^N
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _E)_X/'O^41>B_\
M9W'P8_\ 42^*]?;G_!LY_P H._V#_P#L6_C/_P"M*?&:OB/_ (/'O^41>B_]
MG<?!C_U$OBO7VY_P;.?\H._V#_\ L6_C/_ZTI\9J /W:HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)(H41?Y]_P#@J7_P;4?\/+/V]=)_;>_X;2_X4M_9?A[X4Z#_ ,*Q_P"&<O\
MA8_G_P#"L;N:Z^U_\)I_PO?P'Y7]M^;Y?D?\(G)_9NW=YU_G:/ZE: /SV^!O
M_!)S_@FE^S9XST7XC_!#]AW]FSP#\0_#5_)JGACQY8?"_P .ZEXS\+:G)%%
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M335\3:K;V\%Q=^7#J&K7,:S7^I76W[3J=_-<_6=% !1110!^;'Q6_P"".?\
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M"TO_ $\?A_CA_P BK(_^QAB?_49'TC1117ZL?S>%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% ']@7[,W_ ";?^S]_V1'X4?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O\V[_@\Y_Y2/?L
M1?\ 9M6B?^KW\?5_I(U_FW?\'G/_ "D>_8B_[-JT3_U>_CZ@#_21HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% ']@7[,W_)M_P"S]_V1'X4?
M^H'H->W5XC^S-_R;?^S]_P!D1^%'_J!Z#7MU?SAC?]\Q?_837_\ 3LS^\,I_
MY%66?]B_!?\ J-2"BBBN8] **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#^4G_@\>_Y1%Z+_ -G<?!C_ -1+XKU]N?\ !LY_
MR@[_ &#_ /L6_C/_ .M*?&:OB/\ X/'O^41>B_\ 9W'P8_\ 42^*]?;G_!LY
M_P H._V#_P#L6_C/_P"M*?&:@#]VJ*** "BBB@ HHHH **** "BBB@ HHHH
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MXGA=VNI-72U2S,6HO,NGSPW,@!^J%%><_"SXP_"3XY^$;3X@?!/XI?#GXP^
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M.TN>]6X:VL]8N/"FK:JNCZA(;2\C.G:I]DOHIK.\MY;=)[2XCC]MH **\?\
MC7^T+\ OV:_"NG^.OVC/CC\'_@#X)U;Q!:^$]+\8_&OXE^"_A7X5U+Q5?:=J
MNL6/AG3_ !#XZUK0=(O/$%YI&A:YJEKHUO>2:C<:=HVJWT-L]MIUY+#%X?\
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M%J5GJ^D:E:MXKNT6YL-2T^:XLKR LC*)K>>2,LK -D$  _2__@CA_P %.O\
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M]6!JE ']^?[6/QT_X9?_ &6/VEOVE_\ A%O^$X_X9W_9_P#C)\=/^$*_MO\
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?YM_\
MP3S_ .5RKX\_]G*?\% __5;_ !BK_20K_-O_ .">?_*Y5\>?^SE/^"@?_JM_
MC%7^DA0!_FW_ /!G+_RE/_;E_P"S:_'_ /ZT7\+:_P!)"O\ -O\ ^#.7_E*?
M^W+_ -FU^/\ _P!:+^%M?Z2% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?Z8/[4G_ ";+^T7_ -D)^+O_ *K_ ,0U_F??\&;'_*6[Q3_V9Y\9/_4\^#E
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MY\8Z_P!3>O\ +(_X/)_^4MWA;_LSSX-_^IY\8Z_U-Z /\PW_ (+-?%GX]?\
M!8[_ (+X:1_P3&L/C->_#3]G_P #_'GPG^SAX!T6Y3Q-J7@GPKXC\-:/='XO
M_&O7/AW'KFGZ3XX^*4.J:I\1](\*WJ/X5_M/PE8>$?!+^(]!T^?6?%MU_29X
M4_X,\?\ @D1H?@NP\-Z^/VF?&OB2#3[NVO\ XAZM\9+32O$-_?7DMS,-132/
M#7@_1_!MF=,-PEMI%HGAN:!;*QLEUDZY?'4-0U#\X/\ @OW_ ,&]O[8/B?\
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MA::EKLTEY>W]EK6LV5QO_M:>XC_U** /\OW_ (*R?\$5OVBO^#?7Q?\ "_\
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M^ ?_ &?_ /"S_P!9U_:JKP7_ ((L?L!^ O\ @IA_P;'^(_V3?&\\&CZGXO\
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M<-(WGRY\Q@#TJOX2O^#,7_DKO_!9C_LH_P"R]_ZD_P"V97]VM?DW_P $R?\
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M5]+(CMVD\-W_ ,1O!VE&Q\.^$-(\+VD?P_\ @O%I\T/@>?Q%K$&A>*]!]?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% '^;?_P3S_Y7*OCS_P!G*?\ !0/_ -5O\8J_TD*_
MS;_^">?_ "N5?'G_ +.4_P""@?\ ZK?XQ5_I(4 ?YM__  9R_P#*4_\ ;E_[
M-K\?_P#K1?PMK_20K_-O_P"#.7_E*?\ MR_]FU^/_P#UHOX6U_I(4 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 5_FW?\ !YS_ ,I'OV(O^S:M$_\ 5[^/J_TD:_S;O^#SG_E(]^Q%
M_P!FU:)_ZO?Q]0!_I(T444 %%%% !1110!X3^U)_R;+^T7_V0GXN_P#JO_$-
M?YGW_!FQ_P I;O%/_9GGQD_]3SX.5_IO_'OPSK?C7X%_&CP=X9LO[2\2>+?A
M-\1O#/A_3OM-I9_VAK>O>#]8TO2K+[9J%Q:V%K]JO[JW@^TWMU;6D'F>;<W$
M,*/(O^6/\ _^" '_  <J?LL>/D^*?[-_[/GQ&^!_Q%71]2\.MXQ^&/[8W[*G
M@_7;CP_K!MVU/0KV]T;]HRU>_P!'O9K.QNY],O?M%DU]I^G7_D"]T^RG@ /]
M9"O&OC[^T1\#/V6/A=XC^-7[1?Q6\#_!KX6>%+=Y]9\:>/=>L]"TI9_(N+BU
MT?3%N9!>:_XFU?[-+:^'O">@6NI^)O$NI&+2O#^DZEJ=Q;VDO^=A_P ,3_\
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MX!_]G_\ PL_]9U_:JK[#_P"#4+_E"1^S;_V/G[1/_J]?'E1_\'0/[!7[6/\
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ML:7K'B+2=)U_Q;XMU_2=!N_$UWH/A6WM_"OAZ+P]))K'ZU_\%"?A;X[^./[
MO[</P4^%NA?\)1\3?C!^R!^TM\+?AUX9_M/1]$_X2+QW\0/@OXU\)^$="_MG
MQ%J&D>'](_M?Q!J^GZ?_ &GKNJZ9H]A]H^U:GJ%E913W,0!_$-_P8Y_\E/\
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MU'3K^TDFM;ZPOK6:*YL[RVEEM[FWECFAD>-U8@'\B/\ P>K?\HLO@'_V?_\
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MF*6WN;>62&:-XW93?HHH **** "BBB@ HHHH **** /Y>?\ @[Y_Y0X^*?\
MLXCX%_\ IRUZOQ__ &,)XKC]C_\ 96DAD61%_9S^"D#,O($MM\-_#=M/&?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&C+#X+!X>?QT,+AZ,MOBI480EMIO%[:!1116)U!1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !7^;=_P><_\I'OV(O\ LVK1/_5[^/J_TD:_S;O^#SG_ )2/?L1?]FU:
M)_ZO?Q]0!_I(T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MI-NEII>A>'?#^G6^DZ)HVFVL8$=MI^EZ9:6UC9VZ )#;P1QJ,**WJ "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M  [E_8T_Z(Y_YD+XJ?\ S<5]N44?VUG/_0VS/_POQ7_RT/\ 5/A7_HF>'_\
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M/^B.?^9"^*G_ ,W%?;E%']M9S_T-LS_\+\5_\M#_ %3X5_Z)GA__ ,,V7?\
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M_F0OBI_\W%'_  [E_8T_Z(Y_YD+XJ?\ S<5]N44?VUG/_0VS/_POQ7_RT/\
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M/^B.?^9"^*G_ ,W%?;E%']M9S_T-LS_\+\5_\M#_ %3X5_Z)GA__ ,,V7?\
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M_F0OBI_\W%'_  [E_8T_Z(Y_YD+XJ?\ S<5]N44?VUG/_0VS/_POQ7_RT/\
M5/A7_HF>'_\ PS9=_P#,Q\1_\.Y?V-/^B.?^9"^*G_S<4?\ #N7]C3_HCG_F
M0OBI_P#-Q7VY11_;6<_]#;,__"_%?_+0_P!4^%?^B9X?_P##-EW_ ,S'Q'_P
M[E_8T_Z(Y_YD+XJ?_-Q1_P .Y?V-/^B.?^9"^*G_ ,W%?;E%']M9S_T-LS_\
M+\5_\M#_ %3X5_Z)GA__ ,,V7?\ S,?$?_#N7]C3_HCG_F0OBI_\W%'_  [E
M_8T_Z(Y_YD+XJ?\ S<5]N44?VUG/_0VS/_POQ7_RT/\ 5/A7_HF>'_\ PS9=
M_P#,Q\1_\.Y?V-/^B.?^9"^*G_S<4?\ #N7]C3_HCG_F0OBI_P#-Q7VY11_;
M6<_]#;,__"_%?_+0_P!4^%?^B9X?_P##-EW_ ,S'Q'_P[E_8T_Z(Y_YD+XJ?
M_-Q1_P .Y?V-/^B.?^9"^*G_ ,W%?;E%']M9S_T-LS_\+\5_\M#_ %3X5_Z)
MGA__ ,,V7?\ S,?$?_#N7]C3_HCG_F0OBI_\W%'_  [E_8T_Z(Y_YD+XJ?\
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M/_POQ7_RT/\ 5/A7_HF>'_\ PS9=_P#,Q\1_\.Y?V-/^B.?^9"^*G_S<4?\
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MP[E_8T_Z(Y_YD+XJ?_-Q7VY11_;6<_\ 0VS/_P +\5_\M#_5/A7_ *)GA_\
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M_P W%'_#N7]C3_HCG_F0OBI_\W%?;E%']M9S_P!#;,__  OQ7_RT/]4^%?\
MHF>'_P#PS9=_\S'Q'_P[E_8T_P"B.?\ F0OBI_\ -Q1_P[E_8T_Z(Y_YD+XJ
M?_-Q7VY11_;6<_\ 0VS/_P +\5_\M#_5/A7_ *)GA_\ \,V7?_,Q\1_\.Y?V
M-/\ HCG_ )D+XJ?_ #<4?\.Y?V-/^B.?^9"^*G_S<5]N44?VUG/_ $-LS_\
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M'_P[E_8T_P"B.?\ F0OBI_\ -Q1_P[E_8T_Z(Y_YD+XJ?_-Q7VY11_;6<_\
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M]M9S_P!#;,__  OQ7_RT/]4^%?\ HF>'_P#PS9=_\S'Q'_P[E_8T_P"B.?\
MF0OBI_\ -Q1_P[E_8T_Z(Y_YD+XJ?_-Q7VY11_;6<_\ 0VS/_P +\5_\M#_5
M/A7_ *)GA_\ \,V7?_,Q\1_\.Y?V-/\ HCG_ )D+XJ?_ #<4?\.Y?V-/^B.?
M^9"^*G_S<5]N44?VUG/_ $-LS_\ "_%?_+0_U3X5_P"B9X?_ /#-EW_S,?$?
M_#N7]C3_ *(Y_P"9"^*G_P W%'_#N7]C3_HCG_F0OBI_\W%?;E%']M9S_P!#
M;,__  OQ7_RT/]4^%?\ HF>'_P#PS9=_\S'Q'_P[E_8T_P"B.?\ F0OBI_\
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M &#_ /L6_C/_ .M*?&:@#]VJ*** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K_-N
M_P"#SG_E(]^Q%_V;5HG_ *O?Q]7^DC7^;=_P><_\I'OV(O\ LVK1/_5[^/J
M/])&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** /Y>?^#OG_ )0X^*?^SB/@7_Z<M>KWS_@UH_Y07?L5?]?G
M[2W_ *UI\=*\#_X.^?\ E#CXI_[.(^!?_IRUZO?/^#6C_E!=^Q5_U^?M+?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_S;?"7_*Z[=_\ 9RWC
M7_UCS7J_TDJ_S;?"7_*Z[=_]G+>-?_6/->H _P!)*BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MN_X/.?\ E(]^Q%_V;5HG_J]_'U?Z2-?YMW_!YS_RD>_8B_[-JT3_ -7OX^H
M_P!)&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** /Y>?^#OG_E#CXI_[.(^!?_IRUZO?/^#6C_E!=^Q5_P!?
MG[2W_K6GQTKP/_@[Y_Y0X^*?^SB/@7_Z<M>KWS_@UH_Y07?L5?\ 7Y^TM_ZU
MI\=* /Z"J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /\ -O\
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M->K_ $DJ_P VWPE_RNNW?_9RWC7_ -8\UZ@#_22HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@#_-O_ .">?_*Y5\>?^SE/^"@?_JM_C%7^DA7^;?\ \$\_^5RKX\_]G*?\
M% __ %6_QBK_ $D* /\ -O\ ^#.7_E*?^W+_ -FU^/\ _P!:+^%M?Z2%?YM_
M_!G+_P I3_VY?^S:_'__ *T7\+:_TD* "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_P V[_@\Y_Y2
M/?L1?]FU:)_ZO?Q]7^DC7^;=_P 'G/\ RD>_8B_[-JT3_P!7OX^H _TD:***
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *_P VWPE_RNNW?_9RWC7_ -8\UZO]
M)*O\VWPE_P KKMW_ -G+>-?_ %CS7J /])*BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** /Y2?\ @\>_Y1%Z+_V=Q\&/_42^*]?;G_!LY_R@[_8/_P"Q
M;^,__K2GQFKXC_X/'O\ E$7HO_9W'P8_]1+XKU]N?\&SG_*#O]@__L6_C/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_S;O^#SG_E(]^Q%_P!F
MU:)_ZO?Q]7^DC7^;=_P><_\ *1[]B+_LVK1/_5[^/J /])&BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /Y
M>?\ @[Y_Y0X^*?\ LXCX%_\ IRUZO?/^#6C_ )07?L5?]?G[2W_K6GQTKP/_
M (.^?^4./BG_ +.(^!?_ *<M>KWS_@UH_P"4%W[%7_7Y^TM_ZUI\=* /Z"J*
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /\V_]E'_E=>\4_P#9
MRG[9O_K'7QTK_20K_-__ &58M)'_  >J>*'BO=1>]_X:1_;()MY-,MHK42G]
MCKXY><@O%U>:8QQ@R>5(;$--M0/%!O8Q_P"D!0 4444 %%%% !1110 4444
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M_P!H?RY;BWCM9FS^UC\=R^^"*YO$3:Y95VW$FY KG86,:_O70 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %?YMOA+_E==N_^SEO&O\ ZQYK
MU?Z25?YP/A*'1/\ B-5NV_M#5/M?_#1_C5O)_L>T^S_:O^&.->/D_:O[<\SR
M/._=_:?LGF>5^]^R[OW- '^C]1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%UO^C^OV:_\ Q*7]L/\ ^ATH_P"(3S_@NM_T?U^S7_XE+^V'_P#0Z5_I(44
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M^OV:_P#Q*7]L/_Z'2C_B$\_X+K?]']?LU_\ B4O[8?\ ]#I7^DA10!_FW_\
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MK?\ 1_7[-?\ XE+^V'_]#I7^DA10!_FW_P#$)Y_P76_Z/Z_9K_\ $I?VP_\
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M?LU_^)2_MA__ $.E?Z2%% '^;?\ \0GG_!=;_H_K]FO_ ,2E_;#_ /H=*/\
MB$\_X+K?]']?LU_^)2_MA_\ T.E?Z2%% '^;?_Q">?\ !=;_ */Z_9K_ /$I
M?VP__H=*/^(3S_@NM_T?U^S7_P")2_MA_P#T.E?Z2%% '^;?_P 0GG_!=;_H
M_K]FO_Q*7]L/_P"ATH_XA//^"ZW_ $?U^S7_ .)2_MA__0Z5_I(44 ?YM_\
MQ">?\%UO^C^OV:__ !*7]L/_ .ATH_XA//\ @NM_T?U^S7_XE+^V'_\ 0Z5_
MI(44 ?YM_P#Q">?\%UO^C^OV:_\ Q*7]L/\ ^ATH_P"(3S_@NM_T?U^S7_XE
M+^V'_P#0Z5_I(44 ?YM__$)Y_P %UO\ H_K]FO\ \2E_;#_^ATH_XA//^"ZW
M_1_7[-?_ (E+^V'_ /0Z5_I(44 ?YM__ !">?\%UO^C^OV:__$I?VP__ *'2
MC_B$\_X+K?\ 1_7[-?\ XE+^V'_]#I7^DA10!_FW_P#$)Y_P76_Z/Z_9K_\
M$I?VP_\ Z'2C_B$\_P""ZW_1_7[-?_B4O[8?_P!#I7^DA10!_FW_ /$)Y_P7
M6_Z/Z_9K_P#$I?VP_P#Z'2C_ (A//^"ZW_1_7[-?_B4O[8?_ -#I7^DA10!_
MFW_\0GG_  76_P"C^OV:_P#Q*7]L/_Z'2C_B$\_X+K?]']?LU_\ B4O[8?\
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M_1_7[-?_ (E+^V'_ /0Z4?\ $)Y_P76_Z/Z_9K_\2E_;#_\ H=*_TD** /\
M-O\ ^(3S_@NM_P!']?LU_P#B4O[8?_T.E'_$)Y_P76_Z/Z_9K_\ $I?VP_\
MZ'2O])"B@#_-O_XA//\ @NM_T?U^S7_XE+^V'_\ 0Z4?\0GG_!=;_H_K]FO_
M ,2E_;#_ /H=*_TD** /\V__ (A//^"ZW_1_7[-?_B4O[8?_ -#I1_Q">?\
M!=;_ */Z_9K_ /$I?VP__H=*_P!)"B@#_-O_ .(3S_@NM_T?U^S7_P")2_MA
M_P#T.E'_ !">?\%UO^C^OV:__$I?VP__ *'2O])"B@#_ #;_ /B$\_X+K?\
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MFO\ \2E_;#_^ATK_ $D** /\V_\ XA//^"ZW_1_7[-?_ (E+^V'_ /0Z4?\
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M !">?\%UO^C^OV:__$I?VP__ *'2O])"B@#_ #;_ /B$\_X+K?\ 1_7[-?\
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MLU_^)2_MA_\ T.E'_$)Y_P %UO\ H_K]FO\ \2E_;#_^ATK_ $D** /\V_\
MXA//^"ZW_1_7[-?_ (E+^V'_ /0Z4?\ $)Y_P76_Z/Z_9K_\2E_;#_\ H=*_
MTD** /\ -O\ ^(3S_@NM_P!']?LU_P#B4O[8?_T.E'_$)Y_P76_Z/Z_9K_\
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MM_\ Q">?\%UO^C^OV:__ !*7]L/_ .ATH_XA//\ @NM_T?U^S7_XE+^V'_\
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MM_\ Q">?\%UO^C^OV:__ !*7]L/_ .ATH_XA//\ @NM_T?U^S7_XE+^V'_\
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MH_XA//\ @NM_T?U^S7_XE+^V'_\ 0Z5_I(44 ?YM_P#Q">?\%UO^C^OV:_\
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M5_I(44 ?YM__ !">?\%UO^C^OV:__$I?VP__ *'2C_B$\_X+K?\ 1_7[-?\
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M^V'_ /0Z5_I(44 ?YM__ !">?\%UO^C^OV:__$I?VP__ *'2C_B$\_X+K?\
M1_7[-?\ XE+^V'_]#I7^DA10!_E2_P#!!+X"_%+]G;_@YE^&_P !_BUXLT;Q
MA\3_ (%^.OVQ?!'Q/\5:%KOB+Q!HWBKQ)X9_9X^-WAG6=3T?7/$NCZ)XAURS
MO=;GAOK>\\0Z/I%_<VZ&ZNK2"[5+<_ZK5?YM_P#P3S_Y7*OCS_V<I_P4#_\
M5;_&*O\ 20H _P V_P#X,Y?^4I_[<O\ V;7X_P#_ %HOX6U_I(5_FW_\&<O_
M "E/_;E_[-K\?_\ K1?PMK_20H **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K_ #;O^#SG_E(]^Q%_
MV;5HG_J]_'U?Z2-?YMW_  ><_P#*1[]B+_LVK1/_ %>_CZ@#_21HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@#^7G_@[Y_Y0X^*?^SB/@7_ .G+7J]\_P"#6C_E!=^Q5_U^?M+?^M:?'2O
M_P#@[Y_Y0X^*?^SB/@7_ .G+7J]\_P"#6C_E!=^Q5_U^?M+?^M:?'2@#^@JB
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_-O_ &4?^5U[Q3_V
M<I^V;_ZQU\=*_P!)"O\ -O\ V4?^5U[Q3_V<I^V;_P"L=?'2O])"@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ K^6'_@\+_Y0_7'_9T'P2_](?'5
M?U/5_+#_ ,'A?_*'ZX_[.@^"7_I#XZH ^K/^#7__ )07?L+?]>?[1/\ ZUI\
M>:_?*OP-_P"#7_\ Y07?L+?]>?[1/_K6GQYK]\J "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ K_ #;?"7_*Z[=_]G+>-?\ UCS7J_TDJ_S;
M?"7_ "NNW?\ V<MXU_\ 6/->H _TDJ*** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_20H _S;_P#@SE_Y2G_MR_\ 9M?C_P#]:+^%M?Z2%?YM_P#P9R_\I3_VY?\
MLVOQ_P#^M%_"VO\ 20H **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ K_-N_X/.?^4CW[$7_ &;5HG_J
M]_'U?Z2-?YMW_!YS_P I'OV(O^S:M$_]7OX^H _TD:*** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "O\VWPE_P KKMW_ -G+>-?_ %CS7J_TDJ_S;?"7
M_*Z[=_\ 9RWC7_UCS7J /])*BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** /Y2?^#Q[_ )1%Z+_V=Q\&/_42^*]?;G_!LY_R@[_8/_[%OXS_ /K2GQFK
MXC_X/'O^41>B_P#9W'P8_P#42^*]?;G_  ;.?\H._P!@_P#[%OXS_P#K2GQF
MH _=JBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_-O_X)Y_\
M*Y5\>?\ LY3_ (*!_P#JM_C%7^DA7^;?_P $\_\ E<J^//\ V<I_P4#_ /5;
M_&*O])"@#_-O_P"#.7_E*?\ MR_]FU^/_P#UHOX6U_I(5_FW_P#!G+_RE/\
MVY?^S:_'_P#ZT7\+:_TD* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** /\V_]E'_ )77O%/_ &<I^V;_
M .L=?'2O])"O\V_]E'_E=>\4_P#9RG[9O_K'7QTK_20H **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /\ -O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MS^S?_P!' _!'_P .MX#_ /E]1]2QG_0)BO\ PGJ__(>:^\/[6RK_ *&>7_\
MA;AO_EA[=17B/_#3/[-__1P/P1_\.MX#_P#E]1_PTS^S?_T<#\$?_#K> _\
MY?4?4L9_T"8K_P )ZO\ \AYK[P_M;*O^AGE__A;AO_EA[=17B/\ PTS^S?\
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M^AGE_P#X6X;_ .6'MU%>(_\ #3/[-_\ T<#\$?\ PZW@/_Y?4?\ #3/[-_\
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M_P!' _!'_P .MX#_ /E]1_PTS^S?_P!' _!'_P .MX#_ /E]1]2QG_0)BO\
MPGJ__(>:^\/[6RK_ *&>7_\ A;AO_EA[=17B/_#3/[-__1P/P1_\.MX#_P#E
M]1_PTS^S?_T<#\$?_#K> _\ Y?4?4L9_T"8K_P )ZO\ \AYK[P_M;*O^AGE_
M_A;AO_EA[=17B/\ PTS^S?\ ]' _!'_PZW@/_P"7U'_#3/[-_P#T<#\$?_#K
M> __ )?4?4L9_P! F*_\)ZO_ ,AYK[P_M;*O^AGE_P#X6X;_ .6'MU%>(_\
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MS^S?_P!' _!'_P .MX#_ /E]1]2QG_0)BO\ PGJ__(>:^\/[6RK_ *&>7_\
MA;AO_EA[=17B/_#3/[-__1P/P1_\.MX#_P#E]1_PTS^S?_T<#\$?_#K> _\
MY?4?4L9_T"8K_P )ZO\ \AYK[P_M;*O^AGE__A;AO_EA[=17B/\ PTS^S?\
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M /"W#?\ RP]NHKQ'_AIG]F__ *.!^"/_ (=;P'_\OJ/^&F?V;_\ HX'X(_\
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M_P#R^H_X:9_9O_Z.!^"/_AUO ?\ \OJ/J6,_Z!,5_P"$]7_Y#S7WA_:V5?\
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M"/\ X=;P'_\ +ZC_ (:9_9O_ .C@?@C_ .'6\!__ "^H^I8S_H$Q7_A/5_\
MD/-?>']K95_T,\O_ /"W#?\ RP]NHKQ'_AIG]F__ *.!^"/_ (=;P'_\OJ/^
M&F?V;_\ HX'X(_\ AUO ?_R^H^I8S_H$Q7_A/5_^0\U]X?VME7_0SR__ ,+<
M-_\ +#VZBO$?^&F?V;_^C@?@C_X=;P'_ /+ZC_AIG]F__HX'X(_^'6\!_P#R
M^H^I8S_H$Q7_ (3U?_D/-?>']K95_P!#/+__  MPW_RP]NHKQ'_AIG]F_P#Z
M.!^"/_AUO ?_ ,OJ/^&F?V;_ /HX'X(_^'6\!_\ R^H^I8S_ *!,5_X3U?\
MY#S7WA_:V5?]#/+_ /PMPW_RP]NHKQ'_ (:9_9O_ .C@?@C_ .'6\!__ "^H
M_P"&F?V;_P#HX'X(_P#AUO ?_P OJ/J6,_Z!,5_X3U?_ )#S7WA_:V5?]#/+
M_P#PMPW_ ,L/;J*\1_X:9_9O_P"C@?@C_P"'6\!__+ZC_AIG]F__ *.!^"/_
M (=;P'_\OJ/J6,_Z!,5_X3U?_D/-?>']K95_T,\O_P#"W#?_ "P]NHKQ'_AI
MG]F__HX'X(_^'6\!_P#R^H_X:9_9O_Z.!^"/_AUO ?\ \OJ/J6,_Z!,5_P"$
M]7_Y#S7WA_:V5?\ 0SR__P +<-_\L/;J*\1_X:9_9O\ ^C@?@C_X=;P'_P#+
MZC_AIG]F_P#Z.!^"/_AUO ?_ ,OJ/J6,_P"@3%?^$]7_ .0\U]X?VME7_0SR
M_P#\+<-_\L/;J*\1_P"&F?V;_P#HX'X(_P#AUO ?_P OJ/\ AIG]F_\ Z.!^
M"/\ X=;P'_\ +ZCZEC/^@3%?^$]7_P"0\U]X?VME7_0SR_\ \+<-_P#+#VZB
MO$?^&F?V;_\ HX'X(_\ AUO ?_R^H_X:9_9O_P"C@?@C_P"'6\!__+ZCZEC/
M^@3%?^$]7_Y#S7WA_:V5?]#/+_\ PMPW_P L/;J*\1_X:9_9O_Z.!^"/_AUO
M ?\ \OJ/^&F?V;_^C@?@C_X=;P'_ /+ZCZEC/^@3%?\ A/5_^0\U]X?VME7_
M $,\O_\ "W#?_+#VZBO$?^&F?V;_ /HX'X(_^'6\!_\ R^H_X:9_9O\ ^C@?
M@C_X=;P'_P#+ZCZEC/\ H$Q7_A/5_P#D/-?>']K95_T,\O\ _"W#?_+#VZBO
M$?\ AIG]F_\ Z.!^"/\ X=;P'_\ +ZC_ (:9_9O_ .C@?@C_ .'6\!__ "^H
M^I8S_H$Q7_A/5_\ D/-?>']K95_T,\O_ /"W#?\ RP]NHKQ'_AIG]F__ *.!
M^"/_ (=;P'_\OJU]*^/'P.UV3RM$^,WPHUB7.WR]*^(GA#4)-W]W9::Q,V?;
M&:3P>+BKRPN)26[="JDOFXVZHJ.:99.2C#,<#*3T48XO#RDWV251M_(]7K^6
M'_@\+_Y0_7'_ &=!\$O_ $A\=5_4Y'(DJ)+$Z21R(LD<D;!TD1P&1T=259&4
MAE920P(()!K^6/\ X/"_^4/UQ_V=!\$O_2'QU7,=V^Q]6?\ !K__ ,H+OV%O
M^O/]HG_UK3X\U^^5?@;_ ,&O_P#R@N_86_Z\_P!HG_UK3X\U^^5 !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5_FV^$O^5UV[_[.6\:_P#K
M'FO5_I)5_FV^$O\ E==N_P#LY;QK_P"L>:]0!_I)4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!_*3_ ,'CW_*(O1?^SN/@Q_ZB7Q7K[<_X-G/^4'?[
M!_\ V+?QG_\ 6E/C-7Q'_P 'CW_*(O1?^SN/@Q_ZB7Q7K[<_X-G/^4'?[!__
M &+?QG_]:4^,U '[M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 ?YM_\ P3S_ .5RKX\_]G*?\% __5;_ !BK_20K_-O_ .">?_*Y5\>?^SE/
M^"@?_JM_C%7^DA0!_FW_ /!G+_RE/_;E_P"S:_'_ /ZT7\+:_P!)"O\ -O\
M^#.7_E*?^W+_ -FU^/\ _P!:+^%M?Z2% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?YMW_!YS_RD
M>_8B_P"S:M$_]7OX^K_21K_-N_X/.?\ E(]^Q%_V;5HG_J]_'U '^DC1110
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MU12BW%N%G+FE]G?2^Y_551117DG:%%%?R8?\%X?^"\/[7G_!+W]KSX<_ 'X
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M.&"P\+KEC&BG:I-)+FKU>>K)KXE'EC$HHHKUSY@**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ]
MZ^#W[37QN^!>HVMW\/?'NM6.G6[?O?"NI74^K^#[Z(GYXKOPW>RR:<K.I95O
M+..TU*W#LUI>V\AWU\\_\'(7[:'AW]J?_@C7K6BW>D'PQ\4?"_[17P3UKQ+X
M=M%NKO1[K0D;Q7I3>)=$OY%=HM-&I:KI=C=V.I2B\T^^U&TMDGU&&:.\DN5S
M'C3P7X5^(OA/Q!X%\<:%I_B;PEXJTJ[T7Q!H6J1&:QU/3;V,Q3P2JK)+&X!$
MEO<V\D5U9W"175I/!<PQ3)\[G?#>!SBC-^SIX?&\K=+%PBHR<TGRQKJ*7M:;
M>CYDYQ6L))W3^ZX1X]SGA;%48^WK8W*'.*Q&6UJCG!4FTI3PCFW]6KQBKPY'
M&E-I1K0DK./[2_\ !K__ ,H+OV%O^O/]HG_UK3X\U^^5?D5_P0L^$ND? #_@
MF5\"_@/H^N1:]!\*/%G[06AB8.7O+/3_ !+^T1\4_B1X4L-6.U5_MA/ WC?P
MM=:B8\Q-/=&2/:KA%_76OP_$4*N%KUL/6BX5J%2=*I%])PDXR7FKK1K1JS6C
M/Z\P6,P^88/#8["5%5PV+H4L10J+[5*K!3@VMXRL[2B_>C).,DFF@HHHK$Z@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K_-M\)?\KKMW_P!G+>-?
M_6/->K_22K_-M\)?\KKMW_V<MXU_]8\UZ@#_ $DJ*** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH _E)_X/'O^41>B_P#9W'P8_P#42^*]?;G_  ;.?\H.
M_P!@_P#[%OXS_P#K2GQFKXC_ .#Q[_E$7HO_ &=Q\&/_ %$OBO7VY_P;.?\
M*#O]@_\ [%OXS_\ K2GQFH _=JBBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3Q+I<-U>:3J5M9ZD^FOI&IFS>XTK4;^RFMKJ?^0/_@SL_P"3X/VGO^S5)O\
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MT;.P\,Z+J?C?P]H_@WQ3XIOY_+2P\/>#_%/B'5;YIHH[2VFF8QK^M-?Y_?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ H_S_ /J]?\,GM110!^TW_!(#QQ>IJ_QA^&TKA].GTW0O'%A$
M6(-M>VET^@ZL\:?=87T%[HJRL2"G]GP@;@YV_N57\[?_  2.=Q^T;XWC#$(W
MP3\0NR9^5GC\=?#E48CN5$D@4]@[>M?T25^)<:TXT\_Q+BK>UI8:I*W\SHQ@
MW\U!-]W=[G];^$V(J5^"L#&I)R^K8G'8>FV[M4UB9U8QN^D75<8KI%)+1)!1
M117RA^DA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7^;;X2_Y77;O
M_LY;QK_ZQYKU?Z25?YMOA+_E==N_^SEO&O\ ZQYKU '^DE1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% '\I/_!X]_RB+T7_ +.X^#'_ *B7Q7K[<_X-
MG/\ E!W^P?\ ]BW\9_\ UI3XS5\1_P#!X]_RB+T7_L[CX,?^HE\5Z^W/^#9S
M_E!W^P?_ -BW\9__ %I3XS4 ?NU1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!_FW_ /!//_E<J^//_9RG_!0/_P!5O\8J_P!)"O\ -O\ ^">?
M_*Y5\>?^SE/^"@?_ *K?XQ5_I(4 ?YM__!G+_P I3_VY?^S:_'__ *T7\+:_
MTD*_S;_^#.7_ )2G_MR_]FU^/_\ UHOX6U_I(4 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[Q!<1;_,U75[?]I/XM^&(+^YW,R^='H'AS0],7RPB?9].M\J9-[OXS_P=/\
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MM&ZYIY5C(P764N?#RLO.T6_1-E<6?\BN#Z1QE!M]E:HKORNTOF?Z55?S$?\
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M )*K^P;_ -D^^.__ *D?PSK^O/\ X)@?\HTO^">'_9C/[)7_ *H+X?UOGO\
MR0'!_P#V$YC_ .I&*,\O_P"2ESO_ *\X7_TU1/S@_P""J/\ P7'_ &$/^";G
MCV^\ ZI\/+/]HK]KW2H]#UK4_AAX3TS2M#OO!'V_P[#KW@G4_B-\6M8\-ZO8
M^%KC4K :#<Z7IFB6OB[QKIFAZAH_B&?PQ:Z+>Z%<ZG^4_@O_ (+=_P#!?O\
M;(T2/Q)^QA_P2Z\'Z9X!OX+:XL/'?BOP-\3M>TK4X+\R:OI=QX3^(/C+Q[\(
MOAYKD#Z-:>1J4ECI6OHPU"QN4;1Y]8T2*;\6OV'O"7@W]HS_ (.0+W1/VW)=
M%U$ZQ^V1^TW?^*_"OQ)CM)M"\2_%;P?<_$^Z^'WPQU*TUR:?1TLHO'^B>'/#
M^@^#[U;O3=772=*^'&F:?.VKZ;9'_4"K;.:&2\(T\LPCR>EG698G+Z&.K8[,
MJ^(E@X>U<H>QP^%HSI4YTU*G.UY<T(>RYYU9-\F> J8_.Y8JO]>G@,+2Q-2A
M3P^%ITE7?(HRYZM:<9RC)J44U:SESVC%)7_S?_\ @M5\0O\ @X!\9?LI:?%_
MP4L^!7PK^$W[-(^,G@F[LKKX?ZO\!=2G;XCP>&_&%KX9TLKX(^,?Q+\;_8;R
MPE\1ZE<R26XL5O;:&.;4;6!K>PG_ *0/^#5;_E$KX1_[+I\:O_3SIE? O_!V
MG^W3^SIJ/[.W@O\ 86\)^.M(\;?M"CXV>$?B=X]\+^%]1L=6@^%'A3PKX4\9
MV<5K\0;RSGN%T/QGXDOO%6C3:#X)N%CUH^'!>^)]732=-N/"_P#PE/WU_P &
MJW_*)7PC_P!ET^-7_IYTRN[.:]7$^'6&Q%7+,)E2JYU3G2P^"P]3#4)T?95U
M#$*G5JUIMU;/]XYVJ1C&4?=:;PP-.%+BBK2ABZV,Y,!*,ZN(JPK5(SYZ;E3<
MH0A%<EU[O+>+;3UNE^4__!Z%_P XVO\ N\3_ -]9K^G'_@CG_P HK_V O^S6
MOA)_ZB]E7\SO_!Y]IE]+IG_!.;68X-VFV%_^UEIEW<^9"/*OM6M_V;KK3X/)
M:03R?:(-%U.3S(HGAB^S;9Y(WFMUE_I!_P"")GBG1/&'_!)W]@S5O#]];ZA8
M6G[/?A/PM//;7-I=QQZWX&DOO!/B6Q:6RN+J%+C3/$?A_5=-N[9Y%N[*ZM)K
M/4+>TOX+FT@\O-TWX<\*22NHYEF49-;*4L5F4HI]FU%M+JDV=>"TXISA=7A,
M,UYI4L(FUY)NWJ?J11117YT?4!1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 ?R\_\'?/_*''Q3_V<1\"_P#TY:]7Y"?L;?\ )H/[*G_9MWP-_P#5
M8>%Z_7O_ (.^?^4./BG_ +.(^!?_ *<M>K\A/V-O^30?V5/^S;O@;_ZK#PO7
MZ%X>_P"^YA_V"TO_ $\?A_CA_P BK(_^QAB?_49'TC1117ZL?S>%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!^I7_!(_P#Y.0\;?]D1\2?^IY\-J_HFK^=G_@D?
M_P G(>-O^R(^)/\ U//AM7]$U?BW''_(^J_]@V&_](9_6'A!_P D90_[&&/_
M /3D HHHKY _4 HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K_ #;?
M"7_*Z[=_]G+>-?\ UCS7J_TDJ_S;?"7_ "NNW?\ V<MXU_\ 6/->H _TDJ**
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH _E)_P"#Q[_E$7HO_9W'P8_]
M1+XKU]N?\&SG_*#O]@__ +%OXS_^M*?&:OB/_@\>_P"41>B_]G<?!C_U$OBO
M7VY_P;.?\H._V#_^Q;^,_P#ZTI\9J /W:HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH _S;_\ @GG_ ,KE7QY_[.4_X*!_^JW^,5?Z2%?YM_\
MP3S_ .5RKX\_]G*?\% __5;_ !BK_20H _S;_P#@SE_Y2G_MR_\ 9M?C_P#]
M:+^%M?Z2%?YM_P#P9R_\I3_VY?\ LVOQ_P#^M%_"VO\ 20H **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9:MX0O\ 2Y-!C\$?"WXB0W5O!#X?O%OWU"?2Y(I);46\5TKRO#^['[''P?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'ZE?\$C_ /DY#QM_
MV1'Q)_ZGGPVK^B:OYV?^"1__ "<AXV_[(CXD_P#4\^&U?T35^+<<?\CZK_V#
M8;_TAG]8>$'_ "1E#_L88_\ ].0"BBBOD#]0"BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "O\V[_@\Y_Y2/?L1?\ 9M6B?^KW\?5_I(U_
MFW?\'G/_ "D>_8B_[-JT3_U>_CZ@#_21HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#^7G_ (.^?^4./BG_
M +.(^!?_ *<M>K\A/V-O^30?V5/^S;O@;_ZK#PO7Z]_\'?/_ "AQ\4_]G$?
MO_TY:]7Y"?L;?\F@_LJ?]FW? W_U6'A>OT+P]_WW,/\ L%I?^GC\/\</^15D
M?_8PQ/\ ZC(^D:***_5C^;PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /U*_P""
M1_\ R<AXV_[(CXD_]3SX;5_1-7\[/_!(_P#Y.0\;?]D1\2?^IY\-J_HFK\6X
MX_Y'U7_L&PW_ *0S^L/"#_DC*'_8PQ__ *<@%%%%?('Z@%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %?YMOA+_E==N_\ LY;QK_ZQYKU?Z25?YMOA
M+_E==N_^SEO&O_K'FO4 ?Z25%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 ?RD_\'CW_ "B+T7_L[CX,?^HE\5Z^W/\ @V<_Y0=_L'_]BW\9_P#UI3XS
M5\1_\'CW_*(O1?\ L[CX,?\ J)?%>OMS_@V<_P"4'?[!_P#V+?QG_P#6E/C-
M0!^[5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '^;?_P3S_Y7
M*OCS_P!G*?\ !0/_ -5O\8J_TD*_S;_^">?_ "N5?'G_ +.4_P""@?\ ZK?X
MQ5_I(4 ?YM__  9R_P#*4_\ ;E_[-K\?_P#K1?PMK_20K_-O_P"#.7_E*?\
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M#JIC<+]3K<\H^RYU.\%;EGIK&]VN5MOW>;:204445XYW!1110 4444 %%%%
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M -C#$_\ J,CZ1HHHK]6/YO"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _4K_@D?
M_P G(>-O^R(^)/\ U//AM7]$U?SL_P#!(_\ Y.0\;?\ 9$?$G_J>?#:OZ)J_
M%N./^1]5_P"P;#?^D,_K#P@_Y(RA_P!C#'_^G(!1117R!^H!1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !7^;;X2_Y77;O_LY;QK_ZQYKU?Z25?YMO
MA+_E==N_^SEO&O\ ZQYKU '^DE1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% '\I/_!X]_RB+T7_ +.X^#'_ *B7Q7K[<_X-G/\ E!W^P?\ ]BW\9_\
MUI3XS5\1_P#!X]_RB+T7_L[CX,?^HE\5Z^W/^#9S_E!W^P?_ -BW\9__ %I3
MXS4 ?NU1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&F\$_%;X>6MO826K&2>*^LM1N&N,/'=11_NJ\7_:Y_X.BK#P;:_"SX*_L/\
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M\+^#-7N+G0M UNST%PWAO3H(+?3+6VC:^:&34;O^?S_@J'_P09_;._X*%_\
M!6"']H[5]8^#LG['L^O?L[^#KJRO_'GB+2_B58_!3PKI/@\?%ZSL] L?#;0'
M7)M?OOB??>'8;7Q1IOVU+[3':_TRXFDGA\7(\!D,L_Q-'-\?3ED^!6+JPK*<
MJ*S)4*JIX>G2E%J<7B(R5;DC*,W"$X1G%^\N_,,3F*RVE4P6&FL=B/81E3<5
M-X5U(\U64TTTU2:<+M-*34G%K0^1_ G_  6;_P"#D']LBTU'XG_LJ?L8Z)!\
M))K^1_#VH^$_V>?$VJ>%KW3;MY8K"ST[Q[\3/%CV'CJ_TR/3I#KFH>%)(H(-
M0O6FO=+T6TU'1-,M^M\!_P#!S1_P41_9#^.?A;X-_P#!57]C/0O#'APOIUKX
MHU7PUX!\<_";XPVVC7E[&+SX@:18^)?%?B+X<_$FRT^SG\R#1O"NG>#M,U=[
M<6L7BFRN&>2O[@K:#P=\.?"FFZ;9P^&? G@?PEI6DZ#I%A;1Z7X7\*>&=#TZ
M*UT;0]&TVUB%CI&BZ58P+9:5I.G6L=M9VT2VMC9PH@AB'\F/_!VKJW[/7Q%_
M80^%&M:=X]^'GB+XP_#3]I;PO9^&;#0?'?A[4O%%AX;\=?#_ ,<-XQT^?P]9
M:G=7<FE:JN@^$]8N9VL4N()]"TF>&\ALI;VWO_HLGS/(\]S3#Y35X1RZA@,9
M4EAZ=?">WCCL,Y0M3JU,5%KVCC+E]HVH6YE*\G'EJ>9CL)F&78.IC89WBJN(
MH1565*M[-X>K9KGA&BT^5-)\MG)Z-:7;7]/,/QRT'XE?LU7O[0O[.&JZ3\7-
M&\3?"'6OB3\'K[1+/5-:TWQS<'PO?:QX5LHM'L3I_B"XGU'4X;;2[[PXJZ;X
MDMK\W.B7$&G:S!+!!_F4?\%=O^"FG_!1[]NOX>_![P=^W%^RMX8_9Y\->!O&
M7B#Q-X#U30_@=\=_A+<^)-<O=$M]+U;3Y;[XO>/?%]AK$%C8/!<FUT:UM+RU
MDFCFN;AX9$C/]FW_  :[>+_$GBG_ ()$_":P\0:M/JMMX)^*'QH\(>%UN4@\
MS2O#<?C6Y\1PZ2MQ'$EQ=P6^K>)-8FM7OI;J>UM;F'3+:6+2[#3[.U_/7_@\
MB_Y-J_8T_P"RY>/O_4!MZOA-87)>,ZV2SP-#&U8YGB<-A<QJSE'$82&&IXI<
MT(QBH2E6I\JJIJ*C*_*VK$9TZV.R&&81Q%2A!X2C4K86$4Z5:56I0TDVW)*G
M*[@U=M6O;4_(S]@?_@M?_P %C?V;_P!D7X,_ _\ 9E_86\#_ !>^!OP[TGQ%
MHW@+XBWG[,?[4GC^[\1VL_C7Q+JFLR7/B[X?_%;0O"&L3Z;XEO\ 6=&E;1M)
ML8[-].;3[N(W]I=R/_>K^S-\;_C!\2_V%_A/^T+\9/ ^G_#_ .-WBO\ 9\TO
MXG^.O '_  C7BCPKI7AKQM=>$7U^]T+_ (17Q3JU_P"+=&T^WO0L7]F:QK5S
MJT-L?+EU!I2)J^,O^#??_E#M^Q!_V(GCG_U<?Q'K]4/BU_R2KXF_]D^\9_\
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M7@ZJC&I7C&-6I&GAZ"E:-."C%N51WDFHJ-[R/X7)?^#DW_@M-^R!\0/#UO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _4K
M_@D?_P G(>-O^R(^)/\ U//AM7]$U?SL_P#!(_\ Y.0\;?\ 9$?$G_J>?#:O
MZ)J_%N./^1]5_P"P;#?^D,_K#P@_Y(RA_P!C#'_^G(!1117R!^H!1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !7^;;X2_Y77;O_LY;QK_ZQYKU?Z25
M?YMOA+_E==N_^SEO&O\ ZQYKU '^DE1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_MR_]FU^/_\ UHOX6U_I(4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5_FW?\'G/_ "D>_8B_[-JT
M3_U>_CZO])&O\V[_ (/.?^4CW[$7_9M6B?\ J]_'U '^DC1110 4444 %%%%
M !1110 4444 %%%% !1110!_#/\ \'H7_.-K_N\3_P!]9K^@?_@WW_Y0[?L0
M?]B)XY_]7'\1Z_GX_P"#T+_G&U_W>)_[ZS7] _\ P;[_ /*';]B#_L1/'/\
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M ,$G?@YX0U;6/ OQD\2_M$^,X-)DO="^'WPH^'/CNSNM8OY+RWL+*RO?%WQ
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M5XB\::OXVT&7S_"$6H7^GZ[I,GBK4O#MW:7VBVUM+I^@Z?J9U6]U#4KJ./\
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MQ;X#\17$>GSVNHFRT_Q5H>E_VO%93B6]T274].EAO;2]N;&Y^MXLQU++?$7
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>?\ RN5?'G_LY3_@H'_ZK?XQ5_I(5_FW_P#!//\ Y7*OCS_V<I_P4#_]5O\
M&*O])"@#_-O_ .#.7_E*?^W+_P!FU^/_ /UHOX6U_I(5_FW_ /!G+_RE/_;E
M_P"S:_'_ /ZT7\+:_P!)"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "O\V[_@\Y_Y2/?L1?\ 9M6B
M?^KW\?5_I(U_FW?\'G/_ "D>_8B_[-JT3_U>_CZ@#_21HHHH **** "BBB@
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MVNXVL?!>MW*>!+F<7=G;W":AK'AC5-4MMLMO9WUM9W=Y;7'U#^V'_P $E_\
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M***]$\,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P!)"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "O\V[_@\Y_Y2/?L1?\ 9M6B?^KW\?5_I(U_FW?\
M'G/_ "D>_8B_[-JT3_U>_CZ@#_21HHHH **** "BBB@ HHHH **** "BBB@
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M  [E_8T_Z(Y_YD+XJ?\ S<5]N44?VUG/_0VS/_POQ7_RT/\ 5/A7_HF>'_\
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M  [E_8T_Z(Y_YD+XJ?\ S<5]N44?VUG/_0VS/_POQ7_RT/\ 5/A7_HF>'_\
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M/^B.?^9"^*G_ ,W%?;E%']M9S_T-LS_\+\5_\M#_ %3X5_Z)GA__ ,,V7?\
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M_F0OBI_\W%'_  [E_8T_Z(Y_YD+XJ?\ S<5]N44?VUG/_0VS/_POQ7_RT/\
M5/A7_HF>'_\ PS9=_P#,Q\1_\.Y?V-/^B.?^9"^*G_S<4?\ #N7]C3_HCG_F
M0OBI_P#-Q7VY11_;6<_]#;,__"_%?_+0_P!4^%?^B9X?_P##-EW_ ,S'Q'_P
M[E_8T_Z(Y_YD+XJ?_-Q1_P .Y?V-/^B.?^9"^*G_ ,W%?;E%']M9S_T-LS_\
M+\5_\M#_ %3X5_Z)GA__ ,,V7?\ S,?$?_#N7]C3_HCG_F0OBI_\W%'_  [E
M_8T_Z(Y_YD+XJ?\ S<5]N44?VUG/_0VS/_POQ7_RT/\ 5/A7_HF>'_\ PS9=
M_P#,Q\1_\.Y?V-/^B.?^9"^*G_S<4?\ #N7]C3_HCG_F0OBI_P#-Q7VY11_;
M6<_]#;,__"_%?_+0_P!4^%?^B9X?_P##-EW_ ,S'Q'_P[E_8T_Z(Y_YD+XJ?
M_-Q1_P .Y?V-/^B.?^9"^*G_ ,W%?;E%']M9S_T-LS_\+\5_\M#_ %3X5_Z)
MGA__ ,,V7?\ S,?$?_#N7]C3_HCG_F0OBI_\W%'_  [E_8T_Z(Y_YD+XJ?\
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M/_POQ7_RT/\ 5/A7_HF>'_\ PS9=_P#,Q\1_\.Y?V-/^B.?^9"^*G_S<4?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5_FV^$O^5UV[_[.6\:_P#K
M'FO5_I)5_FV^$O\ E==N_P#LY;QK_P"L>:]0!_I)4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!_*3_ ,'CW_*(O1?^SN/@Q_ZB7Q7K[<_X-G/^4'?[
M!_\ V+?QG_\ 6E/C-7Q'_P 'CW_*(O1?^SN/@Q_ZB7Q7K[<_X-G/^4'?[!__
M &+?QG_]:4^,U '[M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 ?YM_\ P3S_ .5RKX\_]G*?\% __5;_ !BK_20K_-O_ .">?_*Y5\>?^SE/
M^"@?_JM_C%7^DA0!_FW_ /!G+_RE/_;E_P"S:_'_ /ZT7\+:_P!)"O\ -O\
M^#.7_E*?^W+_ -FU^/\ _P!:+^%M?Z2% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?YMW_!YS_RD
M>_8B_P"S:M$_]7OX^K_21K_-N_X/.?\ E(]^Q%_V;5HG_J]_'U '^DC1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% '\O/\ P=\_\H<?%/\ V<1\"_\ TY:]7OG_  :T?\H+OV*O^OS]I;_U
MK3XZ5X'_ ,'?/_*''Q3_ -G$? O_ -.6O5[Y_P &M'_*"[]BK_K\_:6_]:T^
M.E ']!5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '^;?^RC_R
MNO>*?^SE/VS?_6.OCI7^DA7^;?\ LH_\KKWBG_LY3]LW_P!8Z^.E?Z2% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !7\L/\ P>%_\H?KC_LZ#X)?
M^D/CJOZGJ_EA_P"#PO\ Y0_7'_9T'P2_](?'5 'U9_P:_P#_ "@N_86_Z\_V
MB?\ UK3X\U^^5?@;_P &O_\ R@N_86_Z\_VB?_6M/CS7[Y4 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !7^;;X2_P"5UV[_ .SEO&O_ *QY
MKU?Z25?YMOA+_E==N_\ LY;QK_ZQYKU '^DE1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% '\I/_  >/?\HB]%_[.X^#'_J)?%>OMS_@V<_Y0=_L'_\
M8M_&?_UI3XS5\1_\'CW_ "B+T7_L[CX,?^HE\5Z^W/\ @V<_Y0=_L'_]BW\9
M_P#UI3XS4 ?NU1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_F
MW_\ !//_ )7*OCS_ -G*?\% _P#U6_QBK_20K_-O_P"">?\ RN5?'G_LY3_@
MH'_ZK?XQ5_I(4 ?YM_\ P9R_\I3_ -N7_LVOQ_\ ^M%_"VO])"O\V_\ X,Y?
M^4I_[<O_ &;7X_\ _6B_A;7^DA0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^.E ']!5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '^;?^RC_
M ,KKWBG_ +.4_;-_]8Z^.E?Z2%?YM_[*/_*Z]XI_[.4_;-_]8Z^.E?Z2% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !7\L/_  >%_P#*'ZX_[.@^
M"7_I#XZK^IZOY8?^#PO_ )0_7'_9T'P2_P#2'QU0!]6?\&O_ /R@N_86_P"O
M/]HG_P!:T^/-?OE7X&_\&O\ _P H+OV%O^O/]HG_ -:T^/-?OE0 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %?YMOA+_E==N_\ LY;QK_ZQ
MYKU?Z25?YMOA+_E==N_^SEO&O_K'FO4 ?Z25%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!_+S_P=\_\ *''Q3_V<1\"__3EKU>^?\&M'_*"[]BK_ *_/VEO_
M %K3XZ5X'_P=\_\ *''Q3_V<1\"__3EKU>^?\&M'_*"[]BK_ *_/VEO_ %K3
MXZ4 ?T%4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?YM_[*/_
M "NO>*?^SE/VS?\ UCKXZ5_I(5_FW_LH_P#*Z]XI_P"SE/VS?_6.OCI7^DA0
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 5_+#_P>%_\ *'ZX_P"S
MH/@E_P"D/CJOZGJ_EA_X/"_^4/UQ_P!G0?!+_P!(?'5 'U9_P:__ /*"[]A;
M_KS_ &B?_6M/CS7[Y5^!O_!K_P#\H+OV%O\ KS_:)_\ 6M/CS7[Y4 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !7^;;X2_Y77;O_LY;QK_Z
MQYKU?Z25?YMOA+_E==N_^SEO&O\ ZQYKU '^DE1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% '\I/_!X]_RB+T7_ +.X^#'_ *B7Q7K[<_X-G/\ E!W^
MP?\ ]BW\9_\ UI3XS5\1_P#!X]_RB+T7_L[CX,?^HE\5Z^W/^#9S_E!W^P?_
M -BW\9__ %I3XS4 ?NU1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MS2/_  PW[4O_ ,X^C_B)S_X(:?\ 1]FD?^&&_:E_^<?0!^\]%?@Q_P 1.?\
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M?9I'_AAOVI?_ )Q] '[ST5^#'_$3G_P0T_Z/LTC_ ,,-^U+_ /./H_XB<_\
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MS2/_  PW[4O_ ,X^C_B)S_X(:?\ 1]FD?^&&_:E_^<?0!^\]%?@Q_P 1.?\
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M?9I'_AAOVI?_ )Q] '[ST5^#'_$3G_P0T_Z/LTC_ ,,-^U+_ /./H_XB<_\
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MS2/_  PW[4O_ ,X^C_B)S_X(:?\ 1]FD?^&&_:E_^<?0!^\]%?@Q_P 1.?\
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M3_H^S2/_  PW[4O_ ,X^C_B)S_X(:?\ 1]FD?^&&_:E_^<?0!_*M_P $\_\
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MY5?^(.K_ ()"_P#/S^U9_P"'JT'_ .=O1_Q!U?\ !(7_ )^?VK/_  ]6@_\
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M /Y5?^(.K_@D+_S\_M6?^'JT'_YV]'_$'5_P2%_Y^?VK/_#U:#_\[>OZJJ*
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M:L_\/5H/_P [>OZJJ* /Y5?^(.K_ ()"_P#/S^U9_P"'JT'_ .=O1_Q!U?\
M!(7_ )^?VK/_  ]6@_\ SMZ_JJHH _E5_P"(.K_@D+_S\_M6?^'JT'_YV]'_
M !!U?\$A?^?G]JS_ ,/5H/\ \[>OZJJ* /Y5?^(.K_@D+_S\_M6?^'JT'_YV
M]'_$'5_P2%_Y^?VK/_#U:#_\[>OZJJ* /Y5?^(.K_@D+_P _/[5G_AZM!_\
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MJJHH _E5_P"(.K_@D+_S\_M6?^'JT'_YV]'_ !!U?\$A?^?G]JS_ ,/5H/\
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M:L_\/5H/_P [>C_B#J_X)"_\_/[5G_AZM!_^=O7]55% '\JO_$'5_P $A?\
MGY_:L_\ #U:#_P#.WH_X@ZO^"0O_ #\_M6?^'JT'_P"=O7]55% '\JO_ !!U
M?\$A?^?G]JS_ ,/5H/\ \[>C_B#J_P""0O\ S\_M6?\ AZM!_P#G;U_5510!
M_*K_ ,0=7_!(7_GY_:L_\/5H/_SMZ/\ B#J_X)"_\_/[5G_AZM!_^=O7]55%
M '\JO_$'5_P2%_Y^?VK/_#U:#_\ .WH_X@ZO^"0O_/S^U9_X>K0?_G;U_551
M0!_*K_Q!U?\ !(7_ )^?VK/_  ]6@_\ SMZ/^(.K_@D+_P _/[5G_AZM!_\
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M_P [>C_B#J_X)"_\_/[5G_AZM!_^=O7]55% '\JO_$'5_P $A?\ GY_:L_\
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M!_*K_P 0=7_!(7_GY_:L_P##U:#_ /.WH_X@ZO\ @D+_ ,_/[5G_ (>K0?\
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M )V]'_$'5_P2%_Y^?VK/_#U:#_\ .WK^JJB@#^57_B#J_P""0O\ S\_M6?\
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M^JJB@#^57_B#J_X)"_\ /S^U9_X>K0?_ )V]'_$'5_P2%_Y^?VK/_#U:#_\
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MY5?^(.K_ ()"_P#/S^U9_P"'JT'_ .=O1_Q!U?\ !(7_ )^?VK/_  ]6@_\
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M /Y5?^(.K_@D+_S\_M6?^'JT'_YV]'_$'5_P2%_Y^?VK/_#U:#_\[>OZJJ*
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M:L_\/5H/_P [>OZJJ* /Y5?^(.K_ ()"_P#/S^U9_P"'JT'_ .=O1_Q!U?\
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M &B?_6M/CS7[Y4 ?RJ_\0=7_  2%_P"?G]JS_P /5H/_ ,[>C_B#J_X)"_\
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M%_Y^?VK/_#U:#_\ .WH_X@ZO^"0O_/S^U9_X>K0?_G;U_5510!_*K_Q!U?\
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M@ZO^"0O_ #\_M6?^'JT'_P"=O7]55% '\JO_ !!U?\$A?^?G]JS_ ,/5H/\
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MZ/\ B#J_X)"_\_/[5G_AZM!_^=O7]55% '\JO_$'5_P2%_Y^?VK/_#U:#_\
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M*?&:@#XO_P"(.K_@D+_S\_M6?^'JT'_YV]'_ !!U?\$A?^?G]JS_ ,/5H/\
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MY5?^(.K_ ()"_P#/S^U9_P"'JT'_ .=O1_Q!U?\ !(7_ )^?VK/_  ]6@_\
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M /Y5?^(.K_@D+_S\_M6?^'JT'_YV]'_$'5_P2%_Y^?VK/_#U:#_\[>OZJJ*
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7^;
M=_P><_\ *1[]B+_LVK1/_5[^/J_TD:_S;O\ @\Y_Y2/?L1?]FU:)_P"KW\?4
M ?Z2-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 ?R\_\'?/_*''Q3_V<1\"_P#TY:]7OG_!K1_R@N_8J_Z_
M/VEO_6M/CI7@?_!WS_RAQ\4_]G$? O\ ].6O5[Y_P:T?\H+OV*O^OS]I;_UK
M3XZ4 ?T%4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?YM_P"R
MC_RNO>*?^SE/VS?_ %CKXZ5_I(5_FW_LH_\ *Z]XI_[.4_;-_P#6.OCI7^DA
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5_+#_P>%_\H?KC_LZ#
MX)?^D/CJOZGJ_EA_X/"_^4/UQ_V=!\$O_2'QU0!]6?\ !K__ ,H+OV%O^O/]
MHG_UK3X\U^^5?@;_ ,&O_P#R@N_86_Z\_P!HG_UK3X\U^^5 !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 5_FV^$O^5UV[_[.6\:_P#K'FO5
M_I)5_FV^$O\ E==N_P#LY;QK_P"L>:]0!_I)4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!_*3_ ,'CW_*(O1?^SN/@Q_ZB7Q7K[<_X-G/^4'?[!_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?YMW_!YS_RD>_8B
M_P"S:M$_]7OX^K_21K_-N_X/.?\ E(]^Q%_V;5HG_J]_'U '^DC1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% '\O/\ P=\_\H<?%/\ V<1\"_\ TY:]7OG_  :T?\H+OV*O^OS]I;_UK3XZ
M5X'_ ,'?/_*''Q3_ -G$? O_ -.6O5[Y_P &M'_*"[]BK_K\_:6_]:T^.E '
M]!5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '^;?^RC_RNO>*
M?^SE/VS?_6.OCI7^DA7^;?\ LH_\KKWBG_LY3]LW_P!8Z^.E?Z2% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !7\L/\ P>%_\H?KC_LZ#X)?^D/C
MJOZGJ_EA_P"#PO\ Y0_7'_9T'P2_](?'5 'U9_P:_P#_ "@N_86_Z\_VB?\
MUK3X\U^^5?@;_P &O_\ R@N_86_Z\_VB?_6M/CS7[Y4 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !7^;;X2_P"5UV[_ .SEO&O_ *QYKU?Z
M25?YMOA+_E==N_\ LY;QK_ZQYKU '^DE1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% '\I/_  >/?\HB]%_[.X^#'_J)?%>OMS_@V<_Y0=_L'_\ 8M_&
M?_UI3XS5\1_\'CW_ "B+T7_L[CX,?^HE\5Z^W/\ @V<_Y0=_L'_]BW\9_P#U
MI3XS4 ?NU1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_FW_\
M!//_ )7*OCS_ -G*?\% _P#U6_QBK_20K_-O_P"">?\ RN5?'G_LY3_@H'_Z
MK?XQ5_I(4 ?YM_\ P9R_\I3_ -N7_LVOQ_\ ^M%_"VO])"O\V_\ X,Y?^4I_
M[<O_ &;7X_\ _6B_A;7^DA0 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !7^;=_P><_\I'OV(O^S:M$
M_P#5[^/J_P!)&O\ -N_X/.?^4CW[$7_9M6B?^KW\?4 ?Z2-%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?R
M\_\ !WS_ ,H<?%/_ &<1\"__ $Y:]7OG_!K1_P H+OV*O^OS]I;_ -:T^.E>
M!_\ !WS_ ,H<?%/_ &<1\"__ $Y:]7OG_!K1_P H+OV*O^OS]I;_ -:T^.E
M']!5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '^;?^RC_ ,KK
MWBG_ +.4_;-_]8Z^.E?Z2%?YM_[*/_*Z]XI_[.4_;-_]8Z^.E?Z2% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !7\L/_  >%_P#*'ZX_[.@^"7_I
M#XZK^IZOY8?^#PO_ )0_7'_9T'P2_P#2'QU0!]6?\&O_ /R@N_86_P"O/]HG
M_P!:T^/-?OE7X&_\&O\ _P H+OV%O^O/]HG_ -:T^/-?OE0 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %?YMOA+_E==N_\ LY;QK_ZQYKU?
MZ25?YMOA+_E==N_^SEO&O_K'FO4 ?Z25%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 ?RD_\'CW_ "B+T7_L[CX,?^HE\5Z^W/\ @V<_Y0=_L'_]BW\9
M_P#UI3XS5\1_\'CW_*(O1?\ L[CX,?\ J)?%>OMS_@V<_P"4'?[!_P#V+?QG
M_P#6E/C-0!^[5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '^;
M?_P3S_Y7*OCS_P!G*?\ !0/_ -5O\8J_TD*_S;_^">?_ "N5?'G_ +.4_P""
M@?\ ZK?XQ5_I(4 ?YM__  9R_P#*4_\ ;E_[-K\?_P#K1?PMK_20K_-O_P"#
M.7_E*?\ MR_]FU^/_P#UHOX6U_I(4 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5_FW?\ !YS_ ,I'
MOV(O^S:M$_\ 5[^/J_TD:_S;O^#SG_E(]^Q%_P!FU:)_ZO?Q]0!_I(T444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!_+S_P=\_\ *''Q3_V<1\"__3EKU>^?\&M'_*"[]BK_ *_/VEO_ %K3
MXZ5X'_P=\_\ *''Q3_V<1\"__3EKU>^?\&M'_*"[]BK_ *_/VEO_ %K3XZ4
M?T%4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?YM_[*/_ "NO
M>*?^SE/VS?\ UCKXZ5_I(5_FW_LH_P#*Z]XI_P"SE/VS?_6.OCI7^DA0 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 5_+#_P>%_\ *'ZX_P"SH/@E
M_P"D/CJOZGJ_EA_X/"_^4/UQ_P!G0?!+_P!(?'5 'U9_P:__ /*"[]A;_KS_
M &B?_6M/CS7[Y5^!O_!K_P#\H+OV%O\ KS_:)_\ 6M/CS7[Y4 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !7^;;X2_Y77;O_LY;QK_ZQYKU
M?Z25?YMOA+_E==N_^SEO&O\ ZQYKU '^DE1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% '\I/_!X]_RB+T7_ +.X^#'_ *B7Q7K[<_X-G/\ E!W^P?\
M]BW\9_\ UI3XS5\1_P#!X]_RB+T7_L[CX,?^HE\5Z^W/^#9S_E!W^P?_ -BW
M\9__ %I3XS4 ?NU1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!
M_FW_ /!//_E<J^//_9RG_!0/_P!5O\8J_P!)"O\ -O\ ^">?_*Y5\>?^SE/^
M"@?_ *K?XQ5_I(4 ?YM__!G+_P I3_VY?^S:_'__ *T7\+:_TD*_S;_^#.7_
M )2G_MR_]FU^/_\ UHOX6U_I(4 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5_FW?\'G/_ "D>_8B_
M[-JT3_U>_CZO])&O\V[_ (/.?^4CW[$7_9M6B?\ J]_'U '^DC1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M '\O/_!WS_RAQ\4_]G$? O\ ].6O5[Y_P:T?\H+OV*O^OS]I;_UK3XZ5X'_P
M=\_\H<?%/_9Q'P+_ /3EKU>^?\&M'_*"[]BK_K\_:6_]:T^.E ']!5%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% '^;?\ LH_\KKWBG_LY3]LW
M_P!8Z^.E?Z2%?YM_[*/_ "NO>*?^SE/VS?\ UCKXZ5_I(4 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %?RP_\'A?_*'ZX_[.@^"7_I#XZK^IZOY8
M?^#PO_E#]<?]G0?!+_TA\=4 ?5G_  :__P#*"[]A;_KS_:)_]:T^/-?OE7X&
M_P#!K_\ \H+OV%O^O/\ :)_]:T^/-?OE0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %?YMOA+_E==N_^SEO&O\ ZQYKU?Z25?YMOA+_ )77
M;O\ [.6\:_\ K'FO4 ?Z25%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M ?RD_P#!X]_RB+T7_L[CX,?^HE\5Z^W/^#9S_E!W^P?_ -BW\9__ %I3XS5\
M1_\ !X]_RB+T7_L[CX,?^HE\5Z^W/^#9S_E!W^P?_P!BW\9__6E/C-0!^[5%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '^;?_ ,$\_P#E<J^/
M/_9RG_!0/_U6_P 8J_TD*_S;_P#@GG_RN5?'G_LY3_@H'_ZK?XQ5_I(4 ?YM
M_P#P9R_\I3_VY?\ LVOQ_P#^M%_"VO\ 20K_ #;_ /@SE_Y2G_MR_P#9M?C_
M /\ 6B_A;7^DA0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !7^;=_P><_\I'OV(O\ LVK1/_5[^/J_
MTD:_S;O^#SG_ )2/?L1?]FU:)_ZO?Q]0!_I(T444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_+S_ ,'?/_*'
M'Q3_ -G$? O_ -.6O5[Y_P &M'_*"[]BK_K\_:6_]:T^.E>!_P#!WS_RAQ\4
M_P#9Q'P+_P#3EKU>^?\ !K1_R@N_8J_Z_/VEO_6M/CI0!_051110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110!_FW_LH_\KKWBG_LY3]LW_UCKXZ5
M_I(5_FW_ +*/_*Z]XI_[.4_;-_\ 6.OCI7^DA0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 5_+#_ ,'A?_*'ZX_[.@^"7_I#XZK^IZOY8?\ @\+_
M .4/UQ_V=!\$O_2'QU0!]6?\&O\ _P H+OV%O^O/]HG_ -:T^/-?OE7X&_\
M!K__ ,H+OV%O^O/]HG_UK3X\U^^5 !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M=Z]KU]#INE6E_P"*_&OPB\/>$] @NKVXAMSJ?B'7-+TNW:16NKV"/+C\<_\
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M4H25X\T;2E=V^RZ***^)/?"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ K_-N_P"#SG_E(]^Q%_V;5HG_ *O?Q]7^DC7^;=_P><_\I'OV
M(O\ LVK1/_5[^/J /])&BBB@ HHHH **** "BBO(/V@/C7X)_9N^!WQ:^/OQ
M&U"WTSP/\'OA[XK^(?B2XN+C[.9M/\+:/=ZJ=-LR(KB:XU76)K>+2-&L+2UO
M+_4]6OK+3M.LKV^NK>UFNG3G5J0I4XN=2I.-.G"*O*<YR48QBNKE)I)=6R92
MC",IR:C&,7*4GHE&*NVWV23;/Y,?^"R/_!R;^T-^PS^V_P"+?V7?V4/!/[,_
MQ#\+?"_P=X.M/B1KGQ4\,?$WQ5K5I\6]<M[WQ)KN@Z9JG@?XM_#W0DTK0_"V
MK^#-/O=.&FZKJ&E^*XO$UAJ6L+>02Z)HO[__ /!(S]O&[_X*/?L*?"G]IKQ'
M9^%-%^)6JWWB_P '?%OPOX)L=;T[PSX7^('@_P 1WUA/I^DVGB#5_$6I0V&K
M>&)/#'BVPBG\0ZY)!8>)+6WN;_[;#=6UM_"[_P $7?\ @G1JO_!8SXY?\%!_
MVA?CS:Z7>07?P^^,=U9:_JMOK]MH(_:U_:FMO'-QX2\8Z?,EQ>F\C^%]]-XA
M\=WEK=?\)-<Z/J=QX&O+W3KN>\L+B3[4_P"#2/\ :E\3?"7]J#]I#]@'XB:G
M?:1IOQ&T+4?B1X/\(:O/?RPZ'\;?A#=P^'?B%H^CV-O<2Z9I^N>*_ ,TE[XI
MOIK4G4++X-Z#:#4X7L+.RU']<XAX:R6ED.-P>6T:;SOAJAEF(S6O"+Y\3'$T
M9NNGJTXQBWBI62]G&G"+D[N_Q669KCYYCAZ^+G+ZAFU3%TL'2D_=I.E."IM:
M)IMKV*U?,Y2E9:6_O\HHKYO_ &JOVN?V>OV)?A)>?'3]IWX@_P#"LOA78:[H
MGAJ[\4_\(IXW\9^5K?B*:6WT:R_L3X?>&O%?B.3[9-#*GVF/2'M+?;NNIX%9
M6/Y)2HU<15IT*%*I6K59QITJ-*$JE6I.3M&%.G!2G.<GI&,4VWHD?:SG"G"5
M2I.-.G!.4YSDH0C%:N4I2:C%):MMI(^D**^8?V2OVROV;?VZ/A9<?&O]ECXC
M_P#"T?AE:^*]7\$3^)?^$0\>>"=GBC0K/2K_ %73/[&^(OA?PCX@;[+::WID
MOVU-*;3Y_M/EVUW-+#<)%]/4ZU&MAZM2AB*56A7I2<*M&M3E2JTYK>-2G-1G
M"2ZQDDUU0H5(581J4YPJ4YI2A.$E.$HO:491;C)/HTVF%%?FC\>/^"P?_!.C
M]F;]HA?V4?C=^T1_PA/Q]>^\%::O@+_A4GQT\29O?B);:7>>#H?^$I\(_#+7
M_!8_MBVUG39/,/B,1:?]IV:I)8R0W"Q?7?[2?[2?P5_9"^"OC3]HC]HCQI_P
MKWX._#W_ (1S_A,/&'_".>+/%G]D?\)9XLT+P/X?_P"*?\#Z%XF\4ZA_:'BG
MQ-HFE_\ $KT2]^R_;?MM[]FTZVN[NWWEEV80>$4\#C(/'\CP"EAJT7C54<%3
M>$3@OK/.ZE-0]CS\SG!1NY1OFL3AI*LXXB@UAN;ZPU5IM8?E4G+VUI?NN51D
MY<_+91DW:S,+XP?MC_LA_L\^)K'P7\?OVJ?V;_@=XQU/0K;Q1IOA/XP?''X8
M_#/Q-J/AF]U#4])L_$5CH/C3Q1HFJ7>A7>J:)K.FVVKV]K)I\^H:1J=G%</<
M6%U'%]$6EW::A:6M_875O>V-[;PW=E>VDT=S:7=I<QK-;W5K<0L\-Q;W$+I+
M#-$[QRQNLD;,K G_ "W/^#D+]MW]F#]O?]N'X5_&#]DWXG?\+7^'7AO]E+P/
M\-=:\1?\(7\0O OV+QKH_P 7?CGXHU'1?[(^)7A/P=KMQ]GT+QCX<OO[1M-,
MGTF;^T?LT%_+>6=_;VO]GOPG_P"#B;_@CFGA+X:>"V_;!QXE7P[X-\+MIO\
MPS]^U(<:ZNFZ;I)L?M@^"1T\XU ?9_M(NC9_\M1<>3^\KZS,^"LQP>5Y-C<+
M@LVQ6*Q]*O/'X2.7UY2P$J7LN2-2%.DZE/VG/-KVT8M\CM>SMXV$S_"U\9CJ
M%:O@Z-'#SIQPU=XFFEB5-3YG%RFH3Y7%7]FVO>5[:'Z'_P#!2;XP?';X!?L)
M_M/?&']F;PO/XO\ CIX#^&&IZQ\/=(M?#TWBRYM=1>\L+'4?$UOX9AAN1KL_
M@K0;S5?&46EW%I>V%Y)H*PZE8WVGO=6DWX4_\&UO_!2S_@HG^WQ=?M$6'[84
MM]\4_AKX/TWPYK7P^^/4GPL\&?#BRM_%=YJ$FDZO\+HK[X?>'_!?A+Q0#I]L
MWB6%+/PW?Z[H$T&I)XAU]++5_#&FQ_TU_&/XO_#OX ?"OQ_\;/BWXA_X1+X8
M_"[PMJ_C7QUXF_LG7->_L/PSH5J][JNI_P!C>&=,UGQ!J?V6VC>7['H^E:AJ
M$^-EM:32$(?F/]B__@I/^Q5_P4+_ .%D_P##'WQH_P"%O?\ "H?^$._X6)_Q
M;KXL> /^$>_X3_\ X2K_ (1+_DJ'@3P5_:W]K?\ "%>)O^0'_:?V#^S/^)G]
MB^VZ?]K\K!XCDX=S2A_J]'&*>(HR>?NC4D\L]ZC%4/;QH2C3]K+E4(O$45*5
M=J<*O-"*[*]+FS/!U/[3=#EI5$LM4XKZWI-NI[-U$Y\BNY-4IM*G>,H6DW]S
M445^./[2W_!?7_@E1^ROXU\1?#/X@?M0:7XH^(WA.XELO$/A+X1^$/&OQ5.D
MZE;?;XKW1;_Q?X/T'4/AS9^(=+U'3Y=&UOPU=>,X?$'A_5I([37=,TWR[J2W
M\?!X#'9C4=' 8/%8VK&/-*GA:%6O*,;VYIJG&3C&[MS2M&^ESMKXG#X6*GB:
M]&A!NRE6J0IIO>T7-J[MT5WY'['45^&7P._X.._^"1OQQ\0P^%8?VE3\)];O
M;ZULM-_X7CX)\5_#;P]>_:GCB^US>/+_ $Z[^'V@6-O++&EU<>*_%6@")#)=
M;6LK>YN8?V_TO5-,US3-.UK1=1L-8T;6+"TU32=6TN[M]0TS5-,U"WCN[#4=
M.O[22:UO;"]M9HKFTN[:66WN;>6.:&1XW5C6-RW,,MG&&88'%X*4TW!8FA5H
M\Z5KN#J1BII75W%M)Z/46'Q>%Q47+#8BC72^)TJD*G+Y246W%OHFE<O45\W_
M +57[7/[/7[$OPDO/CI^T[\0?^%9?"NPUW1/#5WXI_X13QOXS\K6_$4TMOHU
ME_8GP^\->*_$<GVR:&5/M,>D/:6^W==3P*RL?/?A/_P43_8I^-7[-M_^U_X%
M_:#\&Q_LUZ7JVN:%J'Q:\>6WB+X1^';/5_#DBQ:MI\\'Q9T3P3K"7,4SK#:(
M=,_XFLS+#I1O9"%J(8'&U*$<53P>*GAI5EAHXB&'JRH2Q#5U0C64'3=9IIJD
MI.;3NHV*>(P\:CHRKT8UE3=5TG5@JBI+1U'!RYE33T<VN7S/M*BOY\/%G_!S
M_P#\$@O#/BF7PW9?&KXA^,;.WGAMI_%_A/X)_$67PLLCR^5=-%+KVCZ!KM[!
M8,&::ZT_0;NUNXE\W2)M3C>)I/UV_95_;'_9D_;=^&\GQ:_98^+_ (;^,'@2
MVU670=2U/1(-9TG4M"UN*VMKUM'\2^%O%&EZ%XL\,:HUC>6E]%8>(=#TRZGL
MKF"[ABDMY4E;IQ>2YO@*,<1C<KQ^$H3:2K8C"5Z-/FE\,7.<(QC*72,FI.SL
MM';*AC\#B9NEA\7AJU2-VX4JU.<K+=J,9-M+JU=+JSZ9HK\JOVR/^"U?_!-[
M]A3QC/\ #3X[_M#:6WQ4LXI)-5^&/PWT+7_B?XQ\.,MHM[%:>,H/!VGZGI'@
M75;R&>PET_1/&NL>']:OK35+#5K73Y=$DFU.#RK]F#_@X-_X)8?M6_$31/A-
MX*_:!G\"?$+Q5JD.C>$-!^,W@WQ'\-;'Q7JEQ$S6NFZ3XQU:TE\!0ZMJ-UY6
ME:)H>L^*=*UWQ'K=W9:-X<TS5M2O+:VDN&19U4POUV&4YC/"<CJK$1P>(=)T
MDKNJIJG9TTDVZBO!)-MV39,LQP$:WU>6-PL:_-R>R=>FIJ?2#BY74V]%%VDV
MTDKL_:JBBBO).T*_FH_X*V_\''_P0_X)X^/[_P#9X^"W@&V_:5_:-T&>*W^(
MFGR^)KGPI\-OA%)<:?'J-MIOB+Q!9Z-K-YXO\9O'<V/VOP=X=%A;:+!<W(U_
MQ;I6NZ:WAJ[_ *1]7N;^STK4[O2M-_MG5+73[VYTW2/MD.G_ -JW\%M++9Z;
M]ON5:WL?MUPL=K]LG5H;;S?.E4HC _Y8_P#P0(^$_P .?VT_^"OOP]F_:FTV
MP^*B:B/B_P#'?5M!\4IIK:'\0_BII6F:EXLM+CQ3H?V6.S\06$'B"_N_&UUX
M9MX;?2]1N]$@@UBRO_"R:QH>H?<<'9+EN.I9UF^;PJ8C Y%A(XF>"HS=.>*J
M5(8B<8RE&49JG&.&FK*=-3G.#E/V<*D)?/YYC\7AYX#!8*4:6(S&NZ2Q$X\R
MHQC*E%M1:<7)NJM6I<L8RM'FE&2_0WPW_P %Y/\ @XH^/#IXF^"G[*=_XC\/
MZG8KK&GP?!K]B'XN^/\ PX^DWA@U"TU#3]2FF\<ZA<Z:UEK&E):7KZW=0S6$
M^EW#3SSWIN[OV'X!?\'97[6GP3\=:=\.?^"B?[(FE:I8V<]E9^)=6^'N@^*/
M@I\:?#^G37\(O?$%[\.OB)?ZIX5\8:I;6D6I167AR"Y^$FG:C<BT27Q!I@M+
MN:\_O2M+2TT^TM;"PM;>RL;*WAM+*RM(8[:TM+2VC6&WM;6WA5(;>WMX42*&
M&)$CBC18XU55 'Y2_P#!9/\ X)[> ?\ @H!^Q%\:_"+?#/2?%_[0'@CX>>*O
M&_[-WB"UT^RC\<V/Q2\+:-J.M>&_!NAZ_-J>A>1I7Q%O87\%:KIFM:LWA56U
M^#Q!J.FW.H:%I=Q:]N&XCX6Q^)IX+'\(Y?@\%B*D*+Q6$KSI8G"J<E%5YU8P
MHNI&G=2FN>'NJ4FI_!+GJY7F^&I3KX;.\37Q%.$I^QKTXSI5N5)^S4'*:@Y6
M:B^66K2O&[D?;/[*O[57P._;2^!W@S]HC]G?QG!XV^&?C:"Y^Q7OV:XTW5]&
MU?3;A[+6_#'B?1+U([_0?$F@W\<EIJ6FW<>UU\C4=.GO]&O]-U*\^B:_D'_X
M-BOV0/\ @HQ^PSXQ_:=^%/[57[/_ (G^%/P0^)?AKPG\0O">J>(_$/A75[:T
M^*OA/5#X;OK#1;3PMXJUN*UG\7>$?$27&O7-_9I)<Q^ ?#T5K<QK;7,4_P#3
M1^U5^US^SU^Q+\)+SXZ?M._$'_A67PKL-=T3PU=^*?\ A%/&_C/RM;\132V^
MC67]B?#[PUXK\1R?;)H94^TQZ0]I;[=UU/ K*Q^7SK*:6#SNOEN55UFM&52G
M]1J824,7.O&O&,Z=)?5N=5*\)2=&2A%.<X.4814E%>O@,;.O@*>+QE-X.HH2
M^L1K*5&--TVU*;]KRN-.22G%R;48RLY.S9](45\7?!S_ (*(_L5_'K]FSQ)^
MV!\-OV@O!UU^S5X/U36-$\6?%OQA:^(_A;X<\-ZMH4NEP:A8:Y#\4]$\&:QI
M=Q]HUO1K>P6\TR$:Q<:OID&D&^EO[5)?S(\:_P#!SO\ \$AO!OC*^\(0?&SQ
MYXT@TZ^&G7?C'P5\'?'FI>#?M$=PUK>R6.HZEIFCZCK%C8R([G5-%TC4=,U.
MW"W>@W>KVTT$LO/A\CSG%5*]+#95F-:KAINGB*<,'7<J%2-KTZR]G>G45U^[
MG:?]TUJYA@*,*<ZN,PT(54I4I2KTTJD7M*#YO?CI\4;Q\S^@BBOEG]E']MK]
ME/\ ;B\$WWQ"_93^-_@[XR^&M(N+2TU\:!)J6F>(_"UUJ"W4FFVWC#P1XFT_
M0_&OA"?5([&]ETJ+Q-X>TE]3ALKN:P6XBMIW3ZFKSZU&MAZLZ&(HU:%:F^6I
M1K4YTJM.5K\LZ<U&<79IVDD[,Z:=2%6$:E*<*E.:O&=.2G"2[QE%N+7FFT%%
M>7_&3XV?"']GCX=^(/BU\=/B3X,^$WPU\+PQS:YXT\>>(-.\.:#9//((+&Q6
M\U&>%;S5]5NVBT_1=$L5N=7US4Y[;2](L;W4+JWMI?PJ\0_\'2?_  2&T74Y
M[#3?BI\6?%MK$T@CUKP]\#?'EMIER$N)X5:&+Q79>&=959HXH[N,7&DV["WN
M8%F6*Z6YMK?MP.3YKF49SR_+L;C(0DHSJ8?#5:M.$FKJ,IPBX*5M>5RO;6UC
M#$8[!X1QCB<50H2DKQC5JPA*2VNHMJ35]+I6OU/Z):*^#_V._P#@IK^PO^WK
M;7/_  RW^T/X.^(>OZ?;K<ZMX"O(M9\%?$K2H1$)+BXN/A]XYTSP[XLNM-LW
MWV]QK^E:5J/AQIXV6VUBX0QR/]X5R8G"XG!UI8?%X>MA:\+<]'$4IT:L;[<U
M.I&,E?=-K5:HVI5:5>"J4:E.K3E\,Z<XS@_246T_O"BJ]W=VFGVEU?W]U;V5
MC96\UW>WMW-';6EI:6T;37%U=7$S)#;V]O"CRS32ND<4:-)(RJI(_%7]H/\
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M7A(^VYL3AX_5W%8B]:FO8.5^55KR_=.5GR\_+>SM>S/LFBOY]_A__P '._\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ K_-M\)?\KKMW_P!G+>-?_6/->K_22K_-M\)?\KKM
MW_V<MXU_]8\UZ@#_ $DJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _
ME)_X/'O^41>B_P#9W'P8_P#42^*]?;G_  ;.?\H._P!@_P#[%OXS_P#K2GQF
MKXC_ .#Q[_E$7HO_ &=Q\&/_ %$OBO7VY_P;.?\ *#O]@_\ [%OXS_\ K2GQ
MFH _=JBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_ #;_ /@G
MG_RN5?'G_LY3_@H'_P"JW^,5?Z2%?YM__!//_E<J^//_ &<I_P % _\ U6_Q
MBK_20H _S;_^#.7_ )2G_MR_]FU^/_\ UHOX6U_I(5_FW_\ !G+_ ,I3_P!N
M7_LVOQ__ .M%_"VO])"@ HHHH **** /XV?^#R+_ )-J_8T_[+EX^_\ 4!MZ
M_DX_X):_L!7/_!1?Q?\ M;?!WPS'<3_%CP!^Q=X]^./P.M8]3ETZTU+XH^!?
MC!\"M*M?#^HB*SOEOH/%?A#Q5XP\*6%I/'#;1:[K>D:E->6:Z?\ :8OZQ_\
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M;&_:;_X1S_C]_P"0#_PNOQO_ &/_ ,A'_B8?\@_[/_Q__P"F_P#/U^_\RO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M98+$4J52G7P/U=4'B(.+7O)2C3;IZ2:IJ<O<4IV44?F'_P '5/\ RB5\7?\
M9=/@K_Z>=3K^9+_@B?\ \$G_ (W?\%7_ (2:)HOQK^,'BKX;_P#!.C]GKXR>
M)M4'P^\)/+I_B'XK_&CQ5X:L)O%>J>&;B^TW4?#UOJ.BZ%'X*T#6?&6MVVL/
MH.@WD_A_P7HEIJVO^+];C_IM_P"#JG_E$KXN_P"RZ?!7_P!/.IUQ'_!I7_RB
MRU[_ +.K^+?_ *B'PKK?*LSQ64^'6(Q>"<(8EY].C2KRA&<\.ZN'HQG6H<Z:
MA6]GSTX5+-P523C:5FHQ>$HXWBB%&NI2I?V=&I.FI.,:O)5DXPJ6:<J?-RRE
M&]I.*3NKI^X>.?\ @V'_ ."/GB?X>:]X0\+_ +/WBOX;^+-3T!]+T?XK>'?C
MG\<=:\6^&]7$2+#XEM-#\;?$3Q-\.]1OO.C\VZT_5?!EWHTR37$-M861-M+:
M_P +7[.-S_P4/_8&_P""@'Q]_85_8I^)EY8?M ?$?QQXY_8IU6[\,7.EZ=H_
MC9K+QE<Z-I7CC0Y_$MPVG>"-<L$TV;Q+X2^($T]AXM^'&EZQKJVFJZ3+?ZW#
M/_K65_F,6]U<VG_!TZTMI<3VLK_\%3[JU>2WEDAD:VO?BM+97MNSQLK-!=V=
MQ/:741)CN+::6"57BD=&Z.!LYS+,*/$6'S/$U,VH4,KGCJ=#-)SQU+V^'DY0
M35>4Y>R<E%SI1DHMQC**C)<QEQ#@,+AJF5U,)2C@JE3&1P\JF$C'#R]G424G
M^[27.DVE-INS:=UH?TS?LA?\&KG[ ?PU^'%BW[8^F^)?VM?CAKL$>J^./$D_
MQ'^*/P[\$:1XAO[:PGU;3O!=C\._%7@CQ%JVF66J1ZB+?Q%XTU&]U?7TO9M2
MO-)T5Y;;2M,_![_@Y&_X(N_LX?\ !/SPA\$_VF/V0O#.N?#[X5>/?',WP;^(
M'PXU/QIKOC71?#_C:?PKJGB[P3K7A74_'6MZ_P"/R/$VD>$?'I\26VIZYKND
MV5YI.E-ISZ&E\MA>?Z,5?S$?\':G_*++0?\ LZOX2?\ J(?%2O'X6XIS_%<4
MY;]:S3%UZ6,Q7L*V%G6G]4<*T91M#"IJA2]FVI4W3IQ<7%:V<D^[.,GRVCD^
M*]CA*%.="C[2G6C3C[?F@T_>K->TGS*ZES2::>UTK?HI_P $.?VE/$_[5W_!
M+;]D[XK>.M;G\0^/;7P=K?PV\9ZQ>6DMM?:CJ_PE\8^(?AS::EJ,CRW":CJ>
MK^'O#>B:SJ>KPSNNIW^HW%Y/#87LMUIME^L=?SB_\&K=S<3_ /!)'P1%/<33
M16?QN^-EM9QRRR2):V[>(;.\:WMD=BL$+7=U=7311!(S<7-Q.5,LTC-_1U7R
MO$E"GA>(,ZH4HJ%*GF>-5.$4E&$'7G*,(I))1@FHI)6221[&55)5LMP%2;<I
MSPE!RD]7*7LXIR;ZN35WYL*_S?\ _@K/_P $0/VVOV#OVJ?&'[9W[!7AGXD>
M*O@;?_$C6?BIX!U_X!77B+6?C'^S9JNHQ3>*M7TKQ!X?\-6,'B^Q\#^'KZ7Q
M-:>&?'.B+XFT73O ^FZ?9?$SQ!IFN7\7]O\ ^D!16_#O$>,X<Q56OAH4L11Q
M-+V.+PF(3='$4DVTG9WC.%Y*$[224YQE"<)2B\\SRNAFE&%.K*=*I2G[2A7I
M-*I2GI=J^CB[+F6CO&+3C))K_/?_ &4O^#N[]J3X8QZ?X*_;2_9_\&_'J+18
M)-&U7Q]X#N6^"OQ7DU*VN5%SJWBOPW_9FM_#C6=5B*7=C<Z+X:\,_"JP1VMI
M<V\UC=1:I_1?^R+_ ,')G_!+O]J[5=*\)7_Q.\2?LV>/]8GL;'3O#'[1^@V?
M@W2-3U&Z\V.:+3_B3X?UCQ7\,K2WBN8XH;1_%GBSPIJ&IB^L19Z4]R;VTL?O
MW]HO_@EU_P $\?VL?[<N?CW^Q]\#/&GB#Q+?-J6O>/+'P79>!OBGJMZ_VXRS
M7GQ:^'I\*?$R7SY=1O+JXC_X2P0W%[(E]/')>06\\7\OO[?'_!HQX#MO!'BW
MXB?\$_?B_P",K7QCH6DW&N6OP(^-MS9^)=(\6-IZ7=W?Z#X)^(GAS0--US0=
M8O;"*"V\+Z5XJT+Q7;:KXAVV>L>,/#VEZE_:6A_5QQ'A[GT^2O@\9PSC*SBE
M6P\U4P"J2LE>/[RG3IJ3M)+"X:FH6?M(:N/C.EQ-ERYJ=>AFU"";=.K'DQ#@
MEKK[LI2MJG[6K)R^S+1/^VC2]4TS7-,T[6M%U&PUC1M8L+35-)U;2[NWU#3-
M4TS4+>.[L-1TZ_M))K6]L+VUFBN;2[MI9;>YMY8YH9'C=6/\YO\ P=4_\HE?
M%W_9=/@K_P"GG4Z_"3_@U;_X*,?&_P )?M3)_P $Z/BAXM\6>*?A#\1/"?CJ
M\^$/A'Q7JS7+?!OXC?#S2M5\=Z_I'A6UUR3^T]%\+^)/#6C^,)];\%Z.XL+/
MQ5:0>([71;*XO_%^I7G[M_\ !U3_ ,HE?%W_ &73X*_^GG4ZX</D-?ASCG)<
MNKU85XO,,!B,/7@G%5L/5Q'+";@VW":E3G"<.:24H/EE*+C)]%7,:>:</8_%
M4X.F_JV(IU:<G=TZL*=Y14DES)J491=DW&2ND[I?RZ_\$3/^"8OQO_X*U>!=
M'^'GQ>^(7BKX>?\ !-_]F3XJ^+_$NM:;X.OWL-<^)_Q\\<^'?#<NJ:'X>2_C
MU;P]'X@T'PA!X7;7O&6JZ-=W'A#PGKMKH?AO3I=0\=ZKK&F?U_:E_P &WO\
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MKQWX,\4:_P##OX@VNA+?7%W??\(XOCCPCX@?PX;Z[N[UM"?3VN[JXN#),_\
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M#<=OJEIX_P#$R6E@FGBTTIKR%]/B@>SMC'^<?_!N5_P1_P#V'?\ @HC^S?\
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MV]\/:?IL%UJVKW-YJ6H7 @A5IKJ\N9999&9LJNU%_:RORE_X+D?\HE/V[_\
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MRNNW?_9RWC7_ -8\UZ@#_22HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@#^4G_@\>_Y1%Z+_P!G<?!C_P!1+XKU]N?\&SG_ "@[_8/_ .Q;^,__ *TI
M\9J^(_\ @\>_Y1%Z+_V=Q\&/_42^*]?;G_!LY_R@[_8/_P"Q;^,__K2GQFH
M_=JBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.5_:&_[+E\6O_4^\05YWA'_O.>?]>,#_ .G,2='&W\/+O\>)_P#2:!_KL?\
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M:I+<S23R+:V/QS\=65E;*\K,RP6=E;V]I:P@B.WM8(;>%4BB1%_N1_X,_?\
ME&E\</\ L^;XE_\ J@OV9J_JRK:MQ3_JMQEQ-B/J'U_ZU65'E^M?5?9\CA/F
MYOJ^(YN;1<O+&UKW>Q$,G_MC(\II_6?J_L:?/?V/MN;F3C:WM:5K;WN^UD?X
MXG@/_@J3_P %&/A=X+\+_#GX<_MJ_M'>"/ ?@G0].\->$?"'ACXH>)=&\/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX<2I8K-,VP&-_L^KE]' \\JE7$<D*^(<XI0I\D;R<8N+5VVE&<[M-J+^$_\
M@ZI_Y1*^+O\ LNGP5_\ 3SJ=<1_P:5_\HLM>_P"SJ_BW_P"HA\*Z_0__ (+5
M?L'?%[_@H[^P[KO[,_P0\1_#?PMX[U/XD_#WQC;ZM\5=7\3Z'X233/"5_>76
MHP37_A'P?XYUE;^>.X1;*)-!DMY'#">ZME 9N=_X(=_\$]_C/_P30_8OU/\
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MSX@\52VEU\+_  %X.U.Z70/#%MX<34;?79+BQ<^+-+DTM)+BWU%K?\RO"?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** /[ OV9O^3;_P!G[_LB/PH_]0/0:]NKQ']F;_DV_P#9^_[(C\*/_4#T
M&O;J_G#&_P"^8O\ [":__IV9_>&4_P#(JRS_ +%^"_\ 4:D%%%%<QZ 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7\L/\
MP>%_\H?KC_LZ#X)?^D/CJOZGJ_EA_P"#PO\ Y0_7'_9T'P2_](?'5 'U9_P:
M_P#_ "@N_86_Z\_VB?\ UK3X\U^^5?@;_P &O_\ R@N_86_Z\_VB?_6M/CS7
M[Y4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7^;;X2_P"5
MUV[_ .SEO&O_ *QYKU?Z25?YMOA+_E==N_\ LY;QK_ZQYKU '^DE1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% '\I/_  >/?\HB]%_[.X^#'_J)?%>O
MMS_@V<_Y0=_L'_\ 8M_&?_UI3XS5\1_\'CW_ "B+T7_L[CX,?^HE\5Z^W/\
M@V<_Y0=_L'_]BW\9_P#UI3XS4 ?NU1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!_FW_\ !//_ )7*OCS_ -G*?\% _P#U6_QBK_20K_-O_P""
M>?\ RN5?'G_LY3_@H'_ZK?XQ5_I(4 ?YM_\ P9R_\I3_ -N7_LVOQ_\ ^M%_
M"VO])"O\V_\ X,Y?^4I_[<O_ &;7X_\ _6B_A;7^DA0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %>[M+34+2ZL+^UM[VQ
MO;>:TO;*[ACN;2[M+F-H;BUNK>97AN+>XA=XIH94>.6-VCD5E8@^;:'\#_@M
MX8\1P^,?#7P@^%WA[Q=;S7US!XIT/P!X3TGQ'!<:G;W-IJ5Q#KEAI-OJ<<VH
M6M[>6U]*ETLEW;W=S#.TD<\JOZC15QJ3BI1C.<8R5I*,FE)/=22:37D[DN,9
M--QBVG=-I-I]TWL_0****@H**** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %?YMOA+_ )77;O\ [.6\:_\
MK'FO5_I)5_FV^$O^5UV[_P"SEO&O_K'FO4 ?Z25%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 ?RD_\ !X]_RB+T7_L[CX,?^HE\5Z^W/^#9S_E!W^P?
M_P!BW\9__6E/C-7Q'_P>/?\ *(O1?^SN/@Q_ZB7Q7K[<_P"#9S_E!W^P?_V+
M?QG_ /6E/C-0!^[5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M'^;?_P $\_\ E<J^//\ V<I_P4#_ /5;_&*O])"O\V__ ()Y_P#*Y5\>?^SE
M/^"@?_JM_C%7^DA0!_FW_P#!G+_RE/\ VY?^S:_'_P#ZT7\+:_TD*_S;_P#@
MSE_Y2G_MR_\ 9M?C_P#]:+^%M?Z2% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M,Z5:"G!R7++E=]UK9Z;!1117&;A1110 4444 %%%% '\O/\ P=\_\H<?%/\
MV<1\"_\ TY:]7Y"?L;?\F@_LJ?\ 9MWP-_\ 58>%Z_7O_@[Y_P"4./BG_LXC
MX%_^G+7J_(3]C;_DT']E3_LV[X&_^JP\+U^A>'O^^YA_V"TO_3Q^'^.'_(JR
M/_L88G_U&1](T445^K'\WA1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\>_Y1%Z+_P!G<?!C_P!1+XKU]N?\&SG_ "@[_8/_ .Q;^,__ *TI\9J^(_\
M@\>_Y1%Z+_V=Q\&/_42^*]?;G_!LY_R@[_8/_P"Q;^,__K2GQFH _=JBBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_-O_ .">?_*Y5\>?^SE/
M^"@?_JM_C%7^DA7^;?\ \$\_^5RKX\_]G*?\% __ %6_QBK_ $D* /\ -O\
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M/'WA?7=1T:X\5:I\8(M+\97>G20Z7K#>"?#=HOF7WA^^6$ _1?PM_P 'G?\
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MZ<=?FC_P5$_X*J_LW_\ !)3X*^!?CC^TCH7Q1\7Z%\1/BC8_"GPYX4^#&E^
M_$'CV;5KOPGXK\7W/B&30O'GQ$^&]G)X0T6S\*'3=<U:PU:^N=.UGQ%X5LY-
M.:+5_M-MZE_P3<_; T_]OG]A7]F']KRRL].TR^^-7PNTG6O&&CZ,DR:)H7Q,
MT*ZO?!WQ8\/:$+K4=6O3H7A[XF^'/%NBZ*^H:A<:G)I=A:2:F8[]KF&/^*?_
M (/6/BAK_P 0OVCO^"?'['OA'3_[5U^Q\#^.OBA;:-8M8RZKX@U_XV>.]#^%
M_@C3TBDE^VVVR]^%/B&TT]F%G8ZC<ZS<K)+>RZ:HTT _LW_X)N_\%(_V=/\
M@J5^SK%^TG^S<?%^F>%X?%_B+P-XA\%?$BW\(Z7\2O!7B3P]/$38^,- \%^,
M_'FDZ0VM:3=Z9XET +XAN9+_ ,/:OIU])';2RRVL'W[7^>'_ ,&TGQ$\6_\
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M**_F6_X.?_\ @JY-_P $]OV*)/@K\)/%1T?]J;]L'3_%/P_\$W.E3ZC;Z_\
M#GX2QZ>FF?%;XKV.J:3/:7'AGQ#;6NN:=X1^'6J'4-/U>/Q3KUSXK\+_ &Z7
MX>ZW]A .G\/?\'2O_!-7QC^W!X9_82\%>'_VEO&'CGQE^T/X<_9G\,?%W0/
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M^!O_ *K#PO7Z]_\ !WS_ ,H<?%/_ &<1\"__ $Y:]7Y"?L;?\F@_LJ?]FW?
MW_U6'A>OT+P]_P!]S#_L%I?^GC\/\</^15D?_8PQ/_J,CZ1HHHK]6/YO"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#_P>%_\ *'ZX_P"SH/@E_P"D/CJOZGJ_EA_X/"_^4/UQ_P!G0?!+_P!(?'5
M'U9_P:__ /*"[]A;_KS_ &B?_6M/CS7[Y5^!O_!K_P#\H+OV%O\ KS_:)_\
M6M/CS7[Y4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7^;;
MX2_Y77;O_LY;QK_ZQYKU?Z25?YMOA+_E==N_^SEO&O\ ZQYKU '^DE1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% '\I/_!X]_RB+T7_ +.X^#'_ *B7
MQ7K[<_X-G/\ E!W^P?\ ]BW\9_\ UI3XS5\1_P#!X]_RB+T7_L[CX,?^HE\5
MZ^W/^#9S_E!W^P?_ -BW\9__ %I3XS4 ?NU1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!_FW_ /!//_E<J^//_9RG_!0/_P!5O\8J_P!)"O\
M-O\ ^">?_*Y5\>?^SE/^"@?_ *K?XQ5_I(4 ?YM__!G+_P I3_VY?^S:_'__
M *T7\+:_TD*_S;_^#.7_ )2G_MR_]FU^/_\ UHOX6U_I(4 %%%% !1110!_&
MA_P>5?MWWGP6_8\^$W[$'@V:YA\4_M=^*+WQ5\0]1M;N6!-*^#'P8U+P_JK:
M%<16UW:7!N_'WQ%U7PHUC*Z:AI<F@^!/&FF:E9+<:EI5U#_0+_P2#_8EL?\
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MZ9^VEIOC3Q;^RQ_P3K^'FL6WB'7/!VMWW[0/QF\,:7:ZG?ZOIGC+Q!H8\%_
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MSWH!_:/1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&+A]AJFXIQ^RU;H9\00JPX<HPK-.M".!A5:ES)U8QBJC4OM)S3?-UW/[3?\
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M)1O./BXO YGD=&>,P&9U<1AJ'+*>#QEZB]ES)-1=^5[KF]G&A)14G&5[1?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_8%^S-
M_P FW_L_?]D1^%'_ *@>@U[=7B/[,W_)M_[/W_9$?A1_Z@>@U[=7\X8W_?,7
M_P!A-?\ ].S/[PRG_D599_V+\%_ZC4@HHHKF/0"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *_EA_X/"_\ E#]<?]G0?!+_
M -(?'5?U/5_+#_P>%_\ *'ZX_P"SH/@E_P"D/CJ@#ZL_X-?_ /E!=^PM_P!>
M?[1/_K6GQYK]\J_ W_@U_P#^4%W["W_7G^T3_P"M:?'FOWRH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "O\VWPE_RNNW?_ &<MXU_]8\UZ
MO])*O\VWPE_RNNW?_9RWC7_UCS7J /\ 22HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** /\ -O\ ^">?_*Y5\>?^SE/^"@?_ *K?XQ5_I(5_FW_\$\_^5RKX\_\
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M>9J6@:3XEU.\BT*#2]=^$^F2V'^@Y7G_ ,+?A/\ "SX'>!-"^%OP4^&GP_\
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MZ/X/\=Z;X,T;7-9\-:YX'6ZM?#VA^(K?1I?#FK>$H=-/B&XT35]!U'6_%/\
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MHECJEU>6<&J-K^@^'O&R:;<>%/$5G'?_ .F=7D'QS^ 'P5_:9^'6J_"7X_\
MPQ\'?%SX;ZS<65[J'A#QQHUMK6DOJ&FS?:-.U.V2=?.T_5=/F+/9:II\UKJ%
MIYDJP7,:RR!_F>&N(5D=;%TL3AECLJS.A]5S+!.7*ZE*TE&I2E=)5J2J5%&[
M2E&<XJ5.;A5I^KFN6?VA"C.E5^KXS"5/;86O:ZA.\6XS76$W"-[7:<4[27-"
M7Y7?##_@XA_X)"_$[P8GB\?M;:'\/9X;*.ZUCP;\3_!OC[PEXST6X:V>ZDTU
M]./AJ_TWQ'>P1H4DD\#:OXKTV2Y*VEKJ%Q<NL1_E&_X+Z_\ !7#P-_P5H\2_
ML[?L7_L&>'/B%\4_!6A?$ZY\2G5AX1\0:7K?QD^,.J0ZAX!^'6D_#SP%?6]M
MXG72M)T#7/$]Q%?^)-&T_7M8NO&T5D-!\-Q^';Z7Q!_2)XA_X-;/^"0VM:G/
M?Z;\*_BSX2M96D,>B^'OCEX\N=,M@]Q/,JPR^*[WQ-K++#'+':1FXU:X8V]M
M TS2W37-S<?I#^R!_P $K_V OV$;P:Y^S'^S5X&\"^-6T\Z;+\2M5?6O'OQ/
M:TGAEAU*"S^('C_5/$WBC0K+6A/(VLZ1X;U+1M$U$+:P3:8;73].M[3W<#FO
M!.18I9KE>'S['X^BIRP6&S!X.EA:%2=.4.>K4H-U)N*FU"T:EMVN=1J+SL1@
M\_S&B\'C*F78?#3<57JX95YUJD(RC*T(U/=C=Q]Z[C>]OAO%V/\ @EM^R9J_
M[#7_  3^_9?_ &7?$ES!<^+_ (:_#Z6Z\>?8[A;RPM/B)\0/$FO?$[XAZ5IE
M\MQ<IJ.E:+XV\9Z]I&E:G$\46I:=8VU_%9V$=PMC;_P^_P#!X%_RDM^!_P#V
M8S\-/_5^_M,U_H_5^<'[8/\ P2/_ .">O[>_Q+T/XP?M9?L_?\+7^(OAOP+I
MGPUT7Q%_PM;XW>!?L7@K1]?\3>*-.T7^R/AK\2?!VA7'V?7?&/B.^_M&[TR?
M5IO[1^S3W\MG9V%O:^9PSQ)1ROB.KGF:0Q%?ZPL;.NL+"G*I*OC).I*2A5K4
M8*//*3?[RZ3T3.S-LJGC,KAEV$E3I^S^KQINM*:@J=!**3E"$Y7Y4DO=LWO8
M^WOA+_R2KX9?]D^\&?\ J.:;7H-9^D:58:%I6F:)I4'V72]&T^RTK3;7S9I_
MLUAI]M%:6<'G7,DUQ-Y-O#''YL\LLTFW?+([EF.A7R,VI3E);2DVK[V;;U/:
MBK12?1)?<@K^5'_@[H^#-_XY_P"">?PP^+6FR6X/P-_:(\.7>N0S1Z@9'\,?
M$7PWXA\'32VDEJLUFEQ%XJ?P>C)J<-M#):SW)MM4M[R.'2]:_JNKY1_;G_9:
MT']MC]D+]H/]E?Q%>6.EV_QG^&^M>&-'UW4]+36K'PMXTMS#KGP^\8W&DL\+
M:@O@[QWI/ASQ2MK!<V5Y+)I"+8ZAI]YY%[!ZW#^81RK.\LS";:I8;&4I5FDV
MU0E+V==I)-MJC.=DE=O1'%F>%>-R_%X:.LZM&:IIZ+VD5STKO2R]I&-WT1^<
M_P#P;C_%N/XM?\$@?V6&DBA@U;X:P_$7X2:U%:VEQ:68D\$_$CQ1#X?E@-U>
M7LEU-=>";[PM=ZM=I)#;RZ[<:JMI9V5M'#:Q?)O_  =6?MF_\,]?\$_-._9T
MT%!_PG'[9_BN3P7]K,HA;1OA9\,;[PSXT^)>I616;?<7^I:E=^ ? \MI+:2V
M3^'_ !IX@NGN[/4+/2TN_P Z_P#@TL^/WB'X._%;]M+_ ()K?&.+_A"_'NA>
M*;OXK>'O NN/)9ZWIGQ'^'][%\(_V@O#$ZM/-IEWKNFQZ1\.6.EV+QZI':>%
MO$VH@:MI>G7,^A_U!?MC_P#!*O\ 8,_;_P#%_A+QW^UQ\#)_BWXH\"^&Y_"7
MA._;XK_&SP+;:/H%UJ=QK-S:1:/\-?B/X-T6XGN=1NI)KC4KS3KG5)XTM;66
M]>TLK."#ZC,8X#(./:V+S*G7KY?3Q\LWHQPD*=2598F+QF$=/VE:C3E2IXF<
M5-^T:DJ,X)2N>1A7B,RX<IT<).G3Q,L.L%4=:4H*FZ35&LI<E.I)3G2BW%<J
M:]I&5U8_&W_@TR_91D^#/[ 'C/\ :-US3KBR\4?M;_$^ZU72YI6M56Y^%'P;
MDUCP)X++6J*U_!._CF\^+E_')?2QI>Z3J.CWEA8Q6DR:EJ_]3E>;_![X0_#?
MX _"SX?_  4^#_A2P\#_  O^%WA31O!/@;PIITU]=V^B^'=!LXK'3[:34-5N
M]0UG6+]XXOM&J:[KFHZEKVNZG-=ZQKFIZCJU]>7L_I%?*9YF<LXS?,,SDI)8
MO$SJ4XSMS0H1M3P].5G)<U.A"G3=FU>.FECV<OPBP."PV$5FZ-*,9./PRJ/W
MJLE=)VE4E*2ND[/74XSXC^ /"WQ8^'GCWX6>.=,AUKP3\2_!GBCP!XPT>YB@
MGM]6\+>,M#OO#OB#3)X;J&YM9H;_ $G4KNUEBN;>>"1)62:&6,LC?YFW_!'#
MXM>/?^"4_P#P6ZC_ &</B+KLVD^%O$_Q=\9?L4?&>/4]/O-.TS7VU/Q5-X>^
M%OC2VL7FOK;2H)/B;IW@/Q%I/BEWOK2W\!:]KZ0:W#X?\17^L'_3\K\K/CM_
MP1-_X)D?M*?'GQ+^TY\8OV:YO$'QU\7:MX<U_7?B#H7QM_:'^'E]-KOA/1=$
MT#P_K5AI7PW^+7A'P]HFK:?IWAW1V_M+0](TZ\N]2M7UR]FN=;N[W4+CVN&,
M_P %E>%SO+<UI8FOE^<8+V+CA:=&K4I8F//&E64*]:A"*C&K.?/&;DJE.BU%
MVYH\&;9;B,96R_%8.=*GB<#B.>]:4X1G1ERN<'*G3J2;;@H\KCRN,ZFJO9_E
MS_P="?\ !,;XF?MF_L__  S_ &DOV?O#&H>-OB]^RW_PF$7BSP#H</VCQ!XX
M^"OBFVL=5UV\\.V*1S7FO^*?AWKOARSU;1_"NFK#>ZWH'B7QL]B-4UZP\/Z'
MJ/Y!?\$:/^#F3PE^R=\"O _[)/[:_@?QAXA\!?#*&+PU\*?C-\,].TO5-:\.
M^ HH;N73O"GC[P==7VD2:Q!X8N1!IFA^)/#EU-J<OA^>UL-2T"[O=%?5]:_T
M%J_,_P#:F_X(Z_\ !-3]LO6]5\6_'G]DSX<ZQX]UN]GU76/B-X*;7_A/\0-;
MUN>TN;,:WXG\6?"S6/!^J^-=1B2YWJ?&TWB*TGEM=/-Y:W2:?9I#U93Q-EDL
MFCP]Q)E]?&Y?0JRK8'$X*<88W!SG*<I1@JDJ<*D>:I4E%NHDHSE3G3JQY%3Q
MQN4XM8Z69Y5B:>'Q52"IXBE7BY4*ZBHI.3BI.+M"*:4&VXJ490?,Y?$_B#_@
MY]_X([Z-X1?Q+IOQ\\>>+=94R ?#_P /_ 7XPVWBZ0(]PJLE[XJ\(^&? 0$J
MPQR1[_&Z,$N[<2K%(MW':_R,_P#!6+_@K%\;/^"Z'QL^#7[*W[*WP:^(.G_"
M?3_B"\_PA^$,[Z5J/Q&^+/Q&U'2KC2-.\=^.].TB>^\/>%KOPMX>OO%5M:VM
MMXKU?PUX/\-:OXHUW7?%#V;WM[I_]9.F?\&MG_!(:PU^WUBZ^%?Q9UK3H;][
MN3PIJ?QR\>1:!=V[.[#2[BYT:]TGQ0M@BLL:26OB2VU,I&A?47D,DC_K'^R=
M_P $_P#]C/\ 8:TG4=)_93_9X^'WP>;6H([/7?$6CV=]K?CSQ!80&W>WTSQ#
M\2/%U_X@^(&OZ3:SVT=W::5K'B:]TZUOGN;^WM8KV\NYY^[!YUP5P_5>/R;
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M/\V__@GG_P KE7QY_P"SE/\ @H'_ .JW^,5?Z2%?YM__  3S_P"5RKX\_P#9
MRG_!0/\ ]5O\8J_TD* /\V__ (,Y?^4I_P"W+_V;7X__ /6B_A;7^DA7^;?_
M ,&<O_*4_P#;E_[-K\?_ /K1?PMK_20H **** "BBB@#\M?^"E__  2._9O_
M ."IO_#/=]\<_&WQN^&OBG]F+QIKWCKX3>.?@/XC\!>&O%NDZOXD_P"$7FU.
MVN[OQ_\ #7XFZ=-ILFH^"O">L)#::78W(U/0;"62[D@1[>3]0[6&2WM;:WFN
MKB^E@MX89;ZZ6U2ZO)(HU1[JY2QMK.R6XN&4S3+9V=K:K(["WMH(@D2ST4 %
M%%% !1110!^3?_!3S_@C?^RY_P %6[KX":W\>/&7QX^%_C;]F[6_$^M_##XB
M_L[>-O"W@3QOI[^+)/"]WJ-G>ZGXJ\ _$"SFM[/5O!OAO7="O+/3K#7/#^KV
M$MQH^KV<6IZM!??J[:PR6]K;6\UU<7TL%O##+?72VJ75Y)%&J/=7*6-M9V2W
M%PRF:9;.SM;59'86]M!$$B6>B@ KS'XS_#G4?B]\*_'7PQTKXI_$[X)WOCCP
M_=^'5^*?P8U'PKHWQ4\&6^H;(K[4_ NM^,_"'CO0-"\02V/VFQM->E\+W^IZ
M)]K?5?#UQI/B&TTO6=/].HH _-K_ ()D_P#!*G]E/_@D[\'?$OP>_9@L_'&I
MIXY\4MXO^(/Q'^*>O:1XF^)?CO5;=)[308-?U3P[X;\'>&[?2/">E7$FD^'-
M&\.^%-"TZTAEOM3N[>^\1:UKVM:I^DM%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 5^>7_!2?_@G'\/?^"H'P*M_V;OC)\<OV
MCOA/\'[KQ!8>(O&WA?\ 9\\3?#/PH/BC<:%?:?J_A;3/B%?^/OA-\3;[4O#_
M (5U_3;7Q+I&@Z//H6F3^(X-/UK7+?6+[0/#4VB_H;10!XS^SQ^S_P#";]E;
MX(_#3]G;X%^%+?P1\)?A'X6L?"'@CPU;W-Y?M8:59F2:2>]U+49[K4M6U?5+
M^XO-7UO6=2NKG4=8UB_OM3O[B>[NYI6]FHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH _E)_X/'O^41>B_\ 9W'P8_\
M42^*]?;G_!LY_P H._V#_P#L6_C/_P"M*?&:OB/_ (/'O^41>B_]G<?!C_U$
MOBO7VY_P;.?\H._V#_\ L6_C/_ZTI\9J /W:HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH _S;_P#@GG_RN5?'G_LY3_@H'_ZK?XQ5_I(5_FW_
M /!//_E<J^//_9RG_!0/_P!5O\8J_P!)"@#_ #;_ /@SE_Y2G_MR_P#9M?C_
M /\ 6B_A;7^DA7^;?_P9R_\ *4_]N7_LVOQ__P"M%_"VO])"@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "O\ -N_X/.?^4CW[$7_9M6B?^KW\?5_I(U_FW?\ !YS_ ,I'OV(O^S:M
M$_\ 5[^/J /])&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#3%?^!1_^1\OS[L/]0.#/^B>R_\ \ J?_+#\M?\ AT?^S?\ ]#M\;O\ PI/
M?_SMJ/\ AT?^S?\ ]#M\;O\ PI/ ?_SMJ_4JBC_6;/O^AIBO_ H__(^7Y]V'
M^H'!G_1/9?\ ^ 5/_EA^6O\ PZ/_ &;_ /H=OC=_X4G@/_YVU'_#H_\ 9O\
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M_P#SMJ_4JBC_ %FS[_H:8K_P*/\ \CY?GW8?Z@<&?]$]E_\ X!4_^6'Y:_\
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M=M1_PZ/_ &;_ /H=OC=_X4G@/_YVU?J511_K-GW_ $-,5_X%'_Y'R_/NP_U
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M)X#_ /G;5^I5%'^LV??]#3%?^!1_^1\OS[L/]0.#/^B>R_\ \ J?_+#\M?\
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MM1_PZ/\ V;_^AV^-W_A2> __ )VU?J511_K-GW_0TQ7_ (%'_P"1\OS[L/\
M4#@S_HGLO_\  *G_ ,L/RU_X='_LW_\ 0[?&[_PI/ ?_ ,[:C_AT?^S?_P!#
MM\;O_"D\!_\ SMJ_4JBC_6;/O^AIBO\ P*/_ ,CY?GW8?Z@<&?\ 1/9?_P"
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MQU7]3U?RP_\ !X7_ ,H?KC_LZ#X)?^D/CJ@#ZL_X-?\ _E!=^PM_UY_M$_\
MK6GQYK]\J_ W_@U__P"4%W["W_7G^T3_ .M:?'FOWRH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "O\VWPE_P KKMW_ -G+>-?_ %CS7J_T
MDJ_S;?"7_*Z[=_\ 9RWC7_UCS7J /])*BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** /Y2?^#Q[_ )1%Z+_V=Q\&/_42^*]?;G_!LY_R@[_8/_[%OXS_
M /K2GQFKXC_X/'O^41>B_P#9W'P8_P#42^*]?;G_  ;.?\H._P!@_P#[%OXS
M_P#K2GQFH _=JBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_S;O\ @\Y_Y2/?
ML1?]FU:)_P"KW\?5_I(U_FW?\'G/_*1[]B+_ +-JT3_U>_CZ@#_21HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@#^7G_@[Y_P"4./BG_LXCX%_^G+7J]\_X-:/^4%W[%7_7Y^TM_P"M:?'2
MO _^#OG_ )0X^*?^SB/@7_Z<M>KWS_@UH_Y07?L5?]?G[2W_ *UI\=* /Z"J
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /\V_]E'_ )77O%/_
M &<I^V;_ .L=?'2O])"O\V_]E'_E=>\4_P#9RG[9O_K'7QTK_20H **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH *_EA_X/"_\ E#]<?]G0?!+_ -(?
M'5?U/5_+#_P>%_\ *'ZX_P"SH/@E_P"D/CJ@#ZL_X-?_ /E!=^PM_P!>?[1/
M_K6GQYK]\J_ W_@U_P#^4%W["W_7G^T3_P"M:?'FOWRH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "O\VWPE_RNNW?_ &<MXU_]8\UZO])*
MO\VWPE_RNNW?_9RWC7_UCS7J /\ 22HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#^7G_@[Y_Y0X^*?^SB/@7_Z<M>KWS_@UH_Y07?L5?\ 7Y^TM_ZUI\=*
M\#_X.^?^4./BG_LXCX%_^G+7J]\_X-:/^4%W[%7_ %^?M+?^M:?'2@#^@JBB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M HHHH **** "BBB@ HHHH **** "O\VWPE_RNNW?_9RWC7_UCS7J_P!)*O\
M-M\)?\KKMW_V<MXU_P#6/->H _TDJ*** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "O\ -N_X/.?^4CW[$7_9M6B?
M^KW\?5_I(U_FW?\ !YS_ ,I'OV(O^S:M$_\ 5[^/J /])&BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /Y>
M?^#OG_E#CXI_[.(^!?\ Z<M>KWS_ (-:/^4%W[%7_7Y^TM_ZUI\=*\#_ .#O
MG_E#CXI_[.(^!?\ Z<M>KWS_ (-:/^4%W[%7_7Y^TM_ZUI\=* /Z"J*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** /\V_\ 91_Y77O%/_9RG[9O
M_K'7QTK_ $D*_P V_P#91_Y77O%/_9RG[9O_ *QU\=*_TD* "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "OY8?^#PO_E#]<?]G0?!+_TA\=5_4]7\
ML/\ P>%_\H?KC_LZ#X)?^D/CJ@#ZL_X-?_\ E!=^PM_UY_M$_P#K6GQYK]\J
M_ W_ (-?_P#E!=^PM_UY_M$_^M:?'FOWRH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "O\ -M\)?\KKMW_V<MXU_P#6/->K_22K_-M\)?\
M*Z[=_P#9RWC7_P!8\UZ@#_22HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_AJ'_@]>_P"A9_:5_P#$0?V._P#YR=?Z2-% '^;=_P -0_\ !Z]_T+/[2O\
MXB#^QW_\Y.C_ (:A_P"#U[_H6?VE?_$0?V.__G)U_I(T4 ?YMW_#4/\ P>O?
M]"S^TK_XB#^QW_\ .3H_X:A_X/7O^A9_:5_\1!_8[_\ G)U_I(T4 ?YMW_#4
M/_!Z]_T+/[2O_B(/['?_ ,Y.C_AJ'_@]>_Z%G]I7_P 1!_8[_P#G)U_I(T4
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M% '^;=_PU#_P>O?]"S^TK_XB#^QW_P#.3H_X:A_X/7O^A9_:5_\ $0?V._\
MYR=?Z2-% '^;=_PU#_P>O?\ 0L_M*_\ B(/['?\ \Y.C_AJ'_@]>_P"A9_:5
M_P#$0?V._P#YR=?Z2-% '^;=_P -0_\ !Z]_T+/[2O\ XB#^QW_\Y.C_ (:A
M_P"#U[_H6?VE?_$0?V.__G)U_I(T4 ?YMW_#4/\ P>O?]"S^TK_XB#^QW_\
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M3H_X:A_X/7O^A9_:5_\ $0?V._\ YR=?Z2-% '^;=_PU#_P>O?\ 0L_M*_\
MB(/['?\ \Y.C_AJ'_@]>_P"A9_:5_P#$0?V._P#YR=?Z2-% '^;=_P -0_\
M!Z]_T+/[2O\ XB#^QW_\Y.C_ (:A_P"#U[_H6?VE?_$0?V.__G)U_I(T4 ?Y
MMW_#4/\ P>O?]"S^TK_XB#^QW_\ .3H_X:A_X/7O^A9_:5_\1!_8[_\ G)U_
MI(T4 ?YMW_#4/_!Z]_T+/[2O_B(/['?_ ,Y.C_AJ'_@]>_Z%G]I7_P 1!_8[
M_P#G)U_I(T4 ?YMW_#4/_!Z]_P!"S^TK_P"(@_L=_P#SDZ/^&H?^#U[_ *%G
M]I7_ ,1!_8[_ /G)U_I(T4 ?YMW_  U#_P 'KW_0L_M*_P#B(/['?_SDZ/\
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MX/7O^A9_:5_\1!_8[_\ G)T?\-0_\'KW_0L_M*_^(@_L=_\ SDZ_TD:* /\
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M]CO_ .<G1_PU#_P>O?\ 0L_M*_\ B(/['?\ \Y.O])&B@#_-N_X:A_X/7O\
MH6?VE?\ Q$']CO\ ^<G1_P -0_\ !Z]_T+/[2O\ XB#^QW_\Y.O])&B@#_-N
M_P"&H?\ @]>_Z%G]I7_Q$']CO_YR='_#4/\ P>O?]"S^TK_XB#^QW_\ .3K_
M $D:* /\V[_AJ'_@]>_Z%G]I7_Q$']CO_P"<G1_PU#_P>O?]"S^TK_XB#^QW
M_P#.3K_21HH _P V[_AJ'_@]>_Z%G]I7_P 1!_8[_P#G)T?\-0_\'KW_ $+/
M[2O_ (B#^QW_ /.3K_21HH _S;O^&H?^#U[_ *%G]I7_ ,1!_8[_ /G)T?\
M#4/_  >O?]"S^TK_ .(@_L=__.3K_21HH _S;O\ AJ'_ (/7O^A9_:5_\1!_
M8[_^<G1_PU#_ ,'KW_0L_M*_^(@_L=__ #DZ_P!)&B@#_-N_X:A_X/7O^A9_
M:5_\1!_8[_\ G)T?\-0_\'KW_0L_M*_^(@_L=_\ SDZ_TD:* /\ -N_X:A_X
M/7O^A9_:5_\ $0?V._\ YR='_#4/_!Z]_P!"S^TK_P"(@_L=_P#SDZ_TD:*
M/\V[_AJ'_@]>_P"A9_:5_P#$0?V._P#YR='_  U#_P 'KW_0L_M*_P#B(/['
M?_SDZ_TD:* /\V[_ (:A_P"#U[_H6?VE?_$0?V.__G)T?\-0_P#!Z]_T+/[2
MO_B(/['?_P Y.O\ 21HH _S;O^&H?^#U[_H6?VE?_$0?V.__ )R='_#4/_!Z
M]_T+/[2O_B(/['?_ ,Y.O])&B@#_ #;O^&H?^#U[_H6?VE?_ !$']CO_ .<G
M1_PU#_P>O?\ 0L_M*_\ B(/['?\ \Y.O])&B@#_-N_X:A_X/7O\ H6?VE?\
MQ$']CO\ ^<G1_P -0_\ !Z]_T+/[2O\ XB#^QW_\Y.O])&B@#_-N_P"&H?\
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M3H_X:A_X/7O^A9_:5_\ $0?V._\ YR=?Z2-% '^;=_PU#_P>O?\ 0L_M*_\
MB(/['?\ \Y.C_AJ'_@]>_P"A9_:5_P#$0?V._P#YR=?Z2-% '^;=_P -0_\
M!Z]_T+/[2O\ XB#^QW_\Y.C_ (:A_P"#U[_H6?VE?_$0?V.__G)U_I(T4 ?Y
MMW_#4/\ P>O?]"S^TK_XB#^QW_\ .3H_X:A_X/7O^A9_:5_\1!_8[_\ G)U_
MI(T4 ?YMW_#4/_!Z]_T+/[2O_B(/['?_ ,Y.C_AJ'_@]>_Z%G]I7_P 1!_8[
M_P#G)U_I(T4 ?YMW_#4/_!Z]_P!"S^TK_P"(@_L=_P#SDZ/^&H?^#U[_ *%G
M]I7_ ,1!_8[_ /G)U_I(T4 ?YMW_  U#_P 'KW_0L_M*_P#B(/['?_SDZ/\
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M_"7B76])-I'X*2QL!>_;M,MK+4K>TO(/TA_X:A_X/7O^A9_:5_\ $0?V._\
MYR=?Z2-% '^;=_PU#_P>O?\ 0L_M*_\ B(/['?\ \Y.C_AJ'_@]>_P"A9_:5
M_P#$0?V._P#YR=?Z2-% '^;=_P -0_\ !Z]_T+/[2O\ XB#^QW_\Y.C_ (:A
M_P"#U[_H6?VE?_$0?V.__G)U_I(T4 ?YMW_#4/\ P>O?]"S^TK_XB#^QW_\
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M3H_X:A_X/7O^A9_:5_\ $0?V._\ YR=?Z2-% '^;=_PU#_P>O?\ 0L_M*_\
MB(/['?\ \Y.C_AJ'_@]>_P"A9_:5_P#$0?V._P#YR=?Z2-% '^;=_P -0_\
M!Z]_T+/[2O\ XB#^QW_\Y.C_ (:A_P"#U[_H6?VE?_$0?V.__G)U_I(T4 ?Y
MMW_#4/\ P>O?]"S^TK_XB#^QW_\ .3H_X:A_X/7O^A9_:5_\1!_8[_\ G)U_
MI(T4 ?YMW_#4/_!Z]_T+/[2O_B(/['?_ ,Y.C_AJ'_@]>_Z%G]I7_P 1!_8[
M_P#G)U_I(T4 ?YMW_#4/_!Z]_P!"S^TK_P"(@_L=_P#SDZ/^&H?^#U[_ *%G
M]I7_ ,1!_8[_ /G)U_I(T4 ?YMW_  U#_P 'KW_0L_M*_P#B(/['?_SDZ/\
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M1_PU#_P>O?\ 0L_M*_\ B(/['?\ \Y.O])&B@#_-N_X:A_X/7O\ H6?VE?\
MQ$']CO\ ^<G1_P -0_\ !Z]_T+/[2O\ XB#^QW_\Y.O])&B@#_-N_P"&H?\
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MO?\ 0L_M*_\ B(/['?\ \Y.O])&B@#_-N_X:A_X/7O\ H6?VE?\ Q$']CO\
M^<G1_P -0_\ !Z]_T+/[2O\ XB#^QW_\Y.O])&B@#_-N_P"&H?\ @]>_Z%G]
MI7_Q$']CO_YR='_#4/\ P>O?]"S^TK_XB#^QW_\ .3K_ $D:* /\V[_AJ'_@
M]>_Z%G]I7_Q$']CO_P"<G1_PU#_P>O?]"S^TK_XB#^QW_P#.3K_21HH _P V
M[_AJ'_@]>_Z%G]I7_P 1!_8[_P#G)T?\-0_\'KW_ $+/[2O_ (B#^QW_ /.3
MK_21HH _S;O^&H?^#U[_ *%G]I7_ ,1!_8[_ /G)T?\ #4/_  >O?]"S^TK_
M .(@_L=__.3K_21HH _S;O\ AJ'_ (/7O^A9_:5_\1!_8[_^<G1_PU#_ ,'K
MW_0L_M*_^(@_L=__ #DZ_P!)&B@#_-N_X:A_X/7O^A9_:5_\1!_8[_\ G)T?
M\-0_\'KW_0L_M*_^(@_L=_\ SDZ_TD:* /\ -N_X:A_X/7O^A9_:5_\ $0?V
M._\ YR='_#4/_!Z]_P!"S^TK_P"(@_L=_P#SDZ_TD:* /\V[_AJ'_@]>_P"A
M9_:5_P#$0?V._P#YR='_  U#_P 'KW_0L_M*_P#B(/['?_SDZ_TD:* /\V[_
M (:A_P"#U[_H6?VE?_$0?V.__G)T?\-0_P#!Z]_T+/[2O_B(/['?_P Y.O\
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MM_A@/.\)7,^D_9!X*%C&'^W16R:DJ7B_ZV5% '^;=_PU#_P>O?\ 0L_M*_\
MB(/['?\ \Y.C_AJ'_@]>_P"A9_:5_P#$0?V._P#YR=?Z2-% '^;=_P -0_\
M!Z]_T+/[2O\ XB#^QW_\Y.C_ (:A_P"#U[_H6?VE?_$0?V.__G)U_I(T4 ?Y
MMW_#4/\ P>O?]"S^TK_XB#^QW_\ .3H_X:A_X/7O^A9_:5_\1!_8[_\ G)U_
MI(T4 ?YMW_#4/_!Z]_T+/[2O_B(/['?_ ,Y.C_AJ'_@]>_Z%G]I7_P 1!_8[
M_P#G)U_I(T4 ?YMW_#4/_!Z]_P!"S^TK_P"(@_L=_P#SDZ/^&H?^#U[_ *%G
M]I7_ ,1!_8[_ /G)U_I(T4 ?YMW_  U#_P 'KW_0L_M*_P#B(/['?_SDZ/\
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M%7AZTU6QT?5?[:^&WP^\'>(F-G:ZYJD7V)M7;3I_M6^YM)I(;=XNW_9HN_\
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M#^QW_P#.3H_X:A_X/7O^A9_:5_\ $0?V._\ YR=?Z2-% '^;=_PU#_P>O?\
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M/7O^A9_:5_\ $0?V._\ YR=?Z2-% '^;=_PU#_P>O?\ 0L_M*_\ B(/['?\
M\Y.C_AJ'_@]>_P"A9_:5_P#$0?V._P#YR=?Z2-% '^;=_P -0_\ !Z]_T+/[
M2O\ XB#^QW_\Y.C_ (:A_P"#U[_H6?VE?_$0?V.__G)U_I(T4 ?YMW_#4/\
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=SH-I867A."SLGO+V*UT^UCLO/C7_ $IZ** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>12
<FILENAME>mnmd-20250331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-05-07T16:04:57.7343+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.mindmed.co/20250331" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:mnmd="http://www.mindmed.co/20250331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd" namespace="http://xbrl.sec.gov/ecd-sub/2024"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2024/currency-2024.xsd" namespace="http://xbrl.sec.gov/currency/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" namespace="http://fasb.org/srt/2024"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2024-01-31"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" namespace="http://fasb.org/us-gaap/2024"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" namespace="http://xbrl.sec.gov/ecd/2024"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" namespace="http://fasb.org/us-types/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2023/calculation-1.1.xsd" namespace="https://xbrl.org/2023/calculation-1.1"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.mindmed.co/20250331/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" id="StatementCondensedConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" id="StatementCondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" id="StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited">
        <link:definition>100030 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited" id="StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited">
        <link:definition>100040 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" id="StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited">
        <link:definition>100050 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mindmed.co/20250331/taxonomy/role/DisclosureNatureOfOperations" id="DisclosureNatureOfOperations">
        <link:definition>995455 - Disclosure - Nature of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" id="DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies">
        <link:definition>995465 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mindmed.co/20250331/taxonomy/role/DisclosureInvestments" id="DisclosureInvestments">
        <link:definition>995475 - Disclosure - Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureFairValueOfFinancialInstruments" id="Role_DisclosureFairValueOfFinancialInstruments">
        <link:definition>995485 - Disclosure - Fair Value of Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mindmed.co/20250331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNet1" id="DisclosureGoodwillAndIntangibleAssetsNet1">
        <link:definition>995495 - Disclosure - Goodwill and Intangible Assets, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureAccruedExpenses" id="Role_DisclosureAccruedExpenses">
        <link:definition>995505 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureShareholdersEquity" id="Role_DisclosureShareholdersEquity">
        <link:definition>995515 - Disclosure - Shareholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureWarrants" id="Role_DisclosureWarrants">
        <link:definition>995525 - Disclosure - Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensation" id="Role_DisclosureStockBasedCompensation">
        <link:definition>995535 - Disclosure - Stock-based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>995545 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacility" id="DisclosureCreditFacility">
        <link:definition>995555 - Disclosure - Credit Facility</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mindmed.co/20250331/taxonomy/role/DisclosureSegmentReporting" id="DisclosureSegmentReporting">
        <link:definition>995565 - Disclosure - SEGMENT REPORTING</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mindmed.co/20250331/taxonomy/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>995575 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>995585 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" id="DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>995595 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mindmed.co/20250331/taxonomy/role/DisclosureInvestmentsTables" id="DisclosureInvestmentsTables">
        <link:definition>995605 - Disclosure - Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables" id="Role_DisclosureFairValueOfFinancialInstrumentsTables">
        <link:definition>995615 - Disclosure - Fair Value of Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mindmed.co/20250331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetTables" id="DisclosureGoodwillAndIntangibleAssetsNetTables">
        <link:definition>995625 - Disclosure - Goodwill and Intangible Assets, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureAccruedExpensesTables" id="Role_DisclosureAccruedExpensesTables">
        <link:definition>995635 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureShareholdersEquityTables" id="Role_DisclosureShareholdersEquityTables">
        <link:definition>995645 - Disclosure - Shareholders&#8217; Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureWarrantsTables" id="Role_DisclosureWarrantsTables">
        <link:definition>995655 - Disclosure - Warrants (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationTables" id="Role_DisclosureStockBasedCompensationTables">
        <link:definition>995665 - Disclosure - Stock-based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacilityTables" id="DisclosureCreditFacilityTables">
        <link:definition>995675 - Disclosure - Credit Facility (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mindmed.co/20250331/taxonomy/role/DisclosureSegmentInformationTables" id="DisclosureSegmentInformationTables">
        <link:definition>995685 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mindmed.co/20250331/taxonomy/role/DisclosureDescriptionOfTheBusinessAdditionalInformationDetails" id="DisclosureDescriptionOfTheBusinessAdditionalInformationDetails">
        <link:definition>995695 - Disclosure - Description of the Business - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>995705 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails" id="DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails">
        <link:definition>995715 - Disclosure - Basis of presentation and summary of significant accounting policies - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilut" id="DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilut">
        <link:definition>995725 - Disclosure - Basis of presentation and summary of significant accounting policies - Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share due to Anti-dilutive Effect (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mindmed.co/20250331/taxonomy/role/DisclosureInvestmentsScheduleOfAvailableforsaleInvestmentsDetails" id="DisclosureInvestmentsScheduleOfAvailableforsaleInvestmentsDetails">
        <link:definition>995735 - Disclosure - Investments - Schedule of available-for-sale investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mindmed.co/20250331/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails" id="DisclosureInvestmentsAdditionalInformationDetails">
        <link:definition>995745 - Disclosure - Investments (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mindmed.co/20250331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" id="DisclosureFairValueOfFinancialInstrumentsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
        <link:definition>995755 - Disclosure - Fair Value of Financial Instruments - Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails" id="Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails">
        <link:definition>995765 - Disclosure - Fair Value of Financial Instruments - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mindmed.co/20250331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssumptionsUsedToDetermineFairValueOf2022UsdFinancingWarrantsDetails" id="DisclosureFairValueOfFinancialInstrumentsScheduleOfAssumptionsUsedToDetermineFairValueOf2022UsdFinancingWarrantsDetails">
        <link:definition>995775 - Disclosure - Fair Value of Financial Instruments - Schedule of Assumptions used to Determine Fair Value of 2022 USD Financing Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mindmed.co/20250331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetAdditionalInformationDetails" id="DisclosureGoodwillAndIntangibleAssetsNetAdditionalInformationDetails">
        <link:definition>995785 - Disclosure - Goodwill and Intangible Assets, Net - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mindmed.co/20250331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetSummaryOfCarryingValueOfIntangibleAssetsDetails" id="DisclosureGoodwillAndIntangibleAssetsNetSummaryOfCarryingValueOfIntangibleAssetsDetails">
        <link:definition>995795 - Disclosure - Goodwill and Intangible Assets, Net - Summary of Carrying Value of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails" id="Role_DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails">
        <link:definition>995805 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails" id="Role_DisclosureShareholdersEquityAdditionalInformationDetails">
        <link:definition>995815 - Disclosure - Shareholders' Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mindmed.co/20250331/taxonomy/role/DisclosureShareholdersEquitySummaryOfSharesReservedForIssuanceDetails" id="DisclosureShareholdersEquitySummaryOfSharesReservedForIssuanceDetails">
        <link:definition>995825 - Disclosure - Shareholders' Equity - Summary of Shares Reserved For Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureWarrantsAdditionalInformationDetails" id="Role_DisclosureWarrantsAdditionalInformationDetails">
        <link:definition>995835 - Disclosure - Warrants - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mindmed.co/20250331/taxonomy/role/DisclosureWarrantsSummaryOfOutstandingLiabilityClassifiedAsWarrantsDetails" id="DisclosureWarrantsSummaryOfOutstandingLiabilityClassifiedAsWarrantsDetails">
        <link:definition>995845 - Disclosure - Warrants - Summary of Outstanding Liability Classified as Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mindmed.co/20250331/taxonomy/role/DisclosureWarrantsSummaryOfActivityOfOutstandingWarrantLiabilityDetails" id="DisclosureWarrantsSummaryOfActivityOfOutstandingWarrantLiabilityDetails">
        <link:definition>995855 - Disclosure - Warrants - Summary of Activity of Outstanding Warrant Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" id="Role_DisclosureStockBasedCompensationAdditionalInformationDetails">
        <link:definition>995865 - Disclosure - Stock-based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfFairValueAssumptionsOfOptionsDetails" id="Role_DisclosureStockBasedCompensationScheduleOfFairValueAssumptionsOfOptionsDetails">
        <link:definition>995875 - Disclosure - Stock-based compensation - Schedule of Fair Value Assumptions of Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails" id="Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails">
        <link:definition>995885 - Disclosure - Stock-based Compensation - Schedule of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mindmed.co/20250331/taxonomy/role/DisclosureStockbasedCompensationScheduleOfRestrictedShareUnitsDetails" id="DisclosureStockbasedCompensationScheduleOfRestrictedShareUnitsDetails">
        <link:definition>995895 - Disclosure - Stock-based Compensation - Schedule of Restricted Share Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" id="Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails">
        <link:definition>995905 - Disclosure - Stock-based Compensation - Summary of Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>995915 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetails" id="DisclosureCreditFacilityAdditionalInformationDetails">
        <link:definition>995925 - Disclosure - Credit Facility - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacilityScheduleOfFutureExpectedRepaymentsOfPrincipalAmountDueOnCreditFacilityDetails" id="DisclosureCreditFacilityScheduleOfFutureExpectedRepaymentsOfPrincipalAmountDueOnCreditFacilityDetails">
        <link:definition>995935 - Disclosure - Credit Facility - Schedule of Future Expected Repayments of Principal Amount Due on Credit Facility (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mindmed.co/20250331/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails" id="DisclosureSegmentInformationAdditionalInformationDetails">
        <link:definition>995945 - Disclosure - Segment Information (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mindmed.co/20250331/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalExpenseDetailsDetails" id="DisclosureSegmentInformationSummaryOfAdditionalExpenseDetailsDetails">
        <link:definition>995955 - Disclosure - Segment Information - Summary of Additional Expense Details (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mindmed.co/20250331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" id="DisclosureSubsequentEventsAdditionalInformationDetails">
        <link:definition>995965 - Disclosure - Subsequent Events (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" xlink:href="mnmd-20250331.xsd#StatementCondensedConsolidatedBalanceSheets" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" xlink:href="mnmd-20250331.xsd#StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="mnmd-20250331.xsd#StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails" xlink:href="mnmd-20250331.xsd#DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mindmed.co/20250331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetSummaryOfCarryingValueOfIntangibleAssetsDetails" xlink:href="mnmd-20250331.xsd#DisclosureGoodwillAndIntangibleAssetsNetSummaryOfCarryingValueOfIntangibleAssetsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails" xlink:href="mnmd-20250331.xsd#Role_DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacilityScheduleOfFutureExpectedRepaymentsOfPrincipalAmountDueOnCreditFacilityDetails" xlink:href="mnmd-20250331.xsd#DisclosureCreditFacilityScheduleOfFutureExpectedRepaymentsOfPrincipalAmountDueOnCreditFacilityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mindmed.co/20250331/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalExpenseDetailsDetails" xlink:href="mnmd-20250331.xsd#DisclosureSegmentInformationSummaryOfAdditionalExpenseDetailsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" xlink:href="mnmd-20250331.xsd#StatementCondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited" xlink:href="mnmd-20250331.xsd#StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="mnmd-20250331.xsd#DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilut" xlink:href="mnmd-20250331.xsd#DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilut" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mindmed.co/20250331/taxonomy/role/DisclosureInvestmentsScheduleOfAvailableforsaleInvestmentsDetails" xlink:href="mnmd-20250331.xsd#DisclosureInvestmentsScheduleOfAvailableforsaleInvestmentsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mindmed.co/20250331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="mnmd-20250331.xsd#DisclosureFairValueOfFinancialInstrumentsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails" xlink:href="mnmd-20250331.xsd#Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mindmed.co/20250331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssumptionsUsedToDetermineFairValueOf2022UsdFinancingWarrantsDetails" xlink:href="mnmd-20250331.xsd#DisclosureFairValueOfFinancialInstrumentsScheduleOfAssumptionsUsedToDetermineFairValueOf2022UsdFinancingWarrantsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mindmed.co/20250331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetAdditionalInformationDetails" xlink:href="mnmd-20250331.xsd#DisclosureGoodwillAndIntangibleAssetsNetAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails" xlink:href="mnmd-20250331.xsd#Role_DisclosureShareholdersEquityAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mindmed.co/20250331/taxonomy/role/DisclosureShareholdersEquitySummaryOfSharesReservedForIssuanceDetails" xlink:href="mnmd-20250331.xsd#DisclosureShareholdersEquitySummaryOfSharesReservedForIssuanceDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureWarrantsAdditionalInformationDetails" xlink:href="mnmd-20250331.xsd#Role_DisclosureWarrantsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mindmed.co/20250331/taxonomy/role/DisclosureWarrantsSummaryOfOutstandingLiabilityClassifiedAsWarrantsDetails" xlink:href="mnmd-20250331.xsd#DisclosureWarrantsSummaryOfOutstandingLiabilityClassifiedAsWarrantsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mindmed.co/20250331/taxonomy/role/DisclosureWarrantsSummaryOfActivityOfOutstandingWarrantLiabilityDetails" xlink:href="mnmd-20250331.xsd#DisclosureWarrantsSummaryOfActivityOfOutstandingWarrantLiabilityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:href="mnmd-20250331.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfFairValueAssumptionsOfOptionsDetails" xlink:href="mnmd-20250331.xsd#Role_DisclosureStockBasedCompensationScheduleOfFairValueAssumptionsOfOptionsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails" xlink:href="mnmd-20250331.xsd#Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mindmed.co/20250331/taxonomy/role/DisclosureStockbasedCompensationScheduleOfRestrictedShareUnitsDetails" xlink:href="mnmd-20250331.xsd#DisclosureStockbasedCompensationScheduleOfRestrictedShareUnitsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" xlink:href="mnmd-20250331.xsd#Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetails" xlink:href="mnmd-20250331.xsd#DisclosureCreditFacilityAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mindmed.co/20250331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:href="mnmd-20250331.xsd#DisclosureSubsequentEventsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd#eedm" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mindmed.co/20250331/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="mnmd-20250331.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mindmed.co/20250331/taxonomy/role/DisclosureNatureOfOperations" xlink:href="mnmd-20250331.xsd#DisclosureNatureOfOperations" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:href="mnmd-20250331.xsd#DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mindmed.co/20250331/taxonomy/role/DisclosureInvestments" xlink:href="mnmd-20250331.xsd#DisclosureInvestments" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureFairValueOfFinancialInstruments" xlink:href="mnmd-20250331.xsd#Role_DisclosureFairValueOfFinancialInstruments" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mindmed.co/20250331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNet1" xlink:href="mnmd-20250331.xsd#DisclosureGoodwillAndIntangibleAssetsNet1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureAccruedExpenses" xlink:href="mnmd-20250331.xsd#Role_DisclosureAccruedExpenses" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureShareholdersEquity" xlink:href="mnmd-20250331.xsd#Role_DisclosureShareholdersEquity" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureWarrants" xlink:href="mnmd-20250331.xsd#Role_DisclosureWarrants" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensation" xlink:href="mnmd-20250331.xsd#Role_DisclosureStockBasedCompensation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:href="mnmd-20250331.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacility" xlink:href="mnmd-20250331.xsd#DisclosureCreditFacility" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mindmed.co/20250331/taxonomy/role/DisclosureSegmentReporting" xlink:href="mnmd-20250331.xsd#DisclosureSegmentReporting" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mindmed.co/20250331/taxonomy/role/DisclosureSubsequentEvents" xlink:href="mnmd-20250331.xsd#DisclosureSubsequentEvents" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="mnmd-20250331.xsd#DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="mnmd-20250331.xsd#DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mindmed.co/20250331/taxonomy/role/DisclosureInvestmentsTables" xlink:href="mnmd-20250331.xsd#DisclosureInvestmentsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables" xlink:href="mnmd-20250331.xsd#Role_DisclosureFairValueOfFinancialInstrumentsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mindmed.co/20250331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetTables" xlink:href="mnmd-20250331.xsd#DisclosureGoodwillAndIntangibleAssetsNetTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureAccruedExpensesTables" xlink:href="mnmd-20250331.xsd#Role_DisclosureAccruedExpensesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureShareholdersEquityTables" xlink:href="mnmd-20250331.xsd#Role_DisclosureShareholdersEquityTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureWarrantsTables" xlink:href="mnmd-20250331.xsd#Role_DisclosureWarrantsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationTables" xlink:href="mnmd-20250331.xsd#Role_DisclosureStockBasedCompensationTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacilityTables" xlink:href="mnmd-20250331.xsd#DisclosureCreditFacilityTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mindmed.co/20250331/taxonomy/role/DisclosureSegmentInformationTables" xlink:href="mnmd-20250331.xsd#DisclosureSegmentInformationTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mindmed.co/20250331/taxonomy/role/DisclosureDescriptionOfTheBusinessAdditionalInformationDetails" xlink:href="mnmd-20250331.xsd#DisclosureDescriptionOfTheBusinessAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mindmed.co/20250331/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails" xlink:href="mnmd-20250331.xsd#DisclosureInvestmentsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="mnmd-20250331.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mindmed.co/20250331/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails" xlink:href="mnmd-20250331.xsd#DisclosureSegmentInformationAdditionalInformationDetails" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_WeightedAverageNumberOfDilutedCommonSharesOutstanding" xlink:label="mnmd_WeightedAverageNumberOfDilutedCommonSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_UnpaidIssuanceCostsForOfferingAndPrivatePlacement" xlink:label="mnmd_UnpaidIssuanceCostsForOfferingAndPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_OfferingPrice" xlink:label="mnmd_OfferingPrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_TwoThousandTwentyFourAtTheMarketOfferingProgramMember" xlink:label="mnmd_TwoThousandTwentyFourAtTheMarketOfferingProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedInPeriod" xlink:label="mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="us-gaap_BusinessCombinationsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_ShareBasedPaymentArrangementDirectorsDeferredShareUnitPlanActivityTableTextBlock" xlink:label="mnmd_ShareBasedPaymentArrangementDirectorsDeferredShareUnitPlanActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_WeightedAverageFairValueOfSharesPurchasedUponExerciseOfWarrants" xlink:label="mnmd_WeightedAverageFairValueOfSharesPurchasedUponExerciseOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_DebtInstrumentExtendedMaturityDate" xlink:label="mnmd_DebtInstrumentExtendedMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_K2HealthventuresLlcMember" xlink:label="mnmd_K2HealthventuresLlcMember"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_SubordinateVotingSharesMember" xlink:label="mnmd_SubordinateVotingSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_AtTheMarketOfferingProgramMember" xlink:label="mnmd_AtTheMarketOfferingProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_DebtInstrumentConvertibleConvertedIntoCommonShares" xlink:label="mnmd_DebtInstrumentConvertibleConvertedIntoCommonShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_DebtRepaymentsOfPrincipalInYearTwoBeforeUnamortizedDebtIssuanceCost" xlink:label="mnmd_DebtRepaymentsOfPrincipalInYearTwoBeforeUnamortizedDebtIssuanceCost"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_UnpaidIssuanceCostsForCommonShares" xlink:label="mnmd_UnpaidIssuanceCostsForCommonShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_ProceedsFromAtTheMarketOfferingProgramNetOfIssuanceCosts" xlink:label="mnmd_ProceedsFromAtTheMarketOfferingProgramNetOfIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain" xlink:label="currency_AllCurrenciesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_UnderwrittenOfferingMember" xlink:label="mnmd_UnderwrittenOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_CAD" xlink:label="currency_CAD"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_OptionsIssuedAndOutstandingUnderStockOptionPlanMember" xlink:label="mnmd_OptionsIssuedAndOutstandingUnderStockOptionPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockTypeOfStockConverted" xlink:label="us-gaap_ConversionOfStockTypeOfStockConverted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_DirectorsDeferredShareUnitsLiabilityMember" xlink:label="mnmd_DirectorsDeferredShareUnitsLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_DebtRepaymentsOfPrincipalInYearThreeBeforeUnamortizedDebtIssuanceCosts" xlink:label="mnmd_DebtRepaymentsOfPrincipalInYearThreeBeforeUnamortizedDebtIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="mnmd_StockIssuedDuringPeriodSharesWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue" xlink:label="mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_GrossProceedsFromIssuanceOfCommonShares" xlink:label="mnmd_GrossProceedsFromIssuanceOfCommonShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_BoughtDealFinancingMember" xlink:label="mnmd_BoughtDealFinancingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_StockIssuedDuringPeriodSharesSettlementOfRestrictedStockUnitAwards" xlink:label="mnmd_StockIssuedDuringPeriodSharesSettlementOfRestrictedStockUnitAwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember" xlink:label="mnmd_TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateTerms" xlink:label="us-gaap_DebtInstrumentInterestRateTerms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_PercentageOfFinalPaymentFee" xlink:label="mnmd_PercentageOfFinalPaymentFee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermLineOfCredit" xlink:label="us-gaap_LongTermLineOfCredit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_AggregateNumberOfCommonSharesOwnedByHolderPercentage" xlink:label="mnmd_AggregateNumberOfCommonSharesOwnedByHolderPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" xlink:label="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_SubordinateVotingMember" xlink:label="mnmd_SubordinateVotingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_UnderwrittenPublicOfferingMember" xlink:label="mnmd_UnderwrittenPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_UnvestedRestrictedStockUnitsRsusMember" xlink:label="mnmd_UnvestedRestrictedStockUnitsRsusMember"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_StockIssuedDuringPeriodSharesUponSettlementOfRestrictedStockUnitAwardsNetOfSharesWithheldForTax" xlink:label="mnmd_StockIssuedDuringPeriodSharesUponSettlementOfRestrictedStockUnitAwardsNetOfSharesWithheldForTax"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_ExerciseOfWarrantShares" xlink:label="mnmd_ExerciseOfWarrantShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_WeightedAverageNumberOfCommonSharesOutstandingBasic" xlink:label="mnmd_WeightedAverageNumberOfCommonSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_IndicationOfImpairmentOfGoodwillAndLongLivedAssets" xlink:label="mnmd_IndicationOfImpairmentOfGoodwillAndLongLivedAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_SharesAvailableForGrantUnderStockOptionPlanMember" xlink:label="mnmd_SharesAvailableForGrantUnderStockOptionPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" xlink:label="mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_OtherNonCashAdjustments" xlink:label="mnmd_OtherNonCashAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_CadFinancingAndCompensationWarrantsMember" xlink:label="mnmd_CadFinancingAndCompensationWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_DebtRepaymentsOfPrincipalRemainderOfFiscalYearBeforeUnamortizedDebtIssuanceCost" xlink:label="mnmd_DebtRepaymentsOfPrincipalRemainderOfFiscalYearBeforeUnamortizedDebtIssuanceCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachUnit" xlink:label="mnmd_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachUnit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_WeightedAverageNumberOfDilutedPreFundedWarrantsOutstanding" xlink:label="mnmd_WeightedAverageNumberOfDilutedPreFundedWarrantsOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriod" xlink:label="mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_OtherLiabilitiesLongTerm" xlink:label="mnmd_OtherLiabilitiesLongTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_AccruedOtherResearchAndDevelopmentCostsCurrent" xlink:label="mnmd_AccruedOtherResearchAndDevelopmentCostsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WorkersCompensationLiabilityCurrent" xlink:label="us-gaap_WorkersCompensationLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" xlink:label="us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorizedUnlimited" xlink:label="us-gaap_CommonStockSharesAuthorizedUnlimited"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" xlink:label="mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_MultipleVotingMember" xlink:label="mnmd_MultipleVotingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="us-gaap_BusinessAcquisitionSharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_ScheduleOfWarrantLiabilityTableTextBlock" xlink:label="mnmd_ScheduleOfWarrantLiabilityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_StockIssuedDuringPeriodValueUponSettlementOfRestrictedStockUnitAwardsNetOfSharesWithheldForTax" xlink:label="mnmd_StockIssuedDuringPeriodValueUponSettlementOfRestrictedStockUnitAwardsNetOfSharesWithheldForTax"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_LoanExtendedTerm" xlink:label="mnmd_LoanExtendedTerm"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_FirstTrancheTermLoanMember" xlink:label="mnmd_FirstTrancheTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_LongTermInvestmentsMember" xlink:label="mnmd_LongTermInvestmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_SaleOfEquityRemainingOfferingAmount" xlink:label="mnmd_SaleOfEquityRemainingOfferingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="us-gaap_LineOfCreditFacilityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_WarrantsDisclosureTextBlock" xlink:label="mnmd_WarrantsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_StockBasedCompensationReversal" xlink:label="mnmd_StockBasedCompensationReversal"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_PercentageOfOutstandingSharesToBeHeldToVote" xlink:label="mnmd_PercentageOfOutstandingSharesToBeHeldToVote"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_FinancingWarrantsMember" xlink:label="mnmd_FinancingWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_ProceedsFromExerciseOfOptionsInPrepaidAndOtherCurrentAssets" xlink:label="mnmd_ProceedsFromExerciseOfOptionsInPrepaidAndOtherCurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_WarrantsPolicyTextBlock" xlink:label="mnmd_WarrantsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitment" xlink:label="us-gaap_OtherCommitment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_SaleOfEquityAggregatePublicOfferingAmount" xlink:label="mnmd_SaleOfEquityAggregatePublicOfferingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrimeRateMember" xlink:label="us-gaap_PrimeRateMember"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="mnmd_StockIssuedDuringPeriodValueWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_USD" xlink:label="currency_USD"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_LoanMember" xlink:label="mnmd_LoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockConversionFeatures" xlink:label="us-gaap_CommonStockConversionFeatures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_ResearchAndDevelopmentInternalExpense" xlink:label="mnmd_ResearchAndDevelopmentInternalExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_SecondMilestoneBasedTrancheTermLoanMember" xlink:label="mnmd_SecondMilestoneBasedTrancheTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_GeneralAndAdministrativeInternalExpense" xlink:label="mnmd_GeneralAndAdministrativeInternalExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_DebtRepaymentsOfPrincipalInYearFourBeforeUnamortizedDebtIssuanceCosts" xlink:label="mnmd_DebtRepaymentsOfPrincipalInYearFourBeforeUnamortizedDebtIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_FinancingWarrantsLiability" xlink:label="mnmd_FinancingWarrantsLiability"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_WarrantsExercised" xlink:label="mnmd_WarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_PercentageOfGrossProceedsSaleOfCommonSharesPayableAsSalesAgentsCommissionRate" xlink:label="mnmd_PercentageOfGrossProceedsSaleOfCommonSharesPayableAsSalesAgentsCommissionRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="us-gaap_DebtInstrumentFeeAmount"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_WeightedAverageNumberOfPreFundedWarrantsOutstandingBasic" xlink:label="mnmd_WeightedAverageNumberOfPreFundedWarrantsOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_ResearchAndDevelopmentExternalExpense" xlink:label="mnmd_ResearchAndDevelopmentExternalExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate201613Member" xlink:label="us-gaap_AccountingStandardsUpdate201613Member"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_UsdFinancingWarrantsMember" xlink:label="mnmd_UsdFinancingWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_CommonStockNumberOfVotesPerShare" xlink:label="mnmd_CommonStockNumberOfVotesPerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_GeneralAndAdministrativeExternalExpense" xlink:label="mnmd_GeneralAndAdministrativeExternalExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_ReclassOfDeferredFinancingFeesToAdditionalPaidInCapital" xlink:label="mnmd_ReclassOfDeferredFinancingFeesToAdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_VestedAndUnissuedRestrictedStockUnitsRsusMember" xlink:label="mnmd_VestedAndUnissuedRestrictedStockUnitsRsusMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_SummaryOfSharesReservedForIssuanceTableTextBlock" xlink:label="mnmd_SummaryOfSharesReservedForIssuanceTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_RestructuredAgreementMember" xlink:label="mnmd_RestructuredAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_CommonShareAndWarrantPublicOfferingMember" xlink:label="mnmd_CommonShareAndWarrantPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_LoanMaturityTerm" xlink:label="mnmd_LoanMaturityTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_CovenantShallBeWaivedDuringMarketCapitalizationExceeds" xlink:label="mnmd_CovenantShallBeWaivedDuringMarketCapitalizationExceeds"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriodWeightedAverageGrantDateFairValue" xlink:label="mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:label="us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="dei_EntityIncorporationDateOfIncorporation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockNoParValue" xlink:label="us-gaap_CommonStockNoParValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_WarrantsIssued" xlink:label="mnmd_WarrantsIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="us-gaap_LineOfCreditFacilityTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_ShareIssuanceCosts" xlink:label="mnmd_ShareIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_DebtRepaymentsOfPrincipalInNextTwelveMonthsBeforeUnamortizedDebtIssuanceCost" xlink:label="mnmd_DebtRepaymentsOfPrincipalInNextTwelveMonthsBeforeUnamortizedDebtIssuanceCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_DirectorsDeferredShareUnitPlanMember" xlink:label="mnmd_DirectorsDeferredShareUnitPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_AmendmentTermLoansMember" xlink:label="mnmd_AmendmentTermLoansMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_CommonStockConvertibleConversionRatio" xlink:label="mnmd_CommonStockConvertibleConversionRatio"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_CompensationWarrantsMember" xlink:label="mnmd_CompensationWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_CommonShareAndWarrantPublicOfferingExpireDate" xlink:label="mnmd_CommonShareAndWarrantPublicOfferingExpireDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_CommonStockClassDMember" xlink:label="mnmd_CommonStockClassDMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_MindMedStockOptionPlanMember" xlink:label="mnmd_MindMedStockOptionPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_WarrantsExpired" xlink:label="mnmd_WarrantsExpired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_PreFundedWarrantsMember" xlink:label="mnmd_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="us-gaap_DevelopedTechnologyRightsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_ChangeInFairValueOnDirectorsDeferredShareUnits" xlink:label="mnmd_ChangeInFairValueOnDirectorsDeferredShareUnits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_PercentageOfIncreaseOrDecreaseOfOwnershipByPreFundedWarrantsHolder" xlink:label="mnmd_PercentageOfIncreaseOrDecreaseOfOwnershipByPreFundedWarrantsHolder"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingValuationTechniqueExtensibleList" xlink:label="us-gaap_WarrantsAndRightsOutstandingValuationTechniqueExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="us-gaap_ShortTermInvestmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_SubsequentTrancheTermLoanMember" xlink:label="mnmd_SubsequentTrancheTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="us-gaap_GoodwillAcquiredDuringPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy" xlink:label="us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterestAndDividend" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_ConversionSharesMember" xlink:label="mnmd_ConversionSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_NatureOfOperationsAbstract" xlink:label="mnmd_NatureOfOperationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_BusinessCombinationMaximumMeasurementPeriod" xlink:label="mnmd_BusinessCombinationMaximumMeasurementPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_TermLoanMember" xlink:label="mnmd_TermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_TwoThousandTwentyTwoAtTheMarketOfferingProgramMember" xlink:label="mnmd_TwoThousandTwentyTwoAtTheMarketOfferingProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_AccruedClinicalAndManufacturingCosts" xlink:label="mnmd_AccruedClinicalAndManufacturingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_AdditionalTrancheTermLoanMember" xlink:label="mnmd_AdditionalTrancheTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_ProceedsFromOfferingAndPrivatePlacement" xlink:label="mnmd_ProceedsFromOfferingAndPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockConversionBasis" xlink:label="us-gaap_CommonStockConversionBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate201912Member" xlink:label="us-gaap_AccountingStandardsUpdate201912Member"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_CommonStockSharesIssuedAndOutstanding" xlink:label="mnmd_CommonStockSharesIssuedAndOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedInPeriodWeightedAverageGrantDateFairValue" xlink:label="mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_WarrantExercise" xlink:label="mnmd_WarrantExercise"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_LoanAndSecurityAgreementMember" xlink:label="mnmd_LoanAndSecurityAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CurrencyAxis" xlink:label="srt_CurrencyAxis"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_WeightedAverageNumberOfDilutedCommonSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Diluted Common Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_WeightedAverageNumberOfDilutedCommonSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted average number of diluted common shares outstanding.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_WeightedAverageNumberOfDilutedCommonSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares used in computing net loss per share attributable to common shareholders, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_UnpaidIssuanceCostsForOfferingAndPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unpaid issuance costs for the offering and private placement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_UnpaidIssuanceCostsForOfferingAndPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unpaid Issuance Costs For Offering And Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_UnpaidIssuanceCostsForOfferingAndPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unpaid issuance costs for the Offering and Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_OfferingPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Offering price.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_OfferingPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Offering Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_OfferingPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_TwoThousandTwentyFourAtTheMarketOfferingProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024 at the Market Offering Program</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_TwoThousandTwentyFourAtTheMarketOfferingProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Four At The Market Offering Program [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_TwoThousandTwentyFourAtTheMarketOfferingProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand Twenty Four At The Market Offering Program.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of shares, vested and unissued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested and Unissued in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award, equity instruments other than options, vested and unissued in period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Outstanding Liability Classified as Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combinations Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Combinations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted, Adjustment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Adjustment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Incremental shares from 2022 USD Financing Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity, Reverse Stock Split</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_ShareBasedPaymentArrangementDirectorsDeferredShareUnitPlanActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Directors' Deferred Share Unit Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_ShareBasedPaymentArrangementDirectorsDeferredShareUnitPlanActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Directors' Deferred Share Unit Plan, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_ShareBasedPaymentArrangementDirectorsDeferredShareUnitPlanActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based payment arrangement, directors' deferred share unit plan, activity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of assets transfers into Level 3</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_WeightedAverageFairValueOfSharesPurchasedUponExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted average fair value of shares purchased upon exercise of warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_WeightedAverageFairValueOfSharesPurchasedUponExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Fair Value Of Shares Purchased Upon Exercise Of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_WeightedAverageFairValueOfSharesPurchasedUponExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average fair value of shares purchased upon exercise of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock, Class of Stock [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_DebtInstrumentExtendedMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Extended Maturity Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_DebtInstrumentExtendedMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument extended maturity date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_DebtInstrumentExtendedMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument extended maturity date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets by Major Class</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lender Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Investing and Financing Items [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental Noncash Disclosures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated ESPP awards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shareholders&#8217; Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title and Position [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_K2HealthventuresLlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">K2 HealthVentures LLC.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_K2HealthventuresLlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">K2 HealthVentures LLC [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_K2HealthventuresLlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">K2HV</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_SubordinateVotingSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Subordinate voting shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_SubordinateVotingSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subordinate Voting Shares [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_SubordinateVotingSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subordinate Voting Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Warrant or Right</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_AtTheMarketOfferingProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">At The Market Offering Program [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_AtTheMarketOfferingProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">At the market offering program.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_AtTheMarketOfferingProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">At-the-market Offering Program</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total principal repayments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_DebtInstrumentConvertibleConvertedIntoCommonShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Converted into common shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_DebtInstrumentConvertibleConvertedIntoCommonShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">DebtInstrument Convertible Converted Into Common Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_DebtInstrumentConvertibleConvertedIntoCommonShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debtinstrument convertible converted into common shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Intangible assets, useful life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets, Useful Lives (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible assets (acquired technology), Useful life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_DebtRepaymentsOfPrincipalInYearTwoBeforeUnamortizedDebtIssuanceCost_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt repayments of principal in year two before unamortized debt issuance cost.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_DebtRepaymentsOfPrincipalInYearTwoBeforeUnamortizedDebtIssuanceCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Repayments of Principal in Year Two Before Unamortized Debt Issuance Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_DebtRepaymentsOfPrincipalInYearTwoBeforeUnamortizedDebtIssuanceCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_UnpaidIssuanceCostsForCommonShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unpaid issuance costs for common shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_UnpaidIssuanceCostsForCommonShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unpaid Issuance Costs for Common Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_UnpaidIssuanceCostsForCommonShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unpaid issuance costs for common shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of options, forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Shares, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free rate, minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Prepaid Expense and Other Assets, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_ProceedsFromAtTheMarketOfferingProgramNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the at-the-market offering program, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_ProceedsFromAtTheMarketOfferingProgramNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from the at-the-market offering program, net of issuance costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_ProceedsFromAtTheMarketOfferingProgramNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From At-The-Market Offering Program, Net of Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common shares under employee share purchase plan ("ESPP") Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="currency_AllCurrenciesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">All Currencies [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Warrant Or Right [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_UnderwrittenOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Underwritten offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_UnderwrittenOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Underwritten Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_UnderwrittenOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwritten Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="currency_CAD_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">CAD</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="currency_CAD_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Canada, Dollars</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_OptionsIssuedAndOutstandingUnderStockOptionPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Issued and Outstanding Under Stock Option Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_OptionsIssuedAndOutstandingUnderStockOptionPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Options Issued and Outstanding Under Stock Option Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_OptionsIssuedAndOutstandingUnderStockOptionPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Options issued and outstanding under stock option plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits, interest charges or penalties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockTypeOfStockConverted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion of Stock, Type of Stock Converted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockTypeOfStockConverted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of stock, type of stock converted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liability Class [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_DirectorsDeferredShareUnitsLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Directors' Deferred Share Unit Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_DirectorsDeferredShareUnitsLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">DDSU Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_DirectorsDeferredShareUnitsLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Directors' deferred share units liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair value of liabilities transfers into Level 3</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss per common share, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized Gain</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_DebtRepaymentsOfPrincipalInYearThreeBeforeUnamortizedDebtIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt repayments of principal in year three before unamortized debt issuance costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_DebtRepaymentsOfPrincipalInYearThreeBeforeUnamortizedDebtIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Repayments of Principal in Year Three Before Unamortized Debt Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_DebtRepaymentsOfPrincipalInYearThreeBeforeUnamortizedDebtIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2028</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments, Debt and Equity Securities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total share-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock-based compensation expense recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares warrants exercised.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Warrants Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of financing warrants, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value, cancelled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Weighted average grant date fair value, cancelled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Cancelled in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award, equity instruments other than options, cancelled in period, weighted average grant date fair value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Retained Earnings (Accumulated Deficit), Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Retained Earnings (Accumulated Deficit), Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of options, outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of options, outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total shares reserved for issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subordinate Voting</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_GrossProceedsFromIssuanceOfCommonShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gross proceeds from issuance of common shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_GrossProceedsFromIssuanceOfCommonShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gross Proceeds From Issuance Of Common Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_GrossProceedsFromIssuanceOfCommonShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross proceeds before deducting share issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of 2022 USD Financing Warrants to common shares upon exercise of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of options, vested and exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of options, vested and exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recurring</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock Option</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_BoughtDealFinancingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Bought deal financing.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_BoughtDealFinancingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Bought Deal Financing [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_BoughtDealFinancingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Bought Deal Financing</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_StockIssuedDuringPeriodSharesSettlementOfRestrictedStockUnitAwards_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares settlement of restricted stock unit awards.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_StockIssuedDuringPeriodSharesSettlementOfRestrictedStockUnitAwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Settlement of Restricted Stock Unit Awards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_StockIssuedDuringPeriodSharesSettlementOfRestrictedStockUnitAwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Settlement of restricted share unit awards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Computation of Basic and Diluted Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares, granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Asset, Finite-Lived [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022 USD Financing Warrant Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Two USD Financing Warrant Liability [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty two usd financing warrant liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share due to Anti-dilutive Effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate principal amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of shares, beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of shares, ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2016-02</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2016-02 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument, Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional paid-in capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Additional Paid in Capital, Common Stock, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Additional Paid in Capital, Common Stock, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share issued price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss attributable to common shareholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of options, exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableRateDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Rate [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Interest Rate Terms</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of the interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_PercentageOfFinalPaymentFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Final Payment Fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_PercentageOfFinalPaymentFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of final payment fee.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_PercentageOfFinalPaymentFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of final payment fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermLineOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Line of Credit, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermLineOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit facility, long-term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Expense, Debt, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense, Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total income/(expense), net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total other income/(loss), net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_AggregateNumberOfCommonSharesOwnedByHolderPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate number of common shares owned by holder percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_AggregateNumberOfCommonSharesOwnedByHolderPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Number Of Common Shares Owned By Holder Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_AggregateNumberOfCommonSharesOwnedByHolderPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate number of common shares owned by holder percentage.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Government Corporations and Agencies Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. agency bonds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payables and Accruals [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_SubordinateVotingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Subordinate Voting Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_SubordinateVotingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Subordinate voting.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_SubordinateVotingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subordinate Voting [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_SubordinateVotingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subordinate Voting</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nominal amount of expense in relation to ESPP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common shares under employee share purchase plan ("ESPP") share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Short-Term Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, vested and exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free rate, maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Share Price [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Summary of Carrying Value of Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss and comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchases of investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets, Major Class Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_UnderwrittenPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwritten Public Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_UnderwrittenPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Underwritten Public Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_UnderwrittenPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Underwritten public offering Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_UnvestedRestrictedStockUnitsRsusMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested RSUs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_UnvestedRestrictedStockUnitsRsusMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unvested Restricted Stock Units (RSUs) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_UnvestedRestrictedStockUnitsRsusMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unvested restricted stock units (RSUs).</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_StockIssuedDuringPeriodSharesUponSettlementOfRestrictedStockUnitAwardsNetOfSharesWithheldForTax_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares upon settlement of restricted stock unit awards, net of shares withheld for tax.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_StockIssuedDuringPeriodSharesUponSettlementOfRestrictedStockUnitAwardsNetOfSharesWithheldForTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Upon Settlement Of Restricted Stock Unit Awards Net Of Shares Withheld For Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_StockIssuedDuringPeriodSharesUponSettlementOfRestrictedStockUnitAwardsNetOfSharesWithheldForTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common shares upon settlement of restricted share unit ("RSU") awards, net of shares withheld for tax, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_ExerciseOfWarrantShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Exercise of Warrant shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_ExerciseOfWarrantShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_ExerciseOfWarrantShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exercise of Warrant shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_WeightedAverageNumberOfCommonSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares used in computing net loss per share attributable to common shareholders, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_WeightedAverageNumberOfCommonSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Common Shares Outstanding Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_WeightedAverageNumberOfCommonSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted average number of common shares outstanding basic.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Restricted Share Units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_IndicationOfImpairmentOfGoodwillAndLongLivedAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Indication of impairment of goodwill and long-lived assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_IndicationOfImpairmentOfGoodwillAndLongLivedAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Indication of Impairment of Goodwill and Long-lived Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_IndicationOfImpairmentOfGoodwillAndLongLivedAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Indication of impairment of goodwill and long-lived assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Voting shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subordinate Voting Shares of the Company issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentQuarterlyReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Quarterly Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentQuarterlyReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Quarterly Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Assets, Fair Value Disclosure, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_SharesAvailableForGrantUnderStockOptionPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Available for Grant Under Stock Option Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_SharesAvailableForGrantUnderStockOptionPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Available for Grant Under Stock Option Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_SharesAvailableForGrantUnderStockOptionPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares available for grant under stock option plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares, issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award, equity instruments other than options, issued in period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Issued in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_OtherNonCashAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Other non-cash adjustments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_OtherNonCashAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Non Cash Adjustments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_OtherNonCashAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other non-cash adjustments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_DirectorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Director [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_DirectorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Director</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Finite-Lived Intangible Assets, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets, Gross Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Presentation and Summary of Significant Accounting Policies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value, granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average period for recognition of unvested options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from private placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Expected term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_CadFinancingAndCompensationWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">CAD financing and compensation warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_CadFinancingAndCompensationWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">CAD Financing And Compensation Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_CadFinancingAndCompensationWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CAD financing and Compensation Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares, vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_DebtRepaymentsOfPrincipalRemainderOfFiscalYearBeforeUnamortizedDebtIssuanceCost_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt repayments of principal, remainder of fiscal year, before unamortized debt issuance cost.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_DebtRepaymentsOfPrincipalRemainderOfFiscalYearBeforeUnamortizedDebtIssuanceCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Repayments Of Principal Remainder Of Fiscal Year Before Unamortized Debt Issuance Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_DebtRepaymentsOfPrincipalRemainderOfFiscalYearBeforeUnamortizedDebtIssuanceCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remainder of 2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recent Accounting Pronouncements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated OCI</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Assets, Fair Value Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Stock Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment of share issuance cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment of issuance costs from the Offering and Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Future Expected Repayments of Principal Amount Due on Credit Facility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining contractual life (Years), vested and exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Share price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair market value of vested shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Convertible, Beneficial Conversion Feature</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument convertible, conversion feature principal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachUnit_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or right number of securities called by each unit.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachUnit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Number Of Securities Called By Each Unit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachUnit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares purchasable for each unit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private Placement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of options, expired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of options, expired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_WeightedAverageNumberOfDilutedPreFundedWarrantsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Diluted Pre Funded Warrants Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_WeightedAverageNumberOfDilutedPreFundedWarrantsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted average number of diluted pre funded warrants outstanding.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_WeightedAverageNumberOfDilutedPreFundedWarrantsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average pre-funded warrants used in computing net loss per share attributable to common shareholders, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of shares, vested and issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested and issued in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award, equity instruments other than options, vested and issued in period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_OtherLiabilitiesLongTerm_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other liabilities, long-term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_OtherLiabilitiesLongTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities, Long-Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_OtherLiabilitiesLongTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Other liabilities, long-term.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common shares, net of share issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_AccruedOtherResearchAndDevelopmentCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Other Research and Development Costs Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_AccruedOtherResearchAndDevelopmentCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued other research and development costs current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_AccruedOtherResearchAndDevelopmentCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued other research and development costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WorkersCompensationLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WorkersCompensationLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Workers' Compensation Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Convertible, If-converted Value in Excess of Principal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument convertible, converted principal amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and Cash Equivalents, at Carrying Value, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and Cash Equivalents, at Carrying Value, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value, exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Withholding taxes paid on vested RSUs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Excluding Current Maturities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total credit facility, non-current, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total credit facility, non-current, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of options, granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorizedUnlimited_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorizedUnlimited_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized, Unlimited [Fixed List]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of shares, cancelled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Cancelled in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award, equity instruments other than options, cancelled in period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Expected Term [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Fair Value Assumptions of Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_MultipleVotingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Multiple voting.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_MultipleVotingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Multiple Voting [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_MultipleVotingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Multiple Voting</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionSharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Share Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionSharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business acquisition, fair value share price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionSharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Business acquisition, issued price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common shares at an initial excercise price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance, weighted average exercise price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance, weighted average exercise price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant exercise price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrealized Gain (Loss), Foreign Currency Transaction, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unrealized foreign exchange</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_ScheduleOfWarrantLiabilityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Warrant Liability [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_ScheduleOfWarrantLiabilityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of warrant liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_ScheduleOfWarrantLiabilityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Activity of Outstanding Warrant Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Warrant Or Right [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_StockIssuedDuringPeriodValueUponSettlementOfRestrictedStockUnitAwardsNetOfSharesWithheldForTax_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value upon settlement of restricted stock unit awards, net of shares withheld for tax.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_StockIssuedDuringPeriodValueUponSettlementOfRestrictedStockUnitAwardsNetOfSharesWithheldForTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Upon Settlement Of Restricted Stock Unit Awards Net Of Shares Withheld For Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_StockIssuedDuringPeriodValueUponSettlementOfRestrictedStockUnitAwardsNetOfSharesWithheldForTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common shares upon settlement of restricted share unit ("RSU") awards, net of shares withheld for tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_LoanExtendedTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan extended term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_LoanExtendedTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loan Extended Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_LoanExtendedTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Loan extended term.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_FirstTrancheTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">First tranche term loan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_FirstTrancheTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">First Tranche Term Loan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_FirstTrancheTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">First Tranche Term Loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_LongTermInvestmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_LongTermInvestmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Investments [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_LongTermInvestmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Long Term Investments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Note Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_SaleOfEquityRemainingOfferingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sale of equity, remaining offering amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_SaleOfEquityRemainingOfferingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Equity Remaining Offering Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_SaleOfEquityRemainingOfferingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of securities remaining availablility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Intangible assets, Net Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Finite-Lived Intangible Assets, Net, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Finite-Lived Intangible Assets, Net, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other accruals</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and Shareholders&#8217; Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_WarrantsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_WarrantsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants disclosure.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_WarrantsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive securities excluded from computation of loss per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_StockBasedCompensationReversal_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock based compensation reversal.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_StockBasedCompensationReversal_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock-based compensation reversal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Recognized of incremental compensation cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investment, Ownership Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage number of equity awards.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Conversion, Converted Instrument, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of conversion shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_PercentageOfOutstandingSharesToBeHeldToVote_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of outstanding shares to be held to vote.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_PercentageOfOutstandingSharesToBeHeldToVote_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Outstanding Shares To Be Held To Vote</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_PercentageOfOutstandingSharesToBeHeldToVote_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of outstanding shares to be held to vote</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_FinancingWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Financing warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_FinancingWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financing Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_FinancingWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_ProceedsFromExerciseOfOptionsInPrepaidAndOtherCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from exercise of options in prepaid and other current assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_ProceedsFromExerciseOfOptionsInPrepaidAndOtherCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Exercise of Options in Prepaid and Other Current Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_ProceedsFromExerciseOfOptionsInPrepaidAndOtherCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of options in prepaid and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableRateAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Rate [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total shareholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment of Intangible Assets, Finite-Lived</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at March 31, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at March 31, 2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Convertible, Conversion Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units (RSUs) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RSUs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Number of Shares Issued in Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Goodwill, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Goodwill, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Goodwill, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in accounting principle, accounting standards update, adopted [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Selling, General and Administrative Expenses, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock-based Compensation Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of the Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nature of Operations [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Aggregate intrinsic value, vested and exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value, vested and exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized stock-based compensation expense related to unvested options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_WarrantsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants policy.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_WarrantsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_WarrantsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Price Volatility [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCommitment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other commitment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCommitment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Commitment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCommitment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Commitment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Expected dividend yield</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value by Liability Class [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Risk Free Interest Rate [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_SaleOfEquityAggregatePublicOfferingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of securities aggregate public offering price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_SaleOfEquityAggregatePublicOfferingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Equity Aggregate Public Offering Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_SaleOfEquityAggregatePublicOfferingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sale Of equity aggregate public offering amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Instruments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value of options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion of Stock, Shares Converted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and shareholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental Cash Flow Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Financial liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">DDSU Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at December 31, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at March 31, 2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrimeRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prime Rate [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value warrants exercised.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Warrants Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of financing warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss per common share, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="currency_USD_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">USD</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="currency_USD_lbl" xlink:role="http://www.xbrl.org/2003/role/label">United States of America, Dollars</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Voting Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, voting rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_LoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Loan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_LoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_LoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockConversionFeatures_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, conversion rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockConversionFeatures_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Terms of Conversion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common shares, net of share issuance costs, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock issued during period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_ResearchAndDevelopmentInternalExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Internal Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_ResearchAndDevelopmentInternalExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development internal expense.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_ResearchAndDevelopmentInternalExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Internal expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_SecondMilestoneBasedTrancheTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Second Milestone Based Tranche Term Loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_SecondMilestoneBasedTrancheTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Second Milestone Based Tranche Term Loan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_SecondMilestoneBasedTrancheTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Second milestone based tranche term loan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_GeneralAndAdministrativeInternalExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Internal expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_GeneralAndAdministrativeInternalExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Internal Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_GeneralAndAdministrativeInternalExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">General and administrative internal expense .</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill and Intangible Assets, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_DebtRepaymentsOfPrincipalInYearFourBeforeUnamortizedDebtIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt repayments of principal in year four before unamortized debt issuance costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_DebtRepaymentsOfPrincipalInYearFourBeforeUnamortizedDebtIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Repayments of Principal in Year Four Before Unamortized Debt Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_DebtRepaymentsOfPrincipalInYearFourBeforeUnamortizedDebtIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2029</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares purchasable for each warrant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss) Available to Common Stockholders, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss attributable to common shareholders, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_FinancingWarrantsLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022 USD Financing Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_FinancingWarrantsLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financing Warrants Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_FinancingWarrantsLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Financing warrants liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_WarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Exercised, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_WarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_WarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants exercised.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregated fair value of options vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_PercentageOfGrossProceedsSaleOfCommonSharesPayableAsSalesAgentsCommissionRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of gross proceeds from sales of common shares payable as sales agent commission rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_PercentageOfGrossProceedsSaleOfCommonSharesPayableAsSalesAgentsCommissionRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Gross Proceeds Sale Of Common Shares Payable As Sales Agents Commission Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_PercentageOfGrossProceedsSaleOfCommonSharesPayableAsSalesAgentsCommissionRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of gross proceeds sale of common shares payable as sales agents commission rate.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Aggregate intrinsic value, outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Aggregate intrinsic value, outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFeeAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Fee Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFeeAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued final payment fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_WeightedAverageNumberOfPreFundedWarrantsOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average pre-funded warrants used in computing net loss per share attributable to common shareholders, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_WeightedAverageNumberOfPreFundedWarrantsOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Pre Funded Warrants Outstanding Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_WeightedAverageNumberOfPreFundedWarrantsOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted average number of pre funded warrants outstanding basic.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_ResearchAndDevelopmentExternalExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development External Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_ResearchAndDevelopmentExternalExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development external expense.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_ResearchAndDevelopmentExternalExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">External expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of reportable segment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Reportable Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in accounting principle, accounting standards update, early adoption [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Maturity Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, maturity date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201613Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2016-13</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201613Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2016-13 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_UsdFinancingWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022 USD Financing Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_UsdFinancingWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">2022 USD Financing Warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_UsdFinancingWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">2022 USD Financing Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average common shares, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total weighted-average shares used in computing net loss per share attributable to common shareholders, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common shares, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net proceeds from common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_CommonStockNumberOfVotesPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock number of votes per share.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_CommonStockNumberOfVotesPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Number Of Votes Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_CommonStockNumberOfVotesPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, number of votes per share held</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common shares under ESPP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average exercise price, granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization of Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortization of Intangible Assets, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_GeneralAndAdministrativeExternalExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative External Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_GeneralAndAdministrativeExternalExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">General and administrative external expense.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_GeneralAndAdministrativeExternalExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">External expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining contractual life (Years), outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_ReclassOfDeferredFinancingFeesToAdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reclass of deferred financing fees to additional paid-in capital.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_ReclassOfDeferredFinancingFeesToAdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reclass of Deferred Financing Fees to Additional Paid-In Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_ReclassOfDeferredFinancingFeesToAdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclass of deferred financing fees to additional paid-in capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill, Impairment Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment charges of goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Debt Securities Available-for-sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Stock Option Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Line of Credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-Term Line of Credit, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Line of Credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_VestedAndUnissuedRestrictedStockUnitsRsusMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested and Unissued RSUs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_VestedAndUnissuedRestrictedStockUnitsRsusMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vested and Unissued Restricted Stock Units (RSUs) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_VestedAndUnissuedRestrictedStockUnitsRsusMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Vested and unissued restricted stock units (RSUs).</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shareholders' Equity:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_SummaryOfSharesReservedForIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Shares Reserved for Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_SummaryOfSharesReservedForIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of shares reserved for issuance.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_SummaryOfSharesReservedForIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary of Shares Reserved For Issuance [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effect of exchange rate changes on cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_RestructuredAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructured Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_RestructuredAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructured Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_RestructuredAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Restructured Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_CommonShareAndWarrantPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Share and Warrant Public Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_CommonShareAndWarrantPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Share and Warrant Public Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_CommonShareAndWarrantPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common Share and Warrant Public Offering Member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_LoanMaturityTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loan Maturity Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_LoanMaturityTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Loan maturity term.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_LoanMaturityTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan maturity term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Requisite service period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_CovenantShallBeWaivedDuringMarketCapitalizationExceeds_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Covenant shall be waived during market capitalization exceeds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_CovenantShallBeWaivedDuringMarketCapitalizationExceeds_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Covenant Shall be Waived During Market Capitalization Exceeds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_CovenantShallBeWaivedDuringMarketCapitalizationExceeds_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Covenant shall be waived during market capitalization exceeds.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted average grant date fair value, vested and issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And issued In Period Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Fair Value of Amount Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of credit facility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Change in fair value of 2022 USD Financing Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Change in fair value of 2022 USD Financing Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of the warrant liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Adjustment of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Reporting</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase/(decrease) in cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Outstanding, Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense, Operating and Nonoperating</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationDateOfIncorporation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, Date of Incorporation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationDateOfIncorporation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity date of incorporation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued, price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockNoParValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, no par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockNoParValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, No Par Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_WarrantsIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants issued.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_WarrantsIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_WarrantsIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_WarrantsIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issued, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Professional services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Assumptions used to Determine Fair Value of 2022 USD Financing Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Interest Rate, Effective Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Warrant or Right</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss) Available to Common Stockholders, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss attributable to common shareholders, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in accounting principle, accounting standards update, adoption date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_ShareIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share issuance costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_ShareIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_ShareIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_DebtRepaymentsOfPrincipalInNextTwelveMonthsBeforeUnamortizedDebtIssuanceCost_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt repayments of principal in next twelve months before unamortized debt issuance cost.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_DebtRepaymentsOfPrincipalInNextTwelveMonthsBeforeUnamortizedDebtIssuanceCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Repayments of Principal in Next Twelve Months Before Unamortized Debt Issuance Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_DebtRepaymentsOfPrincipalInNextTwelveMonthsBeforeUnamortizedDebtIssuanceCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Intangible assets, Accumulated Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_DirectorsDeferredShareUnitPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Directors' Deferred Share Unit Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_DirectorsDeferredShareUnitPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Directors' Deferred Share Unit Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents, end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents, beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-Term Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement input</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Outstanding, Measurement Input</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_AmendmentTermLoansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Term Loans [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_AmendmentTermLoansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amendment term loans.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_AmendmentTermLoansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Term Loans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Lender [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_CommonStockConvertibleConversionRatio_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common sock convertible conversion ratio.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_CommonStockConvertibleConversionRatio_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Convertible Conversion Ratio</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_CommonStockConvertibleConversionRatio_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ratio of multiple voting shares converted into subordinate voting shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_CompensationWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Compensation warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_CompensationWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Compensation Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_CompensationWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Compensation Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exchange of shares, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Subordinate Voting Shares conversion to Multiple Voting Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_CommonShareAndWarrantPublicOfferingExpireDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common share and warrant public offering expire date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_CommonShareAndWarrantPublicOfferingExpireDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Share and Warrant Public Offering Expire Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_CommonShareAndWarrantPublicOfferingExpireDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common share and warrant public offering expire date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_CommonStockClassDMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock class D.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_CommonStockClassDMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Class D [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_CommonStockClassDMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class D Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Private placement shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Warrant Exercises</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_MindMedStockOptionPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">MindMed stock option plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_MindMedStockOptionPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Mind Med Stock Option Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_MindMedStockOptionPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">MindMed Stock Option Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_WarrantsExpired_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants expired.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_WarrantsExpired_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Expired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_WarrantsExpired_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expired, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, by Balance Sheet Grouping [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value By Balance Sheet Grouping [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-Funded Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre-Funded Warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Funded Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Liabilities Fair Value Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Amortized Cost, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DevelopedTechnologyRightsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development Technology</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DevelopedTechnologyRightsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Developed Technology Rights [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of assets transfers out of Level 3</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">(Loss)/gain on foreign currency translation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_ChangeInFairValueOnDirectorsDeferredShareUnits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in fair value on directors' deferred share units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_ChangeInFairValueOnDirectorsDeferredShareUnits_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Change in fair value on directors' deferred share units.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_ChangeInFairValueOnDirectorsDeferredShareUnits_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in fair value on directors' deferred share units ("DDSU")</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average market price of options exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_PercentageOfIncreaseOrDecreaseOfOwnershipByPreFundedWarrantsHolder_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Increase Or Decrease Of Ownership By Pre-funded Warrants Holder</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_PercentageOfIncreaseOrDecreaseOfOwnershipByPreFundedWarrantsHolder_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of increase or decrease of ownership by pre-funded warrants holder.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_PercentageOfIncreaseOrDecreaseOfOwnershipByPreFundedWarrantsHolder_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of increase or decrease of ownership by pre-funded warrants holder</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unamortized debt issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrealized Gain (Loss) on Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gain on investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingValuationTechniqueExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants, Valuation Technique [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingValuationTechniqueExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Outstanding, Valuation Technique [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted average grant date fair value, ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted average grant date fair value, beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other noncurrent assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Noncurrent Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-In Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign Currency</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Investments [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other non-current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of liabilities transfers out of Level 3</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PerformanceSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Performance shares units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PerformanceSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance Shares [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments of Financing Costs, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Financing Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment of facility fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment of credit facility issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_SubsequentTrancheTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Subsequent tranche term loan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_SubsequentTrancheTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent tranche term loan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_SubsequentTrancheTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Tranche Term Loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAcquiredDuringPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill, Acquired During Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAcquiredDuringPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill acquired during period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Accounting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Premium on Purchased Options [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title and Position [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Investment Income, Interest and Dividend, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income, Interest and Dividend</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Value, Issued, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Value, Issued, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Value, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common shares, no par value, unlimited authorized as of March 31, 2025 and December 31, 2024; 75,511,375 and 75,100,763 issued and outstanding as of March 31, 2025 and December 31, 2024, respectively</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Expected Future Amortization Expense for Finite-lived Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_ConversionSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion Shares [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_ConversionSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Conversion shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_ConversionSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income (Expense) [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income/(expense):</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_NatureOfOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Nature of operations.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_NatureOfOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nature Of Operations [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of available-for-sale investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accrued Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Accrued Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 9)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation incremental cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Plan Modification, Incremental Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_BusinessCombinationMaximumMeasurementPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business combination, maximum measurement period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_BusinessCombinationMaximumMeasurementPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Maximum Measurement Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_BusinessCombinationMaximumMeasurementPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business combination, maximum measurement period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average common shares, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total weighted-average shares used in computing net loss per share attributable to common shareholders, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Additional Expense Details</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_TermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Term loan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_TermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Term Loan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_TermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term Loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_TwoThousandTwentyTwoAtTheMarketOfferingProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Two At The Market Offering Program [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_TwoThousandTwentyTwoAtTheMarketOfferingProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty two at the market offering program.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_TwoThousandTwentyTwoAtTheMarketOfferingProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022 at the Market offering program</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Outstanding, Maturity Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants expiration date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Information [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Basis Spread on Variable Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term Loan bears a variable interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit Facility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_AccruedClinicalAndManufacturingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued clinical and manufacturing costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_AccruedClinicalAndManufacturingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued clinical trial costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Bankruptcy Proceedings, Reporting Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Bankruptcy Proceedings, Reporting Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_AdditionalTrancheTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Tranche Term Loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_AdditionalTrancheTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional Tranche Term Loan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_AdditionalTrancheTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Tranche Term Loan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock split conversion ratio</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Treasury Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. treasury securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Foreign exchange</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Realized and unrealized gains and losses from foreign exchange</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Foreign Currency Transaction Gain (Loss), before Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss), Foreign Currency Transaction, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign exchange loss, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_ProceedsFromOfferingAndPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from offering and private placement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_ProceedsFromOfferingAndPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Offering and Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_ProceedsFromOfferingAndPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the Offering and Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockConversionBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock conversion basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockConversionBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Conversion Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, expired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted average exercise price, outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted average exercise price, outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201912Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2019-12</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201912Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2019-12 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_CommonStockSharesIssuedAndOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock shares issued and outstanding.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_CommonStockSharesIssuedAndOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Issued And Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_CommonStockSharesIssuedAndOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares issued and outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value, vested and unissued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested and Unissued in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award, equity instruments other than options, vested and unissued in period, weighted average grant date fair value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_WarrantExercise_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant exercise.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_WarrantExercise_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant Exercise</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_WarrantExercise_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant exercise</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_LoanAndSecurityAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan and Security Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_LoanAndSecurityAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Loan and security agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="mnmd_LoanAndSecurityAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loan and Security Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting rights, description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in accounting principle, accounting standards update, immaterial effect [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accrued Liabilities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CurrencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Currency [Axis]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_WeightedAverageNumberOfDilutedCommonSharesOutstanding" xlink:to="mnmd_WeightedAverageNumberOfDilutedCommonSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_UnpaidIssuanceCostsForOfferingAndPrivatePlacement" xlink:to="mnmd_UnpaidIssuanceCostsForOfferingAndPrivatePlacement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_OfferingPrice" xlink:to="mnmd_OfferingPrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_TwoThousandTwentyFourAtTheMarketOfferingProgramMember" xlink:to="mnmd_TwoThousandTwentyFourAtTheMarketOfferingProgramMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedInPeriod" xlink:to="mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsPolicy" xlink:to="us-gaap_BusinessCombinationsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_ShareBasedPaymentArrangementDirectorsDeferredShareUnitPlanActivityTableTextBlock" xlink:to="mnmd_ShareBasedPaymentArrangementDirectorsDeferredShareUnitPlanActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_WeightedAverageFairValueOfSharesPurchasedUponExerciseOfWarrants" xlink:to="mnmd_WeightedAverageFairValueOfSharesPurchasedUponExerciseOfWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_DebtInstrumentExtendedMaturityDate" xlink:to="mnmd_DebtInstrumentExtendedMaturityDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_K2HealthventuresLlcMember" xlink:to="mnmd_K2HealthventuresLlcMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_SubordinateVotingSharesMember" xlink:to="mnmd_SubordinateVotingSharesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_AtTheMarketOfferingProgramMember" xlink:to="mnmd_AtTheMarketOfferingProgramMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_DebtInstrumentConvertibleConvertedIntoCommonShares" xlink:to="mnmd_DebtInstrumentConvertibleConvertedIntoCommonShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_DebtRepaymentsOfPrincipalInYearTwoBeforeUnamortizedDebtIssuanceCost" xlink:to="mnmd_DebtRepaymentsOfPrincipalInYearTwoBeforeUnamortizedDebtIssuanceCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_UnpaidIssuanceCostsForCommonShares" xlink:to="mnmd_UnpaidIssuanceCostsForCommonShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_ProceedsFromAtTheMarketOfferingProgramNetOfIssuanceCosts" xlink:to="mnmd_ProceedsFromAtTheMarketOfferingProgramNetOfIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpenseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_AllCurrenciesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_UnderwrittenOfferingMember" xlink:to="mnmd_UnderwrittenOfferingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_CAD" xlink:to="currency_CAD_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_OptionsIssuedAndOutstandingUnderStockOptionPlanMember" xlink:to="mnmd_OptionsIssuedAndOutstandingUnderStockOptionPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockTypeOfStockConverted" xlink:to="us-gaap_ConversionOfStockTypeOfStockConverted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueByLiabilityClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_DirectorsDeferredShareUnitsLiabilityMember" xlink:to="mnmd_DirectorsDeferredShareUnitsLiabilityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_DebtRepaymentsOfPrincipalInYearThreeBeforeUnamortizedDebtIssuanceCosts" xlink:to="mnmd_DebtRepaymentsOfPrincipalInYearThreeBeforeUnamortizedDebtIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="mnmd_StockIssuedDuringPeriodSharesWarrantsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue" xlink:to="mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_GrossProceedsFromIssuanceOfCommonShares" xlink:to="mnmd_GrossProceedsFromIssuanceOfCommonShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_BoughtDealFinancingMember" xlink:to="mnmd_BoughtDealFinancingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_StockIssuedDuringPeriodSharesSettlementOfRestrictedStockUnitAwards" xlink:to="mnmd_StockIssuedDuringPeriodSharesSettlementOfRestrictedStockUnitAwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember" xlink:to="mnmd_TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpenseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201602Member" xlink:to="us-gaap_AccountingStandardsUpdate201602Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_VariableRateDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateTerms" xlink:to="us-gaap_DebtInstrumentInterestRateTerms_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_PercentageOfFinalPaymentFee" xlink:to="mnmd_PercentageOfFinalPaymentFee_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermLineOfCredit" xlink:to="us-gaap_LongTermLineOfCredit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_AggregateNumberOfCommonSharesOwnedByHolderPercentage" xlink:to="mnmd_AggregateNumberOfCommonSharesOwnedByHolderPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" xlink:to="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:to="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_SubordinateVotingMember" xlink:to="mnmd_SubordinateVotingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputSharePriceMember" xlink:to="us-gaap_MeasurementInputSharePriceMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInvestments" xlink:to="us-gaap_PaymentsToAcquireInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_UnderwrittenPublicOfferingMember" xlink:to="mnmd_UnderwrittenPublicOfferingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_UnvestedRestrictedStockUnitsRsusMember" xlink:to="mnmd_UnvestedRestrictedStockUnitsRsusMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_StockIssuedDuringPeriodSharesUponSettlementOfRestrictedStockUnitAwardsNetOfSharesWithheldForTax" xlink:to="mnmd_StockIssuedDuringPeriodSharesUponSettlementOfRestrictedStockUnitAwardsNetOfSharesWithheldForTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_ExerciseOfWarrantShares" xlink:to="mnmd_ExerciseOfWarrantShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_WeightedAverageNumberOfCommonSharesOutstandingBasic" xlink:to="mnmd_WeightedAverageNumberOfCommonSharesOutstandingBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_IndicationOfImpairmentOfGoodwillAndLongLivedAssets" xlink:to="mnmd_IndicationOfImpairmentOfGoodwillAndLongLivedAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_MarketableSecuritiesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_SharesAvailableForGrantUnderStockOptionPlanMember" xlink:to="mnmd_SharesAvailableForGrantUnderStockOptionPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" xlink:to="mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_OtherNonCashAdjustments" xlink:to="mnmd_OtherNonCashAdjustments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_CadFinancingAndCompensationWarrantsMember" xlink:to="mnmd_CadFinancingAndCompensationWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_DebtRepaymentsOfPrincipalRemainderOfFiscalYearBeforeUnamortizedDebtIssuanceCost" xlink:to="mnmd_DebtRepaymentsOfPrincipalRemainderOfFiscalYearBeforeUnamortizedDebtIssuanceCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:to="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachUnit" xlink:to="mnmd_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachUnit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_WeightedAverageNumberOfDilutedPreFundedWarrantsOutstanding" xlink:to="mnmd_WeightedAverageNumberOfDilutedPreFundedWarrantsOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriod" xlink:to="mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_OtherLiabilitiesLongTerm" xlink:to="mnmd_OtherLiabilitiesLongTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_AccruedOtherResearchAndDevelopmentCostsCurrent" xlink:to="mnmd_AccruedOtherResearchAndDevelopmentCostsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WorkersCompensationLiabilityCurrent" xlink:to="us-gaap_WorkersCompensationLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" xlink:to="us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorizedUnlimited" xlink:to="us-gaap_CommonStockSharesAuthorizedUnlimited_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" xlink:to="mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_MultipleVotingMember" xlink:to="mnmd_MultipleVotingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionSharePrice" xlink:to="us-gaap_BusinessAcquisitionSharePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_ScheduleOfWarrantLiabilityTableTextBlock" xlink:to="mnmd_ScheduleOfWarrantLiabilityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_StockIssuedDuringPeriodValueUponSettlementOfRestrictedStockUnitAwardsNetOfSharesWithheldForTax" xlink:to="mnmd_StockIssuedDuringPeriodValueUponSettlementOfRestrictedStockUnitAwardsNetOfSharesWithheldForTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_LoanExtendedTerm" xlink:to="mnmd_LoanExtendedTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_FirstTrancheTermLoanMember" xlink:to="mnmd_FirstTrancheTermLoanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_LongTermInvestmentsMember" xlink:to="mnmd_LongTermInvestmentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_SaleOfEquityRemainingOfferingAmount" xlink:to="mnmd_SaleOfEquityRemainingOfferingAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_WarrantsDisclosureTextBlock" xlink:to="mnmd_WarrantsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_StockBasedCompensationReversal" xlink:to="mnmd_StockBasedCompensationReversal_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_PercentageOfOutstandingSharesToBeHeldToVote" xlink:to="mnmd_PercentageOfOutstandingSharesToBeHeldToVote_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_FinancingWarrantsMember" xlink:to="mnmd_FinancingWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_ProceedsFromExerciseOfOptionsInPrepaidAndOtherCurrentAssets" xlink:to="mnmd_ProceedsFromExerciseOfOptionsInPrepaidAndOtherCurrentAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_WarrantsPolicyTextBlock" xlink:to="mnmd_WarrantsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitment" xlink:to="us-gaap_OtherCommitment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_SaleOfEquityAggregatePublicOfferingAmount" xlink:to="mnmd_SaleOfEquityAggregatePublicOfferingAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrimeRateMember" xlink:to="us-gaap_PrimeRateMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="mnmd_StockIssuedDuringPeriodValueWarrantsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_USD" xlink:to="currency_USD_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_LoanMember" xlink:to="mnmd_LoanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockConversionFeatures" xlink:to="us-gaap_CommonStockConversionFeatures_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_ResearchAndDevelopmentInternalExpense" xlink:to="mnmd_ResearchAndDevelopmentInternalExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_SecondMilestoneBasedTrancheTermLoanMember" xlink:to="mnmd_SecondMilestoneBasedTrancheTermLoanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_GeneralAndAdministrativeInternalExpense" xlink:to="mnmd_GeneralAndAdministrativeInternalExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_DebtRepaymentsOfPrincipalInYearFourBeforeUnamortizedDebtIssuanceCosts" xlink:to="mnmd_DebtRepaymentsOfPrincipalInYearFourBeforeUnamortizedDebtIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_FinancingWarrantsLiability" xlink:to="mnmd_FinancingWarrantsLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_WarrantsExercised" xlink:to="mnmd_WarrantsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_PercentageOfGrossProceedsSaleOfCommonSharesPayableAsSalesAgentsCommissionRate" xlink:to="mnmd_PercentageOfGrossProceedsSaleOfCommonSharesPayableAsSalesAgentsCommissionRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFeeAmount" xlink:to="us-gaap_DebtInstrumentFeeAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_WeightedAverageNumberOfPreFundedWarrantsOutstandingBasic" xlink:to="mnmd_WeightedAverageNumberOfPreFundedWarrantsOutstandingBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_ResearchAndDevelopmentExternalExpense" xlink:to="mnmd_ResearchAndDevelopmentExternalExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201613Member" xlink:to="us-gaap_AccountingStandardsUpdate201613Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_UsdFinancingWarrantsMember" xlink:to="mnmd_UsdFinancingWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_CommonStockNumberOfVotesPerShare" xlink:to="mnmd_CommonStockNumberOfVotesPerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_GeneralAndAdministrativeExternalExpense" xlink:to="mnmd_GeneralAndAdministrativeExternalExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_ReclassOfDeferredFinancingFeesToAdditionalPaidInCapital" xlink:to="mnmd_ReclassOfDeferredFinancingFeesToAdditionalPaidInCapital_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCredit" xlink:to="us-gaap_LineOfCredit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_VestedAndUnissuedRestrictedStockUnitsRsusMember" xlink:to="mnmd_VestedAndUnissuedRestrictedStockUnitsRsusMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_SummaryOfSharesReservedForIssuanceTableTextBlock" xlink:to="mnmd_SummaryOfSharesReservedForIssuanceTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_RestructuredAgreementMember" xlink:to="mnmd_RestructuredAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_CommonShareAndWarrantPublicOfferingMember" xlink:to="mnmd_CommonShareAndWarrantPublicOfferingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_LoanMaturityTerm" xlink:to="mnmd_LoanMaturityTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_CovenantShallBeWaivedDuringMarketCapitalizationExceeds" xlink:to="mnmd_CovenantShallBeWaivedDuringMarketCapitalizationExceeds_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriodWeightedAverageGrantDateFairValue" xlink:to="mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:to="us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationDateOfIncorporation" xlink:to="dei_EntityIncorporationDateOfIncorporation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockNoParValue" xlink:to="us-gaap_CommonStockNoParValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_WarrantsIssued" xlink:to="mnmd_WarrantsIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_LineOfCreditFacilityTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_ShareIssuanceCosts" xlink:to="mnmd_ShareIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_DebtRepaymentsOfPrincipalInNextTwelveMonthsBeforeUnamortizedDebtIssuanceCost" xlink:to="mnmd_DebtRepaymentsOfPrincipalInNextTwelveMonthsBeforeUnamortizedDebtIssuanceCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_DirectorsDeferredShareUnitPlanMember" xlink:to="mnmd_DirectorsDeferredShareUnitPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermInvestments" xlink:to="us-gaap_LongTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_AmendmentTermLoansMember" xlink:to="mnmd_AmendmentTermLoansMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_CommonStockConvertibleConversionRatio" xlink:to="mnmd_CommonStockConvertibleConversionRatio_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_CompensationWarrantsMember" xlink:to="mnmd_CompensationWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_CommonShareAndWarrantPublicOfferingExpireDate" xlink:to="mnmd_CommonShareAndWarrantPublicOfferingExpireDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_CommonStockClassDMember" xlink:to="mnmd_CommonStockClassDMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_MindMedStockOptionPlanMember" xlink:to="mnmd_MindMedStockOptionPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_WarrantsExpired" xlink:to="mnmd_WarrantsExpired_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_PreFundedWarrantsMember" xlink:to="mnmd_PreFundedWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DevelopedTechnologyRightsMember" xlink:to="us-gaap_DevelopedTechnologyRightsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_ChangeInFairValueOnDirectorsDeferredShareUnits" xlink:to="mnmd_ChangeInFairValueOnDirectorsDeferredShareUnits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_PercentageOfIncreaseOrDecreaseOfOwnershipByPreFundedWarrantsHolder" xlink:to="mnmd_PercentageOfIncreaseOrDecreaseOfOwnershipByPreFundedWarrantsHolder_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnInvestments" xlink:to="us-gaap_UnrealizedGainLossOnInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingValuationTechniqueExtensibleList" xlink:to="us-gaap_WarrantsAndRightsOutstandingValuationTechniqueExtensibleList_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestmentsMember" xlink:to="us-gaap_ShortTermInvestmentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PerformanceSharesMember" xlink:to="us-gaap_PerformanceSharesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_SubsequentTrancheTermLoanMember" xlink:to="mnmd_SubsequentTrancheTermLoanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="us-gaap_GoodwillAcquiredDuringPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy" xlink:to="us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterestAndDividend" xlink:to="us-gaap_InvestmentIncomeInterestAndDividend_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_ConversionSharesMember" xlink:to="mnmd_ConversionSharesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_NatureOfOperationsAbstract" xlink:to="mnmd_NatureOfOperationsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_BusinessCombinationMaximumMeasurementPeriod" xlink:to="mnmd_BusinessCombinationMaximumMeasurementPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_TermLoanMember" xlink:to="mnmd_TermLoanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_TwoThousandTwentyTwoAtTheMarketOfferingProgramMember" xlink:to="mnmd_TwoThousandTwentyTwoAtTheMarketOfferingProgramMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_AccruedClinicalAndManufacturingCosts" xlink:to="mnmd_AccruedClinicalAndManufacturingCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_AdditionalTrancheTermLoanMember" xlink:to="mnmd_AdditionalTrancheTermLoanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_ProceedsFromOfferingAndPrivatePlacement" xlink:to="mnmd_ProceedsFromOfferingAndPrivatePlacement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockConversionBasis" xlink:to="us-gaap_CommonStockConversionBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201912Member" xlink:to="us-gaap_AccountingStandardsUpdate201912Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_CommonStockSharesIssuedAndOutstanding" xlink:to="mnmd_CommonStockSharesIssuedAndOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedInPeriodWeightedAverageGrantDateFairValue" xlink:to="mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_WarrantExercise" xlink:to="mnmd_WarrantExercise_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mnmd_LoanAndSecurityAgreementMember" xlink:to="mnmd_LoanAndSecurityAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CurrencyAxis" xlink:to="srt_CurrencyAxis_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.mindmed.co/20250331/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentQuarterlyReport" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent" order="79.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="80.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_SubordinateVotingMember" xlink:label="mnmd_SubordinateVotingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_MultipleVotingMember" xlink:label="mnmd_MultipleVotingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermLineOfCredit" xlink:label="us-gaap_LongTermLineOfCredit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_FinancingWarrantsLiability" xlink:label="mnmd_FinancingWarrantsLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mnmd_SubordinateVotingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mnmd_MultipleVotingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LongTermLineOfCredit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Goodwill" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="mnmd_FinancingWarrantsLiability" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_LongTermInvestments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_SubordinateVotingMember" xlink:label="mnmd_SubordinateVotingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorizedUnlimited" xlink:label="us-gaap_CommonStockSharesAuthorizedUnlimited"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_MultipleVotingMember" xlink:label="mnmd_MultipleVotingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mnmd_SubordinateVotingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorizedUnlimited" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mnmd_MultipleVotingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterestAndDividend" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_UnrealizedGainLossOnInvestments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterestAndDividend" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_SubordinateVotingMember" xlink:label="mnmd_SubordinateVotingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_UsdFinancingWarrantsMember" xlink:label="mnmd_UsdFinancingWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_MultipleVotingMember" xlink:label="mnmd_MultipleVotingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_StockIssuedDuringPeriodValueUponSettlementOfRestrictedStockUnitAwardsNetOfSharesWithheldForTax" xlink:label="mnmd_StockIssuedDuringPeriodValueUponSettlementOfRestrictedStockUnitAwardsNetOfSharesWithheldForTax"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_StockIssuedDuringPeriodSharesUponSettlementOfRestrictedStockUnitAwardsNetOfSharesWithheldForTax" xlink:label="mnmd_StockIssuedDuringPeriodSharesUponSettlementOfRestrictedStockUnitAwardsNetOfSharesWithheldForTax"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_StockIssuedDuringPeriodSharesSettlementOfRestrictedStockUnitAwards" xlink:label="mnmd_StockIssuedDuringPeriodSharesSettlementOfRestrictedStockUnitAwards"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="mnmd_StockIssuedDuringPeriodValueWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="mnmd_StockIssuedDuringPeriodSharesWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_15"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_16"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mnmd_SubordinateVotingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="mnmd_UsdFinancingWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mnmd_MultipleVotingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mnmd_StockIssuedDuringPeriodValueUponSettlementOfRestrictedStockUnitAwardsNetOfSharesWithheldForTax" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mnmd_StockIssuedDuringPeriodSharesUponSettlementOfRestrictedStockUnitAwardsNetOfSharesWithheldForTax" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mnmd_StockIssuedDuringPeriodSharesSettlementOfRestrictedStockUnitAwards" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mnmd_StockIssuedDuringPeriodValueWarrantsExercised" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mnmd_StockIssuedDuringPeriodSharesWarrantsExercised" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_15" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_16" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_ProceedsFromOfferingAndPrivatePlacement" xlink:label="mnmd_ProceedsFromOfferingAndPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_UnpaidIssuanceCostsForCommonShares" xlink:label="mnmd_UnpaidIssuanceCostsForCommonShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_ChangeInFairValueOnDirectorsDeferredShareUnits" xlink:label="mnmd_ChangeInFairValueOnDirectorsDeferredShareUnits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_UnpaidIssuanceCostsForOfferingAndPrivatePlacement" xlink:label="mnmd_UnpaidIssuanceCostsForOfferingAndPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_ProceedsFromExerciseOfOptionsInPrepaidAndOtherCurrentAssets" xlink:label="mnmd_ProceedsFromExerciseOfOptionsInPrepaidAndOtherCurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_ProceedsFromAtTheMarketOfferingProgramNetOfIssuanceCosts" xlink:label="mnmd_ProceedsFromAtTheMarketOfferingProgramNetOfIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_ReclassOfDeferredFinancingFeesToAdditionalPaidInCapital" xlink:label="mnmd_ReclassOfDeferredFinancingFeesToAdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_OtherLiabilitiesLongTerm" xlink:label="mnmd_OtherLiabilitiesLongTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_OtherNonCashAdjustments" xlink:label="mnmd_OtherNonCashAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_6"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_StockIssued1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireInvestments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="mnmd_ProceedsFromOfferingAndPrivatePlacement" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="mnmd_UnpaidIssuanceCostsForCommonShares" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="mnmd_ChangeInFairValueOnDirectorsDeferredShareUnits" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="mnmd_UnpaidIssuanceCostsForOfferingAndPrivatePlacement" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfFinancingCosts" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="mnmd_ProceedsFromExerciseOfOptionsInPrepaidAndOtherCurrentAssets" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="mnmd_ProceedsFromAtTheMarketOfferingProgramNetOfIssuanceCosts" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="mnmd_ReclassOfDeferredFinancingFeesToAdditionalPaidInCapital" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="mnmd_OtherLiabilitiesLongTerm" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="mnmd_OtherNonCashAdjustments" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_6" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mindmed.co/20250331/taxonomy/role/DisclosureNatureOfOperations" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_NatureOfOperationsAbstract" xlink:label="mnmd_NatureOfOperationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mnmd_NatureOfOperationsAbstract" xlink:to="us-gaap_NatureOfOperations" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mindmed.co/20250331/taxonomy/role/DisclosureInvestments" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureFairValueOfFinancialInstruments" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mindmed.co/20250331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNet1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureAccruedExpenses" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureShareholdersEquity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureWarrants" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_WarrantsDisclosureTextBlock" xlink:label="mnmd_WarrantsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="mnmd_WarrantsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacility" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mindmed.co/20250331/taxonomy/role/DisclosureSegmentReporting" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mindmed.co/20250331/taxonomy/role/DisclosureSubsequentEvents" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy" xlink:label="us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="us-gaap_BusinessCombinationsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_WarrantsPolicyTextBlock" xlink:label="mnmd_WarrantsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BusinessCombinationsPolicy" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="mnmd_WarrantsPolicyTextBlock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mindmed.co/20250331/taxonomy/role/DisclosureInvestmentsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mindmed.co/20250331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureAccruedExpensesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureShareholdersEquityTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_SummaryOfSharesReservedForIssuanceTableTextBlock" xlink:label="mnmd_SummaryOfSharesReservedForIssuanceTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="mnmd_SummaryOfSharesReservedForIssuanceTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureWarrantsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_ScheduleOfWarrantLiabilityTableTextBlock" xlink:label="mnmd_ScheduleOfWarrantLiabilityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="mnmd_ScheduleOfWarrantLiabilityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_ShareBasedPaymentArrangementDirectorsDeferredShareUnitPlanActivityTableTextBlock" xlink:label="mnmd_ShareBasedPaymentArrangementDirectorsDeferredShareUnitPlanActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="mnmd_ShareBasedPaymentArrangementDirectorsDeferredShareUnitPlanActivityTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacilityTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mindmed.co/20250331/taxonomy/role/DisclosureSegmentInformationTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mindmed.co/20250331/taxonomy/role/DisclosureDescriptionOfTheBusinessAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_PreFundedWarrantsMember" xlink:label="mnmd_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate201613Member" xlink:label="us-gaap_AccountingStandardsUpdate201613Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate201912Member" xlink:label="us-gaap_AccountingStandardsUpdate201912Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="dei_EntityIncorporationDateOfIncorporation"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_BusinessCombinationMaximumMeasurementPeriod" xlink:label="mnmd_BusinessCombinationMaximumMeasurementPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="mnmd_PreFundedWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201613Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201912Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="dei_EntityIncorporationDateOfIncorporation" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_AwardTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="mnmd_BusinessCombinationMaximumMeasurementPeriod" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_WeightedAverageNumberOfPreFundedWarrantsOutstandingBasic" xlink:label="mnmd_WeightedAverageNumberOfPreFundedWarrantsOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_WeightedAverageNumberOfDilutedPreFundedWarrantsOutstanding" xlink:label="mnmd_WeightedAverageNumberOfDilutedPreFundedWarrantsOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_WeightedAverageNumberOfCommonSharesOutstandingBasic" xlink:label="mnmd_WeightedAverageNumberOfCommonSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_WeightedAverageNumberOfDilutedCommonSharesOutstanding" xlink:label="mnmd_WeightedAverageNumberOfDilutedCommonSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="mnmd_WeightedAverageNumberOfPreFundedWarrantsOutstandingBasic" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="mnmd_WeightedAverageNumberOfDilutedPreFundedWarrantsOutstanding" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="mnmd_WeightedAverageNumberOfCommonSharesOutstandingBasic" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="mnmd_WeightedAverageNumberOfDilutedCommonSharesOutstanding" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilut" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_UsdFinancingWarrantsMember" xlink:label="mnmd_UsdFinancingWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_ConversionSharesMember" xlink:label="mnmd_ConversionSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="mnmd_UsdFinancingWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="mnmd_ConversionSharesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mindmed.co/20250331/taxonomy/role/DisclosureInvestmentsScheduleOfAvailableforsaleInvestmentsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="us-gaap_ShortTermInvestmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_LongTermInvestmentsMember" xlink:label="mnmd_LongTermInvestmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_ShortTermInvestmentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="mnmd_LongTermInvestmentsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mindmed.co/20250331/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mindmed.co/20250331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_DirectorsDeferredShareUnitsLiabilityMember" xlink:label="mnmd_DirectorsDeferredShareUnitsLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember" xlink:label="mnmd_TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="mnmd_DirectorsDeferredShareUnitsLiabilityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="mnmd_TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember" xlink:label="mnmd_TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="mnmd_TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mindmed.co/20250331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssumptionsUsedToDetermineFairValueOf2022UsdFinancingWarrantsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember" xlink:label="mnmd_TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingValuationTechniqueExtensibleList" xlink:label="us-gaap_WarrantsAndRightsOutstandingValuationTechniqueExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputSharePriceMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="mnmd_TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingValuationTechniqueExtensibleList" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mindmed.co/20250331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="us-gaap_DevelopedTechnologyRightsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="us-gaap_GoodwillAcquiredDuringPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_IndicationOfImpairmentOfGoodwillAndLongLivedAssets" xlink:label="mnmd_IndicationOfImpairmentOfGoodwillAndLongLivedAssets"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_DevelopedTechnologyRightsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_GoodwillAcquiredDuringPeriod" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="mnmd_IndicationOfImpairmentOfGoodwillAndLongLivedAssets" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mindmed.co/20250331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetSummaryOfCarryingValueOfIntangibleAssetsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="us-gaap_DevelopedTechnologyRightsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_DevelopedTechnologyRightsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WorkersCompensationLiabilityCurrent" xlink:label="us-gaap_WorkersCompensationLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_AccruedClinicalAndManufacturingCosts" xlink:label="mnmd_AccruedClinicalAndManufacturingCosts"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_AccruedOtherResearchAndDevelopmentCostsCurrent" xlink:label="mnmd_AccruedOtherResearchAndDevelopmentCostsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_WorkersCompensationLiabilityCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="mnmd_AccruedClinicalAndManufacturingCosts" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="mnmd_AccruedOtherResearchAndDevelopmentCostsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_TwoThousandTwentyFourAtTheMarketOfferingProgramMember" xlink:label="mnmd_TwoThousandTwentyFourAtTheMarketOfferingProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockNoParValue" xlink:label="us-gaap_CommonStockNoParValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_AtTheMarketOfferingProgramMember" xlink:label="mnmd_AtTheMarketOfferingProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_PreFundedWarrantsMember" xlink:label="mnmd_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_TwoThousandTwentyTwoAtTheMarketOfferingProgramMember" xlink:label="mnmd_TwoThousandTwentyTwoAtTheMarketOfferingProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_CommonStockSharesIssuedAndOutstanding" xlink:label="mnmd_CommonStockSharesIssuedAndOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_UnderwrittenOfferingMember" xlink:label="mnmd_UnderwrittenOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_SaleOfEquityAggregatePublicOfferingAmount" xlink:label="mnmd_SaleOfEquityAggregatePublicOfferingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_PercentageOfGrossProceedsSaleOfCommonSharesPayableAsSalesAgentsCommissionRate" xlink:label="mnmd_PercentageOfGrossProceedsSaleOfCommonSharesPayableAsSalesAgentsCommissionRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_SaleOfEquityRemainingOfferingAmount" xlink:label="mnmd_SaleOfEquityRemainingOfferingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_CommonStockNumberOfVotesPerShare" xlink:label="mnmd_CommonStockNumberOfVotesPerShare"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_PercentageOfOutstandingSharesToBeHeldToVote" xlink:label="mnmd_PercentageOfOutstandingSharesToBeHeldToVote"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_CommonStockConvertibleConversionRatio" xlink:label="mnmd_CommonStockConvertibleConversionRatio"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockConversionBasis" xlink:label="us-gaap_CommonStockConversionBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockConversionFeatures" xlink:label="us-gaap_CommonStockConversionFeatures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="us-gaap_BusinessAcquisitionSharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_OfferingPrice" xlink:label="mnmd_OfferingPrice"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_GrossProceedsFromIssuanceOfCommonShares" xlink:label="mnmd_GrossProceedsFromIssuanceOfCommonShares"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_ShareIssuanceCosts" xlink:label="mnmd_ShareIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_WarrantsIssued" xlink:label="mnmd_WarrantsIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockTypeOfStockConverted" xlink:label="us-gaap_ConversionOfStockTypeOfStockConverted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_AggregateNumberOfCommonSharesOwnedByHolderPercentage" xlink:label="mnmd_AggregateNumberOfCommonSharesOwnedByHolderPercentage"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_PercentageOfIncreaseOrDecreaseOfOwnershipByPreFundedWarrantsHolder" xlink:label="mnmd_PercentageOfIncreaseOrDecreaseOfOwnershipByPreFundedWarrantsHolder"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="mnmd_TwoThousandTwentyFourAtTheMarketOfferingProgramMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockNoParValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="mnmd_AtTheMarketOfferingProgramMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="mnmd_PreFundedWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="mnmd_TwoThousandTwentyTwoAtTheMarketOfferingProgramMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mnmd_CommonStockSharesIssuedAndOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="mnmd_UnderwrittenOfferingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mnmd_SaleOfEquityAggregatePublicOfferingAmount" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mnmd_PercentageOfGrossProceedsSaleOfCommonSharesPayableAsSalesAgentsCommissionRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mnmd_SaleOfEquityRemainingOfferingAmount" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mnmd_CommonStockNumberOfVotesPerShare" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mnmd_PercentageOfOutstandingSharesToBeHeldToVote" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockVotingRights" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mnmd_CommonStockConvertibleConversionRatio" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockConversionBasis" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockConversionFeatures" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_BusinessAcquisitionSharePrice" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mnmd_OfferingPrice" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mnmd_GrossProceedsFromIssuanceOfCommonShares" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mnmd_ShareIssuanceCosts" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mnmd_WarrantsIssued" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ConversionOfStockTypeOfStockConverted" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mnmd_AggregateNumberOfCommonSharesOwnedByHolderPercentage" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mnmd_PercentageOfIncreaseOrDecreaseOfOwnershipByPreFundedWarrantsHolder" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="34" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mindmed.co/20250331/taxonomy/role/DisclosureShareholdersEquitySummaryOfSharesReservedForIssuanceDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_OptionsIssuedAndOutstandingUnderStockOptionPlanMember" xlink:label="mnmd_OptionsIssuedAndOutstandingUnderStockOptionPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_UnvestedRestrictedStockUnitsRsusMember" xlink:label="mnmd_UnvestedRestrictedStockUnitsRsusMember"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_VestedAndUnissuedRestrictedStockUnitsRsusMember" xlink:label="mnmd_VestedAndUnissuedRestrictedStockUnitsRsusMember"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_CompensationWarrantsMember" xlink:label="mnmd_CompensationWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_FinancingWarrantsMember" xlink:label="mnmd_FinancingWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_SharesAvailableForGrantUnderStockOptionPlanMember" xlink:label="mnmd_SharesAvailableForGrantUnderStockOptionPlanMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mnmd_OptionsIssuedAndOutstandingUnderStockOptionPlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mnmd_UnvestedRestrictedStockUnitsRsusMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mnmd_VestedAndUnissuedRestrictedStockUnitsRsusMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mnmd_CompensationWarrantsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mnmd_FinancingWarrantsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mnmd_SharesAvailableForGrantUnderStockOptionPlanMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureWarrantsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_BoughtDealFinancingMember" xlink:label="mnmd_BoughtDealFinancingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_UnderwrittenPublicOfferingMember" xlink:label="mnmd_UnderwrittenPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_SubordinateVotingSharesMember" xlink:label="mnmd_SubordinateVotingSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_CadFinancingAndCompensationWarrantsMember" xlink:label="mnmd_CadFinancingAndCompensationWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember" xlink:label="mnmd_TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_ExerciseOfWarrantShares" xlink:label="mnmd_ExerciseOfWarrantShares"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_CompensationWarrantsMember" xlink:label="mnmd_CompensationWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_CommonShareAndWarrantPublicOfferingMember" xlink:label="mnmd_CommonShareAndWarrantPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_FinancingWarrantsMember" xlink:label="mnmd_FinancingWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_CommonShareAndWarrantPublicOfferingExpireDate" xlink:label="mnmd_CommonShareAndWarrantPublicOfferingExpireDate"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachUnit" xlink:label="mnmd_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachUnit"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_WeightedAverageFairValueOfSharesPurchasedUponExerciseOfWarrants" xlink:label="mnmd_WeightedAverageFairValueOfSharesPurchasedUponExerciseOfWarrants"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mnmd_BoughtDealFinancingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="mnmd_UnderwrittenPublicOfferingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="mnmd_SubordinateVotingSharesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="mnmd_CadFinancingAndCompensationWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="mnmd_TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="mnmd_ExerciseOfWarrantShares" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="mnmd_CompensationWarrantsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="mnmd_CommonShareAndWarrantPublicOfferingMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="mnmd_FinancingWarrantsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="mnmd_CommonShareAndWarrantPublicOfferingExpireDate" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="mnmd_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachUnit" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="mnmd_WeightedAverageFairValueOfSharesPurchasedUponExerciseOfWarrants" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mindmed.co/20250331/taxonomy/role/DisclosureWarrantsSummaryOfOutstandingLiabilityClassifiedAsWarrantsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember" xlink:label="mnmd_TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_WarrantsIssued" xlink:label="mnmd_WarrantsIssued"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_WarrantsExercised" xlink:label="mnmd_WarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_WarrantsExpired" xlink:label="mnmd_WarrantsExpired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_4"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="mnmd_TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="mnmd_WarrantsIssued" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="mnmd_WarrantsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="mnmd_WarrantsExpired" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mindmed.co/20250331/taxonomy/role/DisclosureWarrantsSummaryOfActivityOfOutstandingWarrantLiabilityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember" xlink:label="mnmd_TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_WarrantExercise" xlink:label="mnmd_WarrantExercise"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_3"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="mnmd_TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="mnmd_WarrantExercise" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_MindMedStockOptionPlanMember" xlink:label="mnmd_MindMedStockOptionPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain" xlink:label="currency_AllCurrenciesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_CAD" xlink:label="currency_CAD"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_LoanMember" xlink:label="mnmd_LoanMember"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_SubordinateVotingSharesMember" xlink:label="mnmd_SubordinateVotingSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_CommonStockClassDMember" xlink:label="mnmd_CommonStockClassDMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CurrencyAxis" xlink:label="srt_CurrencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_USD" xlink:label="currency_USD"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_DirectorsDeferredShareUnitPlanMember" xlink:label="mnmd_DirectorsDeferredShareUnitPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" xlink:label="mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_StockBasedCompensationReversal" xlink:label="mnmd_StockBasedCompensationReversal"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="mnmd_MindMedStockOptionPlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_CAD" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="mnmd_LoanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="mnmd_SubordinateVotingSharesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mnmd_CommonStockClassDMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_USD" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_DebtInstrumentAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="mnmd_DirectorsDeferredShareUnitPlanMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_CurrencyAxis" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mnmd_StockBasedCompensationReversal" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfFairValueAssumptionsOfOptionsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_MindMedStockOptionPlanMember" xlink:label="mnmd_MindMedStockOptionPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="mnmd_MindMedStockOptionPlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharePrice" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain" xlink:label="currency_AllCurrenciesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_CAD" xlink:label="currency_CAD"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CurrencyAxis" xlink:label="srt_CurrencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_USD" xlink:label="currency_USD"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_12"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_18"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_CAD" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_CurrencyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_USD" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_12" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_18" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mindmed.co/20250331/taxonomy/role/DisclosureStockbasedCompensationScheduleOfRestrictedShareUnitsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain" xlink:label="currency_AllCurrenciesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_CAD" xlink:label="currency_CAD"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CurrencyAxis" xlink:label="srt_CurrencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_USD" xlink:label="currency_USD"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedInPeriod" xlink:label="mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriod" xlink:label="mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" xlink:label="mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedInPeriodWeightedAverageGrantDateFairValue" xlink:label="mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriodWeightedAverageGrantDateFairValue" xlink:label="mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue" xlink:label="mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_11"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_CAD" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_USD" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_CurrencyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedInPeriodWeightedAverageGrantDateFairValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriodWeightedAverageGrantDateFairValue" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_11" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitment" xlink:label="us-gaap_OtherCommitment"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OtherCommitment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_LoanAndSecurityAgreementMember" xlink:label="mnmd_LoanAndSecurityAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_FirstTrancheTermLoanMember" xlink:label="mnmd_FirstTrancheTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrimeRateMember" xlink:label="us-gaap_PrimeRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="us-gaap_LineOfCreditFacilityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_TermLoanMember" xlink:label="mnmd_TermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="us-gaap_LineOfCreditFacilityTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_K2HealthventuresLlcMember" xlink:label="mnmd_K2HealthventuresLlcMember"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_SecondMilestoneBasedTrancheTermLoanMember" xlink:label="mnmd_SecondMilestoneBasedTrancheTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_SubsequentTrancheTermLoanMember" xlink:label="mnmd_SubsequentTrancheTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_AdditionalTrancheTermLoanMember" xlink:label="mnmd_AdditionalTrancheTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" xlink:label="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_PercentageOfFinalPaymentFee" xlink:label="mnmd_PercentageOfFinalPaymentFee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="us-gaap_DebtInstrumentFeeAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" xlink:label="us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_DebtInstrumentConvertibleConvertedIntoCommonShares" xlink:label="mnmd_DebtInstrumentConvertibleConvertedIntoCommonShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateTerms" xlink:label="us-gaap_DebtInstrumentInterestRateTerms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:label="us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mnmd_LoanAndSecurityAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="mnmd_FirstTrancheTermLoanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_PrimeRateMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="mnmd_TermLoanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LineOfCreditFacilityTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_CreditFacilityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="mnmd_K2HealthventuresLlcMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="mnmd_SecondMilestoneBasedTrancheTermLoanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_PaymentsOfFinancingCosts" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="mnmd_SubsequentTrancheTermLoanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="mnmd_AdditionalTrancheTermLoanMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_VariableRateAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="srt_RangeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_DebtInstrumentAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_LineOfCreditFacilityLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="mnmd_PercentageOfFinalPaymentFee" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentFeeAmount" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="mnmd_DebtInstrumentConvertibleConvertedIntoCommonShares" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_InterestExpenseDebt" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateTerms" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacilityScheduleOfFutureExpectedRepaymentsOfPrincipalAmountDueOnCreditFacilityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_DebtRepaymentsOfPrincipalRemainderOfFiscalYearBeforeUnamortizedDebtIssuanceCost" xlink:label="mnmd_DebtRepaymentsOfPrincipalRemainderOfFiscalYearBeforeUnamortizedDebtIssuanceCost"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_DebtRepaymentsOfPrincipalInNextTwelveMonthsBeforeUnamortizedDebtIssuanceCost" xlink:label="mnmd_DebtRepaymentsOfPrincipalInNextTwelveMonthsBeforeUnamortizedDebtIssuanceCost"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_DebtRepaymentsOfPrincipalInYearTwoBeforeUnamortizedDebtIssuanceCost" xlink:label="mnmd_DebtRepaymentsOfPrincipalInYearTwoBeforeUnamortizedDebtIssuanceCost"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_DebtRepaymentsOfPrincipalInYearThreeBeforeUnamortizedDebtIssuanceCosts" xlink:label="mnmd_DebtRepaymentsOfPrincipalInYearThreeBeforeUnamortizedDebtIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_DebtRepaymentsOfPrincipalInYearFourBeforeUnamortizedDebtIssuanceCosts" xlink:label="mnmd_DebtRepaymentsOfPrincipalInYearFourBeforeUnamortizedDebtIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="us-gaap_DebtInstrumentFeeAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="mnmd_DebtRepaymentsOfPrincipalRemainderOfFiscalYearBeforeUnamortizedDebtIssuanceCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="mnmd_DebtRepaymentsOfPrincipalInNextTwelveMonthsBeforeUnamortizedDebtIssuanceCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="mnmd_DebtRepaymentsOfPrincipalInYearTwoBeforeUnamortizedDebtIssuanceCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="mnmd_DebtRepaymentsOfPrincipalInYearThreeBeforeUnamortizedDebtIssuanceCosts" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="mnmd_DebtRepaymentsOfPrincipalInYearFourBeforeUnamortizedDebtIssuanceCosts" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentFeeAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtNoncurrent" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mindmed.co/20250331/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfReportableSegments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mindmed.co/20250331/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalExpenseDetailsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_GeneralAndAdministrativeInternalExpense" xlink:label="mnmd_GeneralAndAdministrativeInternalExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_ResearchAndDevelopmentInternalExpense" xlink:label="mnmd_ResearchAndDevelopmentInternalExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_GeneralAndAdministrativeExternalExpense" xlink:label="mnmd_GeneralAndAdministrativeExternalExpense"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_ResearchAndDevelopmentExternalExpense" xlink:label="mnmd_ResearchAndDevelopmentExternalExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="mnmd_GeneralAndAdministrativeInternalExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="mnmd_ResearchAndDevelopmentInternalExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_SegmentReportingInformationLineItems" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpenseAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="mnmd_GeneralAndAdministrativeExternalExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="mnmd_ResearchAndDevelopmentExternalExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpenseAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_NetIncomeLoss" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mindmed.co/20250331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_RestructuredAgreementMember" xlink:label="mnmd_RestructuredAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_FirstTrancheTermLoanMember" xlink:label="mnmd_FirstTrancheTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_TermLoanMember" xlink:label="mnmd_TermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_K2HealthventuresLlcMember" xlink:label="mnmd_K2HealthventuresLlcMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_AmendmentTermLoansMember" xlink:label="mnmd_AmendmentTermLoansMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_SubsequentTrancheTermLoanMember" xlink:label="mnmd_SubsequentTrancheTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_AdditionalTrancheTermLoanMember" xlink:label="mnmd_AdditionalTrancheTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_DebtInstrumentExtendedMaturityDate" xlink:label="mnmd_DebtInstrumentExtendedMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_CovenantShallBeWaivedDuringMarketCapitalizationExceeds" xlink:label="mnmd_CovenantShallBeWaivedDuringMarketCapitalizationExceeds"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_LoanMaturityTerm" xlink:label="mnmd_LoanMaturityTerm"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_LoanExtendedTerm" xlink:label="mnmd_LoanExtendedTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mnmd_RestructuredAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LineOfCredit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="mnmd_FirstTrancheTermLoanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="mnmd_TermLoanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="mnmd_K2HealthventuresLlcMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mnmd_AmendmentTermLoansMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="mnmd_SubsequentTrancheTermLoanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_CreditFacilityAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="mnmd_AdditionalTrancheTermLoanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_DebtInstrumentAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_RangeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="mnmd_DebtInstrumentExtendedMaturityDate" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="mnmd_CovenantShallBeWaivedDuringMarketCapitalizationExceeds" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="mnmd_LoanMaturityTerm" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="mnmd_LoanExtendedTerm" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_SubordinateVotingMember" xlink:label="mnmd_SubordinateVotingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_MultipleVotingMember" xlink:label="mnmd_MultipleVotingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermLineOfCredit" xlink:label="us-gaap_LongTermLineOfCredit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_FinancingWarrantsLiability" xlink:label="mnmd_FinancingWarrantsLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mnmd_SubordinateVotingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mnmd_MultipleVotingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LongTermLineOfCredit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Goodwill" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="mnmd_FinancingWarrantsLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_LongTermInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_SubordinateVotingMember" xlink:label="mnmd_SubordinateVotingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorizedUnlimited" xlink:label="us-gaap_CommonStockSharesAuthorizedUnlimited"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_MultipleVotingMember" xlink:label="mnmd_MultipleVotingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mnmd_SubordinateVotingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorizedUnlimited" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mnmd_MultipleVotingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_SubordinateVotingMember" xlink:label="mnmd_SubordinateVotingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_UsdFinancingWarrantsMember" xlink:label="mnmd_UsdFinancingWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_MultipleVotingMember" xlink:label="mnmd_MultipleVotingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_StockIssuedDuringPeriodValueUponSettlementOfRestrictedStockUnitAwardsNetOfSharesWithheldForTax" xlink:label="mnmd_StockIssuedDuringPeriodValueUponSettlementOfRestrictedStockUnitAwardsNetOfSharesWithheldForTax"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_StockIssuedDuringPeriodSharesUponSettlementOfRestrictedStockUnitAwardsNetOfSharesWithheldForTax" xlink:label="mnmd_StockIssuedDuringPeriodSharesUponSettlementOfRestrictedStockUnitAwardsNetOfSharesWithheldForTax"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_StockIssuedDuringPeriodSharesSettlementOfRestrictedStockUnitAwards" xlink:label="mnmd_StockIssuedDuringPeriodSharesSettlementOfRestrictedStockUnitAwards"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="mnmd_StockIssuedDuringPeriodValueWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="mnmd_StockIssuedDuringPeriodSharesWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mnmd_SubordinateVotingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="mnmd_UsdFinancingWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mnmd_MultipleVotingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mnmd_StockIssuedDuringPeriodValueUponSettlementOfRestrictedStockUnitAwardsNetOfSharesWithheldForTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mnmd_StockIssuedDuringPeriodSharesUponSettlementOfRestrictedStockUnitAwardsNetOfSharesWithheldForTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mnmd_StockIssuedDuringPeriodSharesSettlementOfRestrictedStockUnitAwards" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mnmd_StockIssuedDuringPeriodValueWarrantsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mnmd_StockIssuedDuringPeriodSharesWarrantsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_PreFundedWarrantsMember" xlink:label="mnmd_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate201613Member" xlink:label="us-gaap_AccountingStandardsUpdate201613Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate201912Member" xlink:label="us-gaap_AccountingStandardsUpdate201912Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="dei_EntityIncorporationDateOfIncorporation"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_BusinessCombinationMaximumMeasurementPeriod" xlink:label="mnmd_BusinessCombinationMaximumMeasurementPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="mnmd_PreFundedWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201613Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201912Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="dei_EntityIncorporationDateOfIncorporation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="mnmd_BusinessCombinationMaximumMeasurementPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilut">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_UsdFinancingWarrantsMember" xlink:label="mnmd_UsdFinancingWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_ConversionSharesMember" xlink:label="mnmd_ConversionSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="mnmd_UsdFinancingWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="mnmd_ConversionSharesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.mindmed.co/20250331/taxonomy/role/DisclosureInvestmentsScheduleOfAvailableforsaleInvestmentsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="us-gaap_ShortTermInvestmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_LongTermInvestmentsMember" xlink:label="mnmd_LongTermInvestmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_MarketableSecuritiesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_ShortTermInvestmentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="mnmd_LongTermInvestmentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.mindmed.co/20250331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_DirectorsDeferredShareUnitsLiabilityMember" xlink:label="mnmd_DirectorsDeferredShareUnitsLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember" xlink:label="mnmd_TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="mnmd_DirectorsDeferredShareUnitsLiabilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="mnmd_TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember" xlink:label="mnmd_TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="mnmd_TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.mindmed.co/20250331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssumptionsUsedToDetermineFairValueOf2022UsdFinancingWarrantsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember" xlink:label="mnmd_TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingValuationTechniqueExtensibleList" xlink:label="us-gaap_WarrantsAndRightsOutstandingValuationTechniqueExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputSharePriceMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="mnmd_TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_MeasurementInputTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingValuationTechniqueExtensibleList" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.mindmed.co/20250331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="us-gaap_DevelopedTechnologyRightsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="us-gaap_GoodwillAcquiredDuringPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_IndicationOfImpairmentOfGoodwillAndLongLivedAssets" xlink:label="mnmd_IndicationOfImpairmentOfGoodwillAndLongLivedAssets"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_DevelopedTechnologyRightsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_GoodwillAcquiredDuringPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="mnmd_IndicationOfImpairmentOfGoodwillAndLongLivedAssets" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.mindmed.co/20250331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetSummaryOfCarryingValueOfIntangibleAssetsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="us-gaap_DevelopedTechnologyRightsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_DevelopedTechnologyRightsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_TwoThousandTwentyFourAtTheMarketOfferingProgramMember" xlink:label="mnmd_TwoThousandTwentyFourAtTheMarketOfferingProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockNoParValue" xlink:label="us-gaap_CommonStockNoParValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_AtTheMarketOfferingProgramMember" xlink:label="mnmd_AtTheMarketOfferingProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_PreFundedWarrantsMember" xlink:label="mnmd_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_TwoThousandTwentyTwoAtTheMarketOfferingProgramMember" xlink:label="mnmd_TwoThousandTwentyTwoAtTheMarketOfferingProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_CommonStockSharesIssuedAndOutstanding" xlink:label="mnmd_CommonStockSharesIssuedAndOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_UnderwrittenOfferingMember" xlink:label="mnmd_UnderwrittenOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_SaleOfEquityAggregatePublicOfferingAmount" xlink:label="mnmd_SaleOfEquityAggregatePublicOfferingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_PercentageOfGrossProceedsSaleOfCommonSharesPayableAsSalesAgentsCommissionRate" xlink:label="mnmd_PercentageOfGrossProceedsSaleOfCommonSharesPayableAsSalesAgentsCommissionRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_SaleOfEquityRemainingOfferingAmount" xlink:label="mnmd_SaleOfEquityRemainingOfferingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_CommonStockNumberOfVotesPerShare" xlink:label="mnmd_CommonStockNumberOfVotesPerShare"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_PercentageOfOutstandingSharesToBeHeldToVote" xlink:label="mnmd_PercentageOfOutstandingSharesToBeHeldToVote"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_CommonStockConvertibleConversionRatio" xlink:label="mnmd_CommonStockConvertibleConversionRatio"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockConversionBasis" xlink:label="us-gaap_CommonStockConversionBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockConversionFeatures" xlink:label="us-gaap_CommonStockConversionFeatures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="us-gaap_BusinessAcquisitionSharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_OfferingPrice" xlink:label="mnmd_OfferingPrice"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_GrossProceedsFromIssuanceOfCommonShares" xlink:label="mnmd_GrossProceedsFromIssuanceOfCommonShares"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_ShareIssuanceCosts" xlink:label="mnmd_ShareIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_WarrantsIssued" xlink:label="mnmd_WarrantsIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockTypeOfStockConverted" xlink:label="us-gaap_ConversionOfStockTypeOfStockConverted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_AggregateNumberOfCommonSharesOwnedByHolderPercentage" xlink:label="mnmd_AggregateNumberOfCommonSharesOwnedByHolderPercentage"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_PercentageOfIncreaseOrDecreaseOfOwnershipByPreFundedWarrantsHolder" xlink:label="mnmd_PercentageOfIncreaseOrDecreaseOfOwnershipByPreFundedWarrantsHolder"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="mnmd_TwoThousandTwentyFourAtTheMarketOfferingProgramMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockNoParValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="mnmd_AtTheMarketOfferingProgramMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="mnmd_PreFundedWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="mnmd_TwoThousandTwentyTwoAtTheMarketOfferingProgramMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mnmd_CommonStockSharesIssuedAndOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="mnmd_UnderwrittenOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mnmd_SaleOfEquityAggregatePublicOfferingAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mnmd_PercentageOfGrossProceedsSaleOfCommonSharesPayableAsSalesAgentsCommissionRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mnmd_SaleOfEquityRemainingOfferingAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mnmd_CommonStockNumberOfVotesPerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mnmd_PercentageOfOutstandingSharesToBeHeldToVote" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockVotingRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mnmd_CommonStockConvertibleConversionRatio" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockConversionBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockConversionFeatures" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_BusinessAcquisitionSharePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mnmd_OfferingPrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mnmd_GrossProceedsFromIssuanceOfCommonShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mnmd_ShareIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mnmd_WarrantsIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ConversionOfStockTypeOfStockConverted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="31" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="32" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mnmd_AggregateNumberOfCommonSharesOwnedByHolderPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="33" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mnmd_PercentageOfIncreaseOrDecreaseOfOwnershipByPreFundedWarrantsHolder" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="34" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.mindmed.co/20250331/taxonomy/role/DisclosureShareholdersEquitySummaryOfSharesReservedForIssuanceDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_OptionsIssuedAndOutstandingUnderStockOptionPlanMember" xlink:label="mnmd_OptionsIssuedAndOutstandingUnderStockOptionPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_UnvestedRestrictedStockUnitsRsusMember" xlink:label="mnmd_UnvestedRestrictedStockUnitsRsusMember"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_VestedAndUnissuedRestrictedStockUnitsRsusMember" xlink:label="mnmd_VestedAndUnissuedRestrictedStockUnitsRsusMember"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_CompensationWarrantsMember" xlink:label="mnmd_CompensationWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_FinancingWarrantsMember" xlink:label="mnmd_FinancingWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_SharesAvailableForGrantUnderStockOptionPlanMember" xlink:label="mnmd_SharesAvailableForGrantUnderStockOptionPlanMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mnmd_OptionsIssuedAndOutstandingUnderStockOptionPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mnmd_UnvestedRestrictedStockUnitsRsusMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mnmd_VestedAndUnissuedRestrictedStockUnitsRsusMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mnmd_CompensationWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mnmd_FinancingWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mnmd_SharesAvailableForGrantUnderStockOptionPlanMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureWarrantsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_BoughtDealFinancingMember" xlink:label="mnmd_BoughtDealFinancingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_UnderwrittenPublicOfferingMember" xlink:label="mnmd_UnderwrittenPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_SubordinateVotingSharesMember" xlink:label="mnmd_SubordinateVotingSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_CadFinancingAndCompensationWarrantsMember" xlink:label="mnmd_CadFinancingAndCompensationWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember" xlink:label="mnmd_TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_ExerciseOfWarrantShares" xlink:label="mnmd_ExerciseOfWarrantShares"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_CompensationWarrantsMember" xlink:label="mnmd_CompensationWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_CommonShareAndWarrantPublicOfferingMember" xlink:label="mnmd_CommonShareAndWarrantPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_FinancingWarrantsMember" xlink:label="mnmd_FinancingWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_CommonShareAndWarrantPublicOfferingExpireDate" xlink:label="mnmd_CommonShareAndWarrantPublicOfferingExpireDate"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachUnit" xlink:label="mnmd_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachUnit"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_WeightedAverageFairValueOfSharesPurchasedUponExerciseOfWarrants" xlink:label="mnmd_WeightedAverageFairValueOfSharesPurchasedUponExerciseOfWarrants"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mnmd_BoughtDealFinancingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="mnmd_UnderwrittenPublicOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="mnmd_SubordinateVotingSharesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="mnmd_CadFinancingAndCompensationWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="mnmd_TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="mnmd_ExerciseOfWarrantShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="mnmd_CompensationWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="mnmd_CommonShareAndWarrantPublicOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="mnmd_FinancingWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="mnmd_CommonShareAndWarrantPublicOfferingExpireDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="mnmd_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachUnit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="mnmd_WeightedAverageFairValueOfSharesPurchasedUponExerciseOfWarrants" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.mindmed.co/20250331/taxonomy/role/DisclosureWarrantsSummaryOfOutstandingLiabilityClassifiedAsWarrantsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember" xlink:label="mnmd_TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_WarrantsIssued" xlink:label="mnmd_WarrantsIssued"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_WarrantsExercised" xlink:label="mnmd_WarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_WarrantsExpired" xlink:label="mnmd_WarrantsExpired"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="mnmd_TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="mnmd_WarrantsIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="mnmd_WarrantsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="mnmd_WarrantsExpired" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.mindmed.co/20250331/taxonomy/role/DisclosureWarrantsSummaryOfActivityOfOutstandingWarrantLiabilityDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember" xlink:label="mnmd_TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_WarrantExercise" xlink:label="mnmd_WarrantExercise"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="mnmd_TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="mnmd_WarrantExercise" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_MindMedStockOptionPlanMember" xlink:label="mnmd_MindMedStockOptionPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain" xlink:label="currency_AllCurrenciesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_CAD" xlink:label="currency_CAD"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_LoanMember" xlink:label="mnmd_LoanMember"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_SubordinateVotingSharesMember" xlink:label="mnmd_SubordinateVotingSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_CommonStockClassDMember" xlink:label="mnmd_CommonStockClassDMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CurrencyAxis" xlink:label="srt_CurrencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain" xlink:label="currency_AllCurrenciesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_USD" xlink:label="currency_USD"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_DirectorsDeferredShareUnitPlanMember" xlink:label="mnmd_DirectorsDeferredShareUnitPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" xlink:label="mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_StockBasedCompensationReversal" xlink:label="mnmd_StockBasedCompensationReversal"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="mnmd_MindMedStockOptionPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_CAD" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="mnmd_LoanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="mnmd_SubordinateVotingSharesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mnmd_CommonStockClassDMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_USD" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="mnmd_DirectorsDeferredShareUnitPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_CurrencyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mnmd_StockBasedCompensationReversal" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfFairValueAssumptionsOfOptionsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_MindMedStockOptionPlanMember" xlink:label="mnmd_MindMedStockOptionPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="mnmd_MindMedStockOptionPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain" xlink:label="currency_AllCurrenciesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_CAD" xlink:label="currency_CAD"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CurrencyAxis" xlink:label="srt_CurrencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_USD" xlink:label="currency_USD"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_CAD" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_CurrencyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_USD" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.mindmed.co/20250331/taxonomy/role/DisclosureStockbasedCompensationScheduleOfRestrictedShareUnitsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain" xlink:label="currency_AllCurrenciesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_CAD" xlink:label="currency_CAD"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CurrencyAxis" xlink:label="srt_CurrencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_USD" xlink:label="currency_USD"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedInPeriod" xlink:label="mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriod" xlink:label="mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" xlink:label="mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedInPeriodWeightedAverageGrantDateFairValue" xlink:label="mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriodWeightedAverageGrantDateFairValue" xlink:label="mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue" xlink:label="mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_CAD" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_USD" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_CurrencyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="us-gaap_LineOfCreditFacilityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="us-gaap_LineOfCreditFacilityTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_LoanAndSecurityAgreementMember" xlink:label="mnmd_LoanAndSecurityAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_FirstTrancheTermLoanMember" xlink:label="mnmd_FirstTrancheTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrimeRateMember" xlink:label="us-gaap_PrimeRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_TermLoanMember" xlink:label="mnmd_TermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_K2HealthventuresLlcMember" xlink:label="mnmd_K2HealthventuresLlcMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_SecondMilestoneBasedTrancheTermLoanMember" xlink:label="mnmd_SecondMilestoneBasedTrancheTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_SubsequentTrancheTermLoanMember" xlink:label="mnmd_SubsequentTrancheTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_AdditionalTrancheTermLoanMember" xlink:label="mnmd_AdditionalTrancheTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" xlink:label="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_PercentageOfFinalPaymentFee" xlink:label="mnmd_PercentageOfFinalPaymentFee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="us-gaap_DebtInstrumentFeeAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" xlink:label="us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_DebtInstrumentConvertibleConvertedIntoCommonShares" xlink:label="mnmd_DebtInstrumentConvertibleConvertedIntoCommonShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateTerms" xlink:label="us-gaap_DebtInstrumentInterestRateTerms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:label="us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mnmd_LoanAndSecurityAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="mnmd_FirstTrancheTermLoanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_PrimeRateMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="mnmd_TermLoanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_CreditFacilityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="mnmd_K2HealthventuresLlcMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="mnmd_SecondMilestoneBasedTrancheTermLoanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_PaymentsOfFinancingCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="mnmd_SubsequentTrancheTermLoanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="mnmd_AdditionalTrancheTermLoanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_VariableRateAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="mnmd_PercentageOfFinalPaymentFee" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentFeeAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="mnmd_DebtInstrumentConvertibleConvertedIntoCommonShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_InterestExpenseDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateTerms" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.mindmed.co/20250331/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalExpenseDetailsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_GeneralAndAdministrativeInternalExpense" xlink:label="mnmd_GeneralAndAdministrativeInternalExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_ResearchAndDevelopmentInternalExpense" xlink:label="mnmd_ResearchAndDevelopmentInternalExpense"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_GeneralAndAdministrativeExternalExpense" xlink:label="mnmd_GeneralAndAdministrativeExternalExpense"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_ResearchAndDevelopmentExternalExpense" xlink:label="mnmd_ResearchAndDevelopmentExternalExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="mnmd_GeneralAndAdministrativeInternalExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="mnmd_ResearchAndDevelopmentInternalExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpenseAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="mnmd_GeneralAndAdministrativeExternalExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="mnmd_ResearchAndDevelopmentExternalExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpenseAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_OperatingIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.mindmed.co/20250331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_RestructuredAgreementMember" xlink:label="mnmd_RestructuredAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_FirstTrancheTermLoanMember" xlink:label="mnmd_FirstTrancheTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_TermLoanMember" xlink:label="mnmd_TermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_K2HealthventuresLlcMember" xlink:label="mnmd_K2HealthventuresLlcMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_AmendmentTermLoansMember" xlink:label="mnmd_AmendmentTermLoansMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_SubsequentTrancheTermLoanMember" xlink:label="mnmd_SubsequentTrancheTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_AdditionalTrancheTermLoanMember" xlink:label="mnmd_AdditionalTrancheTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_DebtInstrumentExtendedMaturityDate" xlink:label="mnmd_DebtInstrumentExtendedMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_CovenantShallBeWaivedDuringMarketCapitalizationExceeds" xlink:label="mnmd_CovenantShallBeWaivedDuringMarketCapitalizationExceeds"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_LoanMaturityTerm" xlink:label="mnmd_LoanMaturityTerm"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_LoanExtendedTerm" xlink:label="mnmd_LoanExtendedTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mnmd_RestructuredAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LineOfCredit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="mnmd_FirstTrancheTermLoanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="mnmd_TermLoanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="mnmd_K2HealthventuresLlcMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mnmd_AmendmentTermLoansMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="mnmd_SubsequentTrancheTermLoanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_CreditFacilityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="mnmd_AdditionalTrancheTermLoanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="mnmd_DebtInstrumentExtendedMaturityDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="mnmd_CovenantShallBeWaivedDuringMarketCapitalizationExceeds" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="mnmd_LoanMaturityTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="mnmd_LoanExtendedTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrimeRateMember" xlink:label="us-gaap_PrimeRateMember"/>
        </link:definitionLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_LongTermInvestments" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ShortTermInvestments" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Goodwill" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LongTermLineOfCredit" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="mnmd_FinancingWarrantsLiability" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="4" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermLineOfCredit" xlink:label="us-gaap_LongTermLineOfCredit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_FinancingWarrantsLiability" xlink:label="mnmd_FinancingWarrantsLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_UnrealizedGainLossOnInvestments" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterestAndDividend" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpense" order="3" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="4" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterestAndDividend" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireInvestments" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="mnmd_ProceedsFromOfferingAndPrivatePlacement" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="mnmd_ChangeInFairValueOnDirectorsDeferredShareUnits" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="mnmd_ProceedsFromAtTheMarketOfferingProgramNetOfIssuanceCosts" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="3" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfFinancingCosts" order="5" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="mnmd_OtherNonCashAdjustments" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" order="7" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="8" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="8" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="9" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="10" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="11" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="mnmd_OtherLiabilitiesLongTerm" order="13" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="14" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="17" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="18" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_ProceedsFromOfferingAndPrivatePlacement" xlink:label="mnmd_ProceedsFromOfferingAndPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_ChangeInFairValueOnDirectorsDeferredShareUnits" xlink:label="mnmd_ChangeInFairValueOnDirectorsDeferredShareUnits"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_ProceedsFromAtTheMarketOfferingProgramNetOfIssuanceCosts" xlink:label="mnmd_ProceedsFromAtTheMarketOfferingProgramNetOfIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_OtherNonCashAdjustments" xlink:label="mnmd_OtherNonCashAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_OtherLiabilitiesLongTerm" xlink:label="mnmd_OtherLiabilitiesLongTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="mnmd_WeightedAverageNumberOfPreFundedWarrantsOutstandingBasic" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="mnmd_WeightedAverageNumberOfCommonSharesOutstandingBasic" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_WeightedAverageNumberOfPreFundedWarrantsOutstandingBasic" xlink:label="mnmd_WeightedAverageNumberOfPreFundedWarrantsOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_WeightedAverageNumberOfCommonSharesOutstandingBasic" xlink:label="mnmd_WeightedAverageNumberOfCommonSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.mindmed.co/20250331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetSummaryOfCarryingValueOfIntangibleAssetsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_WorkersCompensationLiabilityCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="mnmd_AccruedOtherResearchAndDevelopmentCostsCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="mnmd_AccruedClinicalAndManufacturingCosts" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="5" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WorkersCompensationLiabilityCurrent" xlink:label="us-gaap_WorkersCompensationLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_AccruedOtherResearchAndDevelopmentCostsCurrent" xlink:label="mnmd_AccruedOtherResearchAndDevelopmentCostsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_AccruedClinicalAndManufacturingCosts" xlink:label="mnmd_AccruedClinicalAndManufacturingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacilityScheduleOfFutureExpectedRepaymentsOfPrincipalAmountDueOnCreditFacilityDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="mnmd_DebtRepaymentsOfPrincipalRemainderOfFiscalYearBeforeUnamortizedDebtIssuanceCost" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="mnmd_DebtRepaymentsOfPrincipalInNextTwelveMonthsBeforeUnamortizedDebtIssuanceCost" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="mnmd_DebtRepaymentsOfPrincipalInYearTwoBeforeUnamortizedDebtIssuanceCost" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="mnmd_DebtRepaymentsOfPrincipalInYearThreeBeforeUnamortizedDebtIssuanceCosts" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="mnmd_DebtRepaymentsOfPrincipalInYearFourBeforeUnamortizedDebtIssuanceCosts" order="4" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_DebtRepaymentsOfPrincipalRemainderOfFiscalYearBeforeUnamortizedDebtIssuanceCost" xlink:label="mnmd_DebtRepaymentsOfPrincipalRemainderOfFiscalYearBeforeUnamortizedDebtIssuanceCost"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_DebtRepaymentsOfPrincipalInNextTwelveMonthsBeforeUnamortizedDebtIssuanceCost" xlink:label="mnmd_DebtRepaymentsOfPrincipalInNextTwelveMonthsBeforeUnamortizedDebtIssuanceCost"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_DebtRepaymentsOfPrincipalInYearTwoBeforeUnamortizedDebtIssuanceCost" xlink:label="mnmd_DebtRepaymentsOfPrincipalInYearTwoBeforeUnamortizedDebtIssuanceCost"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_DebtRepaymentsOfPrincipalInYearThreeBeforeUnamortizedDebtIssuanceCosts" xlink:label="mnmd_DebtRepaymentsOfPrincipalInYearThreeBeforeUnamortizedDebtIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_DebtRepaymentsOfPrincipalInYearFourBeforeUnamortizedDebtIssuanceCosts" xlink:label="mnmd_DebtRepaymentsOfPrincipalInYearFourBeforeUnamortizedDebtIssuanceCosts"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.mindmed.co/20250331/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalExpenseDetailsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="mnmd_GeneralAndAdministrativeInternalExpense" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="mnmd_ResearchAndDevelopmentInternalExpense" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="mnmd_GeneralAndAdministrativeExternalExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="mnmd_ResearchAndDevelopmentExternalExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_GeneralAndAdministrativeInternalExpense" xlink:label="mnmd_GeneralAndAdministrativeInternalExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_ResearchAndDevelopmentInternalExpense" xlink:label="mnmd_ResearchAndDevelopmentInternalExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_GeneralAndAdministrativeExternalExpense" xlink:label="mnmd_GeneralAndAdministrativeExternalExpense"/>
          <link:loc xlink:type="locator" xlink:href="mnmd-20250331.xsd#mnmd_ResearchAndDevelopmentExternalExpense" xlink:label="mnmd_ResearchAndDevelopmentExternalExpense"/>
        </link:calculationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="mnmd_WeightedAverageNumberOfDilutedCommonSharesOutstanding" name="WeightedAverageNumberOfDilutedCommonSharesOutstanding" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="mnmd_WarrantsPolicyTextBlock" name="WarrantsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="mnmd_SaleOfEquityAggregatePublicOfferingAmount" name="SaleOfEquityAggregatePublicOfferingAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="mnmd_OtherNonCashAdjustments" name="OtherNonCashAdjustments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="mnmd_UsdFinancingWarrantsMember" name="UsdFinancingWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="mnmd_LongTermInvestmentsMember" name="LongTermInvestmentsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="mnmd_ProceedsFromExerciseOfOptionsInPrepaidAndOtherCurrentAssets" name="ProceedsFromExerciseOfOptionsInPrepaidAndOtherCurrentAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="mnmd_RestructuredAgreementMember" name="RestructuredAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="mnmd_DebtRepaymentsOfPrincipalInYearFourBeforeUnamortizedDebtIssuanceCosts" name="DebtRepaymentsOfPrincipalInYearFourBeforeUnamortizedDebtIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="mnmd_WeightedAverageNumberOfPreFundedWarrantsOutstandingBasic" name="WeightedAverageNumberOfPreFundedWarrantsOutstandingBasic" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="mnmd_CommonStockClassDMember" name="CommonStockClassDMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="mnmd_ShareIssuanceCosts" name="ShareIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="mnmd_PreFundedWarrantsMember" name="PreFundedWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="mnmd_CommonStockConvertibleConversionRatio" name="CommonStockConvertibleConversionRatio" type="xbrli:pureItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="mnmd_ProceedsFromAtTheMarketOfferingProgramNetOfIssuanceCosts" name="ProceedsFromAtTheMarketOfferingProgramNetOfIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="mnmd_StockBasedCompensationReversal" name="StockBasedCompensationReversal" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="mnmd_WarrantsExpired" name="WarrantsExpired" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="mnmd_StockIssuedDuringPeriodValueWarrantsExercised" name="StockIssuedDuringPeriodValueWarrantsExercised" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="mnmd_TermLoanMember" name="TermLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="mnmd_UnderwrittenOfferingMember" name="UnderwrittenOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="mnmd_AccruedClinicalAndManufacturingCosts" name="AccruedClinicalAndManufacturingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="mnmd_SubordinateVotingSharesMember" name="SubordinateVotingSharesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="mnmd_StockIssuedDuringPeriodSharesSettlementOfRestrictedStockUnitAwards" name="StockIssuedDuringPeriodSharesSettlementOfRestrictedStockUnitAwards" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="mnmd_WarrantExercise" name="WarrantExercise" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="mnmd_SummaryOfSharesReservedForIssuanceTableTextBlock" name="SummaryOfSharesReservedForIssuanceTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="mnmd_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachUnit" name="ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachUnit" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="mnmd_UnpaidIssuanceCostsForCommonShares" name="UnpaidIssuanceCostsForCommonShares" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="mnmd_IndicationOfImpairmentOfGoodwillAndLongLivedAssets" name="IndicationOfImpairmentOfGoodwillAndLongLivedAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="mnmd_SecondMilestoneBasedTrancheTermLoanMember" name="SecondMilestoneBasedTrancheTermLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="mnmd_ExerciseOfWarrantShares" name="ExerciseOfWarrantShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="mnmd_SubordinateVotingMember" name="SubordinateVotingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="mnmd_PercentageOfGrossProceedsSaleOfCommonSharesPayableAsSalesAgentsCommissionRate" name="PercentageOfGrossProceedsSaleOfCommonSharesPayableAsSalesAgentsCommissionRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="mnmd_ScheduleOfWarrantLiabilityTableTextBlock" name="ScheduleOfWarrantLiabilityTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="mnmd_StockIssuedDuringPeriodValueUponSettlementOfRestrictedStockUnitAwardsNetOfSharesWithheldForTax" name="StockIssuedDuringPeriodValueUponSettlementOfRestrictedStockUnitAwardsNetOfSharesWithheldForTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="mnmd_WeightedAverageNumberOfCommonSharesOutstandingBasic" name="WeightedAverageNumberOfCommonSharesOutstandingBasic" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="mnmd_ReclassOfDeferredFinancingFeesToAdditionalPaidInCapital" name="ReclassOfDeferredFinancingFeesToAdditionalPaidInCapital" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="mnmd_TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember" name="TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="mnmd_StockIssuedDuringPeriodSharesUponSettlementOfRestrictedStockUnitAwardsNetOfSharesWithheldForTax" name="StockIssuedDuringPeriodSharesUponSettlementOfRestrictedStockUnitAwardsNetOfSharesWithheldForTax" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="mnmd_PercentageOfOutstandingSharesToBeHeldToVote" name="PercentageOfOutstandingSharesToBeHeldToVote" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="mnmd_K2HealthventuresLlcMember" name="K2HealthventuresLlcMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="mnmd_ResearchAndDevelopmentInternalExpense" name="ResearchAndDevelopmentInternalExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="mnmd_AccruedOtherResearchAndDevelopmentCostsCurrent" name="AccruedOtherResearchAndDevelopmentCostsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="mnmd_MultipleVotingMember" name="MultipleVotingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="mnmd_AtTheMarketOfferingProgramMember" name="AtTheMarketOfferingProgramMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriodWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriodWeightedAverageGrantDateFairValue" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="mnmd_GrossProceedsFromIssuanceOfCommonShares" name="GrossProceedsFromIssuanceOfCommonShares" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="mnmd_PercentageOfFinalPaymentFee" name="PercentageOfFinalPaymentFee" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="mnmd_ShareBasedPaymentArrangementDirectorsDeferredShareUnitPlanActivityTableTextBlock" name="ShareBasedPaymentArrangementDirectorsDeferredShareUnitPlanActivityTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="mnmd_DebtRepaymentsOfPrincipalInNextTwelveMonthsBeforeUnamortizedDebtIssuanceCost" name="DebtRepaymentsOfPrincipalInNextTwelveMonthsBeforeUnamortizedDebtIssuanceCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="mnmd_AdditionalTrancheTermLoanMember" name="AdditionalTrancheTermLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="mnmd_TwoThousandTwentyFourAtTheMarketOfferingProgramMember" name="TwoThousandTwentyFourAtTheMarketOfferingProgramMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="mnmd_SubsequentTrancheTermLoanMember" name="SubsequentTrancheTermLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="mnmd_ProceedsFromOfferingAndPrivatePlacement" name="ProceedsFromOfferingAndPrivatePlacement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="mnmd_ResearchAndDevelopmentExternalExpense" name="ResearchAndDevelopmentExternalExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="mnmd_FirstTrancheTermLoanMember" name="FirstTrancheTermLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedInPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="mnmd_LoanMaturityTerm" name="LoanMaturityTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="mnmd_StockIssuedDuringPeriodSharesWarrantsExercised" name="StockIssuedDuringPeriodSharesWarrantsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="mnmd_CadFinancingAndCompensationWarrantsMember" name="CadFinancingAndCompensationWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="mnmd_WeightedAverageNumberOfDilutedPreFundedWarrantsOutstanding" name="WeightedAverageNumberOfDilutedPreFundedWarrantsOutstanding" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="mnmd_SaleOfEquityRemainingOfferingAmount" name="SaleOfEquityRemainingOfferingAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedInPeriodWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedInPeriodWeightedAverageGrantDateFairValue" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="mnmd_DebtRepaymentsOfPrincipalInYearThreeBeforeUnamortizedDebtIssuanceCosts" name="DebtRepaymentsOfPrincipalInYearThreeBeforeUnamortizedDebtIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="mnmd_BusinessCombinationMaximumMeasurementPeriod" name="BusinessCombinationMaximumMeasurementPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="mnmd_OptionsIssuedAndOutstandingUnderStockOptionPlanMember" name="OptionsIssuedAndOutstandingUnderStockOptionPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="mnmd_FinancingWarrantsMember" name="FinancingWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="mnmd_LoanMember" name="LoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="mnmd_LoanAndSecurityAgreementMember" name="LoanAndSecurityAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="mnmd_GeneralAndAdministrativeExternalExpense" name="GeneralAndAdministrativeExternalExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="mnmd_LoanExtendedTerm" name="LoanExtendedTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="mnmd_DebtInstrumentExtendedMaturityDate" name="DebtInstrumentExtendedMaturityDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="mnmd_FinancingWarrantsLiability" name="FinancingWarrantsLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="mnmd_AggregateNumberOfCommonSharesOwnedByHolderPercentage" name="AggregateNumberOfCommonSharesOwnedByHolderPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="mnmd_ConversionSharesMember" name="ConversionSharesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="mnmd_CommonStockNumberOfVotesPerShare" name="CommonStockNumberOfVotesPerShare" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="mnmd_UnpaidIssuanceCostsForOfferingAndPrivatePlacement" name="UnpaidIssuanceCostsForOfferingAndPrivatePlacement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="mnmd_VestedAndUnissuedRestrictedStockUnitsRsusMember" name="VestedAndUnissuedRestrictedStockUnitsRsusMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="mnmd_TwoThousandTwentyTwoAtTheMarketOfferingProgramMember" name="TwoThousandTwentyTwoAtTheMarketOfferingProgramMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="mnmd_OtherLiabilitiesLongTerm" name="OtherLiabilitiesLongTerm" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="mnmd_AmendmentTermLoansMember" name="AmendmentTermLoansMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="mnmd_CommonShareAndWarrantPublicOfferingExpireDate" name="CommonShareAndWarrantPublicOfferingExpireDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="mnmd_DebtRepaymentsOfPrincipalRemainderOfFiscalYearBeforeUnamortizedDebtIssuanceCost" name="DebtRepaymentsOfPrincipalRemainderOfFiscalYearBeforeUnamortizedDebtIssuanceCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="mnmd_DirectorsDeferredShareUnitsLiabilityMember" name="DirectorsDeferredShareUnitsLiabilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="mnmd_WarrantsDisclosureTextBlock" name="WarrantsDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="mnmd_DebtInstrumentConvertibleConvertedIntoCommonShares" name="DebtInstrumentConvertibleConvertedIntoCommonShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="mnmd_CommonStockSharesIssuedAndOutstanding" name="CommonStockSharesIssuedAndOutstanding" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="mnmd_UnvestedRestrictedStockUnitsRsusMember" name="UnvestedRestrictedStockUnitsRsusMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="mnmd_WeightedAverageFairValueOfSharesPurchasedUponExerciseOfWarrants" name="WeightedAverageFairValueOfSharesPurchasedUponExerciseOfWarrants" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="mnmd_CompensationWarrantsMember" name="CompensationWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="mnmd_BoughtDealFinancingMember" name="BoughtDealFinancingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="mnmd_NatureOfOperationsAbstract" name="NatureOfOperationsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="mnmd_CovenantShallBeWaivedDuringMarketCapitalizationExceeds" name="CovenantShallBeWaivedDuringMarketCapitalizationExceeds" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="mnmd_PercentageOfIncreaseOrDecreaseOfOwnershipByPreFundedWarrantsHolder" name="PercentageOfIncreaseOrDecreaseOfOwnershipByPreFundedWarrantsHolder" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="mnmd_WarrantsExercised" name="WarrantsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="mnmd_CommonShareAndWarrantPublicOfferingMember" name="CommonShareAndWarrantPublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="mnmd_OfferingPrice" name="OfferingPrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="mnmd_SharesAvailableForGrantUnderStockOptionPlanMember" name="SharesAvailableForGrantUnderStockOptionPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="mnmd_UnderwrittenPublicOfferingMember" name="UnderwrittenPublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="mnmd_ChangeInFairValueOnDirectorsDeferredShareUnits" name="ChangeInFairValueOnDirectorsDeferredShareUnits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="mnmd_GeneralAndAdministrativeInternalExpense" name="GeneralAndAdministrativeInternalExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="mnmd_WarrantsIssued" name="WarrantsIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="mnmd_MindMedStockOptionPlanMember" name="MindMedStockOptionPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="mnmd_DirectorsDeferredShareUnitPlanMember" name="DirectorsDeferredShareUnitPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="mnmd_DebtRepaymentsOfPrincipalInYearTwoBeforeUnamortizedDebtIssuanceCost" name="DebtRepaymentsOfPrincipalInYearTwoBeforeUnamortizedDebtIssuanceCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Apr. 23, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Mind Medicine (MindMed) Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001813814<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MNMD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Shares, no par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">A1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-1582438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">One World Trade Center<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 8500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">220-6633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,553,266<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 82,854<span></span>
</td>
<td class="nump">$ 273,741<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">129,587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="nump">9,259<span></span>
</td>
<td class="nump">7,879<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">221,700<span></span>
</td>
<td class="nump">281,620<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">19,918<span></span>
</td>
<td class="nump">19,918<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">33,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">606<span></span>
</td>
<td class="nump">613<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">275,323<span></span>
</td>
<td class="nump">302,151<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,268<span></span>
</td>
<td class="nump">2,010<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">11,497<span></span>
</td>
<td class="nump">12,829<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnmd_FinancingWarrantsLiability', window );">2022 USD Financing Warrants</a></td>
<td class="nump">16,716<span></span>
</td>
<td class="nump">24,010<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">30,481<span></span>
</td>
<td class="nump">38,849<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermLineOfCredit', window );">Credit facility, long-term</a></td>
<td class="nump">22,036<span></span>
</td>
<td class="nump">21,854<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">52,517<span></span>
</td>
<td class="nump">60,703<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common shares, no par value, unlimited authorized as of March 31, 2025 and December 31, 2024; 75,511,375 and 75,100,763 issued and outstanding as of March 31, 2025 and December 31, 2024, respectively</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">644,231<span></span>
</td>
<td class="nump">639,508<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">802<span></span>
</td>
<td class="nump">819<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(422,227)<span></span>
</td>
<td class="num">(398,879)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' equity</a></td>
<td class="nump">222,806<span></span>
</td>
<td class="nump">241,448<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders' equity</a></td>
<td class="nump">$ 275,323<span></span>
</td>
<td class="nump">$ 302,151<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnmd_FinancingWarrantsLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financing warrants liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnmd_FinancingWarrantsLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481573/470-10-45-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481573/470-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorizedUnlimited', window );">Common stock, shares authorized</a></td>
<td class="text">Unlimited<span></span>
</td>
<td class="text">Unlimited<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">75,511,375<span></span>
</td>
<td class="nump">75,100,763<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">75,511,375<span></span>
</td>
<td class="nump">75,100,763<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorizedUnlimited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether number of common shares permitted to be issued is unlimited. Acceptable value is "Unlimited".</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorizedUnlimited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:authorizedUnlimitedItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total</a></td>
<td class="nump">$ 23,357<span></span>
</td>
<td class="nump">$ 11,705<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total</a></td>
<td class="nump">8,802<span></span>
</td>
<td class="nump">10,499<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">32,159<span></span>
</td>
<td class="nump">22,204<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(32,159)<span></span>
</td>
<td class="num">(22,204)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other income/(expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterestAndDividend', window );">Interest income</a></td>
<td class="nump">2,433<span></span>
</td>
<td class="nump">1,656<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(602)<span></span>
</td>
<td class="num">(434)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange loss, net</a></td>
<td class="num">(19)<span></span>
</td>
<td class="num">(525)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of 2022 USD Financing Warrants</a></td>
<td class="nump">6,999<span></span>
</td>
<td class="num">(32,893)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total income/(expense), net</a></td>
<td class="nump">8,811<span></span>
</td>
<td class="num">(32,196)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(23,348)<span></span>
</td>
<td class="num">(54,400)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Comprehensive loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain on investments</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">(Loss)/gain on foreign currency translation</a></td>
<td class="num">(27)<span></span>
</td>
<td class="nump">493<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (23,365)<span></span>
</td>
<td class="num">$ (53,907)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share, basic</a></td>
<td class="num">$ (0.27)<span></span>
</td>
<td class="num">$ (1.14)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share, diluted</a></td>
<td class="num">$ (0.35)<span></span>
</td>
<td class="num">$ (1.14)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares, basic</a></td>
<td class="nump">85,067,855<span></span>
</td>
<td class="nump">47,860,757<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares, diluted</a></td>
<td class="nump">87,091,461<span></span>
</td>
<td class="nump">47,860,757<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481839/830-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterestAndDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterestAndDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>2022 USD Financing Warrants</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Common Stock </div>
<div>2022 USD Financing Warrants</div>
</th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>2022 USD Financing Warrants</div>
</th>
<th class="th"><div>Accumulated OCI</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 78,134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 367,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 343<span></span>
</td>
<td class="num">$ (290,200)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,101,303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common shares, net of share issuance costs</a></td>
<td class="nump">164,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares, net of share issuance costs, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,338,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnmd_StockIssuedDuringPeriodValueUponSettlementOfRestrictedStockUnitAwardsNetOfSharesWithheldForTax', window );">Issuance of common shares upon settlement of restricted share unit ("RSU") awards, net of shares withheld for tax</a></td>
<td class="num">(54)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(54)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnmd_StockIssuedDuringPeriodSharesUponSettlementOfRestrictedStockUnitAwardsNetOfSharesWithheldForTax', window );">Issuance of common shares upon settlement of restricted share unit ("RSU") awards, net of shares withheld for tax, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">204,968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnmd_StockIssuedDuringPeriodValueWarrantsExercised', window );">Exercise of financing warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnmd_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Exercise of financing warrants, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">3,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118,896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Net loss and comprehensive loss</a></td>
<td class="num">(53,907)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">493<span></span>
</td>
<td class="num">(54,400)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2024</a></td>
<td class="nump">196,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">539,823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">836<span></span>
</td>
<td class="num">(344,600)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,163,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2024</a></td>
<td class="nump">241,448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">639,508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">819<span></span>
</td>
<td class="num">(398,879)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,100,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common shares under employee share purchase plan ("ESPP") Value</a></td>
<td class="nump">186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common shares under employee share purchase plan ("ESPP") share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnmd_StockIssuedDuringPeriodSharesUponSettlementOfRestrictedStockUnitAwardsNetOfSharesWithheldForTax', window );">Issuance of common shares upon settlement of restricted share unit ("RSU") awards, net of shares withheld for tax, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186,708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnmd_StockIssuedDuringPeriodValueWarrantsExercised', window );">Exercise of financing warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnmd_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Exercise of financing warrants, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">3,426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, Shares</a></td>
<td class="nump">53,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Net loss and comprehensive loss</a></td>
<td class="num">$ (23,365)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17)<span></span>
</td>
<td class="num">(23,348)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2025</a></td>
<td class="nump">$ 222,806<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 644,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 802<span></span>
</td>
<td class="num">$ (422,227)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Mar. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,511,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnmd_StockIssuedDuringPeriodSharesUponSettlementOfRestrictedStockUnitAwardsNetOfSharesWithheldForTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares upon settlement of restricted stock unit awards, net of shares withheld for tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnmd_StockIssuedDuringPeriodSharesUponSettlementOfRestrictedStockUnitAwardsNetOfSharesWithheldForTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnmd_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnmd_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnmd_StockIssuedDuringPeriodValueUponSettlementOfRestrictedStockUnitAwardsNetOfSharesWithheldForTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value upon settlement of restricted stock unit awards, net of shares withheld for tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnmd_StockIssuedDuringPeriodValueUponSettlementOfRestrictedStockUnitAwardsNetOfSharesWithheldForTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnmd_StockIssuedDuringPeriodValueWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnmd_StockIssuedDuringPeriodValueWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (23,348)<span></span>
</td>
<td class="num">$ (54,400)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">3,426<span></span>
</td>
<td class="nump">3,689<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnmd_ChangeInFairValueOnDirectorsDeferredShareUnits', window );">Change in fair value on directors' deferred share units ("DDSU")</a></td>
<td class="num">(18)<span></span>
</td>
<td class="nump">781<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">527<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of 2022 USD Financing Warrants</a></td>
<td class="num">(6,999)<span></span>
</td>
<td class="nump">32,893<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Unrealized foreign exchange</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">514<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnmd_OtherNonCashAdjustments', window );">Other non-cash adjustments</a></td>
<td class="num">(19)<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid and other current assets</a></td>
<td class="num">(1,380)<span></span>
</td>
<td class="nump">468<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other noncurrent assets</a></td>
<td class="num">(10)<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">258<span></span>
</td>
<td class="nump">1,509<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(1,329)<span></span>
</td>
<td class="num">(2,703)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnmd_OtherLiabilitiesLongTerm', window );">Other liabilities, long-term</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(29,419)<span></span>
</td>
<td class="num">(16,598)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(162,458)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(162,458)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnmd_ProceedsFromOfferingAndPrivatePlacement', window );">Proceeds from the Offering and Private Placement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">175,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of issuance costs from the Offering and Private Placement</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(8,720)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Payment of credit facility issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(128)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnmd_ProceedsFromAtTheMarketOfferingProgramNetOfIssuanceCosts', window );">Proceeds from the at-the-market offering program, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">984<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="nump">579<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of options</a></td>
<td class="nump">237<span></span>
</td>
<td class="nump">465<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans', window );">Proceeds from issuance of common shares under ESPP</a></td>
<td class="nump">186<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Withholding taxes paid on vested RSUs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(54)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">1,002<span></span>
</td>
<td class="nump">169,247<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of exchange rate changes on cash</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase/(decrease) in cash and cash equivalents</a></td>
<td class="num">(190,887)<span></span>
</td>
<td class="nump">152,628<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">273,741<span></span>
</td>
<td class="nump">99,704<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">82,854<span></span>
</td>
<td class="nump">252,332<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Cash Flow Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">602<span></span>
</td>
<td class="nump">434<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental Noncash Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Conversion of 2022 USD Financing Warrants to common shares upon exercise of warrants</a></td>
<td class="nump">295<span></span>
</td>
<td class="nump">1,669<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnmd_UnpaidIssuanceCostsForOfferingAndPrivatePlacement', window );">Unpaid issuance costs for the Offering and Private Placement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,340<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnmd_ProceedsFromExerciseOfOptionsInPrepaidAndOtherCurrentAssets', window );">Proceeds from exercise of options in prepaid and other current assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnmd_ReclassOfDeferredFinancingFeesToAdditionalPaidInCapital', window );">Reclass of deferred financing fees to additional paid-in capital</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 332<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnmd_ChangeInFairValueOnDirectorsDeferredShareUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value on directors' deferred share units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnmd_ChangeInFairValueOnDirectorsDeferredShareUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnmd_OtherLiabilitiesLongTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other liabilities, long-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnmd_OtherLiabilitiesLongTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnmd_OtherNonCashAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other non-cash adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnmd_OtherNonCashAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnmd_ProceedsFromAtTheMarketOfferingProgramNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from the at-the-market offering program, net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnmd_ProceedsFromAtTheMarketOfferingProgramNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnmd_ProceedsFromExerciseOfOptionsInPrepaidAndOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from exercise of options in prepaid and other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnmd_ProceedsFromExerciseOfOptionsInPrepaidAndOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnmd_ProceedsFromOfferingAndPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from offering and private placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnmd_ProceedsFromOfferingAndPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnmd_ReclassOfDeferredFinancingFeesToAdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reclass of deferred financing fees to additional paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnmd_ReclassOfDeferredFinancingFeesToAdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnmd_UnpaidIssuanceCostsForOfferingAndPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unpaid issuance costs for the offering and private placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnmd_UnpaidIssuanceCostsForOfferingAndPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (23,348)<span></span>
</td>
<td class="num">$ (54,400)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnmd_NatureOfOperationsAbstract', window );"><strong>Nature Of Operations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Description of the Business</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DESCRIPTION OF THE BUSINESS</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Mind Medicine (MindMed) Inc. (the &#8220;Company&#8221; or &#8220;MindMed&#8221;) is incorporated under the laws of the Province of British Columbia. Its wholly owned subsidiaries, Mind Medicine, Inc. (&#8220;MindMed US&#8221;), HealthMode, Inc., MindMed Pty Ltd., and MindMed GmbH are incorporated in Delaware, Delaware, Australia and Switzerland respectively. MindMed US was incorporated on May 30, 2019.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">MindMed is a late-stage clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders. The Company&#8217;s mission is to be the global leader in the development and delivery of treatments for brain health disorders that unlock new opportunities to improve patient outcomes. The Company is developing a pipeline of innovative product candidates targeting neurotransmitter pathways that play key roles in brain health. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, the Company&#8217;s lead product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Liquidity</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of March 31, 2025, the Company had an accumulated deficit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">422.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. Through March 31, 2025, the Company&#8217;s financial support has primarily been provided by proceeds from the issuance of its common shares, no par value per share (&#8220;Common Shares&#8221;) and warrants to purchase Common Shares, and the Company&#8217;s credit facility.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As the Company continues its expansion, it may seek additional financing and/or strategic investments; however, there can be no assurance that any additional financing or strategic investments will be available to the Company on acceptable terms, if at all. If events or circumstances occur such that the Company does not obtain additional funding, it will most likely be required to reduce its plans and/or certain discretionary spending, which could have a material adverse effect on the Company&#8217;s ability to achieve its intended business objectives. The accompanying unaudited condensed consolidated financial statements do not include any adjustments that might be necessary if it were unable to continue as a going concern. Management believes that it has sufficient working capital on hand to fund operations through at least the next twelve months from the date of the issuance of these unaudited condensed consolidated financial statements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Emerging Growth Company Status</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use the extended transition period for complying with new or revised accounting standards, and as a result of this election, the unaudited condensed consolidated financial statements may not be comparable to companies that comply with public company Financial Accounting Standards Board (&#8220;FASB&#8221;) standards&#8217; effective dates. The Company may take advantage of these exemptions up until the last day of the fiscal year following the fifth anniversary of the first sale of its common equity securities under an effective Securities Act of 1933 (the "Securities Act") registration statement or such earlier time that it is no longer an emerging growth company.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the opinion of management, these unaudited condensed consolidated financial statements reflect all adjustments necessary for a fair presentation of the Company's financial position and results of operations and cash flows for the periods presented.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnmd_NatureOfOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nature of operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnmd_NatureOfOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Summary of Significant Accounting Policies</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">BASIS OF pRESENTATION AND Summary of Significant Accounting Policies</span></div></div><div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basis of Presentation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification and as amended by Accounting Standards Updates of FASB. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the related notes thereto for the year ended December 31, 2024, which are included in the Company&#8217;s 2024 Annual Report on Form 10-K filed with the SEC on March 6, 2025 (the &#8220;2024 Annual Report&#8221;). The Company&#8217;s significant accounting policies are disclosed in the audited consolidated financial statements for the periods ended December 31, 2024 and 2023, included in the 2024 Annual Report. Since the date of those financial statements, there have been no changes to the Company's significant accounting policies.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make a number of estimates and assumptions relating to the reporting of assets and liabilities and the disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates under different assumptions or conditions.</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intercompany balances and transactions, and any unrealized income and expenses arising from intercompany transactions, are eli</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">minated in preparing the unaudited condensed consolidated financial statements.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Foreign Currency</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to April 1, 2024, the Company&#8217;s functional currency was the Canadian dollar (&#8220;CAD&#8221;). Translation gains and losses from the application of the U.S. dollar (&#8220;USD&#8221;) as the reporting currency during the period that the Canadian dollar was the functional currency were included as part of cumulative currency translation adjustment, which is reported as a component of shareholders&#8217; equity as accumulated other comprehensive income.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following the Company&#8217;s voluntary delisting from Cboe Canada in April 2024, the Company reassessed its functional currency and determined that, as of April 1, 2024, its functional currency had changed from the CAD to the USD.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For periods commencing April 1, 2024, monetary assets and liabilities denominated in currencies other than USD are remeasured at period-end using the period-end exchange rate. Opening balances related to non-monetary assets and liabilities are based on prior period translated amounts, and non-monetary assets acquired, and non-monetary liabilities incurred after April 1, 2024, are translated at the approximate exchange rate prevailing at the date of the transaction. Income and expense accounts are translated at the average rates in effect during the fiscal year. Foreign exchange gains and losses are included in the unaudited condensed cons</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">olidated statements of operations and comprehensive loss.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash Equivalents</span></p><p style="text-indent:4.535%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.037%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company considers all investments with an original maturity date at the time of purchase of three months or less to be cash equivalents. As of March 31, 2025, the Company&#8217;s cash equivalents consisted of U.S. government money market funds at a high-credit quality and federally insured financial institution. The Company&#8217;s accounts may, at times, exceed federally insured limits. The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company had cash equivalents of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of March 31, 2025, and $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">271.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of December 31, 2024.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investments</span></p><p style="text-indent:4.535%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.037%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All investments have been classified as &#8220;available-for-sale&#8221; and are carried at fair value as determined based upon quoted market prices or pricing models for similar securities at period end. Investments with contractual maturities within 12 months at the balance sheet date are considered short-term investments. Those investments with contractual maturities greater than 12 months at the balance sheet date are considered long-term investments. Dividend and interest income are recognized when earned. Realized gains and losses are included in earnings and are derived using the specific identification method for determining the cost of securities sold. Unrealized gains and losses are reported as a component of accumulated other comprehensive income (loss). The Company reviews its portfolio of available-for-sale debt securities, using both quantitative and qualitative factors, to determine if declines in fair value below cost have resulted from a credit-related loss or other factors. If the decline in fair value is due to credit-related factors, a loss is recognized in statements of operations, whereas if the decline in fair value is not due to credit-related factors, the loss is recorded in other co</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">mprehensive income (loss).</span></p></div><div><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net Loss per Share</span></p><p style="text-indent:4.535%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.037%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the three-month period ended March 31, 2025, the Company determined that the 2022 USD Financing Warrants had a dilutive impact to the calculation of net loss per share. As a result, the Company calculated the diluted net loss per Common Share for the three months ended March 31, 2025.</span></p></div><div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth the computation of basic and diluted net loss per share attributable to common shareholders (in thousands, except sh</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">are and per share amounts). As the exercise price of the Company&#8217;s pre-funded warrants is $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, it was determined to be non-substantive for accounting purposes and the pre-funded warrants were included in the denominator of both basic and diluted loss per share:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
         <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
          <tr style="visibility:collapse;">
           <td style="width:66.673%;box-sizing:content-box;"></td>
           <td style="width:1.64%;box-sizing:content-box;"></td>
           <td style="width:1%;box-sizing:content-box;"></td>
           <td style="width:13.023%;box-sizing:content-box;"></td>
           <td style="width:1%;box-sizing:content-box;"></td>
           <td style="width:1.64%;box-sizing:content-box;"></td>
           <td style="width:1%;box-sizing:content-box;"></td>
           <td style="width:13.023%;box-sizing:content-box;"></td>
           <td style="width:1%;box-sizing:content-box;"></td>
          </tr>
          <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Numerator:</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
           <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss attributable to common shareholders, basic</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,348</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">54,400</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
           <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value of the 2022 USD Financing Warrants</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,999</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
           <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss attributable to common shareholders, diluted</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,347</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">54,400</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Denominator:</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
           <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average pre-funded warrants used in computing net loss<br/>per share attributable to common shareholders, basic</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,753,775</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
           <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average shares used in computing net loss per share<br/>attributable to common shareholders, basic</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75,314,080</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47,860,757</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
           <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total weighted-average shares used in computing net loss per<br/>share attributable to common shareholders, basic</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85,067,855</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47,860,757</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
           <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Incremental shares from 2022 USD Financing Warrants</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,023,606</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
           <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total weighted-average shares used in computing net loss per<br/>share attributable to common shareholders, diluted</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">87,091,461</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47,860,757</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Net loss per share:</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
           <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Basic</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.27</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.14</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
           <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Diluted</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.35</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.14</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          </tr>
         </table></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following potentially dilutive securities have been excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
         <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
          <tr style="visibility:collapse;">
           <td style="width:66.967%;box-sizing:content-box;"></td>
           <td style="width:1.16%;box-sizing:content-box;"></td>
           <td style="width:1%;box-sizing:content-box;"></td>
           <td style="width:13.357%;box-sizing:content-box;"></td>
           <td style="width:1%;box-sizing:content-box;"></td>
           <td style="width:1.16%;box-sizing:content-box;"></td>
           <td style="width:1%;box-sizing:content-box;"></td>
           <td style="width:13.357%;box-sizing:content-box;"></td>
           <td style="width:1%;box-sizing:content-box;"></td>
          </tr>
          <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2022 USD Financing Warrants</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,949,954</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,631,823</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,465,831</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,696,128</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">RSUs</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,948,852</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,112,546</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Conversion Shares</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">249,377</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">997,506</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Estimated ESPP awards</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,939</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
           <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
           <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,641,953</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,438,003</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
         </table></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Investments</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INVESTMENTS</span></div></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company's available-for-sale investments consisted of the following (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50.4%;box-sizing:content-box;"></td>
         <td style="width:1.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.18%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.18%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.18%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.18%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized Cost</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Gain</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Losses</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated Fair Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Short-term:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,725</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,722</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. agency bonds</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">96,868</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">96,865</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">129,593</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">129,587</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Long-term:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. agency bonds</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,083</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,099</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,083</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,099</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has determined that there were no material declines in the fair value of its investments due to credit-related factors as of March 31, 2025. The Company held </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> available-for-sale investments as of December 31, 2024.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 940<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/940-320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph b<br> -Publisher SEC<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/320/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/942-320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FAIR VALUE OF FINANCIAL INSTRUMENTS</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents information about the Company&#8217;s assets and liabilities measured at the fair value on a recurring basis as of March 31, 2025 and December 31, 2024 (in thousands), and the fair value hierarchy of the valuation techniques utilized.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company classifies its assets and liabilities as either short-term or long-term based on maturity and anticipated realization dates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p><div style="font-size:10pt;font-family:Times New Roman;">
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50.4%;box-sizing:content-box;"></td>
         <td style="width:1.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.18%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.18%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.18%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.18%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial assets:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80,444</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80,444</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,722</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,722</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. agency bonds</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">129,964</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">129,964</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">113,166</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">129,964</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">243,130</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial liabilities:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">DDSU Liability</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,129</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,129</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2022 USD Financing Warrant Liability</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,716</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,716</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,129</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,716</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,845</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial assets:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">271,537</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">271,537</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">271,537</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">271,537</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial liabilities:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">DDSU Liability</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,148</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,148</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2022 USD Financing Warrant Liability</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,010</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,010</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,148</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,010</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,158</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> transfers into or out of Level 1, Level 2, or Level 3 during the three months ended March 31, 2</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">25 and the year ended December 31, 2024.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company issued liability-classified warrants to purchase Common Shares in our underwritten public offering that closed on September 30, 2022 (the &#8220;2022 USD Financing Warrants&#8221;). The warrant liability is measured at fair value on a recurring basis and is classified as Level 3 in the fair value hierarchy. Its fair value is determined using the Black-Scholes option pricing model using the following assumptions:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:35.24%;box-sizing:content-box;"></td>
         <td style="width:2.86%;box-sizing:content-box;"></td>
         <td style="width:29.52%;box-sizing:content-box;"></td>
         <td style="width:2.86%;box-sizing:content-box;"></td>
         <td style="width:29.52%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Share price</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.85</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.96</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">79.2</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">90.70</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free rate</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.85</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.18</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected life</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.5 </span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">years</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.75 </span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">years</span></p></td>
        </tr>
       </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, Net<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets, Net</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GOODWILL</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the three months ended March 31, 2025, the Company has made </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> additions to its outstanding goodwill. There were no triggering events identified, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> indication of impairment of the Company&#8217;s goodwill, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> impairment charges recorded during the three months ended March 31, 2025 and 2024, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ACCRUED EXPENSES</span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At March 31, 2025 and December 31, 2024, accrued expenses consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:64.167%;box-sizing:content-box;"></td>
         <td style="width:1.76%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14.157%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.76%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14.157%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,361</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,405</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued clinical trial costs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,537</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,332</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued other research and development costs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">901</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">841</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Professional services</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,437</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">973</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other accruals</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">261</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">278</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,497</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,829</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders&#8217; Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Shareholders&#8217; Equity</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">7.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SHAREHOLDERS' EQUITY</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Common Shares</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is authorized to issue an unlimited number of Common Shares, which have </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> par value. As of March 31, 2025, the Company ha</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">d </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75,511,375</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Common Shares issued and outstanding.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">At-The-Market Facilities</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 4, 2022, the Company filed a shelf registration statement on Form S-3 (the &#8220;2022 Registration Statement&#8221;), as well as an accompanying prospectus supplement (the &#8220;Prior ATM Prospectus&#8221;). </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the filing of the 2022 Registration Statement and Prior ATM Prospectus, the Company also entered into a sales agreement (the &#8220;Prior Sales Agreement&#8221;) with Cantor Fitzgerald &amp; Co. and Oppenheimer &amp; Co. Inc. as sales agents (together, the &#8220;Prior Sales Agents&#8221;), pursuant to which the Company was able to issue and sell Common Shares for an aggregate offering price of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million under an at-the-market offering program (the &#8220;Prior ATM&#8221;). During the three months ended March 31, 2024, the Company sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">171,886</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Common Shares for net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million under the Prior ATM. As of March 7, 2024, the Company had raised an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million under the ATM and had the remaining availability of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. On March 7, 2024, the Company announced that it had delivered written notice to the Sales Agents that it was suspending and terminating the Prior ATM Prospectus. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 28, 2024, the Company delivered written notice to the Prior Sales Agents that it was terminating the Prior Sales Agreement.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On June 28, 2024, the Company filed a shelf registration statement on Form S-3 (the &#8220;2024 Registration Statement&#8221;), as well as an accompanying prospectus supplement (&#8220;New ATM Prospectus&#8221;). In connection with the filing of the 2024 Registration Statement and the New ATM Prospectus, the Company entered into a sales agreement (the "Sales Agreement") with Leerink Partners LLC (the &#8220;Sales Agent&#8221;) pursuant to which the Company may issue and sell from time to time Common Shares for an aggregate offering price of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">150.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in accordance with the New ATM Prospectus under an at-the-market offering program (the "2024 ATM"). Pursuant to the 2024 ATM, the Company will pay the Sales Agent a commission rate of up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the gross proceeds from the sale of any Common Shares. The Company is not obligated to make any sales of its Common Shares under the 2024 ATM. The Company has not sold any Common Shares under the 2024 ATM as of March 31, 2025.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The March 2024 Offering and Private Placement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 7, 2024, the Company entered into an underwriting agreement with Leerink Partners LLC and Cantor Fitzgerald &amp; Co., as representatives of the underwriters named therein, in connection with the issuance and sale by the Company in an underwritten offering (the &#8220;March 2024 Offering&#8221;) of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,666,667</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Common Shares, at an offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, less underwriting discounts and commissions.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The net proceeds to the Company from the March 2024 Offering were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Also on March 7, 2024, the Company entered into a securities purchase agreement with certain investors, pursuant to which the investors agreed to purchase, and the Company agreed to sell </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,500,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Common Shares (the &#8220;Private Placement Shares&#8221;), at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per Private Placement Share, in a private placement transaction (the &#8220;March 2024 Private Placement&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The net proceeds to the Company from the March 2024 Private Placement were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, after deducting fees and expenses payable by the Company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company intends to use the net proceeds from the March 2024 Offering and the March 2024 Private Placement for (i) the research and development of the Company&#8217;s product candidates and (ii) working capital and general corporate purposes.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The March 2024 Offering and the March 2024 Private Placement closed on March 11, 2024.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The August 2024 Offering</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On August 9, 2024, the Company entered into an underwriting agreement with Leerink Partners LLC and Evercore Group L.L.C., as representatives of the several underwriters named therein, in connection with an underwritten public offering (the &#8220;August 2024 Offering&#8221;) of (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,285,511</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Common Shares (the &#8220;Shares&#8221;), and (ii) to certain investors, pre-funded warrants (the &#8220;Pre-Funded Warrants&#8221;) to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,428,775</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Common Shares (the "Pre-Funded Warrant Shares"). The offering price for the Shares was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, less underwriting discounts and commissions. The offering price for the Pre-Funded Warrants was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.999</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per Pre-Funded Warrant, which represents the per share public offering price for the Shares less a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share exercise price for each such Pre-Funded Warrant.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The net proceeds to the Company from the August 2024 Offering were approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, after deducting underwriting discounts and commissions and other offering expenses payable by the Company. The August 2024 Offering closed on August 12, 2024.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company intends to use the net proceeds from the August 2024 Offering to fund the research and development of its product candidates and for working capital and general corporate purposes.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Pre-Funded Warrants are exercisable at any time after the date of issuance. The exercise price and the number of Pre-Funded Warrant Shares are subject to appropriate adjustment in the event of certain share dividends and distributions, share splits, share combinations, reclassifications or similar events affecting the Common Shares as well as upon any distribution of assets, including cash, securities or other property, to the Company&#8217;s shareholders. The Pre-Funded Warrants will not expire and are exercisable in cash or by means of a cashless exercise. A holder of Pre-Funded Warrants may not exercise such Pre-Funded Warrants if the aggregate number of Common Shares beneficially owned by such holder, together with its affiliates, would exceed more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.99</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% or </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.99</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% (at the initial election of the holder) of the number of Common Shares outstanding following such exercise, as such percentage ownership is determined in accordance with the terms of the Pre-Funded Warrants. A holder of Pre-Funded Warrants may increase or decrease this percentage not in excess of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.99</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% by providing at least 61 days&#8217; prior notice to the Company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">October 2024 Exchange Agreements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 17, 2024, the Company entered into exchange agreements (the &#8220;Exchange Agreements&#8221;) with Commodore Capital Master LP, Deep Track Biotechnology Master Fund, LTD and certain other investors (collectively, the &#8220;Holders&#8221;) pursuant to which the Holders exchanged an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,325,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Common Shares for pre-funded warrants to purchase an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,325,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Common Shares with an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. Such Common Shares were retired upon exchange. The exchange transactions represented offsetting increases and decreases with additional paid-in capital that had no overall impact to the Company&#8217;s financial statements.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants and Rights Note Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnmd_WarrantsDisclosureTextBlock', window );">Warrants</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">8.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WARRANTS</span></div></div><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2022 USD Financing Warrants</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On September 30, 2022, the Company closed an underwritten public offering of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,058,823</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Common Shares and accompanying 2022 USD Financing Warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,058,823</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Common Shares. Each 2022 USD Financing Warrant is immediately exercis</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">able for one Common Share at an initial exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per Common Share, subject to certain adjustments, and will expire on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">September 30, 2027</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The table below represents the activity </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">associated with the Company's outstanding liability-classified 2022 USD Financing Warrants for the three months ended March 31, 2025.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.02%;box-sizing:content-box;"></td>
         <td style="width:2.88%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:29.1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022 USD Financing Warrants</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,086,300</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issued</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">136,346</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expired</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,949,954</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The 2022 USD Financing Warrants are liability-classified. Accordingly, the 2022 USD Financing Warrants are recognized at fair value upon issuance and are adjusted to fair value at the end of each reporting period. Any change in fair value is recognized on the condensed consolidated statements of operations and comprehensive loss.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The below table summarizes the activity of the outstanding liability for the 2022 USD Financing Warrants for the three months ended March 31, 2025 (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:67.725%;box-sizing:content-box;"></td>
         <td style="width:2.5%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:27.775000000000002%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,010</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrant exercise</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">295</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value of the warrant liability</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,999</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,716</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnmd_WarrantsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnmd_WarrantsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based Compensation</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">9.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">STOCK-BASED COMPENSATION</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is authorized to issue such number of equity awards equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the Company&#8217;s issued and outstanding Common Shares under the terms of the MindMed Stock Option Plan (the &#8220;Stock Option Plan&#8221;), together with Common Shares that are issuable pursuant to outstanding awards or grants under any other compensation or incentive mechanism involving the issuance or potential issuance of Common Shares, including the Performance and Restricted Share Unit Plan (the &#8220;PRSU Plan&#8221;) and ESPP. The Option Plan and the PRSU Plan were retired effective March 14, 2025, and no further grants will be made under the Option Plan or the PRSU Plan. With the retirement of the Option Plan and the PRSU Plan, the ESPP and any other compensation or incentive mechanism involving the issuance or potential issuance of Common Shares (including inducement grants made outside a plan) are no longer subject to the </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% cap from the Option Plan and PRSU Plan.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock Options</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the Company&#8217;s stock option activity for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three months ended March 31, 2025:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:37.305%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.695%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.399%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.235%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.695%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.399%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.275%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of Options</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted Average Exercise Price</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted Average Remaining Contractual Life (Years)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate Intrinsic <br/>Value (USD$)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options outstanding at December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,225,032</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.35</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.6</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,147,893</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">755,500</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.65</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53,541</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.42</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">385,629</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.75</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expired</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75,531</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17.39</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options outstanding at March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,465,831</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.88</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.9</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,681,194</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options vested and exercisable at March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,879,772</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.52</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.0</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">805,673</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The expense recognized related to options during the three months ended March 31, 2025 and 2024 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Share Units</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the Company's restricted share activity for the three months ended March 31, 2025:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:63.593%;box-sizing:content-box;"></td>
         <td style="width:1.26%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14.943%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.74%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14.463%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of RSUs</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted Average Grant Date Fair Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,371,266</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.35</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,024,500</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.34</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested and issued</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">186,708</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.76</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cancelled</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">260,206</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.74</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,948,852</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.23</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the three months ended March 31, 2025, RSUs granted include </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,696,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> performance share units that vest based on the achievement of certain clinical milestones and require service for </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">36</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> months after grant. As of March 31, 2025, the Company has determined that all of these milestones are probable of achievement. The Company will recognize the related compensation expense for awards that are probable of vesting over the </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">36</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> month requisite service period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The expense recognized related to RSUs during the three months ended March 31, 2025 and 2024 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Employee Share Purchase Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In August 2024, the Company commenced the first offering under the ESPP. Subsequent to this offering, new offerings under the ESPP will commence every six months. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the three months ended March 31, 2025, the Company recognized a nominal amount of expense in relation to its ESPP and issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34,017</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares under the ESPP.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-based Compensation Expense</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation expense for all equity arrangements for the three months ended March 31, 2025 and 2024 was as follows (in thousands):</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:67.033%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.863000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.863000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,053</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,455</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,373</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,234</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,426</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,689</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of March</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> 31, 2025, there was approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of total unrecognized stock-based compensation expense, related to unvested options granted to employees under the Option Plan that is expected to be recognized over a weighted average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.1</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years. As of March 31, 2025, there was approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of total unrecognized stock-based compensation expense, related to restricted share units granted to employees under the PRSU Plan that is expected to be recognized over a </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">weighted average period of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.0</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Directors' Deferred Share Unit Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 16, 2021, the Company adopted the MindMed Director&#8217;s Deferred Share Unit Plan (the &#8220;DDSU Plan&#8221;). The DDSU Plan sets out a framework to grant non-employee directors DDSUs, which are cash settled awards. The DDSUs generally vest ratably over twelve months after grant and are settled within 90 days of the date the director ceases service to the Company. For the three months ended March 31, 2025 and 2024, compensation expense of a nominal amount and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, was recognized relating to the revaluation of the vested DDSUs, recorded in general and administrative expense in the accompanying condensed consolidated statements of operations and comprehensive loss. During the three months ended March 31, 2025, the Company did not issue any additional DDSUs. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">178,697</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> DDSUs vested as of March 31, 2025. The liability associated with the outstanding vested DDSU&#8217;s was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of March 31, 2025, and was recorded to accrued expenses in the accompanying condensed consolidated balance sheets.</span></p><p style="text-indent:4.535%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.037%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To conform with the current year presentation, certain prior year amounts related to DDSUs expense have been reclassified and separately presented from stock-based compensation on the statement of cash flows.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">10.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">COMMITMENTS AND CONTINGENCIES</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of March 31, 2025, the Company had obligations to make future payments, representing significant research and development contracts and other commitments that are known and committed in the amount of approxima</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">tely $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">114.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> mi</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">llion. Most of these agreements are cancelable by the Company with notice. These commitments include agreements related to the conduct of the clinical trials, sponsored research, manufacturing and preclinical studies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company enters into research, development and license agreements in the ordinary course of business where the Company receives research services and rights to proprietary technologies. Milestone and royalty payments that may become due under various agreements are dependent on, among other factors, clinical trials, regulatory approvals and ultimately the successful development of a new drug, the outcome and timing of which are uncertain.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company periodically enters into research and license agreements with third parties that include indemnification provisions customary in the industry. These guarantees generally require the Company to compensate the other party for certain damages and costs incurred as a result of claims arising from research and development activities undertaken by or on behalf of the Company. In some cases, the maximum potential amount of future payments that could be required under these indemnification provisions could be unlimited. These indemnification provisions generally survive termination of the underlying agreement. The nature of the indemnification obligations prevents the Company from making a reasonable estimate of the maximum potential amount it could be required to pay. Historically, the Company has not made any indemnification payments under such agreements and no amount has been accrued in the unaudited condensed consolidated financial statements with respect to these indemnification obligations.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Credit Facility<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Credit Facility</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">11.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CREDIT FACILITY</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On August 11, 2023 (the &#8220;Closing Date&#8221;), the Company and certain of its subsidiaries party thereto, as co-borrowers (together wi</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th the Company, the &#8220;Borrowers&#8221;) entered into a Loan and Security Agreement (the &#8220;Loan Agreement&#8221;) with K2 HealthVentures LLC (&#8220;K2HV&#8221;), as administrative agent and Canadian collateral agent for lenders thereunder (K2HV, together with any other lender from time to time, the "Lenders"), and Ankura Trust Company, LLC, as collateral trustee for the Lenders. The Loan Agreement provides for up to an aggregate principal amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in term loans (the &#8220;Term Loan&#8221;) consisting of a first tranche term loan of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million funded on the Closing Date, subsequent tranches of term loans totaling $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to be funded upon the achievement of certain time-based, clinical and regulatory milestones, and an additional tranche term loan of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upon the Company&#8217;s request, subject to the Lenders' review of certain information from the Company and discretionary approval by the Lenders. On the Closing Date, the Company paid a facility fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to K2HV. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The second milestone-based tranche of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was funded in the second quarter of 2024.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Term Loan matures on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">August 1, 2027</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and the Company's obligations under the Loan Agreement are secured by substantially all of the assets of the Company, excluding intellectual property.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Term Loan bears a variable interest rate equal to the greater of (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.95</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% and (ii) the sum of (a) the </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_878b4f9e-49e3-4bfc-bf0e-3f4c1e867bf8;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">prime rate</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> as reported in The Wall Street Journal plus (b) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.95</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company may prepay, at its option, all, but not less than all, of the outstanding principal balance and all accrued and unpaid interest with respect to the principal balance being prepaid of the Term Loan, subject to certain prepayment notice requirements; provided that such prepayment notice may be conditioned upon the effectiveness of a refinancing or any other transaction, in which case such prepayment notice may be revoked by the Company. Principal payments were postponed from March 2025 to March 2026 as the interest-only extension event per the Loan Agreement was met. Additionally, the Term Loan contains a final payment fee of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.95</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the original principal amount borrowed due upon the final maturity date or upon prepayment of the Term Loan. As of March 31, 2025, the Company has accrued $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in relation to this final payment fee.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Lenders may elect at any time following the Closing Date and prior to the full repayment of the Term Loan to convert any portion of the principal amount of the term loans then outstanding, up to an aggregate principal amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, into the Company&#8217;s Common Shares (the &#8220;Conversion Shares&#8221;), at a conversion price equal to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.01</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per Conversion Share, subject to certain limitations. The embedded conversion option qualifies for a scope exception from derivative accounting because it is both indexed to the Company&#8217;s shares and meets the conditions for equity classification. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 11, 2024, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of principal was converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">748,129</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Company's Common Shares. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of March 31, 2025, the Company estimated the fair value of the Conversion Shares to be $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million using the Black-Scholes option pricing model.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Loan Agreement contains customary representations and warranties and affirmative and negative covenants, including covenants that limit or restrict the Company's ability to, among other things, dispose of assets; make changes to the Company's business, management, ownership, or business locations; merge or consolidate; incur additional indebtedness, encumbrances, or liens; pay dividends or other distributions or repurchase equity; make investments; and enter into certain transactions with affiliates, in each case subject to certain exceptions. The Company was in compliance with the Loan Agreement as of March 31, 2025. On April 18, 2025, the Company entered into an amendment to the Loan Agreement. See Note 13 for additional information.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in interest expense for the three months ended March 31, 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Future expected repayments of principal amount due on the credit facility as of March 31, 2025 were as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:76.08%;box-sizing:content-box;"></td>
         <td style="width:2.36%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:19.56%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Remainder of 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,999</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,001</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total principal repayments</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,000</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unamortized debt issuance costs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">567</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued final payment fee</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">603</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total credit facility, non-current, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,036</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of March 31, 2025, the Company estimated the fair value of the credit facility to be </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">21.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million, assuming the full $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of principal is converted into Conversion Shares.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT REPORTING<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">12.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SEGMENT REPORTING</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reportable segment related to the research and development of the Company&#8217;s product candidates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s Chief Operating Decision Maker (the &#8220;CODM&#8221;), its Chief Executive Officer, reviews the Company&#8217;s operations, including reviewing budgets and trial-related data, and decides how to allocate resources and assess performance. When evaluating the Company&#8217;s financial performance, the CODM regularly reviews total expenses and total assets and the CODM makes decisions using this information on a consolidated basis. The CODM uses consolidated net income or loss as a measure of profit or loss in allocating resources </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and assessing segment performance. </span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to the expense categories included within net income presented on the Company's Consolidated Statements of Operations and Comprehensive Loss, see below for additional expense details that are routinely reviewed by the CODM: </span></span><span style=""></span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50.89%;box-sizing:content-box;"></td>
         <td style="width:2.42%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:20.136%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:2.42%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:20.136%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Internal expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,846</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,452</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">External expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,511</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,253</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,357</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,705</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Internal expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,822</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,163</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">External expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,980</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,336</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,802</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,499</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,159</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,204</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total other income/(loss), net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,811</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,196</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,348</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">54,400</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
       </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">13.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SUBSEQUENT EVENTS</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 18, 2025 (the &#8220;Effective Date&#8221;), the Borrowers, entered into the First Amendment to the Loan Agreement with K2HV (as amended by the First Amendment, the &#8220;Amended Loan Agreement&#8221;).</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Amended Loan Agreement provide for, among other things: (i) an aggregate principal amount of term loans (the &#8220;Amendment Term Loans&#8221;) of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">120.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">consisting of (A) a new Restatement First Tranche Term Loan (as defined in the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Loan Agreement) of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which was funded on the Effective Date, a portion of the proceeds of which was used on the Effective Date to refinance in full all Term Loans outstanding under the Loan Agreement, and to pay fees and expenses in connection with the Amended Loan Agreement and the refinancing of the existing term loans, (B) subsequent tranches of Amendment Term Loans totaling up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, subject to the occurrence of certain time-based clinical and regulatory milestones and (C) an additional tranche of Amendment Term Loans of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upon the Company&#8217;s request, subject to review by the Lenders of certain information from the Company and discretionary approval by the Lenders, (ii) to the extent any Amendment Term Loans other than the Restatement First Tranche Term Loans are made during the term of the Amended Loan Agreement, a minimum liquidity covenant, beginning on the earlier to occur of (x) July 1, 2026 (which may be extended to July 1, 2027 to the extent the Company has achieved certain fundraising milestones) and (y) the date on which certain clinical and regulatory milestones are not achieved, which covenant shall be waived in any period where the Company&#8217;s market capitalization exceeds $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">500.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, (iii) a decrease in the interest rate applicable to all Amendment Term Loans under the Amended Loan Agreement to the greater of (x) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% and (y) the sum of (a) the Prime Rate as reported in The Wall Street Journal plus (b) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.75</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% per annum, and (iv) a conversion right at the election of the Lenders at any time following the Effective Date and prior to the full repayment of the Amendment Term Loans to convert up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of the outstanding Amendment Term Loans into the Company&#8217;s common shares (the &#8220;Amendment Conversion Shares&#8221;), at conversion prices ranging from $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.01</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per Amendment Conversion Share to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per Amendment Conversion Share. The Amendment Term Loans mature on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">April 1, 2029</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, provided that upon the occurrence of certain events the maturity date may be extended to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 1, 2029</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The obligations of the Borrowers under the Amended Loan Agreement are secured by substantially all of the assets of the Borrowers, excluding intellectual property. Other than as described above, the proceeds of borrowings under the Amended Loan Agreement are expected to be used for working capital and other general corporate purposes and/or to further support commercial activities and/or business development opportunities. Once repaid, the Amendment Term Loans may not be reborrowed.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basis of Presentation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification and as amended by Accounting Standards Updates of FASB. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the related notes thereto for the year ended December 31, 2024, which are included in the Company&#8217;s 2024 Annual Report on Form 10-K filed with the SEC on March 6, 2025 (the &#8220;2024 Annual Report&#8221;). The Company&#8217;s significant accounting policies are disclosed in the audited consolidated financial statements for the periods ended December 31, 2024 and 2023, included in the 2024 Annual Report. Since the date of those financial statements, there have been no changes to the Company's significant accounting policies.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make a number of estimates and assumptions relating to the reporting of assets and liabilities and the disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates under different assumptions or conditions.</span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intercompany balances and transactions, and any unrealized income and expenses arising from intercompany transactions, are eli</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">minated in preparing the unaudited condensed consolidated financial statements.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Foreign Currency</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to April 1, 2024, the Company&#8217;s functional currency was the Canadian dollar (&#8220;CAD&#8221;). Translation gains and losses from the application of the U.S. dollar (&#8220;USD&#8221;) as the reporting currency during the period that the Canadian dollar was the functional currency were included as part of cumulative currency translation adjustment, which is reported as a component of shareholders&#8217; equity as accumulated other comprehensive income.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following the Company&#8217;s voluntary delisting from Cboe Canada in April 2024, the Company reassessed its functional currency and determined that, as of April 1, 2024, its functional currency had changed from the CAD to the USD.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For periods commencing April 1, 2024, monetary assets and liabilities denominated in currencies other than USD are remeasured at period-end using the period-end exchange rate. Opening balances related to non-monetary assets and liabilities are based on prior period translated amounts, and non-monetary assets acquired, and non-monetary liabilities incurred after April 1, 2024, are translated at the approximate exchange rate prevailing at the date of the transaction. Income and expense accounts are translated at the average rates in effect during the fiscal year. Foreign exchange gains and losses are included in the unaudited condensed cons</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">olidated statements of operations and comprehensive loss.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash Equivalents</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash Equivalents</span></p><p style="text-indent:4.535%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.037%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company considers all investments with an original maturity date at the time of purchase of three months or less to be cash equivalents. As of March 31, 2025, the Company&#8217;s cash equivalents consisted of U.S. government money market funds at a high-credit quality and federally insured financial institution. The Company&#8217;s accounts may, at times, exceed federally insured limits. The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company had cash equivalents of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of March 31, 2025, and $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">271.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of December 31, 2024.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy', window );">Investments</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investments</span></p><p style="text-indent:4.535%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.037%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All investments have been classified as &#8220;available-for-sale&#8221; and are carried at fair value as determined based upon quoted market prices or pricing models for similar securities at period end. Investments with contractual maturities within 12 months at the balance sheet date are considered short-term investments. Those investments with contractual maturities greater than 12 months at the balance sheet date are considered long-term investments. Dividend and interest income are recognized when earned. Realized gains and losses are included in earnings and are derived using the specific identification method for determining the cost of securities sold. Unrealized gains and losses are reported as a component of accumulated other comprehensive income (loss). The Company reviews its portfolio of available-for-sale debt securities, using both quantitative and qualitative factors, to determine if declines in fair value below cost have resulted from a credit-related loss or other factors. If the decline in fair value is due to credit-related factors, a loss is recognized in statements of operations, whereas if the decline in fair value is not due to credit-related factors, the loss is recorded in other co</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">mprehensive income (loss).</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net Loss per Share</span></p><p style="text-indent:4.535%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.037%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the three-month period ended March 31, 2025, the Company determined that the 2022 USD Financing Warrants had a dilutive impact to the calculation of net loss per share. As a result, the Company calculated the diluted net loss per Common Share for the three months ended March 31, 2025.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth the computation of basic and diluted net loss per share attributable to common shareholders (in thousands, except sh</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">are and per share amounts). As the exercise price of the Company&#8217;s pre-funded warrants is $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, it was determined to be non-substantive for accounting purposes and the pre-funded warrants were included in the denominator of both basic and diluted loss per share:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
         <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
          <tr style="visibility:collapse;">
           <td style="width:66.673%;box-sizing:content-box;"></td>
           <td style="width:1.64%;box-sizing:content-box;"></td>
           <td style="width:1%;box-sizing:content-box;"></td>
           <td style="width:13.023%;box-sizing:content-box;"></td>
           <td style="width:1%;box-sizing:content-box;"></td>
           <td style="width:1.64%;box-sizing:content-box;"></td>
           <td style="width:1%;box-sizing:content-box;"></td>
           <td style="width:13.023%;box-sizing:content-box;"></td>
           <td style="width:1%;box-sizing:content-box;"></td>
          </tr>
          <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Numerator:</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
           <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss attributable to common shareholders, basic</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,348</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">54,400</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
           <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value of the 2022 USD Financing Warrants</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,999</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
           <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss attributable to common shareholders, diluted</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,347</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">54,400</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Denominator:</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
           <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average pre-funded warrants used in computing net loss<br/>per share attributable to common shareholders, basic</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,753,775</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
           <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average shares used in computing net loss per share<br/>attributable to common shareholders, basic</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75,314,080</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47,860,757</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
           <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total weighted-average shares used in computing net loss per<br/>share attributable to common shareholders, basic</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85,067,855</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47,860,757</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
           <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Incremental shares from 2022 USD Financing Warrants</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,023,606</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
           <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total weighted-average shares used in computing net loss per<br/>share attributable to common shareholders, diluted</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">87,091,461</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47,860,757</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Net loss per share:</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
           <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Basic</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.27</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.14</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
           <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Diluted</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.35</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.14</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          </tr>
         </table></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following potentially dilutive securities have been excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
         <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
          <tr style="visibility:collapse;">
           <td style="width:66.967%;box-sizing:content-box;"></td>
           <td style="width:1.16%;box-sizing:content-box;"></td>
           <td style="width:1%;box-sizing:content-box;"></td>
           <td style="width:13.357%;box-sizing:content-box;"></td>
           <td style="width:1%;box-sizing:content-box;"></td>
           <td style="width:1.16%;box-sizing:content-box;"></td>
           <td style="width:1%;box-sizing:content-box;"></td>
           <td style="width:13.357%;box-sizing:content-box;"></td>
           <td style="width:1%;box-sizing:content-box;"></td>
          </tr>
          <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2022 USD Financing Warrants</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,949,954</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,631,823</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,465,831</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,696,128</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">RSUs</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,948,852</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,112,546</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Conversion Shares</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">249,377</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">997,506</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Estimated ESPP awards</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,939</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
           <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
           <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,641,953</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,438,003</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
         </table></div><div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for premium paid to acquire option for investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Computation of Basic and Diluted Net Loss Per Share</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth the computation of basic and diluted net loss per share attributable to common shareholders (in thousands, except sh</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">are and per share amounts). As the exercise price of the Company&#8217;s pre-funded warrants is $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, it was determined to be non-substantive for accounting purposes and the pre-funded warrants were included in the denominator of both basic and diluted loss per share:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
         <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
          <tr style="visibility:collapse;">
           <td style="width:66.673%;box-sizing:content-box;"></td>
           <td style="width:1.64%;box-sizing:content-box;"></td>
           <td style="width:1%;box-sizing:content-box;"></td>
           <td style="width:13.023%;box-sizing:content-box;"></td>
           <td style="width:1%;box-sizing:content-box;"></td>
           <td style="width:1.64%;box-sizing:content-box;"></td>
           <td style="width:1%;box-sizing:content-box;"></td>
           <td style="width:13.023%;box-sizing:content-box;"></td>
           <td style="width:1%;box-sizing:content-box;"></td>
          </tr>
          <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Numerator:</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
           <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss attributable to common shareholders, basic</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,348</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">54,400</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
           <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value of the 2022 USD Financing Warrants</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,999</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
           <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss attributable to common shareholders, diluted</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,347</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">54,400</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Denominator:</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
           <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average pre-funded warrants used in computing net loss<br/>per share attributable to common shareholders, basic</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,753,775</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
           <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average shares used in computing net loss per share<br/>attributable to common shareholders, basic</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75,314,080</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47,860,757</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
           <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total weighted-average shares used in computing net loss per<br/>share attributable to common shareholders, basic</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85,067,855</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47,860,757</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
           <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Incremental shares from 2022 USD Financing Warrants</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,023,606</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
           <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total weighted-average shares used in computing net loss per<br/>share attributable to common shareholders, diluted</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">87,091,461</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47,860,757</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Net loss per share:</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
           <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Basic</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.27</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.14</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
           <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Diluted</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.35</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.14</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          </tr>
         </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share due to Anti-dilutive Effect</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following potentially dilutive securities have been excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
         <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
          <tr style="visibility:collapse;">
           <td style="width:66.967%;box-sizing:content-box;"></td>
           <td style="width:1.16%;box-sizing:content-box;"></td>
           <td style="width:1%;box-sizing:content-box;"></td>
           <td style="width:13.357%;box-sizing:content-box;"></td>
           <td style="width:1%;box-sizing:content-box;"></td>
           <td style="width:1.16%;box-sizing:content-box;"></td>
           <td style="width:1%;box-sizing:content-box;"></td>
           <td style="width:13.357%;box-sizing:content-box;"></td>
           <td style="width:1%;box-sizing:content-box;"></td>
          </tr>
          <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
           <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2022 USD Financing Warrants</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,949,954</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,631,823</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,465,831</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,696,128</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">RSUs</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,948,852</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,112,546</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Conversion Shares</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">249,377</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">997,506</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Estimated ESPP awards</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,939</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
           <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
           <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,641,953</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,438,003</span></p></td>
           <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          </tr>
         </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of available-for-sale investments</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company's available-for-sale investments consisted of the following (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50.4%;box-sizing:content-box;"></td>
         <td style="width:1.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.18%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.18%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.18%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.18%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized Cost</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Gain</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized Losses</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated Fair Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Short-term:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,725</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,722</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. agency bonds</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">96,868</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">96,865</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">129,593</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">129,587</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Long-term:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. agency bonds</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,083</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,099</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,083</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,099</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents information about the Company&#8217;s assets and liabilities measured at the fair value on a recurring basis as of March 31, 2025 and December 31, 2024 (in thousands), and the fair value hierarchy of the valuation techniques utilized.</span>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50.4%;box-sizing:content-box;"></td>
         <td style="width:1.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.18%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.18%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.18%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.18%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial assets:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80,444</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80,444</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,722</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,722</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. agency bonds</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">129,964</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">129,964</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">113,166</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">129,964</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">243,130</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial liabilities:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">DDSU Liability</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,129</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,129</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2022 USD Financing Warrant Liability</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,716</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,716</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,129</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,716</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,845</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial assets:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">271,537</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">271,537</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">271,537</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">271,537</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial liabilities:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">DDSU Liability</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,148</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,148</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2022 USD Financing Warrant Liability</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,010</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,010</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,148</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,010</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,158</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Assumptions used to Determine Fair Value of 2022 USD Financing Warrants</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company issued liability-classified warrants to purchase Common Shares in our underwritten public offering that closed on September 30, 2022 (the &#8220;2022 USD Financing Warrants&#8221;). The warrant liability is measured at fair value on a recurring basis and is classified as Level 3 in the fair value hierarchy. Its fair value is determined using the Black-Scholes option pricing model using the following assumptions:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:35.24%;box-sizing:content-box;"></td>
         <td style="width:2.86%;box-sizing:content-box;"></td>
         <td style="width:29.52%;box-sizing:content-box;"></td>
         <td style="width:2.86%;box-sizing:content-box;"></td>
         <td style="width:29.52%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Share price</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.85</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.96</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">79.2</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">90.70</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free rate</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.85</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.18</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected life</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.5 </span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">years</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.75 </span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">years</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Summary of Accrued Expenses</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At March 31, 2025 and December 31, 2024, accrued expenses consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:64.167%;box-sizing:content-box;"></td>
         <td style="width:1.76%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14.157%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.76%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14.157%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,361</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,405</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued clinical trial costs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,537</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,332</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued other research and development costs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">901</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">841</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Professional services</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,437</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">973</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other accruals</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">261</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">278</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,497</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,829</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants and Rights Note Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Summary of Outstanding Liability Classified as Warrants</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The table below represents the activity </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">associated with the Company's outstanding liability-classified 2022 USD Financing Warrants for the three months ended March 31, 2025.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.02%;box-sizing:content-box;"></td>
         <td style="width:2.88%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:29.1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022 USD Financing Warrants</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,086,300</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issued</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">136,346</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expired</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,949,954</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnmd_ScheduleOfWarrantLiabilityTableTextBlock', window );">Summary of Activity of Outstanding Warrant Liability</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The below table summarizes the activity of the outstanding liability for the 2022 USD Financing Warrants for the three months ended March 31, 2025 (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:67.725%;box-sizing:content-box;"></td>
         <td style="width:2.5%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:27.775000000000002%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,010</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrant exercise</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">295</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in fair value of the warrant liability</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,999</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,716</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnmd_ScheduleOfWarrantLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnmd_ScheduleOfWarrantLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the Company&#8217;s stock option activity for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three months ended March 31, 2025:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:37.305%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.695%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.399%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.235%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.695%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.399%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.275%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of Options</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted Average Exercise Price</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted Average Remaining Contractual Life (Years)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate Intrinsic <br/>Value (USD$)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options outstanding at December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,225,032</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.35</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.6</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,147,893</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">755,500</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.65</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53,541</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.42</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">385,629</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.75</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expired</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75,531</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17.39</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options outstanding at March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,465,831</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.88</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.9</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,681,194</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options vested and exercisable at March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,879,772</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.52</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.0</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">805,673</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of Restricted Share Units</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the Company's restricted share activity for the three months ended March 31, 2025:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:63.593%;box-sizing:content-box;"></td>
         <td style="width:1.26%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14.943%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.74%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14.463%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of RSUs</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted Average Grant Date Fair Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,371,266</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.35</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,024,500</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.34</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested and issued</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">186,708</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.76</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cancelled</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">260,206</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.74</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,948,852</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.23</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Stock-based Compensation Expense</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation expense for all equity arrangements for the three months ended March 31, 2025 and 2024 was as follows (in thousands):</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:67.033%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.863000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.863000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,053</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,455</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,373</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,234</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,426</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,689</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Credit Facility (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Future Expected Repayments of Principal Amount Due on Credit Facility</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Future expected repayments of principal amount due on the credit facility as of March 31, 2025 were as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:76.08%;box-sizing:content-box;"></td>
         <td style="width:2.36%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:19.56%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Remainder of 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,999</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,001</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total principal repayments</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,000</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unamortized debt issuance costs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">567</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued final payment fee</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">603</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total credit facility, non-current, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,036</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Summary of Additional Expense Details</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to the expense categories included within net income presented on the Company's Consolidated Statements of Operations and Comprehensive Loss, see below for additional expense details that are routinely reviewed by the CODM: </span><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50.89%;box-sizing:content-box;"></td>
         <td style="width:2.42%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:20.136%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:2.42%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:20.136%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Internal expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,846</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,452</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">External expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,511</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,253</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,357</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,705</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Internal expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,822</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,163</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">External expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,980</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,336</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,802</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,499</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,159</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,204</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total other income/(loss), net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,811</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,196</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,348</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">54,400</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Description of the Business - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (422,227)<span></span>
</td>
<td class="num">$ (398,879)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Oct. 17, 2024</div></th>
<th class="th"><div>Aug. 09, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 80.4<span></span>
</td>
<td class="nump">$ 271.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=mnmd_PreFundedWarrantsMember', window );">Pre Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 6.999<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477123/405-50-65-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-5<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 66: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 67: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 68: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 69: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480530/250-10-S99-5<br><br>Reference 70: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 71: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 72: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 73: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 74: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 75: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 76: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 77: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 78: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 79: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 80: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 81: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 82: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 83: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 84: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 85: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 86: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-6<br><br>Reference 87: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 88: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 89: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 90: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 91: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 92: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 93: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 94: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 95: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 96: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 97: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 98: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-3<br><br>Reference 99: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 100: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=mnmd_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=mnmd_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of presentation and summary of significant accounting policies - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common shareholders, basic</a></td>
<td class="num">$ (23,348)<span></span>
</td>
<td class="num">$ (54,400)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of 2022 USD Financing Warrants</a></td>
<td class="num">(6,999)<span></span>
</td>
<td class="nump">32,893<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss attributable to common shareholders, diluted</a></td>
<td class="num">$ (30,347)<span></span>
</td>
<td class="num">$ (54,400)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnmd_WeightedAverageNumberOfPreFundedWarrantsOutstandingBasic', window );">Weighted-average pre-funded warrants used in computing net loss per share attributable to common shareholders, basic</a></td>
<td class="nump">9,753,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnmd_WeightedAverageNumberOfCommonSharesOutstandingBasic', window );">Weighted-average shares used in computing net loss per share attributable to common shareholders, basic</a></td>
<td class="nump">75,314,080<span></span>
</td>
<td class="nump">47,860,757<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Total weighted-average shares used in computing net loss per share attributable to common shareholders, basic</a></td>
<td class="nump">85,067,855<span></span>
</td>
<td class="nump">47,860,757<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Incremental shares from 2022 USD Financing Warrants</a></td>
<td class="nump">2,023,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Total weighted-average shares used in computing net loss per share attributable to common shareholders, diluted</a></td>
<td class="nump">87,091,461<span></span>
</td>
<td class="nump">47,860,757<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic</a></td>
<td class="num">$ (0.27)<span></span>
</td>
<td class="num">$ (1.14)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted</a></td>
<td class="num">$ (0.35)<span></span>
</td>
<td class="num">$ (1.14)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnmd_WeightedAverageNumberOfCommonSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average number of common shares outstanding basic.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnmd_WeightedAverageNumberOfCommonSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnmd_WeightedAverageNumberOfPreFundedWarrantsOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average number of pre funded warrants outstanding basic.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnmd_WeightedAverageNumberOfPreFundedWarrantsOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of presentation and summary of significant accounting policies - Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share due to Anti-dilutive Effect (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of loss per share</a></td>
<td class="nump">15,641,953<span></span>
</td>
<td class="nump">13,438,003<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mnmd_UsdFinancingWarrantsMember', window );">2022 USD Financing Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of loss per share</a></td>
<td class="nump">4,949,954<span></span>
</td>
<td class="nump">6,631,823<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of loss per share</a></td>
<td class="nump">4,465,831<span></span>
</td>
<td class="nump">3,696,128<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of loss per share</a></td>
<td class="nump">5,948,852<span></span>
</td>
<td class="nump">2,112,546<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mnmd_ConversionSharesMember', window );">Conversion Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of loss per share</a></td>
<td class="nump">249,377<span></span>
</td>
<td class="nump">997,506<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember', window );">Estimated ESPP awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of loss per share</a></td>
<td class="nump">27,939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mnmd_UsdFinancingWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mnmd_UsdFinancingWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mnmd_ConversionSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mnmd_ConversionSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Schedule of available-for-sale investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 129,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(15)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">129,587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=mnmd_LongTermInvestmentsMember', window );">Long-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">33,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">33,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasury securities | Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">32,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">32,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">U.S. agency bonds | Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">96,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">96,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">U.S. agency bonds | Long-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">33,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 33,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=mnmd_LongTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=mnmd_LongTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments (Additional Information) (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt Securities Available-for-sale</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Financial Instruments - Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 80,444<span></span>
</td>
<td class="nump">$ 271,537<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">243,130<span></span>
</td>
<td class="nump">271,537<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial Liabilities Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Financial liabilities</a></td>
<td class="nump">17,845<span></span>
</td>
<td class="nump">25,158<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Directors' Deferred Share Unit Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial Liabilities Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Financial liabilities</a></td>
<td class="nump">1,129<span></span>
</td>
<td class="nump">1,148<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">2022 USD Financing Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial Liabilities Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Financial liabilities</a></td>
<td class="nump">16,716<span></span>
</td>
<td class="nump">24,010<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">80,444<span></span>
</td>
<td class="nump">271,537<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">113,166<span></span>
</td>
<td class="nump">271,537<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial Liabilities Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Financial liabilities</a></td>
<td class="nump">1,129<span></span>
</td>
<td class="nump">1,148<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Directors' Deferred Share Unit Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial Liabilities Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Financial liabilities</a></td>
<td class="nump">1,129<span></span>
</td>
<td class="nump">1,148<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">129,964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial Liabilities Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Financial liabilities</a></td>
<td class="nump">16,716<span></span>
</td>
<td class="nump">24,010<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | 2022 USD Financing Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial Liabilities Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Financial liabilities</a></td>
<td class="nump">16,716<span></span>
</td>
<td class="nump">$ 24,010<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">US Treasury Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">32,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">US Treasury Securities [Member] | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">32,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">129,964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. agency bonds | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets, Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 129,964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=mnmd_DirectorsDeferredShareUnitsLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=mnmd_DirectorsDeferredShareUnitsLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=mnmd_TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=mnmd_TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3', window );">Fair value of assets transfers into Level 3</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3', window );">Fair value of assets transfers out of Level 3</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3', window );">Fair value of liabilities transfers into Level 3</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3', window );">Fair value of liabilities transfers out of Level 3</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as a liability into level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 101<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-101<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 101<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-101<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Financial Instruments - Schedule of Assumptions used to Determine Fair Value of 2022 USD Financing Warrants (Details) - Level 3 - 2022 USD Financing Warrant Liability - Recurring<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input</a></td>
<td class="nump">5.85<span></span>
</td>
<td class="nump">6.96<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0.792<span></span>
</td>
<td class="nump">0.907<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0.0385<span></span>
</td>
<td class="nump">0.0418<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected life</a></td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">2 years 9 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=mnmd_TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=mnmd_TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, Net - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill acquired during period</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment charges of goodwill</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of Intangible Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">527,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnmd_IndicationOfImpairmentOfGoodwillAndLongLivedAssets', window );">Indication of impairment of goodwill and long-lived assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnmd_IndicationOfImpairmentOfGoodwillAndLongLivedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indication of impairment of goodwill and long-lived assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnmd_IndicationOfImpairmentOfGoodwillAndLongLivedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses - Summary of Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WorkersCompensationLiabilityCurrent', window );">Accrued compensation</a></td>
<td class="nump">$ 4,361<span></span>
</td>
<td class="nump">$ 6,405<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnmd_AccruedClinicalAndManufacturingCosts', window );">Accrued clinical trial costs</a></td>
<td class="nump">4,537<span></span>
</td>
<td class="nump">4,332<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnmd_AccruedOtherResearchAndDevelopmentCostsCurrent', window );">Accrued other research and development costs</a></td>
<td class="nump">901<span></span>
</td>
<td class="nump">841<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional services</a></td>
<td class="nump">1,437<span></span>
</td>
<td class="nump">973<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accruals</a></td>
<td class="nump">261<span></span>
</td>
<td class="nump">278<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 11,497<span></span>
</td>
<td class="nump">$ 12,829<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnmd_AccruedClinicalAndManufacturingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued clinical and manufacturing costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnmd_AccruedClinicalAndManufacturingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnmd_AccruedOtherResearchAndDevelopmentCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued other research and development costs current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnmd_AccruedOtherResearchAndDevelopmentCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WorkersCompensationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations and payables pertaining to claims incurred of a workers compensation nature. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WorkersCompensationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 17, 2024</div></th>
<th class="th"><div>Aug. 09, 2024</div></th>
<th class="th"><div>Jun. 28, 2024</div></th>
<th class="th"><div>Mar. 07, 2024</div></th>
<th class="th"><div>May 04, 2022</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNoParValue', window );">Common stock, no par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnmd_CommonStockSharesIssuedAndOutstanding', window );">Number of shares issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,511,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,511,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,100,763<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,511,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,100,763<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of share issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 8,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=mnmd_PreFundedWarrantsMember', window );">Pre Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">8,325,000<span></span>
</td>
<td class="nump">1,428,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 6.999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Private placement shares</a></td>
<td class="nump">8,325,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mnmd_TwoThousandTwentyFourAtTheMarketOfferingProgramMember', window );">2024 at the Market Offering Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnmd_SaleOfEquityAggregatePublicOfferingAmount', window );">Sale of securities aggregate public offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnmd_PercentageOfGrossProceedsSaleOfCommonSharesPayableAsSalesAgentsCommissionRate', window );">Percentage of gross proceeds from sales of common shares payable as sales agent commission rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mnmd_TwoThousandTwentyTwoAtTheMarketOfferingProgramMember', window );">2022 at the Market offering program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnmd_SaleOfEquityAggregatePublicOfferingAmount', window );">Sale of securities aggregate public offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,900<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnmd_SaleOfEquityRemainingOfferingAmount', window );">Sale of securities remaining availablility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">171,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mnmd_UnderwrittenOfferingMember', window );">Underwritten Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Share issued price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,666,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Net proceeds from private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Share issued price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnmd_AggregateNumberOfCommonSharesOwnedByHolderPercentage', window );">Aggregate number of common shares owned by holder percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnmd_AggregateNumberOfCommonSharesOwnedByHolderPercentage', window );">Aggregate number of common shares owned by holder percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnmd_PercentageOfIncreaseOrDecreaseOfOwnershipByPreFundedWarrantsHolder', window );">Percentage of increase or decrease of ownership by pre-funded warrants holder</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Pre Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnmd_AggregateNumberOfCommonSharesOwnedByHolderPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares owned by holder percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnmd_AggregateNumberOfCommonSharesOwnedByHolderPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnmd_CommonStockSharesIssuedAndOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock shares issued and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnmd_CommonStockSharesIssuedAndOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnmd_PercentageOfGrossProceedsSaleOfCommonSharesPayableAsSalesAgentsCommissionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of gross proceeds sale of common shares payable as sales agents commission rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnmd_PercentageOfGrossProceedsSaleOfCommonSharesPayableAsSalesAgentsCommissionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnmd_PercentageOfIncreaseOrDecreaseOfOwnershipByPreFundedWarrantsHolder">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of increase or decrease of ownership by pre-funded warrants holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnmd_PercentageOfIncreaseOrDecreaseOfOwnershipByPreFundedWarrantsHolder</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnmd_SaleOfEquityAggregatePublicOfferingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of equity aggregate public offering amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnmd_SaleOfEquityAggregatePublicOfferingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnmd_SaleOfEquityRemainingOfferingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of equity, remaining offering amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnmd_SaleOfEquityRemainingOfferingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=mnmd_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=mnmd_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mnmd_TwoThousandTwentyFourAtTheMarketOfferingProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mnmd_TwoThousandTwentyFourAtTheMarketOfferingProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mnmd_TwoThousandTwentyTwoAtTheMarketOfferingProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mnmd_TwoThousandTwentyTwoAtTheMarketOfferingProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mnmd_UnderwrittenOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mnmd_UnderwrittenOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Warrants - Additional Information (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Aug. 09, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class Of Warrant Or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,511,375<span></span>
</td>
<td class="nump">75,100,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnmd_CommonShareAndWarrantPublicOfferingExpireDate', window );">Common share and warrant public offering expire date</a></td>
<td class="text">Sep. 30,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mnmd_UnderwrittenPublicOfferingMember', window );">Underwritten Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class Of Warrant Or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">7,058,823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,285,511<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mnmd_TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember', window );">2022 USD Financing Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class Of Warrant Or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">7,058,823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mnmd_CommonShareAndWarrantPublicOfferingMember', window );">Common Share and Warrant Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class Of Warrant Or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Common shares at an initial excercise price</a></td>
<td class="nump">$ 4.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnmd_CommonShareAndWarrantPublicOfferingExpireDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common share and warrant public offering expire date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnmd_CommonShareAndWarrantPublicOfferingExpireDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mnmd_UnderwrittenPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mnmd_UnderwrittenPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mnmd_TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mnmd_TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mnmd_CommonShareAndWarrantPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mnmd_CommonShareAndWarrantPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants - Summary of Outstanding Liability Classified as Warrants (Details) - 2022 USD Financing Warrant Liability<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Balance at March 31, 2025</a></td>
<td class="nump">5,086,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnmd_WarrantsIssued', window );">Issued, shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnmd_WarrantsExercised', window );">Exercised, shares</a></td>
<td class="num">(136,346)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnmd_WarrantsExpired', window );">Expired, shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Balance at March 31, 2024</a></td>
<td class="nump">4,949,954<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnmd_WarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnmd_WarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnmd_WarrantsExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnmd_WarrantsExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnmd_WarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnmd_WarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=mnmd_TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=mnmd_TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants - Summary of Activity of Outstanding Warrant Liability (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class Of Warrant Or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of the warrant liability</a></td>
<td class="num">$ (6,999)<span></span>
</td>
<td class="nump">$ 32,893<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mnmd_TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember', window );">2022 USD Financing Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class Of Warrant Or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Balance at December 31, 2024</a></td>
<td class="nump">24,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnmd_WarrantExercise', window );">Warrant exercise</a></td>
<td class="num">(295)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of the warrant liability</a></td>
<td class="num">(6,999)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Balance at March 31, 2025</a></td>
<td class="nump">$ 16,716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnmd_WarrantExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant exercise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnmd_WarrantExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mnmd_TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mnmd_TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, issued</a></td>
<td class="nump">$ 6.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense recognized</a></td>
<td class="nump">$ 3,426<span></span>
</td>
<td class="nump">$ 3,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">11,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,829<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock-based compensation expense related to unvested options granted</a></td>
<td class="nump">$ 12,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period for recognition of unvested options granted</a></td>
<td class="text">3 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">Estimated ESPP awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Nominal amount of expense in relation to ESPP</a></td>
<td class="nump">34,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period for recognition of unvested options granted</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares, granted</a></td>
<td class="nump">5,024,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense recognized</a></td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock-based compensation expense related to unvested options granted</a></td>
<td class="nump">$ 35,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=mnmd_DirectorsDeferredShareUnitPlanMember', window );">Directors' Deferred Share Unit Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of shares, vested</a></td>
<td class="nump">178,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense recognized</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense recognized</a></td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance shares units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares, granted</a></td>
<td class="nump">3,696,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Requisite service period</a></td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=mnmd_DirectorsDeferredShareUnitPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=mnmd_DirectorsDeferredShareUnitPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Schedule of Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, outstanding</a></td>
<td class="nump">4,225,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options, granted</a></td>
<td class="nump">755,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of options, exercised</a></td>
<td class="num">(53,541)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of options, forfeited</a></td>
<td class="num">(385,629)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Number of options, expired</a></td>
<td class="num">(75,531)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, outstanding</a></td>
<td class="nump">4,465,831<span></span>
</td>
<td class="nump">4,225,032<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Number of options, vested and exercisable</a></td>
<td class="nump">1,879,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, outstanding</a></td>
<td class="nump">$ 12.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, granted</a></td>
<td class="nump">6.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, exercised</a></td>
<td class="nump">4.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, forfeited</a></td>
<td class="nump">6.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, expired</a></td>
<td class="nump">17.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, outstanding</a></td>
<td class="nump">11.88<span></span>
</td>
<td class="nump">$ 12.35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, vested and exercisable</a></td>
<td class="nump">$ 18.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (Years), outstanding</a></td>
<td class="text">6 years 10 months 24 days<span></span>
</td>
<td class="text">6 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual life (Years), vested and exercisable</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, outstanding</a></td>
<td class="nump">$ 4,147,893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, outstanding</a></td>
<td class="nump">1,681,194<span></span>
</td>
<td class="nump">$ 4,147,893<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate intrinsic value, vested and exercisable</a></td>
<td class="nump">$ 805,673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Schedule of Restricted Share Units (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, beginning balance | $ / shares</a></td>
<td class="nump">$ 6.35<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares, beginning balance | shares</a></td>
<td class="nump">1,371,266<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares, granted | shares</a></td>
<td class="nump">5,024,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriod', window );">Number of shares, vested and issued | shares</a></td>
<td class="num">(186,708)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod', window );">Number of shares, cancelled | shares</a></td>
<td class="num">(260,206)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares, ending balance | shares</a></td>
<td class="nump">5,948,852<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, granted | $ / shares</a></td>
<td class="nump">$ 6.34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, vested and issued | $ / shares</a></td>
<td class="nump">10.76<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, cancelled | $ / shares</a></td>
<td class="nump">5.74<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, ending balance | $ / shares</a></td>
<td class="nump">$ 6.23<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, equity instruments other than options, cancelled in period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, equity instruments other than options, cancelled in period, weighted average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, equity instruments other than options, vested and issued in period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And issued In Period Weighted Average Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Summary of Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 3,426<span></span>
</td>
<td class="nump">$ 3,689<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">2,053<span></span>
</td>
<td class="nump">1,455<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 1,373<span></span>
</td>
<td class="nump">$ 2,234<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Other commitment</a></td>
<td class="nump">$ 114.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Credit Facility - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 11, 2024</div></th>
<th class="th"><div>Aug. 11, 2023</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Payment of facility fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 128,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Accrued final payment fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">603,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateTerms', window );">Description of the interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Term Loan bears a variable interest rate equal to the greater of (i) 10.95% and (ii) the sum of (a) the prime rate as reported in The Wall Street Journal plus (b) 2.95%.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=mnmd_TermLoanMember', window );">Term Loan | Loan and Security Agreement | K2HV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Payment of facility fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt instrument, maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug.  01,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Term Loan bears a variable interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration', window );">Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Prime Rate [Member]<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnmd_PercentageOfFinalPaymentFee', window );">Percentage of final payment fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Accrued final payment fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal', window );">Debt instrument convertible, converted principal amount</a></td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnmd_DebtInstrumentConvertibleConvertedIntoCommonShares', window );">Converted into common shares</a></td>
<td class="nump">748,129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Fair value of conversion shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding', window );">Fair value of credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=mnmd_TermLoanMember', window );">Term Loan | Loan and Security Agreement | K2HV | First Tranche Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=mnmd_TermLoanMember', window );">Term Loan | Loan and Security Agreement | K2HV | Second Milestone Based Tranche Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=mnmd_TermLoanMember', window );">Term Loan | Loan and Security Agreement | K2HV | Subsequent Tranche Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=mnmd_TermLoanMember', window );">Term Loan | Loan and Security Agreement | K2HV | Additional Tranche Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=mnmd_TermLoanMember', window );">Term Loan | Loan and Security Agreement | K2HV | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature', window );">Debt instrument convertible, conversion feature principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=mnmd_TermLoanMember', window );">Term Loan | Loan and Security Agreement | K2HV | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt instrument interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnmd_DebtInstrumentConvertibleConvertedIntoCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debtinstrument convertible converted into common shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnmd_DebtInstrumentConvertibleConvertedIntoCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnmd_PercentageOfFinalPaymentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of final payment fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnmd_PercentageOfFinalPaymentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount by which the convertible debt's if-converted value exceeds its principle amount at the balance sheet date, regardless of whether the instrument is currently convertible. This element applies to public companies only.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the interest rate as being fixed or variable, and, if variable, identification of the index or rate on which the interest rate is based and the number of points or percentage added to that index or rate to set the rate, and other pertinent information, such as frequency of rate resets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates type of variable interest rate on debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 470<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of the amount outstanding under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=mnmd_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=mnmd_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mnmd_LoanAndSecurityAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mnmd_LoanAndSecurityAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=mnmd_K2HealthventuresLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=mnmd_K2HealthventuresLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mnmd_FirstTrancheTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mnmd_FirstTrancheTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mnmd_SecondMilestoneBasedTrancheTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mnmd_SecondMilestoneBasedTrancheTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mnmd_SubsequentTrancheTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mnmd_SubsequentTrancheTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mnmd_AdditionalTrancheTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mnmd_AdditionalTrancheTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Credit Facility - Schedule of Future Expected Repayments of Principal Amount Due on Credit Facility (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnmd_DebtRepaymentsOfPrincipalInNextTwelveMonthsBeforeUnamortizedDebtIssuanceCost', window );">2026</a></td>
<td class="nump">$ 12,999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnmd_DebtRepaymentsOfPrincipalInYearTwoBeforeUnamortizedDebtIssuanceCost', window );">2027</a></td>
<td class="nump">9,001<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total principal repayments</a></td>
<td class="nump">22,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized debt issuance costs</a></td>
<td class="num">(567)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Accrued final payment fee</a></td>
<td class="nump">603<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Total credit facility, non-current, net</a></td>
<td class="nump">$ 22,036<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnmd_DebtRepaymentsOfPrincipalInNextTwelveMonthsBeforeUnamortizedDebtIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt repayments of principal in next twelve months before unamortized debt issuance cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnmd_DebtRepaymentsOfPrincipalInNextTwelveMonthsBeforeUnamortizedDebtIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnmd_DebtRepaymentsOfPrincipalInYearTwoBeforeUnamortizedDebtIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt repayments of principal in year two before unamortized debt issuance cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnmd_DebtRepaymentsOfPrincipalInYearTwoBeforeUnamortizedDebtIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Additional Information) (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Summary of Additional Expense Details (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Research and Development Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnmd_ResearchAndDevelopmentInternalExpense', window );">Internal expenses</a></td>
<td class="nump">$ 7,846<span></span>
</td>
<td class="nump">$ 5,452<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnmd_ResearchAndDevelopmentExternalExpense', window );">External expenses</a></td>
<td class="nump">15,511<span></span>
</td>
<td class="nump">6,253<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total</a></td>
<td class="nump">23,357<span></span>
</td>
<td class="nump">11,705<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and Administrative Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnmd_GeneralAndAdministrativeInternalExpense', window );">Internal expenses</a></td>
<td class="nump">3,822<span></span>
</td>
<td class="nump">5,163<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnmd_GeneralAndAdministrativeExternalExpense', window );">External expenses</a></td>
<td class="nump">4,980<span></span>
</td>
<td class="nump">5,336<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total</a></td>
<td class="nump">8,802<span></span>
</td>
<td class="nump">10,499<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(32,159)<span></span>
</td>
<td class="num">(22,204)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other income/(loss), net</a></td>
<td class="nump">8,811<span></span>
</td>
<td class="num">(32,196)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (23,348)<span></span>
</td>
<td class="num">$ (54,400)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnmd_GeneralAndAdministrativeExternalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>General and administrative external expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnmd_GeneralAndAdministrativeExternalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnmd_GeneralAndAdministrativeInternalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>General and administrative internal expense .</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnmd_GeneralAndAdministrativeInternalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnmd_ResearchAndDevelopmentExternalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development external expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnmd_ResearchAndDevelopmentExternalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnmd_ResearchAndDevelopmentInternalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development internal expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnmd_ResearchAndDevelopmentInternalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Additional Information) (Details) - Subsequent Event - K2HV - Amendment Term Loans<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th">
<div>Apr. 18, 2025 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Term Loan bears a variable interest rate</a></td>
<td class="nump">2.75%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt instrument, maturity date</a></td>
<td class="text">Apr.  01,  2029<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnmd_DebtInstrumentExtendedMaturityDate', window );">Debt instrument extended maturity date</a></td>
<td class="text">Oct.  01,  2029<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mnmd_CovenantShallBeWaivedDuringMarketCapitalizationExceeds', window );">Covenant shall be waived during market capitalization exceeds</a></td>
<td class="nump">$ 500.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt instrument interest rate</a></td>
<td class="nump">10.25%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price per share | $ / shares</a></td>
<td class="nump">$ 4.01<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Line of Credit</a></td>
<td class="nump">$ 120.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price per share | $ / shares</a></td>
<td class="nump">$ 9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature', window );">Debt instrument convertible, conversion feature principal</a></td>
<td class="nump">$ 7.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">First Tranche Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Line of Credit</a></td>
<td class="nump">42.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Tranche Term Loan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Line of Credit</a></td>
<td class="nump">28.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Additional Tranche Term Loan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Line of Credit</a></td>
<td class="nump">$ 50.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnmd_CovenantShallBeWaivedDuringMarketCapitalizationExceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Covenant shall be waived during market capitalization exceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnmd_CovenantShallBeWaivedDuringMarketCapitalizationExceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnmd_DebtInstrumentExtendedMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument extended maturity date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnmd_DebtInstrumentExtendedMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=mnmd_K2HealthventuresLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=mnmd_K2HealthventuresLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mnmd_AmendmentTermLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mnmd_AmendmentTermLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mnmd_FirstTrancheTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mnmd_FirstTrancheTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mnmd_SubsequentTrancheTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mnmd_SubsequentTrancheTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mnmd_AdditionalTrancheTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mnmd_AdditionalTrancheTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>69
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( "@[J%I&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( "@[J%H1M0/\\@   "L"   1
M9&]C4')O<',O8V]R92YX;6S-DL%*Q# 0AE]%<F^GZ5*5T.U%\:0@N*!X"\GL
M;MBF"<E(NV]O&G>[BCZ D$MF_GSS#:157B@7\#DXCX$,QJO)]D,4RJ_9GL@+
M@*CV:&4L4V)(S:T+5E*ZAAUXJ0YRAU!7U358)*DE29B!A5^(K&NU$BJ@)!=.
M>*T6O/\(?89I!=BCQ8$B\)(#Z^:)_CCU+5P ,XPPV/A50+T0<_5/;.X .R6G
M:);4.([EN,JYM .'MZ?'E[QN889(<E"87D4CZ.AQS<Z37U=W]YL'UM55W115
M.K<;SD7="-Z\SZX__"["UFFS-?_,^.:;\5FP:^'7O^@^ 5!+ P04    "  H
M.ZA:F5R<(Q &  "<)P  $P   'AL+W1H96UE+W1H96UE,2YX;6SM6EMSVC@4
M?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.'X416(UL>621A'^_1S80RY8-[9)-
MNIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X8-DOV]:[MR_>X%<R)!%!,!FGK_#
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M"CS<_N\-L,+$CN'MB[\!4$L#!!0    ( "@[J%JXB[B/# 8  +P@   8
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M\ARY>(Z(0WR+^VK:_2U+6G?OV'T!S%OZI*5/ZGCN&/U*2E9J1)4"GA<V/DT
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MYX3:1Y<!@DD[+DSC9/CE-?V7%['+=T,\S=PBZ)%+BWP:VDH=-Z;3'VK\>?O
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M8R^7C$)[;03@_PLA],N-^8'=>S&S_P-02P,$%     @ *#NH6KXEX^A, @
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MJ.=7N)7@#,5K.U5KKO2,VF.AMR@($Z#O-YRKO6$2]'LY_0U02P,$%     @
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M@[N%^3MEU_FZB1:UZS9[H4WO<L/2?"Q V@#S/A="'R=V@^'SD_X!4$L#!!0
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M1\*G;S?I)KJ6OY>L7(RNX<N:7VMH L8KYV)_0QL,'] N_@M02P,$%     @
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M&I7:CSO!P1JT ,\W"O#P7VB#^G\17/P'4$L#!!0    ( "@[J%KI:KKU40,
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MTHY&2%B6-+/1> <ZS[5V6\,'Z/X%TK]02P,$%     @ *#NH6JGSQ7C( @
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MG^E;<?B M9ZNP8M%INP7#I5O&#H0[Y46>1U,#')>5"-[K/-P$C#P7@@(ZH#
M\JX.LBROF6;3L10'D,:;T,S$2K711(X7YE+66M(NIS@]G<6QW&,"RT>Z9H5J
M[&I"-7MN7"/,*X3@!800;D2A4P7+(L'DSWB7V#24@B.E>7 1\(;)#H1^&P(O
MZ%[ "QN)H<4+7\!;L2>VR5 !*Q*P>EFFX,=LH[2D1_'SG.0*,3J/: IEI$H6
MX\2A2E H']"9OG[E][QW%_A&#=_H$OI_7<E%A//\>AV8+1:W=\MK6'Y?+3^M
MEVN8::!LQVF3;INC:XPQWZ \6J,V%4_%"6M.$ NJ2Z7))+:@4X2MR*C >;&#
M-[P@B]@KPE)O1ZV_3O@'O744'(O<H#-;KE<0M<.>3V.O'7G=9R<2RV.6@9:<
MOK%06I%K-^R;@#!H' 6QDF#DV_.-L 0?J N5U%-T'3CT?!A$?FLEQ1:5Z32$
M:1+&8Q+IMR."'?;#UF<+QHZ/)R!B07_0^B(T^5^!3Y[#OID$[4$PA'.OP#TI
MTASESK8BD\A]H:MZ;:Q-MYM51?[L7K5*RNB.%PHRW%*HU^EW'9!5^ZD66I2V
MY#="4P.QTY0Z-DKC0/M;(?1Q80YH_@'3WU!+ P04    "  H.ZA:R*D$@H,*
M  #L(   &0   'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6RU6FUSV[@1_BL8
M77I-9F19DM_SXAG'<9ITG,:-<[WI=/H!(B$1%Y+@ : 5W:_OLPN2(B5*>>M]
MB,478'>Q^^RS"S#/E\9^<HE27GS.TMR]&"3>%T\/#UV4J$RZD2E4CC=S8S/I
M<6L7AZZP2L8\*4L/I^/QZ6$F=3ZX?,[/[NSE<U/Z5.?JS@I79IFTJY<J-<L7
M@\F@?O!!+Q)/#PXOGQ=RH>Z5_Z6XL[@[;*3$.E.YTR875LU?#*XF3U\>TW@>
M\"^MEJYU+6@E,V,^T<W;^,5@3 :I5$6>)$C\/*AKE:8D"&;\7LD<-"II8ONZ
MEOZ:UXZUS*13UR;]5<<^>3$X'XA8S669^@]F^495ZSDA>9%)'?\5RS!V"HU1
MZ;S)JLFXSW0>?N7GR@^M">?C'1.FU80IVQT4L96OI)>7SZU9"DNC(8TN>*D\
M&\;IG()R[RW>:LSSE_>)M"HQ::RL^_FG\^GD[)FX^;W4?O7\T$,^C3J,*EDO
M@ZSI#EE'XIW)?>+$31ZKN#O_$'8UQDUKXUY.]PI\)^U('$V&8CJ>GNR1=]0L
M]HCE'>V0%Q8F_G,U<]X"#__M6V,0<=PO@G+DJ2MDI%X,D 1.V0<UN/SYI\GI
M^-D> X\; X_W2?_&:.R7=382]V^N/MR\>7_[ZN;#_5_%S3]_>?OQW^+:9!G2
M@54Y\3%1]*20^4IH)V3I$V/U'RH6WN"!*Y60N2@A/=,>3_,RFRDKS+PK9RB6
MB8X2D<@')7(C"FG%@TQ+-1)7CD8CE'A=QW(H?$MO(D4LSDZ&)Y/)\.CL9,-"
M-B*&%;$ J3B/"YTO(-<?P/@#"/X$[GHM(YUJKS'A?0YM*W',JJ9=57.=DBR!
MA$GG()6%)B0P/T"R5Z ;+W!#&2_N#X[$8YI-H9B.GY$X\:$]Y[Z>PR,FSYX,
MA71B"8ZA7TFD$P7-,%D4UK@";%0Z<&!1I$%;6\.=U<:*JX_OQ%TSMA8]$F]S
M$9D\K_ALJ7W":\.:2#J<3'=[C&0?]JGH^DBFS@@,5Q:NTCEP '_)%)Z5"ZMV
M&7W/(Z[J$;75P<QK"3%6O-;^CX6R,HW%SS(KGD'EB(UZ7Z#() IL;UMOWN;1
MB/Q8*X=8!\UFH:#=!J-[;:"!ZX@4I74E#"!$!Y2V5[ND0,U2U<9[+!R%L(M#
M%$".Z )+7,"C</A<V1!7'=&M* N2\DA,QN/1&&R=IN3_$FP8IOH#:#[( F);
MT\W"RJP?".OHORIY- WR";PLLD"VBLBVFU_'W8 Z$(J8G$V&Y^>G/8O*80QL
MB)2*.54?B?'H;,-Z$M?8U,WILSZ5B8R%E=IQXG9\!O''X]%%CWS")/F>YM*]
M5=14T)KE@]2IG%&"KX*(DXO1I!8Q"AF_TQ:9YZ;,(Z*T1'JA/6N(58IV@""^
MM-I[E8.V/,41$:39;2PU$PDLKD36, >QM4@3E&5D6A6;OOP:U9PT/>\S\$NF
M;(.[8U"_!1OYR";\O<S5#AM^E!B/_P1BK*3_ ZW=CU+B+O-""#%F6TG7/U_#
MAX,-GP\J]KM5E.B?Q)VT/D=E%[>WUQW_M4+;\.9^ULKD:I.MYM9DPH-"&3;T
M^_W\==+F+QVB96.))%K[>-MCW\9T PX+) P0Q[O6:IN0X5TW"$M8A-9BM9F@
M" C0E,$AO%6HB":LY@@K^4N-A 5L=6NR"R[#<PHGC2$E':^--ALD9*8PLU23
M![E'RN0GQ?,")"!$(S^[KE]S7+VNKMQ$!L%,U%LV]$RG)-IJJH+,\(P'OJ_]
M7M7]!W+,78KFE3&[GS6[@*]XFOB)!3; WPUP4KJG[C,A6,5-=(YT! .Z.DR-
M+I*5RXRI&];H?$AH[,MX2@;&)^<#A7.VZJR'4-Q:!;%L@\MV+O;XK\E)F#<Y
M'9Z>TK^SS098$IGT)-4C<3H:CT6!$#H:.A3 B>OZ,]8N0HWRCLU?8[G"7Z="
M5QG2$'>-X;[ +^$T&'!Q-#JITQF&SN%7%)VXC%CYUUD2&G *@U .],+X;U:K
M/J,F.D00V<G=5-?[Z!BHJ33?@#B06E3:T-&#"R/DB-K$7:2L1XN &0 /@.9V
M-7O-@""!$[<6.FQJ0-,P-&.86"?3X<EX/!PCB-V\W&C8-M(K#&K5/Z*I/E3L
MF,I0YQG\MFC>HHCE3@;\[T#NELAUQ?P>/&U;6 'K;+QNP[:!-5<JP.:+Z.B0
M+&"0![M*IWA<Q]Z]@*]#N==XJH2/]9.JR72*Q]+,6#VHU!2AUYFW3:PVXUP[
M:'DBHFUH#+EAA8\UY-'Y$QD1R4)[F?(+E"<B/F22+0Q7)N"N,*XN+=^]B"@U
MU%TW*36I6O\@]JI<E,YOR 7A5\\O_C3&OT$CB[4J\3=K4(!O1[>CZ[U<[^!S
M<M W<OXFEQ<EBG+43^E]SFAS.F'A8C@]YQ.(/3F^E=%UX.&O/BJRZF!>\NYL
M*2V2UF]2ACIX'=[_6KUOK&KQDY@,C]&SGVT=C(0N:EM*]7Y0)?M&12+P<_L4
MA- & GG\HQ5JAY*>)58:3T<7%Q<5_6V.J0^3&L0X%M;8MQ7LWI7Q&B3O9L?C
M26NV^@R(8FO:FJ8DU+D2?[:M^0;*[,TZIDI98/)GKIKI*A#G^/]8D;^^#N\D
MAS6?5*]1]EJ$\LWLW*L$LR@COLB\U$+O8%H*U_<0;1\46VA@9W$+MPJ;IQ 3
M,C2N]A-UBQGD;:"HYNSU^>C.Q&2UKIS]!CXCCS V((74R/@W>(W= #(A@7!,
M\$G-, '$L7[0,4>"W4=;6STKB1_!/&&(*U+XL;X#<&9\2L CK(I2"1C-=10>
M";C5:2!2VJ 2@A&UJ#E5Z')/:S-?%O1QA8XQ6D;P9LHY1?IU'J5E'.+EDF&[
ML8/2 &#R -:W&F[D5E-W7>MD?'= >8-(.RGD@;8A*IM!IF(".T@WDB-3,N=:
M)/DIDT8=6G2M(JCLCZ?C;7A05X%A!X<XH4.U6^^^=QRDBQEPC*AHF8(HS#*'
M$)C)<H,MY*)P AHJH0ZATBD!B [B39E2RT7Y*#(JQ3Y!M3P&X=)&V(J+</48
M: ^],6*!Q&D^E%6%.6A[4M_NLK=U)H_<3%.SI"NVM_8*EW]^@AA'U $L%"_-
MND07M*N.53C$XNZC][2!WC<]0X^#ORY6@*)55%,-T6UU[1-8T+*, @HKR(..
M54XJCR$.P"GRCALBCPHCP7"G$S#$JOE<4_#I6_< KV'?]Y$WY$5FQ9O/J.\Y
M%#8'1OSMHAXS^?(F2=42Y%I"N\/HT;!Q+D^AC DCUQ65OL.2H/SV;BA>*56(
MCU9&G\1+;;R*DMRD9K&JQY"#A^+VXZM0F"IZ"OF\WG ]C@ *Q=]>TU7GS/[-
M^CO7GA.O:E2SUNT#Y?/AT?2D9WM&E:*O!VOW5E\KJ^XY-UB_.BWO]!<C<4]0
MWYA/38!57E/LF#'K]=35I(I4:W/7:IG#5AMTRG1<H[CB?E7?!2/C6--L22=E
M.CY@N@NQY4-C.OO.L17GKCL5&K"*_"[6G:-BY,1%ZT-@-^K[SGG8^@*=*;O@
M[^Q.<.,2/D8W3YM/^5?A"_9Z>/A_ -C.+'1._=L<4\>CLY.!L.';>KCQIN#O
MV3/CO<GX,E$2(*$!>#\W &MU0PJ:_^!P^3]02P,$%     @ *#NH6L324D!.
M!   .@H  !D   !X;"]W;W)K<VAE971S+W-H965T,38N>&ULK59-<]I($+WS
M*[J45-:ITH(0 H,#5.&/U.:0K,LDZ\/6'@:I09-(,]J9D;'WUV_W"##>PLIE
M+R"-^KW^>CTSTZTV/VR.Z."Q+)2=!;ESU46O9],<2V&[ND)%7];:E,+1J]GT
M;&509!Y4%KTXBD:]4D@5S*=^[=;,I[IVA51X:\#692G,TR46>CL+^L%^X4YN
M<L<+O?FT$AM<HOM6W1IZZQU8,EFBLE(K,+B>!8O^Q67"]M[@#XE;>_0,G,E*
MZQ_\\BF;!1$'A 6FCAD$_3W@%18%$U$8?^\X@X-+!AX_[]D_^MPIEY6P>*6+
M>YFY?!:, \AP+>K"W>GM;[C+9\A\J2ZL_X5M8YN<!Y#6UNER!Z8(2JF:?_&X
MJ\,18!R] HAW@-C'W3CR45X+)^93H[=@V)K8^,&GZM$4G%3<E*4S]%42SLWO
MA3%".3OM.6+CM5ZZ0UXVR/@5Y  ^:^5R"S<JP^PEOD=1'$*)]Z%<QJV$GX7I
MPJ ?0AS%PQ:^P2&U@><;_"0U$"H#KS8+7[1#N)8V+;2M#<*?BY5UAJ3QUZD"
M-/S):7X>EPM;B11G <V#1?. P?S=F_XH^M 2?7*(/FEC;VU,*_)T7.,NW"_N
M[A9?OBZYOC%\6U[#1ZF$2J7:P*%6ORM88N6P7*&!0>2;$8?@<H0K759"/0'7
M#C.J*M34>;,UTCE44-6K0J:@UVLT3*G7<!Y&PW$XC@>,+6D&E[F@B'Q#1)HV
M?&S;%I'31&W2G$;O-<(NW(@T;V$!:4&6)692."R> !_1I+0F5@4"[6R@%;Z@
M!.$X0:FDDZ+8VR-41J;(J;V%I!L/H:(J'>-"VMU6WVG'X;!3-(ZV11#9=QID
MVLF<#7WN6UDP9R7)D3Y1\'/HPE>JN//QK7CGI W0-]-7A#[YW4RZ)Q#6ZI33
M8EJ7'W?J%PNT#5M'+KD6A10K61#FU[0@E%Q+PK15G@O#="XWB% VTXX\[4"S
M2@7?#VNWTT+3N10%+?F27F.Z2[1!)C ,H_$H'$11YY.U-3&_>S..^_&'SLVN
MY!F<07] )LD(WM,J%^W9ZHC[94B0A)-D$DZ&28<KV98FM_M4;;JP((T:KEWQ
MU(S SV@,IGJCY#\\'@[60AIX$$6-4%?49TD9-M&R_EED7AAD3&(Y,B8H.Z-*
ML]*0I4W=U\:Q/U*<U!P;3V(NU 9)I<=HDO51&.26N5)-;5-<37JRNI"95PQI
M@Y3G146>Z*0W@L_*9D)Y/@WF?  _4(6TM8TJ&STVVFS.<O+T'U42&[^?E-]!
M5_^+]N!,<HJZMN3'OK_H+'PN+XW:-?@6XB2,^E%GOUL<QOT,XLF09'=UJM"[
M'+<[T'-^9S *)Y,)X5Z7YUOHC\+S_@A.'16]H_.\1+/QMQ9+#:F5:X[VP^KA
M8K1H[@//YLVMBMQN)#6TP#5!H^[Y, #3W%2:%Z<K?SM8:4=W#?^8T^4.#1O0
M][6F(W/WP@X.U\7YOU!+ P04    "  H.ZA:W&*SPE8)   %&0  &0   'AL
M+W=O<FMS:&5E=',O<VAE970Q-RYX;6R]66UOVS@2_NY?07CW=E- =:P7O[5)
M@+SUKKAK:S1]P>%P'VB)MGF51"U)Q?']^IL94K*<VND&N[@OL222,\.99YX9
M,F<;I;^9M1"6/11Y:<[[:VNK5Z>G)EV+@IN!JD0)(TNE"V[A5:].3:4%SVA1
MD9]&P^'XM."R[%^<T;>YOCA3M<UE*>::F;HHN-Y>B5QMSOMAO_GP4:[6%C^<
M7IQ5?"7NA/U<S36\G;92,EF(TDA5,BV6Y_W+\-55@O-IPA<I-J;SS' G"Z6^
MX<O;[+P_1(-$+E*+$CC\W(MKD><H",SXS<OLMRIQ8?>YD?Z&]@Y[67 CKE7^
M569V?=Z?]EDFEKS.[4>U^9OP^QFAO%3EAOZRC9N;Q'V6UL:JPB\&"PI9NE_^
MX/W063 ='ED0^041V>T4D94WW/*+,ZTV3.-LD(8/M%5:#<;)$H-R9S6,2EAG
M+^ZL2K^]Q'UE[%H5$&O#T5UGIQ:DXYS3U$NZ<I*B(Y)B]DZ5=FW8;9F);'_]
M*5C5FA8UIEU%3PI\Q_6 Q6' HF$T>D)>W&XU)GGQL:VNN18OKVBK<[X%9%EV
MJ34O5X*>_W6Y,%8#3/Y]:/-.=G)8-J;.*U/Q5)SW(3>,T/>B?_'+3^%X^/H)
MRY/6\N0IZ<\*TM.29@-V]^G#]=]?7EW>W=ZPZP_OYK?O[RX_O?WPGGU:"Y+.
MRRV3AO':KI66_P6=5L$'4PM(W73-RKI8",W4DHG?:FFWC&^XS@R^\1SGAB/V
M%QRV.X&__#2-PLEKX^1DC)<9 XHP%AYDN<)I!>0HA<BP&A"D:;D5NC"-K'>R
MS-[!8G('^U!16L]S7K(3'$8=T?#U=Z/T/7S](@#;5@)F:L@QNWZDTZZY9?!$
M%O)%+EA5:W@"8,"6NK;Z[2K-5@ >VYB+;E,D/>V$"*?),@5\ ?FP0J1K7DI3
MP+=[E=^C.#2==,(LG%TIB[/!E;NORWUC Q29UUFS?"XTT3/.1<]^% !DF5KT
M%2Y@GTMIO_?4_./=YST/T>+;N_E\0&#H>AA'2%6SAFT$"-;"2@UJQ'(IB%\9
M9"U@)$Q<V@:TL%1L66ORC7?91N8Y6X!#>"8ZX>YJ5'I?X8!]Q:CA-Z>5DM9#
MXTE3 WK%?='8_S%0[&07* !OG3JCO1-H\X@L";^<56#J"X(@^"M70$M8/!?_
M <<B!%$]95;**[;4JCBX\8Z[NHE@**!+E4,1IKT0PETEAA0W!W/5D !5[<HG
M9OO2!\:NM0!'.<X7R/D^]@UEO^J];YFBL>(K54F8>GDO-!1]=OL@="H-1 L
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M8-I'1/OA],I?W'/MZ!G@ER6]N]"P )TOM':;#S;0O^2F_P%02P,$%     @
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M8*/B$S;J:@6?XWW6$'^KML(PA=AP7]E(\GZJTCG':L*TJ0G3HXQ^P\V6O4-
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M0S)Z.6Z,Q^4C'2_>O?%B]\,)MN' -CR%OEAAS>9M14W0;D3=M'T\<6D"G=G
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MY@*>%P+3HU\8!<,_#8M_ %!+ P04    "  H.ZA:/H*C9?L"  !Z!@  &0
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MLC#$NRJ()?\<T'H'/E\:0WO%!VA_-[.?4$L#!!0    ( "@[J%K")!'.S 0
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M6;8S5/N@Q=K.+7.A:0JRRQ6-G2B- >TOA-"[!Q.@&V0G_P%02P,$%     @
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M>]0N@=83I>PV<!LT_Q_3OU!+ P04    "  H.ZA:[_Z]P68#   5!P  &0
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M-L5:T4Q-P8[2!ICW"R'T:\=6;/5?@/ ?4$L#!!0    ( "@[J%H[3+-&$P0
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M5TQ$)^C?UYRKYYWH"V7V17KV'U!+ P04    "  H.ZA:S#K,MQT"  !+!
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MVP5.UZ%=UMI1\X5I2:\=C4^@_8W6[A#X#CS^/[*_4$L#!!0    ( "@[J%I
MV*T[L 4  ,XH   9    >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;+U:86_:
M.A3]*Q9O>F^3MA+;(4 ?(+5%U9NT2E59MP_3^V# @+60,-O *KT?_YR0Q@D8
M-VD-7UH"]O&]YYXX)S?I;6/^4RPHE>#W,HQ$O[&0<G79;(K)@BZ)N(A7-%*_
MS&*^)%(=\GE3K#@ETW32,FPBSPN:2\*BQJ"7?G?/![UX+4,6T7L.Q'JY)/SI
MFH;QMM^ C><O'MA\(9,OFH/>BLSIB,K'U3U71\T<9<J6-!(LC@"GLW[C"E[>
M^"B9D([XQNA6%#Z#))5Q'/],#CY/^PTOB8B&="(3"*+^;>@-#<,$2<7Q*P-M
MY&LF$XN?G]%OT^15,F,BZ$T<?F=3N>@W.@TPI3.R#N5#O/V'9@FU$KQ)'(KT
M+]AF8[T&F*R%C)?99!7!DD6[_^1W1D1A O2/3$#9!%1U LXFX#31761I6D,B
MR:#'XRW@R6B%EGQ(N4EGJVQ8E)1Q)+GZE:EY<G!+& ??2+BF()Z!6Q:1:,)(
M"#Y'0O*UJI<4X!,8*?5,UV$ZYDH(JKXDT11\863,0B89%>".$K'F= J(!$70
M"#S0R9IS%LW!-1%,@/=#*@D+Q0<%K'_[!!Y'0_#^W0?P#K (?%W$:Z'6$+VF
M5&DFP38G64K7NY30D93N"+\ &'X$R$,MP_0;^_0AG>33_?+TIB(W9QCE#*,4
M#Q]C..=TQ]S'(CU#)B9AG! '?ER-%>5*UO^:4MZMX9O72,[U2[$B$]IOJ)-9
M4+ZAC<&??\# ^]M$@".P$ATXIP/;T <W1"P _;5F&Q(FZC(ENT,(4H1D']H,
M.I[OJV)LBED<CD)MV,+M?%@I/C^/S[?&I\M%TG*9XMLAM(HK^QAB;R] PS!+
M@*T\P%9%/15/O]=HJN524X[ 2I0$.25!Q9J%FA)3QL%!16"[X[?VZG8X"K5@
MJV,N6SN/L6V-<<BXNG+%7/P%AG1&>;)5CA9$%>DQ8C*OY9,I;"MRW4(Y BN1
MT,E)Z)Q)NQV7E#@"*U'2S2GINM%N]U"[$'7WI&L:Y!]1+O2T1_"L,:HK(4HO
MSUFPZG+]G7!.HA=T:X>M6R57:&42"D8)GDF[V4*N:'&$5J9%NQMH=0O5]9OA
ME+09M&&PIV##,.1[T#NB86T[H-UW?*$;&@)HC,PZLW8]'*&5\]3V!?IGL)O0
M:I)J4^((K4R)-DS0:CXJ6<X,HB@[D^<T#+-Y.J@=#*QJ88[;3FBP+Q##X. 4
M,A@86Y#:PL#VN;9 IY;&%5J9%FUJH-4@U-@".U6NX<911R_BVF= N]'(-D#P
M'WB+%;4O4KMPCM#*-^;:UR#O3'I&3IV.*[0R+=KI(*MEJ*[G#.<%/1M''=,S
M*K15[,9CIV=DC,MMM^04[1*DC0O"Y^@?.?4XKM#*E&B/@][>HT&'W1<ES6ZP
M?T6W+_7:5+0W079OLE,Q-F;@M#_C"JV<I_8W*#C75FLU4K5I<816ID4[*F3O
M"E7?:MN5[IX,PRQW3TA;'&2W.)E,E7EX;2_ OD#MLIVB98.TET+=<ZG9J9]R
MA5;N[&L_A>U]HLIJSG!>4G,V+*BF9JP-#K8;G,<1^,K3YU5/8)0\@=K5[\<=
M78XI-];)CEBW3J[0ROEKZX3/\4@*.W59KM#*E!2>2CEX+(4/5(M1&Z%]U9["
M'&%MCK#='+T@;K6%6UIA=NS:-3V%M\+:6^&J3\K>)'.G-LP56ID2;<.PO<U4
M2>:'[2.CS$_AG+!V3MCNG!XO1A> S&DT>0+C^,B+ G:,VK4[19L):P^&JSX\
M>Y.<G?HP5VAE2K0/P_:>5B4Y&YZ)F6X$[4N],A5?>R??[IT.])QOU,86AQVM
M;AE=H95SUW[,K_IH[2W*]IU:-%=H94JT1?/MW:TJRLX@@I>4;5^J;BK-PLMF
MR9M^=X3/621 2&<*WKMHJS.-[UZ>VQW(>)6^?S:.I8R7Z<<%)5/*DP'J]UD<
MR^>#Y)6V_!7&P?]02P,$%     @ *#NH6LG>L^K% @  2@@  !D   !X;"]W
M;W)K<VAE971S+W-H965T,S@N>&ULK59=;YLP%/TK%INF5NH*@7Q,'4%JDG6K
MU$I5HW8/TQX<N"16C<ULDW3_?M>&L&1*B:KN)6#[GN-SSS77B3=2/>D5@"'/
M!1=Z[*V,*2]\7Z<K**@^ER4(7,FE*JC!H5KZNE1 ,P<JN!\&P= O*!->$KNY
M.Y7$LC*<";A31%=%0=7O"7"Y&7L];SMQSY8K8R?\)"[I$N9@'LH[A2._9<E8
M 4(S*8B"?.Q=]BZF(QOO AX9;/3..[&9+*1\LH/K;.P%5A!P2(UEH/A8PQ0X
MMT0HXU?#Z;5;6N#N^Y;]RN6.N2RHAJGDWUEF5F/ODT<RR&G%S;W<?(,FGX'E
M2R77[I=LFMC (VFEC2P:,"HHF*B?]+GQ80> /(<!80,(_P4,7P!$#2!RB=;*
M7%HS:F@2*[DARD8CFWUQWC@T9L.$K>+<*%QEB#/)%66*/%)> 9$YN6*"BI11
M3JZ%-JK"<AE-/I+++&/6=;=0'QU;@Y,9&,JX/L60A_F,G+P_C7V#JBRWGS8*
M)K6"\ 4%$;F5PJPT^2(RR [@I]WX7MA!X*,=K2?AUI-)V,EX2]4YB7IG) S"
MP2%!W? 9I"V\WR$G:DL4.;[H:(G.R(1R+!"0N?O"ORI9E4PLSW8*-S?4@*T;
MF=+25DF3'S?(2*YQ6O\\5)]Z^_[A[6T;N= E36'L89_0H-;@)1_>]8;!YT/>
M_">R/:?ZK5/]+O;:J?7V,%.M 4^O453H')0F3!A);F -G$2'?*C)AX[<=K]U
M$L3^>C>YKH@]Q8-6\> MBK'MVOD.S37]H$-S5\2>YF&K>?@*S9S1!>/8'> U
M5@^/RNZ*V),]:F6/WBS[N-^CHV>D*Z(6[N^TZP+4TMUBFJ2R$J;NW.UL>U%>
MNOO!_QM>W[+8JI8,/W$..4*#\Q$:INJ;JQX86;KFOY &KQ+WNL++'I0-P/5<
M2K,=V W:OP_)'U!+ P04    "  H.ZA:EFN:2W4#   C#P  &0   'AL+W=O
M<FMS:&5E=',O<VAE970S.2YX;6S%5UUOVS@0_"L+77&X U+KRW;LU#;0.)<V
M0 ($-MH^'/K R&N;""7J2,I._GV7DJ)8K:Q+4 %YL4EI9[2S.Z+(R5ZJ>[U%
M-/ 0BT1/G:TQZ9GKZFB+,=,]F6)"=]92Q<S05&U<G2IDJQP4"S?PO*$;,YXX
MLTE^[5;-)C(S@B=XJT!G<<S4XSD*N9\ZOO-T8<$W6V,ON+-)RC:X1/,EO54T
M<RN6%8\QT5PFH' ]=3[Z9W,_M( \XBO'O3X8@Y5R)^6]G5RMIHYG,T*!D;$4
MC/YV.$<A+!/E\5])ZE3/M,##\1/[92Z>Q-PQC7,IOO&5V4Z=D0,K7+-,F(7<
M?\92T,#R15+H_!?V9:SG0)1I(^,23!G$/"G^V4-9B - ,#@""$I \%) 6 +R
MRKE%9KFL"V;8;*+D'I2-)C8[R&N3HTD-3VP;ET;174XX,[MD7,%7)C($N89+
MGK DXDS 5:*-RJA?1L-[6))[5IG(8SYJ:GEJ>Z AT[@"(^$"#2K*#J'.%WA!
M %^6%T_$R0:^,:689?V+0(P+_3?Q7^,.!80T.HZ :\[NN.#FD<(6&&5*T=V)
M:Z@*5HL;E8K/"\7!$<4W3/4@]$_LHP;P#ES06Z90-S#-VYDN,*J8^D>97.I(
MU9:@:DN04_>/4"\M$:2*1]BDL!5LW_PSG;((IPZ]VAK5#IW9GW_X0^]#D\B.
MR&HZPTIGF+.'_VN_$SAG@CJ.L,R7KT]*9BDU^.3 E$O##%I/PIR5#OSWVKKN
MBB[K[TV5"KNL5$=DM4KUJTKU6QUQ@TQGJE#/DS0S36H+"M_+.>P*OIL->J/!
MQ-T=RFB(&O;&PRJJEM^@RF_0FM\_#RFMS+0<[*1@)G]/FS)L)7EM/SHBJ^D=
M5GJ';^O<89>5ZHBL5JG3JE*GO^_<@L+W#SSI]4['P4_6;0P;>Z?-WAU5&8Y:
M,UQP??]^K1!A06UJ2J\5_]IF=$16DSJNI([?UK;C+BO5$5FM4K[WO#7R?M^X
M)8<?U"SIA;^LND<"^_ZHV;S^P1;.?]G2*_BZT;WM^-<VI2NVNMKGG9$?O*V#
M_4YW5UVQU:OUO+_R6S<E+_!&.SZ 1V1*PQ!BF9AM\R[Y913C1HI"EWMP@K''
M1]JD;SCU2N":..E+0)]Z59S(BHF1:7ZHN9.&CDCY<$NG6%0V@.ZOI31/$WM.
MJL[%LQ]02P,$%     @ *#NH6G'-?F?7 @  #0@  !D   !X;"]W;W)K<VAE
M971S+W-H965T-# N>&ULK59=3]LP%/TK5C9-( %)TZ^)M9':,E@EF!"([6':
M@YO<)A:.'6RW9?OUNW;24" -T[27QG;N/3[GQ+ZWHXU4]SH#,.0QYT*/O<R8
MXM3W=9Q!3O6)+$#@FZ54.34X5:FO"P4T<4DY]\,@&/@Y9<*+1F[M6D4CN3*<
M";A61*_RG*I?4^!R,_8ZWG;AAJ69L0M^-"IH"K=@[HIKA3._1DE8#D(S*8B"
MY=B;=$YG0QOO KXQV.B=,;%*%E+>V\D\&7N!)00<8F,1*#[6, /.+1#2>*@P
MO7I+F[@[WJ*?.^VH94$US"3_SA*3C;V/'DE@25?<W,C-%ZCT]"U>++EVOV13
MQ08>B5?:R+Q*1@8Y$^63/E8^["0@3G-"6"6$+Q-Z>Q*Z54+7"2V9.5EGU-!H
MI.2&*!N-:';@O''9J(8)^Q5OC<*W#/-,="%ELF&<$RH2,A>&BI0M.)")UF#T
M$?F*!^F83)*$6=<IQYCRZ-AO<' &AC*N#S'D[O:,'+P_'/D&65EL/ZX83$L&
MX1X&77(EA<DT^2P22)[G^ZBFEA1N)4W#5L KJDY(MW-$PB#L-_"9_7UZKX5.
MMW:XZ_"Z>_#.F6 &CB_QM#8X3'Y<8CR9&\CUSR;S2O!>,[B]XZ>ZH#&,/;S$
M&M0:O.C#N\X@^-2D_#^!/?.A5_O0:T/?.6GQPXHI-"-9*2924H!B,FG27@(.
M'* M1^LH&/GK74&M6_ZCH'XMJ-\J:)X7E"FL:(;$&54I:"*7)*UD-NDI\?HM
M>OHMBI^1'-0D!ZTD)[E4AOTN[RO2>W4 FW@.WN3Y.J(?#H-@#]EA37;8[JA(
M6%Q394_^[OCJ"A67(CWF[D;1O2J&;YZ>MHA2@+]367/ ;VP;CB:Q7 E35J1Z
MM>QI4^QIKO:_6,=>-W$EWG^"*1LEUIN4"4TX+!$R.!FBJZIL/N7$R,+5[X4T
MV W<,,-^#<H&X/NEE&8[L1O4_P"B/U!+ P04    "  H.ZA:@*52#=\"  !;
M"   &0   'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6RMEEUOFS 4AO^*Q:JI
ME;;R36B7(+7)INUB6M2TV\6T"P=.@E7 S':2]M_O&"A*@Q/U8C?!QN>\/._Q
M5\8[+AYE#J#(4UE4<F+E2M77MBW3'$HJ+WD-%8ZLN"BIPJY8V[(60+,FJ2QL
MSW$BNZ2LLI)Q\VXNDC'?J()5,!=$;LJ2BN=;*/AN8KG6RXL[MLZ5?F$GXYJN
M80'JH9X+[-F]2L9*J"3C%1&PFE@W[O4TUO%-P$\&.[G7)MK)DO-'W?F632Q'
M T$!J=(*%!];F$)1:"'$^-MI6OTG=>)^^T7]2^,=O2RIA"DO?K%,Y1,KMD@&
M*[HIU!W??87.3ZCU4E[(YI?LNEC'(NE&*EYVR4A0LJI]TJ>N#GL);G DP>L2
MO+<F^%V"WQAMR1I;,ZIH,A9\1X2.1C7=:&K39*,;5NE97"B!HPSS5'*3IF(#
M&?G\A.M"@B0?R:*=4,)79#!Z/@-%62$O,.YA,2/G9Q?DC+"*W.=\(VF5R;&M
M$$N+VVF'<-LB>$<0OE-Q27SW _$<+S2D3T^GSR#MTX/7Z386HZ^(UU?$:_3\
M(WIS^DR7!7I%-VT!:"')[YNE5 (7W1^3P58Q,"OJC7@M:YK"Q,*=)D%LP4K>
MOW,CYY/)[G\2>V7>[\W[I]3[Y9#R4L\XU5O-9+A5B1H5?5!LD\"/W+&]W3<R
M#(H")^R#7@$&/6#P-D <8"DMB!(,?U,NE7'IM6KA/FCHCPY #4&^[YE!PQXT
M?!,H5SD(HF>*BC1O%E4&6SP]:SP+U7'P<,!TY1P6>!@3!ZX9.^JQHY/8<\%7
M(/49C575JXNE8.2+!M]V@T%AAT%7(]\,..H!1R<!?S3UI-V^-)&-!A_U!DO3
M$#.*S6!Q#Q:?!+OG"DM&NVF'[L0T <:#?>&ZP=5A[0Q17NQ='4#:>T>_OG;Q
M,%VS2I("5ICG7([0HVBOLK:C>-W<!DNN\&YIFCG>_B!T (ZO.%<O'7W!]/\G
MDG]02P,$%     @ *#NH6H)GKB@^"@  B'<  !D   !X;"]W;W)K<VAE971S
M+W-H965T-#(N>&ULQ9U;;^NX%87_"N$.VAG@3*R+KVD2((DN9-',!).>SD/1
M!\:F;>'(DD>2XQ.@/[[4Q98IRXQ5K"+GX426N;]-)4O4EI8HW>SBY%NZ$B(C
MW]=AE-[V5EFVN>[WT]E*K'EZ%6]$)+]9Q,F:9_)CLNRGFT3P>1&T#ON688SZ
M:QY$O;N;8MUS<G<3;[,PB,1S0M+M>LV3]P<1QKO;GMG;K_@M6*ZR?$7_[F;#
ME^)%9%\WSXG\U#]0YL%:1&D01R01B]O>O7G-!G8>4+3X9R!VZ=$RR3?E-8Z_
MY1_8_+9GY#T2H9AE.8++'V_B481A3I+]^*."]@XY\\#CY3W=*S9>;LPK3\5C
M'/X>S+/5;6_2(W.QX-LP^RW>45%MT##GS>(P+?XGNZJMT2.S;9K%ZRI8]F =
M1.5/_KWZ11P%F(,S 5858%T:8%<!]J4!@RI@<&G L H8-@/L,P&C*F#4#!B>
M"1A7 >-+NS2I B:7!DRK@&DAA_+O5_SQ'9[QNYLDWI$D;RUI^4*AH"):_LV#
M*!?[2Y;(;P,9E]V]K'@B5G$X%TGZ%^+^L0VR=_(SN9_/@UR,/"0L*G>I7)H_
M.B+C09C^))M\?7'(CS_\1'X@?9+FE)0$$?D:!5GZ1:Z4R_]8Q=N41_/TII_)
MKN8)^[.J6W[9+>M,MVSR%$?9*B5N-!=S-;XO-_&PG=9^.Q\L+?#7679%S/$7
M8AG6H*4_C_KP^^WRBAC3L^&./OQOV^B*6).SX:X^_(DG,OOYSGL?A;\38U!$
M6VU_B@N2VV81/FP)IY>'M_6=Z<,=,3L7KNC /NC=+GBV3N_D00Z/<_(8K^4Q
M(RVE?9\D/%H*.8YGY.&='+=[YN_%ZOL=3^;D7W^72,(RL4[_W;(]#V7^07O^
M_-AUG6[X3-SVY,$I%<F;Z-W]^4_FR/AKFRJ1, <)<Y$P#PGSD3"*A#$03!'^
MX"#\@8Y^)\6^EC*7!Y39MR\DBLF&)^2-AUO1)F(MJZN(D3 '"7.1, \)\TO8
MJ(#E!>O;G7'3?SM6)C(= \$490X/RAQJE?G+=OTJ$A(O#F5$FF[EL"LK!R++
M\S23"T&T;).I%MQ5IDB8@X2Y2)B'A/DE;'@DT_%P:)KV>-A0*S(K \$4M8X.
M:AUU&$<5Q;8I5 OKJE DS$'"7"3,0\+\T:4*169E;5E-PQB/[$-617WC@_K&
MW=7WP2"I)7:5(!+F(&$N$N8A8?[X4@DBL[*VK#H)3@X2G&@EN#\;VA^OB\&/
M1S-!9G&:M0E0R^LJ0"3,0<)<),Q#POS)A\7D:8O)V&HT8J ^*:J;'E0WU:M.
M"LW;YA>#R.\\/U7/VJXJ/6@A7:6&A#E(F(N$>4B8CX11)(R!8(IZ3:.^S&I\
M\G6GJ@,@[4-I#I3F0FD>E.9#:11*8RB:N@L<.0TF\LRIHAT7,!/;&AI&X[#T
MV-+0'%B3<;.\<O3]ZZQ"),V#TGPHC4)I#$5356C5*K2T*JRJ!R*^BV06I()L
MDF#6>@VT DV/RZ8KPS";\CMM-KJ:3J=-\6F[U5E\2)H'I?F7_=XH-"E#T515
MU:Z2J;UV+\O3X(UG4DRAS%$<M,OQK557]J4#&]3]@=)<*,V#TGPHC4)I#$53
M=5J;0*;>!<I=5,(SDJT$>>+)-Y&17Q<+D031DCPG\3+AZU;)0OT@*,V!TEPH
MS8/2?"B-0FD,15-U75M(YO"S3Z^@7A.4YD!I+I3F06D^E$:A-(:BJ;M [4N9
M>F/JA8>BN"@K9MLDR )Y<L67RT0LB[ID^QH&,_EU-=:?+WJAAA64YE2TXZN4
M9EXV->HF%YK5@])\*(U":0Q%4P5<6UNFWMMZEB=D<CSFRT+&RR1.4ZG3>";$
M/"6+)%Z35$H\S;^<59<2RFL(&_[.7Z7X>5JUD @YKN>-@K2\*U?N ZUJAWIC
M4)I3T4Q;/8^RFV*'^EY0F@^E42B-H6BJV&L3S=2[:/F]F(U"_&AP/E^(0[TT
M*,V!TEPHS8/2?"B-0FD,15-U7=MTYO2S"W&HQP>E.5":"Z5Y4)H/I5$HC:%H
MZD2#VNJSM#X*J!#7)^DJ<RC-@=+<BG9<U@^,:;.J]UJ:F<9I]>]#.T>A-(:B
MJ<JL'3A+[\#](JL,M:*>'7ERK2I$6C^/4)H#I;E0F@>E^5 :K6C'.]*XN1<Q
M5$I5J;5+9^E=NI8Q-!'YW,U\S.1O/ CE&5\0!ME[JVJ1UM(CE.9 :6Y%._:2
MAE/S=.R$&GQ0&H72&(JFZK;V 2V]#_B2#Z3["0SS;7F(ET?ZN/46!SVLLTZA
M=B&4YD)I'I3F0VG4.G5WS;$YF8R: ^S_PPBT:B/0TAN!7Z.Y2'9R:,U$=+
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MZV)Q);@LOO,&\OM%'&?[#WF"P\MW[_X+4$L#!!0    ( "@[J%I%X>0(U@,
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M0(/CH5&734]M)EK4KH_-A39=T0U+\QM":0/,_D((O9U8@>['EOT"4$L#!!0
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M)%&>9!S_%4Z-<DYE>'B]]_Y+#B]AIIB3"4V^QY%8#(W  !&9X54BOM'-KZ0
M<I6_D"8\_PLVQ5C+ .&*"YH6QC*"-,YV__%+D8@# ^2=,$"% :H;."<,[,+
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M9U?(*OOC;OMV@UZK/<E@X9D=J$ >P$N_^R9,@A\'O!LWWHV'M*>?7 $;9'(
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MN10;K>$929@L+ZKS(X,Y.["SA/;J%8X2<=PSHFV9BU:+#%F?$$JC*)HI;NU
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M) BBR(X 9G<0!!@"=R..8 [  X8$0?4>W'D?>>OWE+?YE7;\!U!+ P04
M"  H.ZA:EXJ[',     3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">
M, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]
M$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<
MUYVE/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A
M(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X
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MP> !  #L(   &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSS=H[3L-
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M_?^DNIS/3=?+7Y;?.T<WU 7G #\W/'X!4$L#!!0    ( "@[J%H4U''DT $
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M8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  H.ZA:$;4#_/(    K @  $0
M            @ '#    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    "  H
M.ZA:F5R<(Q &  "<)P  $P              @ 'D 0  >&PO=&AE;64O=&AE
M;64Q+GAM;%!+ 0(4 Q0    ( "@[J%JXB[B/# 8  +P@   8
M  " @24(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    "  H
M.ZA:;8 [ %X%  "W%0  &               @(%G#@  >&PO=V]R:W-H965T
M<R]S:&5E=#(N>&UL4$L! A0#%     @ *#NH6B@0_JEY @  %P<  !@
M         ("!^Q,  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0
M   ( "@[J%H[YZ#.QP0  )L2   8              " @:H6  !X;"]W;W)K
M<VAE971S+W-H965T-"YX;6Q02P$"% ,4    "  H.ZA:5/N/[3D(   (3
M&               @(&G&P  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L!
M A0#%     @ *#NH6AO\P9#J!P  (R,  !@              ("!%B0  'AL
M+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( "@[J%J^)>/H3 (
M *,%   8              " @38L  !X;"]W;W)K<VAE971S+W-H965T-RYX
M;6Q02P$"% ,4    "  H.ZA:$ZV'ZT0"  "*!@  &               @(&X
M+@  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ *#NH6A<W
M$()C"   3!,  !@              ("!,C$  'AL+W=O<FMS:&5E=',O<VAE
M970Y+GAM;%!+ 0(4 Q0    ( "@[J%H<G_P0L@L  %$@   9
M  " @<LY  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @
M*#NH6NEJNO51 P  , <  !D              ("!M$4  'AL+W=O<FMS:&5E
M=',O<VAE970Q,2YX;6Q02P$"% ,4    "  H.ZA:Y*:TYR<%  !W#   &0
M            @($\20  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4
M Q0    ( "@[J%KYK&_TJ0(  !$&   9              " @9I.  !X;"]W
M;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ *#NH6JGSQ7C( @
M#P8  !D              ("!>E$  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX
M;6Q02P$"% ,4    "  H.ZA:R*D$@H,*  #L(   &0              @(%Y
M5   >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( "@[J%K$
MTE) 3@0  #H*   9              " @3-?  !X;"]W;W)K<VAE971S+W-H
M965T,38N>&UL4$L! A0#%     @ *#NH6MQBL\)6"0  !1D  !D
M     ("!N&,  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "@[J%I)#F)>WPL  /(A   9              "
M@1"(  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ *#NH
M6F3Y"%K[!   0 P  !D              ("!)I0  'AL+W=O<FMS:&5E=',O
M<VAE970R,RYX;6Q02P$"% ,4    "  H.ZA:/H*C9?L"  !Z!@  &0
M        @(%8F0  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0
M   ( "@[J%K")!'.S 0  #T,   9              " @8J<  !X;"]W;W)K
M<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ *#NH6EA)\>7# @  #P8
M !D              ("!C:$  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q0
M2P$"% ,4    "  H.ZA:KQ*LJE$#   ="   &0              @(&'I
M>&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( "@[J%JKY,=M
M>P0  -0*   9              " @0^H  !X;"]W;W)K<VAE971S+W-H965T
M,C@N>&UL4$L! A0#%     @ *#NH6HDKCTK@ @  2P8  !D
M ("!P:P  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    "  H
M.ZA:[_Z]P68#   5!P  &0              @('8KP  >&PO=V]R:W-H965T
M<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( "@[J%H!6/)G7P(  %8%   9
M          " @76S  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#
M%     @ *#NH6HZ@?'$< P  #@P  !D              ("!"[8  'AL+W=O
M<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    "  H.ZA:.TRS1A,$   J
M#@  &0              @(%>N0  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM
M;%!+ 0(4 Q0    ( "@[J%JUO_=W/@0  ,(5   9              " @:B]
M  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ *#NH6E(%
M-*:[!   G1X  !D              ("!'<(  'AL+W=O<FMS:&5E=',O<VAE
M970S-2YX;6Q02P$"% ,4    "  H.ZA:S#K,MQT"  !+!   &0
M    @($/QP  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    (
M "@[J%I V*T[L 4  ,XH   9              " @6/)  !X;"]W;W)K<VAE
M971S+W-H965T,S<N>&UL4$L! A0#%     @ *#NH6LG>L^K% @  2@@  !D
M             ("!2L\  'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"
M% ,4    "  H.ZA:EFN:2W4#   C#P  &0              @(%&T@  >&PO
M=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( "@[J%IQS7YGUP(
M  T(   9              " @?+5  !X;"]W;W)K<VAE971S+W-H965T-# N
M>&UL4$L! A0#%     @ *#NH6H"E4@W? @  6P@  !D              ("!
M -D  'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    "  H.ZA:
M@F>N*#X*  "(=P  &0              @($6W   >&PO=V]R:W-H965T<R]S
M:&5E=#0R+GAM;%!+ 0(4 Q0    ( "@[J%I%X>0(U@,  +86   9
M      " @8OF  !X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%
M  @ *#NH6NPH,J"F @  Y 8  !D              ("!F.H  'AL+W=O<FMS
M:&5E=',O<VAE970T-"YX;6Q02P$"% ,4    "  H.ZA:28%A13 #  !$"P
M&0              @(%U[0  >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+
M 0(4 Q0    ( "@[J%K!2DV&% 8  + H   9              " @=SP  !X
M;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ *#NH6HXRXH>\
M!   ,18  !D              ("!)_<  'AL+W=O<FMS:&5E=',O<VAE970T
M-RYX;6Q02P$"% ,4    "  H.ZA:F 59>'D#   W#   &0
M@($:_   >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( "@[
MJ%KMBN3(,@,  .\+   9              " @<K_  !X;"]W;W)K<VAE971S
M+W-H965T-#DN>&UL4$L! A0#%     @ *#NH6O[YUD,7 @  3P0  !D
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M=#4T+GAM;%!+ 0(4 Q0    ( "@[J%HW*;#=% 0  &H1   9
M  " @147 0!X;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%     @
M*#NH6HQWRK=- P  LA4   T              ( !8!L! 'AL+W-T>6QE<RYX
M;6Q02P$"% ,4    "  H.ZA:EXJ[',     3 @  "P              @ '8
M'@$ 7W)E;',O+G)E;'-02P$"% ,4    "  H.ZA:*0^S6ZX$  "S)   #P
M            @ '!'P$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ *#NH
M6KP!UL'@ 0  ["   !H              ( !G"0! 'AL+U]R96QS+W=O<FMB
M;V]K+GAM;"YR96QS4$L! A0#%     @ *#NH6A34<>30 0  K2   !,
M         ( !M"8! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     #\ /P P
)$0  M2@!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>142</ContextCount>
  <ElementCount>257</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>51</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="mnmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mindmed.co/20250331/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="mnmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="mnmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="mnmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="mnmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Shareholders' Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="mnmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="mnmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="mnmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="mnmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995455 - Disclosure - Nature of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mindmed.co/20250331/taxonomy/role/DisclosureNatureOfOperations</Role>
      <ShortName>Nature of Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="mnmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995465 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="mnmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995475 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mindmed.co/20250331/taxonomy/role/DisclosureInvestments</Role>
      <ShortName>Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="mnmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995485 - Disclosure - Fair Value of Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureFairValueOfFinancialInstruments</Role>
      <ShortName>Fair Value of Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="mnmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995495 - Disclosure - Goodwill and Intangible Assets, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mindmed.co/20250331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNet1</Role>
      <ShortName>Goodwill and Intangible Assets, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="mnmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995505 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureAccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="mnmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995515 - Disclosure - Shareholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureShareholdersEquity</Role>
      <ShortName>Shareholders??? Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="mnmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995525 - Disclosure - Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureWarrants</Role>
      <ShortName>Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="mnmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995535 - Disclosure - Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="mnmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995545 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="mnmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995555 - Disclosure - Credit Facility</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacility</Role>
      <ShortName>Credit Facility</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="mnmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995565 - Disclosure - SEGMENT REPORTING</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mindmed.co/20250331/taxonomy/role/DisclosureSegmentReporting</Role>
      <ShortName>SEGMENT REPORTING</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="mnmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995575 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mindmed.co/20250331/taxonomy/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="mnmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995585 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="mnmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995595 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="mnmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995605 - Disclosure - Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mindmed.co/20250331/taxonomy/role/DisclosureInvestmentsTables</Role>
      <ShortName>Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mindmed.co/20250331/taxonomy/role/DisclosureInvestments</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="mnmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995615 - Disclosure - Fair Value of Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables</Role>
      <ShortName>Fair Value of Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureFairValueOfFinancialInstruments</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="mnmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995635 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureAccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureAccruedExpenses</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="mnmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995655 - Disclosure - Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureWarrantsTables</Role>
      <ShortName>Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureWarrants</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="mnmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995665 - Disclosure - Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensation</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="mnmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995675 - Disclosure - Credit Facility (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacilityTables</Role>
      <ShortName>Credit Facility (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacility</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="mnmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995685 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mindmed.co/20250331/taxonomy/role/DisclosureSegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="mnmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995695 - Disclosure - Description of the Business - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mindmed.co/20250331/taxonomy/role/DisclosureDescriptionOfTheBusinessAdditionalInformationDetails</Role>
      <ShortName>Description of the Business - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="mnmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995705 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="mnmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995715 - Disclosure - Basis of presentation and summary of significant accounting policies - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails</Role>
      <ShortName>Basis of presentation and summary of significant accounting policies - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="mnmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995725 - Disclosure - Basis of presentation and summary of significant accounting policies - Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share due to Anti-dilutive Effect (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilut</Role>
      <ShortName>Basis of presentation and summary of significant accounting policies - Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share due to Anti-dilutive Effect (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="mnmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995735 - Disclosure - Investments - Schedule of available-for-sale investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mindmed.co/20250331/taxonomy/role/DisclosureInvestmentsScheduleOfAvailableforsaleInvestmentsDetails</Role>
      <ShortName>Investments - Schedule of available-for-sale investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="mnmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995745 - Disclosure - Investments (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mindmed.co/20250331/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails</Role>
      <ShortName>Investments (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.mindmed.co/20250331/taxonomy/role/DisclosureInvestmentsTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="mnmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995755 - Disclosure - Fair Value of Financial Instruments - Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mindmed.co/20250331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Fair Value of Financial Instruments - Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="mnmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995765 - Disclosure - Fair Value of Financial Instruments - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails</Role>
      <ShortName>Fair Value of Financial Instruments - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="mnmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995775 - Disclosure - Fair Value of Financial Instruments - Schedule of Assumptions used to Determine Fair Value of 2022 USD Financing Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mindmed.co/20250331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssumptionsUsedToDetermineFairValueOf2022UsdFinancingWarrantsDetails</Role>
      <ShortName>Fair Value of Financial Instruments - Schedule of Assumptions used to Determine Fair Value of 2022 USD Financing Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="mnmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>995785 - Disclosure - Goodwill and Intangible Assets, Net - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mindmed.co/20250331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetAdditionalInformationDetails</Role>
      <ShortName>Goodwill and Intangible Assets, Net - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="mnmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>995805 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses - Summary of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="mnmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>995815 - Disclosure - Shareholders' Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Shareholders' Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="mnmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>995835 - Disclosure - Warrants - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureWarrantsAdditionalInformationDetails</Role>
      <ShortName>Warrants - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="mnmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>995845 - Disclosure - Warrants - Summary of Outstanding Liability Classified as Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mindmed.co/20250331/taxonomy/role/DisclosureWarrantsSummaryOfOutstandingLiabilityClassifiedAsWarrantsDetails</Role>
      <ShortName>Warrants - Summary of Outstanding Liability Classified as Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="mnmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>995855 - Disclosure - Warrants - Summary of Activity of Outstanding Warrant Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mindmed.co/20250331/taxonomy/role/DisclosureWarrantsSummaryOfActivityOfOutstandingWarrantLiabilityDetails</Role>
      <ShortName>Warrants - Summary of Activity of Outstanding Warrant Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="mnmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>995865 - Disclosure - Stock-based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="mnmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>995885 - Disclosure - Stock-based Compensation - Schedule of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails</Role>
      <ShortName>Stock-based Compensation - Schedule of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="mnmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>995895 - Disclosure - Stock-based Compensation - Schedule of Restricted Share Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mindmed.co/20250331/taxonomy/role/DisclosureStockbasedCompensationScheduleOfRestrictedShareUnitsDetails</Role>
      <ShortName>Stock-based Compensation - Schedule of Restricted Share Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="mnmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>995905 - Disclosure - Stock-based Compensation - Summary of Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-based Compensation - Summary of Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="mnmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>995915 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="mnmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>995925 - Disclosure - Credit Facility - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetails</Role>
      <ShortName>Credit Facility - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="mnmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>995935 - Disclosure - Credit Facility - Schedule of Future Expected Repayments of Principal Amount Due on Credit Facility (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacilityScheduleOfFutureExpectedRepaymentsOfPrincipalAmountDueOnCreditFacilityDetails</Role>
      <ShortName>Credit Facility - Schedule of Future Expected Repayments of Principal Amount Due on Credit Facility (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="mnmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>995945 - Disclosure - Segment Information (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mindmed.co/20250331/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails</Role>
      <ShortName>Segment Information (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.mindmed.co/20250331/taxonomy/role/DisclosureSegmentInformationTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="mnmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>995955 - Disclosure - Segment Information - Summary of Additional Expense Details (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mindmed.co/20250331/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalExpenseDetailsDetails</Role>
      <ShortName>Segment Information - Summary of Additional Expense Details (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="mnmd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>995965 - Disclosure - Subsequent Events (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mindmed.co/20250331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails</Role>
      <ShortName>Subsequent Events (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.mindmed.co/20250331/taxonomy/role/DisclosureSubsequentEvents</ParentRole>
      <Position>55</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="mnmd-20250331.htm">mnmd-20250331.htm</File>
    <File>mnmd-20250331.xsd</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img196101975_0.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="424">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="31">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>75
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "mnmd-20250331.htm": {
   "nsprefix": "mnmd",
   "nsuri": "http://www.mindmed.co/20250331",
   "dts": {
    "inline": {
     "local": [
      "mnmd-20250331.htm"
     ]
    },
    "schema": {
     "local": [
      "mnmd-20250331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/currency/2024/currency-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    }
   },
   "keyStandard": 212,
   "keyCustom": 45,
   "axisStandard": 19,
   "axisCustom": 0,
   "memberStandard": 25,
   "memberCustom": 20,
   "hidden": {
    "total": 11,
    "http://fasb.org/us-gaap/2024": 7,
    "http://xbrl.sec.gov/dei/2024": 4
   },
   "contextCount": 142,
   "entityCount": 1,
   "segmentCount": 51,
   "elementCount": 622,
   "unitCount": 5,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 424,
    "http://xbrl.sec.gov/dei/2024": 31,
    "http://xbrl.sec.gov/ecd/2024": 4
   },
   "report": {
    "R1": {
     "role": "http://www.mindmed.co/20250331/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_eb56ad75-806f-4117-8a10-7450fb345387",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_eb56ad75-806f-4117-8a10-7450fb345387",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets",
     "longName": "100010 - Statement - Condensed Consolidated Balance Sheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_fbd55b55-3ca4-42cd-ba02-af13b09e1256",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_fbd55b55-3ca4-42cd-ba02-af13b09e1256",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
     "longName": "100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_fbd55b55-3ca4-42cd-ba02-af13b09e1256",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "U_UsdShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_fbd55b55-3ca4-42cd-ba02-af13b09e1256",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "U_UsdShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited",
     "longName": "100030 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_eb56ad75-806f-4117-8a10-7450fb345387",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_eb56ad75-806f-4117-8a10-7450fb345387",
      "name": "us-gaap:OperatingExpenses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited",
     "longName": "100040 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Shareholders' Equity (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_ebfcf44a-8b21-4107-a576-08b906d78af5",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ebfcf44a-8b21-4107-a576-08b906d78af5",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
     "longName": "100050 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_eb56ad75-806f-4117-8a10-7450fb345387",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_eb56ad75-806f-4117-8a10-7450fb345387",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_eb56ad75-806f-4117-8a10-7450fb345387",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_eb56ad75-806f-4117-8a10-7450fb345387",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_eb56ad75-806f-4117-8a10-7450fb345387",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.mindmed.co/20250331/taxonomy/role/DisclosureNatureOfOperations",
     "longName": "995455 - Disclosure - Nature of Operations",
     "shortName": "Nature of Operations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_53549879-ba1d-4877-b935-3c96fc46f9bb",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_53549879-ba1d-4877-b935-3c96fc46f9bb",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies",
     "longName": "995465 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_eb56ad75-806f-4117-8a10-7450fb345387",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_eb56ad75-806f-4117-8a10-7450fb345387",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.mindmed.co/20250331/taxonomy/role/DisclosureInvestments",
     "longName": "995475 - Disclosure - Investments",
     "shortName": "Investments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_eb56ad75-806f-4117-8a10-7450fb345387",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_eb56ad75-806f-4117-8a10-7450fb345387",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureFairValueOfFinancialInstruments",
     "longName": "995485 - Disclosure - Fair Value of Financial Instruments",
     "shortName": "Fair Value of Financial Instruments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_eb56ad75-806f-4117-8a10-7450fb345387",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_eb56ad75-806f-4117-8a10-7450fb345387",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.mindmed.co/20250331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNet1",
     "longName": "995495 - Disclosure - Goodwill and Intangible Assets, Net",
     "shortName": "Goodwill and Intangible Assets, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_eb56ad75-806f-4117-8a10-7450fb345387",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_eb56ad75-806f-4117-8a10-7450fb345387",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureAccruedExpenses",
     "longName": "995505 - Disclosure - Accrued Expenses",
     "shortName": "Accrued Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_eb56ad75-806f-4117-8a10-7450fb345387",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_eb56ad75-806f-4117-8a10-7450fb345387",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureShareholdersEquity",
     "longName": "995515 - Disclosure - Shareholders\u2019 Equity",
     "shortName": "Shareholders\u2019 Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_eb56ad75-806f-4117-8a10-7450fb345387",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_eb56ad75-806f-4117-8a10-7450fb345387",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureWarrants",
     "longName": "995525 - Disclosure - Warrants",
     "shortName": "Warrants",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_eb56ad75-806f-4117-8a10-7450fb345387",
      "name": "mnmd:WarrantsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_eb56ad75-806f-4117-8a10-7450fb345387",
      "name": "mnmd:WarrantsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensation",
     "longName": "995535 - Disclosure - Stock-based Compensation",
     "shortName": "Stock-based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_eb56ad75-806f-4117-8a10-7450fb345387",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_eb56ad75-806f-4117-8a10-7450fb345387",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureCommitmentsAndContingencies",
     "longName": "995545 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_eb56ad75-806f-4117-8a10-7450fb345387",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_eb56ad75-806f-4117-8a10-7450fb345387",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacility",
     "longName": "995555 - Disclosure - Credit Facility",
     "shortName": "Credit Facility",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_eb56ad75-806f-4117-8a10-7450fb345387",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_eb56ad75-806f-4117-8a10-7450fb345387",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.mindmed.co/20250331/taxonomy/role/DisclosureSegmentReporting",
     "longName": "995565 - Disclosure - SEGMENT REPORTING",
     "shortName": "SEGMENT REPORTING",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_eb56ad75-806f-4117-8a10-7450fb345387",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_eb56ad75-806f-4117-8a10-7450fb345387",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.mindmed.co/20250331/taxonomy/role/DisclosureSubsequentEvents",
     "longName": "995575 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_eb56ad75-806f-4117-8a10-7450fb345387",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_eb56ad75-806f-4117-8a10-7450fb345387",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "995585 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_eb56ad75-806f-4117-8a10-7450fb345387",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_eb56ad75-806f-4117-8a10-7450fb345387",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables",
     "longName": "995595 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_eb56ad75-806f-4117-8a10-7450fb345387",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_eb56ad75-806f-4117-8a10-7450fb345387",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.mindmed.co/20250331/taxonomy/role/DisclosureInvestmentsTables",
     "longName": "995605 - Disclosure - Investments (Tables)",
     "shortName": "Investments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_eb56ad75-806f-4117-8a10-7450fb345387",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_eb56ad75-806f-4117-8a10-7450fb345387",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables",
     "longName": "995615 - Disclosure - Fair Value of Financial Instruments (Tables)",
     "shortName": "Fair Value of Financial Instruments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_eb56ad75-806f-4117-8a10-7450fb345387",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_eb56ad75-806f-4117-8a10-7450fb345387",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureAccruedExpensesTables",
     "longName": "995635 - Disclosure - Accrued Expenses (Tables)",
     "shortName": "Accrued Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_eb56ad75-806f-4117-8a10-7450fb345387",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_eb56ad75-806f-4117-8a10-7450fb345387",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureWarrantsTables",
     "longName": "995655 - Disclosure - Warrants (Tables)",
     "shortName": "Warrants (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_eb56ad75-806f-4117-8a10-7450fb345387",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_eb56ad75-806f-4117-8a10-7450fb345387",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationTables",
     "longName": "995665 - Disclosure - Stock-based Compensation (Tables)",
     "shortName": "Stock-based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_eb56ad75-806f-4117-8a10-7450fb345387",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_eb56ad75-806f-4117-8a10-7450fb345387",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacilityTables",
     "longName": "995675 - Disclosure - Credit Facility (Tables)",
     "shortName": "Credit Facility (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_eb56ad75-806f-4117-8a10-7450fb345387",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_eb56ad75-806f-4117-8a10-7450fb345387",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.mindmed.co/20250331/taxonomy/role/DisclosureSegmentInformationTables",
     "longName": "995685 - Disclosure - Segment Information (Tables)",
     "shortName": "Segment Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_eb56ad75-806f-4117-8a10-7450fb345387",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_eb56ad75-806f-4117-8a10-7450fb345387",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.mindmed.co/20250331/taxonomy/role/DisclosureDescriptionOfTheBusinessAdditionalInformationDetails",
     "longName": "995695 - Disclosure - Description of the Business - Additional Information (Details)",
     "shortName": "Description of the Business - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_fbd55b55-3ca4-42cd-ba02-af13b09e1256",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R32": {
     "role": "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "longName": "995705 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_fbd55b55-3ca4-42cd-ba02-af13b09e1256",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_fbd55b55-3ca4-42cd-ba02-af13b09e1256",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails",
     "longName": "995715 - Disclosure - Basis of presentation and summary of significant accounting policies - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details)",
     "shortName": "Basis of presentation and summary of significant accounting policies - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_eb56ad75-806f-4117-8a10-7450fb345387",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_eb56ad75-806f-4117-8a10-7450fb345387",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilut",
     "longName": "995725 - Disclosure - Basis of presentation and summary of significant accounting policies - Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share due to Anti-dilutive Effect (Details)",
     "shortName": "Basis of presentation and summary of significant accounting policies - Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share due to Anti-dilutive Effect (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_eb56ad75-806f-4117-8a10-7450fb345387",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_eb56ad75-806f-4117-8a10-7450fb345387",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.mindmed.co/20250331/taxonomy/role/DisclosureInvestmentsScheduleOfAvailableforsaleInvestmentsDetails",
     "longName": "995735 - Disclosure - Investments - Schedule of available-for-sale investments (Details)",
     "shortName": "Investments - Schedule of available-for-sale investments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_9530e32c-7cf2-41f3-bd67-a92ee6762331",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.mindmed.co/20250331/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails",
     "longName": "995745 - Disclosure - Investments (Additional Information) (Details)",
     "shortName": "Investments (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R37": {
     "role": "http://www.mindmed.co/20250331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
     "longName": "995755 - Disclosure - Fair Value of Financial Instruments - Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "shortName": "Fair Value of Financial Instruments - Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_36b4af29-5d76-4291-b73b-cd8c72915e01",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_36b4af29-5d76-4291-b73b-cd8c72915e01",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
     "longName": "995765 - Disclosure - Fair Value of Financial Instruments - Additional Information (Details)",
     "shortName": "Fair Value of Financial Instruments - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_eb56ad75-806f-4117-8a10-7450fb345387",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_eb56ad75-806f-4117-8a10-7450fb345387",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.mindmed.co/20250331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssumptionsUsedToDetermineFairValueOf2022UsdFinancingWarrantsDetails",
     "longName": "995775 - Disclosure - Fair Value of Financial Instruments - Schedule of Assumptions used to Determine Fair Value of 2022 USD Financing Warrants (Details)",
     "shortName": "Fair Value of Financial Instruments - Schedule of Assumptions used to Determine Fair Value of 2022 USD Financing Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_97bfc649-2b8e-41f0-8976-f5330877ad56",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "unitRef": "U_UsdShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_97bfc649-2b8e-41f0-8976-f5330877ad56",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "unitRef": "U_UsdShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.mindmed.co/20250331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetAdditionalInformationDetails",
     "longName": "995785 - Disclosure - Goodwill and Intangible Assets, Net - Additional Information (Details)",
     "shortName": "Goodwill and Intangible Assets, Net - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_eb56ad75-806f-4117-8a10-7450fb345387",
      "name": "us-gaap:GoodwillAcquiredDuringPeriod",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_eb56ad75-806f-4117-8a10-7450fb345387",
      "name": "us-gaap:GoodwillAcquiredDuringPeriod",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails",
     "longName": "995805 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Details)",
     "shortName": "Accrued Expenses - Summary of Accrued Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_fbd55b55-3ca4-42cd-ba02-af13b09e1256",
      "name": "us-gaap:WorkersCompensationLiabilityCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_fbd55b55-3ca4-42cd-ba02-af13b09e1256",
      "name": "us-gaap:WorkersCompensationLiabilityCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails",
     "longName": "995815 - Disclosure - Shareholders' Equity - Additional Information (Details)",
     "shortName": "Shareholders' Equity - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_fbd55b55-3ca4-42cd-ba02-af13b09e1256",
      "name": "us-gaap:CommonStockNoParValue",
      "unitRef": "U_UsdShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_fbd55b55-3ca4-42cd-ba02-af13b09e1256",
      "name": "us-gaap:CommonStockNoParValue",
      "unitRef": "U_UsdShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureWarrantsAdditionalInformationDetails",
     "longName": "995835 - Disclosure - Warrants - Additional Information (Details)",
     "shortName": "Warrants - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_fbd55b55-3ca4-42cd-ba02-af13b09e1256",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_fc88df44-67ae-47e8-a51a-83bbbe2805d6",
      "name": "mnmd:CommonShareAndWarrantPublicOfferingExpireDate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "mnmd:WarrantsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.mindmed.co/20250331/taxonomy/role/DisclosureWarrantsSummaryOfOutstandingLiabilityClassifiedAsWarrantsDetails",
     "longName": "995845 - Disclosure - Warrants - Summary of Outstanding Liability Classified as Warrants (Details)",
     "shortName": "Warrants - Summary of Outstanding Liability Classified as Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "C_4ea41252-c084-4a13-8fad-6ff6f7cfeccf",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4ea41252-c084-4a13-8fad-6ff6f7cfeccf",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.mindmed.co/20250331/taxonomy/role/DisclosureWarrantsSummaryOfActivityOfOutstandingWarrantLiabilityDetails",
     "longName": "995855 - Disclosure - Warrants - Summary of Activity of Outstanding Warrant Liability (Details)",
     "shortName": "Warrants - Summary of Activity of Outstanding Warrant Liability (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "C_eb56ad75-806f-4117-8a10-7450fb345387",
      "name": "us-gaap:FairValueAdjustmentOfWarrants",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b58805d9-68aa-4a81-99f4-2a397090939f",
      "name": "us-gaap:FinancialLiabilitiesFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "mnmd:ScheduleOfWarrantLiabilityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
     "longName": "995865 - Disclosure - Stock-based Compensation - Additional Information (Details)",
     "shortName": "Stock-based Compensation - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "C_eb56ad75-806f-4117-8a10-7450fb345387",
      "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
      "unitRef": "U_UsdShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_fbd55b55-3ca4-42cd-ba02-af13b09e1256",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails",
     "longName": "995885 - Disclosure - Stock-based Compensation - Schedule of Stock Option Activity (Details)",
     "shortName": "Stock-based Compensation - Schedule of Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_eb56ad75-806f-4117-8a10-7450fb345387",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.mindmed.co/20250331/taxonomy/role/DisclosureStockbasedCompensationScheduleOfRestrictedShareUnitsDetails",
     "longName": "995895 - Disclosure - Stock-based Compensation - Schedule of Restricted Share Units (Details)",
     "shortName": "Stock-based Compensation - Schedule of Restricted Share Units (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
      "unitRef": "U_UsdShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
      "unitRef": "U_UsdShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails",
     "longName": "995905 - Disclosure - Stock-based Compensation - Summary of Stock-based Compensation Expense (Details)",
     "shortName": "Stock-based Compensation - Summary of Stock-based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "C_eb56ad75-806f-4117-8a10-7450fb345387",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7f0ccbf3-018b-4d47-8587-c44623598ad3",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
     "longName": "995915 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "C_fbd55b55-3ca4-42cd-ba02-af13b09e1256",
      "name": "us-gaap:OtherCommitment",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_fbd55b55-3ca4-42cd-ba02-af13b09e1256",
      "name": "us-gaap:OtherCommitment",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetails",
     "longName": "995925 - Disclosure - Credit Facility - Additional Information (Details)",
     "shortName": "Credit Facility - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "C_eb56ad75-806f-4117-8a10-7450fb345387",
      "name": "us-gaap:PaymentsOfFinancingCosts",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_eb56ad75-806f-4117-8a10-7450fb345387",
      "name": "us-gaap:InterestExpenseDebt",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacilityScheduleOfFutureExpectedRepaymentsOfPrincipalAmountDueOnCreditFacilityDetails",
     "longName": "995935 - Disclosure - Credit Facility - Schedule of Future Expected Repayments of Principal Amount Due on Credit Facility (Details)",
     "shortName": "Credit Facility - Schedule of Future Expected Repayments of Principal Amount Due on Credit Facility (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "C_fbd55b55-3ca4-42cd-ba02-af13b09e1256",
      "name": "mnmd:DebtRepaymentsOfPrincipalInNextTwelveMonthsBeforeUnamortizedDebtIssuanceCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_fbd55b55-3ca4-42cd-ba02-af13b09e1256",
      "name": "mnmd:DebtRepaymentsOfPrincipalInNextTwelveMonthsBeforeUnamortizedDebtIssuanceCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.mindmed.co/20250331/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails",
     "longName": "995945 - Disclosure - Segment Information (Additional Information) (Details)",
     "shortName": "Segment Information (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "C_eb56ad75-806f-4117-8a10-7450fb345387",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "U_Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_eb56ad75-806f-4117-8a10-7450fb345387",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "U_Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.mindmed.co/20250331/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalExpenseDetailsDetails",
     "longName": "995955 - Disclosure - Segment Information - Summary of Additional Expense Details (Details)",
     "shortName": "Segment Information - Summary of Additional Expense Details (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "C_eb56ad75-806f-4117-8a10-7450fb345387",
      "name": "mnmd:ResearchAndDevelopmentInternalExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_eb56ad75-806f-4117-8a10-7450fb345387",
      "name": "mnmd:ResearchAndDevelopmentInternalExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.mindmed.co/20250331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
     "longName": "995965 - Disclosure - Subsequent Events (Additional Information) (Details)",
     "shortName": "Subsequent Events (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "C_6ad17a66-7ef6-4b6b-947f-8a82218b53f9",
      "name": "us-gaap:DebtInstrumentBasisSpreadOnVariableRate1",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6ad17a66-7ef6-4b6b-947f-8a82218b53f9",
      "name": "us-gaap:DebtInstrumentBasisSpreadOnVariableRate1",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mnmd-20250331.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingStandardsUpdate201602Member",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASU 2016-02",
        "label": "Accounting Standards Update 2016-02 [Member]",
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842)."
       }
      }
     },
     "auth_ref": [
      "r557"
     ]
    },
    "us-gaap_AccountingStandardsUpdate201613Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingStandardsUpdate201613Member",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASU 2016-13",
        "label": "Accounting Standards Update 2016-13 [Member]",
        "documentation": "Accounting Standards Update 2016-13 Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments."
       }
      }
     },
     "auth_ref": [
      "r276"
     ]
    },
    "us-gaap_AccountingStandardsUpdate201912Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingStandardsUpdate201912Member",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASU 2019-12",
        "label": "Accounting Standards Update 2019-12 [Member]",
        "documentation": "Accounting Standards Update 2019-12 Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes."
       }
      }
     },
     "auth_ref": [
      "r457",
      "r458"
     ]
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureAccruedExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "terseLabel": "Accrued Expenses",
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r447"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accounts Payable, Current, Total",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r793"
     ]
    },
    "mnmd_AccruedClinicalAndManufacturingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "AccruedClinicalAndManufacturingCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued clinical and manufacturing costs.",
        "label": "Accrued clinical trial costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "mnmd_AccruedOtherResearchAndDevelopmentCostsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "AccruedOtherResearchAndDevelopmentCostsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Other Research and Development Costs Current",
        "documentation": "Accrued other research and development costs current.",
        "terseLabel": "Accrued other research and development costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional services",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r15",
      "r69",
      "r146",
      "r623",
      "r644",
      "r648"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated OCI",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r8",
      "r15",
      "r493",
      "r496",
      "r567",
      "r639",
      "r640",
      "r907",
      "r908",
      "r909",
      "r916",
      "r917",
      "r918",
      "r919"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r844"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "periodEndLabel": "Additional Paid in Capital, Common Stock, Ending Balance",
        "periodStartLabel": "Additional Paid in Capital, Common Stock, Beginning Balance",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r659",
      "r916",
      "r917",
      "r918",
      "r919",
      "r1000",
      "r1034"
     ]
    },
    "mnmd_AdditionalTrancheTermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "AdditionalTrancheTermLoanMember",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Tranche Term Loan",
        "documentation": "Additional Tranche Term Loan.",
        "label": "Additional Tranche Term Loan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Axis]",
        "documentation": "Information by amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r175",
      "r176",
      "r177",
      "r178",
      "r189",
      "r239",
      "r240",
      "r278",
      "r279",
      "r280",
      "r281",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r316",
      "r317",
      "r325",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r537",
      "r538",
      "r558",
      "r559",
      "r560",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r608",
      "r609",
      "r610",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Recognized of incremental compensation cost",
        "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r46",
      "r403"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "mnmd_AggregateNumberOfCommonSharesOwnedByHolderPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "AggregateNumberOfCommonSharesOwnedByHolderPercentage",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate number of common shares owned by holder percentage",
        "label": "Aggregate Number Of Common Shares Owned By Holder Percentage",
        "documentation": "Aggregate number of common shares owned by holder percentage."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r890"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r816",
      "r826",
      "r836",
      "r868"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r819",
      "r829",
      "r839",
      "r871"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "currency_AllCurrenciesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2024",
     "localname": "AllCurrenciesDomain",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureStockbasedCompensationScheduleOfRestrictedShareUnitsDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Currencies [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r864"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r820",
      "r830",
      "r840",
      "r864",
      "r872",
      "r876",
      "r884"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r882"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "verboseLabel": "Total share-based compensation expense",
        "label": "Stock-based compensation expense recognized",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r435",
      "r445"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "mnmd_AmendmentTermLoansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "AmendmentTermLoansMember",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Term Loans [Member]",
        "documentation": "Amendment term loans.",
        "terseLabel": "Amendment Term Loans"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of intangible assets",
        "label": "Amortization of Intangible Assets",
        "totalLabel": "Amortization of Intangible Assets, Total",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r306",
      "r312",
      "r766"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilut"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of loss per share",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r204"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilut"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilut"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilut"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r479"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r110",
      "r140",
      "r168",
      "r207",
      "r215",
      "r228",
      "r231",
      "r275",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r481",
      "r485",
      "r540",
      "r620",
      "r693",
      "r757",
      "r758",
      "r793",
      "r806",
      "r969",
      "r970",
      "r1017"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r147",
      "r168",
      "r275",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r481",
      "r485",
      "r540",
      "r793",
      "r969",
      "r970",
      "r1017"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Assets, Fair Value Disclosure, Total",
        "terseLabel": "Financial assets",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r513",
      "r514",
      "r781"
     ]
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosureAbstract",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Assets, Fair Value Disclosure [Abstract]",
        "label": "Assets, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "mnmd_AtTheMarketOfferingProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "AtTheMarketOfferingProgramMember",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "At The Market Offering Program [Member]",
        "documentation": "At the market offering program.",
        "terseLabel": "At-the-market Offering Program"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureInvestmentsScheduleOfAvailableforsaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Unrealized Gain",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r248"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureInvestmentsScheduleOfAvailableforsaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r249"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureInvestmentsScheduleOfAvailableforsaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortized Cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Debt Securities, Available-for-Sale, Amortized Cost, Total",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r245",
      "r294",
      "r619"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureInvestmentsScheduleOfAvailableforsaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated Fair Value",
        "verboseLabel": "Debt Securities Available-for-sale",
        "label": "Debt Securities, Available-for-Sale",
        "totalLabel": "Debt Securities, Available-for-Sale, Total",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r294",
      "r513",
      "r614",
      "r781",
      "r785",
      "r929",
      "r1004",
      "r1005",
      "r1006"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesPurchasedOptionsPricePolicy",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Premium on Purchased Options [Policy Text Block]",
        "terseLabel": "Investments",
        "documentation": "Disclosure of accounting policy for premium paid to acquire option for investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureStockbasedCompensationScheduleOfRestrictedShareUnitsDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r406",
      "r407",
      "r408",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r877"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r876"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r876"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation and Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "mnmd_BoughtDealFinancingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "BoughtDealFinancingMember",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bought deal financing.",
        "label": "Bought Deal Financing [Member]",
        "terseLabel": "Bought Deal Financing"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Voting shares issued",
        "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares",
        "terseLabel": "Subordinate Voting Shares of the Company issued",
        "documentation": "Number of shares of equity interests issued or issuable to acquire entity."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "us-gaap_BusinessAcquisitionSharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionSharePrice",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Share Price",
        "terseLabel": "Business acquisition, fair value share price",
        "verboseLabel": "Business acquisition, issued price per share",
        "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination."
       }
      }
     },
     "auth_ref": []
    },
    "mnmd_BusinessCombinationMaximumMeasurementPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "BusinessCombinationMaximumMeasurementPeriod",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business combination, maximum measurement period.",
        "label": "Business Combination Maximum Measurement Period",
        "terseLabel": "Business combination, maximum measurement period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationsPolicy",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Business Combinations",
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r95",
      "r96",
      "r97"
     ]
    },
    "currency_CAD": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2024",
     "localname": "CAD",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureStockbasedCompensationScheduleOfRestrictedShareUnitsDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "CAD",
        "label": "Canada, Dollars"
       }
      }
     },
     "auth_ref": []
    },
    "mnmd_CadFinancingAndCompensationWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "CadFinancingAndCompensationWarrantsMember",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CAD financing and compensation warrants.",
        "label": "CAD Financing And Compensation Warrants [Member]",
        "terseLabel": "CAD financing and Compensation Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance",
        "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r135",
      "r746"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1002",
      "r1003"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "periodStartLabel": "Cash and cash equivalents, beginning of period",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r77",
      "r165"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase/(decrease) in cash and cash equivalents",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r77"
     ]
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents",
        "label": "Cash Equivalents, at Carrying Value",
        "totalLabel": "Cash Equivalents, at Carrying Value, Total",
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r904",
      "r1029"
     ]
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in accounting principle, accounting standards update, adopted [true false]",
        "documentation": "Indicates (true false) whether accounting standards update was adopted."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r121",
      "r131",
      "r174",
      "r239",
      "r277",
      "r278",
      "r279",
      "r285",
      "r286",
      "r316",
      "r325",
      "r459",
      "r462",
      "r463",
      "r471",
      "r472",
      "r474",
      "r488",
      "r489",
      "r501",
      "r502",
      "r537",
      "r538",
      "r559",
      "r562",
      "r563",
      "r608",
      "r609",
      "r637",
      "r638"
     ]
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in accounting principle, accounting standards update, adoption date",
        "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r121",
      "r131",
      "r239",
      "r277",
      "r278",
      "r279",
      "r285",
      "r286",
      "r287",
      "r316",
      "r325",
      "r459",
      "r462",
      "r463",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r487",
      "r488",
      "r489",
      "r490",
      "r501",
      "r502",
      "r503",
      "r506",
      "r537",
      "r538",
      "r559",
      "r562",
      "r563",
      "r608",
      "r609",
      "r637",
      "r638",
      "r896"
     ]
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in accounting principle, accounting standards update, early adoption [true false]",
        "documentation": "Indicates (true false) whether accounting standards update was early adopted."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r174",
      "r239",
      "r277",
      "r280",
      "r287",
      "r316",
      "r325",
      "r460",
      "r464",
      "r473",
      "r475",
      "r490",
      "r503",
      "r506",
      "r537",
      "r538",
      "r610",
      "r637",
      "r638"
     ]
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in accounting principle, accounting standards update, immaterial effect [true false]",
        "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r188",
      "r282"
     ]
    },
    "mnmd_ChangeInFairValueOnDirectorsDeferredShareUnits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "ChangeInFairValueOnDirectorsDeferredShareUnits",
     "crdr": "credit",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value on directors' deferred share units",
        "documentation": "Change in fair value on directors' deferred share units.",
        "negatedLabel": "Change in fair value on directors' deferred share units (\"DDSU\")"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r855"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r852"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureShareholdersEquitySummaryOfSharesReservedForIssuanceDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r143",
      "r144",
      "r145",
      "r168",
      "r193",
      "r194",
      "r201",
      "r203",
      "r209",
      "r210",
      "r275",
      "r335",
      "r337",
      "r338",
      "r339",
      "r342",
      "r343",
      "r376",
      "r377",
      "r380",
      "r383",
      "r390",
      "r540",
      "r653",
      "r654",
      "r655",
      "r656",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r681",
      "r703",
      "r722",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r895",
      "r913",
      "r920"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureShareholdersEquitySummaryOfSharesReservedForIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class Of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r144",
      "r145",
      "r209",
      "r376",
      "r377",
      "r378",
      "r380",
      "r383",
      "r388",
      "r390",
      "r653",
      "r654",
      "r655",
      "r656",
      "r772",
      "r895",
      "r913"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureWarrantsSummaryOfOutstandingLiabilityClassifiedAsWarrantsDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureWarrantsAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureWarrantsSummaryOfOutstandingLiabilityClassifiedAsWarrantsDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureWarrantsAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common shares at an initial excercise price",
        "periodEndLabel": "Ending balance, weighted average exercise price",
        "periodStartLabel": "Beginning balance, weighted average exercise price",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Warrant exercise price",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r391"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureWarrantsSummaryOfActivityOfOutstandingWarrantLiabilityDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureWarrantsSummaryOfOutstandingLiabilityClassifiedAsWarrantsDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Class Of Warrant Or Right [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "mnmd_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachUnit": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachUnit",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant or right number of securities called by each unit.",
        "label": "Class Of Warrant Or Right Number Of Securities Called By Each Unit",
        "terseLabel": "Number of shares purchasable for each unit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "terseLabel": "Number of shares purchasable for each warrant",
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureWarrantsSummaryOfOutstandingLiabilityClassifiedAsWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Outstanding",
        "periodEndLabel": "Balance at March 31, 2024",
        "periodStartLabel": "Balance at March 31, 2025",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureWarrantsSummaryOfActivityOfOutstandingWarrantLiabilityDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureWarrantsSummaryOfOutstandingLiabilityClassifiedAsWarrantsDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Table]",
        "terseLabel": "Class Of Warrant Or Right [Table]",
        "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies (Note 9)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r103",
      "r621",
      "r680"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureCommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r327",
      "r328",
      "r741",
      "r961",
      "r966"
     ]
    },
    "mnmd_CommonShareAndWarrantPublicOfferingExpireDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "CommonShareAndWarrantPublicOfferingExpireDate",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common share and warrant public offering expire date",
        "label": "Common Share and Warrant Public Offering Expire Date",
        "documentation": "Common share and warrant public offering expire date."
       }
      }
     },
     "auth_ref": []
    },
    "mnmd_CommonShareAndWarrantPublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "CommonShareAndWarrantPublicOfferingMember",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Share and Warrant Public Offering",
        "label": "Common Share and Warrant Public Offering [Member]",
        "documentation": "Common Share and Warrant Public Offering Member."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureShareholdersEquitySummaryOfSharesReservedForIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total shares reserved for issuance",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Subordinate Voting",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "mnmd_CommonStockClassDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "CommonStockClassDMember",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock class D.",
        "label": "Common Stock Class D [Member]",
        "terseLabel": "Class D Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockConversionBasis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockConversionBasis",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock conversion basis",
        "label": "Common Stock, Conversion Basis",
        "documentation": "Description of basis for conversion of convertible common stock."
       }
      }
     },
     "auth_ref": [
      "r145"
     ]
    },
    "us-gaap_CommonStockConversionFeatures": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockConversionFeatures",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, conversion rights",
        "label": "Common Stock, Terms of Conversion",
        "documentation": "Description of common stock conversion feature. Includes, but is not limited to, conversion price; conversion right; timing of right; terms, event or change in circumstance causing contingency to be met or adjustment to conversion price or number of shares; manner of settlement upon conversion; and method of settlement."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r118",
      "r119",
      "r391"
     ]
    },
    "mnmd_CommonStockConvertibleConversionRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "CommonStockConvertibleConversionRatio",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common sock convertible conversion ratio.",
        "label": "Common Stock Convertible Conversion Ratio",
        "terseLabel": "Ratio of multiple voting shares converted into subordinate voting shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r796",
      "r797",
      "r798",
      "r800",
      "r801",
      "r802",
      "r803",
      "r916",
      "r917",
      "r919",
      "r1000",
      "r1031",
      "r1034"
     ]
    },
    "us-gaap_CommonStockNoParValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockNoParValue",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, no par value",
        "label": "Common Stock, No Par Value",
        "documentation": "Face amount per share of no-par value common stock."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "mnmd_CommonStockNumberOfVotesPerShare": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "CommonStockNumberOfVotesPerShare",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock number of votes per share.",
        "label": "Common Stock Number Of Votes Per Share",
        "terseLabel": "Common stock, number of votes per share held"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_CommonStockSharesAuthorizedUnlimited": {
     "xbrltype": "authorizedUnlimitedItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorizedUnlimited",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock, shares authorized",
        "label": "Common Stock, Shares Authorized, Unlimited [Fixed List]",
        "documentation": "Indicates whether number of common shares permitted to be issued is unlimited. Acceptable value is \"Unlimited\"."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureWarrantsAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Common Stock, Shares, Issued, Total",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "mnmd_CommonStockSharesIssuedAndOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "CommonStockSharesIssuedAndOutstanding",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock shares issued and outstanding.",
        "label": "Common Stock Shares Issued And Outstanding",
        "terseLabel": "Number of shares issued and outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r63",
      "r681",
      "r699",
      "r1034",
      "r1035"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance",
        "totalLabel": "Common Stock, Value, Issued, Total",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common shares, no par value, unlimited authorized as of March 31, 2025 and December 31, 2024; 75,511,375 and 75,100,763 issued and outstanding as of March 31, 2025 and December 31, 2024, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r622",
      "r793"
     ]
    },
    "us-gaap_CommonStockVotingRights": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockVotingRights",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Voting Rights",
        "terseLabel": "Common stock, voting rights",
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r861"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r860"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r862"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "mnmd_CompensationWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "CompensationWarrantsMember",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureShareholdersEquitySummaryOfSharesReservedForIssuanceDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Compensation warrants.",
        "label": "Compensation Warrants [Member]",
        "terseLabel": "Compensation Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited",
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss",
        "terseLabel": "Net loss and comprehensive loss",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r149",
      "r151",
      "r156",
      "r615",
      "r630",
      "r631"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r114"
     ]
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockSharesConverted1",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Stock, Shares Converted",
        "terseLabel": "Conversion of convertible shares",
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21",
      "r22"
     ]
    },
    "us-gaap_ConversionOfStockTypeOfStockConverted": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockTypeOfStockConverted",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Stock, Type of Stock Converted",
        "terseLabel": "Conversion of stock, type of stock converted",
        "documentation": "The type of stock (i.e. preferred, common, treasury, etc.) being converted in a noncash (or part noncash) transaction."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21",
      "r22"
     ]
    },
    "mnmd_ConversionSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "ConversionSharesMember",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilut"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion Shares [Member]",
        "documentation": "Conversion shares.",
        "terseLabel": "Conversion Shares"
       }
      }
     },
     "auth_ref": []
    },
    "mnmd_CovenantShallBeWaivedDuringMarketCapitalizationExceeds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "CovenantShallBeWaivedDuringMarketCapitalizationExceeds",
     "crdr": "debit",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Covenant shall be waived during market capitalization exceeds",
        "label": "Covenant Shall be Waived During Market Capitalization Exceeds",
        "documentation": "Covenant shall be waived during market capitalization exceeds."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r967"
     ]
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r967",
      "r968"
     ]
    },
    "srt_CurrencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CurrencyAxis",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureStockbasedCompensationScheduleOfRestrictedShareUnitsDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1013"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Conversion, Converted Instrument, Amount",
        "terseLabel": "Fair value of conversion shares",
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r22"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacility"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r166",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r333",
      "r334",
      "r344",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r360",
      "r367",
      "r368",
      "r370",
      "r555"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r53",
      "r54",
      "r101",
      "r102",
      "r169",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r351",
      "r356",
      "r357",
      "r358",
      "r359",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r792",
      "r914",
      "r962",
      "r963",
      "r964",
      "r1014",
      "r1015"
     ]
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Term Loan bears a variable interest rate",
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacilityScheduleOfFutureExpectedRepaymentsOfPrincipalAmountDueOnCreditFacilityDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacilityScheduleOfFutureExpectedRepaymentsOfPrincipalAmountDueOnCreditFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Gross",
        "totalLabel": "Total principal repayments",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r102",
      "r371"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentConvertibleBeneficialConversionFeature",
     "crdr": "credit",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Convertible, Beneficial Conversion Feature",
        "terseLabel": "Debt instrument convertible, conversion feature principal",
        "documentation": "Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Conversion price per share",
        "documentation": "The price per share of the conversion feature embedded in the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r347"
     ]
    },
    "mnmd_DebtInstrumentConvertibleConvertedIntoCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "DebtInstrumentConvertibleConvertedIntoCommonShares",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Converted into common shares",
        "label": "DebtInstrument Convertible Converted Into Common Shares",
        "documentation": "Debtinstrument convertible converted into common shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal",
     "crdr": "credit",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Convertible, If-converted Value in Excess of Principal",
        "terseLabel": "Debt instrument convertible, converted principal amount",
        "documentation": "The amount by which the convertible debt's if-converted value exceeds its principle amount at the balance sheet date, regardless of whether the instrument is currently convertible. This element applies to public companies only."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "mnmd_DebtInstrumentExtendedMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "DebtInstrumentExtendedMaturityDate",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument Extended Maturity Date",
        "documentation": "Debt instrument extended maturity date.",
        "terseLabel": "Debt instrument extended maturity date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentFeeAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFeeAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacilityScheduleOfFutureExpectedRepaymentsOfPrincipalAmountDueOnCreditFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Fee Amount",
        "terseLabel": "Accrued final payment fee",
        "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Debt instrument interest rate",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r373",
      "r555",
      "r556",
      "r792"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateTerms": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateTerms",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate Terms",
        "terseLabel": "Description of the interest rate",
        "documentation": "Description of the interest rate as being fixed or variable, and, if variable, identification of the index or rate on which the interest rate is based and the number of points or percentage added to that index or rate to set the rate, and other pertinent information, such as frequency of rate resets."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentMaturityDate",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Maturity Date",
        "terseLabel": "Debt instrument, maturity date",
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r767",
      "r1005",
      "r1006"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r169",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r351",
      "r356",
      "r357",
      "r358",
      "r359",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r792",
      "r914",
      "r962",
      "r963",
      "r964",
      "r1014",
      "r1015"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "crdr": "debit",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacilityScheduleOfFutureExpectedRepaymentsOfPrincipalAmountDueOnCreditFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedLabel": "Unamortized debt issuance costs",
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r356",
      "r372",
      "r554",
      "r555",
      "r556",
      "r768",
      "r769",
      "r792"
     ]
    },
    "us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentVariableInterestRateTypeExtensibleEnumeration",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]",
        "documentation": "Indicates type of variable interest rate on debt instrument."
       }
      }
     },
     "auth_ref": [
      "r618"
     ]
    },
    "mnmd_DebtRepaymentsOfPrincipalInNextTwelveMonthsBeforeUnamortizedDebtIssuanceCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "DebtRepaymentsOfPrincipalInNextTwelveMonthsBeforeUnamortizedDebtIssuanceCost",
     "crdr": "credit",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacilityScheduleOfFutureExpectedRepaymentsOfPrincipalAmountDueOnCreditFacilityDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacilityScheduleOfFutureExpectedRepaymentsOfPrincipalAmountDueOnCreditFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt repayments of principal in next twelve months before unamortized debt issuance cost.",
        "label": "Debt Repayments of Principal in Next Twelve Months Before Unamortized Debt Issuance Cost",
        "terseLabel": "2026"
       }
      }
     },
     "auth_ref": []
    },
    "mnmd_DebtRepaymentsOfPrincipalInYearFourBeforeUnamortizedDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "DebtRepaymentsOfPrincipalInYearFourBeforeUnamortizedDebtIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacilityScheduleOfFutureExpectedRepaymentsOfPrincipalAmountDueOnCreditFacilityDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacilityScheduleOfFutureExpectedRepaymentsOfPrincipalAmountDueOnCreditFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt repayments of principal in year four before unamortized debt issuance costs.",
        "label": "Debt Repayments of Principal in Year Four Before Unamortized Debt Issuance Costs",
        "terseLabel": "2029"
       }
      }
     },
     "auth_ref": []
    },
    "mnmd_DebtRepaymentsOfPrincipalInYearThreeBeforeUnamortizedDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "DebtRepaymentsOfPrincipalInYearThreeBeforeUnamortizedDebtIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacilityScheduleOfFutureExpectedRepaymentsOfPrincipalAmountDueOnCreditFacilityDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacilityScheduleOfFutureExpectedRepaymentsOfPrincipalAmountDueOnCreditFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt repayments of principal in year three before unamortized debt issuance costs.",
        "label": "Debt Repayments of Principal in Year Three Before Unamortized Debt Issuance Costs",
        "terseLabel": "2028"
       }
      }
     },
     "auth_ref": []
    },
    "mnmd_DebtRepaymentsOfPrincipalInYearTwoBeforeUnamortizedDebtIssuanceCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "DebtRepaymentsOfPrincipalInYearTwoBeforeUnamortizedDebtIssuanceCost",
     "crdr": "credit",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacilityScheduleOfFutureExpectedRepaymentsOfPrincipalAmountDueOnCreditFacilityDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacilityScheduleOfFutureExpectedRepaymentsOfPrincipalAmountDueOnCreditFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt repayments of principal in year two before unamortized debt issuance cost.",
        "label": "Debt Repayments of Principal in Year Two Before Unamortized Debt Issuance Cost",
        "terseLabel": "2027"
       }
      }
     },
     "auth_ref": []
    },
    "mnmd_DebtRepaymentsOfPrincipalRemainderOfFiscalYearBeforeUnamortizedDebtIssuanceCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "DebtRepaymentsOfPrincipalRemainderOfFiscalYearBeforeUnamortizedDebtIssuanceCost",
     "crdr": "credit",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacilityScheduleOfFutureExpectedRepaymentsOfPrincipalAmountDueOnCreditFacilityDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacilityScheduleOfFutureExpectedRepaymentsOfPrincipalAmountDueOnCreditFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt repayments of principal, remainder of fiscal year, before unamortized debt issuance cost.",
        "label": "Debt Repayments Of Principal Remainder Of Fiscal Year Before Unamortized Debt Issuance Cost",
        "terseLabel": "Remainder of 2025"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureInvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "terseLabel": "Schedule of available-for-sale investments",
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941"
     ]
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DevelopedTechnologyRightsMember",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetSummaryOfCarryingValueOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development Technology",
        "label": "Developed Technology Rights [Member]",
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r956",
      "r958",
      "r959"
     ]
    },
    "srt_DirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "DirectorMember",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Director"
       }
      }
     },
     "auth_ref": [
      "r928",
      "r1032"
     ]
    },
    "mnmd_DirectorsDeferredShareUnitPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "DirectorsDeferredShareUnitPlanMember",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Directors' Deferred Share Unit Plan",
        "documentation": "Directors' Deferred Share Unit Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "mnmd_DirectorsDeferredShareUnitsLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "DirectorsDeferredShareUnitsLiabilityMember",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Directors' Deferred Share Unit Liability",
        "terseLabel": "DDSU Liability",
        "documentation": "Directors' deferred share units liability."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-based Compensation",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r401",
      "r405",
      "r436",
      "r437",
      "r440",
      "r777"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r811"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r854"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic",
        "totalLabel": "Earnings Per Share, Basic, Total",
        "terseLabel": "Basic",
        "verboseLabel": "Net loss per common share, basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r190",
      "r193",
      "r201",
      "r202",
      "r203",
      "r206",
      "r469",
      "r478",
      "r510",
      "r511",
      "r616",
      "r632",
      "r749"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted",
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "terseLabel": "Diluted",
        "verboseLabel": "Net loss per common share, diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r193",
      "r201",
      "r202",
      "r203",
      "r206",
      "r469",
      "r478",
      "r510",
      "r511",
      "r616",
      "r632",
      "r749"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r25",
      "r205"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of exchange rate changes on cash",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "totalLabel": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1012"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted average period for recognition of unvested options granted",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r439"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized stock-based compensation expense related to unvested options granted",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r998"
     ]
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilut",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock [Member]",
        "terseLabel": "Estimated ESPP awards",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilut",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "verboseLabel": "Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "terseLabel": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Ex Transition Period",
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "dei_EntityIncorporationDateOfIncorporation": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationDateOfIncorporation",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, Date of Incorporation",
        "terseLabel": "Entity date of incorporation",
        "documentation": "Date when an entity was incorporated"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "verboseLabel": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureWarrantsAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r128",
      "r153",
      "r154",
      "r155",
      "r170",
      "r171",
      "r172",
      "r176",
      "r183",
      "r185",
      "r187",
      "r208",
      "r281",
      "r288",
      "r317",
      "r392",
      "r457",
      "r458",
      "r465",
      "r466",
      "r467",
      "r470",
      "r477",
      "r478",
      "r491",
      "r493",
      "r494",
      "r495",
      "r496",
      "r498",
      "r509",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r559",
      "r561",
      "r567",
      "r628",
      "r639",
      "r640",
      "r641",
      "r659",
      "r722"
     ]
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Percentage number of equity awards.",
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r274"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r816",
      "r826",
      "r836",
      "r868"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r813",
      "r823",
      "r833",
      "r865"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r864"
     ]
    },
    "mnmd_ExerciseOfWarrantShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "ExerciseOfWarrantShares",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise of Warrant shares.",
        "terseLabel": "Warrants exercised",
        "label": "Exercise of Warrant shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 4.0
      },
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureWarrantsSummaryOfActivityOfOutstandingWarrantLiabilityDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Change in fair value of 2022 USD Financing Warrants",
        "verboseLabel": "Change in fair value of 2022 USD Financing Warrants",
        "terseLabel": "Change in fair value of the warrant liability",
        "label": "Fair Value Adjustment of Warrants",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r6"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Assumptions used to Determine Fair Value of 2022 USD Financing Warrants",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r515",
      "r516",
      "r785"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureInvestmentsScheduleOfAvailableforsaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Domain]",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r528",
      "r783"
     ]
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssumptionsUsedToDetermineFairValueOf2022UsdFinancingWarrantsDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureInvestmentsScheduleOfAvailableforsaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Axis]",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r528",
      "r783"
     ]
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByBalanceSheetGroupingTable",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssumptionsUsedToDetermineFairValueOf2022UsdFinancingWarrantsDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value By Balance Sheet Grouping [Table]",
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r49"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssumptionsUsedToDetermineFairValueOf2022UsdFinancingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r358",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r512",
      "r514",
      "r515",
      "r516",
      "r517",
      "r526",
      "r527",
      "r529",
      "r574",
      "r575",
      "r576",
      "r768",
      "r769",
      "r773",
      "r774",
      "r775",
      "r781",
      "r785"
     ]
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByLiabilityClassAxis",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssumptionsUsedToDetermineFairValueOf2022UsdFinancingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability Class [Axis]",
        "documentation": "Information by class of liability."
       }
      }
     },
     "auth_ref": [
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r528"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssumptionsUsedToDetermineFairValueOf2022UsdFinancingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r513",
      "r514",
      "r515",
      "r517",
      "r781",
      "r1005",
      "r1008"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureFairValueOfFinancialInstruments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value of Financial Instruments",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r522",
      "r524",
      "r525",
      "r526",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r612",
      "r781",
      "r786"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r358",
      "r394",
      "r399",
      "r514",
      "r527",
      "r574",
      "r773",
      "r774",
      "r775",
      "r781"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r358",
      "r394",
      "r399",
      "r514",
      "r515",
      "r527",
      "r575",
      "r768",
      "r769",
      "r773",
      "r774",
      "r775",
      "r781"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssumptionsUsedToDetermineFairValueOf2022UsdFinancingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r358",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r514",
      "r515",
      "r516",
      "r517",
      "r527",
      "r576",
      "r768",
      "r769",
      "r773",
      "r774",
      "r775",
      "r781",
      "r785"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssumptionsUsedToDetermineFairValueOf2022UsdFinancingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value by Liability Class [Domain]",
        "documentation": "Represents classes of liabilities measured and disclosed at fair value."
       }
      }
     },
     "auth_ref": [
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r528"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssumptionsUsedToDetermineFairValueOf2022UsdFinancingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r513",
      "r514",
      "r515",
      "r517",
      "r781",
      "r1005",
      "r1008"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3",
     "crdr": "credit",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of liabilities transfers into Level 3",
        "documentation": "Amount of transfers of financial instrument classified as a liability into level 3 of the fair value hierarchy."
       }
      }
     },
     "auth_ref": [
      "r522",
      "r528"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3",
     "crdr": "debit",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of liabilities transfers out of Level 3",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3",
        "documentation": "Amount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy."
       }
      }
     },
     "auth_ref": [
      "r522",
      "r528"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3",
     "crdr": "debit",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of assets transfers into Level 3",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3",
        "documentation": "Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy."
       }
      }
     },
     "auth_ref": [
      "r522",
      "r528",
      "r783"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3",
     "crdr": "credit",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of assets transfers out of Level 3",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3",
        "documentation": "Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy."
       }
      }
     },
     "auth_ref": [
      "r522",
      "r528",
      "r783"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssumptionsUsedToDetermineFairValueOf2022UsdFinancingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r358",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r512",
      "r514",
      "r515",
      "r516",
      "r517",
      "r526",
      "r527",
      "r529",
      "r574",
      "r575",
      "r576",
      "r768",
      "r769",
      "r773",
      "r774",
      "r775",
      "r781",
      "r785"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssumptionsUsedToDetermineFairValueOf2022UsdFinancingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recurring",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r781",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1008"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureInvestmentsScheduleOfAvailableforsaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r295",
      "r296",
      "r297",
      "r369",
      "r388",
      "r499",
      "r534",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r629",
      "r764",
      "r781",
      "r783",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r794",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r941",
      "r942",
      "r943",
      "r944",
      "r1001",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008"
     ]
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureWarrantsSummaryOfActivityOfOutstandingWarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial liabilities",
        "totalLabel": "Financial liabilities",
        "label": "DDSU Liability",
        "periodStartLabel": "Balance at December 31, 2024",
        "periodEndLabel": "Balance at March 31, 2025",
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities."
       }
      }
     },
     "auth_ref": [
      "r1002",
      "r1003",
      "r1007"
     ]
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialLiabilitiesFairValueDisclosureAbstract",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Liabilities Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "mnmd_FinancingWarrantsLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "FinancingWarrantsLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2022 USD Financing Warrants",
        "label": "Financing Warrants Liability",
        "documentation": "Financing warrants liability."
       }
      }
     },
     "auth_ref": []
    },
    "mnmd_FinancingWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "FinancingWarrantsMember",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureShareholdersEquitySummaryOfSharesReservedForIssuanceDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing warrants.",
        "label": "Financing Warrants [Member]",
        "terseLabel": "Financing Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetSummaryOfCarryingValueOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Intangible assets, useful life",
        "terseLabel": "Intangible assets, Useful Lives (in years)",
        "label": "Intangible assets (acquired technology), Useful life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetSummaryOfCarryingValueOfIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetSummaryOfCarryingValueOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Intangible assets, Accumulated Amortization",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r298",
      "r311",
      "r766"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetSummaryOfCarryingValueOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r313",
      "r314",
      "r607",
      "r611",
      "r744"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetSummaryOfCarryingValueOfIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetSummaryOfCarryingValueOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Finite-Lived Intangible Assets, Gross, Total",
        "terseLabel": "Intangible assets, Gross Carrying Value",
        "label": "Finite-Lived Intangible Assets, Gross",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r298",
      "r311",
      "r611",
      "r766"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetSummaryOfCarryingValueOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r311",
      "r313",
      "r314",
      "r315",
      "r607",
      "r744",
      "r766"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetSummaryOfCarryingValueOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r313",
      "r314",
      "r744"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetSummaryOfCarryingValueOfIntangibleAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetSummaryOfCarryingValueOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Intangible assets, Net Carrying Value",
        "label": "Finite-Lived Intangible Assets, Net",
        "periodEndLabel": "Finite-Lived Intangible Assets, Net, Ending Balance",
        "periodStartLabel": "Finite-Lived Intangible Assets, Net, Beginning Balance",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r607",
      "r956"
     ]
    },
    "mnmd_FirstTrancheTermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "FirstTrancheTermLoanMember",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First tranche term loan.",
        "label": "First Tranche Term Loan [Member]",
        "terseLabel": "First Tranche Term Loan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Foreign exchange",
        "verboseLabel": "Realized and unrealized gains and losses from foreign exchange",
        "totalLabel": "Foreign Currency Transaction Gain (Loss), before Tax, Total",
        "label": "Gain (Loss), Foreign Currency Transaction, before Tax",
        "terseLabel": "Foreign exchange loss, net",
        "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r542",
      "r543",
      "r544",
      "r545",
      "r719"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionGainLossUnrealized",
     "crdr": "credit",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrealized Gain (Loss), Foreign Currency Transaction, before Tax",
        "negatedLabel": "Unrealized foreign exchange",
        "documentation": "Amount, before tax, of unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r701",
      "r804",
      "r1010",
      "r1011",
      "r1033"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r541"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r820",
      "r830",
      "r840",
      "r872"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r820",
      "r830",
      "r840",
      "r872"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r820",
      "r830",
      "r840",
      "r872"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r820",
      "r830",
      "r840",
      "r872"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r820",
      "r830",
      "r840",
      "r872"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r853"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalExpenseDetailsDetails": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalExpenseDetailsDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense",
        "terseLabel": "Total",
        "totalLabel": "Total",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r705"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseAbstract",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalExpenseDetailsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "mnmd_GeneralAndAdministrativeExternalExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "GeneralAndAdministrativeExternalExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalExpenseDetailsDetails": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalExpenseDetailsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative External Expense",
        "documentation": "General and administrative external expense.",
        "terseLabel": "External expenses"
       }
      }
     },
     "auth_ref": []
    },
    "mnmd_GeneralAndAdministrativeInternalExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "GeneralAndAdministrativeInternalExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalExpenseDetailsDetails": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalExpenseDetailsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Internal expenses",
        "label": "General and Administrative Internal Expense",
        "documentation": "General and administrative internal expense ."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill",
        "terseLabel": "Goodwill",
        "periodEndLabel": "Goodwill, Ending Balance",
        "periodStartLabel": "Goodwill, Beginning Balance",
        "totalLabel": "Goodwill, Total",
        "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r300",
      "r613",
      "r758",
      "r765",
      "r782",
      "r793",
      "r947",
      "r948"
     ]
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAcquiredDuringPeriod",
     "crdr": "debit",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Goodwill acquired during period",
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination."
       }
      }
     },
     "auth_ref": [
      "r302",
      "r765"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNet1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill and Intangible Assets, Net",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r946",
      "r949"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill",
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined."
       }
      }
     },
     "auth_ref": [
      "r299",
      "r304",
      "r765"
     ]
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Impairment charges of goodwill",
        "documentation": "Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r301",
      "r303",
      "r304",
      "r765",
      "r782"
     ]
    },
    "mnmd_GrossProceedsFromIssuanceOfCommonShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "GrossProceedsFromIssuanceOfCommonShares",
     "crdr": "debit",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross proceeds from issuance of common shares.",
        "label": "Gross Proceeds From Issuance Of Common Shares",
        "terseLabel": "Gross proceeds before deducting share issuance costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "crdr": "debit",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of intangible assets",
        "label": "Impairment of Intangible Assets, Finite-Lived",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value."
       }
      }
     },
     "auth_ref": [
      "r306",
      "r912",
      "r960"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "terseLabel": "Income Statement Location",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r318",
      "r324",
      "r326",
      "r519",
      "r523",
      "r528",
      "r634",
      "r636",
      "r706",
      "r744",
      "r784",
      "r1030"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "terseLabel": "Income Statement Location",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r324",
      "r326",
      "r519",
      "r523",
      "r528",
      "r634",
      "r636",
      "r706",
      "r744",
      "r784",
      "r1030"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r450",
      "r451",
      "r453",
      "r454",
      "r455",
      "r456",
      "r652"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "totalLabel": "Increase (Decrease) in Accrued Liabilities, Total",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other noncurrent assets",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid and other current assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "mnmd_IndicationOfImpairmentOfGoodwillAndLongLivedAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "IndicationOfImpairmentOfGoodwillAndLongLivedAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indication of impairment of goodwill and long-lived assets.",
        "label": "Indication of Impairment of Goodwill and Long-lived Assets",
        "terseLabel": "Indication of impairment of goodwill and long-lived assets"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r820",
      "r830",
      "r840",
      "r864",
      "r872",
      "r876",
      "r884"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r882"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r812",
      "r888"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r812",
      "r888"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r812",
      "r888"
     ]
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets",
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets."
       }
      }
     },
     "auth_ref": [
      "r603",
      "r604",
      "r605",
      "r607",
      "r747",
      "r949"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Interest Expense, Total",
        "negatedLabel": "Interest expense",
        "label": "Interest Expense, Operating and Nonoperating",
        "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r215",
      "r216",
      "r217",
      "r231",
      "r553",
      "r757",
      "r758"
     ]
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Interest Expense, Debt, Total",
        "label": "Interest Expense, Debt",
        "terseLabel": "Interest expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r364",
      "r374",
      "r770",
      "r771"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for interest",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r163",
      "r164"
     ]
    },
    "us-gaap_InvestmentIncomeInterestAndDividend": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeInterestAndDividend",
     "crdr": "credit",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Investment Income, Interest and Dividend, Total",
        "label": "Investment Income, Interest and Dividend",
        "terseLabel": "Interest income",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r73"
     ]
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureInvestments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Investments",
        "documentation": "The entire disclosure for investments in certain debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r125",
      "r242",
      "r243",
      "r535",
      "r536",
      "r1026"
     ]
    },
    "mnmd_K2HealthventuresLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "K2HealthventuresLlcMember",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "K2 HealthVentures LLC.",
        "label": "K2 HealthVentures LLC [Member]",
        "terseLabel": "K2HV"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r53",
      "r54",
      "r55",
      "r58",
      "r59",
      "r60",
      "r61",
      "r168",
      "r275",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r482",
      "r485",
      "r486",
      "r540",
      "r679",
      "r750",
      "r806",
      "r969",
      "r1017",
      "r1018"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders' equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r104",
      "r625",
      "r793",
      "r915",
      "r945",
      "r1009"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Shareholders\u2019 Equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r134",
      "r168",
      "r275",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r482",
      "r485",
      "r486",
      "r540",
      "r793",
      "r969",
      "r1017",
      "r1018"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCredit",
     "crdr": "credit",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Line of Credit",
        "totalLabel": "Long-Term Line of Credit, Total",
        "terseLabel": "Line of Credit",
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r102",
      "r1028"
     ]
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityAxis",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lender Name [Axis]",
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r57",
      "r914",
      "r967",
      "r968"
     ]
    },
    "us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityFairValueOfAmountOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility, Fair Value of Amount Outstanding",
        "terseLabel": "Fair value of credit facility",
        "documentation": "Fair value of the amount outstanding under the credit facility."
       }
      }
     },
     "auth_ref": [
      "r539"
     ]
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityLenderDomain",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility, Lender [Domain]",
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r57",
      "r914",
      "r967"
     ]
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityLineItems",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r914",
      "r967"
     ]
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Aggregate principal amount",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r57"
     ]
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityTable",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility [Table]",
        "documentation": "Disclosure of information about short-term and long-term contractual arrangements with lender under which borrowing can occur up to maximum amount. Includes, but is not limited to, letter of credit, standby letter of credit, and revolving credit arrangement."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r57",
      "r334",
      "r914",
      "r967"
     ]
    },
    "mnmd_LoanAndSecurityAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "LoanAndSecurityAgreementMember",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan and Security Agreement",
        "documentation": "Loan and security agreement.",
        "label": "Loan and Security Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "mnmd_LoanExtendedTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "LoanExtendedTerm",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan extended term",
        "label": "Loan Extended Term",
        "documentation": "Loan extended term."
       }
      }
     },
     "auth_ref": []
    },
    "mnmd_LoanMaturityTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "LoanMaturityTerm",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan Maturity Term",
        "documentation": "Loan maturity term.",
        "terseLabel": "Loan maturity term"
       }
      }
     },
     "auth_ref": []
    },
    "mnmd_LoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "LoanMember",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan.",
        "label": "Loan [Member]",
        "terseLabel": "Loan"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacilityScheduleOfFutureExpectedRepaymentsOfPrincipalAmountDueOnCreditFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Excluding Current Maturities",
        "totalLabel": "Total credit facility, non-current, net",
        "terseLabel": "Total credit facility, non-current, net",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r142"
     ]
    },
    "us-gaap_LongTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Long-Term Investments, Total",
        "label": "Long-term investments",
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle)."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "mnmd_LongTermInvestmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "LongTermInvestmentsMember",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureInvestmentsScheduleOfAvailableforsaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term investments",
        "label": "Long Term Investments [Member]",
        "documentation": "Long Term Investments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermLineOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermLineOfCredit",
     "crdr": "credit",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Line of Credit, Noncurrent",
        "terseLabel": "Credit facility, long-term",
        "documentation": "The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r32",
      "r33"
     ]
    },
    "us-gaap_MarketableSecuritiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesTable",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureInvestmentsScheduleOfAvailableforsaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities [Table]",
        "documentation": "Disclosure of information about investment in marketable security."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfFairValueAssumptionsOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum"
       }
      }
     },
     "auth_ref": [
      "r329",
      "r330",
      "r331",
      "r332",
      "r400",
      "r446",
      "r517",
      "r602",
      "r633",
      "r635",
      "r649",
      "r671",
      "r672",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r742",
      "r743",
      "r763",
      "r772",
      "r776",
      "r785",
      "r786",
      "r790",
      "r791",
      "r795",
      "r971",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssumptionsUsedToDetermineFairValueOf2022UsdFinancingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected life",
        "label": "Measurement Input, Expected Term [Member]",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r1004",
      "r1005",
      "r1006"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssumptionsUsedToDetermineFairValueOf2022UsdFinancingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Measurement Input, Price Volatility [Member]",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r785",
      "r1004",
      "r1005",
      "r1006"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssumptionsUsedToDetermineFairValueOf2022UsdFinancingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free Rate",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r1004",
      "r1005",
      "r1006"
     ]
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputSharePriceMember",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssumptionsUsedToDetermineFairValueOf2022UsdFinancingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share price",
        "label": "Measurement Input, Share Price [Member]",
        "documentation": "Measurement input using share price of saleable stock."
       }
      }
     },
     "auth_ref": [
      "r1004",
      "r1005",
      "r1006"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssumptionsUsedToDetermineFairValueOf2022UsdFinancingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r515",
      "r516",
      "r517",
      "r785"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssumptionsUsedToDetermineFairValueOf2022UsdFinancingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r515",
      "r516",
      "r517",
      "r785"
     ]
    },
    "mnmd_MindMedStockOptionPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "MindMedStockOptionPlanMember",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfFairValueAssumptionsOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MindMed stock option plan.",
        "label": "Mind Med Stock Option Plan [Member]",
        "terseLabel": "MindMed Stock Option Plan"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfFairValueAssumptionsOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "auth_ref": [
      "r329",
      "r330",
      "r331",
      "r332",
      "r400",
      "r446",
      "r517",
      "r602",
      "r633",
      "r635",
      "r649",
      "r671",
      "r672",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r742",
      "r743",
      "r763",
      "r772",
      "r776",
      "r785",
      "r786",
      "r790",
      "r795",
      "r971",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r883"
     ]
    },
    "mnmd_MultipleVotingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "MultipleVotingMember",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Multiple voting.",
        "label": "Multiple Voting [Member]",
        "terseLabel": "Multiple Voting"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureNatureOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Description of the Business",
        "label": "Nature of Operations [Text Block]",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r123"
     ]
    },
    "mnmd_NatureOfOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "NatureOfOperationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature of operations.",
        "label": "Nature Of Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r78",
      "r79"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalExpenseDetailsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalExpenseDetailsDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss attributable to common shareholders",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r79",
      "r107",
      "r132",
      "r148",
      "r150",
      "r155",
      "r168",
      "r175",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r186",
      "r187",
      "r199",
      "r275",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r469",
      "r478",
      "r511",
      "r540",
      "r627",
      "r702",
      "r720",
      "r721",
      "r804",
      "r969"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net Income (Loss) Available to Common Stockholders, Basic, Total",
        "terseLabel": "Net loss attributable to common shareholders, basic",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r179",
      "r180",
      "r181",
      "r182",
      "r190",
      "r191",
      "r200",
      "r203",
      "r478"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "crdr": "credit",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "totalLabel": "Net Income (Loss) Available to Common Stockholders, Diluted, Total",
        "terseLabel": "Net loss attributable to common shareholders, diluted",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r192",
      "r195",
      "r196",
      "r197",
      "r198",
      "r200",
      "r203"
     ]
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r173",
      "r175",
      "r176",
      "r177",
      "r178",
      "r181",
      "r189",
      "r206",
      "r239",
      "r240",
      "r278",
      "r279",
      "r280",
      "r281",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r316",
      "r317",
      "r325",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r537",
      "r538",
      "r558",
      "r559",
      "r560",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r608",
      "r609",
      "r610",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r650"
     ]
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "documentation": "Disclosure of information about change in accounting principle or amendment to accounting standards or both. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards and other change in accounting principle."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r126",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r173",
      "r175",
      "r176",
      "r177",
      "r178",
      "r181",
      "r189",
      "r206",
      "r239",
      "r240",
      "r278",
      "r279",
      "r280",
      "r281",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r316",
      "r317",
      "r325",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r537",
      "r538",
      "r558",
      "r559",
      "r560",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r608",
      "r609",
      "r610",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r650"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r820",
      "r830",
      "r840",
      "r864",
      "r872"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r847"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r846"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r864"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r883"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r883"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplemental Noncash Disclosures"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reportable segment",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r752",
      "r762",
      "r923"
     ]
    },
    "mnmd_OfferingPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "OfferingPrice",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Offering price.",
        "label": "Offering Price",
        "terseLabel": "Offering price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalExpenseDetailsDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalExpenseDetailsDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r751",
      "r922",
      "r924",
      "r925",
      "r926",
      "r927"
     ]
    },
    "mnmd_OptionsIssuedAndOutstandingUnderStockOptionPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "OptionsIssuedAndOutstandingUnderStockOptionPlanMember",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureShareholdersEquitySummaryOfSharesReservedForIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options Issued and Outstanding Under Stock Option Plan",
        "label": "Options Issued and Outstanding Under Stock Option Plan [Member]",
        "documentation": "Options issued and outstanding under stock option plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accruals",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "us-gaap_OtherCommitment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitment",
     "crdr": "credit",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other commitment",
        "totalLabel": "Other Commitment, Total",
        "label": "Other Commitment",
        "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "(Loss)/gain on foreign currency translation",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r628"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Comprehensive loss"
       }
      }
     },
     "auth_ref": []
    },
    "mnmd_OtherLiabilitiesLongTerm": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "OtherLiabilitiesLongTerm",
     "crdr": "credit",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other liabilities, long-term",
        "label": "Other Liabilities, Long-Term",
        "documentation": "Other liabilities, long-term."
       }
      }
     },
     "auth_ref": []
    },
    "mnmd_OtherNonCashAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "OtherNonCashAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other non-cash adjustments.",
        "label": "Other Non Cash Adjustments",
        "terseLabel": "Other non-cash adjustments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalExpenseDetailsDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalExpenseDetailsDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income (Expense)",
        "totalLabel": "Total income/(expense), net",
        "terseLabel": "Total other income/(loss), net",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income/(expense):"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r818",
      "r828",
      "r838",
      "r870"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r821",
      "r831",
      "r841",
      "r873"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r821",
      "r831",
      "r841",
      "r873"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r845"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfFinancingCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Payments of Financing Costs, Total",
        "label": "Payments of Financing Costs",
        "terseLabel": "Payment of facility fee",
        "negatedLabel": "Payment of credit facility issuance costs",
        "documentation": "The cash outflow for loan and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Payment of share issuance cost",
        "negatedLabel": "Payment of issuance costs from the Offering and Private Placement",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "credit",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "negatedLabel": "Withholding taxes paid on vested RSUs",
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Investments",
        "totalLabel": "Payments to Acquire Investments, Total",
        "terseLabel": "Purchases of investments",
        "negatedLabel": "Purchases of investments",
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r855"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r855"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r847"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r864"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r846"
     ]
    },
    "mnmd_PercentageOfFinalPaymentFee": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "PercentageOfFinalPaymentFee",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of Final Payment Fee",
        "documentation": "Percentage of final payment fee.",
        "terseLabel": "Percentage of final payment fee"
       }
      }
     },
     "auth_ref": []
    },
    "mnmd_PercentageOfGrossProceedsSaleOfCommonSharesPayableAsSalesAgentsCommissionRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "PercentageOfGrossProceedsSaleOfCommonSharesPayableAsSalesAgentsCommissionRate",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of gross proceeds from sales of common shares payable as sales agent commission rate",
        "label": "Percentage Of Gross Proceeds Sale Of Common Shares Payable As Sales Agents Commission Rate",
        "documentation": "Percentage of gross proceeds sale of common shares payable as sales agents commission rate."
       }
      }
     },
     "auth_ref": []
    },
    "mnmd_PercentageOfIncreaseOrDecreaseOfOwnershipByPreFundedWarrantsHolder": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "PercentageOfIncreaseOrDecreaseOfOwnershipByPreFundedWarrantsHolder",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage Of Increase Or Decrease Of Ownership By Pre-funded Warrants Holder",
        "documentation": "Percentage of increase or decrease of ownership by pre-funded warrants holder.",
        "terseLabel": "Percentage of increase or decrease of ownership by pre-funded warrants holder"
       }
      }
     },
     "auth_ref": []
    },
    "mnmd_PercentageOfOutstandingSharesToBeHeldToVote": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "PercentageOfOutstandingSharesToBeHeldToVote",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of outstanding shares to be held to vote.",
        "label": "Percentage Of Outstanding Shares To Be Held To Vote",
        "terseLabel": "Percentage of outstanding shares to be held to vote"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PerformanceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PerformanceSharesMember",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance shares units",
        "label": "Performance Shares [Member]",
        "documentation": "Share-based payment arrangement awarded for meeting performance target."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfFairValueAssumptionsOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfFairValueAssumptionsOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r847"
     ]
    },
    "mnmd_PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "PreFundedWarrantsMember",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Funded Warrants [Member]",
        "documentation": "Pre-Funded Warrants.",
        "terseLabel": "Pre Funded Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "us-gaap_PrimeRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrimeRateMember",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prime Rate [Member]",
        "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "mnmd_ProceedsFromAtTheMarketOfferingProgramNetOfIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "ProceedsFromAtTheMarketOfferingProgramNetOfIssuanceCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the at-the-market offering program, net of issuance costs",
        "documentation": "Proceeds from the at-the-market offering program, net of issuance costs.",
        "label": "Proceeds From At-The-Market Offering Program, Net of Issuance Costs"
       }
      }
     },
     "auth_ref": []
    },
    "mnmd_ProceedsFromExerciseOfOptionsInPrepaidAndOtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "ProceedsFromExerciseOfOptionsInPrepaidAndOtherCurrentAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from exercise of options in prepaid and other current assets.",
        "label": "Proceeds from Exercise of Options in Prepaid and Other Current Assets",
        "terseLabel": "Proceeds from exercise of options in prepaid and other current assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common shares, net of issuance costs",
        "verboseLabel": "Net proceeds from common stock",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Private Placement",
        "terseLabel": "Net proceeds from private placement",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans",
     "crdr": "debit",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common shares under ESPP",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised",
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r12"
     ]
    },
    "mnmd_ProceedsFromOfferingAndPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "ProceedsFromOfferingAndPrivatePlacement",
     "crdr": "debit",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from offering and private placement.",
        "label": "Proceeds From Offering and Private Placement",
        "terseLabel": "Proceeds from the Offering and Private Placement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of options",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r12"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Proceeds from exercise of warrants",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r148",
      "r150",
      "r161",
      "r168",
      "r175",
      "r183",
      "r186",
      "r187",
      "r275",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r469",
      "r478",
      "r480",
      "r483",
      "r484",
      "r511",
      "r540",
      "r617",
      "r626",
      "r658",
      "r702",
      "r720",
      "r721",
      "r779",
      "r780",
      "r805",
      "r909",
      "r969"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r845"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r845"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfFairValueAssumptionsOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "auth_ref": [
      "r329",
      "r330",
      "r331",
      "r332",
      "r393",
      "r400",
      "r431",
      "r432",
      "r433",
      "r446",
      "r517",
      "r577",
      "r586",
      "r602",
      "r633",
      "r635",
      "r649",
      "r671",
      "r672",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r742",
      "r743",
      "r763",
      "r772",
      "r776",
      "r785",
      "r786",
      "r790",
      "r791",
      "r795",
      "r798",
      "r965",
      "r971",
      "r1005",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfFairValueAssumptionsOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "auth_ref": [
      "r329",
      "r330",
      "r331",
      "r332",
      "r393",
      "r400",
      "r431",
      "r432",
      "r433",
      "r446",
      "r517",
      "r577",
      "r586",
      "r602",
      "r633",
      "r635",
      "r649",
      "r671",
      "r672",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r742",
      "r743",
      "r763",
      "r772",
      "r776",
      "r785",
      "r786",
      "r790",
      "r791",
      "r795",
      "r798",
      "r965",
      "r971",
      "r1005",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024"
     ]
    },
    "mnmd_ReclassOfDeferredFinancingFeesToAdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "ReclassOfDeferredFinancingFeesToAdditionalPaidInCapital",
     "crdr": "credit",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reclass of deferred financing fees to additional paid-in capital.",
        "label": "Reclass of Deferred Financing Fees to Additional Paid-In Capital",
        "terseLabel": "Reclass of deferred financing fees to additional paid-in capital"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r813",
      "r823",
      "r833",
      "r865"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalExpenseDetailsDetails": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalExpenseDetailsDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense",
        "terseLabel": "Total",
        "totalLabel": "Total",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r449",
      "r744",
      "r757",
      "r1025"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseAbstract",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalExpenseDetailsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r448"
     ]
    },
    "mnmd_ResearchAndDevelopmentExternalExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "ResearchAndDevelopmentExternalExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalExpenseDetailsDetails": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalExpenseDetailsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development External Expense",
        "documentation": "Research and development external expense.",
        "terseLabel": "External expenses"
       }
      }
     },
     "auth_ref": []
    },
    "mnmd_ResearchAndDevelopmentInternalExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "ResearchAndDevelopmentInternalExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalExpenseDetailsDetails": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalExpenseDetailsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Internal Expense",
        "documentation": "Research and development internal expense.",
        "terseLabel": "Internal expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r814",
      "r824",
      "r834",
      "r866"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r815",
      "r825",
      "r835",
      "r867"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r822",
      "r832",
      "r842",
      "r874"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilut",
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureStockbasedCompensationScheduleOfRestrictedShareUnitsDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "RSUs",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "mnmd_RestructuredAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "RestructuredAgreementMember",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructured Agreement",
        "label": "Restructured Agreement [Member]",
        "documentation": "Restructured Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureDescriptionOfTheBusinessAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance",
        "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r89",
      "r624",
      "r643",
      "r648",
      "r657",
      "r682",
      "r793"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r170",
      "r171",
      "r172",
      "r176",
      "r183",
      "r185",
      "r187",
      "r281",
      "r288",
      "r317",
      "r457",
      "r458",
      "r465",
      "r466",
      "r467",
      "r470",
      "r477",
      "r478",
      "r491",
      "r494",
      "r495",
      "r498",
      "r509",
      "r559",
      "r561",
      "r639",
      "r641",
      "r659",
      "r1034"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r883"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r883"
     ]
    },
    "mnmd_SaleOfEquityAggregatePublicOfferingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "SaleOfEquityAggregatePublicOfferingAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of securities aggregate public offering price",
        "label": "Sale Of Equity Aggregate Public Offering Amount",
        "documentation": "Sale Of equity aggregate public offering amount."
       }
      }
     },
     "auth_ref": []
    },
    "mnmd_SaleOfEquityRemainingOfferingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "SaleOfEquityRemainingOfferingAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of equity, remaining offering amount.",
        "label": "Sale Of Equity Remaining Offering Amount",
        "terseLabel": "Sale of securities remaining availablility"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureWarrantsSummaryOfActivityOfOutstandingWarrantLiabilityDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Sale of shares",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Share issued price per share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureAccruedExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Summary of Accrued Expenses",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilut"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share due to Anti-dilutive Effect",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureInvestmentsScheduleOfAvailableforsaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Computation of Basic and Diluted Net Loss Per Share",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of Stock-based Compensation Expense",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r1002",
      "r1003"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetSummaryOfCarryingValueOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Asset, Finite-Lived [Table]",
        "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r311",
      "r313",
      "r314",
      "r315",
      "r607",
      "r744",
      "r766"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of Carrying Value of Intangible Assets",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Summary of Intangible Assets",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r766",
      "r955"
     ]
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacilityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Future Expected Repayments of Principal Amount Due on Credit Facility",
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalExpenseDetailsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r30",
      "r31"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureSegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Summary of Additional Expense Details",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r30",
      "r31"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureStockbasedCompensationScheduleOfRestrictedShareUnitsDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfFairValueAssumptionsOfOptionsDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r404",
      "r406",
      "r407",
      "r408",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Restricted Share Units",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r11",
      "r91"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Fair Value Assumptions of Options",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureShareholdersEquitySummaryOfSharesReservedForIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock, Class of Stock [Table]",
        "terseLabel": "Schedule Of Stock By Class [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36",
      "r37",
      "r38",
      "r39",
      "r40",
      "r85",
      "r87",
      "r88",
      "r89",
      "r143",
      "r144",
      "r145",
      "r209",
      "r376",
      "r377",
      "r378",
      "r380",
      "r383",
      "r388",
      "r390",
      "r653",
      "r654",
      "r655",
      "r656",
      "r772",
      "r895",
      "r913"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureWarrantsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Summary of Outstanding Liability Classified as Warrants",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "mnmd_ScheduleOfWarrantLiabilityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "ScheduleOfWarrantLiabilityTableTextBlock",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureWarrantsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Warrant Liability [Table Text Block]",
        "documentation": "Schedule of warrant liability.",
        "terseLabel": "Summary of Activity of Outstanding Warrant Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Expected Future Amortization Expense for Finite-lived Intangible Assets",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r766",
      "r957"
     ]
    },
    "mnmd_SecondMilestoneBasedTrancheTermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "SecondMilestoneBasedTrancheTermLoanMember",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Second Milestone Based Tranche Term Loan",
        "label": "Second Milestone Based Tranche Term Loan [Member]",
        "documentation": "Second milestone based tranche term loan."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureSegmentReporting"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r207",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r218",
      "r219",
      "r220",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r235",
      "r236",
      "r238",
      "r752",
      "r755",
      "r756",
      "r757",
      "r759",
      "r761",
      "r762"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureSegmentInformationSummaryOfAdditionalExpenseDetailsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segments",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r234",
      "r237",
      "r753",
      "r754",
      "r760"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]",
        "terseLabel": "General and Administrative",
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption."
       }
      }
     },
     "auth_ref": [
      "r999"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period",
        "terseLabel": "Requisite service period",
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights",
        "terseLabel": "Vesting rights, description",
        "documentation": "Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureStockbasedCompensationScheduleOfRestrictedShareUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of shares, cancelled",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Cancelled in Period",
        "documentation": "Share-based compensation arrangement by share-based payment award, equity instruments other than options, cancelled in period."
       }
      }
     },
     "auth_ref": []
    },
    "mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureStockbasedCompensationScheduleOfRestrictedShareUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average grant date fair value, cancelled",
        "negatedLabel": "Weighted average grant date fair value, cancelled",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Cancelled in Period, Weighted Average Grant Date Fair Value",
        "documentation": "Share-based compensation arrangement by share-based payment award, equity instruments other than options, cancelled in period, weighted average grant date fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureStockbasedCompensationScheduleOfRestrictedShareUnitsDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares, granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureStockbasedCompensationScheduleOfRestrictedShareUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average grant date fair value, granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares, issued",
        "documentation": "Share-based compensation arrangement by share-based payment award, equity instruments other than options, issued in period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Issued in Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureStockbasedCompensationScheduleOfRestrictedShareUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of shares, beginning balance",
        "periodEndLabel": "Number of shares, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r418",
      "r419"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureStockbasedCompensationScheduleOfRestrictedShareUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted average grant date fair value, ending balance",
        "periodStartLabel": "Weighted average grant date fair value, beginning balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r418",
      "r419"
     ]
    },
    "mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriod",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureStockbasedCompensationScheduleOfRestrictedShareUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of shares, vested and issued",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested and issued in Period",
        "documentation": "Share-based compensation arrangement by share-based payment award, equity instruments other than options, vested and issued in period."
       }
      }
     },
     "auth_ref": []
    },
    "mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureStockbasedCompensationScheduleOfRestrictedShareUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average grant date fair value, vested and issued",
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And issued In Period Weighted Average Grant Date Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedInPeriod",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureStockbasedCompensationScheduleOfRestrictedShareUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of shares, vested and unissued",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested and Unissued in Period",
        "documentation": "Share-based compensation arrangement by share-based payment award, equity instruments other than options, vested and unissued in period."
       }
      }
     },
     "auth_ref": []
    },
    "mnmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureStockbasedCompensationScheduleOfRestrictedShareUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average grant date fair value, vested and unissued",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested and Unissued in Period, Weighted Average Grant Date Fair Value",
        "documentation": "Share-based compensation arrangement by share-based payment award, equity instruments other than options, vested and unissued in period, weighted average grant date fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares, vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r422"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair market value of vested shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash."
       }
      }
     },
     "auth_ref": [
      "r425"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfFairValueAssumptionsOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield",
        "verboseLabel": "Expected dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfFairValueAssumptionsOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility, maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfFairValueAssumptionsOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility, minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfFairValueAssumptionsOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free rate, maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfFairValueAssumptionsOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free rate, minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureStockbasedCompensationScheduleOfRestrictedShareUnitsDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfFairValueAssumptionsOfOptionsDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r404",
      "r406",
      "r407",
      "r408",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, exercised",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r425"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of options, expired",
        "terseLabel": "Number of options, expired",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r417"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of options, forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r416"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Number of options, granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r414"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average grant date fair value of options granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r424"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Aggregate intrinsic value, outstanding",
        "periodStartLabel": "Aggregate intrinsic value, outstanding",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Number of options, outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodStartLabel": "Number of options, outstanding",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r411"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average exercise price, outstanding",
        "periodStartLabel": "Weighted average exercise price, outstanding",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r411"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Aggregate intrinsic value, vested and exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, vested and exercisable",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Number of options, vested and exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "terseLabel": "Number of options, vested and exercisable",
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, vested and exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost",
     "crdr": "debit",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation incremental cost",
        "label": "Share-Based Payment Arrangement, Plan Modification, Incremental Cost",
        "documentation": "An excess of the fair value of the modified award over the fair value of the award immediately before the modification."
       }
      }
     },
     "auth_ref": [
      "r438"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureStockbasedCompensationScheduleOfRestrictedShareUnitsDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r406",
      "r407",
      "r408",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, exercised",
        "verboseLabel": "Weighted average market price of options exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, expired",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r417"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, forfeited",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r416"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, issued",
        "verboseLabel": "Weighted average exercise price, granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r414"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r401",
      "r409",
      "r428",
      "r429",
      "r430",
      "r431",
      "r434",
      "r441",
      "r442",
      "r443",
      "r444"
     ]
    },
    "mnmd_ShareBasedPaymentArrangementDirectorsDeferredShareUnitPlanActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "ShareBasedPaymentArrangementDirectorsDeferredShareUnitPlanActivityTableTextBlock",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Directors' Deferred Share Unit Plan",
        "label": "Share-based Payment Arrangement, Directors' Deferred Share Unit Plan, Activity [Table Text Block]",
        "documentation": "Share-based payment arrangement, directors' deferred share unit plan, activity."
       }
      }
     },
     "auth_ref": []
    },
    "mnmd_ShareIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "ShareIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share issuance costs.",
        "label": "Share Issuance Costs",
        "terseLabel": "Share issuance costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharePrice",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfFairValueAssumptionsOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Price",
        "terseLabel": "Share price",
        "verboseLabel": "Share price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vesting percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r972"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfFairValueAssumptionsOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Expected term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected life",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r430"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining contractual life (Years), outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining contractual life (Years), vested and exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregated fair value of options vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock."
       }
      }
     },
     "auth_ref": [
      "r425"
     ]
    },
    "mnmd_SharesAvailableForGrantUnderStockOptionPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "SharesAvailableForGrantUnderStockOptionPlanMember",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureShareholdersEquitySummaryOfSharesReservedForIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares Available for Grant Under Stock Option Plan",
        "label": "Shares Available for Grant Under Stock Option Plan [Member]",
        "documentation": "Shares available for grant under stock option plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Shares issued, price per share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance, Shares",
        "periodStartLabel": "Balance, Shares",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Short-Term Investments, Total",
        "label": "Short-term investments",
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r106",
      "r905"
     ]
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermInvestmentsMember",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureInvestmentsScheduleOfAvailableforsaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Investments [Member]",
        "terseLabel": "Short-term investments",
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet."
       }
      }
     },
     "auth_ref": [
      "r732",
      "r733",
      "r734",
      "r745"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureShareholdersEquitySummaryOfSharesReservedForIssuanceDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r143",
      "r144",
      "r145",
      "r168",
      "r193",
      "r194",
      "r201",
      "r203",
      "r209",
      "r210",
      "r275",
      "r335",
      "r337",
      "r338",
      "r339",
      "r342",
      "r343",
      "r376",
      "r377",
      "r380",
      "r383",
      "r390",
      "r540",
      "r653",
      "r654",
      "r655",
      "r656",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r681",
      "r703",
      "r722",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r895",
      "r913",
      "r920"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureWarrantsAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r63",
      "r66",
      "r67",
      "r128",
      "r153",
      "r154",
      "r155",
      "r170",
      "r171",
      "r172",
      "r176",
      "r183",
      "r185",
      "r187",
      "r208",
      "r281",
      "r288",
      "r317",
      "r392",
      "r457",
      "r458",
      "r465",
      "r466",
      "r467",
      "r470",
      "r477",
      "r478",
      "r491",
      "r493",
      "r494",
      "r495",
      "r496",
      "r498",
      "r509",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r559",
      "r561",
      "r567",
      "r628",
      "r639",
      "r640",
      "r641",
      "r659",
      "r722"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r171",
      "r172",
      "r208",
      "r561",
      "r606",
      "r651",
      "r670",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r681",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r700",
      "r704",
      "r705",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r722",
      "r799"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r171",
      "r172",
      "r208",
      "r241",
      "r561",
      "r606",
      "r651",
      "r670",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r681",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r700",
      "r704",
      "r705",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r722",
      "r799"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r817",
      "r827",
      "r837",
      "r869"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "mnmd_StockBasedCompensationReversal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "StockBasedCompensationReversal",
     "crdr": "credit",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock based compensation reversal.",
        "label": "Stock-based compensation reversal"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssued1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssued1",
     "crdr": "credit",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of 2022 USD Financing Warrants to common shares upon exercise of warrants",
        "label": "Stock Issued",
        "documentation": "The fair value of stock issued in noncash financing activities."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21",
      "r22"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange of shares, shares",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "verboseLabel": "Subordinate Voting Shares conversion to Multiple Voting Shares",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r37",
      "r63",
      "r66",
      "r89",
      "r361"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Nominal amount of expense in relation to ESPP",
        "verboseLabel": "Issuance of common shares under employee share purchase plan (\"ESPP\") share",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r62",
      "r63",
      "r89"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common shares, net of share issuance costs, Shares",
        "verboseLabel": "Stock issued during period",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r62",
      "r63",
      "r89",
      "r653",
      "r722",
      "r736"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesOther",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private placement shares",
        "label": "Stock Issued During Period, Shares, Other",
        "documentation": "Number of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "mnmd_StockIssuedDuringPeriodSharesSettlementOfRestrictedStockUnitAwards": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "StockIssuedDuringPeriodSharesSettlementOfRestrictedStockUnitAwards",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares settlement of restricted stock unit awards.",
        "label": "Stock Issued During Period Shares Settlement of Restricted Stock Unit Awards",
        "terseLabel": "Settlement of restricted share unit awards"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "terseLabel": "Exercise of stock options, Shares",
        "negatedLabel": "Number of options, exercised",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r62",
      "r63",
      "r89",
      "r415"
     ]
    },
    "mnmd_StockIssuedDuringPeriodSharesUponSettlementOfRestrictedStockUnitAwardsNetOfSharesWithheldForTax": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "StockIssuedDuringPeriodSharesUponSettlementOfRestrictedStockUnitAwardsNetOfSharesWithheldForTax",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares upon settlement of restricted stock unit awards, net of shares withheld for tax.",
        "label": "Stock Issued During Period Shares Upon Settlement Of Restricted Stock Unit Awards Net Of Shares Withheld For Tax",
        "terseLabel": "Issuance of common shares upon settlement of restricted share unit (\"RSU\") awards, net of shares withheld for tax, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "mnmd_StockIssuedDuringPeriodSharesWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercised",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares warrants exercised.",
        "label": "Stock Issued During Period Shares Warrants Exercised",
        "terseLabel": "Exercise of financing warrants, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common shares under employee share purchase plan (\"ESPP\") Value",
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r62",
      "r63",
      "r89"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common shares, net of share issuance costs",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r62",
      "r63",
      "r89",
      "r659",
      "r722",
      "r736",
      "r805"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r63",
      "r66",
      "r67",
      "r89"
     ]
    },
    "mnmd_StockIssuedDuringPeriodValueUponSettlementOfRestrictedStockUnitAwardsNetOfSharesWithheldForTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "StockIssuedDuringPeriodValueUponSettlementOfRestrictedStockUnitAwardsNetOfSharesWithheldForTax",
     "crdr": "credit",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value upon settlement of restricted stock unit awards, net of shares withheld for tax.",
        "label": "Stock Issued During Period Value Upon Settlement Of Restricted Stock Unit Awards Net Of Shares Withheld For Tax",
        "terseLabel": "Issuance of common shares upon settlement of restricted share unit (\"RSU\") awards, net of shares withheld for tax"
       }
      }
     },
     "auth_ref": []
    },
    "mnmd_StockIssuedDuringPeriodValueWarrantsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "StockIssuedDuringPeriodValueWarrantsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value warrants exercised.",
        "label": "Stock Issued During Period Value Warrants Exercised",
        "terseLabel": "Exercise of financing warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total shareholders' equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r66",
      "r67",
      "r81",
      "r683",
      "r699",
      "r723",
      "r724",
      "r793",
      "r806",
      "r915",
      "r945",
      "r1009",
      "r1034"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "terseLabel": "Shareholders' Equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Text Block]",
        "terseLabel": "Shareholders\u2019 Equity",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r167",
      "r375",
      "r377",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r389",
      "r392",
      "r500",
      "r725",
      "r726",
      "r740"
     ]
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock split conversion ratio",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityReverseStockSplit",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reverse stock split description",
        "label": "Stockholders' Equity, Reverse Stock Split",
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "mnmd_SubordinateVotingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "SubordinateVotingMember",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Subordinate Voting Shares",
        "documentation": "Subordinate voting.",
        "label": "Subordinate Voting [Member]",
        "terseLabel": "Subordinate Voting"
       }
      }
     },
     "auth_ref": []
    },
    "mnmd_SubordinateVotingSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "SubordinateVotingSharesMember",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subordinate voting shares.",
        "label": "Subordinate Voting Shares [Member]",
        "terseLabel": "Subordinate Voting Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r552",
      "r569"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r552",
      "r569"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r552",
      "r569"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r552",
      "r569"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r552",
      "r569"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureSubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r568",
      "r570"
     ]
    },
    "mnmd_SubsequentTrancheTermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "SubsequentTrancheTermLoanMember",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsequent tranche term loan.",
        "label": "Subsequent tranche term loan [Member]",
        "terseLabel": "Subsequent Tranche Term Loan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureWarrantsSummaryOfActivityOfOutstandingWarrantLiabilityDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "mnmd_SummaryOfSharesReservedForIssuanceTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "SummaryOfSharesReservedForIssuanceTableTextBlock",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureShareholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Shares Reserved for Issuance",
        "documentation": "Summary of shares reserved for issuance.",
        "label": "Summary of Shares Reserved For Issuance [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental Cash Flow Information",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r863"
     ]
    },
    "mnmd_TermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "TermLoanMember",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term loan.",
        "label": "Term Loan [Member]",
        "terseLabel": "Term Loan"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "auth_ref": [
      "r928",
      "r1016"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Domain]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r855"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r862"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r882"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureInvestmentsScheduleOfAvailableforsaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r369",
      "r388",
      "r499",
      "r534",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r629",
      "r781",
      "r783",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r794",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r941",
      "r942",
      "r943",
      "r944",
      "r1001",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r886"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r886"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "mnmd_TwoThousandTwentyFourAtTheMarketOfferingProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "TwoThousandTwentyFourAtTheMarketOfferingProgramMember",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024 at the Market Offering Program",
        "label": "Two Thousand Twenty Four At The Market Offering Program [Member]",
        "documentation": "Two Thousand Twenty Four At The Market Offering Program."
       }
      }
     },
     "auth_ref": []
    },
    "mnmd_TwoThousandTwentyTwoAtTheMarketOfferingProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "TwoThousandTwentyTwoAtTheMarketOfferingProgramMember",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand Twenty Two At The Market Offering Program [Member]",
        "documentation": "Two thousand twenty two at the market offering program.",
        "terseLabel": "2022 at the Market offering program"
       }
      }
     },
     "auth_ref": []
    },
    "mnmd_TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssumptionsUsedToDetermineFairValueOf2022UsdFinancingWarrantsDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureWarrantsSummaryOfActivityOfOutstandingWarrantLiabilityDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureWarrantsSummaryOfOutstandingLiabilityClassifiedAsWarrantsDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2022 USD Financing Warrant Liability",
        "label": "Two Thousand Twenty Two USD Financing Warrant Liability [Member]",
        "documentation": "Two thousand twenty two usd financing warrant liability."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfAdoptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfAdoptionMember",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Domain]",
        "documentation": "Amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r175",
      "r176",
      "r177",
      "r178",
      "r189",
      "r239",
      "r240",
      "r278",
      "r279",
      "r280",
      "r281",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r316",
      "r317",
      "r325",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r537",
      "r538",
      "r558",
      "r559",
      "r560",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r608",
      "r609",
      "r610",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r479"
     ]
    },
    "currency_USD": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2024",
     "localname": "USD",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureStockbasedCompensationScheduleOfRestrictedShareUnitsDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "USD",
        "label": "United States of America, Dollars"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureInvestmentsScheduleOfAvailableforsaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Government Corporations and Agencies Securities [Member]",
        "terseLabel": "U.S. agency bonds",
        "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac)."
       }
      }
     },
     "auth_ref": [
      "r1027"
     ]
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureInvestmentsScheduleOfAvailableforsaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. treasury securities",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r748",
      "r773",
      "r775",
      "r781",
      "r1027"
     ]
    },
    "mnmd_UnderwrittenOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "UnderwrittenOfferingMember",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwritten offering.",
        "label": "Underwritten Offering [Member]",
        "terseLabel": "Underwritten Offering"
       }
      }
     },
     "auth_ref": []
    },
    "mnmd_UnderwrittenPublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "UnderwrittenPublicOfferingMember",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underwritten Public Offering",
        "label": "Underwritten Public Offering [Member]",
        "documentation": "Underwritten public offering Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "mnmd_UnpaidIssuanceCostsForCommonShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "UnpaidIssuanceCostsForCommonShares",
     "crdr": "credit",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unpaid issuance costs for common shares.",
        "label": "Unpaid Issuance Costs for Common Shares",
        "terseLabel": "Unpaid issuance costs for common shares"
       }
      }
     },
     "auth_ref": []
    },
    "mnmd_UnpaidIssuanceCostsForOfferingAndPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "UnpaidIssuanceCostsForOfferingAndPrivatePlacement",
     "crdr": "credit",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unpaid issuance costs for the offering and private placement.",
        "label": "Unpaid Issuance Costs For Offering And Private Placement",
        "terseLabel": "Unpaid issuance costs for the Offering and Private Placement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrealizedGainLossOnInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrealized Gain (Loss) on Investments",
        "terseLabel": "Unrealized gain on investments",
        "documentation": "Amount of unrealized gain (loss) on investment."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense, Total",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "terseLabel": "Unrecognized tax benefits, interest charges or penalties",
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r452",
      "r778"
     ]
    },
    "mnmd_UnvestedRestrictedStockUnitsRsusMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "UnvestedRestrictedStockUnitsRsusMember",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureShareholdersEquitySummaryOfSharesReservedForIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unvested RSUs",
        "label": "Unvested Restricted Stock Units (RSUs) [Member]",
        "documentation": "Unvested restricted stock units (RSUs)."
       }
      }
     },
     "auth_ref": []
    },
    "mnmd_UsdFinancingWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "UsdFinancingWarrantsMember",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilut",
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2022 USD Financing Warrants",
        "documentation": "2022 USD Financing Warrants.",
        "label": "2022 USD Financing Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r28",
      "r112",
      "r113",
      "r115",
      "r116"
     ]
    },
    "us-gaap_VariableRateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableRateAxis",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Rate [Axis]",
        "documentation": "Information by type of variable rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableRateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableRateDomain",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Rate [Domain]",
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index."
       }
      }
     },
     "auth_ref": []
    },
    "mnmd_VestedAndUnissuedRestrictedStockUnitsRsusMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "VestedAndUnissuedRestrictedStockUnitsRsusMember",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureShareholdersEquitySummaryOfSharesReservedForIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and Unissued RSUs",
        "label": "Vested and Unissued Restricted Stock Units (RSUs) [Member]",
        "documentation": "Vested and unissued restricted stock units (RSUs)."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "mnmd_WarrantExercise": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "WarrantExercise",
     "crdr": "debit",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureWarrantsSummaryOfActivityOfOutstandingWarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant exercise.",
        "label": "Warrant Exercise",
        "terseLabel": "Warrant exercise"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsNoteDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsNoteDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Note Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsOutstandingMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingMaturityDate",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Outstanding, Maturity Date",
        "terseLabel": "Warrants expiration date",
        "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r1004",
      "r1005",
      "r1006"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssumptionsUsedToDetermineFairValueOf2022UsdFinancingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement input",
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur."
       }
      }
     },
     "auth_ref": [
      "r1004",
      "r1005",
      "r1006"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssumptionsUsedToDetermineFairValueOf2022UsdFinancingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected life",
        "label": "Warrants and Rights Outstanding, Term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1004",
      "r1005",
      "r1006"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingValuationTechniqueExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingValuationTechniqueExtensibleList",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfAssumptionsUsedToDetermineFairValueOf2022UsdFinancingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, Valuation Technique [Extensible Enumeration]",
        "label": "Warrants and Rights Outstanding, Valuation Technique [Extensible Enumeration]",
        "documentation": "Indicates valuation technique for measuring outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur."
       }
      }
     },
     "auth_ref": [
      "r1004"
     ]
    },
    "mnmd_WarrantsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "WarrantsDisclosureTextBlock",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureWarrants"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants",
        "documentation": "Warrants disclosure.",
        "label": "Warrants Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "mnmd_WarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "WarrantsExercised",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureWarrantsSummaryOfOutstandingLiabilityClassifiedAsWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Exercised, shares",
        "label": "Warrants Exercised",
        "documentation": "Warrants exercised."
       }
      }
     },
     "auth_ref": []
    },
    "mnmd_WarrantsExpired": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "WarrantsExpired",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureWarrantsSummaryOfOutstandingLiabilityClassifiedAsWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants expired.",
        "label": "Warrants Expired",
        "terseLabel": "Expired, shares"
       }
      }
     },
     "auth_ref": []
    },
    "mnmd_WarrantsIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "WarrantsIssued",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureWarrantsSummaryOfOutstandingLiabilityClassifiedAsWarrantsDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants issued.",
        "label": "Warrants Issued",
        "terseLabel": "Warrants issued",
        "verboseLabel": "Issued, shares"
       }
      }
     },
     "auth_ref": []
    },
    "mnmd_WarrantsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "WarrantsPolicyTextBlock",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants policy.",
        "label": "Warrants [Policy Text Block]",
        "terseLabel": "Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "mnmd_WeightedAverageFairValueOfSharesPurchasedUponExerciseOfWarrants": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "WeightedAverageFairValueOfSharesPurchasedUponExerciseOfWarrants",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value of shares purchased upon exercise of warrants.",
        "label": "Weighted Average Fair Value Of Shares Purchased Upon Exercise Of Warrants",
        "terseLabel": "Weighted average fair value of shares purchased upon exercise of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment, Total",
        "terseLabel": "Incremental shares from 2022 USD Financing Warrants",
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation."
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "mnmd_WeightedAverageNumberOfCommonSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "WeightedAverageNumberOfCommonSharesOutstandingBasic",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average shares used in computing net loss per share attributable to common shareholders, basic",
        "label": "Weighted Average Number Of Common Shares Outstanding Basic",
        "documentation": "Weighted average number of common shares outstanding basic."
       }
      }
     },
     "auth_ref": []
    },
    "mnmd_WeightedAverageNumberOfDilutedCommonSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "WeightedAverageNumberOfDilutedCommonSharesOutstanding",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number Of Diluted Common Shares Outstanding",
        "documentation": "Weighted average number of diluted common shares outstanding.",
        "terseLabel": "Weighted-average shares used in computing net loss per share attributable to common shareholders, diluted"
       }
      }
     },
     "auth_ref": []
    },
    "mnmd_WeightedAverageNumberOfDilutedPreFundedWarrantsOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "WeightedAverageNumberOfDilutedPreFundedWarrantsOutstanding",
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number Of Diluted Pre Funded Warrants Outstanding",
        "documentation": "Weighted average number of diluted pre funded warrants outstanding.",
        "terseLabel": "Weighted-average pre-funded warrants used in computing net loss per share attributable to common shareholders, diluted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average common shares, diluted",
        "totalLabel": "Total weighted-average shares used in computing net loss per share attributable to common shareholders, diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r203"
     ]
    },
    "mnmd_WeightedAverageNumberOfPreFundedWarrantsOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.mindmed.co/20250331",
     "localname": "WeightedAverageNumberOfPreFundedWarrantsOutstandingBasic",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average pre-funded warrants used in computing net loss per share attributable to common shareholders, basic",
        "label": "Weighted Average Number Of Pre Funded Warrants Outstanding Basic",
        "documentation": "Weighted average number of pre funded warrants outstanding basic."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.mindmed.co/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average common shares, basic",
        "totalLabel": "Total weighted-average shares used in computing net loss per share attributable to common shareholders, basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r203"
     ]
    },
    "us-gaap_WorkersCompensationLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WorkersCompensationLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mindmed.co/20250331/taxonomy/role/Role_DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation",
        "label": "Workers' Compensation Liability, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations and payables pertaining to claims incurred of a workers compensation nature. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "13",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481766/480-10-25-13"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-13"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-14"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-5"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-9"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-12"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-5"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/942-320/tableOfContent"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "326",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-3"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "326",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-3"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "326",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-3"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1403",
   "Paragraph": "b",
   "Publisher": "SEC"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-6"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-3"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-10"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-2"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-20/tableOfContent"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-2"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477123/405-50-65-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-5"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-5"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-4"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "470",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-3"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-6"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "SubTopic": "320",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-20/tableOfContent"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "35",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479424/830-30-S99-1"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "940",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/940-320/tableOfContent"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>76
<FILENAME>0000950170-25-066387-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-25-066387-xbrl.zip
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M64$/BGTI^'VC8/^9<DPQBXL$:K!PIL2NZ87)*$.VR.-0<;_N*$OVQ^R*G;1
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MI-W<Y7B.[I"H4=J,OE_G-7<^,D.PWPY4+6U^+7DV!R;2(<]I9 DA??"I88I
MCC/95PV-S;7!LR,H9!GSLTPQG"0*0%%4=..^.S=QB#WZ\;10LU,+,])C?V4S
MI]T[.CVGEDN\+&;3(_*"M>Y_=H6?3'4U#]OW^=3MY-LI@],F+KG5NW-T.Q>#
M'-&-9U1S6+ZQF/>,17,MEUMM#D\T!M.1,YL.'Z=#.'<3-8B76/LUBO_XUT$<
MI[]/$^PK D=>GM]U<RU-%BL/R$4PZ+&*'37UV"" 7$%A3S/R/)7-(K:"'&Q?
MC%_%4V;,1NOF$I7U+&P9Q!AS=%!0I?<_<I/>TZQPX7Z#R?VSWS9/]?G47SJ1
MJ=IYQ?JR2^PR+3$$G7MK9EGUOMV"[$S<V(EUCI&<CH5B5I5%D;UT?FUHW9AK
MD]OXIQ6Y]@!HYB4$%\4 ,QV:F]@Q$J3.&5@I8WOV=AW%_&5"0\1:*@'S_4C=
MIJ& FQO.-/1F5^6LP]+[HBYTN__QO-Y[$B$!>TC+?R*'PG1C\0-"2),^3_$1
MV#M#P+HLT/M7P".2;<)]2KW98[?W(7MI0%X@#<0;-=V;2$=]<&#0$Q_(/S+7
MZQ>=ZSITSPR6%C:$<"4]EP@FU)5%H$M-'MJF8-P[43YPLQ[-%O0X]_V#\$YR
MBG>6&0P6X#-2>#;?-=[\N5Q^4(15>BF9O3\D7W"EA=X(>[9?NY)#?M@1Q!ZF
MY&[\T:4*P"@P"7!N>9T+4J6HB''(\>O!^S&-O0]J7[A:/B-B0KR;GD\81IZ3
M7+S1,'9SY:O/@3+FE>1OX^M2F;YR&B2-5YHVS@']SH$+Y4T!M:Y(HRKS[-P@
M0ZIC>6ZCHS\5?HGZ<8^L\X6SUK(7=_R[D-O$@3/T+2@3CH(1'-L-)87U8 \O
MK[/@T5WB9,"D&'#UXIC3%3IL640))(J&Z=I"4M?^7E,PEV*SF,<F$2<<B[Q(
MWP(/;5YQME9K]!RZNZIE-93<?_7VX< 7';[^5]ECE[R0XTH7H_-93GJ.Q]?S
M67+E*XKOBA R[K(:KEE(DM+%F*"AXQD9)!K2VJ3K;][+8K(_N!9+\>QS9-KT
M3X<7T8U3LH3Q?N/G\U ,E#+6OA[P*/WY)%.')\>@3^67%LX>(226Y\Q\'VRD
M!%?D'04B"58E>@4,77O16[HD].!X9^%K(^J,J'IK,S O$)W;$L7^?/8H-6IL
M9B\_ITMF$:D?;P23FEZ<.<I!I738M+CZ>^]DR\?5CJ[V=6EUU=>[D\?K?K4+
M,JP5LR89"R'3EFKC35YZWUW?K4VW?PR_\+DDW_=I\IXKHZG&*1>ZD@/?EFOI
M;FG81-^J#BJEJQ6,.K:4N@:I>LS>">6<Z'X;PWJ<%W/5NK3\H\-=W>76.E*0
M6GO#!2 Q45!'GBTBL]$BE+3W9"X2B-]RQ.KP*T-Q-!O]&"16< )(FP6+DT=X
M=CG)4R(.Z5@V-)G8X</HO(%+(DOKF(.5NLL^QOBZ_@'OLXP?MW@FP;4S"XKE
M177O PH/3Y(SD?G59H,&;3)]<Y@7S IJQ<*E= (RL\C9VB'[4C6US-TD.2,Y
M7_8Z\?7'@D*#'4F#BS;9IY)*3*V=-%_+N"0%>1L0-+NGRG-=VA:SWH');_'(
M0^NHUV#^-0*'*QY'BN?)Z3/2T@0Z4<-T2;)?F@@0SAA.DV%\;O'EI%'PTEA8
MK1<:SN!K]T4OV3>S$3VH!'>#A6L#EYL3AL,KWG_DUZHG>QQV-YW[C@,TB3QI
M ^X3<)!< Z%[U^@T:#]]M[DO;$ ,IDS'. H.8#(&"H\FP9,8RP+I1TB49$NJ
MI2+/+,).#]^/]!CMSU.I:=21_[RRG.R^%#9G>^:UW]..\M.+TF\R,KW%32.N
M,^PFTEMTB8IV0TOLNGF?04Y]3PVZ=^RR>X;;<JNN9E7 S,9$D'5 ZP]?:UE$
MU9U86>=_[/G?&HA5U#)HX_>N"&AT]L75J?8>.DF^.S@1+,[BS'<P5]"4MD-Y
M)3QG#I%2(-\OZ068],EW'1G[U$7EJ;,=^FDZ[E3Z94?=1]- ]&>/($63%W$3
MU]ZI'[SZ[/=356(R3YF55S7L2P.T2)[.86H*]B?:'#_VRZ =B]\F&\O()%<L
M7/5_2[*6-]EWC!8=8'J&5'PW,:J")UM,MH?-EN'8#BB:B$#4A[.+,="+HXGU
M0T7,?>JP</:](E;DSJ59>H(YFBFN-6Q/);4V*:RL/^8%L3<8*W-=?VW\:?[$
MVM>GPM.H'A'Q8NZXU ^BY]63F)OW5++U19%R[/'B.7N2\0=U.?5#3)K3:V=T
M$/4H2?'%@\82;VF">Y[][?2F8IJ+'=&0^@,<(J^]_U/?(CVVI*(&Z-)"2#".
MAF.D+>>Q<5?8^G&"HSR$$!)#%4A]1#/="<0O@OT-X&]YQFJ2I5H@N+21:;$\
M Y;R/?J*HOPCTAG',\N61\:P*\B(?7I1 WZZ%#YQ20A9\0&'XG74#*I^>'F!
MX\/-!_(X:*[-)'8/.[P7Q<["Y)UGJZ=9G@J,TN^B@@FGQI"L?NXY1^0E_(#_
M) +O/_8[3O_BY-H+\ZRLKI%.%Y-OG/LSK@_[+[[T.3EV GAC7_KEZJ*I5I9;
M8$.)'46CZ<=BS\74ZIFD,QISP ?K_4]S#S_(TG )<=.BZ%TVNYT\/W0/WRYJ
M W?$5_(6G;U$8CJTF5!EH+K7<A\[->=.'8;8[_W+2(<V(^702+%GK4^?Y:]C
MM4TI\@[- 9_B]KP8,](>1)]'!A0GV)UZ=NRW#[U;FDF" Y/ 2_J^5#)LA3)[
M6'!:".F1,RXGBS&!7VN'V+, /_25GB[OEZA3L+ZER/M8$[VJH]1RS@O <+*9
M2SQ>!HW^BC1ZGJ,SG7 *F\)@Y?I<C<G6?'71A>!=C5=-S,\MLJ\F[&NEF&69
M_I('--VK4?%,?2.'>-3[NJ$XHV*LLMLVEVLWEB];^L.K1.G5M _07-Q&AV+D
M*3@Q7A@+%5=H/C+'WDBU5 9:^J+V< H?&E&R/M&@B3RU&F]_E:,CG]NIMX(-
MERI#/Z+@'0WIS)YO7U^'_S&(#C$7/T)\A:A7L'%.+E'[MYRY^#-MY@80;I!L
M91R-<P/*J8X>8!HE5 5\H;[7*$Z\]D\>27L-+A %S?3NST ::"3.\2N6A9 ;
M]/A"_7==*I2KLWA)K -G-:WC+,%KZ5Z7U,]G/Y5%K#K'=<TM?,,('S#Q;JT<
MB42>4?$"[1_CA@DW7HR[1W2Z](_.W)]<;Q?L?PC.KL'_GJ(BHGYZ^\J./5MV
M"^ \:HD1J"PJ>@"U##K@FH/:;V[+@(FA<YN?,59@E,UC)WA.0)%\DN&6>(A[
M8Q+E4-\7A IT9"Y82@97=GE))L!;3SNAX>8AW_C7)R]OAH8<0#1>NOV-X/'=
M;/1.F8);BN;%,JWT*\]3D,\S\Q+MOMOPU^Z^B5(50RC92F@R*KY'V%==&L^4
MSJ3%E%<Y6I]YU2-M_W;5-GAN$_23_K/_UW[R_ZFH^\[PZQU",U?[5N.AHCR3
ML++W0!(3E_;S6>Q_=$ZJMS>/W%PG*@+Q3NR9K+":*^\] L,G-KTZN83=;3%<
MY+VB<+EB1S52UH?7?]J=RKRJX.1H<R(ILY3KG!C4\BD]*$7]>''6AUR[\* I
M_;S39MJ;H"XDP'"S9>2U*["K>)XI#HK;5*CX5QNK/Y,G+0\)(44S8D+(3KP0
M\LL#\GO3 ;X8!QJ*^Z$/&VZ$9=*T-SV!2G!@05_=[290QH2X36)/RB\S.%T;
MCJFB5]G$'G)2;FU:PGI8]F*/V,,R:))@-P#_RS#;>"/<+(9-1T](#Z/+4+WE
M90*"<09A$?=VN \51Y;JD@"&/8$['/1+%2/ BR/1>\JCEPG;P;-FU[7/XA6
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M$KOG;6-8.PY\]F!U",>J1W"PB;J"M:I<;)DQ'OU]M D/!6"];<;QC"E2I\^
MMRK;.X^]<8$TUI2D1#YD7??Q5:EGOWPB)EP)>1AK?.=A);+$F> XD6+J!/?O
MOO1I/F/A\ R\V-?]U7=[R2S[%T=^"Z!XNW!OV6MWM-ZOR7%?SG%/ZU_4(-*$
M$.#X!D\R@ML!+K8B[$$.8F#U#Y@4^880L@]SI@<J1QI^M)F=QWE$$4)DFB1D
MX,R@73TJ>SAE<^LI^&B!!.\?HW/ORD8%O_A/<"=-%(>:_]J,;2;(METW9M,^
M>F]BEGOW9%^=T88^)L3V5MH<K'4?D_V\<OA+7D<A[<A3K+&JO)MSKTM68*VI
MQEEUO<M?U]'6D7 *:/<D!/NM0+V: 5C@=R? 8J#^@$$[W-@$BN D!]=3(,':
MFU>)A4Z:HXC #8D#2P)]SF3T\G(PT3Q@%A6_68I<1A)Z^3>8GVETFU8J%=Y*
M54MRS66BJSWUAU]/BB7VLFZOU5]&/B?&$_>8N?T^'7O>>#33TXZVL ;6.TU:
M3BG^]@7(X.S;V>E)I&7>\L_UWOKT__;".:J.?A V^PC%=@>KFUWLG#[R+D&_
MBG$G.SPU5%M"&K@FA" Y+3W0O8MF<?%5/2UFMXI,XCK\0 \A4!]ED4F8KRNJ
MXVMHT?G&7+$73'1$@F_&]UYN#+]0<"+J-?FPN0];@C7_J!3 <8(9O%P=2WUV
M#&TRCF>MEZ2?T&%2 K2<3_1"]2#[R8RM2KT.&''!Y&VV&8GJ01IIZ#Q$BR6-
MUQRYC!W6I4P40D6?_EY_.M'>I=)*(JD(23K=8R^3N>!:J=EM PKYG&R)ID:[
M\9,1A&ABT;[QVK@^9X)QII9;B4O^L4_YQ26F%!M'BNFQO#;'6BD6J'[W\AG_
M=*'K/Q-R?#VLB!#R"(&;_0MTWR8O5Q^AH!WRG"2N,=5<F3/ @/>2DU5DJ%AG
MCA@K*.=QT^H!W@5V7!K+<>] G_L#^/+WVH5[N2OE.;6TZ44N[59C]0([4.J#
MM5\E?;HTW.7'5&IP]MP)@NNI?N?NGJ9\3?O& *<[5]YJO5K,[HIWE]^3V/_Z
M=L^[@OMG-1W/#?7K3IG<:^J*_VYKC7-'<416>;(M@J3X90,A)%Z?M2J$6!F%
M6&J"K;4!I:S"$DJE;=AQZ,LX5MZ?.0<,\6)8-R GH,+ :I?#$;1Z2I<H!F9/
M#S^:A+Y+R^UO;"-]R)[H_BKS.DWA=D>NPYF7'Q=6+V4BWKHD)JX'J=9_\FAS
M%$+\F(:3Y\L%GZ8CEK,$GW%ZH8@1?-/D<LJ6@Z"?+$D /+<N8@]Q)KOQBNJT
M3\\;.+>R&L]SU+)2!MY_):7M!EJ<LL$RTM*"O8:X6@MC'&.[MQ/]3WD=R^8L
MZAO>2NKCB0 P9C!-B9763?S#4JSK7=/P8=X=H):].@M6Z.OZLE<6#WDK4#L<
M.0:435CTFM*JE'> V8V6*J2_>VYY"_I.]8>%-F-BQ5G"P!W=PF>XVT]H@VM2
M?8QYJZ6+M?;E2E-M59VF_67J]IJOQE+.F]I<M#,9.C3^Y'.;FQO*1RLDQ3M,
MPD_CQ9!CN\:+5\?+[F7EVF:.H$;G!]( HW#!?HDM<]Y!8(BSU8\_3/8)@G?3
M=W7)\GX#NIE#)CU"B&27\0R0Y\P>[H7M0ZL83M9@S_A51PV;'<\)K_NX\$!M
MO.M)4"7:S 9O6:36@<@MB&U_%2;_W?;*LWM!V9_?5;KJ]COWGTL>TWJ=%'3N
M[I77I]J0I"ICRN_UES7/G:Z2*=(D:&B6YJ??"_+H+$Q[H_&O[V'\NUC$ROR\
MW7*!<^/1K'Z\B@0'WB>AC*F^F'2>38[FR3#XGI0H'<[QZMN'N\O]+8^\"])?
M3_&Y^%3U<$W3TIFD9SOKS^>)['=)OC9WO.0P0=/>4:-?TZMYYK%:=?!O)!^[
MYG3'YE$[;7##,5)0YY-!9U0'_@!NEI8&Z$CTU<JBOT<-T6"]20HK*WJA[RW5
ML4C@*F,%[9PZ]W74S5*)RH/7 DE6+YX;U^>UP^46O*%MUSN;TE\K]9GH!GV#
MK<#^AS7,%O0+]N<Q82OB6VK 5H_*CL;T2^-87\9'U$NR'-:$\871[-"JCW6K
MYJER_%*7.S3+[CM5Y X\/C[:5'GKT7L*9J/^U:TNMR-;JGV(3=(!EDYUPMV+
M*8J89<-%I^#E'JFJCW:ZN=$9<)N,=\N%7D]="2N!O]^Y77;+S^7R@Y'HM/MV
M/2/PDJR,CU[0W%!GZP<#DO_E%XC'H/42O,*TY7AP-9UE@]KB3HY9FMO<?,3]
M50C)&.'_*80L?[&$""&+D^R"$!_<!PZ.*XX20APO3,1SOOR\\8C;O +G_DG\
M=@#@@*E;[^=E;'\AY$B408 9G">[BTL;7:O59Y+[',]<H!JNTH@L4BJ>$,"U
MU)_0K:G1T:GMN"]'*B@H:W+VI-&F*4<.L6V>_/9842MM_3N1<XI?C/LT&_7S
M?3,?H$ (J6QN025BG.-ZF=KS:*ES*6&*I^7ED)E:%2WF;A_NL[2]7W-)R\3Z
MC0^^[K5:]W$-E2X%\X_)Q^;$IBZ2?B [VU ^-4#]EH]@$J?2=):!3\61X"M0
MT+Q?.Z^F @7J.0/,\#XO20?T[99[#>+J_2H:$SKF@^A2SZ?0Y:VB%VZYIQH@
MO?/[-8@?-)W+SAW)#' M$6MY92]%$.NDZT@C(KU(,,O\>>?O3G?S:V\%O'HU
M=;-N^I[M5[__X./:LS("\7IPVYB@'[IQ!_7S[3=E]-86>$:7A9#71X606\0M
MU4="B(L0(C;)_! FA*AMB.,F:_*$$,3EWE5,N,#NS30/L\K_QU^X)Q3<<QQ/
M6I_;,H:[)0&H(Y9;MZPP::[D"7,<D6>9U .3"_-R'[ 975?V81)[=6VV&/0^
MJ#2\',#4/?81239W8.2M*@3<HP5UX6_FFB08+@<HJN:,+.,&>LBM.,"@A%O3
MDH(+7'V?YDE^'GV?,((+A,9-B/E6Z954G#E;A-4!!G0GRKV]#G1?%2=TJY8&
M/#3DW[ *8RJ-F8W'-@DA[#0^['$K:O(%;NEYRI*O&\O+2"4@$MF><N WUX^V
MN9?00\LEYU8"PC[=+C18_(%_GED+5W"ZM/PQAT1XD)GW=;G*-:W 07>='PJ>
MG5]_OD=7SH_^^>Y!-QP;4??%S#NUT)A?8201)X3L7#'L2#%QY.>O19R/TL48
MS]O&O'_?F?E@'$_!2V""4<\SAJ.'O8"K:G5_CBZ<\%PRVY@E\Y2WME#O 3IK
M'CSS6X<P\+Y#DQ.P75CM"JPG4$\(F#3..3G%LP&*Q,L(#]?$(P]YZ.L8"2$'
ML*>I2A3CYF#Q7#NPUDAJ"]KJW/Q(2SFSM<:!)H2B]@$1WAS48R.E2-7>KL,C
M)+CDTB9IZ@ZZ[$N;;O)F=G7%AZ?C'SRG+D_#0T[^%B[5-^V6"AIJ>2%D6I^;
M,@E#$VDMW$?\,MY9[HM52T.L.R<^54='/WM/Z[L.@\I%*O%1AUX/S8[QC:?.
MT B%BWL^";FW$ESV&]5[YLWUMKQ/+_86JB9@\N3Z#F\,ZY#%SHFNRC^NC+NL
MI1OB%1!?XEV:/F'D*SKS=97&M'-Y_2W7](;"W0$Y9&GNB)&]7&3'1,&B4[[;
M1O2=<5U8%10P0#,1L:%I::AF<L^9%9O3YGXL>BQTOWDDH]:(V?FQ H-C!">9
M>Q1AFC&W7(;6*!GP3J">H4.[LFA,RWJ#N/MA84(QMBRN/J1,T(GK?B^$[# /
MX/@)1(D,?$+A@=%C$S[\0DL8QI:IG\IJ\:R\M;8:CUR-[?!E;UR:J%VIC2EF
M6AA0++78UVE%Z9!L1=7 W+Z6[.;<(-H5'(3\?'BE@!/"W<DO[SHBH-+WWBK&
MR6 4N4QQ5*]9RE<"FD&$ F<0,5.8G)<SNO$.[4VY6U83-5.^*;X&>CEU'OY=
M1YO^6,S5PQ]#+;IMR>.ZX;!9/(KMEA;3$J7"-DGF[6#JHOJ]%<=#]1-1#;C^
MIQTG\%*_C@;K-$U+R'Z)4@6\F*;Z.H*CP-[/^M(!-$=Z(M8HB$F.;VL/+#G;
M-D;U3'-[5V/V8GC7T^OYB!CFLJ5BN?:>X=C*QZ'4]!)S"PU&X&@52W[YJJ?X
MX2VMQ@Z+TM*\-F?,I]/)QE<SW%]I3:0H<JOWVSNJGQ[/JQ7M-FZ=VU_[O3OB
M0Z5121#NSQ5<M0E/*9Y=W8\2!8W7G["&CSFIADE#(FZ<USQ;H+IL 1G;[OF1
M\"CJ5YXMQY(\:W&ETL_C)L]C]M6:OH+_QKYSP\68>,<G6=?U2AK?P6;I,$!U
M/MY2W822!WM?W8WH.JIR+(-RCW:0S((E=AT#? *JX!:4\:$J'G02>[\"J]O!
M_D#]\/<(8.#&3BV:Y5ON;GD^VJ0M;CPQ\U8;SW;% ;K0Y5@PH0X#(76TQ2YM
M]BI%@B9GN-1I\!+6F/9'V,K!+8IH79*XB^[![TQ#XQR!7V]P?'-;76ZVV4PC
M+NAX0S/3'WN2,2P9>,(H\?8=6SD]HZ*'KT[IM"B;-5"H?>-A17;P0MFJT9A?
M*MUJ]XUXS[A6>]<LV!QY,F+]VM8)GM$17:YZXLV=R_[=SED:6Z:._:/YQS]]
M8#BVDF^4[+^=_*$53VN I>B#$X0)C>.A0:&^P!9"XM:TER(Z71GRRP1V!F,^
MN991<#SC N<X@05-)!_2O7F+!<^=8,+W8>'L\M+G#CEHKW.T3U%?F2=1+Z!L
M/SCO6?@*_&>.#19"JDI>KO,D>?<!.D>=FPE:.!/6/%@^2E[!E#!1%*(".NHT
M)ZK>P/YHQJ6)U6.M6WMST#J->ED,_J'WTU^Z%-X%>86N2F BX%1#"SVER#-P
M4C3L2Y) _"DHA64\6?[#+F-L('!FZP)0!8/PCO#+:KJ@'P*@TNM)>$DOP(^Q
MT4??X0TD71A9"4M1M1M==_!2.L<1/&-5YP5+ ]_6%C:#XZ'=70HY?>%_8D*]
M ]O4IS@'SR817IY\Q7Z>K2WWL/=W7ZW0:_-:WXN0^1SO?IAL[0.2)D7=U&:_
M5%)^NKE.XZD2RV.8Q2'GDH3J!'LWQ<3R*M=,_^^=62O[7GVTMD<$61M')>"Z
M/V^J/*?%\V3H?4GE,Y8/Y? K)XN&:XY)6^*#:J[ V<:"2<>VMG^,(&>\ISR]
MO2Z?O3WR*G)/7(G:TX+0)58P[P)&OZ<M/K7#AP';O6#@,;W8=9*C%\OP.L5R
M3L>$ D82DHO9;8Z9D]^F/3]^H/C)#7V AZEUEHTM[&RW#C9_>"V8>X4SW*O_
MGBC8+PJ:Y$$6[H!@&$^:[_$W$D/) ?"+3P%5)EB\U)(T:^IT:[%G&;7!3G@D
M=:5.;VVZNMIWS##OR]!G_!V+=CNCI@957/X\[X@?VY,!70X"9XP%N^OAEB[/
MF(UZN2H!X&;QW<,)N;;QO#V,CP;V[V[RT/*/>7ZWS<\9NK?D.11^LPOUTJUS
M_SR*1M?[*7J=/:4@QR,?!/X;;^\9U-3:_HW&[58W(B)=0,A6*0("6Z43R&,!
M-B!$:J1&1(00$1&0*"&Q4*1OI2DM&P%##P@!@4"$4!Y!1 A%@I0$ >DKB&%)
M"B>^W\Z<_YEWSIPSYT,RDUDS*VO=Z[I^9=WW==W/Y?YZ<5L!ZSE2]];LZ'(%
M]:>;?'N]6=^Y)_BQ<X@CQ6JSXV]GO/3:-?M*E7Z$$T(<L0]^_ 5PPUH+,_T=
M*.KK)A3;AA'RAOKPXLY%81_\#;D#\;EU%O&(%DA\Z'N80546176'TMT+SSR[
M"^R['JQRK 3-<U#9Y;,&.;DBQ+*YK]@V2O%:6G@Y^?Y-TU_H1G>C>S.+W;R;
MA(Y1 G %GDR0YOL2WU@WB9AN(GHVQ?+/EO1W\M7 ]W>JYF!3!=9167]UY;[P
MSY5V"P8LBH71#?3,MV=KB;C_]R!F*/\$PYL)WF-T6VHFV^9U/=C8%H'5[R._
MROR%'U& <_JC:0G.(AVJ#%HSYG['BPT9IJ?"][P:7UO@C'>FR[ZY2,(^'UN\
M1.7I-9>!&G#IY#S40>Q\Q.<&LA3Z[E+3X5N1]LG5&H/L]&04$#+.E];L1<GB
MO#B,'L)!G \+R[>I65$]RR'&1Q!35<\!373SZD ?6MO(CP&K-:*[$BG^5BC%
MX8)7]S#.F.VSE[[C^&?MIZTI';M$@QWP\A/%S*\3-4%@OT[77-VZD^L<2A(A
M/X=BNF9KN 6Q@R\4>+"52[4-F>7*UHYGG<H_")//%J7V7@,(GZ_V7<69.;QG
M5&J+#<\_+BERSO0N4K)U<,P->U#""*N;0P&WQM=HO #A%*%^%[*FQ5'@O@7+
MR_A>EE)@-VMP'P[^:V5)K% 5O'KU#[Y<2 U(MHZ'[P%1G>PMNJ".U3H!=7O\
MK8,+CO7=^'Y[F'9&1 !;^C][Q@73FL*= <)E*("@32*YFN N9 Z>3GBSN*I.
MPIJA1**RCI" /[!T%DMF!60GD_BJHQ1XTA#_BA9K)D'LU465UQ02:#?(*D$Q
MA;J-Z A!-')<[WAM[H^(<HJ/_4^B*%$^T1:54=M8(F_%<.G.EH"<:&)7J>MQ
M*9CJX'G_+ND@"EGL<H)L9ESJ*,MR=$/;R2W*_;'95^G@NSK_8>Y])^5?3JC*
M*>V_"K7Z7+CU\7Z.AKJF=L[/8T?*NYO->PXRKWXG_D_+BN%"R8/Q[J*HP>$'
M%<1EX_^@W2**7U3K.-I]K)XO#;*!KLT]=6HO===5U6Y*G.@X]^<)31V^* 0[
M: 3 &9Y  QS(DX]7>@C'*/ C:$+]1D]H?.Y,)R&1V9ZAGVAH+KG75P5UD4-X
M+#R% L7I#WSK8^:2TP\O3Q]K =(G5B.XXPWP0_R+G'MU_Q9<8(OQ#=G0K=Y6
M>-WVV@_ TT$),_B00*&]0RAGM6*\'! =< 6A*J8>#+WJJN#4%O>QJ:2QE$4[
M,O'4$WO#P>;\V)KGU/3@E4=SCNMZV2>/SU49'QGO=*]^&"KF*?.Z^F!A_\%:
M2KEUI6,N^8"8*S<\+"/YR;V4D8^WGCE_P-ZK\7!L,\.FSUQPRJ 6#R*9G;<5
MG"/F/Q0/RHZ./*>^8A.20^1XO[JCR.('";_O0FZB0*W%KM!X @2O!*)8QO0A
M8)QUX.EQ /7DM&,6JU(7Y0:$O J.>G#[G^>&V3F"?[EA/KY>2T.>S"^HMK'2
MT[IE*-\O7_!*R-6?]XP* QYV+,@6F45PW@:;O+A TH>=])3*36GV2C=PK6*&
MF ?A-'0D3^MIM"O=32F]4+5DYT0[G:_&9K8X?AQ'(N$$^"R3, $3,@B *RU6
MJ#YF4$^814U$VXS!@S:DWUL\_G)U%])YGJ5X*P(5=Z\_VL2H\4$WN5M2"NO5
MW1+AI4EKK@?BR;JQ?PG2YEP9\!HX:&;.':P3Y-%F"SR)[ZI/.KU] ^;P;F T
M6:\?ZTH\*YQD#<9&0B7 O+G]Q6I1QK9G:MN&]")0D!G;$'_\D&8Z(T]L>FQ'
M54<H<4GP_#IX4H1,6Z.[D*"8:&M[Q#'\&$V*DB[C,?-EJ6XBN!+(8U&Z%Q_R
MQ5\CU"I"%]XT<RR(70@%=,9_/WG,H"VU&?JG0Y2FYD9^Z"\0A(>S!95YW(>_
MRCM6H&(&(=;VY-_Q[PM_ [8[,2;^4H3 0<Y>5!R,P-%!-L8,W@T]T3*^)?E;
M<.5?37%Z0NCUL9&B&!MG_JM[['1I__W- ,Q"(8*20GI8_F&#I#O_TCU%K>#G
MM^'&?L2;U,TTN;N('*F7E,!1&QG9+$I;MO1A6W)\R4;K^$_*JR0=[D76XZ13
M__[V_^BCLTWF2HAR_=XN)"04/!6U.L4*92;/-G5+3H3252&<>Q3VE+C#D/ 4
M.,[^F#SWAQY?F2T^<SCX+@HME '5YT+D== ;51K9'6O\\^&G&U.5OUS$G F2
M2?CK0ZVBV[[$#V&NM9GJS@99GM5E+<]32H_Z:*S/B5%>#P5:*XLE]KA&U#8$
M>KY*SHN5#CEOD%_ '#*U@KOB#SJA1G/XYT4^>9_N+N05BW=H%\+J!T6_/PVX
MK8L0\!,<U$IMHV9<Y.1PC].>&84T-(!YG/=ZZE^6$_HQ&Q/M'T=NN9^%YX6K
M.AW5^'G06FB\L]@YLV7>09@-1^4?WE@]-B>, ]/Y^^'\'.*/FP3M!N1RX-JO
MWC0!H@<9*T(3BRV13%3&$4!UW=Y.<^6!$YV(5*)$Y( Q^P#]5 VEA.%7[Q"\
M"[&-X$ ?^V=XC[" :DIO%_00:#>)Y)RHCG^D1Y;C9D26X3W&VV)[6&>V_!/?
ML8.N?[.=<*./QGGBWFNPY_>/!,J.&ZBCK5IM->Z/?D/272/J9"N<RBAW*L4N
MN$>;VVJPUTJR&)[_:^YM^,;_>>YMA%B'6,WCB',7!>66AX5]*/'0AA"='N)1
MV,684@^,[_'HN*$(B9/_ ;CU<U!Y,-G)RX34^K9)I!!B<>8U*PX!:&7O&4K2
MY\G,;)8*H61P4E\HH0_6\XSP'XBR>$N<EJ#:@,P4[T:)4=7+1>3B"SKHOTL>
MC&]J&8_%Z9=.K>#/9G1:JB6P-[IL#<G22V9N6=WKR:R7N'.D ?:CWQN-C,=V
MNEKP+\NPS0E2-R;<STD\_'!F"_A,O?ZDR"YBQ3[74-OL2OZR2ZF9JY_VLTS7
M%<=\KQ1*PXUQO+).[]PIMRY6[6:E]9/GY8;:P1_/N&3Z*SJ>S<_TO&TPIUDQ
MO(;Z*2F*>*;)_R:XO]!N$B;FV(BU0,XV"[XZ \0/.E+!5$YRCR?J">R<H/Z^
M'K'H,P(_J,MM)L],,F>F/$ "O<6M34@C>T^@=[*+#C][/?W>[W6P<>6^3(YS
MJ9G!LGNE":/43J;<N829<MQ1ZF[^O.:KE.OY)=.)&GVQZLYAL2?F3?O^BKU.
M_O5&LUN]-:0DQWU0XA7M#2)]%P($SO0@XHF_P2(Y"JP#:W&LC=09>>IQE@?,
M_C5.J1U4T:1;F/<@S;R=IE?:CWT2JDWQ SBWC%KZESC!4J###]H?Z!;WUJK>
MUTL[T\4L<8D+*Q[#M-26S<W\;:U!]%AYEO_QY#35,)+GR(I3@:F#Z<7<PA,%
MVOGU=MY9LMX:<X:*QF+JXZG]=<T118<"Q)PB3\P[;I),WELQW;-,/QHG8W*-
M%Y+"0M35?RW@]F;_[Q;,P/_= (V00I=]/(-=R.=BSN(NQ-6F2VD7XJR]"]&=
M^;\[QD?T[$)^:M\E\]0W!P7V']+; 9[PTF<:3_DZ;:OGR"Y$*O3_TJ"G#<K.
MX:>KBLY5-]A%VXFBD4W(WTZO"+:%\\#,3K#FP@O)6?@.SV478B>Z,FI&@\YZ
M**AQ@%_2)!03R=G  9XZ85D $E"'QK_, )<E?]J&\F7HPL$\KMTN9)0'"-_6
MZ_]4\-^%K(K_*M[05CF*V*;J"V*==B&,9_#/*TB:L&\XTL*E[_LNI#YB97(7
M<O+#)G6C;M(^;/Y^J]HF?U _\.7\^WKS1B,C(EO2402I@PT_(\7_H(2"FNKS
M:5GJ\Q7!42U1:YC]Y64>2QMFNFNC\2_#>89!7&;J?%M=MI>7>*J7_>/U"/O[
MD<I'OV)>T!II"H3_EK,)/ 4*66#T91S$(EGX8\ Z@MAK(ASMC$&S?/?X,;NN
MEYGAI_PM2+RV8#O<=!^1([O6O\[<I'WS=LKU?S/^:*> <+WRM'U96Y92OG#@
MTU>AKNG;R4*4>.I&]6JUL'$&L$>!NI*KY2*P=:WEQ"<#KR>[X8>$!CASQNPX
MS!] L,V#DMF!0,GWSU<)G=&SU?:71LA5L(!9C$.@RQM@O:Z\5SZK&AONT\((
MH=JS!E3[N]H/C^!L?R:(M(FU"$H-\$?Y&,%SOAL/"^K0F<@$6E#ZQ$>XN \X
MB:I[+&Z?GD3;MT[)0QQ<+H1RQ VGXDK'6F=-*6O&W=/*' D6=?0DL/"$#.H-
MCU_)\/@D8\/W%0VN%3R0F&QY0M!D>0H_S)V6'+L&0@&1B$RU5%Z>D;H=<DGU
M6!M8,*="8"T4%?/APZ&:V0JCN(O0^%L_$+(K9]!W9NBL-FV)8V":@P9* >L0
M25S9A0C%$^>(!_F6(@ZX+)QZ,)ABB-T*,7<'%6I 98>"-7*HTO=NE!2Y868/
M:/QW_ RBL;7E+$95BR/_C*2<\<<;QO7F'-?1FEL&R3H\WJTS+^R\]7O?'C.R
M\B1KCKT!'1^7+7_4470^0GY4-CKO;*CUWE"1Y*Q=HO)E3K'ME'MA*/U%;G.J
M27CT,?M41]^_FRY(9\$NN0R?3<G*2W:Z?=;=*2-1>&D+^4/$4/OQNY ^>[P)
M82+E5U.K41[O''+[#.^>L(/P!WSVW_:CH#@P-]>=U=,*-+$TUQ19M/1I-> &
M\LT2=]J"\ ??"*R<%4 [S;H K_YPS82-2-I3I9CMIZ>K:R+>_] ]Z4!E,)R;
M>$ZV!)O!MSOQYPMV(0'7[RZ-%BD9K+CV7)3-9%>XY(_XQ6%ODG2Z+QAW=1BK
M329=_GFK*7[YYM4#*:5)*=IFSTE*TL78)D4K4[LW%?EN>1D4+8.LYR'$N356
M>BQ-#A<B2LHC8%,'\9#P3["ULUVJ=I2"DL?FT54/<51IHH.'T _V9;63:I9]
MCX]%5!MM. S=,O Q6A^_,DHVU,G#Q!CU+4RO;_Y]+==4>;!2X$Z8+8$V[D+X
M,M$LA55Q'EKX7O6@H(00@-B+[9'\3.(F@O[ ]UE)^H8RWX(1,$3QB9[-26V0
MW,^W^ 23F.4]\V--7>!RUSM[K8%\=\^8/G5N_J<ESB3*X[TQYY%(%QP6Q80>
M%-0:[Y:(9O?V)$\.2'+/@\IL'TT'SE1V5G@T"<R9TT]=:$CV?L*")U"B];41
MAX/<F:ZY^'*.?K=\4[;P)&-+-_3B$.S/[);!)#CK#&#C[M9SISO (SL\=U9[
M_BA,SB[L5859EO;U(G<M!M?.-:@B2]NA1RK5G)Z+S+*277C3<\.Y-+GSVAWL
M"_]*]DE-)WKV7\6GX-$%/9''_.7NV_8-OQG6<] $E6<']X(,-CPQ8F8_#@8D
M),'NSTD$KA$_"V6 FX\JL<5=+61N9-Q891GAYC=/E5)N>0Q71:]GVYG*TZVB
M!=36MU") 6W484TOCN3L+ZR.O<+\PK\*&G.0K+BVK=KS ? N>$*A'N!JG.%=
MNIK]B=G/=CAYV3[QMLSE$=\_V('W71!M071QVP^$5;$Y!!3?\:N6%C&QP[C"
ML2X"D-S_@'M8O((+]$O#6]50!/ ZHQQS=Q(S_5?;$$R3I7\(S<!,&W&R*R5(
M3RG_;9"4"-K92/HQ&3L2V%#7WOK\/T(OGB&A T&;S84#3CX7O<'SP$GN0Q##
M:;U*96Q,NH-.<Y('P*9.S\%$@YBS.O9KCM%P$18IXI19NC8]2A:Q+I-?9KR7
MS"S)).;3U\_O'_D\==0R4'CBMF5)L/^=+[K)E5E.&:F7492J.3GY#>VLI=G2
M^&)U!?DEN_#Y*,&*@^$*H0(;]/939;Y3_%FTR=#7UWDANB<=KSX=S6U;4S\Z
MY?5E>)"//T7>,!<>_DT$500\!(N</="5/IG 505#H9TT.;Y.VG8O4:G]('BX
M[Q(8R48EV*I78LD]A>+ JRF;4KYA!JLF2V4QV;!-IO/>/=\CQ$YYS_F!QH37
M,^BZ]P3^T?%O'OL)C]BG#_9>\V87&UNW'>P[4WVAP5_1Q,':.=GQ;$J1R?N>
ML!@-TA_\CP'9[+/4BW2VK%>8"\E9XJWKDQ MJX9<-$G1VM:$,J9W-B#:041[
M4[Q+2[[B;\","MSO(.,UWWRD 1,JA9ZVI(%><WGP?3,@_KMMS .&SQN.0T^<
M:D)DL4]0V/MJK^!_4+8!EAG*RV<<QX(9DELB$?WX#*%# K^'T %KEP85V*AN
M^.]8+W;Z6C5;%V['(20+-;#D_S ,7^(/81ZDI?UW%W)8*)Z\14.(G6=A0A!.
MGR@;*FC]$#8-NBRSO)VS/:8J1Z0+#P$S([2&7K[\BE LFG><[]T&*G-FN!7
M=H)0_=O80JALD*HL@.B63"J?[4\WVYR(0!T-1AW$R<SY&-.GM62N?M"C'B_S
ML6$7:$][25ST&-I:,W8?)NOCH7)L*[N).&\%R:]7\Y=EC^6O.&?=?E#W9+[
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MI.A\E"#K6G)8N 0E5^S ?!3_F CD?F\!S_'<A=V[$ 5:<,S>S@<*\?!@R8E
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M@>XQVBLT<#'T?OG9)6Z][8G>,)Q5R>7OSU0(5=MK+T48NT_P!#[[#TT,=B"
M<]O'G!6:\",$ZLO '^1+@+K POY1JCU:I!5M&/O&$_CB+,G#GM\*)8"/!:\G
MI['1%^JH'+WJV8T#G[\L>UH3+>O];MMW+,(!!.I7S;RZZ/1_C\*<@/'9UZ5S
M*$F^-0-VK@S3,M.1GBH\,L0W9U=[=23B#!Q<7&K3+W(44JDR[!B]<_>O&_K
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M4_7T:I9+K'\D;D1_>SOIU3_O)-!M Y[7KTZ*%&[S<TN\_QXD!2ZPQ86[@ V
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M1H][YKKP/&=\*:P'(U/+&4.9LM'4_N.U3R8\,^,-CN TR.,DEB _"#[[W3U
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MX^ 8_^H'>'><5_UL3$I8FU>-;IK+(L-/X?Y(TE>[1E#C(XG]6PD-M]$22J=
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M_[1;97'%QK188(U./LE>T?X?>_Q(>H#VR8+=0@T*=*U^!ZWY%1.J%^L%_8G
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MB*[*@7%T2;%SF%IV$SL&%<DKG^2'J'9J7>N8=V";()S,;0]]'[<#2CYR_":
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MR_-D:R5S3DFK<RJXDJ."D5%:0 @0@@,BGP5E3G+\^DH_.$+1+K\5<&$*+M-
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M#@P0Y$C(+>9LQ (>[PIEF"GXOA3='GVI%V%$CB5?\R2YCP5B]&SNO0&1I6;
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MX;YK#,(V=$B\?TRCNW%;:!I;,)Z7#_L@S!/VW1=0N<_MX">@!8[COD!Q#6H
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M^QSCRY<*$,[O^@^#Q:M<WR_\PX. &B.N-X\NCN7B)-U6UX,B*WVG__;%E>.
MQ\2!84'Z*$<\J0=W>-Y??I$/VXW> XBCJ]2 %V%5QJB:[@5:[&M7]+Y ?Z'Z
MN/9K\KIMRUB'J3_PHU>V)NEH/64@=:.TK2WN6Y3._&X2-*B242B\)F)>W+\T
M)+8*9=KT]M^?R \-T/NC==*AS>]1=F4)1C83#3NUDSEQ]HQ%R2@NS@Y9[VN4
MVF I-3:O[D.!'?E?-=5X"5OX"GG.,P##^/DO#_R[ZQ SH)W^*W.K;RL.=\+
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M>ZIQYT1NS![V1>6\<0"+)6UMS*;PQ90F=A96CQ_@<P3+V@7-I[2F@8T!9MZ
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MS?-+Z<H32U;!,>/I+F/)MIE%:M_)GYO#]P6<#Q3<,1B?R14<="_Y*@\%4VK
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M?QUQH139Z<('WU\C#YN+!YE=,YXI?5NB<6^62^1<8]_B#>-.;;OJ]A6*@4N
M[D#AV5P+0XL_ICG7F%KOW)3'/+,M_M#<9G-U[2C0]G7I%QN!M<2'WVJ]+TWE
M_.W2>RZ.H8L[F/6+ ]72..+>+!<*QS&(&<+Z%Y3SK0,O.9O688R P)1&8@).
MHHC4E2US*;2")XLQR.OKTM:/^>XR:Z8/+[D12/#]4==4Y[*:*X:H[.<92CCT
M6P$9AV0KIT>"PGS*2.$6(N8I%JXZG35K#BG4MK:2$M\9ZN@\7O;^&77$(1-)
M=:9ES9H)ZPTF47M^;Q;OKSG!>XY;:*8!;FEG^:D(H1FZ%0WY-10IA3G+3370
MBG2OPPNBLUTU9AD0LJB,8[0A/L%(53,^#(XRH83"CL//(8YRKH_M;(:;QMLE
M(F31T8[33430^%*'X,^#\7NKW :.W<$6<]]T'<5.8J7K<URBZ:,)I?'D+G&+
M!/6!9)XLN@31#I#Z8,)%TCJL$EL24%9;.4I'#9L%;,^)DW4*SS(E1_!1W+^S
MQS%P8^R+F/=7/T@Y7,*+QL9<%B^Q3W'2;W&"+M"=PLIHAN99]ZF97W[6>LK?
M(ZO"U)TO]T^3+X4YC6<K0L]9BX\IZP=;EQ5)?B-?]G52<7[\;3:0&PWSQH/*
M!Z\V<;QC2D"\;=H[DBQ/F',3R$G>KC7MP1J!2DPL[OC70E7_Z_84S0M3&/5%
MOK_23L[+S2%N3FK_V^3LZ!VEY AX)]34-(6-[[AZD4=^+H*!C",TCAQ?Y1VN
M8BH2F*L<0_99#!2DT(5#F1I/7W'T<2*8V^".KT[;KI-AP4!O8-P>ED@$<WI-
M[5W==A%I]F/:I!,^C]MN=.7<G:S1%E%E,08X35^)T01ZJGRLW\<BO%=C,/4[
ME_5KANV24^%(@1^02[#3F]?-/O65]83VM;R_R>_FB3+7Z$+57.[\>=_W-UTO
M'@M.RC^[L2D[Y#:P-XSM@P#.:9_26'G<EQPA9N\B9/,*6PG[@6? [&IGWOW,
M.06^8%MP%(#1-(PH'7\"X\9<B>F"*"6%(B7 ]C^F_,/X"MCP(T:34?WS >7A
M-GNU:6I"^P^3A+!R+1R>Q#DCQ+Q%+R<'@FKEFRBFV@)?5")^X3B 80P$>)<&
MI/*Y.IV8%"IZ%JWFQAO@OL0>]Y$EL303.S0K_'*E*KDY=:M/"I,JN'$\W.LU
M:ABO(&3)S?'S+<BBO^2W+V<DG](WIJ5?+C"AA#/P,R;R,F9DHU%1DV;%U/.7
M8RW:,ECF,;[&PRW*\]8!IOB7WF#RJ. M(;<L[:\3Y?9VQ31#1PI!W](Z)?/"
MR)JYO[%"0;H9A!;.D6UG>_#^Q36,<L07%Z6?\6#825@#[MV6S!JN&=$'D?#M
M$@>[F0/TM%Z8N)_1Z4[P(MM@50=[OOXCQI>1(F[;_K%N!R[N2/%OBHQTU/ZY
M(W+!IB&1_NV21DG2#U'>B39N,<Y[BZK&RN9FAVW-["Z6=X^FMD'BNWY%9_PQ
MO8./QHEW2#*OFW_<<>1$147\^K+&STAH:F?(4.MN[O#XFIK:S*NWZ3/9H<_[
MND>_YQG[QBUP=.024,Q+05E+;HW5[^D%^GZ9KD_<WA.@6UUV5237T]"&P:8W
M51$V17";&-]^.^N,/-OELDY:O'T-)ZT:YBYZ"HWK@;2(;OC^]U1<-Y:C1L=1
M&UCH_W$N/G0;X",:!E:,<06PY37K;=\:*D?]RWUE=5Z4.[NLR1:65[C,SMQS
M=!X-#S>X:ZR0Q*N!2>(6RG  ?-.4CN,C)(*/^,^P?0[3N_._,&,+LE+PFZZ
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M/.GGFFU;H!ID,XN//F0PYZ") ;=Y.^T_O$G<Z_@^T20C52Z>=]X1=+@#I W
M9G;[<:<,S!C5*6*VXYL8F&<)NIBO5ML&GBNUWDOO$=%12S$QRX:VV#]ZA<NQ
MD_P!8Q[_GNN89=![)(5,OX 01XB]KF?9J2A9UOBQE<W(T MFK3,FEJ7%S1EO
M+";W!9R8#3U#(L^+XNN6S&T+O$=/-RD'A[QWLPJ#^C<6YS4LS>\+?-SER,DQ
M&Q:FW\% %>.M5)X^QQGT )R[1=G7.-8?*62D%":2CHPWDO1'W9W&'(+&I7:=
M8\95E_B*5"&-O2/4"PLU1>8^/&[1/*[QVMQF+XK/S^/X_)SX*6T1R1$+9*6
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M2.&!EIL#._8%I#F7/AGJ0.-#0?%000[".RK*FV$=PS=2B%G85)AUHMQ V\!
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MB%;X'8A4[0(GPH;G5LG%\D (+4WZ/4]>.@BAI[=!!\D!)3^Y^I8CACHT2_$
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M+_:V3=,$"I_9:BA%L5C(#C>BS,8V=NV C[,)OQA:<9@R8R2O-B. JQ?+T99
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M?KR-@]N]"9]=%3]$O^?/(-)71(#$>J05A&RTW\2>%Z8B$N0CPEQ#34XA/8:
M$?BJ%'$)#52I,IQD<3++9&#$NC)X_ENR!W?PF:YDN !W.3I H>+7I_4AHQ7]
M3)CG]>ND?.T/35?+GLE/IIS>GMS_X*"&T<M3][ 8I>?>[;RP#%4M?<NVD4M'
M=FP]>KE"EI3JUV)V[Z!&K&]:U<##.^5%-_>E,JZ"*A>LC4,;R6?Q*SCP"Z^*
M(S_K"MU1B23HX[6XY]C5B<S3<#PDP5EJH@Z?;D&^YX)SN] "+D[))QL"&[$;
M T7 Q@96&LBB-* YS= ;IBNICR/1)+31NJ%ERT)*_?R]?3.=IZ9RWTXEM.1W
M^ND.%*6T^/$(\:_@6SF*:R+S8YH-714\D_<^>KOKV#&SSFR/W.)<>A/ID9'<
MD?AK%A=[LO(&8A^-6+]/B'\0_?&6OD#EA A0P_._$P%#]:1"$6!OE$%X'2F0
M6XNL;K2Y#A(!I>^%"?3%4 &.U@W"VE2!O"8O%(URN60O>#-W#R\$ EMQ$A[@
M1B.%&==O&7.AATE@@RMVP%?7Q:0EQ7%!4<E011(.YTJ]YEB9'^L]YE97W_?1
M_MUAU:S[:[X7/!'>,SI$<N?=%-)P;KZ4,9T21B!.@BPKS#*2(/_(O?J0%>QM
MM-0\3(D(W2ZPA.CQNC-8V:'IX?1_?] BT#?+R=/Q]?W<KCQ37_GWN9=\/KD8
MTS'C?B17V:;Q[[=JV+2>/MAJ\T"%J!&3;7K9^;M>;U<SOXHZZW2WZ RG$_G1
MV39''G,OWBPH$!0?BE=5]TQ\/A'4AQ9^A&W@N_L"-+@\]^> PC.!!B)@#P'>
M\S&%=<(=D4KDK[U(&@B8[&;RLF 3_QV.V=R^V4FN I7]<.?IAHHY[6%OX\Z6
MKCBM@/T' BH3SI873FF5W2S2?E(?K$F9[6BC0T': KG@%J,-7.KJ7,\=L&)6
M']D-4:/*--5I1LH"B7N]FG4$D]J^N:SJ!,RP)?NG"M/BS;DD[\GDRQM[FC1_
MB4=(!BI5JP59C\"457?EWPHRXLK[V[0/M\+_O2"309*?>JP4A0W^6T'6$)P[
MK6#;L%J0Z>OUF>AXS'P*Q4*(UYT__!04OV]D=.3^9M/4T]1?N#5M=(?WL0LQ
M<<7"Q,(-BY9S#HLGTE5?0:0X2[R3M&.ZQE%B?[[-(9]!WF\W6P]7FS//)\R4
M5B$#]+(!6@M_?JB&=^>Y,'UQVP)(2:&N,](<%F &<BP,+I;18Y=4UC+8,#&O
M0Z'D4@'QL,D5CDF/CXNNQ1'KOK3+FL&7@JZY528*[CP1QH*^]#BLLBYV'0%Y
MQ2Q7BZTWA+M:\1CV0^WM@N_AA/2C]=R4Z,4\ICW#Z#M/Y/O>HN*RCL)1+[P2
M)5J Y[B<:AT<-!]:I&R:KH#*6\:13A%P"0L?CQS'1]5B<DCF/ 0.Y&A'8N5T
M+(X;/WL!ET#44[&M=$QMB,[WPQ>GQ[X;K-WC;?0[&XQ<Z6S^9%2T+_(Q<>Q(
MMWMEK&VPLE#II][:$S<7*N?6HX[)$VPXANPD^<S5;R Y<2+G,!RO(@R^JOMI
MD>%VQ2;<.D>OP<&/.B':K:[[N.\S<DD/SY7VTQPQN/,0[1>!Q[6%Q9JT<:\_
MBYX>%%@J9;:\577"WLYL_-0VT/(Z-4+=R'%S0%(_@?%=FCKK76[7[*1]7,9!
MKQ<6[9K=G>X)[N>;+JL]?*JSO]7G@F/=F1S.J[JXU$>>Q:[X_8U/$LJ3GB2"
M673H!^TW3NP4@5P'LKI'#7:(SW%C1KK#A?IQM2%<Z59[UZV#RLU*&\*#.#(>
M1BD9#EXR.<3+*^^;FH9#*<+RO9M=+K;1S M.YWC>2O]=/FV6V485J* WKJX%
M8T7 U2-0GPC S\\=(02%-N&@&V 33HIDR[F1S[\%[^'=Y48VST>MKL$L"(0^
MF\ RX\R(5&:3501V_4'R6JBO*10#NV4ZPY,<B5]T!U[TZ#(WPG1\?U:*:3TR
M6,==5[^K>N"CKH6[=6G):N2Y@WJEAK.A:#)YGN[5%8G#U@,PGET99KB3A1FB
M-V(E%K7T.1LB63)KF_O@AW^#T[AW6U-2!O5"I;F,9IF#+E(NVNP-\;[>_GY/
M1SPQ>4Z>?N8YIWUEB@;FLQN7%3=?(O7)_?[^C?XV1H1>-MEE;WV^!OQ;J\]6
MPI'$.TEI1ST^9M2,?GJ_? _OM"LWK %OT4<B]67J"9_GFGX:\QQ\[V=FPRAN
M'R3D4*$?F/!W*;/6?Z].XXM#<>0?X F^,>S.=H] M& &"[Q'UH(^+K%>4UAI
MLO.GGT&3466;?TK7A/W917AK@Y0P 3[#$V_PQ-/\,F-)O]I9@=N5-:H($Q!I
M"=0W1\-H(KPN5O@XP$H%>:T4.;>>C1EJ])4F@<W(1F&6S;"YEA<K-V[R!:71
M514*B@O=3=:KZ-$1 ;)>-C/X"L7T;0.^.K1U^ZJRX-=-308_."*YCV>JTQCM
M.,@<C=_Z<S+HY6EP91ZI@Y5@PA$!X49'XK403;($5Z$\*)MDWJ;IM:YDZM;H
MO8SUZ7F('+<XXA/87-ARP\!N(>=EL4Z\?9-=;['K*] 3N[KVS1P!5E-L]MZ@
M" ^Q</>HI=38N860@S/XOD#LMPU<\X;2&7WK_0,Z%$E2Z1^*>*,]@]X+-1F'
MVPK02G[R]H:,R]X^F<_O?/2*U^L8Z/3D5EBD7_[^Q;43/M_]6;+CX]%OS1X&
M9-@S,EY*V=(D>Q,\T^S.U!VS3LZ]>2R/^R/GURN?5B[>*M_UX*K.LF]T0H)M
MDH[=L6Q=2^M48KMLP/N"?9R?$L'5!S^?,BNL!%LK>7>X\RW:D2*@3#NZ7I-,
M%-XG'X/N\)V@H%9,G%ZJ"(A:U,8([)_#T5D7B>D;H;;6$WZJ [5>"G5/O-*/
M)SI S"A=4(X>J64H\]C)0Q'9W%=658;;+.Q '<4E4B0K9W73XF=*:O%72EYP
M*=%T#VH8#SV5D<J<PP^FZ_3.U=H6>*VT_&K_60>>0[8W<(I4/ML'Z/44TS=0
M]F2W5EY][@]N \?G?.%]D;_,?MP#7V$1AH]PTBL&/U<\TL$ 'O4;H*KJZ -[
M[^WT<H+#V442S0:!=5W#'S-B)LT@?%26>?S!62NB3-EPR, DUP+E<_4]^=+0
M;B9DAXF]!<;5[\L*!6#;\3_'F"RK/T#9&?PM6ECMQLKSQBKY14Q/N:$I7W:7
MT@P%*[ @XT.R+[8?>, \V_M4ITACZ$!79/+//-]'?E>Q49KOO"(/;;O5[V>3
M0>I+,TN2YVSK.Y]][ )-)^UF[0DEGQV"SOX4^H<K1PQE)50+'_2]4B%&%TKV
MVAV8V-:8.5!59?E]_-&*_+;A"PG)"67X&N$V=(C2P7)ZI$Z(%2]=&$VV>DI4
M\JEDCPC7\GZ!37)>RM)4"ME.H\=-0 D!H521IC.&O5^6IFP&NQ40;SF?)U8O
M#&:V.-XUJLDA%AOJKQ!1T8^AUSR$:(>.8DN9C;1X--])"5NTBL)MQ[G5T)7?
M>E)E C;HJ^R#[T+4-H54^:[HQY![Y.->[4#,-M)2HV-;6)D%H:E>OF_QA![?
MH7L1H_3&(S4HIO92(,OEFTG!>V0C>?7)C.,"6PC7VG4G]"@C5%EP ?8M'H$I
M#>E'H(G&D_D?5AY)'MA2:&R(5U!*3\Y_X^PRI83<+APF?##:V^V+H@;?M>@O
M<S%#&B?YD4(*:DN0;P1^#-M;J\^_'OK:50]BQGKOAL9^]^/B>+<>&G.#PFN-
M_8_65W*QT;K,2-?#:!@K(FWILB"5Q?;W"8ZQP>@4@Z?XX9ZRY[U9O3JC^BX+
MI)3((Z\DMO2R7^]L:E/68]G*A=G$//+4T)2VT_"Y,&%_;]_=LF1ULS(-LZSE
M"S=_JKK^M$^[><+V9:E9<9B-7[9C5W+;<+!'\/3A\_EF.6^G;).V7KDQ8K6L
M J].:]>B<(4)O.$T5E?8F(SPG@CP>(B3(\4Z5/3NK>>N9KI1KE)0;GBOTYMK
M!Q?IRC"M.7U'WX+5MW#PV=0 @PI:D<N(TW#"@VG5^O3A07!A#;0D4!*B%T[N
M%LAE=' Q+/?8@^33F3#^7&*;T9Y2>))K>P::71FD9OUM;-_@W*5:[E$73>,'
M*\HC\)[J)&EE!;OTO^V^FE^[^M[N>;!AC^#XD]'I:A-*J [\<658_5UD4^A6
M6)4=?,)3R"JKJKHG;2KPP]TE&R2,6JRSWZ0\%]HN7U-;$9Q?]-3^(X^QW([>
M7]GJ\R8JAL+GH4JD)AY1^*N1R@QU+;)68 H-%K&L8D+UX)CJGT2 4FT0J\BC
M\U(!Z;CE<VB07@2;_.&ZA;OAME9K"N?;7?V&A&(XHNL\U:R,H2.C<<(,L^D3
MV\\0;(9KY96V[?#=>(EH1KC8?*9"39K4V92>C=<_D^WKOFTX7BF 25?WMSAC
M>7XX^:!R^WY&ONWFTWI%.FD:EEL+AEH%)>%)+*O?Z6.6-J[3IF=F'A!>,>8P
M;M"(!2P"N!V6\!$>"-NN@*W8Z <$J="7A6->/#I45$3V*FH8)Y1Z#<=VY'G=
M$ %0;%OVLD'=0H*KI_5<;550NOL53K\UX9EMI.K1D^VV/X?].*E_L^N!NK]I
MG7.VU\NZD6OP32.BF;WU^T1RB7U,C4^/RY:A@U'(6Q3BSOEAB:85,)9^C3[D
M:U=56LG5C]'1C@1WDN6N5:1&U0[H4"5<I\?6P11>O,D6#\0UV8^#C;A.3/77
M?5!TJ#^PXT\YNY+2FA"YQ25$5AL= Q/!ZO,!B60%V(&KS O@ZQ7R3X5V]L%_
M>E!EYQ>UL*>?PT7COEBP45<M*D#YA+]C\ F<)3<RLAPC1;Q5&7:O\"G10&8T
M>REF8?24?Q[!HW1(!#ST_<.*0E#$N8F 6&0#O 3M:0VB8D*UR'H#5P?)BAQI
M91EE.^K9^NH^6D!PYPH^JFSTRLF!:_,+:>;G^W1W:COTELN@>>V\S]/Y:Q^U
M)A/TD \X-RO84'E\0]$X'4/$5OC.SG#Q#02Y2XGFO;I,1<$W=QN1X[#7TT3?
MG*8\TFOOM:VNAR!"G.'FJXS>Z<HCI-,6*>SPN8@T]VL\1UY5,'DXD/+NK753
M%2(=3>029'LNMB?P_(LBG9_G6SX]-"-I<SA3_93=,SA54CUX>W7)HX+CMN4&
ME+G#<5U:S6XV+TM-J[]W;I??R=E^RBZD3"DO*4FC-V_$F?LNZ8+/Q,T?$*_Z
M;6!#+17"8Z()FP/F(RL)S^_1H=>:A1W!+E9M3#F!,2M>FL6(?%SUK*H?;]T?
M*,3:<67&<MVWVG>N;R29FW(/9OB"NA5I6C%C;TW6B #KKJ&V\4$J_QC2A5M#
M=Z]3<ZKE'DR&]HRW-<[?=72/6E2^>" 0LPEUS1L-,1GP[@XG^O.*!">OXYWV
M(Z=CD.G!,8?O*M.#8M15=.QQ$4::(N!N'F[\/K*SQV?194\;78D<%.*]]=-I
M%EV*O(5[(KT\%!IV?MNV/@LY2FVHWVGJDW-'\UL9'MU-:G3,Z43_X*!F4+"7
M8!DU7S1/&Y_J4@E%,UD90SPDP=L+![*9OV QY,#LZ71E+J.%$J48NKT&KF,3
M-LP,WZ ]\:K?TEVK_T0_VO X]/X$X5Q]F"LITXP;%&5H=ZWU;.WQ?-*-]^L&
M#I*=NZ1;!;Y.:R-:)S:W/WM!;+?,-M/]N3]#(^;[?-?<04_+.ORVUOXIZU@X
M-8AN& PEOP CI]@:W6V&;IXEIF>.A#N\//-1AS.;J?1S35!2@6[%]%L:E()(
M,;F,!F99KF!K+J\#[H26[)]Q)6X;VG)+FQV#[@I,LUZN6\'%&.J/_W:@5B*3
ME'NFNJ*^_\?ZGEJ+2ZPHW3DUZWL3>.N^<FFO^9*IG/&I07K:!6M"Y:5#W0VL
MG]^8>5>3G$_LT-77]#]Z/E?)VF?8I56#USLYN5BPN@I[KIO&@)J]J7>GC:4/
MHZ9\Y)FUL7SWU:_]3.]?/NM[D@E=HPERI'DH5R4FG"XDCQ*EBV39(4[T+Y^
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MQ\B78'\WKM1(\RVU<%^!MM>3DS<Y(4$-5RS26T6 ;7]V3;)JCPK<M:-GU[W
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M:NT*EEDAY;EMJ<)/M#_^ZFO[KVP>WE"*H+@&K1#=M3@$X97.6_3>+TR/ R+
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M&2D0KX*RM1P,YT3SXW@H0&%Z,F[I.R8.^;KF_HW:@0;;<I<*)S">@P$$J<K
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M5 UF'QX9&E&T&(UV3B1\[-4LUQGKMLX55!@?73#>UBN0XYD.-JE;>_@#75:
M6CP5'C,LGQIJ-_\)MZ^+OAG9$S\[</B-!>)F13R=[2L1HOC\CJNAV.&Q_ ^V
M*(_04!\RPQ4S^=EY].JH<W=H>'BHSMVA]/3TWJIA631:ZJ0)%HO=95AIK5$0
M:):HDE!2D#QE)=AS!*H^&R!ZNOK^-!R$.'G)@96HUH;9&2*Z=(OHC6!LI6<
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MN,GOX,7#@23B/V?Y8H(P8BM]>7VS40C;X2N$W1+"6I+X;_%"V ]9&M./=T@
M&<)DU(_=T/@AULKR2NU/DE1"0N_NZ-A4X_T0<)?7)TDU"0 =T8IN*.FESYQZ
M1"YXSG3,D2)Q/UXA&[E5)#R?(!L[I>W1;NTK*A,=:#^27V'WJ%3W2RJK:E0G
M+WEY!^THQ+MO,55'&KDGB,W0;&\1XXSW#5$:D-.B@H-7>3I 45F!+W%4Z??^
MD.2$"6U@KL6^% RZG,0:XO2[ )SL:2.3UG1TW97>!<:?O3.#57-QL\U'DM?O
MT'*(H($::GB%.)4LA,F5!]_NL.DS/H+?-6"(C@]]*OX;)K9.*>V6DRGUK;,I
M!'R^/3 BN\_J1D*;__;^]R&*:7-?&LZ:Y2@CWWL[V*8=JRWZ35H9$74;E^GR
M*6)@D!E0\X;SK-#"KBMP_5#(Z3_9^^*=VRU3EU4%LBOXY#43/DFP=P%R+K(=
MI >8+8;(B#W/*+P L!888^Z)+G9I?3(VOTEKI<AY-^WNQY;_GK+0?B:WJG'H
MQ=MTM<9*BWUZ9G4U=IXH3@0H"Y@S,Y;&@'!FQSOL0X)L!8"E2T0:2_7A%:8F
M):Z6FY:G%8S%)$[DWJ4O&U0WEGY6R/9JS?E]X.;;09XY2]S$?IB:5=^-MFVH
MS^(E(:<>9V8G/8'R%KKB!X3/OE+\'%&B'^6^_,T[]X*LZKA.8'2N-^.FPI])
MYG"? <JR5D.[[6YC;':@RF5SS6(!?7 3&8_+[)%._?-'P6LV?;AU]<B AU.(
MM+:/5N'1\S(/0V\[J/D%049)JSFXF+O;/US-89!LE55"/A T&F)IES:#C6W7
MIQU[@VG-X"F)<!5 *\%>Q.@*YQLP]-B=C/LH<9#.-<#;U;VNNMG -HLO![&M
M ATPL'QQQS#JA"5>%?FPP9[9,;BN97:6'-VF)-][/6EAXF/O+60U0^ -)=(B
MW^J/-]"EV:'\7O6XR^2_$O3!170F13M"Y8W:/M*D28FZ\4]UJF\&2:^"SA9L
MK0\IRA?F+M4,W-"V,T]"Q4X]M[Z%V']S-5]=S5GZH*Z# B,X4+2O6*ZPP2[#
MN,[L<L+W0.OP'_RC#N_9G3[&EMJOG+FGB@98_5_'7.H""H8^"%"TJ1%L<@UI
M.S275R11GOJ1!H9^%-(;NQ5O"2)85U4?:&1IV=QK.!7(EFA.O_/CE5L[9ZZ#
ML 68(!4MW VT"$M9.#E_Z=.\4WLIM!1P1, E^<<%\O(D5.#TKPAA_1/1F#E%
M2%%H]*_H(D&-Y"4U?W<)D@Y&CC6@:/A/WIA7 <ZY-;,\5V\^1P?I];JB]NTJ
M7<YCM>'EOFLYIR?Y!XE3M?#56-083?!/0+$01F[<TS27]+*?W&%XQE%4??B>
M?4E:QBGRLX^2617U :+GOVW:QSG#C>B5J6^).@^'= 35N4UQ5R^^;PNN2)OQ
M&+)N[%G]R(^B?>$@W2>Y!IC1#2',L>>1'S]OD>>*O$[Y890\LB'XF,&)$,(&
M*YGR0IAW74];S\:'#$'S&]+FW5B\M& E20BC#!"_QS[/2,9OGZ+$N>UBH^C)
M,0*93PW8*83"5Z>,*+PK$R[E4\UHNL\RVHJN3NFQZPOQUUL]XT_1I&@5X@KC
MKBAO.YD6X@C_H@"EMBL_88GV)VIL@Q/'?Z:C,+DLL14T;[N;<QCT"-ZPF_C<
M!G2PE&*+P+5W=<:EH7<F_1J&\5I,(6PO V?5*A_YP7'.<>B[!M]M:'O_RM)G
M(6R$0.N:%NQ)'];)=A;L6F$;T*UI#U;7Z/"=32+>8?P&S4N9CF6!4_'$?2;7
M@W?]5?D^%Q=M.C!XY;5>75IEP/B'TC:F#4)R]XK<@X0O '5U,VVAK_ZVPTLT
MO27;[U9!OF/P2N% 7ZBOWF3"2[OTWZ(.M1T;8)\@B\Y_8-IEFY^^5\24<W8^
M7>^T)"B!DFH0Q4!> T=_=N5XPAR.PU\,*0OE^((=+$IDF-$CSMWTX4PD/0)U
M 1A.:I 5&W<ZZF_9ZFNLP@YX1G:;E'QI*I-XY.D\1_$L*H<X?X>6^'.WLS &
MD^B)&)-GE\TZ6P@,<4<88D5QY["Z;10Z4VNPP3Y-TD*W"IU^Q^5"PLU([;(<
M4X><PT+8Z'8\1?XR.9KU?"%;)5\DGE-MH4)V2S-8UTRQ(*P63,X5+]W45;4_
M^L[2OS9\CU7UF._S&1N#>EJ4QL]?I,NBQC($*'=."Z3;"_DO:.NWP#K:0(=@
M)_:_6C,]0BY%S1,WPX<U>)6T  R41V-B/_/HP<\\8D%UU1X.'J+Q\NPY>X6P
M"H5"(6Q^Q872A[>"I+O7(2'L]7.DH'2!I-9"7-7[@%QLP_ M"@AEMJ;28.#F
M 5O3_;#_50[TOVZ3^7.7S'_=9>T/^+SR?_\H&B)G$4-BLST>Q57 ;P="EXH!
MB?;-Z$=$;RS#&35(Q4CA,NCRV9&46($"?EM_89;)H*[8O6T=KL W*AOE%KXB
M!KFE.M<J^W-DG GKRF; FP*_3<<GMR>SA#  2^$I+ *5K)66GEV$SY@:=*2F
M\2$0PU*\/TCS@J(/+72#Y\9*3^B?%NXT^[/-68E5^T;@>RDQU@^[ITC;/FP0
MI&N!LG&",ON@T_=,SK,B7.AJC6 /;'"=Q'@H$"MFPYF_H8R?^5UG$4>[.%@@
M^XN!QU#IR]&Q16-)0),1R>YMKV O/%%+;(A@^77KT:W?]DK9]MMD[^=P,JLV
M([] $:\$IM\IR8 H8.T=4<Q0O,@D#U1CDA\:(J8D1+YR>L]M;WK"Q.[X>M=8
M$1 \VZ;W>LR)+A[UI(CAU"9-;=AK]OB8R6[;2%.^_:FV*TR;/?\ 9V[.1'4$
M;I=].GN@TVWVT*<T X=#9KKN/N=[6^T*9475#MB5!J"= C#P1_D'IPT_G#CP
MMN0MOH+H0+<E-5HQU&U.9CVL2Z^:T?_P:N9TP(N4=@#3C'U($O^N@-W%.PM:
M SWOW&0K/BFT5!,4 ,Q?/"VF_X[^EJ7'[1,*U;W?C8YUV#S\PYL5JV >]UF'
M]=BL:+SD*#P5BH0M#3P4NF3"C<"?8$M'9K3T_,;;"7*QN;HT.C%I<G>#VG5F
MMI7)X-+[MWW+>'_FI+@0=N,K5,T:U */"CX.ZBR'342X]5C4UAG+#%6)6_M3
M\O@%>;0S+9[WHK9*[?:4DHO)C7TT,'C5@:23&4J],.9P78N\*^YR9L"I>&OR
MNC3P]):I^N6R\VF6=O')*B]>/7'<N$794168ZI3J9*.E\TS@/0G\ 0G?KND>
MGI2]8%?>Y&MLN_5Y(>P">(]-G%9JY.K@;X+70UZ:O_I*D.._\-?52-Z!-V;W
M/&1,VC\T%XPW@/<+O[IMH;&5GH6$%OQLRA#KV2A#.-30RQ,/A%9V83>>_E+0
M2GP316';()/":I;BN<<72 J'V&X9T_\T'5] P@3[)WCV\1T&JLM%^7G@1V2,
MOK%41ELQJU'Y<O\2XCM-4KM<-\*8T]FWT+<JMYS[^"R1H3%-N4_T1-['R""]
M$;$9DZ,3V\%S4YB]N,56^YAOA>G.UGO:K9Z^TLI[4T6K3]EP:)!AN";<Y:#M
M&F>^['IMD4T>9[E,2[2.)DG)/GJ'$D\LB\Z-:FLY6'&UX4:&YC&[!-E3J3_2
M5#^.CQ^R1%P96UM]+NY"%G.*Q%_R_42V*W0Z&6J3N(-RU+I12^;YI'9L)^K"
MDA_O3W ,".+@ 2,AK)661-O?!.<I@1%%UML+5Q*:5'$U)H!7M#*M?E^6XDDC
M-*;I=57MX+I,U,6JQL,,"ZJ1#9/036:,?W0\!40]@VCP9X\O6U\&GQ:U3,1B
M1SNUS&;YW[]^"T$J.GO7_3:NW.!IE2R]>'P$Y];WKN*$M=WBU>A+P>J'7:ON
MF'7SK 6=M,J,G]V?1 P$#*14DYZ@=U(:;PIP.3Z@5?$S7<^^\H*!*F1D&"K!
M="!'$CS$-0:='4P_2<10Q9%T/;2Q'CND[;[WTO=_#+VF9X=X* K.RYPM^]V<
M10%U* +1Z%)P#PJR>ZV8*MHC0\R>)]O+HELCP6?,Y7#'#'35F^.FI7X"Q8&&
MW4U2 [\/("Z$,KX]R_,QEG5..\7PUL^1MSB4,C;8"JSL_O*$?+]G[7E0MXMZ
MCY2)!MV^-/J=P9L$I@W5J2;MVE'JF7!=N=.=6O86+?;3A<]F1\ NR?2IXQ"#
MS*;Z7&EW>'Z,M5_5Q_+Y(8]MC$"7[E+RBMYS]/<.9O)^T+W]9\=LYZD>R:_&
MV@ E1C-WH HNA7-']Z\+81*+82'OCHB;7!P*+HUOU+>K>/[;];K*VDQ1F*K*
M=6>JP'^R(K1CA4$2B#=!<<CNX:H(>@E: X;V7#5PTAE8!2=&D=2R!E$6-I*@
M6S>@:2C'O<33?CVT[PL8Y PDO61$\]0R/9.P_B%9R6*X-69.8;%O6'4B)%-D
MO3'SRFZRDK=Y%08CU^Q:Z?#T61T9#>V._OA'@?LCAH]VBK]O*=/&!74\*W=*
MG?G6:4>6,-?\D'[=IB1;_?J;JTXY'=)16;/!Y++,_VJXFZ%1,732J: 0D260
M$(Q = I?%F?YK6SG;>&7_/P'>9+QB7X=#=)^7S<I$,F&D&GMD?*9D*L8T.D^
MLM:*9D@\X-F6+:1G2A<5EWUE^'^D!/HID7;DELZGWQE7;>._NL.F59GS]DMQ
M#O.?A!S003%.<0I!=2"KM4969FB>*2&%6S13TK>]]R>CD/I%(-K_#=%PS:_0
MPGT&Q:<&Y9L4'&KHOY&R[CFH\_4;K9,N$ UA*W/& .RR0AFX52"Z=IWB0N@C
M5B6W4/8)>@SV%#,SPB.\6@AR;&(,'L["R.":AJ^D7*RBB6O?+P2URLL-_<K>
M[R!-:00A$LM6@KN]Z)LVQ1[\OWAP(>SA.<*6!8;1!I3UMY+'1#@Q8"D[HZW2
MA(62622)S )>#X*#V7>KA@U("0RN"TB&_'Z"VS$P4G>H!K<BD1""!$VH1CZY
MM4,AF#T,UX4Y5)^@5']J_&$T.^Y,$]$I1Z;PM)5X-)V9=JNSGE%FT7[LRNV!
M0XB[SQ>.+%KJ[M\7/*F?^* G2+,S$K@6<L8A@5'J6(9&B5E'/&VKOU)J9W7-
M;,] ?_P3/(-X"5E9LSS,51 ,%:W"1VLX3T%==KQ=_]-$<WJ3./MC?#AKV>!X
MS9X,I^B'1;4U;(>TR)9K$T8YN2'Y;>YAZ>ADGT #ALN!)@IE%9)B#ZJ(S6=^
M;NS;+(J\!;^/V4?TQ"2Y&?S<R((;Q))=6F'K?;\V3]MO*,N"1V\P;$@L(6PG
M6,*]V/=="!/%55@I(*1Q$52Q+B-9ZT^\:\P5:5=OXT. :_7SC>-^\/FS7$7"
MIW0,-7JID&M Z*MVE)$_ 3(!/^9&:R**ONG!VRQ+CN29LHCB/IO1<7A5;(G+
MZ/S:@A43N<^J!/1?^?*FRN^]3LW;5>5]VY5D)8%96<WFF=HFAZ2<ZZF><07>
M@V76=A0SZI&!8@<+4XL:^5C=G:<_IEVUU+N<RC]8JE,63XEK=K_-IKN_?EY>
M<$@[+.203MEI(R=+]MT[:=.G=3Y_R?^>1@C@013VH!G" $$X@(N_#) 2: &D
MT?;^5@/K]=F,4I\Z9*L1HJW")RPGIU=5D%ULS=Q:SAB9O(9"C&HO:Y/C6!.;
M8F.B[E9=8E^UA+!T"G@:)=BEQK4@#!*KS?]K:X0W>K5E=+*OV^_ )!T3?]=-
M;# $(>%+E"5HXDTOWDJF2\@NIHS-WQ[EJ0-F#TO/!4Z?MBE&/%B76U?$VK);
M5Z_B3@[XD$)_WK@!^=RE,U.T*(8AABJ2W*3-\P%I+^>=#">T&H'0^"E A(Z5
M6 QDO#]21L9)6%4 +%R.$&;)]>]G$/UQ]>BZ^L&RX,]G+U=_,E33^IA?9-5K
M'GTR@:;=['G0^BD+H)XZYMLDHM7UU;XT ><YK'VDH13I92.M?+13TE>K;5[]
MBCT9=>Q9D;Y4'"6J\W:5G[DHPBNF[8:OY7XCBM.5 :-Y2SU?:WU/:ERR)ID/
M%_30J)-+-5RTC[[3\-(H]QS^,#CF0VX6__@&"\QUY"BQM=\POWYSS:]14@/6
M([]G"F&1L]D9&WJ"0_TZ8[$.*1=B4RZ.-L51UO)^9BH4(.DF=6+S :K$5L'D
MSXV<L8E(62+3$8=H5U*J9.\I+'%CC.,O@W(L?WO[&M3N1?F.&/PI)E^6;JP%
MFK-(>\40(I^=<20ZY_;8PB8YJN$0ZR(>*Q&?,PM?(@I$MT"\N;,2^J1T 7UR
M#V17_;H-NBZ :063&+P&.)/K<[_]<1'O3\ S*V\<%[=R(<FZQR<75W-Q&']V
M^K/LQ93P41ZR$"SOIP\[Y92%%*)*W.[,N9R-:ID9P:\=Z; Z^9XMG2,?5&HU
MPGI]-;4V;;>#SO(]#4;!%?=0Q8.^=MG6K^4*?4=*:@G(/:_?+EP9O)*+]#%K
M/+*T8)N^T%W:5FNTWN!U@._*?LCIX/\MA'F1I*Z"B.F-97NN/F\/.XF<ZXS+
MMP9([1))R-T$.3#+%NC^EEL\KT<X_.83WH>5*'6E_E/YNK74M7Y_:GCX-9T?
MZ^+*]I5QS&^:VOGQ!> <UP**5Z5:I'/[9)5^.R4*OAVO[;^N$&^-9J$3\4CF
M@?6@0I/=&T,$>/40M@R+MRAIK]%[8Y+W58:13@D-N>?NY>5A]'GYE121A.4I
M;1?"U+5 J*YZG@+ZA3#TRO(IC!M/&T)7E_!Y$G"=E-+G[5<6[#K!AEP@YPX0
MVCJVX\F45XN1;(NLTW!L@Q&0JRMNP&UQS-D'1#66SM=AZ)/1\DT9$>43WDY)
ME2$E8'\;(_H)6\2M7]>9N+^M?%&):BS16>QQ1B_TF1=JR_V.RZ7V,H46#I3E
M'\6OC.%;S3)3%^H><]9*[6Q3\N4# [1L%I.N39S$C1.VBOUU-<%,J4#9K/\+
M>8GQI!@M>4;WP!V:UP%3G=G9I6%M&F/X'9(!GZ(LFP+3*+"1B^29?&I2QY\:
MI(H[6_;QO)B4ZJ;XEY-?T<GD!> :*L+'<P,YNL&V]@C2/-&@'KJ-([B>*?K8
MD,MYP'\KA+E31BVMG#&,LYQG$!5BK]#B6!%(^H0!&/GSKBJG!)GJV/# P"+0
MTFJ.K9V+E6X8:INK[",_LHH@.V/U#=(>H>$QI.KNS\D\A4$A;)O5($%.\ &^
MMP']"F1,=]20=AN+XTW ^U"A;NN(K:(HXOW8B#A\4+D?<-5'H$3]I+W2H#RU
MC&@WR(C6G.LKBE[>M,[^]B*@C)4#&3O2"G@8Q=OK#IGI!_DXJ=;)ZKEE"CN(
M1>9I= >Q;(KS</;G@,D8_SDPGIUU!6BM[I[&R.*F61)QMPSMP]V9U]9K,2VB
MBJE((-,O8Q,35V[VAGGUEHZBO<M,\^TA6[3H4Z^GX_V2CY@\8^,BL2U'F8.7
MZ$I#5<L[\G?9W0X,^/XE*S' PW+_^ 1US>66QO4[/.-]:;<^%LD?2+CDBMZM
M)^<\:6/1:>?ROG!%0TWL3*T*T9OPV_]>O;6-51:2\T!GSG?^TPP[VUN':]CF
M;<@]X#:,5>CM]/2AS"L"PSI@L/K-2^O PV:9=]-T9WZ,'QR+^;C EZNJKQK0
MTL(N:9>MW,+Z,^LK&JLRSV99U5L]'?(++W6.N<9\6_,VLN^J9^S$&?>0%#V/
M/U&K6*[#SV;+R-="6(Q '-<HA'E@]N(]0#]VO>FG]4;,N\DQ@6X_+XB)/.#'
M";,>WT0^Y%F1<>EC%_WU.EP&6%7]_:WRH3%549\8\^L*(U3GJ_)M@OV0$K$6
MPJ9>0%K/F45)IDT]1\K@[4M](=6I(X1%"XZ CP$-4[9J>OZ]$IX1VRNRP;Q0
M+=E8:5YVB1*4A\.Z]*U_MF\CTS=;S//FY3>BUKWZ5/O6DZ4PU_P6)>G/C/6/
M=LSRSCR=/@$?=?N(X^UQCX[4O'#T2IW#_,?(^??:ED\"?<HM0Q2>>^QL+[;2
M[;C.?GM+QB\RUV+Z3'YTZW5?R^!".[W&,V;DAJP["5ABG*VEED4G$KIVX$XH
M+]>9TR.$U8<(84.O06E,%ASPPO">(9?-H7)E2=LL;MB"*?B_^DK7MX@?>M<Z
M^*G!M.\?'=TQ LL/LOPXR->0 [W6Q;D7%H6PRN1HP5ZP&L/H<0)5\_#;!J]7
M?#(,45N6*L9)68,FQ<Z+LIRA3$(\:QA,TS'>W1#M,,#H&^JR'MH=&T$8^M2\
MNV:'JN'<$H5%'!5K)8K9#7-4V!)+G\MY4D!18P0S9AF*:(0S,ZD8J*$3U*(Z
MK(9TD1(J2%%M-2 ]F6):M.BD71Q1$%D]H/QFL*I^,3X02_31I/V- 8(E>+ES
MTQ1^*OPO(6RSFJ>%T2(VDVBKB8BDG[MH[1/"UL\1/@PR^]Z[&^]M]2(YEQ=:
MZ2>)_YG61-'HRT4$K-.HEJ6)RQ5.8R9-N(V#WW(P2SY40ZGR11J+0O ;+3,6
M:UEQG>CX;OK_#AET$IES4)BL$9L7B4NGA+!8/T!,",O9CO_Y!:LAM-I$"3UP
MX HEF2#)?T'0PGN"/<!**T$"-'F!/UC1:ZPHL35[W^(% %+(/.*TL[_=HF ?
M9K<?6@AC5$[RS@^4J:V6YU=Q51.3,P*>1.19$$_P[(6P';&$=P)1H".&Y\6:
M9"QRGD+OC\0KOU@0J+'U&HLM@/1)FUY#Y N?#?GRRM(%*=+_QMZ;!C65?N^B
MZ;85%0$%! $AW2(B,CDP*%-:$1$0(C,F0$1%"!&B A(D).W /*1% 04A,H8Y
MS"A3A#"T(D3F20@)C<B<*(0MF<[F5[?JWKK_?]4]=>Z'<S_<#[L*JG9VLM]W
M/<]ZGOV^>ZV8?\_[%B[4IQNG.^^_>-=2_5E4^=U#TC+E4?0>E:S;(:?J?F]I
M58OV7+IP$-F@<2[_R^# 2!/6?@77P0Y^ZU92">S3N&)V2YB%>%G@X/38YH>M
M\>9#Y@?4Z-8)$&9D$-D&M(7MIXD,D0;UO;X(=Y#7]?^N<POTNS2PD[_;G]G
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MTM7JQP((>RCA"[EV?GO#Y%[-$G#PCH#C7BJ\,<]B)(B.4=IH,OXF+:*\(H1
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M1"5KSL!/03#;-%)M/;/<UOZ.MS5E2LY\T%)K"D5P_YE/;*M#?<],<A=UD";
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M9^U$T&+W;)C@\ $PA!\(&\20Y8L<8U$%+.;@]I[V*S(_;; ".;J(D<FS!0.
MSQ'1!N9%TKO!@#4E3((!>P0'#J@[E X*# ,L<$Q"D-\@VL,"8Z:7KT%<% )$
M5"4N6 PY&@W.C8^'&")T9<%CV:2?:KZTC24I,:0X%,ZS_>^J<A#K-HCQ,BL@
MM#2U^9;$\?M '7CV9JQV'X<DG#<30ZB'H,)S<29G)X'P,( +V[+?(7P FWD)
M_9ZD#VC&"%\REE/%D!))EI#P0/0%Q0E27);@AXOZU;2%A:U'<,]YCP'4K!BB
MZO&-B^N^ JBR25$$!0XI=J/\R."RU*R4M2W7KXVJRB0?7%)P'#]/#5#8:E9H
MS,_ *S\=V>'Z=FAM30RY2/OOOB^R%_6ZYTSWW+76F[$]5:&5J05Q74ZIMJ?G
M[E-TKN2SM M?>^8H7:/XR8\4;;UDG1S[)"V;=B)1>]#%W_Y2P(*-DXW-G<$:
M3*0S.EN1?X;01P3#YQ;Q+[(D[/;:XPPE#BC8]9]Z'ZSE-$27S?'5%XV;CI&O
MCC1;4[^,C2_P&DGQS2BVY JRDZ [S*JL46;$;90C73'^WMP\U ]P#I^087.G
M8%#B\D4 #/R2X+8-48&A"/%?BTNT,MJW4K7O73I==^UC >*=]^D"Q/,@YRS;
MEY_D*>=L%N>TC+6,2P/K<9Y>NP<_'K]PP/'IJ9 _=G<B3B7ZNSO&V]U*L=&+
M@P[2!$I\,+0&@/_$!!=4-"Z*R[VHX52B%NV_K?_PXS#(@!H.86"X@$0P\/O#
MGXJ"N.]B"%^"])4A*2PB_@L*2W\R_P^B @AL"!@H\:K$NOD52Q#<#/[%[=4O
M  SC(HE8;<'5I742&*I3-8PM,03DJ$'<\SG<*/".*(SH("ZXD'AK@!T8FZ6L
M=.'SM5W$Q7.%H]>HF EH5*VY7X=(<R2$*HW#T#/<\JBXF X37IY?OO]#Z9C\
M:[U% 1-]-:4!<L@Q]$.W=!_LO<BB1>/1_=?&K[49]G[JMY1K_$[<0_PW%7]:
M#*F.G&$(K0TF1*:TF>_P!)J<F3Z'P5,#SK$8RIA&33HT ;&VLH<-C\N6&M1K
M_9 /S+H!U\20O0=%4!OVJ;VZ?06^K BR"O#<L7+ [ZV)Y>+F T3G<%)7::Z_
M>P9V[I6:H\ZF6?N<8UFE&((L1V74OIE?9EU(O6-UZ<WK\,*%_I2GGKFOO[@4
M')JB5GXZ5:K7LSBK:NP^-D@)0'__89O/LM7Z0/'_87_.U"@WZ_D#ZZ_= D5K
MD;0*%[L2$S:[-B['.S>\:J;!5X]\@R-VT>3*;PRMD]4(_0?&/H0K5/G]EL((
M-(X2[<6<,:Q& @_L39@=(H/!]8UW7*^YZ"AJ@-JO#:!1>ZP,4F#S]$EA;9W^
M7L(0JCXL:H.YD] MY1O(UO\-T+-W6*-G&P@+?FM0/'6MVT_O6:0?F_R;0 OF
MRW]0,+OS^<51@4^AYT*EX.P[!>7:5N//L-0)_L-!T5[TMI<>7-&]HP.;>4.K
MWTA-2FTV2G-S(]>%=2=@[.SL_$=4(I!('/[AWY.3D^UQ\B<[X@X[YG8KEQ3M
MV%*CRMPX+4@[!Y,<H?LZH,LNF=0&N'3:<A/]$'*4'M&PVTCH7,&A"H3\S/ Y
M)T&74I:.@_ELS</0>_%&(96<>TD'T48YQ\&[>Q>U6DQEVR%24NX[;WO&7W"2
M;2A)_$$6-@8J;::;@U-_[[W[<RUS'V#=;J$T&%B;M(.>L>M9H&IV9OZ"2>#K
M>T@P<"8O/K.2O[SKE]LZRY_P=KP!0.D>WU[T#ZIV;?F'CYE11D,7^2_FP585
M'&%K_I/1%C:N&3E3[F?-Z2J]=SALPH\LG<J6+#=V3!OQNC PL:*+F%CUK4L+
M *-;# ' -"V0;Q"E0/G!1#9" %+Q_"/4PBAHAL\"25Q)]JA ELPS ^*X[MV$
MT\ K[HX.D20W=30.'\J5Z-AB)@INLE5*4?$BB\'RBE"&')#,=QK90*^L\TU-
M=Q^CM;Y-43%%8CS&KS\^"N_")3SA"K2L)3-=/_G?*+$[6; [PB34U<KK4L4Q
M0[\323\BAJ"&4Y,IV.+-<._PZ#X_Y,Y]NK:GDI6=T@W>L!>FY5\?R:T=*,R2
M187]/.EO0HLGR LN]-=]*_/K-POD3'8A'E#57E'1-6W!^3A*V\07X[B;Y6C%
MXIT=9\8")NXV#(5,UD;C_HW'7!LXMR-*#$'_YRV]6=1C(AKZB+F'8"$X-Z2[
M =LA\ $BP$1$4'G;\)9_/@;.=2"A2Y*,."_+OS8,AX17: P89DHV(4V%9]RJ
M6@;K5+2UEY )'L0G<. L3+3;D%OSGGR8H"Z:I%4QZ?9A[/0V:'Q&="E79E:1
MSH2@K3VXI#8F-, ]=ZE+642>*5<;6S)9H\/EO*88[(4-?>FQQ0'<D85F-Y%F
MW6>!!F4!42N&?*+1L9,W>1W .4XW$M#E9/(*A&\(RH*C7.@DK4ZD @KT^>1F
M_9D>\LH-4*L0W&/6 ^\S'*K%D*>/CN+,K'F[=8FL(W78JB4BMN[7 UM&P:D^
M9E8]I\L(UT@Y,=2H8-[GC%#5@W%)FB@I[_T!^=J.Q9?TTD]?+59#6WUW262D
MO9_5YK3J*T5WLDI<*(@OR?JI+B&O6[(0]U/F7F@JU9EB%&^-&GC"^]> LR1>
M"F=^Y=1_WC/.#27MFM8K8$&?,CF)^!W]=1>;D[]+7=AD/4AI#$NBU&(B>I:.
M+Q\!2.&SVN:P9>=8JDY@X(9IK&Z=)+\'1ZO4!PPV9W:5<S)%>YYO[X&2)DE%
MY_!M!.'<^0ZX-+-R3Q$*;\))>\5B1#W\S;A26.@>OQN/FJ'&/LQ.\ZNOSOA*
M1\9OG5TUX)=;?)_=IO['-XAMRC ,#-""=ZSMNP:$M5GH #?YII&-DN186"TY
M :]=/ XH6G,$1U2R+C#>-RBGH$?(LOC04+1ALXEUE, XXF[]J'+:JR*@$$RV
MK8<SO&[#-FX!!SE(,(DMSW+\6&'O45$(:QZ43GVJMG-[?YG$0E^_W8-&_6B#
MID"]B377IG@5XHIYF#/?-(#P^\CMN*"-\B PB;FUH/7U_9X)U&"?*I4>6*5Q
MLB4.[+.Z8]+>??"?H2R30R:>E:[O;LWN!>*_U+5DS1V_)'L_T67AW$-/PZ@.
M=LUAM^#8@A-W2U>R]'R#'J9^!2=GX#[%(8O%N)698M.@5+ XS+46R(?Q/&-X
M T(P^@-DQO]&"DL]@#P.Q:N6<^42NVM$ \ADI==SJ>VE":5)=H$OW(S 6S=F
M(4MYV9B3=W+>N@P9C-NB)B.I5H3ST1VN[>SC-XIZTNJ5ZW2LE(BZB#-)MO?[
M*?GL[*3 =[QA='O=B1<!VNWEYP8SUO9T=ME5+-028[+*&?$$-5SKQ.K!8;SF
M+'8'+D7E9<KB2*"I)V<T'G^F1*>HP<B]LJ SN30O8.1/>TQ84 UB&FE@O+\T
M[XT8@F( Q_P$\MB9=(%\$^\.A]E%C&K<> R,7J[L#X$EPZ2.GJ< "2QB1UP(
MZQBE</I;]:))P0#@C&RL'S*$0H X[(8D=/^W4[6W?YJ=S\<]O]POAOQ"G&F"
M<H*P<42,3"Q!6PBBQL?.?I=^LK<NTHZ9((9 J!M2$NTFQIUD69T,A^>@&I__
M2V!9/OV-(,NA)*V%S+T=$D3XL0/A=I\%Z$@_XWA%EQIN15YY0P(M.@G;+H;4
M-2R?X0:,+67 5G;PCPJ"...IM9/C,\ CCAW;XM7AJC]7PG(7GXDA[>>HY4ES
MY9WE'<K1J2$C[CQWMW2W3;F)+VTZY);9HEO3&KX>)B\]0\T4,$\3YY>/SCI5
MJ(7>A"_):W_^2@'_OD]1M)9SZ&\.3[G/JX7WW=TX]44KD;IW+-R];10=885K
M+[L^M[SH7(R^8'@C?VC!SNO.A.=SV$0TK<]9))T.HB,3KR\L)YP4'!.F$OVH
MJFC8?@M%0E\P$-,)/6"&9NG:V8[BY69E$D0GJ@8-A# X9RW68 %;'MJ$BLX^
M%.,\Z#<<DC W6# J\&-[*;/T5LU,MTL&PHARM)D<6 .IBRQI/X--(-:'K=AP
MH6W&#UT>ZA7,B"&'!#@@DXI#7AL<D,QTLR?2-T7',FVX.WL[Z^:&ZU9SRA&H
M147.%<[TE.>E"Z1*X@P9Q;%<FV2(]DJQ5Y1A>_%ZHQ;2 J64K0/L[2>SAVI5
M_=JG=P^$I"9K-[TSTRI$(1%+8HCLQD+9U(W^=>(>!+S0KL33XSP;)8NSOI2]
MA*KZ^@].>T?[6?+*EQ]&[1]8/LZ+2ZG].0[!3W-.)+O>6G0O_7#N4JIRR-"+
M?PO4PK\?7WHY/Y:XFLY[@'I<EHJVG&CBVZ8DWLK/?2&;=#:X\UR?4TU\S1S)
M4 RQH\T,K(UK7@.*^>&X/%[9< AFG:.Y7,=A=O"V)&*O(&H5C*&*K3H+QMZ0
MP5H/O9QD5>A5#"K:9+0C807Q<7'UZZQ#RAH]S*[ %(4,0(3Q[$%>_0=T6+:$
M*=!A68;"A>;?0M>IRQI\*0'H$Q_C1'W9!X69-#^A KN;KFS8 :K;>#.;4IN#
MC'C14?R?PSHAD_H'!);<K/53="EF;.@_(5FG/UL'[JS/S/O6Z)W$ZE48Z+[8
M7SNI3<R@_==:&!*G&>D'[E6@2!2E;JE]W3KM,[/.-F6&AV\=]M5XD+LXE(7H
MV],*1W^<1#>LO[SR;NZ5M*:,41;:IRJT].T2%&,B:Z]9,/3'H0O"<&S!,C$M
M;!D<(\TJOAJ8B@=$#-I6/5X=M:*(8I5C0D-OA@9&^ :;9ZV\YDPAO"9Z-5J&
MRX>;$PQ;>NLZ=%+:S&1S[?;UFWR0CZ](+'M#*M0C!C(F+;Y/L_M^\)J$E-5R
MO9RTB<61^=FU3O3*:N#\I?B(B%@-[LU.@S,7>P]772X_'/LIN<!&8B/[],S$
M%V?D+VYI)FD'?+3<*<>'\DPJ"",A_[[V#+@P<A5=V(0I;>BZ=6W%+#?[R&O.
M#^H*90]%^5F,_E%/!+K+O64M=.&F,) 61 2.PY9IH'):!VQ*!2["W%;U;][0
M#%/%YVU,Z94-;3M2+!B%ANY9.BL&Y)W !2V-44/_WN6JBO*RR3&[/.#^>\_%
MQJFI@J2R:IGO9X54(AJF(!HC@OF_&SX1T:U06@C$S*(Z2+*XN?7CJX..3]HG
M+/)P_0"J+2TCQ0,=6#R&TV_G;<&B= S/+>MB#55TU20GOXG&S98GF-(T7]JD
M/J^$:Z#(E"+L('P&[:W FKWBUK7'S"8'#^-N)L-JZZ2<IDT3D%/83KI]:U5#
M0^19O9Q[Y9B'=2U1V:1]&04KR\J^M0U@:K_)Y%R" T;&2"!XEKJ/,,CD.)FK
MM$]DK443JYNM.*,\1/37P4Z$)^&/"*240[<WP"+*9+Y9M*8KIMCM0^VK;1BI
MM8<C:J.7.K:F1#&88%8DMJ?GKJ<I:T1.,:'SZ]7NVZ$+1?>=>7<[7)XB7MP=
MNZ,3,/Q"_<3KZE)$V<_(,5N'#)+V4J?[)R"W1=G@;C6=I<7(S/ <H.P:SD+4
MO?91LKFT*,]2X0_8O6JB3JP!QB2>$==X&05.#1VP9M%BE:76HD2: NPHWI)_
M&6_)^9J+G1TR,+=DFQ?&%.+.7!E:%UXLZ(NIF!!H<,CT(H$]:T&G=GP=*B=U
MTW9()[D830P+XS^R.@@$W4PN?S7+?145<6+LDY7GQ5F5MVU#F2D4R:GOS@E7
MHS8<XZ\()25CHN6D+*4<!"^T+KQ 3GL^L_DPZ8 V_>@=2&8O\.^+(1^6"6,H
M7@BM5E%43E9TWWH).B(I,61.EEP9(_Q["C3&\(=S(%JVZP^#:/$A@F#YC +!
MXH5:O G>E/%_"*$=RK,,H0G-EU+YFG'$[U?^A?'D8L20X4CG&0 NNC0>(\25
MBB'%!J3ADN.Y-&F8Y=[CN7_]?^;X;\MYH!;445]!HI-X+89\M*;=T.<;E<N)
M(>XT4M$.X5'__Z/ LABB!P-TTO)".?HBZ4- Z>S: 8UF-V]Y82[-EY'P;.I*
MM37%TU]!M O0GKT\_V.-?#G>/_!Z-$;*P;6YOOJ)8]50H+N32STF1Y27*@ '
MNVV:6)D>N[J!>BR&<*Z2?_UF-.JM,B@XA^$HSD[UD3%83&C>5%O%]")S-]ZG
M=/>M'Z&XT :N8IR93-&2L1&W)Z_^V8RJK%W39*2S??T #0F;F68"VJ1VYB2&
MYP-@^4:XS2XC!&PEDB/YOM'O<;,5R_PA1M5(#&%3'YM!_2=0T:U' 2G\'*C>
M7[WAU$6_PG"E!P8TAM?U91',@-&M$.5==3F+QDP*5U=IWA-*5^K;JU=VNDR]
MY\PA9X?[](^I)O*NB&>(P4)*S/WG*0.',F1I.N_(_\RYJO_5]^/.S@<Y.KZA
M">WO+%P='5R/L1367[P..%JV$5*B':RM/[@&:&VV,4E,**B"H!-R8'9>?E?F
M#1!GF4GKT+UC^',CZV*(TA>\>?/ ABDTEK!_Q%#E'[PO.M0W-"?<1#JKU"!=
M873//0/D,LNFX)W'4=$)&*N;QKD/%1XF)8HA7%,\:#%[)L20BQ.@Z$VD*;?*
MB1@PJ697+G$62Q(8<A@LZN/:TMZ;'01=KEN.:G26+]H78S[9%JAVM'FX#E.T
M\F^"S>>0"*0P&-ER"CUAE$4L\CR/T?]TRPS^ZM:0[Z/WUSF'J&4W(DL\7LM7
MN<ZYY6LYN2S<'TK,('PTJTQ$!K_(: J8;KWYPN?>L'ILAWM'/\_EG4J>EV-A
MCI)MD',SHO%KV'/T-;U1V <F;VB(.%,,J]3L5@$3U#PO6E@FAOBK&K,O9;)H
M,KB2Q=%V6AVT$RJWH)T/9$]CRK4&7>NX%_<WK^V3]OOKF,]9MZ/9L$;09)\S
M[F@]MFVU?W,!)7;F5,"65UCGP_EE+F>MH[$@B3Z5=0.)4L,A.TQ834-K'<J9
M8XNC:@=>502ERHHACG*Z60+4#=K03=@'<OLH-T:@2!))SJ.YZG8<'DVSW6XM
M7G00R&0'GG%\&^-,>L^L3G^OS=C][>_S1*E)=-K#$T#?H,-G ]-,C#;RY7)S
M)-=P]=^:T=55?;\A6H,,H$]<7J.*!F$<6YF)T??34IR?7&BRF38+)2WPX60E
M[C<?R3\&F,_"9 1_<IV^/;C'V-<P\36/\\.2FQU3B.;H#L\)N\KJ'X9&\?+,
M"\IH;[AJ>JDZ:W_YSQ;[G 26S>\<,S:*5LLR<?GFVC'ZOJCX>$./LN%QM^=.
MK\M_*U!5OO^SK.+I?#KW*&>PW%W&Z6 EH.7Z@F+R=YYMR\3$:OX)9]M^Q#<>
M>ON!'N<2&3A.%!R$\DX*7S7?FR&.Y8GVT-GPB5)6>I*%(?"DVX39&:G-(PAS
M1$>/JND2=P(2=,7M1@A/2UFG8N@KV#?HZ<.#H;C:B(9TY\&*9C@Q6.NRX7$%
MFB>,M47FW/43_F'7301B:?4,,>2H,W&&@9J8;Q^%2L'0L+&(#N6I*%)2"%:5
MSK?&&PY0CPY)4]C8?3@R7728 ^TH]3IFHY%NF]S]?HORU$RJN*?@8II)X@_!
M^:$Z.]P&!A.(\%+DHZC:"<'X73MBS^A8G(FZO^R*Q>Q-..C=>MKPE,'BP-.%
MD8"#\JKL(=21N<2<XZ:VNGJ?TG?&=<R]1=2>>>UZ I^LEV02<MC_HVR B_#;
M._]!3*:[DM:=#9#_:, )>2;' PN<2.]$Q1 5"-LT=@*&)L68K-&),0-XT\'
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M8H/1ZAP-O6OCW_NR;#^@9 X-E3'ED"JQR=:/,I-LB^%0K\"8]J9S%Q:HA-P
M;F.S[R'S$\;0+RC@#Z9 EG(1O'L?T4?>0U3"LD&@)>\-T"U- O%':CU1^W@
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MMCH5?FO;EZ8C&%-WBJLS([Q\Y:F<E/*UOY\4!GQ_MS0C\QL//(>#M!=F] 0
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M/6)(-R'B<66W[9.C;):2Z.0H2(LNK7 5C<,?G.&UR,Y+>*.JP-.8?]7M;NU
M,!I.]@J8YDH!.:I<#:S^MZK==0BF3V/ G]GB0"H6D4DBY+54LON?K77^?ZQ;
M)G>IRRF*HB"&)4O(1OC(FGK[LL]5R==+R7&"SNCY<@=!X<O<V2NY<I135T50
M 2&H(BCHST.VK;,'M![&IWAL;;B2\-(EQR0\^!&&;-,JFR@\D[]5U]8@969W
MEB2G.4&[2'LI[T]WE\]'0\RF"348([*,?TJF_=%W46+,R)OB!N8RGP882_IQ
ME;R)VCLFF]W__G67-G;^V.Z(+J^@L=^(7?;&682J'GO#Z1[/PJP^0_&%;D)A
M16[RT:SISKW@PFO<;:IRKZ"_7@?$"TQB0[.O))?/D] 44Y":6#Q49;+!N_DC
M<F$C5J^]:A^+]>Z*J4M!:[V*CK*5AGY9EY7+I$-^_;AI5=FC+U^Z9VZ.W&DS
M2*CRW5+19:/_ZARR\:BH!.W'R_]/7NSW=3#:%%$(&K4%+P[TU(*9 ,9]\?3
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MF,&.Y"#+/9\G >4#+$+?1HHD@JGJ,^SY]OSY]G7?3ZMKT*"=/.DV+82)&(B
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MB_^$A?;@FM )F$J25(4M/@.I(8>* 6,I+I ?6,CA^)B ->*!N'HK67SYB9*
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M@I^FQ>.5*=LK/D?2CXMH<?KLJD##-S\?LJNH[U=*:S+"Q&+V((G3@ #0XQ#
M#U1QC9ZN+4SFSZV;\$QG9J^3HZZP>WYZ:=C]8S%%V%N3_>9E[&GIIST96XWG
M$JR/ET6HZV8?[+Q^*\,[;2Q]0I!W0HOAF:L>DN=F5'*JKO#KU-O0DN/V$=K?
M)68A*?45.7TLSN6?UUZ673GPJ*3VP81S^KD/9Z\E%C[-G^Z]N'7WK^%?!989
M-?@V'*07)U5V7VKU6@%_:-P&%D8+O3&O,54F3<F^7B+L:Z8F.6F2*3#*;.GW
MC*0G-6+(7+U]0\X-+##L7N8)L+5OX:YALHJK"!,[SUQ+CG#MN3IO?^AH!,=R
M)^R-W!&P&FCJ 4#[X67LR[QH8*4%;I04X[.]CY39%&Y9_I3R._0>_''<V\^9
M4, &]6E8P>_>7IP1C;YQ="E&,0#>T1.2LSS0^FPOLUY+,!SFU/\E6[;Z6X64
MF6CP\*;/]RQH?XUQ1[J[YSVUPYQ:$<<U]49:T9'>Z*BT M,CC43;X&O7Q.FF
MOYX_-%KGICM5)=I2MEFGR;G8:XVK<^B%%!L7AT-.!.VG/[L-G' 9QK!!XQ:@
M27-IWC8&=.F\J[D&2D?4X"7TJP@RX6M%63AC[DFQ$BWH@*3)<=+L9\V-$<^:
M.+\JR";L,I\>FW'B1,*'%JCYA[-HH?4..%M<ZK\*6 ?EN_=3;"XNC11::H)_
M#U_#F/9%KGI9A)U9)O(3!T4+XJ8'UJ=+CGVC;A09,5OQ43Y[6#7=%&=@/Q7U
MK!JLB8;W0+2VFZ W@4#<IAOZ^%0(U.7;I]YM=0%;XZD;_B@P&Z=$>]T6ZWUB
MV;UF.X5MZS&*^RW55MA29F\T=>=[KC4J,:UQJM@UI9SJB!M.B']$!GXKO?A\
M?>&^0BVTASLY@95N^S*^/3/=_9%@KT#S9/Y:GS>[QP*].W^3%<E1?K@X.JM]
M>EX4+ Z$2@E&O+_@@^3#SN"]ZOX7[U>*L_7:,\/RB8M7_[8/XKB _0V$ BC.
MSF.W<6<1X>:;L$WB<D-E8!45H8Q12V,!F_"@/2D1LV%IH&@X]!DJY5CJJ)]*
M+R+W"+"M<M2=D15=U)W?^C<$F&1MEZ.2+3=);XI\XI\FDYJ= [(:8I(R^ZD[
MZL&9_KHRQAW64,-ACSYF$+9+,T'XY@C=X)\BX;,JG0O/'^SW39KB!V\S;Q'X
M.6UFX:Z4.*7DY*OJ QFV!V\DIOT^VO7@\I;SS2%$EYSP+0EK2LA)>OC+G@9A
M];<>72F_R5T(8NH:%NR6HU9C^>7X%^R9^Y(KR-;5IQN7D?U>T\$7V*L8%3)1
M?*F/NH.,@Y5I,;EH":D%O2Y@9,T 50\GJRLB)S;S%&<:.:4>Q 4?M_BRH6^9
MEN[W!46S>KEOU;X"_"'>IT0Q71:%O3B70%]J$ZX?BP5++'="J>)R47M+N1J'
M#691CHH&ABBJ992=T%9!I+DG/  1A9U;OKG)4?X#E.U"<\ST5(.#DB=F>JZJ
M\Z)JSEA,Z\!/1:L+/Z1XL?&NG2[7[C=="E9X:'N6X6:4YU%RW67"R&OPU!W7
M(T5-76DIM>(,5I5'((;9\\[;MIMIM^Y9L>W9D+'?OOSZVD W+_J<\Z4P%7:6
MBMA\)ANTHD'[\3/W$:W=('M*-2-KB*D#U/T4G0&*]_J'8'!+UL",@N0HX9DG
MY7"W8<<10SV5/\#Q9,M#_K7C,56ZYF^,[!Z$F">KG&[+BRP.2/5@S3+"0H,G
MPM%->,@"U\S53!;0UAT3=O[/-C$YCZ$(#A?=0H>T3MW/^V:F>=]O/?WI-ZYQ
M*@.J'N'8=5?5*49$;#=W>%X3]>'MA]6!Y7D)6^ZK26:?-$ B,7:2;*%*R8XS
M2#NX2><C)S+X0/G=M%T.CW1^'*#X[?8S<CB0SUBM8X-/WYWR Z\D:&B@6%E0
MB<<+=SXM<0TQ<)DH-K5UJAS+>S>JMO=)@8YA[6PG/QM6I4LU\7+4,?V[6.@F
MFY]+EPX.S,M1DAV0RF@F0@ N("@-OX[-?[RHFID(&T%L_ONYVU@"$S%^>(,>
M@!.=Y,H*RY'8J?+-9R?RV0@]WE^A=7HDC@F!,2E'?4H]/[&8IF:"(600XRMR
M&KE/ZJ\.W2VYTEO4#;_YY_O \1?EZH,.R\^9?4])3+@S&1&>W./NY&AC=*3-
MO;O]IJ+NO;7!]('@=9[%]CTAHI?I/BGVA6-;(HYX>MX8KIE]I1L K,)4Q4DU
MII#S0ZPJ*@+N=0=86.G&Q/:L"I:@]>6 OO0P7X+5()\X"16#4YP%]N! %HW#
MV^@A=:]G@6IM<M2R-S=>&-\O)#++)\/+"^,+N!"-X\F[.WV5]?YR*)L&@&'L
M-HQ2*SA@#YF/DI;C><,G!W)-NBRWPIW .HK-+:)>2\948<>HONKD9LMMX'Q1
M+OS!@_3SB!1;QB$56AO6UH??F"K\(?GPI.&<Z,.!,FTYBO#GK\W7$SC-AA.^
ME=L46*TOFZ4)K--]4:5OAXC#B3>";MQX](BN(9@\F(XK03ZAI/[B1BY&\>Z7
M)X]J0H0"+<69NA=5KD]2L"F=$")SJ4;#*'/PQ*B0^AE;0Z<98N)Y55<>1E1
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M+!!Y;@4(&&B/>P(%)])OMM3HTS>BQ84S[UAX"VA*% "Z]91X/2"C-NZ.U%'
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M2+I:%+H0;;D""CY+=^VM*)>J@75"6L+\;5'8*$5<'E8:H,L(N :1G/JKT.B
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MX;_>%-QB#6$B'#,.R[XP6@70<9<3"BYA)<,"[15 )T2KZ3]Q.E5N4NI =ZO
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MM2OH&XV*S]@<?-*5=Y.&>R$O4TO/AUNXA5I@> [W0TVB % B$7P&O99^P/+
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MJ6_5'G%YKI]A+H(C7W7@S0@-V,B'/^! 9WR:%HVQT+J0EK]+]@*XE(F7A$<
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MZ%W$*$& 2UUOK+..,_/.IGF&#/,'H_9E3=WOJCJDW9EVZIY+*/)GB2_\'M@
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M[Y%Y-:/U&@/61J,VAR+6;H2*) I=PB*2 (H,(DZ6ZH-5K#(A 7(PRU-H(>C
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MOPT]9]>8;(W,B0C;>/OGCZ<Z/',EML?%*I]6-=NCHC#]/':;.F;C>&.H<EO
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M#C?'<U:PUSP80H!0[%IJY0[>F=:9RR":>LL51X,1L,&'<QO<%!PK)9^YJ)I
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MN)70D?TM$%\!/;+^ 7RS\%_X^H  $2IUA+D?45WC[7D'+G8(F!(P)6!*P)2
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M&Z8Z5H)5^9AETY('T[">1-2RW$F@@W_I<_=6\%=_;V5_0>855#"7SQKTZ2+
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MFM-U./C,Q*+W(S(4OJC+7_49A Q0W7IW" '$J5&T44(-:FVLEONI=OS5A\R
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M,\D"TE60B7WQ\OX3DE+G+@2X3:F1.9?4WN\"X6J-%=KRM9IE+2!/L4IX^ E
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M9SI?DC?8W'Y6"9>HVJVE]JO?" ?\I.BF[B=3E*\B/?E9KL1/"O&K'>BR6H-
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M #S[LJ&$=%G+M$)6B[JV1KD-A#6[$Q:((\1)1U[G%1<4"%(X#I&%)L^Z1 ?
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M<WD]Z'+]TUA"U;;UA7_GZ1Y#A+Y\U%^LX\SB*AU C(</>R]JJ!/_MHT_\:M
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MU))%.](=X_?HEF:8_/8^;?![^HX_LRV?Y[176*XU3PV;Q5& =].Z0P8AH/I
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MEM/V=Y\?GS+=<;S3S>2R,W%R?%_3IYWES"?$\G,YBL^O/VR.^A3U_M:J(M;
M+\K[5RA.G\0JKAC<SY";_P57,&''@+'[><7=LM[M"@4V5 ,O)>> BA$7S%QT
M2LI4Z;UB,S/V,,+O[6(POPDN8YUYL?<.L!M9"P)JHG2"^P;9 %HW37!#%\,G
MF$5MZG?D5? >"=D&[)5^)%'(A74'9U:0E[X5MA&7^12U%Z^CWQI.>UC^2UY\
M>?[+J%_V>5NEX_YI50%CL?IUZ*N\POIRM%U<V3JFU9,9Y$U/JSM$_F4('B:
M;6IRB<9Y>XOZTYAP_-(L[B5GY1N7Z@03KU+[#SWRPSF:P4'U8$31@97/8#QJ
M<E4?.+=I>SY%E4NK+<R%;#5#5URIYFP_0ZXX@G U=!X8,^@*_H89!T VD3:W
M,D? +[M <0JR([&\+U+QJ>1T&0,::5S7*<Q/&#CF"_;D5HS^_.X \\%?FPSI
M DVN+A5;T6](#OKOT%ZQD#?NI67"F_"IDXDFNA0L\"&N%@/S,I*SWHV>DU=[
M7=XL2%,H9:O81&M>-3/+L[U0Z.KD'3^QFQ<$S*,#"H]MP:/^#_KV5D9T7&%7
M85)\)\LD.!!0%5%6N#A_<D8\7($JWRO"LIK:8_3'HY?&H3(9>4WMM8_?&V5I
MI3KKT%6W1@;*0\YER'IN;9"=,\JB3N($_\(0)7['U+$P]17'D=M;SVW*.$<Q
M4<(,M3A%,!5U2:,-Z7X(&:4C@1KQ<O_5,],9"$U 76WZ>'2F;!=COLBJQO,"
M_^&[X3KWS(?#>2YW2H9URM##1FGLGPUY0#A3$2T]#'OI,F%+D*L5)Y?[][^+
MH%DWVK'\-/8%Q?+XFM'HRT7]L.! =X!OUWKWG)]-??WT&R:/!?;]Y?-3MB+X
M#T)3X=Q3-1M,8JT1.9<VEPWSP4/ROG,C(P3BCZ$.\-D'L/0@TT5C<OM+#-4J
MD[F/OSVXI?*RSOQRS;CW@_KQ"Q6G<Z?.I./^>",T-6E2^'"YR([[PV2[-ZZ/
M%E;DWOL8%%5X\P&]YO&KT:C3#X?!_K[ EZOZKKN#OBO/G;%>GUWNLV+>Y]8;
ME-/ NUR-=;,8I@U2#%F8P^"M9L>A[T!YJE@="TMU;-A/P\P P'^QMG3N[T1L
M*[  ;^T1.21H">,\XU,L8%<E^+K$4*4;6-2YM\-96#J^MO-\!Z'TX[])CP1H
M:6-3H(GN%[""KZ(I=JCB)+,XWJ!Q!WL70]-.E"AM4!L645.2'*.T/#6LJ."%
M::(HTD'/M['CZ^0RJ_A]]17T2W7M#;_%9S86/!FI^?JOXIJBRRN47P/2$D"5
M0YO,I+S#',=RI2YV%C<430/>?DLPIA- /R:\D<J=,DFD8;[S6@RG*6AC&?V#
M(?M8!^5'6M\LSK_+601OJ.&/3=< ^-,ON*]K\AB7V2\"7ET+/)/X]O<13N__
MTWG]K^-9H\G;0%I2XSI6>  8(,,;P^&MH:;0PKJ^T4%S*"NI&.9+/0?N4RT[
M@D9FEM4R$HLC3PY'+[ V6?C^P=NM8/.F(^LCVO[)QQR?Q!10_2NH-C4<<NM%
M+*IT@1E'GXMY1V[U'\00\K'1/CBUT..4"LRYL96TF?'#P<CU'>7"4\(_?OG]
M5E^=WQ;Q2/.*>7_3%LYMI;X*5,4E.9/M.'*Q$7DEVQS<P'-'S> 3*J8IR^3;
M+T&!GS;4\P^"K_,?]H?0_AH(&1@,C;0^TIZ8D' Y+B'NHEMWMZPC?AP37?]$
M8MW"=/7G0H$QENN]#;<ID^.7:<->>E_.[X3*UG% W>[1!%0[8@L/:#]Q[[D7
M.Z:HX%(581FKZ4M3G,V?@3YE@RRO@.XQ%S>>T8C-;T&QUSU3BM3YABTSGTV\
M(BZXK$]?X8,F8E*D% "C?!%2E6ZJ XB:@*.(\%%E'\<>/G87P^&S65P*IC:2
M>4-S?]3GC8X#8![0- T2;AMJ/_S#\476_0R<&Q\8H@U%H,41\[_TJYB(>31J
M7*QW9\E]8!ZX1V=GR"?-A_#2@,^1A2NA]]PFC+E&0G> -27KCWP;2S"!BT*K
MNV/%ILH'9BM/B]X2G[@X:YZ+LXP=_/<9+@"[(^Y?V8DGL,F@=3-M$<Q5]S;C
M%[#V:'RE$];TCH_H5I#($[D5L:221L>.<S]>%HJ7PV$R]Z"LM')ZA^BBL,;S
M=F:[\$:JW&S+@\OBEQ-]#-V/AE^?(#XE:#M0Q7_)ZQN1-D][Q@YE;.48L=?!
MV/CDS=9Y>P-^HGN$KJL!K;G"Q;%E!2ZV^H\QPU/K7^3\Z=3_?+QP_?-?*?5O
M_^VM\@F68E46 /KA,PLWY+90S($?J'W109#_'[>G3.,.P52UP'C$4_9ENVMN
MGJ$UJ=QU$;3HWO7]G4=Z&I6)JS?50'^M7^)@/ZS?R9'PG]'&N!NF>L>:]4Z(
M$6S[./)?04$C@VOA:%#>U&@'A0JB3C,V%!34/-/T^[NQ_1_W]TLNQKV7/HKL
MW?:D=^9VCU(X$O?E>T/XOV.$<YX]=R 1)I<E6\GNK!S:2N2 X2KE;#NCV6-C
M0)?;@)>:DB)R?#1J\>KWCE#&M/TRX1M;F4V*F8._;Y ^<?*G^_VM/_UKTXUX
MY9A^[I:PX1I&7\[QO<W**BZ64CV055!U3D%<43_[6Y" L<Z""+'9F8Y8DV _
M;U\_##;)RVZP(V8N%2_,K-7=OI$WJABQ<!@(]?%^]:7=L>^7P_..N_WWY88+
M:6Z_S7?8,/<C>R&[Z0S2$>SO24,.__NN_%=B_K=PR'W6]M>?U(4'SHKX^\'S
M\8MX&^_%;JWT3WQ4S>T7#%W*TVDN'YJ9*=.Q#>F4,&6?9U30A"[,D$O&L>=U
MB7:=MKJM<6:J"4W4^2P3&7E]I_/$PZ[RF ES5H8TSYY? 5]K^G-&$YQAZQU^
MN*'VV3D3^NI--Q\;O'QPEI][981W#)TC7 VY4S)IE@#6.D,3WK*_PM7V]T9G
M]BX#GV/!DFO.QW$LLSJ(2T-\M7(SV/<H]-WWK M.)BLG5_6>,/\(]2DV%O:,
M,A=32R/N?I6^Z2X^2XB''>,0B^DFOMEY\M<LFL[:D"7R@!C?0;N@EES(]]O_
M@[TW@6HB:]>%8SN@(D9 0$&)BHJ*F%89NAE2#JVH-!UG%(2HM#()^6Q$(H24
M@A !,>U("RU1$5$9HDQ1AI20 *TT(C,$(5,K,E<IA))4*K?2W[GWGKO^_L[_
MG776^K_UWW58:R]8!52J]GZ'YWGW?M]7>YLV.TA',CXCL[2::*.G#+F%Y;!6
M=DM*.:M<'EP+\9"83_X:_0R*JM PI L? ,>;B*=5,A9!)_E=W>I?X5;:7&T6
M9SI[*3JJ"-UW5FUI44-@,!.4FQ,<T9M?]JXW2(W;-4<>:!J?993]:_R>9OQ5
M[/SVLU'&1Y:K;WWR&"[>;? >X +R1 ('4@U#3H=,!OYI6LO*N/5=%I?PA<&T
MKUNLZI_'O6?WF-9D^3;E_'X+R<N,O9@95DX/7J?QS?WEA';+?\D__,\!4@%]
M1?U[=36 ^C1%7U'_O<#[#]LA@FRMC->L ;N$;",=J>V8(EH;\Y?Y'TN! .87
M!TK7/KRA7,[$<\F&'1_]K74DT0>*VI"0<CJ%BRITI&5Y/+QV 5^[W>._,S?^
M[QB43HNA!D)*9!H [#)&";/RR#K>O\??YB\B(I\3G;6?"8$YYD@(V%#CZ)P<
M?-OA0&T*S)A,W4'0P _N_ZD@P9>=_VPT ^7A9$(8;VS["*FC*#. <1-4P @'
MJXKXG^*A3@"O@2[K2)/-_(6/IDZ$$+;CJW_1(/_C/ SO/],PW'2D]S\)>(#Z
M)SZ\&] 2?FM!KG;YO\5+_C(1X^\!DT JE@VHWQ,:&XKH2'@QHUKZ9\#D/Q-I
M^O_[L,.Z(?EG_I<=$T/;B#EJNP\.3"#CX(-4,",*LX[0D59;:R]!0])BNM8?
MI]TECUW]UT7 8%X\I80Z]$KCT<MJI&LS@:#&"Q1K)K[H2/]9<-X09P[;#P61
M[9]?1J7_4=9J:2^X/%Q!5BX^RS1\-VC*BI!\W?^WT*2 =??6Q>=[!%VGI;&7
MD":B]<&?-8FY3_K3K6\_&HSNS3J6]5'JGO A-W=@,O^]B/\P./HDG[FB!\]Z
M).MY992?FI":M^%=K_^1>K/*DHJ]7@Y)EAO)UPBONHJ+F>I(-1R7%MP"]55_
MT%[!/!'JP5]]^AESQ\C24'E!D2K_AX_]P[F&84"U3U1J0:2FZ\T-WN-+8<5?
MEKM$.X[(BE;_3(I-^C]RKC[_TTF!'1#JVH?O5BGYFF]X%\#)GSIR/YFJG72D
MZYL)$C#4+9JA(PT\A2LY"8I1S<@Q'>EH,32&H. 5RJ<UO^E(0\>2=*36'V-M
MMLWW'JC[S/I79P_]]_@OC2G:"YR_B+0K@2)G+ ,<TNI(/WHH//"[T48QD> W
M :!L/:@V91#"]3L.OP;_.' +[(2F$VZK-2YY54' V_],+!6XP4?=8O ]%O<)
M OJ.O8 0*T]E9>P+'6G&&_#U7$+P="2-.;Y11QK<Q3XIN$08Z7\Z5G\>./OH
M7V@M_QY*M^5C!0>0/OS-/GRV@8[T1*8R^[=(NFDC[KT&)70V</7?-UO;F$BR
M/I8.-$#X',+3W,C!WT'J, Z@([6GH+Z,_J4,?0KB#((IOR84/)RA<=)G#0]N
MP^P%8S__RUSNOV1 #>4XF5CS&SR.A*$.\['%!2"%</(=?YE'2-(G$OX[J?N&
MGNQ/+$Y"*%ROI$J80XW# G23VRSEJ!48$"O4N&I\<6,&><!R5!VHYG91\2JU
MCO0T-FT8.E:IH6;T::^IZC\Q4)J.=*D/&+1@?"D'\!WC6C&GE?_I%%3,T/[,
M3X$F!=A6QH<IQ'KQL#4H ^'ALV\K>3,)M\.44Y(S32B%C)K\0RR&$HC'W%6\
MN:E[Z^N F5F%K8E)REC7_2TS[@6E.:\.9=F+FL+33//V+KFUZ25% ""+^K3'
M!W4DYT =Z96UJ$%[!Y"/Z4B==*7YLWM!8''@4#\RJ#Z-MY9.W8^<O!"KD%WA
M3(?;'SQ[U[ F),K%@38+T8Y<J9_CI"Z[D@#+#K0^A,J37>]\];K:-?4':G_9
M9WQ6GV;*@%-4-.>>9BZGKD-MH6[IDAWJU1_MG3Z2-[IVY#YK75CX< Z\3WPZ
M[+1AQ<:J#6[[OAM==.DW":6>W,W%C6X1$.P WFD]I7V,/PV;#N<,)2$'@T<B
MR89L7VW&F!5S^M9[(18K&W)*VO#Y_6DN3#%E/GIR5$.3KAX++C:B[FTY%BI#
MOZO8J@C-W[>_O(*DS=)F@L&4"Y027K6 S&9J,_ U+$!%J1;,3TEHP@+E^5Z.
MB[\=&>H):'6XL]W@4.1BLG_S^Q/QWK#ZQ8F<T/1M5>:3M_BASB.#W:'8-0*Z
M\*6N:B6!?1F /,??'EV-^-M[^*!'V9L5KDP>WVAL<^1CMKOV'FW&P/44'AD[
MCFZ*S.61.SU5=D8S!O>7HZ#R8$5S>#'5O OE*4#>C\7)LCJ.98HV@&VL8LS$
M=L&,BYQEZ%1)-'"9;: :G1-D[0C34RI<0>83%ECC;XP<O!E<@#(ET>8Y(9]\
M!EQH+[(872'1)[3%/.:Y$Y'3)>N:?LO;!*3J<TEDV*+Z/^L!;@#D]TIEA?RJ
MQBZ9G'<9MV#95/$-*_P0\D'T61@R#^U0FJ#-CLC*HC"X0Y)IC@BX%:[R\IEN
MKAM8/N+#'6X6R(+#+%']P;9UQ3W;:W]G1=.'/!7"RTJ4!P^^!.8IFL9!\E95
MXW26=^WI(.LEA>4MD<-SJ?.##EK^$4T3YC"Z#S,.A4P>EQG:[WJM?M,\TOYI
MUMT7I7%!O<O1>/4C])Z.-"T-YM8RI\@XW7QC0'Z'8Z&]QUGT42VR08^=T^QG
ME:M#FC@;6::;VB*M<HHZ*@Q.(\S=I0B4Z!#K>;!YU+]C/_RYL\L_Q"6R99M;
MFE,$X0ZV$6#N!9G"W@Q;5 MFH%PEM89LA6Y50.+1F?W-@]9KD0Y>A6<6"Z@2
M+6@^]N/.$OH\E"]Q+CN;=+^_R>UJGE!Z<[RD^-1'P:JU=W%F*  ?H:++G1(*
M<KA,4'X?*KP\>3'-\)30TKD&)*,I6TS<_RA=RJ^QIF3L@W\_J&3Y20>\_.SW
M_E[SJ*(^I]'H]_.4)_.]?\76HF+XNHI_,8RVA&V*9L-]*O+YT0\Q,10K]EKB
M=3A+T.UJY3?V(S_&M4@R35K'8RV5/Y:6%S]GW:N,.K0N__T)XP8KYRP"MFV.
MC P-"(V(C8U@!IX(9#JVO7_?VM0ME4J[:UN.''GW[OM7\\WA[WAK6W8-+MJ3
MZUKXY!JP4;2,$(8@4'Z#,MMMYV/6UCH*P62ZPL62,J<L,&O09?MU9)\8MW_1
M-!ZV9H>B=:S2KV+IZ0+QPQ GBPU6=O56_6$C8:/#HWDKDIAG-!_M7P(_K!*8
MH%8:3\X;67%?XD.$-_0>Z5"0ZT!#GXS]4 ?'F+T-3I.XNWIFCH=;2AL//8<?
MYC\IX#W:$4:U<3G[6.WY\6%1A?!6CVWQ\RM &&&@"8:4"A937U*[!-5EX!4H
MJ/$*8( 3SO @,EUP<0Q:@(6B:7(H@6/66G$@-B>DK(:7>$9'FH<.^KP]D](X
MSS_8TOS%$Y^/[1/70IPMSZ8^D6T]I99&_O&T1J$C29W5T0BSZB,8!,[&HM"-
M2N9Y"_/)U/=0'96,[8:WE\#1,5XVC'+B(2/)D@;G(R_@_:63C.13U K'1V_2
MN[>=$'3Y?>RP-\\*<RPDQ=B;?;(=DFG8G%JPU"()7X(":A_M XXY.[:#8Z:]
M61%+J6XTWJ8<WBB&!RP3L[+[HWY"N;MV8N[@L3SB.=,_EB7>?,(X-.BD=K:0
M^M7T7#ZI%-U$>*ENB^%1L0N4REG"*A+3IL-,[G#[9W^$>3ERF"JV7MAD;\W*
MWSOHW5%2GKO8SDL8<ULN/#RZ3I&4D[XJ?N'R;4?GID/K07D!!.^1H9',H4 E
M1=J'SY=A5'"(LA@E5P&P %(0R+SZJ8:!K9S,2P]4\[$5(!S/WOH)*'*#@"$&
MG.JE?O<%#"VN^R4(%(^ \JL,. VL-M:1R NTUZ!2CDR;H9:A1_S-=:2+'L-6
M;HT;<7.#;D#QE69&+U "*I;C]3(-5'J.;\]A@%5=97B"DH\NXU[&-BONA.Y$
MS"\\P9BH863V8+IY=F!NO^7-7%;!L/D'\=Z6#\\+*\X7;DC*[[NVX?5+I\VD
MJ6,0/E.A+QJN(W%+.+\)H1(/;#4%W4T)0%^H@ 0^' =6OR9\<NX'L'KI ]:^
M W@/\519^#QRH@8H!A2VGX!"?4%^9F$LMP%O>J&AIS$GA8S7]+](;X1R0TBK
M")(?#*"K@*%O-=9^W<%@L8XT? RVDJ==HH8-"TZQEZH:DVB6S1418$[/;\>X
M^Y_"2Z",6F?IYJN[/'.E'R."2_LH0667-ESO Z:"\CP0]J)*Z;715#$OCB*T
M&.I2C5[BK("N>\)UYX=HJUA17@@_.?(;97)$#HM1/3G>?C,?O::5WV@PRDP*
M $^?-JO$?O98%MPQ?&K*I.DVLT:TJ";3#+9(8'NI!(M9&6+<$*;'84 >6E1+
M6X^<+,IA152+3&$!UV'P3H"$MA)QOA29DN%NLQG&$QX<[@U)?U/TQ-^G7^I_
MYT_S,;W8Y/7=Q=/-Y/K88RBE*T!]EYB^''QAEOJ6ON1^$ _=K",] Q2.Q!Q;
M(-<5'340NI68T)5X!_&'3-R$3T @#R49]2 N+B$N@?ZX!&_7V*H%ZI4"-;D8
M/-E[CN;^D+ ]GN#1Q3&JT40=Z01DB'= 4RH"-9M9I1\\[0T5WA=H2X)$KLBV
M-UE&!8\?^05[[T9IL>$MN]J&BANL]K25&-D>+'_66CR\;'Z;(#]LK#O7\_%+
MFEP?C7K#H6*'8,I+7@)@C#MB>SKR*];#*@40YT9'R'762\IM7C6SJ8K%UJ-'
MV@5.Y@<S@X9./=0X/OBN\=Q/QTJ$'IE!39 E01!2&/!AF1E8=;Q%?1')3-%8
MAP!%$R]E\;3ES=AB!9@D[:LSHBK-\Q&+&I^[S]L8X@[:]*=HF&(EG)AU']WB
M-55BB5UE9=1$^^4W)JUUB 7VM7WO;1F'.Q#($A2^9KMH[]#(^E 2VT)IE0)8
M<-Y*>WD(7^5T.]B:&[&X[N4HUV=81\*6NI@7"R,:\_IOX6O1QGO]F;9-@N(>
MES9!N&CNP$';(YZ.;6=2Z9/$?,=MQB6E $SGH;:,H1K-QI*?BY$<KH@2++)'
MJY9D*ON&&9:B);6BK]&[2Y^7"0N?IWDULP_D,EC,31L[.]_9<AV\EMEE[%@7
M<#MHZFM]F4P0/@"A$7U#S^04*0.?3\4</#!;2K%! H?@:=5F.I*A!VYFJV9@
MRV5S16M0'4F__#N(A?=C>VF8G9#B,/BCCG0</"J-S=$PB9>1$@BX"PJ OGCB
M,]-T) ,CC" M<6)6!X&BJNT]Y%>UO] <,*>W9_B+6 $O+2"SNII'-%NV6_I0
M/VT5LO*"<AH:##><T6Y]63;<P<TCH-U@P[K0I#RV]_T0J>.'G.G0)26L(]5
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M1?]-^]:0T>V0P@J97O"_E$_)53=V<UK^5+Y=&EJCS=#UD<]I\&?<YE="#OW
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M1FUOMO#W[S>'NP(*4)BCK2#EW)'_.\RI;"\)V6Q7])\PY[=B6D>)O/BSCW_
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MV\>LLH]YD66AAMP"QWT/Z83 4X':UQCVUB9!TB6<K+HDSJ8#@7X;C]K.I(F
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MHE_E/I8?9BSHB9/2[5ZCH$<CNY.GU_0V:I5)*9=;G!U;::[?OLWM8-RO+RI
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MBBO@*KX-6.NF&:4?<K^%!WY/Q Y0PPKR PHNM-++7BKII(A%DC=Y5V\N:@\
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M*8&Q;">'N$V=] Z&'-Z&L[,)76V8UJK."@DO]\*-,S6I4[OND%\&&/[Q=,7
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M=&VV2^;4K0HI6_$]5T(W71:&G;BWRQ+PM>7#F&]=_._CS.3[*AL:OJZ?LD+
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MI+-/KR]?47MO7_A*KJEFT[5C66W2+EH=;+GN%OW%?#W&O*=,>4G&E9R1NKB
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M A56'YP'WJ6I^6WM3/[SE<^/U?J1I) _W9IXO\ 6E$]"UI]E!3-KYM=/&QT
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MF8K8J[B@]J(OQM'7.11E+.'8FO7YGW6Z\^IAL=#1BU%("0%BJ 6_0X#H36G
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M_@E9=^D[AMWUJ<'B79"C*@A;N1=L!ULWPRX*RX[YC[G!PE,"A%HR/F3=0.!
M *=U,S4@;7UT\%]A8QN<T[?#AAZ X9ZDP-%OUIBG_C^B1I@>, $3K$'QTS%$
M6#(YD-0@'#6^MS_[/WIA)M>'_\#+WFY*\4!Q3Y:*"Q".%")<4/E]LU,&5O#X
M[UE[?TOQ.[K^?AS& NQA3-<=C"KL8+J&7?YR,/DXY+]Z)P(X_9VU?BX75FPR
MK@!Z9\?IA$U1'YR&M1KSCT+"=U2A#E&>@C0L5<)KF*5GH*( D6>D3YZY3TE!
M@H8HZ"+_-FRYIUD6 L1Y?-!/2 >@B2Q +#Y<^. "P06;-XGO9TW4YDY@?J;\
M@ZCPO4UD8]3\=[G^MXR:;Z^ 1*KXC0+$=0!4@DF>Y32"N5QW'J8:U!ZSWL>3
M90_^#:]-_H0S8$K'B]NQ;]+E#'<PE2LC>B$YT*)5IK3X9/RSF4'*S8:7U;V_
M51[3_O F;70?4-T%1G=!/_H($*9#>0 CDE\(?&U[+[1P2G)]-<3T8)&+H#]S
MM8B\8_0J..7474,SE=#@@0(^\L9C 2)2EI,O0$PA?T+6+SN.M?'.P5%MBY8
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M'SI$W@"P 6 #P : #0#_-P.8LA8@MJX)$&$AZ#$2A65) I6J:[B6A'=V^'M
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MF^X6] Z=F=,7HYA1IAF:4.0S]?H2/IV&=/N, %IV(&:*G( 6 R#01@S)+J<
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M?A:%_>N2=-G,AX&VONR;(]/',MW3]$W]9-6*[=(Z4.,U37/A_H082+18-O^
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M16<\10,3F6LE1?[UH9/D&>X=4O%;].ATX-Q<XXE@E C"'_%S7K5M7"DN@T,
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ML'IJ'26Y^L$-^WG/8&5"]*KTYQ;N3Y"A>2&^V)E%>Y/XC!"VZLN%1&5K,9C
ML/MV,4^B&K7GGQ@T2ZX!-=S'>#;T>\9(P1B(84UV&DE3)_1I(KB'75PCIE.$
M:PS7>%7WK9E?V*6@D"4:I9\GI<31X4?J>>MZ\I\#_G;?\@X+WGU$G6'-<3&*
M*N!]\H3UG5'QT@_P7?C=A;@\AG;=4X]IM=H1_)E"'/+3^8$YU7H2/^,WQ=4K
MZ=><MLC:J(<98ZG38AFBL8"7\^>P:9EAVJC4J?R^#Y\^?C+GU#>:^$B83F9)
MQB2/O',]LE%"_FF.X(+\R!]*R]-!:*VLANNN9&I\W@0!(4S$&!KXX<80AA:B
MK98J;Q+&VJ 8+Y\V&D."]UFA7>F*"@\9GPL?'M#?[=FVY1=W9&#ERDOW0XTC
M^K<KAC1EUC1ZEAON&= <FBKY4Q!:,%]!BC$"FB=(.4;VM.:Q2%2ZU)>_"V1D
M>4>1%KQ#__S\*M!Z1@@3S> IYUW_<DHMTHDK(E !6(_N4;E*7"7!,=1UKBRS
MM*+.UB^].SOH,T%W^[*WXU:G(DG9I<S;*3C>"9-ITJWULN:QU0=W_ U)J0+6
MVTSI85.$KZOD35M.L&6MU,K*A.7XY)6R9]3O")I RQ\(UH6\J%SU>E8J7)%G
MPS[+M$V?GW0:$4CRM-GDN$8-=%C@\3C2*MZA>+%^3QQ#M<A>I68$KQS&V+V'
M(;'K[M/'QY.;A;#+*%"M_\O!V&V[*]B[J)7$KMVR79F;D><K0>(K9/EOY3@5
MAD$,T>QT6OWR)U"I4^Y. ID&NJ(I6@;3")D/-9EYT;(.S0EF>:XQWO',BS5C
M^Q[YN5]$C+(]7*_$M'D8^M3L:3(*<JQ,R"9^_Z1@PB%XSC$0N7DD_<K/)+>W
M#IV72D='PD^Z$=5J:AVL;%Z7EQI2<E:O,.^J/FO,?Z'Z+![VI0E\@'^O*IX&
MM%K_^F0>,).41Y%FKFP(8=N9A'8YG8B0'213%?QY*K_X=N^W]#N6P?2I/9.<
M%^#[^H5XI03<\>DSG(1[B/,ISL>3S!?)#GYRSBQ#'Y%MJ.,=;UHN,0I=&X>5
MPC]V>'0'9UE2=MYTS)ZP^=@Q;GB5]\>L0<O[L&NZ^ETV;6(1!4O]Z7W!CP.D
MBH=L"M4II=U2)46#P=G8H^5C3+]5])<Y9[F]VGWVTRO"]J&5YL,\NQI+I6'2
M!#N?51NQ=M\^77"XO@I;35O*UQS\('=]=&A2_<02\N%OIZ(/4/>:'A.,09 4
MVE&6$,WVZ["3/$>TT;7*A;-&9G%N;:PBQIL6_F]/[CTP'J[=[WYM!&7?.&.I
M-5PE\Z@9FQNV1LR<GT??T+[AFQ*>$/<^C)@;YO5:<\CZL%^ZQ]5K84<?)314
M&1^_;!E/#>P^B='L1I]+B3(Q5SNZ='FY5;=$;>-V:EW:#A0]R=C8,]<I91YX
M?="FZ]V9]E_CRXM.U(CHW$K)3Y]9MDW;X42MKY @OC;QMCXZ9\0;<+IUNV0P
MPMZ5K$,.$<V<%WQ<VJ*_#&-J*]?]]N*N7I5QW<)I3Y++L_BM[U-<K5[[IXQK
M=W483 ;63([4K$VN3;Z#C.'[KWT Y3_;3BG,AJ087KU]^-% ?/V+4[N>%T@?
M^KCC4,1@$P:R5KBI/MZPR5H(^X[GR*;&S/WXI 7#$/N\_GIDSWOK)D4.)N?8
MUM'+5AUAOB8!EH?-;?$/X_L*U5V>T9%I1B_0Q)V_)%VHWK0]8:.W593$ K-M
M)0H"Z$'2K)'+0TE>IY&I 6:D;#];AQ1,OHT>84;P!XWE_%F'69V\G3!0(^-*
MPZ1KJ!+4/J0O^V*D*F_L^_+B1'S2@H/QO_K+,YNR#Z)8=, !Q4 )#=^730F<
MS+Z/0P[5E&$];AEF66S97T>3_'PA?FGPX^"2<N[$TNC\=MP-K?+#MS-%Z:'Q
M[CE7DW[;+\F[Z+:RP)/@<DJ&5T/>4J\)80>7:/X#^AKA/?U18QF#!*[U2&![
MQD1RI.N\!\SH3N'U6N3#I!OFRX%68ED:P3J<PFI(*&<'V8E>6J0OS7MXZYL-
MV!9IB(IQ3SDA^T@[A+">6AL?IR*2S9!-RUD'*"@*92VW-P;B;\ /,=294A6.
M2;NH)\JPV(/G27+NU[W6.6RRQMGT(V[E958_E*E7%!,M-AWC5<E_)'\X])_>
MC/!G5X*X;9S^\V/D3\3+$#.0PWX^$[JB)83Y -5V @JQ*Y/_D?R*!NH+80)[
M;ZX8,):W*BF$D=#L>2J^^"OOM0AD9?#*&T*%,#^M613_2N]=ZJ 5M;>V%?6Q
M?I7&SZY- C:2]9=@0IBENNJSGW=^A89(S0--P@4.LL^$L/%W^/U"V+ UH^E>
M'83S?4 W)&\@$<25$>@*8<M6^&ODV/_4E=R(.\7_P3]?H_WWCH7_]ZX2^1GQ
MEP?#4?^=>T3^VR89\5D_@?B1?^S]3$*LU.&X7[9^WA78(F;2J2^D(=V'ZA#"
M*+4MM%U=08B.9!BA8_HT.,LR&CUMZVTTY CFSZ 2X=]6EZ'$EXYH&,\U1W00
M]K+=$DW4+J%-;DZ:E2_?-2_4G\N$8C9TPE;7GQT,@<8STT_[;(GM$N<>SXL#
MMJC M0#^0LSQM(_,W:577@S.D2-QW>M9(\%.?QRLN_K8+3(E*!O+-'O9=.!S
M)_ILKDK\J&+I/-&#OM@;4OVBPLTNW[-C':W[\9Q 5 6:JFUL.YZD)&>*9=C9
MTV"#Q,:$CFFQJ)P8UE7731'G88'4<GU?=K-&2I=%^K*-=?(!W#&F+86-C5K1
M6=/,KV-OC]@3!X3Z$I<R$\OX%9#4_#V/Y4(6)?3#7PB26+K0Z#4WJ FH6L3]
M9UAQS,0V?FL'G3:>W#X1GB?%LZR@UD2-NH'W+YDH?LM*%-=*F';'3&NP%7*6
MWH%GKI.%L&^I,XM4\%@UO$IGU3"?, &(X4TUF_<01K<X]4+8WJ=#US<,7K"2
M5Y4EK!EP2:^ T,H?M[Q_ X>*K$MPS//5-F<V=MNUY\J#)-RH#/)>4M8[P(BV
MI_$X>Y+S!]C!$IL1C\%2[."\,VR%KOL(O_Z("5=2\.$*EB NI+P_D+XJN_K#
M9'>]2D3CZ=#RI?KYJA)K,:1_/6;9:#[_T /YDI@R?EH*V_=Z<N+!?*MTN<2R
M*_Z]Y<B4UFGG1<;15>F-@^<#PBTMD4W2D$0.[;YU+QB>TO;#[X.W<I"/HA4+
ML+C2&L<T92K73$71.6=Q.)!,6!C-JX1LF=F.D ,NZTP.<9;8U[( -"N9X\TZ
M%D,G?Q> UO6<Q)%GQ^+Q8:PQNPSSQ);@@YLRA.W@/<9D\C[,BT;"A6&\Y<RO
M[V5E-@U_(:="*_(#8DZ9RK(3YYIBQS6$,#=FVY9 "$/,/,NK%+D/_$0##;^;
M):^064*8K)%?*V2"/M_7C(6,HM^_9(<FZS,?*G[+5FF'[W]G>:?_5D1[\XD1
M"LFQL]7B!_^[%[<(]XD6V,)%5X,7  SXL\,H];>N<[S.I069ZGM?*F%4@%Z[
MD%7N5J="1&P=[="CJ0L^&!\/YYLVQ45^#WO2/1*[?V""E871I-B[QJ.YZL03
M-MC]RG)!]YS#J@/S5M)0C BN'?"Z6_"&QO%JU@*6[C%V"F&8)2%,"CX1+K!U
MXT0+895S;(P0YL3<Z]8.6@@^Y0)CB>*"[/9<ICP@KBV$*4)&;_GD'F2JV[ZD
MU?$!J KF?>HEX*&B?.7P,5"?ZR?HI%8M=-X3=ZEOJAONRV)C7$!#UB82'*.'
M-_QV7<OQ=VI\X_EFG3>W-W(YJB:G&0G68IY$P>_UM56"(<A7)^U =68,U1]X
M2VX7PKYI/@V6]YN!^5PQG(Q&CG6'W%R/,CF6Z@M)B\6SB#VX98=A[?*%EX_M
M0<R>O+ 9FMP/U?&C_>>J68HO-C,F,F(W3MX6PDJ(_/L\")VV04CTX'M!%[4*
M%0M40A_(> M:@4J[1($8V.;!]:]DB7<F[Q;T^4C%M!!4Z^X9:62]7:^;'0E!
M[02S)ST"9.V@P%<2%ZUAK,:\6OL=KX-:3= 1])OJ@D]G+)79;JTTA98KL[3[
M5!F\;K#4A $5[:?_3G  3(!4Q*CAOH2R$V.9@7UQ#(43+O&^X9@$-9;)V\EW
M;<\-X>_?OLL_X.+8>^)ZJWWTX7)T:1#942I(U.>3RPMV2<SS+*"YJ,SRV&)^
M?\DJ#JL0TV4?8RJN$)60=G15,=16HL2FZ7&4FUPU[:-E2^ Q0C+0XH0(1,0B
M6&Y84+6SC)$7G:G80/97/,+&Q@!^Y'%=^O#V.Z/ZB!UYDJ_I0ABL !GXH<I3
M7 ;OPC:M-4P(L5&WW_.H#"29Z&TE\<OC @&=AT"+/?6*,>*M)*=0"(M&>?:O
M(O:"\)G^5TE.#)GBC!-3R"6X)-Z/5=7FHP-&:/\Z:*U^+"Z0D>3G,%1]-/)\
MC'EE1?J%WN%:"4N^..141 3+)JSY$,^!+<*3BF'<^44\@K G0/$HB.&:>DSU
MA-W8ZNJX9]?V!BTXR::]W17D&7!7-@)_@)&5M^M#K1-E+0N1:'*FU-OCN>(A
MUK<VZ,\D*%(W!;HO$R#4?QO'@O22\T+$\KN>8*_3ILJ%K767$V_Q,I3+5E.]
M/U<$D1X0=]ZP9MQ6[:U_3%AG2R^5E >$XO<_5_#PU>T['M@CF=S5]HB"<;A)
M5K/4J2RU53,W-L\Y>6M10V>1)MC%A\@0C;\)B;%Y, ,B43'.-?)2Z?_ .;YN
M,N\ Q(>J@R"T!GZ];!VHT[(KO3Y0Y"]B#LV1YQ50ES4)D>L#+&_GZ-I/8!4[
MIJW&#54-Q*TO9V5=F0$>-!^NSKS0? #9'\#2!1,8&UGGFU4?6LY55X%NQY[F
MHQ8SEMER?=QSO.23K]D>3(7YL!O2I@%O/QM1 G&76.PD1&!L2>DFNN-#EM>G
MFT39_I-$SDO-D(,-,3=_+>V?BI93W]M4Z)I_ZST1?NKT5)ZF<\%Z B)/!]3N
MXDE_UTZ#B&I""(,03X3P3=-"'-7/+C)7\R48SC7^D+D[]ZGT9J<.'-?-O?"&
M@HIS,PK9R,TIF4+AH-4;PAM#:'EAF)2V;K?[[.,)3W1];0+/,>/+"\-M0=!X
M ]Y"P]<UV<W=P3,8&T4W&^$=015&?SQ0K36<F9M3YK&8MW=#9^^B'(ZE$L.\
M72QHTXDQ^8:(-'OF^<YS:NG%TL0R+J%=)C.[GE#EB_'C0@)M>P70HCS+UBZE
MLARI$R*M6A ?<)>;X!Q[UEC<[4#39=M1WAE?D_3<P^"<E%QBJ*0X>#Y$WJ/Q
M%(MI_W!:)J%] !?1?L>I(XS.W[[12/NGJ/F5GP2L1(%,""_!LO5LJF'K)5R6
MZ@PO<Z"GLG1_1U(V$KLO\:',\VP5U7%;YR6KD* ]TQSM6ZX)^7X?7V9+!XS;
M&IIT33$JTE3#=U!\;2-(-FKFVFOJ#E92:>O/'C<LU&T:\@XT"&''1K@0X(W?
M8HD+GAA*;Z!X"GGL!'LP3 C[OF6 H(!V,S<$/W,M>'HLPUBM[[S-M?%*= 4E
M2%G)E/OZ/92EI'KBNEZ9;H-?J<N4?43T; A)?6L]QRN!9N6&$/::0A@'.%Z-
MD.@KWMUA RWG+Y->ABL=W(/36HV]:)&N9'E/N]L5%P+I+^M!O"^E-OUFD>I\
M77S?1VM<3N1C95)/Y_,75DZSRX-16.E9T0)&E>9I%V#A:88CV6:K-)4QEGGZ
MI:TSJ-]MW*@YL\JC!#D2$;ST0(32YR*(+$--O_-'P8$9R($K1W,8.&+>6="C
M%,R8_>/-9);^(PHMTO3@L(G+C)H'4RSJ03_C-#52ISR*0AEY7S-:=>:&)M*I
M#$U;2F+#7RG*@!6L3UU4,9/@HG,DG H#%6'B,".^WW_S^)G3S20Z]H!_Z+0"
M>_MO)H;V[R9Z=PL>EWA/]$CW-K(NI%3:[*I(AWS.@ ;JC<Y/BX/J.2M.[\[M
MJLVK$NG@8D[.I9]\7__2&Z"/S'I.*KU SWM:>Y85Q1_Z*!:.B>N.??HH@W\<
M\[CCH)E?^TN<FM7Q-M^W?N:]Y1Y6E+N5)8J#M^9LK5%37=Z[7Y[-1E26UCP.
M"7)Q7B/?+AF,3U@CW4,T<O,8&NP8^M1"*SP!D&J6#)#-FS 4PL0$2C@:?8KS
ME(-[+J"%S>1)!A#DZAJY1V4GL@VH 5D7PP3]>PJ+S;8+8>K&R]4.)GG+&EQ#
M7#X#L4J!;.,J>*\$=TP(:T.*=V*3A; 76K0(O=V>/L,F=KXSJSH,01,+X\#Z
M7JZSJ@2)7)K^X05KA)J\=TDN:31O3Q/9??&RW]":/O?WGQJ:A3#M/% U@R/.
M,Q'C?!#"(MT$9LG@=>P$5K"O'X00\1=QGC957@B#@J#?+03'X!_%N8@OUTM!
M2]P_QN1U"V%V6/ 0E=//,Y+E[!=,"V')3-!%+N,1I"CR/D+]CQ3".A&LAT!7
MWAKPWD?0 P'C(@#%(X(<3OQ6GD31W",6Y_*PS['<$XFS_=)-U^7)#D;A)^M3
MU3YU^1;<S47L-!^/]HVRX:I=6C(;9ZXL=V8C,T+D4JH^U?%*"% ,QO+?7&VB
MPY,1WS>ZL6L9P,HE!BU"<3]8QYIL1\B:J#W!;<X:E)!Q6?3HA%DM64?V9DRU
MC6$[O"HWZ\F243.%;AWH:3-T/:3)O.U"0V-=-,VQB5*5@IX5PLZJ:WQ^!8$6
M'6@)$\A_N:NE49;$V\G/P9^C(^+@-6-QU\OUYH8"M:MI$CB <ZNJH<:Q60?,
MN;(KPY4\6U13%[T)?7U7B+/'VOF:7$UV6BI!PLC\\2S0%W12<'BVL>V[R.S#
M<>V.+H?-' I7_-\07>U#RL:"YA/5NE+VA"C6)%Z25CMIQK?1-/!H>WG=S+_;
MN<2FTRE$I=\HY4& U"+13\VX)UVL#'MABLP !'M$A_&BI4#+92"0FQ>CZV%'
M!QM#9P*-[>^9&A?/H!2@Q=TN.(A&2#U]A)4XE;1:VSZI(SNYY'@DRR-D?WEA
M19AF[K2%@$&=&:/NPM6V45D7L!%C/BH5S2\JV&[M>4D^*JS+-"^+P_6LU.G3
MP[=Q3)+6]Q][B>Y38(PY6RI]=--^_#7.$./*LKY4.DZ;!F (EBT<5*F%8C=0
M';MJ5XC78!DM#_D_7AY5U. _;39<>AWTW)VGSS(G/Z]N5F(_;"H)D'PRQL.6
MWR\E1^!U@XJ+RF8!2<UGF#(%N9[VW",#B-'-&;<6; Q$T,DM>5&T;PC2:/A;
M8$_S7IQL&TJ\$4XT-M.:^-"\?W"UN@'3Y+JF&BB$56],V:VLEH 1'IG*#:.4
MAAX^<J.@L2G7@IN\+^BE%U7I]4N?G)"X#OJE!VEA37ZV#\5$-?5/C5@V6[TL
ML9XPUWI=&O08K3:4V@Q$?7!MG]^_,NT\I2Z=>]C)4\V9[.&2>HG8M-/R5LWS
MNFS'!D?KD>)G\;RKW!=?^P#,_\;#,M04)FB<P*FM!*]P9?!Z_)3JT]<Z\)>X
MMKP++]@B";<=]#ZA=%K%(T)=?51S&8R)T?,/6T(0\;=XIP*/++M>JQW.9S'C
M#@VND&]4]TRNBF\-D#]^N8MA\;]0]Z913:71VF"J' $1$1 !(64I(B!$91Y3
M2@$" C(+$2(B8H@8$9 @@5/*/*:*L61* 4)DB!&9E"DRER BLP0A4P$R2:(0
MCF3J<._JU:O7K?OUUW_ZKOZ17QE.LM_]/OMY<O;S;N''N;V":H#^ GJX#47J
ML3S!WP5*,8=W"X>W[V8S2+=6G I["0=C95;N4WH$VK]R?D$=CQ<#Y,$:CA-2
M!IMODZ#?.]88 W,;([A9*_<1MV)5YYW/,;6,4[K<2G/=\OP-Y-NWQZF91PIR
M"M)OK;SUP.O951_VPO=T1*9P"!Z#&O;G7:K2L[JMFS:(.FB[IX6A[F/QM<7M
M92.K(DCS,&BDR+7-YUX1?]-K.-574QLNY7PK0=FF=  W@_,NS"I&E1W7CPKP
M9S-'63PG8]VU'KC$ALRN.>?*_A"4?T#MLL\8M3="9V*27 V<H;&]AW;UP-F7
MAD&Q$'L$#R$\;K'N*"S#.4V$PZADIU&2[N:3.P:^0,_6P_5'(@@*+A&L9_<,
MM9U$X!P1F/LS88>N^HC%WK0=$>>9VO<^6L>D\-<Q^*\A</I73/QV3 4I(8DO
M)\;A!YZ&GFRJM[</#LN>;:RHJ&A 2[>32&UPR7_IKQ-+XDXTG-X$2(B+."!M
MN1^,M!?DX[S9:":T$ZJ*S?;YP ^LX;N.F*,JKX%Z_:9[VO$9YF>I!H3?VBQB
M%(3$Y]@@AK &557Y0D>'M"'%0Q2?YZ)Y9B2C56- G?EGJ*71V:&O3_IA[UF9
MW0OW\F#[/(O.@A6:8W'QY\X7,>Q=B!?N]P[H!^HWA,!E]/K_^3IP%KQSQ/!\
M;^"ZC)N$NDV;NE;.M0 33?LLES G#]7Y( .5Y6SDTAB=I@ABF#+QYMHLVM[E
M%^B.0QQ*X@9<$?2ZUFC';)K$&3%]ST]Y?]A$8+^4-K=D2MM>;F]L3=&]_C@\
M,]"[-/.7ORG#4+ZJF)Z?SN5$"O*='U.VH\;%X>6KR/)N#_-V^@Z-^'!V:\_V
M;RU@&@^*_L"7HF2BTU9J9H83SRT94OL[AX*]==,_= :&,)8,8$D^(1GM8S$%
M,HEDC8^K=[Z<.6P/94<X\\N\>FE<7TNQ4E]:=",G#+Q<?NU\+/![!/H;0^^=
MQ<FY;Y4UG:-5%0TU=EUE(RCU,LLDE91,O:0ZXV<^$U^WLU$A2J8A3FHO"G*@
M!4&R8G3/%4$&SC2N\TPI:<!V,DZ;O#1'^1,/ZI.%+H%D8'J"CQ!!QJT8OH#3
M9F\?]*M[$(%[EOR]G'A2!/G#"2F"7&^@;&3S1^'T5MK7%YO-.PU1=4AA.?*
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MB7+_3>/+"WD7BKWZ:R^'>E0[2!^X"YT>>]PMN"_ME%OD<R^]:.VIYGB&S]N
MP@\D!X/N!8,7>N]>Z+/GWHX0]WBZ:X6];>GH\G)[6/ET@E+@<B\.'D.A5T/9
M&,7_J!+(E] ^?#*\/JC30H,;"RZQHQE)Z<*?L2J>8-0S,(O6+=0B=!:X"[7:
MV?GIN!-GJ(*\^H/M1)31MDW^,]3#"&)RPZRGL(]IQFN5BFHHI(CU9YQCAT'L
MZ"'^Z9U6Q9M(?,D1D%P&(A@Z8A7X,VY?(=,HH<WWZ0Q*38V3VT>IQ%FS;9(
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M8<#92S/:F'AJ^[5!Y$(794@$$4H.BW_7+X(FRO5U*K$/VA2YJL @I*AI@2H
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M(WJ$*2-SH0JQY'5OI4"F9T7GQCLKM1KL2RF5&<_7J5Z-KZ+N++QN(FS[B$,
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M.H,M )!1RSVU.K3&<(L,8Q["YU/;6])Z1-TD^Q5^\X\;@APA25"\VMZ8K]'
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M7QA?:B][5MYRM'+^77T5NKAS7W7O1Z#3VMR,=TPX0SML*2N<I!TV]Z8C]^
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MBW@#9X\"*KB(>:O(VJ42I9=@#1V>W 'Y8 Z/9IZNK3W#:B]$@L4HM>+0R)!
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M27:2_</"_J2K ;43:1;^X^&':VY9%^8$'$X/J+N1-E0[&:_6:.*J_<YT#S$
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MSVB9-!;R-]<WNN9UB-#!>V"/5?K4D=DTD;%#;:.H&3WUG%%CWJ;_,8LG*2Q
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M<./;9;".V1BFLYPTX RES7'T*,7SPR8I)<\7/DAZJLCU&.I#^A2!(H-GU#1
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MKU^&(EO3WJ$H+.5\PR-6U*9CN[-#T6A$9#27LBL6"#\ _#OTBG%&9&%YAI#
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M;8=:_?W;0K0'V!51WQ&861/Y'TYMKPE2(D$5MZC[BEG;9$XY!58W$Q*0;7J
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MJYHV4'M@[6%6HD2G=N4@0+T!#19SEGN2]-[VNX9%G^]M4'T2;'L]O\PZ]V)
M<55Q3)C5U*M7E:R#WW7>M_^)::Z>'2[ZE0W&Z;;=$FWSE%WM::<;1N%4@>#0
ML7)_WQ4_62]70]--!E.^$^F"N6)JV$*6+F:4>\ZMWMNGLR#Q%1)G:O :-LEO
M]2D%#<<'"2/YTHR!L,4NTV8VZP%=M2#K0EW_P@R@?EC8DP)HR'UE&C/7]1SS
M#6Z\\HW;<ZMEW$12,O Y/M*E1A+%2[*8JU38G7_/S)*)_W,WO)F'S'GB08Q<
MBP.K%LJ<X?=Z?@,@Q67 'J'.E$UW>]QJ^ZPV26X):W):_+6'%V0RHF^F,]7
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M6.:[@OI)YOIB'$+#5QB7)%UXC-:.3V6O$"Z)NU#Z4$%39$D\A;@5PG4(NH=
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M<=V['5:UW;^/LL[@:A7BABC2UFADRA<,VESVT;RN<K2O5#U]RO%Q?6W=LW0
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M#6"/2%!#>=P0N@05CW^"G\X0GA"=@9+8N)\.<3 KH!0K\1VR9EY3+G1IJ,4
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M]BSP0)Q&/BC@4EH[I#P7B#(0#0IK2LV]W;/?0/NIO]5E"_3Z(0 FPSZM=5_
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MK#^PR'.0;CE!8+<#CW*T4$0Y2XWOZY:N@CVQN^0%*_;T])!U]D9K4S0W2N;
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M&A@V-E'=/TXK ]UD6G:],O^*FLO7+C+G<%[J*0)U]L63SVQE&GY?#._M[ U
MHSKTF=6-A\>/JPG\.<[*B,^@W5RV5\9;/6D\0,@?SV"617,6)C^Q!YENLEB
MBN+G<:=L>01O;J4KY/GLCO&CTG\]<SDAVR&L^NP;\58YGIQS?3)RIR]Z4-$.
MSQG$?S\"*)Z^6D8,/S/&H3X^?2ENQYEK520/V,TS-VKORK,?.ZJK?YTSA^;@
MO'6 9K3OSSS[K1R-9I=@]V=7XP +EV%[LC$@9JIH S@#OV'3NGV"VQU9-"4P
M!0T/^_HP708( >+&BF& ))_3*Y>@0D<-/J)OFU!N7+79",:,M17;:FOQ6=A
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M&[61V;; XB'8R)^KV*A]L(L'):07\!Z4D(>GA'A%<1%U"2T]XHQQ)%T@2-E
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M7V@.)#X@9>^0\J%#<V@+W\NPDL6N[W_*?.KW/K0:'7CT/>$J X^^O] <2'Q
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M Y$F8!1@U"6,DA1[0H5&1+J88^.$D271(..%-U1$9CCK(C:^1XP2%(ZXZ&\
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MB/6;.'];?.>OQ7->)#5U:#[9,!N\S6SH=8D-/NK_HOO#HC4 A0"%?=9:@$*
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M=E^]-I"'FPG395N+\\T[1^)L4=6SR3A4:WWJB;@'2"]N*%L(V.Y!V=NB5LQ
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M%X1A#$62*.**!Z1S^(B,U=Q%RPB6KHL*M+L$1C8R6 $P]@88[Z6MT9V>,S;
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MRKUCYG"MB7EW,H^Q^BW_?5)7SS-##^=;?N]6T;OHJ'9ODW0_)[,,&A<.>]H
M#^Z@Q2C@0>=X0#$5X/?!@8 # 0=R4P=RHS8QX$#ND#@VN;6OG^G7<^9X#VN0
MMVLSS<)"LWA3I?GLM)J=Q;E=E *!4J?S<;P8QQL=W#=\N0\<)7I<1'<HS 6D
M"28.)G[02GGHTKP!4[NO%IC]=R>W<IAR#VKV^R+?P]AHTA=I#GD728]]=:=.
MX,H]DW>PZ\1K9X-R& 4M/>)12F2C\$AY(50RD7+J=[K9."'S10)I+!/BA"BD
M+<%(<8&38UPPK2[O.GDSG^7A_".[N:YW1U(V8ESW;]?)T*U_8/L> 8\&(TW
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M@[-Y_7^R]:4XG^>@LSE5M3'3NOKYT;-G;]\_@BH&H!,]]E0]4,0#I!/W5;R
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MD(RFR'. &[A"'&>BHIVDF:W$2!(5E-N=HO]NHMQU)<7*]W4;UD),"S$MP-)
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MWQIOM:[C>-/ZJE?E'5@\!8,=B.@ .4 1'S!RJ,2"E9(@I@5!G"N)=&0!E3B
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MPA9GW&(L!][&$\24B$(H9BW?245C&5E&!)UC^Y0#?)R1TD@3\C74!LFQH"7
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MF8\QY,!R/CN]L-PX.VO:6Y637O-]FUBTQ)JS''W.*[^<S_,-*EO7$58D@3(
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MWF=[V9@<:<%^NC F?%<KZIW6G[Q:UQ%=HWIHU!8?W-SR[GK&#@DOKB?5Z>Q
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M,>71  SA1" D+&A/:0(8P\"0F(Q)HA&CUKG@5@Q0Z2*U6FN@"9Z (:9!.4Y
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M,@N6(P%<$<6#Q])YM /\*G'7 F@%T J@%4 K@-;Z4"LV6$>C(6#G@6&-0=M
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M3C:-T90KC(V.O/A0"\JUS4!IQZ8N2%:0K"#9]I%,2!.Y$ 1XI#2ADN!@M6%
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M2.DYTYQ+PLVN4D#VDI5FB7#77&7[41&)G(G6L[3<"I/$,;F#6Y*]@+4,*HJ
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MI!MJ C/+\9&:P*+/KKG33E6#1;<'/E&<_K#T0*AM.53W6N])@D6;A7+1$@Z
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MB.JZF2-T*;(+L69LDBK3E^.ZU'4OT_H\S8W0-&)V736CD>#W6HTV:A_/X +
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MMQ(9K*,EO$G#"-TCU7B$$-W$].8ZRBA9I).R=F*AQJO/IC*/#?0^@P/.T,0
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MMP9<7 Y>"S)O+P[>9J<Z$_73.K3N7VO*TACM@V8QC42( S$*A,>%ZX*"IV&
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M1<[3&)#J!'?M!I&3A )GN<#:1PDG40*NDYTXH P#SX^28"@&QK3$3 X*7(?
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MGHAZ;)QV$?BV:FYN?C5[!2N9OLSGS]G&*(</HL+T(\\$1]5R S"T8HN2('%
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MG82!S8@;@K7CF'!VX%HV 3/(#>,P%F#1#&GBF37T832#>IBUDW'2E<$X*[-
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MZ/O^5E25D93%Q"BF @6RR'4&6=L:CTUS;6L<N*WQHEV1?3O;S+-")W8(#Y.
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M<9@5@$%GA6"F>;;#PR#DIO@G?;;YCL-1E>K>%.Y]T^WNHU5;.LXIW#94<NR
MN8E)A)UXQ/&H("'W NP('(5"1)%#DUV8Q5]G427^/</I3A?PH_H&E_LE*_CW
M9X8 ")C"H74Y:WHWP4J)^+2^Z_/]TWHFW]#@&:L /H#,$Y*E54U$)G"@E"3U
M5)3=-(8XK:89NSY),G'57V\/EN!?LZI.D^N6G/(84M6LK%_)M25X^>HD8I7(
M4ER$)2Z8+XHS=NTV&'3_L,VEBJ1%118O1Y2VY9KF 7OAM^]"3.%9LU<MA=(<
M7Y)(0MU F6=_L>QQRW"X%"W/R_M8IOE\Z8H#HL*B['S]_9>O;__O[V\_?C/>
M_@$_OW9BI&!J$3KZ@3ZDIOW\AFB?=\M#/E"\;]<4^I0;I],RS0PK&!G4I*[Q
MHCX7QG__5T"I^>IMD@B.F^J,-ZP6\D/KU<N1@8?\4I1E<2G*:F1(XTW$1IK7
MA?SN75I6M7$*XAJCR!K-Q[\5\,*G9Z60@FQ<IO6Y\7?ZUS^,%ZPR&!X-%XFN
MUUU"W;-YK-/FT,7KM8\W[F/EDU[<;T"R];0RIF5QD<8"#;(1D+[(SYK"KOH<
M+EN=&"_2EP:<P<[@E#-8?#@CS7DZQ8%CDV(&ER@2 Y9]8F1PY6J!;>8+_PT/
MP%M7[>K@:;,I<L1/ZVSE'Z##/KH_N;;P31:3V*<65IY8)!2N2_S$$2[W(TNL
M=BBDENUYEA_ .=A0.6(!B0([($$4>V#>6H''^;)"_0U ]%/R&F0HK3=:U=Z"
M5>W>MG&5@OFYT98> G<:<'X&#S4RAO14\%L%UD:* I$8+TY!"HP<KR- .=9*
M>!0V?2M9SH'I.QZ7,!:+!!83L1 1:TAO9BP8]VLM=/D3K/R^UO^/1,VK$_I*
MF@AQ6@K)2V"&9[-)_FK!_%KVG,8N.$#X0$WJ4'VPUO8 R'@U+:I47KL4F=S,
M#7[7%1("7ZYSP:[NZ%+=:H3? ./S@,00EL[R%]:N7:7S+C/;O$ECX$DS[H3-
MZN+5XA= 8_7QE)T)9242EL"+GK#LDEU7KY[]O+S\BXXUKMZ<(586=K?KMU>'
M;7>+M28,VA>KQJ^9,#B].4G^"W_WG)J6R.X:FCY;L,I_X!V>;7*_[^R8W6'5
MCL1V:NVF(2'XH@TG3:D#,*),'B=N @91&%B,."P1A 5A#'^Z7A*SR(GL%2,J
MMKPP# -&0K# B!.;)AA1G!/FA0DS1>AYYDIL\@&,*(<>C T%]^3GQB58(,E,
M,FXA#1!CT84#6]^8%J5<';3?S]&N+[@0<85_SR\RJS9= DWW$HT<L'X$FCG)
M+ .? /XW-_:-8E:#$LI1<QCX..4:_V\D)Q?#U:;LVD@$4 #_;L<.X)7A/7-E
M;"A?L=[LS\A+P=?MDS7V&WXDKAI[;NZMC(P7O[PTJBZ,9=3*EI-$6.>]P&/6
M@%'X-H?BNY@\#$TK\HGI49<X@>.3P'<28@&BFSPR34JC9;'C(3@ZOL6)'8"7
MXUBN21@-/ +N3.3Y0B2^Y^U![&AP,&('//0O8-$VPE%P/BM+@9(!G,1%B6K=
MJ.%&!&.,,6C_-,>$@V18\*QGH-.+\AHO" X&W%-)P8O7ROL&VPM?'HYO.'0C
M@QZ26QW'U(ICGY/8-7TP-Y@@@: .$0ZE=A+[CBO\9=9TS-"Q'9.1)#(Y<1P[
M)D$2V,1F/J@1S@+7W =KNH?B50,W-/#]NIC <UUC ,;R7U7 =8!Y5;W NZ6X
M2.%F3>SM-X38LNJS<)HKLN"597N?WI4EQX(;R$LAF178F4TQP 1LNWA%P-TT
M?=D*"RRN@N[K#2S=!*28>H\[>. @/*4P)BP61CPK)>;#UQ+W&V6P7GV@6L0>
M8I,9*(CTW[,4&.8:&/!"@"Z!;R,!)FLN=8IZ%L'*+,6'*Y3(RUC!U4OC;[/L
MVK!D)-4S7BAU.@'U%C5OB[>&<WJ'^4O4Z-/U',.B_#P5%X@<S4J@>B]96N'3
MS%'CI8*-ZY?R C'J:=2:\@':,^^"/4"^O*B[N[9V14L*HSI'30^O<\G2"Q7F
MP">=BC(M8CA8P 76,1U8_=]%;7 V35&1_D=QDKA2IL<!8)8;VK[G"$IL,P',
M$GY"P KUB AC!MX3=:)P)</NL=CR&1SD"W2K(B\BH0,G!@QCH4'DVDFXT C^
M=4/FKTCE7\0_)(W?2$[^( GX>H%^;Q7Y=@9MAX)M$D8P/HVO5PI0K$VX#3,0
MP($ #25* *!0!@R/.7H0,F3<M3@S-U W&)>-A,+?<-5.UH?/LY$;44[CB%#;
MQ:RZPP@SN2"<V4$24W"K8F_%\[*I&9L>N&><@IX%;0L^F!N0!*YA)5;, Q8O
MZ]DW(JK?YU5=SI!<[YLU^ +$ZER'SZ+$D!H[6]Q',IV5HF-70OO\ZMS:F7%,
MW4&SZ_,%3*YF4@F]8.K/SR5<U_@BV11U,GIE"D\Q:_,/9-:O-3!@;?RMF,F!
M;--L5ADOHD-@/.;%9L#-$.PT$> /AP3@=Q#P/,+(!<:C/+P/6*YGO%]8E59?
MX258_"G_@Y4I2CY2V-H5S]&Q/W26 TT,; =/KMSK%^D%XB0<<0'V%ZZ0K$TR
MF+(T1-;XUXUYU%I^3)EEZ+@ 1;*LN&R-J:5@ -YC"KJ_;$%21@. G=FUA,Z^
MV;7J4S?/51^.ZV*9H0 O!!C4Q^ZV-J.$\0A^.+9P7;!U;'>%LWW+L424N(0&
M/ $8=FW", KFB"BVW(!&%HY8O8FS7RLRI<#/OXA<)"E/6?:Z6]-WH)<D4^_$
M#O /Q IH>:L?:UK+9UU9PK)1RHO)!*X#-BWHJPT9[#F5C:_RN'D5! A)3ZY
M"CA<!5R2,WP2Z20= $-3FC#AFRX!9SI"7]PD4<Q\(N!S'U$WBE:V4MS?1N@Q
M])S GY&"BUC]>Q5+JG>L;/99F=X6OAV;FULM#(*5$:TW\]J!8&)@<D9=*R;
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M4$%"I5S1ED=?=]#\N@_-<R4ZE[.-J(LL?RFP.KEJKWGKE1I(WX@88^,T:[=
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MVP)(U;(82!GK+;986$T\8?/2Q[.216F&Z4UXDB8I K]'('47DMR*1')I+'H
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M@".\;*!8YLM64++TNU G+%IBRK%HX* 5\$Y#[\]2,;2EHBR59B$WVPDU1E*
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M1+"^IYK(C!MN_5C->)Q^[64\\$;*OJJN<[@6Z%-C4F2"S[(F%2-K!H%PRV2
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M1R[BAB1U [KN0JX>(JMT@8VFT\0!M4*ZA4_1=-:L&VZ-&<""(:D)T$4(P$.
MTF1:\YIG&(434BV>$ D^BQ3F0& E/RX?Q%8"Y(RHC=.)U&V?0ICUZ0AT'B+L
MAO4UB52C,X3;)'(!YRZ ]8B37AU"(P*UI4BFTS"*J3GA>/"Z-_2<Y>B=.8!P
M"+WC#/T$77D@.!O"Y$8U"RB5#.&9)**/>0 O8G@8T7KZ#0 1YJ,74$1/RK.
MCG&D-V%TA7VH>31>*!CX! 7Q*CWHWQ6/HV&/@(V(S26+P^+YH4 XC&OJ,#$&
M;HN'?G@C),/G1$$498?>N $\  P)4A"AZ1V%V.(P-;E@FBD.A-R,X_$"M-#
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MFS6@B570BJ03[]"$,"#Z^1JX$R& (T>\H/2^J4>^Z4>JIOT,JSY._2TLJ +
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M%=(W6!TD$I'M'%RQ"=X":61+D>PK,!J\P4;$K20'1^_ 8'K"281( ]P!\V<
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M=G>?']#3=M=5GQ[,; WK9\IL)U/:*PA<D$WKB=0*=3*-FGW8+ 'M1#D283T
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MO@CVM1 3+:BQS+>N+=DZG%Y:0Z<F5;#HNS)^A7'7J^.N]XV[OBMBM3U'6Z8
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MN[/[:&6'M$3U][?:=K/3ZQZWNLUVK]^Q#^-)JVNWCIIMU[Y$I%C?_(X'+Q(
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MO;;E!96[$]$A(3$FE V*%2/Q82$V+G3"4O%*):JO:W%@C>HNV\^.;[>LF J
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MLX+[!):,Q9"&;Q2.M&8AMK%8*N=+8S2DPXL3B4T*J%<&T-DI2EEXQ:AI3VZ
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M"X'(TF+8_R'D."@[(QP>2?6?&L\@K2S&,UVB&/L/(7,/NELJ%.!*1.$G,B[
M*+\+8^P$8&G5F2.[D-!]/LL=L-CGL7$#W>W=:7W %RW8)BTOC6KC^9[OQ%NE
MXU)+?\CJY\=LS 3^S:LX>O(]R">Z2\" 8CAY4!;#$'+\UKA_#T)VH,7HM<(J
MLI@NCIKU<Q$Y(>U5X#%[LDJBTC.:QW#FQTD*VRG9J&B[E*@)!Z+A:>VZ8>X8
M!1^R?ECU#X\78>-V"CFXF:%R&:7=ZQ.ZOJW[@Z6;(+O7R=QM@0@Y7T$@MO*K
MZ_#:B D,Y<ZO;<=;\SOC'=6Y 37#+U<].D7 #++9UIE\S2^-VQ.)!_K+R2XU
MPK2\-&:Q.#&;H<T4^^]YR!,N$MZYI#8SINV],8H)^7_@4SUL*R?,/3N%]"JX
MXNT:4NW\NN6H*C.[3D,/0$,:(JKYYZ9F<V>EZ-)4WLW6KB*@.R6:6PKM7;];
M']]7D-I*PT0O;1,7HPI05"B)*:7[='EC"CE_MU%-P^;JLL-KS/R8 D.';04*
M[$U3#H)QMB.77W_&Z6/D9=<9Z#\8)X_^NK:'X>[OCYH*E]5_R52US&')/KHZ
M+W'GUS5_M&I_5Z46A#D*;J,C_#,.H"(V*IUX.[\^)K[!3F:M?HNVUDW!3])V
M#)FZ1W4O!P7=*H-]%\".(>]O)AJ;B53X6@#C(>0L&7>WL4-7['9U'Q4/J?+?
M1UO#:D/T!M=OZ;%QJTIR9GM3V4C^P?$NC@K(=G691  W][KK8\>WIQ45Z="G
MI^VUB:63L?V%YAO#X41T3CMA-F8I]Z$TO;3[S(*@@>4F8Z/;^V-FK);;Q=S<
M-6:U-+\SWB+-@G!5J/3GH1+WK5N=NY 8O5*@I1!@Q/WO$;*_I%>/EE_1TA&R
M2\M?W<"N!A&SN[4'IRC V-=G5PZ@.-Z"Q $A]_ )D^N3 W49<V]%CB=PJL$6
MQU.\DVYX;#V)32"]K!/<[3P((M&"HPAH2ZO>NF>:Z>8WGF.18IN '<^[T-<Z
M$,L/3B97$C*+&@SIVL<G9NOH[)0\?WB(\0/9H:Q4S/0?SWB.!*55!!S)8$<I
MS;PR&$1:+I#E;D$F%T/FK&_JJ8?VUP=@KF;BUGD'K? >3;5WX#,Y35)_1::_
M3@>%AR96"-O-E.CV[MBW9[HH+KJE$A:>-10E:]9NXZ.3.8[I??-+1'8XFMNQ
M4_5"];O[=U WH9IGXH%K[S.QL%>;8FK=" ,8-U\%:MO\M*%90_&IKVM-G/@0
MEP^]ZW(Z@CV^EF$Q3E]<>N6&CM,5WOK*Q\:O;E1"2;UK#C- DNYECL;XCO?=
MLZMD^" <"W5??NFYR1QUUW[R^UF,L>A=2??37<Z[!@+C0VBHED]3C4+M\P:S
M?^6%,M\5OEL.<//+X^\Q"A!BYS;RE>_LWR$YC6YD^]9S+ OV\,^/A11D[DEM
M06/K>U.IAF_<5:N?M=H;\K/S E9T;6O(_-\GF\[;,XUWS&6R7K."*2< ;\-9
M$#TKX.5MB$\=WQZS,(%5RRHST+V';]>WQP0"7^%6HZGXE,4J0.%LJ0-,[4%@
M/+]N(768XTC7>6)KGK9:-G'Z0J/A-.^U$B"D\5&M0W5Y93<;K_A7-FCQF]_N
M;DX*@\S]:0I;?_LN/PE\)(:%P>H+:PV8ZJ?'M^&5FUZVY_[L$],Q=A^;:^-V
MHS%R;ZN6_-O<,U.KGZDH-=^M?J:*@($:[*;"XL'US3J_V%+7E [?;<4[4\-/
M9[>BGMCPQ9<UKX]J;$?J3PJ=H!H7<H<7]\^#0/_G"_LLV0PTMAO3Q4*W40JN
M6^^S'Q N4<B&T!D%H?O+FD==ESK683EV?=6J_7E&5!@?DYO'0Q07[\9U3XV>
MLUF!SMQ>?-F3B.;U4]LA]SR$EKAGT::]+6YE]8H>PF/G*^S2X2O_["[E #O1
M'=.D8_UH(6M*9ES=1HIEP5U4S??<W>E8VH&XT9PUA*ZO5J]]U'21FPPH5GUS
M#4\;RIYI]-),R!.CI\^IB$O(FZ'9MJH5[ P6L-+42%%SR&)W_(NDYC0'\9C3
M/R7S!]C5:7)( A>)BBP* PSVSS3F\ZG4>UE)#Z[G-Y&RJS/<C-%0][3N;:RZ
MWU]3HS_(^W K=[N^M*Q<3P$PKM?UM/BBU=O -7Z@UY(PK4E9JGQL/ N)SSEK
MZ@N[&6_D6^ODJG]AK^J\3ITXV-+2K/HRO.%T)U#VU+HQ)W4[<\>NT /I3V1[
M_PQN14"9JT^N;'C!;L!KA>,'J,&+H^?T$;3NA/6.A^JGQP3GJ/YP#C]\_.O'
M[QMCO-W>U7PXW27>#K@=#4^/A^)9?<PS&[;%3NA'8_^LWAU2X5F2SHBY^'P
M(R9D9"@OPO<E+T9IO=NP_3W-GZY"6BQ80":2Z0I5'W#K.^-'C6E2<'(!!N_'
MQOVRZ8U1C]W.$,(U#T]LZ;-=\(Y<F6()' (I<)5[ 444V>D+Z4%^NAMPK378
M)9TVUT:C[PZL<03C65$L_L"! XI!F#KSJ?DE2V&^#M?ZKJ^.GW&IX/75US[4
M/;VWKF7%WBM\'A(X_3@*Z5:]<0*()A>!C,<<R61R*[M52;>]-5XHN1D"IM$R
MZ?:N=C>CRT*9)WB)XQAG-[4SC.LA6*L=C_U(C6=U22.*6MP*DBP%F:"AZ]*7
MUM:<92#1T9,@,@"_B_K&HC4/3P:4)(O YR%$ZHR KJ]/P$-$M[KV'D$-+TS6
M_ZI"C?"\T.9&7!H)3Z*+26UZN?*(YOU?(A#=D0,',C K 02338-[;U<2$X)C
M;>UKK[WM0EW6XF:U<N*MN-="#"]^PM"=2EQY.W2DVY7&>$;?<HG==+$4" 7@
MP5N$D"=>P+W)5A+'Q<G_0GGR/ 3<?[+=D?-W'25.\"F.-FN(@9+S.(*-D"S,
M5K"V"0Q,?QB97*]<2 _WY@\QIA>(^F^YZ7$SCDC:BR$48?5\77G].+N_;**J
M@$>YFCJ[Y9X9'Y&@,6R9?VA$2$X:,V=!=&&X;+LB<'9Y=[H>P,:$^>K.%F:2
M\^MX3:6<O7$A5SVJ?=<BI,E>0U08!$?X%P?0S%G5RF<G_AVJG>BMEKL4R4$"
MONOJ+:P7)=V&A[$>\=(L%/C,_2 IICK*25P81!M .:S%DF78M0/:[TQF_!A?
MUALHZQ;>%N6K?,=Z*0R+FC;6P?!')G/Z=J]\Z?+FJ%B<O6UWMA>4.R)RBUZ]
M);";0UW.G-U!C)=44VQNJ^P?%<9RY]?&MY\72QFPNHH85D*K[Z##J^,U>>&P
M:=4!Q[JGK.Z;4%P4DRV%'O5P]D)X5OE5[6[:^N+XP'U9X52-YJN>'/?VPMML
MT!A_3:Y0^_-3*+6_C*Z<1O"SZF>MKOV;1QP$;4FLN8<,%8:Q26RJ"N-/3,H<
M;KHDUC\_9G GII]*M,2T2LH)(&+:J4%?W4L3L-9I!@TYTYL!6,D#EU$8Y_!8
MX7VZ5=]B]S'TR94^Z10'LL-[(LGY*O(I,_R@-5=;%]'=:%C=]&Z=EW,/,OF6
M/NO^TG)KJGM^9%R?ML!L_J%I5<8WHBLUO6%UH? ]3EXXP=3>%"VIUL?WH "_
MJ?A@5RI3<>"V?1^UCUM:8J*!?88)<$9^4[6ZZI[<JY(_49774.(UF*P)EW4K
M<$G%4_8P5RZ)L7#[C(,G_#D*T\>D%2*E2@*M],=,"_93? '!C6)VM=+024W#
MKL\8WI60[@GWB:E('DY$@B-=8Y#> @4&]<'J3N_MIX=43]K%7B18#+^I1LR=
MR; /F^K)JYZT!9X#24XQ=HXCKQ(P1_WS)/W,Q481/7S.)1*:]Y$YH>S1A N.
M*=>07%?[[!3@<)L]%!4/3LI+=(&A>JSQRM/ZFKGBS,J.U->PAS7D0[6\J'^T
M,A;?7@7>\/0T84O5'@^*4ENSR0<2M9]F=_JR)A9*Q0V@!X'Q8BOQ@Q-RPX\H
M-HD"WW-XY_HKHGCP:+$B/QF.DR&ZMCNI'MJ63O +0B.X>HS"^JR#TB,&MS':
M,*LUD;/TZ'A./&(Q>@!82"X:V5=Y^@)&)O:@"!DVLHV8\&(EVD5+4TQMY*>Y
M9]+TJC[[(GMQ$C7L?(L35<U=ZM)+KVC^H#[[H?<YUXNW^<;9^/R(20?@K[QU
M7KKE]-8^/FH4F771A'O#,;U</N 0JJLZHS?L1L,8WB<<V"UHG^R1\0.)1]LC
M)P!'ULTCQBF]W4-B4$.,M].KNC$XBP"!]5]GW:/CE^XWMSMJ6=F[4IE,M6BA
MS;SPH8+?E(:$ZX[R7<F,&#BF.)#8HS'M*(@>MLSIT5B/WO;6^#N#XJCYQ4\?
M2VU<DWP?UWS35^HZIJV/R"4&W#^+)04#^KYM4S'$=;R;$V\0O8[Q([F@T]8!
M(K!(EC;V'\)CWHB)#IQ\N^SJ0_\5L(N03+.^Q$0D<FC77:7,,!M->=<X=8A-
M[@E#O?&+JGG8<F0S:_?%0N(-H<W2HQ.H'1]X@^H&X*F%B>Y;-8_#9E4:87UD
MJ;KD:#<*TRV7:X.KDA>Q,3&S=AN$04AX43NPB$7UP&*Y> [)^?/HKX^V)7/T
M9YHW4FFY#J<ZXN6-XL2Q,""T#V=N??BI]JI6_\9$D@#5D#^$.S=A2A2_\C<K
M"O]=Z,-"CLM.:8&[4]6KCK:6P7[8W#(X]_?19NHN)%]% $K\1$Y],' 687OL
MM^VM209=RTFS $M'3 =R#%[XI?06+22G4$O0:.V5GQL/<&.U#J(M%D7=-4=;
M0)E3@P:N, \AK$)V=-$/O<VWK9O+=.V/WN7&EQ']E/'.9="3&MJ8'N1"%225
M@@R=M0I.&[$^N[X]GF.J&B&O&?^]\9WQ?#2U=_DD?YE/N@4#^M,;<3:%FR*Y
MC81/".?RMF^CJN:XLO@O:X[;5E1@@M6(VR\Q/@OY;XW?0,,+D_2J";=5=6EW
M6S+"<,(C1P!E;L0%MP0:<[":WQEW?MF!D1T@35-6>G;O_.>R#:$%KWDSK_'R
M!'"\C.(5"RE"WD+COE3W]'C#E\4$$INWJH"B]?'146H;N^RV;*"[T;!;V99=
M&4M=9.KKVYI>THY3*:JSNO?4;GEE_+7DDJM1G$]*:ELZ5:^,)@@-+"Z6!<C?
MCLAY'5^>3+ ^B\9<;6+W$:ZY_ ++H";HN#M&[+O1LNK;O/73@#K7/6*.>QLG
M@,.28H?#L![]]6W$OOI*FZD/A1&-06&L,Q-/%*/3TAVXI81UGV&7-Z?@'NR(
M,C*R4T5$/:-E0XG=V08P8=7J.@X*M!- MQ86HU;*0<Y>OOZL(L6IH<RMV_O:
M\[%%T4&#T=KTY+BW+')GBO)X2'QA=+DIM[^L6=F7@/P+L5!9<E@SS+:G1PTQ
M*HELA4.STP>_$XGQ+\)'6^5Z>A93<]7=-K4OZO#FZ!LZM>H )$A)R-RQGT(K
M@2GF8N^>>3TF&,BSBJM -JM-Z++TDD7<@+S0%HL;3G?_HF^TQB'R)!X0]7_"
M7YU I52!MV"5M>;SYFB3D#E+$L+GW@\I&]X-5=F9*F^U.[\^7NY!=:?=$\C0
MPUZ;JZ0OE0ELX$5LW?.0.A1AELA29'_<H3O.3M0TK]-V3Y$FQU =_^?H]C':
M)&1R;Y^)H%ORBWEZ^X@9VKJH925[Y4/L5"<7]:<SR:R=#NW=.[]N%QYS!9#Y
M?..J]8OFGYH,L+;RT;4=XIU>G4@F(O4CWJQC['B+\(L3^V G JY@79^*SJ^/
M*F!W&/2ZIW6#AS"+_)@\26P-"&)\=L+-$IIYQC7AG.[O6?V*CYSP]WBS3MTM
M+Z6%#'JYUJNQ179]6[?R9;)-Y_!'VRL3ZH9V&:68A9'6Y*Y7  ^I;3>S*YGQ
M\G%O;F-JTFXSST1C^+;AA0GF58ET888%5U^!M0L%[36R6<F\L),HA(;_1'9Z
M<H=B-]3*RH..K^[=1;ZI'FD8S?%<,SF\I 8O6L6#4PC;9%M64_EOPPO3=9VT
MURRM?>Z''K=T:K=AC(GE6Y56*=-E.F=P]B TW576,KOU#>JU+"Y-W,=L!P ;
M>D+&#OMXV05/SCT:VE)^E5T\N.7;=EO1S&1L9941B \_?/SQXV%SZGRG=\UA
M8ZE]4D#=M0[,'5Z<0BR-AO,IFE>W"%KA>1-PT69[!XK&UU/O<;C[.,W@#XF-
MMDH-Q4<TCP!NWD03_$*W[= 2N>6-\3^XJ@!T8T9]ES?'%XMEA;.$[\9MO.F-
M_;.1Z/_ %TMV<^9RUVT'57"83'.(UEA6[?-C6R#"DFKMVE3U\%ZUC#A?K<C_
MQKX3-#>]U$%Z0I6F91.YOF"I_56K2<7"UU=ACI7^7#4P>!2]K +R4_CPCS<X
M/+B[>9,;*S%'HTU<NK.Q$[TQ[*[ "ZM7L]^"^T 0BZ, ,\F)X,_/S]]1X4'N
MPP\?OG\/?WY/&;[Y3\$+<6:(<4.+)>+\$&.(&$>DL/R/]]G0]U,)'H=M8MTO
M,F4X7!DA4T:T1!Y7ALN4D3!E1!GK[_9?&V0C2?!%?ET<"%5PB3?D;$1^"'H@
MM@-A@D*<(G+)3="::(H^A9PTC?W[30H[-DJCG-)XY&,F-&I*;5FX1=1!B@!P
MSR]%$D*_ BE$:?V_Z0]?G56[,M"5>Q>NH<Q>Q;\YB^*&B,3 ;YCQ0SYG2-8>
MX8B648S()8]\R8PO(E\(6C/.:"U8F_V&C6N"+U2N <$(44Z(L$*"%R+,$.>&
M)+O]%EY=YLUK8*&N ;M:R'*=?!</7.A2C#40,[MT!XV;+TLY7DIDNL-5%U)>
MQZ;W^GR"#QB7/54-A%!&"?T*M(P?5<.'KZJ^((/1]5+*4#PCC[:E* X1#BX;
MQ$JBVQ%C@93/@S+9?X'Y8B2\D&"&&#<$[- \);^OE1_]RKB:M4ZL***P<?=4
MB-D=?@1G>F<U_LC4&.(':%C(/Z%+>35C-Y,98F!<]%3?<%;?K,H*5Q<8QL$]
MC .I8T7*8-']%JG/\0$C.N(98F-6-N0$T5&3+<P)$1_W#'W)YD",'6Z+;/3?
M^FP4]@%5VZXZ*TY^5A+E.=[<%#EL5C";%5^9E2B;E4C,2L67 ;.RIE(8VU>$
M70"E/I?."K- 2<\E#$004$&_,CK&S9EAPU9/>SEVX\Z"K'"E,LE4%"?P5N19
M,*#OOL+YP2ZL<ORSV"Z Z0P)MHA<P!AC]"O-N$,P $1'8-Z18DLW.7_+9K5R
MXBWH1_'+(8G5A&@0WU_Z\'4F4E&F=)$E@\\]CSR37)&+L1/\7W\-[4F'",JH
M(DYVAAAA1"@C(+T? @6CRB(6:D5](8=H["F/((A4BHB11+_R_UK\$O4)J*[
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M?RLIZ/F7;"4)&U9(_FX^5"NFE0&M6IWDD34;8U6=,L&(>M(%$E_/=<'I(\F
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M&N!701O-IRM8UI:R]:/KG):N5"T!>P0X86P 2!D!8LDL*KCGUZ:D E+>WT8
M)M5XPM6#D=HYT0Q)R5=R-=CLDI:CVS):] O7#4S6BDV:X0H<DS45PW?GX9?_
MPGW18#B( ">&*#5$R$U^_!5("-:$*.==SI\</X"42++2X):<-3R]&%CG1_?W
MC-P,258'9-$=T"NYS4H^P&> F-D380Q9#O(B2Y.,!R,_X(ST?DD2*$(H5&>
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M#="/'5:XOVMR3*4S--N9)+(!!AX33A[2H(K&+?H;5(0!/Y$R*DMY436 WB<
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MA\I,$84#2IT7J#MQ? ] &WA*S/7-G?F(I@+-<!F%[B ?8QY\ <X5-]A0^41
M, -KV _!RMC7+@/46') C1EK3<:HTV2+/1&LN%..+]A0"R#?XV9(WRF=ME6Y
M4XV5KE434&9+_8:E]B;'-!N*7NYX^]Q-^AC% ')Y%P;^RD]WST7)(R,<\WPK
M8#$3)82.Y+*/ @8YR6Z89*(KLB0_0Y(!^O7,?R'_N? 3\[D>*@([!C!KVN3=
M6X37$$J!Y"/:0.TNC.X3'#]!(OYYN-[0/C\A[&Z\\IZ^3NM-3R+ /AD"GH98
M6>VOC))YE*$-$>V/#=B:3SP)8Y ,&3U$"=)L#./2&,Z,/@9G,I0)FTKF=P6#
M;TY!8Z7ORQ'O?=K^8-V/EK#OJG-@.%%?['=\CX=!T:U<;;@QO+K<2M<-<Z+P
MKU AC"CE0D<5:^7_"O!-Y;>AY@/#.<Z^J:R;BG:(P 8[/9<NS9*H^=:5C6<,
M%,%155@+05G9N ?^LC";?TWWXL^;(/77 ?X207*EEN8T@B1ZHC3-)NGI&+_X
MU,6X&2T[?65TC%]=604AC/=QWB1^B)-D[I)C+J%M-P<##PJ:2"'*+TIVX BU
M"J5.CI3,427+>B+S>B(K>(!:A<S?W:O%Y'6(5+BLLMOX1;X*^4B$M:BL\H\)
M_VLRL)7=L5HJ!LD:Q,Z#P@G 2,,O+J^RL3+)5J0OYFKQ[*M[EG<T0\]%; 01
MVOOJ=*"F:V4)6-^4(H232Z##"3RTB..A97%QMI<KSR3R(?,YBS94D4/"X&JP
M.^.WA&>R),.8AQYKZTW6([0HXBT8E)LTN*:2ZC\-\H%E[1Y4+X0MC]Y9%)-O
M+F2!,G=+]>&X<!Y](NPOHB2Y"V/L!.!X[2E@1@ !3?06J+Z;(<X:"=Y(82Y;
M@=TZ+WNI@DI7GJ*))1>>''>/X"<QZTZ2USK^E<GZ"[UW7@7=47*P>(LU*FO1
M[Z7<3P6^IRBDW9J]T)F2,'?]WJQ63KP%Z>;D4WBBG9R6*DI5>:9'.9(NB!U]
MGN)5WYAK[3&,?@72B-(VO@OK%2U7]% +NVI3/HCS^)Y/5M2-0[U+X$<:TE#>
MX1XVZD:STSC^$J>0:'X51T^^!QBP=PEXT<]#2)N!GK?L._'[0UV5BE660?3,
M&]#X@@UR))_]EYA/YR4$,D%@P0HB!F_O&.S9.R09HHRC->2O!H")NW44WN T
M#7BB^#49)3%:R7E/WP)\8.HU38A\W*.:T.PK''C$Z""FS=!#B"Y_[C;P&"X'
MNV=Q;\EF#==L.43X9&(Y2(YA 0##+!130&U)T#,?+$4C3IT7P^?:I%0M=II:
MZ!/ND8:1H6QHL-5F@^,;% R/>?X3!&M]L119#6*,8 R;M'4GJ.!..$)M*YAZ
M ^D*?OOF^N;NS;N.*]FHGB\B)SQ]23&@./:!D%(U [3()8$10\;1O(8./5!&
M+>@8;>:C9=2%;;6L<[,;WYD?)RE<.XEA#\,'_EKB3)0P2AEE*@@*".U]D48Z
M2$ *3I&%E.D,68D^Z9,FW^*S4B3#'PE+X&76%/4R#1?D0F#9<0-U9;*>6J\8
M028!FP&%HIVUI4V4TOY5(9+Q7!GA#9Z''G,'7T:IOE:QT@,.]4*,/@(&=AO&
M,C.*7F%9II7L7B>:@[(VF$/M>GZ]99E1,Z4+8B1[D%(^A@UR_8*J]W=B!?/T
MNZP'H.RQ.C>*.6%*O)P+C4^BTN(GFT?GR?')6 (KCC-P]"R6K"6KZ,@ZU&]&
MG4=$ND*C5[M>LYQ$@X(P)3%LA5\RO,!BS3RY: TI&U)  AP.$L#<+#9A$?2*
MEP7,"-$#2K4*"^'2?,V07KF*Z0$=!+2-X&)"8#47H)/(UA%;:/(TQV,K(Y<.
M0K@6*&]5^*7[)99ZYC'9'"#M!,;]T^>A&V,GP2>8_?<\Y""8R96S[=/7,K]_
M,J+HK2#_#A+/!0?$65C"T=$N:K"3E'LG7@%0D0FS-BL,0)&<ABG@PWA>#(F#
M[#]@$1T.JA.@1!$G-Q,_(&IJW3Y'>R%0,*XL%0#4D/*C&]I'(<^ZH=O"\S$M
M7\[I4Q#R1NDQ]&]_^OOAQ[_].Q?<!NK/E;">3IQT,'PU#^V< B@)(3?Y\5<B
M%ED2HB5,S//:U#"QF?"P9*2$A_=79M4& <$I6.5:$7PIQ36?"< ZHW'76^9I
MTY)B),CNR]B+_>R$0]*3I TWJ-,G2M&GJOI0+5:;S8DM0#O2D5M?UF*9H;=@
M[RR.5L>TXQW5^&)YZL1P^4O(]D9/G$$>2)6WVG=:<&=9-PI_<':)$< .RTZ]
MF6%'Y:BJRAG1JKX4ER;.Z<O-ZRO?HM!\;D.I8OH:0\/YW>&2*_-L*HJ<8T[?
M0F*,-MF$"UYI=EPID\6F&+<1N0;0(B@GN')\<I >.VN?G(-T\=Z7)6=%4YAE
M[&-F[P#,QD-(J?1"W<N7*'%JD*I-%K(/]U.Z((*\LJ#AP+>F*-5"F5^='\^J
M 1:R^G\ =>1N!DB_@9X02!F$)1?*U-08E#58BT37HL%O375U3=MSGR:V R3)
M+KJ?<?H8>5FX??$<DC$^^FLBL O[QD/?]<$]"(R!$M"?(<D#94SV5EIU2C,J
M2I-HCA+"TON,)S, RAUKPI"0M23;,6056LRBZEO\1ULP9/1EAPH:_,CZ5MBQ
M+4W)FDMXRBJX:8JGX,;S,XV:3]ER6BR5 A:6PWH;'>&?<>#=1E^BW=TO!3M1
M6;@ .:<4R_ TU#1"]QC11%3RXQ/A:-9R-"AZ4/I6%_GZ()[A?!NA(XR #_P(
MG/95XIHMJNM,&S^D-<<IQXQ0&@E."H&X86#<1ZA/B!(:K&-)%)X"RQV.PE^D
M*3=9N#%Y^:2Y0UVG%/SCR$8OG6B6TI&U2)'/12Z*8G:#CB,78R\!GY7 $R!;
M-0-R.@^O8@QPU/.0=14436)I&LC0TYES9JXJK#3SY1AS%%B.\:=Q+89"Q[&(
M>1:5X?/:GG+$^9U3BMKA>)$IY4I1"DOQ$,#:9IO3VM9)[H37L5I,Q@]O8X=:
M-MO5?=37"<AI($9DLJ/-H89;&;(XP[\XL0\Y(]=.B@?4*PLRZ-I\.]Y<:_1<
M['^0!X+<1M,T]N\W*16$&+57C@U3<+@8Q?1*2\F#N@:>@TS:EZ&73=9$21+Y
M,_?F&$\K6Y'=.68%K=6=V@-(.!U4N2I9L#A!(>EZ3R4,JH2K2,M5TW9'P<A0
MKOCZ<;@4XOLF7,V>!UA[GVG;I>\_SM#AA\._[*=@%7MB2;0?QNEUP0Q3V@,1
M/$3DR[@B#)+AG0_K AU?@9C\4VP)@HW1T[*V1W/F,*=@>(," ;6MJC,F=F!=
MC4F;0[;)A+*,=%J!:9%<W]P-<@158GTDZ"TTT7IG#?I<JV3J9-GH!:9 0K%>
M%P)?A$&5G(<*(I\.O*@9REIJ\" %QW<A-WJ%US[+75F(:C345NP"W'.F;/7W
M[3O,,7H1]QUKT0C,FD3;+1X<-G[5ULLDL%X+V'O!*#?A;/AVFJ]39%%92P6
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M=%L?Y"%K//T96*$M1YD1,7-X>;6R&LYP=QF,TPE>XCC&63+#&<;);33W/-I
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M]$R9(H]R)><FL!5Y7Z(0!C/&7X$N@H(:;H0:&#_$&"+&$>59HM.O1@TE WS
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MD(&+"?-C9,)GCHKE)@.;N(\2DO78-9LP\X%@[2)'LN"CCQA0>A/BO8//:5M
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M.0\HQ;- :^X3ZR$T7DBXOD0;?^4/KM/U0P3;]'RPW$TX]$TO8O>0/>?3>PD
MS;H"$.7C,82T8R!"BD T&B691Y/A "\W'9W<70QI,@?WQZ?<OWUU_[BX\(+5
M@8G844K,,VBFO/)MJ$8%:)W5+JTC&B[6.3C FH,#T-"O WSMB DO!]6T8\#
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MI\6PKXP!Z69+G]$K?&+!OE$(H!\V(&AH:@OQ) V7>'#TJB(@Q=T!##/+S27
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M&W031[NLI/T)L$%TN.E0LL4J6%!8 3X'V*<C)?T-R $FD KTZ3@A4G_$9,L
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M%2>8=RO!"_OFO4."UWD4Q]%WFFN)?TFEZ-I-^CM!L! T<1.RL F:Z022MQ)
M$:XO4 PNT*?8([#91$H;PAD-]2TG&#G<S7\7A;2^]  6Z*8?MZZJG^%9KDGM
MU, KX%17?G1B5R@KJ7WYZ?-??]* .!MU=(+$(CJ,_LVO:NL$(?@]Y\.>]P+
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M'M^)G7F'O@MJ?!R%^)_T]DZ,G?9-Q[!N^2L@SUW@?R[CI^A[(:A$T\R)=3.
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MW+]&H2*>IOR[,QN8R%!2W50?I%UNY\2F/,,Z^!K @?&++Q<.5^^@MJ,UH#Z
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MQ12!NF["# ^2J6GUI>Y,!W"(R/L8[;$N>LED!0?F"JF'ZBQ)D++D1LO!;%9
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M.[LBX-MI0PU8WMNUTR)1(SKK(7WOM8M7+]QBCF8 U<OP$BL**]P_X0\,LGO
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MB'(X?IK!; Z8TVE;O4J,#^:$K)]S.M]L+G9/K-FP<A['35!KF\JUO9E)\EM
MKVE.-\>@C[L3JZ6#V$0=,NP]1 7D>%IPIE)O]F1PY*$> %SV6O-=J5'/[]AO
M>$V^L5HJ)J79M.WM6:QZ*TQ<-FUU']@N4U[JY_Y2GCOY'RB\@]^+5 \3ZXRK
M^=3[M_IE71*G MOP?^4LP__QVQ.(#*@ OO;?_/7!"R063W4[NU/]AY^^/J"
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MAQ;#/$Z>C<-(X[9@#(S=O\S"M;6*T<."3F,5!MGY#7 X>$S(B>O3;JE[C;!
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MEN&/N,L 9:Y>FMXNG68XT4[4,Z6W0-EH8(A6)I/S#_8+1$47+'X1&!J/IE<
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MF+_G*$59_A#D>K*3X 5@@+SZ]H8V.=H2U&L!QYBX^KF7Y>=>B_X MZCKV6M
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MNS$.)[I/T75!U(0Z4XW/@'A#9Z@":40$4GF/85@ZL@H5>;.;+"NPEAQO.WF
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M&1#=1&=\5WS!!-/^TLGE8^N=4]]B6"4]3PI2( D%4</C^*HG?S L2EK;8SL
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M,QY7$H\!>4+%"7ZJAB7X8)IH-*X6EZ?T*GCVQ[*55[;9HT/P?_\_4$L#!!0
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M4Y90/:6K+/5>$OTF@0GX>!]@0C&LO96X&*4;!2(1 WWA"KCC$IV@HE4!6E+
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M0DI0];,%T48HCA(^Z9Z]E'!"MR@MUF78:5ZN;O%QN3&S!MS5.KZGN_-(=.S
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MTG_#<<I9GI#3\0+Z60>E;)<^DTC/N%IO1OC]4QF9K!*SYUF/J!;E.1E Q4M
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M_=U7$7KX*I[O"?WN(^E$@U9?1H<V?"\\?.RO/U>/*NTWK_&*MV]>!_ 7X)S
M:KM<J7^_&G*X/+E(_P_'(GR5#C>%N+EPBI9"SZHT"]YIBR"<O+ >(V+C <G5
MK&J]_DM[#204(DW/ V#[KA^V?J[H/^VGX1B9%='S76=^;*O!Y^)A('LR8H8=
M3%$:5(OIHF$=/Y,LDF,-"9!5K=+X)0N5#6,2X8JQ6ATM?;B\.F<?+LXOSRZO
M+M@>'L+1/KN\.K-2[$@.G$UF=E#=3>TBA& J/Y]=?+BXZK)WUYVK[A. )2^)
M+*U5.[;JR#*R;.2P:M6J\%DJZ?2)%:N9SUI>"';MQ*HV3F;0_BM6D>R/5P&W
MOJLC;#_D6G;$\*:A"Q*&*=^5:YJ.ZYO/K/._G>MSUGEW?:'G969&EA):C>]=
M:!U91T?'>815K5I'*P9A61):-23=@51,D\6(AP[KW(5"#.$K!A]KUB(<)KW(
M9ST1C83PV < B7T0CK215O?P$(Z 67NVQ?:B@6"__EQOM$GS[3,_#))U]Y)Q
MKIX\ ;A]Q@%@Q!%GY3^ @0B9QX<P#SWA^B.+_>G'83)= Z[8R]^@NK(WZ"&%
MW(5@P<!P86S< ^)Q8MN05#3@FJZ&'.A*<I<!68WQ9<0P</VQ/F<DHX%^^\P<
ML2 .5<SQ#K[^+G-/_3 F'FP1Z%,U&V577#G\;W83^?97]H&'7T7$KF-7L.91
MO;EG[^\U#,R>'\W?G!)!9$'X]>>'6J5ZVE;LDPC[?@AWLH5^B6NAHE#:"/G-
M@(>"??9 \?SD OA^_Q&66[)$<?B4IB)9FZ+?%S::>$A5]H ='[!:I58_T,0.
M!.D(YX#4BASX(W$OP@--!X9IC*3K B]A=SY\X6G^SCA\% H5P,LI?!?9AX6J
M8OC2+"B\&J=$O^A(P-G1$X+C11K[JM^>?0>R?G5H?/9<H13S83+#D52".:(O
MD0#@6$C/T BPYJ&:? .DD4Z]H9L!!]K'CQ20^^2TH>#X>&7.?X(PV).Z!@RQ
M+_&Q*"%:V3G+N&, I>&A*U5T*%Q]F48JR'ADLE9$W1@1CE2!R\>MOBL>%LUJ
MHM"G(.GS#E7$PZBMY^\0GZI:/:X$ZN9S,ZWYRQ3M>L9P68F]\'(F5K<:C>/3
MZFFUT:Q6CNJG0.HC/W0.>Z'@7UM?A0A@I.X$)NGA6QYJM'*@>?6V.EGF&3^D
M>62U4OEE[H94E%T0?[>WV@X][W0OOGR94!IZ_Y)_UT5QE1VM?2.MU;:2UFYO
M?[^\ONE>=3X H0'9O>],#K0*1EK[,LJFW9Z:(.83YT5*XZI'N;]]ZS?K7ZJ:
M!_Z0:[J^E6MZ!,IO:MW>WM[\IW-]<:/%R<4Y+&NX]!#H#N:-]\#4#*=FF=)F
M60QFF=J*Q0^FCE;17FPFKGS%'S 5@]EE%$CME<J89+Y15AT>B4=F;T;%%(G3
M(#&.S;UZ8S@E1H<73B ,Y$D]MKWC.MO*=1I;R77N@9$@0<[0JS;&T'T%*T#%
MO;]@":3>,1YAI%H;5G!)D/$6^?H\6"IJ1\1;2\3-K23B">4>,#]DF.8"7%ES
MXU#X?>,_"P)7VB@[#U!B GTCY0,YLV:K4F&!-;387M</?0Q'1#"2?;PJ(7HO
M'O9$B 2O?:!;(V=1P)@1TQ.VVKN<$:J*(4>8>H7ZONOZ(RTKM<:S)[@]@*G<
M MC_2'CJ.;P60>"#T+^7VI><\=]B\*0_'QD2#\"4I0#N#@L(0P/2=W 5='H*
M/V1[?*$S;Q\F+X3Y':-\P$O2\-Y4PB T^G+C'>1]T(W26QG2X%YFS;(LI,:5
MF*SR6<&EWP,7MDH6^:P XPXR/Q.!A-O;-K!,+;LF@2'CH%0"I%L<9=^IM4"F
M_<0P-T^/;X'<:EA5=/XF:6\XM3@WE;:^X!"8*#Q!9^:US30=5ZS*Y'2@#I<'
M2K24"#AHF4EB'CXO3!]V+Y7L25=&XU9Z>GH6G.;,<N^FOO<D&2_-/$NR\5Y'
MS@LOA-_"1R-,4P-/=*[$0AK/2"W][R%^L.@U9O(0,==P-ENC<MR$#X&8(Z 8
M-Q'3<.[DO-1_GKDT37LQU[[*R3+#O)BYU?A"+_Z,QE&WCJK57U;EV7]V(LA2
M?".[ F>2&Q>13JF3M<:)J5C-HR;QB?DT982&">),"6?A'$U6*?R";&CE>;AZ
M!KZ[E)QO3B/=N)TP%[%DM[>=]^__N+CIWER\N_GRY;\RV.1+LZ;5;![MI-E
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METU65S[0$?#;_.(Y72O=I!/0+QTFS?[,3MI/K3NC=7.M+VF6F<2##?_,)IO
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MU-(O*%#<Q,HWR$WS(9$[I7MS&@7I8&*-48(RLXT1)4AGT@M(X578+J5TW4
M9:E,;^N#I,NO"=XG$7\42<5M-$N7X5-C@A*D$\-&=^9.DR2P1YVGXW+L(QC
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MZ5O@IRJ!QI_EX]CE=^[R.W?YG5N6W_GF=<]WQF]_>O-Z$ W=M_\/4$L#!!0
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MW*$2X ->%F7IV"_/AGVI*89Y-NS#9,,>[>)O,OKPZFC7_ ZD_P-02P,$%
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MQQUGKBRR02#>3X'XZ$$(Q/-/Z+)4T3NE9^.FK'H7J&6I:.2V*.C2UI8SW6I
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M,X5ZEV.D<N?YKN79)#PR:A\>Z[Y7W823!U)$Z9,V8RIN:>H&-T.#"@Y/8*C
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ME"!5I1L+?,8I9U77II;@=>AP'ZNDP-W3JC$VQE@K\I;@ OQGHZ_B#!?KVE&
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M;D%L,2"W(V+N)1CL\<&/9I@^<-'QGP-=QC^Q5A\AM+GZ-5)>L)1B[JBD.-U
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M]X\Q+V\CF/ZC^X'I=XI!Q:I]'T/'/31K'ZBC]^B>(/A?LLND=PL]BCY(U(I
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M5#DR?I1=X]2WUM;:HKTX)HX#?20L>%(9B\8*W1P!JNJ&Q@SUN50T2(9_W(T
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M4NH&2102!9"("J'MAC-.GXB;"4NDFIF*I1K&R ;-<2!.)[W>J&6C1C93*?-
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M[DR4CH*^!G[3O@%(44\YLXY(:(*!,])7K/+R;;U:O)Q2+N#'K-=JKQ<Z7!O
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MYMI^4MH<_KMI<]0Z.CH\.&BU#NLM_/!4M-GANYO(FU,P^%(0K2[+>ACA%4H
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M6A&Z83# HDV,$9=F2?&%^>T*<==?+J_$'%.Q(<9,X^N]OLKL7X^]2F; 9])
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M)WQJ7$ [WJ,OY'G[XGC/?97/_P%02P,$%     @ *#NH6JV4 Q)3!0  12,
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MF%<0CUYT&O;EQ7\!4$L! A0#%     @ *#NH6D(5?ER3&P8 "Q<* !(
M         ( !     &EM9S$Y-C$P,3DW-5\P+FIP9U!+ 0(4 Q0    ( "@[
MJ%H445AE!8T! &MX&0 1              "  <,;!@!M;FUD+3(P,C4P,S,Q
M+FAT;5!+ 0(4 Q0    ( "@[J%IR0'G&=4,! -X&%  1              "
M ?>H!P!M;FUD+3(P,C4P,S,Q+GAS9%!+ 0(4 Q0    ( "@[J%I755G,3Q@
M #-8 0 /              "  9OL" !M;FUD+65X,3!?,2YH=&U02P$"% ,4
M    "  H.ZA:\ZJ-Z( 9   *5 $ #P              @ $7!0D ;6YM9"UE
M>#$P7S(N:'1M4$L! A0#%     @ *#NH6L>V ZM<&P  PW$!  \
M     ( !Q!X) &UN;60M97@Q,%\S+FAT;5!+ 0(4 Q0    ( "@[J%J!!VG'
MY0H   II   /              "  4TZ"0!M;FUD+65X,3!?-"YH=&U02P$"
M% ,4    "  H.ZA:;ZB]_&QY   .4@0 #P              @ %?10D ;6YM
M9"UE>#$P7S4N:'1M4$L! A0#%     @ *#NH6@60=NDT"0  :$(   \
M         ( !^+X) &UN;60M97@S,5\Q+FAT;5!+ 0(4 Q0    ( "@[J%H.
M*4Y-9PD  -%'   /              "  5G("0!M;FUD+65X,S%?,BYH=&U0
M2P$"% ,4    "  H.ZA:K90#$E,%  !%(P  #P              @ 'MT0D
M;6YM9"UE>#,R7S$N:'1M4$L! A0#%     @ *#NH6D/ZPOR+!0  PR@   \
M             ( !;=<) &UN;60M97@S,E\R+FAT;5!+!08     #  , .,"
(   EW0D    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>mnmd-20250331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:mnmd="http://www.mindmed.co/20250331"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="mnmd-20250331.xsd" xlink:type="simple"/>
    <context id="C_8105c1cf-df27-4598-b667-6e48ef3b3337">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mnmd:TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_81f4f1da-ef96-4aad-9e47-23f8b90a22b7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mnmd:UnderwrittenOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-07</instant>
        </period>
    </context>
    <context id="C_83fc4e0e-c83d-497b-af6e-c962abe5d2fd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_8951a923-02f7-4d9d-aa15-eece5d45babf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_8ddb2856-0c3b-4cce-9cc5-aab5dca27c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mnmd:DirectorsDeferredShareUnitPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_8e014f8c-ec6c-4965-ad7a-4716062b7c4d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_8e1a6127-7406-40c2-a294-e96d17a71e6c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mnmd:UsdFinancingWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_8eca3c03-2aed-492a-b29b-dd10aed0202f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">mnmd:DirectorsDeferredShareUnitsLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_90573d83-d120-4c4b-9277-fd2e39b59277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnmd:TwoThousandTwentyFourAtTheMarketOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-28</startDate>
            <endDate>2024-06-28</endDate>
        </period>
    </context>
    <context id="C_910d296e-b905-4051-81fa-bd26919dc2be">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">mnmd:TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_925b985b-901b-4479-a40b-d64febbd22cf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_92619440-2ce2-4466-9498-1c8dd0f4bb1c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_939e4af1-6bdb-4858-a841-8acd4d2a47f4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_9530e32c-7cf2-41f3-bd67-a92ee6762331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_97bfc649-2b8e-41f0-8976-f5330877ad56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">mnmd:TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_98c96557-3887-4999-b5e8-247c1ed96005">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_9b3887ab-9632-4cdf-8108-dd0d06f5614f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_9e259264-1dab-4ca4-a6a1-b8eba8c5e07f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mnmd:UsdFinancingWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_a39c400a-978e-47bc-a958-d2b3c57c3ab7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a5257296-f7b1-43a0-9556-3801f55d61c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">mnmd:TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_a76dd043-ee75-4b71-a525-e4107e5d3732">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_a897d154-518a-4ffc-a776-063ea244783d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_a8edddb6-a7d1-4462-a57e-b8c66cc64c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_a991fead-ed19-4c7e-a11e-4d30d6b8613d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_ade2e71f-765e-4fb6-86cf-647ae7dd133c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_afb02b48-cbcb-40bd-950a-da13b4f46b8a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">mnmd:LongTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_aff55750-479b-4423-af77-60c8f43e209e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mnmd:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_b180f4c3-0072-43ff-9725-7c3a3e4ad1f1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mnmd:UsdFinancingWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_b2ef454a-9f53-4e0f-adeb-d446b560c825">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mnmd:UnderwrittenOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-09</instant>
        </period>
    </context>
    <context id="C_b58805d9-68aa-4a81-99f4-2a397090939f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mnmd:TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_b72d06dd-d6d5-41b9-91f8-bad834196904">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">mnmd:TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_bc56a365-8e98-4a9c-b1c1-8e03984015fd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">mnmd:TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_bd03d603-030d-4d7d-8bdb-3dd6759f747f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_c223fe50-1eba-4855-9ab8-186a0c6e6c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mnmd:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_c2fa1d86-6d26-4f04-8543-c015b28e335a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_c9514733-173b-4015-8d17-721fcab04ad2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">mnmd:TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_c9d7271c-3855-4150-a286-178b67eef766">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mnmd:SubsequentTrancheTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mnmd:K2HealthventuresLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnmd:AmendmentTermLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-18</instant>
        </period>
    </context>
    <context id="C_cb6db0ce-574c-45c7-a69a-4330f84bb3c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_cb762e0c-1384-4979-be76-95297f6af7c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_cf111989-4654-4f24-8b88-1ac2ede3bffd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">mnmd:TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_cf474416-20d3-4fb7-a080-b12775ae6c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mnmd:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-09</instant>
        </period>
    </context>
    <context id="C_cf6044bc-91e6-4b8c-82c8-fab4740fed04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_d0dd088c-1d9e-451f-88b7-d6ec7c48a41b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mnmd:UnderwrittenOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-09</startDate>
            <endDate>2024-08-09</endDate>
        </period>
    </context>
    <context id="C_d169998a-953e-4d00-b8cc-a69fa0e9660b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mnmd:FirstTrancheTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mnmd:K2HealthventuresLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnmd:AmendmentTermLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-18</instant>
        </period>
    </context>
    <context id="C_d2978ec1-8cd7-4990-abd7-153da97219c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">mnmd:DirectorsDeferredShareUnitsLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_d320d06d-9c2c-4fb0-9558-f2351f1dc8ad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mnmd:K2HealthventuresLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnmd:AmendmentTermLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-18</instant>
        </period>
    </context>
    <context id="C_d6c40bae-8846-460f-9af3-802080fee535">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnmd:TwoThousandTwentyTwoAtTheMarketOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_d74b207d-4c84-4383-8d90-5ecc70a0eeb9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_db671577-db0a-4a9e-b198-84650c9bc0dd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_dd654da2-3037-41d6-b072-b777c8f63fe4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">mnmd:TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_dff63d85-7ca9-411d-a4f5-a8cf59bcaded">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mnmd:TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_e2246019-6180-4085-ac79-bbe6f51150c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">mnmd:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mnmd:K2HealthventuresLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnmd:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-11</startDate>
            <endDate>2024-11-11</endDate>
        </period>
    </context>
    <context id="C_e34dffa8-783f-47f9-b3eb-1d1ea40a50f2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">mnmd:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_e36f91bd-0fb2-41fd-b1b0-74152cad4505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnmd:TwoThousandTwentyTwoAtTheMarketOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-07</startDate>
            <endDate>2024-03-07</endDate>
        </period>
    </context>
    <context id="C_e3b59676-7289-49e6-94f9-2ea1da43b0c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mnmd:TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_e6549b22-6f92-4409-ac7d-193000c6fe21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_e69e4c45-b9fa-4c14-a874-f74d991218c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnmd:TwoThousandTwentyTwoAtTheMarketOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-04</startDate>
            <endDate>2022-05-04</endDate>
        </period>
    </context>
    <context id="C_ea9d77da-eba9-4810-91d9-0f141316dc18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">mnmd:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mnmd:SubsequentTrancheTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mnmd:K2HealthventuresLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnmd:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-11</instant>
        </period>
    </context>
    <context id="C_eb1ae7bc-3517-4ce3-9504-2825a5456a78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">mnmd:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mnmd:AdditionalTrancheTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mnmd:K2HealthventuresLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnmd:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-11</instant>
        </period>
    </context>
    <context id="C_eb56ad75-806f-4117-8a10-7450fb345387">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_ebfcf44a-8b21-4107-a576-08b906d78af5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ec162c56-805d-451c-8646-927ea169440e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-09</instant>
        </period>
    </context>
    <context id="C_f83f983a-590e-4074-8513-66e59d9de42c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">mnmd:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mnmd:K2HealthventuresLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnmd:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_fc88df44-67ae-47e8-a51a-83bbbe2805d6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
        </entity>
        <period>
            <startDate>2022-09-30</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_fd8b6f33-1ed4-4940-897a-df0a934092d1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mnmd:UsdFinancingWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_fe5a097f-3c97-4699-94f4-51951985f607">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">mnmd:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mnmd:FirstTrancheTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mnmd:K2HealthventuresLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnmd:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-11</instant>
        </period>
    </context>
    <context id="C_0054b3c6-4d0e-43c8-b522-a912b7fc8728">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_01a2dc55-35b5-4300-97d4-8821ba88df11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_0229cf68-edf9-4c29-9a29-b011952417f5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_02d3e741-f89c-4731-a810-9c92f1a21ee4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_05d13ef9-8e4a-4163-9c2d-b90faeb5d396">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">mnmd:DirectorsDeferredShareUnitsLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_06e3dec8-4efa-4049-969d-372ad64052f3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_074eb5b5-3385-4cab-a533-970336354d46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_093e9bfe-6581-4ff9-8a14-13447fd595d8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mnmd:ConversionSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_095bf73d-2ada-4710-8b73-6c8b87d5dc15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_0c871994-f7b4-4304-86d5-391aaec3c1e0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">mnmd:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mnmd:K2HealthventuresLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnmd:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-11</startDate>
            <endDate>2023-08-11</endDate>
        </period>
    </context>
    <context id="C_11c49272-f55d-49f3-b7a7-0fefff64a7f1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mnmd:UnderwrittenOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-07</startDate>
            <endDate>2024-03-07</endDate>
        </period>
    </context>
    <context id="C_122040ac-3410-4ee2-92d7-5ca02f09a42e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mnmd:TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_12ece47b-93f1-4de7-b519-aa935811a9f5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_13b67830-d4f4-404f-a407-d676bfd7b796">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_16552037-eed1-494f-9bc7-fe5f2b5e07a7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_21366178-d703-4ba8-b838-8bd6400186cc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mnmd:K2HealthventuresLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnmd:AmendmentTermLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-18</instant>
        </period>
    </context>
    <context id="C_214de9bb-0f67-49d7-91e6-f326f72e5fda">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_21b8ddb5-b023-4fb7-95ad-c159194b8c6f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">mnmd:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mnmd:SecondMilestoneBasedTrancheTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mnmd:K2HealthventuresLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnmd:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_239ca22a-8f41-45e3-9088-34e3006f84b0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">mnmd:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mnmd:K2HealthventuresLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnmd:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-11</startDate>
            <endDate>2023-08-11</endDate>
        </period>
    </context>
    <context id="C_24991487-9f41-4eb3-b745-b05e5c54af14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mnmd:UsdFinancingWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_26a40041-e25c-4e75-bf9d-fa804e8cd077">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">mnmd:DirectorsDeferredShareUnitsLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_2711bf7d-51fa-4c13-8e64-2c94219ab80a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mnmd:UsdFinancingWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_2995588c-67ea-4d43-b4bf-a6059a698028">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mnmd:CommonShareAndWarrantPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_2bdf42cd-b1cd-4bff-9840-27592a404165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-09</instant>
        </period>
    </context>
    <context id="C_2e215081-711a-47c3-8879-d448652f7b35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-07</startDate>
            <endDate>2024-03-07</endDate>
        </period>
    </context>
    <context id="C_2e42dac1-0eaa-4f5d-b79b-b48d8486374e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_307c81b2-2ca0-4668-bba0-7a7b5291fc9f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mnmd:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-09</instant>
        </period>
    </context>
    <context id="C_30b95ea8-0cae-41e0-b81a-309b08ca75f2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">mnmd:TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_36b4af29-5d76-4291-b73b-cd8c72915e01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_3719fe9d-d9b5-450f-af3d-bfac82d59821">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_37fa8a98-03fc-4f71-9bce-63073a3d3907">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_385312b0-168e-450a-8069-c73e69ed32d7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_39a7f94d-b020-4c68-859b-28f61826d359">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_3c75786f-e793-48f9-af75-c6a4be9a5a7f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_3eda8f94-de7e-4394-a39c-79afdb6058ce">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mnmd:UsdFinancingWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_4094340a-fb0c-443d-8f83-3a756fca8506">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mnmd:AdditionalTrancheTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mnmd:K2HealthventuresLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnmd:AmendmentTermLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-18</instant>
        </period>
    </context>
    <context id="C_4167881d-1e68-4b3c-b401-a89cc1d4f259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mnmd:ConversionSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_42ce987a-6c17-43ee-b6d2-679c22b90e37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">mnmd:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mnmd:K2HealthventuresLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnmd:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-11</instant>
        </period>
    </context>
    <context id="C_430d76fe-9c73-4a88-a973-58ab8a42cea6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-07</instant>
        </period>
    </context>
    <context id="C_4350eef0-c7b4-4a27-8d23-cb926ba2db8d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">mnmd:TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_47ed8762-d376-4fac-a861-d53fdd21f2ce">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_4abdbb57-7e44-40e1-a361-dedbe9966b38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_4b6d6580-13c5-46e6-baba-77d54955725a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mnmd:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-17</instant>
        </period>
    </context>
    <context id="C_4ea41252-c084-4a13-8fad-6ff6f7cfeccf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mnmd:TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_4f9c94fe-d4da-4fdb-80c6-934c635c61cf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_528dd0c0-1ac6-48fd-ba94-56b201899f5f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mnmd:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-09</instant>
        </period>
    </context>
    <context id="C_53549879-ba1d-4877-b935-3c96fc46f9bb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_54995453-beb7-498a-8683-7850a8191dba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_54d8dbd9-a485-4061-8471-60237a056875">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">mnmd:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mnmd:K2HealthventuresLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnmd:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_57494605-d58d-4ef0-b4ff-8e96f7bcf04c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_592df924-3dca-44fb-a185-3cc0e5436ffc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_5a13acac-19e1-4c71-912c-83e07c93e680">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
        </entity>
        <period>
            <instant>2025-04-23</instant>
        </period>
    </context>
    <context id="C_5d84c0a3-45aa-4e65-83e3-9a191c580b57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">mnmd:TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_5e3a61c1-28b2-4c74-befa-0a83e0e3f355">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_6011eb25-af6f-4f60-b18a-f48be80a2b48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_62a1dfe7-53cc-4860-88cd-5195a323ecfb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_634127f7-e2ca-4f43-b3c1-b5a15d394d01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_6451cf6d-c95a-4e4b-8351-0fe9c5190c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">mnmd:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mnmd:K2HealthventuresLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnmd:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-11</instant>
        </period>
    </context>
    <context id="C_6a7256ae-8741-49e1-a84a-94da6e3a03ec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_6ad17a66-7ef6-4b6b-947f-8a82218b53f9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mnmd:K2HealthventuresLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnmd:AmendmentTermLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-18</startDate>
            <endDate>2025-04-18</endDate>
        </period>
    </context>
    <context id="C_6e0c796f-cafa-42be-9627-7b5c560ee658">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">mnmd:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mnmd:K2HealthventuresLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnmd:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_6e886f9e-717a-465f-9fee-5b794de40e69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_6f79a0fa-c5d0-4e2a-bc5d-e6aec1b53c1e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mnmd:DirectorsDeferredShareUnitPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_6f8c2f52-b2c4-47bf-b3a7-5478bee3c660">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">mnmd:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mnmd:K2HealthventuresLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnmd:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-11</instant>
        </period>
    </context>
    <context id="C_6feaeecd-fd52-496a-87c2-1985d67f38f0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mnmd:UsdFinancingWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_7141ebf5-28cf-4a53-aafe-4ebd1582b154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">mnmd:K2HealthventuresLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnmd:AmendmentTermLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-18</startDate>
            <endDate>2025-04-18</endDate>
        </period>
    </context>
    <context id="C_71fc6e95-5099-42fb-ad90-d49887a3de3c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mnmd:TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_71fe533e-e23e-4d50-b70c-175f681b0e12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">mnmd:TwoThousandTwentyTwoUsdFinancingWarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_73ffda6d-742d-40f9-a06d-603da3eab457">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_74cedffa-5bb3-47b3-afc1-6024110f7963">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mnmd:DirectorsDeferredShareUnitPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_75bc9303-a477-4604-852c-7370782dc59b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_795cce7f-e02c-4025-a046-7502e810b283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mnmd:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-17</startDate>
            <endDate>2024-10-17</endDate>
        </period>
    </context>
    <context id="C_7cf3b999-3819-4049-8c52-90a0e922de85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_7f0ccbf3-018b-4d47-8587-c44623598ad3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001813814</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <unit id="U_UsdShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U_Segment">
        <measure>mnmd:Segment</measure>
    </unit>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      id="F_15ebbc75-b668-4995-8617-7d98e6a460e7">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:AmendmentFlag
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      id="F_ead768be-ec5e-4935-a087-1de2d31e7076">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      id="F_b837dc70-6f2d-4b50-8836-87bf24950a1f">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      id="F_32a24a42-a095-46f6-8846-c2313fc501f0">0001813814</dei:EntityCentralIndexKey>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256"
      id="F_88461b8f-b10d-4348-8f11-5a095afbfb82"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc"
      id="F_a5f6e01e-d45d-48c2-a8b5-6ec8ed432e26"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommonStockSharesAuthorizedUnlimited
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      id="F_bdc0d770-37db-4b91-b201-46ab50f8b510">Unlimited</us-gaap:CommonStockSharesAuthorizedUnlimited>
    <us-gaap:CommonStockSharesAuthorizedUnlimited
      contextRef="C_62a1dfe7-53cc-4860-88cd-5195a323ecfb"
      id="F_8aef1a60-8a65-43d5-88a7-a12bf6efa231">Unlimited</us-gaap:CommonStockSharesAuthorizedUnlimited>
    <us-gaap:CommonStockValue
      contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256"
      id="F_48b94f86-01e6-4c6b-ba2f-884f3c981c63"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc"
      id="F_f4dfe000-183d-4ac2-8317-e5d26a5c8b53"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:DebtInstrumentVariableInterestRateTypeExtensibleEnumeration
      contextRef="C_0c871994-f7b4-4304-86d5-391aaec3c1e0"
      id="F_878b4f9e-49e3-4bfc-bf0e-3f4c1e867bf8">http://fasb.org/us-gaap/2024#PrimeRateMember</us-gaap:DebtInstrumentVariableInterestRateTypeExtensibleEnumeration>
    <dei:DocumentType
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      id="F_d1574bf2-ba7d-498c-9bd7-14e86380c5f1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      id="F_dc9df8a8-cdf0-419d-8f50-2ccf9743a967">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      id="F_d1256b95-a82f-40d1-9d11-5b58cfc2836b">2025-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      id="F_c5c20c05-61a6-4ee1-a7f1-bfbc600d453d">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      id="F_2e2ca219-7c4f-43ac-8ee4-dc96bac046a1">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      id="F_3d104c0e-a9ff-4120-83ee-a01364128fd7">001-40360</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      id="F_da37d61f-f72b-4ff8-affe-48527386f0cc">Mind Medicine (MindMed) Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      id="F_3de2490e-596a-4e8c-aeef-94e7e29d9aac">A1</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      id="F_12baf33f-9559-44e5-83c5-0ab2ba3e6e10">98-1582438</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      id="F_cc1046d3-cdd3-4cc2-90a3-4d3319a84f6c">One World Trade Center</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      id="F_7184db5f-67f9-4139-bf04-1017f497279d">Suite 8500</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      id="F_b135f0a4-11d2-43c0-af2d-879f993a25cb">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      id="F_fff73cef-b021-448e-8818-cc40c6cf5295">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      id="F_1c952431-2b49-44cc-a274-fd99ab9ee000">10007</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      id="F_aec1bcc5-f763-43e4-892d-bb32b53406d8">212</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      id="F_25e70a73-47a7-4e35-96e0-a6d3224ba8dd">220-6633</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      id="F_73b840cf-0cba-4bfb-b118-808f9a68fe08">Common Shares, no par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      id="F_a0db2fa6-d7bb-4032-8be1-2b93c403d11e">MNMD</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      id="F_61b3d218-84e1-49da-8a3d-bc8b789d717b">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      id="F_c53c55ce-0d83-46e8-ac11-4c5435966767">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      id="F_1c427a37-eb11-4dca-8a62-ebe58b057545">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      id="F_5ca4a22b-c9d9-4409-85f1-4a661657a172">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      id="F_4c10ceb9-c19f-4965-83a7-7489069eec7f">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      id="F_0f4e73fe-8347-4804-a4f5-d6b9c078c551">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      id="F_5b25eb79-03a8-42a7-8457-9d144b1f5c96">false</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      id="F_1fd3ce79-1850-492f-86e5-15134404d463">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_5a13acac-19e1-4c71-912c-83e07c93e680"
      decimals="INF"
      id="F_3df0fa59-788c-405e-8f3d-1979037aa4fc"
      unitRef="U_shares">75553266</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256"
      decimals="-3"
      id="F_e49b335c-d0f2-4c33-b593-c4ddeb462449"
      unitRef="U_USD">82854000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc"
      decimals="-3"
      id="F_01ab89eb-4ad8-4b51-b175-06a25074d0de"
      unitRef="U_USD">273741000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256"
      decimals="-3"
      id="F_d96ea098-e7c6-4764-a944-d9e116f2c415"
      unitRef="U_USD">129587000</us-gaap:ShortTermInvestments>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256"
      decimals="-3"
      id="F_78e1b3f7-b203-40b3-ba87-72ba3646bf51"
      unitRef="U_USD">9259000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc"
      decimals="-3"
      id="F_229ec2f8-b56f-4b50-9aa7-ebc3b5c0d0aa"
      unitRef="U_USD">7879000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256"
      decimals="-3"
      id="F_2e92063c-4a8e-4334-8df1-9cf209b061b5"
      unitRef="U_USD">221700000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc"
      decimals="-3"
      id="F_1a93fb51-84cc-4e74-8bcb-4701f4ef4f0e"
      unitRef="U_USD">281620000</us-gaap:AssetsCurrent>
    <us-gaap:LongTermInvestments
      contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256"
      decimals="-3"
      id="F_69fbe64c-8593-4fd2-96d2-9c17dd77b915"
      unitRef="U_USD">33099000</us-gaap:LongTermInvestments>
    <us-gaap:Goodwill
      contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256"
      decimals="-3"
      id="F_8ad3dfd9-41c6-40d5-990b-ce6377c40fd8"
      unitRef="U_USD">19918000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc"
      decimals="-3"
      id="F_914f7113-f097-489a-ad6a-f8f6140992e0"
      unitRef="U_USD">19918000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256"
      decimals="-3"
      id="F_e1729d32-ecbf-4c82-b90a-54d4402df0b7"
      unitRef="U_USD">606000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc"
      decimals="-3"
      id="F_8c3e5ac2-27f8-4785-a975-69b65af231fe"
      unitRef="U_USD">613000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256"
      decimals="-3"
      id="F_5860ab78-00c7-4ede-9bbd-8337f589e471"
      unitRef="U_USD">275323000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc"
      decimals="-3"
      id="F_18183e36-d99c-4f33-94e3-df56e6e22b05"
      unitRef="U_USD">302151000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256"
      decimals="-3"
      id="F_fdf1d289-5ca3-4e8a-8135-ba2ef8d69317"
      unitRef="U_USD">2268000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc"
      decimals="-3"
      id="F_3fde0b74-f4f3-49d8-9efb-b58d07ca22dc"
      unitRef="U_USD">2010000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256"
      decimals="-3"
      id="F_47000f97-cc65-4681-8957-99476cddee5b"
      unitRef="U_USD">11497000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc"
      decimals="-3"
      id="F_5679a879-34f8-4a7e-9573-9ba6fd13856f"
      unitRef="U_USD">12829000</us-gaap:AccruedLiabilitiesCurrent>
    <mnmd:FinancingWarrantsLiability
      contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256"
      decimals="-3"
      id="F_feedee3b-065a-432b-8ab2-8bb3bf0d5fd8"
      unitRef="U_USD">16716000</mnmd:FinancingWarrantsLiability>
    <mnmd:FinancingWarrantsLiability
      contextRef="C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc"
      decimals="-3"
      id="F_afc04f00-70a4-4a76-ad33-f2f34d6079ea"
      unitRef="U_USD">24010000</mnmd:FinancingWarrantsLiability>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256"
      decimals="-3"
      id="F_0d1c74df-daaf-42bb-aeb5-6d9363966de5"
      unitRef="U_USD">30481000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc"
      decimals="-3"
      id="F_cb837a3f-01b3-414a-aae0-f7b71c9cb43a"
      unitRef="U_USD">38849000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermLineOfCredit
      contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256"
      decimals="-3"
      id="F_776a9324-0ee4-477c-97d6-b60c62ffb0cc"
      unitRef="U_USD">22036000</us-gaap:LongTermLineOfCredit>
    <us-gaap:LongTermLineOfCredit
      contextRef="C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc"
      decimals="-3"
      id="F_5e6d6d7f-371a-45d6-813e-d5bbdb705c43"
      unitRef="U_USD">21854000</us-gaap:LongTermLineOfCredit>
    <us-gaap:Liabilities
      contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256"
      decimals="-3"
      id="F_07dc4012-4f12-44ba-bab3-6ecd119bcac5"
      unitRef="U_USD">52517000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc"
      decimals="-3"
      id="F_0322ecab-004d-4e39-9255-ac47da48ac0c"
      unitRef="U_USD">60703000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256"
      decimals="INF"
      id="F_5c8067cc-6993-4fe3-a253-fb858fe7cd1f"
      unitRef="U_UsdShare">0</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc"
      decimals="INF"
      id="F_0a0c4241-4e1b-4f84-80b2-7d7177715100"
      unitRef="U_UsdShare">0</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256"
      decimals="INF"
      id="F_404bd8c7-01c0-4cdc-abc2-ae6ef42f0b13"
      unitRef="U_shares">75511375</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256"
      decimals="INF"
      id="F_bc958c2f-f2e2-458b-b471-810c29a73037"
      unitRef="U_shares">75511375</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc"
      decimals="INF"
      id="F_788add1e-0804-483b-b377-8ccea53f1061"
      unitRef="U_shares">75100763</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc"
      decimals="INF"
      id="F_9b322a3d-fb0e-40b6-8278-05d85db318f7"
      unitRef="U_shares">75100763</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256"
      decimals="-3"
      id="F_89310f74-3231-4e3a-999f-153060f997fb"
      unitRef="U_USD">644231000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc"
      decimals="-3"
      id="F_44ef3deb-a600-433f-ab56-9653cc16b35a"
      unitRef="U_USD">639508000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256"
      decimals="-3"
      id="F_c96ebbdb-ab62-4e53-9fbf-4ec4e2e0a67c"
      unitRef="U_USD">802000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc"
      decimals="-3"
      id="F_d0df376d-6b84-4b8f-a48d-8105661420a3"
      unitRef="U_USD">819000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256"
      decimals="-3"
      id="F_43702ee0-c5be-4f39-9a7f-398a12902491"
      unitRef="U_USD">-422227000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc"
      decimals="-3"
      id="F_2b81b864-98b4-4279-9d18-4a8513e7eced"
      unitRef="U_USD">-398879000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256"
      decimals="-3"
      id="F_60742cfa-fb5e-4442-8ad9-3d9da72a276e"
      unitRef="U_USD">222806000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc"
      decimals="-3"
      id="F_a85b6ba0-030e-46d0-b5ac-f2628d50a300"
      unitRef="U_USD">241448000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256"
      decimals="-3"
      id="F_c225a96c-6241-4a8e-91e1-9402b4e22216"
      unitRef="U_USD">275323000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc"
      decimals="-3"
      id="F_7d9eff17-1310-4550-9d9a-8ed8b1b26f1a"
      unitRef="U_USD">302151000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="-3"
      id="F_93bb77a6-a126-4cc4-ba41-5531d8b638cb"
      unitRef="U_USD">23357000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb"
      decimals="-3"
      id="F_95332ca9-d96c-40cb-b302-a0ebcc314c17"
      unitRef="U_USD">11705000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="-3"
      id="F_1314d69d-a5b7-4f8a-9e37-3314f5d9456e"
      unitRef="U_USD">8802000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb"
      decimals="-3"
      id="F_b1a74b65-9637-4472-ba28-ce5b7306a52b"
      unitRef="U_USD">10499000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="-3"
      id="F_23ebb5fe-2d36-43f3-adb3-0f0415c4ff4f"
      unitRef="U_USD">32159000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb"
      decimals="-3"
      id="F_06b00695-e2a5-4bed-83fa-f1d4d9bccd95"
      unitRef="U_USD">22204000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="-3"
      id="F_84606b17-2bb8-41b3-afc6-d81d82b1a778"
      unitRef="U_USD">-32159000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb"
      decimals="-3"
      id="F_9da70c3e-d52f-4b98-a773-1a77fa47be97"
      unitRef="U_USD">-22204000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterestAndDividend
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="-3"
      id="F_aa40f28f-4ee7-4a09-97c0-470b422d4295"
      unitRef="U_USD">2433000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InvestmentIncomeInterestAndDividend
      contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb"
      decimals="-3"
      id="F_7a86f410-7fc2-43c1-95a8-36c619f235e9"
      unitRef="U_USD">1656000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InterestExpense
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="-3"
      id="F_a6290542-699d-41da-8ced-6927396d5530"
      unitRef="U_USD">602000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb"
      decimals="-3"
      id="F_b2687579-4de1-441a-b9de-b23325241372"
      unitRef="U_USD">434000</us-gaap:InterestExpense>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="-3"
      id="F_7d283256-c8e6-4524-8851-657683b46dd0"
      unitRef="U_USD">-19000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb"
      decimals="-3"
      id="F_620c1258-16be-44f0-a1e9-9c5c925e3943"
      unitRef="U_USD">-525000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="-3"
      id="F_ea3b3ac8-1207-4b00-9038-37f80695acdf"
      unitRef="U_USD">-6999000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb"
      decimals="-3"
      id="F_e957c067-5031-4c6c-8898-ac39b1cb34f1"
      unitRef="U_USD">32893000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="-3"
      id="F_616e13df-ec18-484a-a46e-9d4b0bf6bdd7"
      unitRef="U_USD">8811000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb"
      decimals="-3"
      id="F_a683b086-319d-4a7e-8132-da21e839b724"
      unitRef="U_USD">-32196000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="-3"
      id="F_93702d9a-53c4-43a8-8478-7d73143ba34c"
      unitRef="U_USD">-23348000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb"
      decimals="-3"
      id="F_13ade13d-0c3c-42fa-a37c-c9ad59327443"
      unitRef="U_USD">-54400000</us-gaap:NetIncomeLoss>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="-3"
      id="F_00561164-01a9-4568-aacc-e1b8deb2d2bb"
      unitRef="U_USD">10000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="-3"
      id="F_53863f66-a6a1-4894-aed3-ac17bd9a84e6"
      unitRef="U_USD">-27000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb"
      decimals="-3"
      id="F_a6b38bf5-35fc-4335-8480-0dcc578e9e10"
      unitRef="U_USD">493000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="-3"
      id="F_e5113b84-b996-4f43-810c-ac57a5c1dc11"
      unitRef="U_USD">-23365000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb"
      decimals="-3"
      id="F_492b73c3-dc05-4336-a99f-82e6d38d2345"
      unitRef="U_USD">-53907000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="2"
      id="F_0160c27f-e942-4a00-aa71-cbbfeb28c631"
      unitRef="U_UsdShare">-0.27</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb"
      decimals="2"
      id="F_5c799877-e248-4b01-a966-5d0e31d66647"
      unitRef="U_UsdShare">-1.14</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="2"
      id="F_ebab1cc7-4c9d-42e9-9daf-90409c3abd4d"
      unitRef="U_UsdShare">-0.35</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb"
      decimals="2"
      id="F_8b357347-2224-4461-943f-157658a10473"
      unitRef="U_UsdShare">-1.14</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="INF"
      id="F_ce1dcb81-c32c-45c8-9421-60f38d1b6aa3"
      unitRef="U_shares">85067855</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb"
      decimals="INF"
      id="F_c72931fe-8fb1-4605-aa68-7eab3fe897aa"
      unitRef="U_shares">47860757</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="INF"
      id="F_45329e87-849f-4667-806c-506fd4f6bc36"
      unitRef="U_shares">87091461</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb"
      decimals="INF"
      id="F_723f1f9d-dfa6-4edc-859f-1166aba7806f"
      unitRef="U_shares">47860757</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="C_a8edddb6-a7d1-4462-a57e-b8c66cc64c46"
      decimals="INF"
      id="F_de7a1b3c-7f19-4cd8-ba3d-4e1ac24187a2"
      unitRef="U_shares">75100763</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_a991fead-ed19-4c7e-a11e-4d30d6b8613d"
      decimals="-3"
      id="F_d87a7b96-3e78-4955-8f42-5699123fa60e"
      unitRef="U_USD">639508000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_385312b0-168e-450a-8069-c73e69ed32d7"
      decimals="-3"
      id="F_2e67503c-a26e-4778-9d69-23e1d2bcacc7"
      unitRef="U_USD">819000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_6e886f9e-717a-465f-9fee-5b794de40e69"
      decimals="-3"
      id="F_07ad578f-76fd-4b8c-a22d-6887d88b8894"
      unitRef="U_USD">-398879000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc"
      decimals="-3"
      id="F_4df2da8f-e2de-4d15-a40d-9fda5a1b96d6"
      unitRef="U_USD">241448000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_cb6db0ce-574c-45c7-a69a-4330f84bb3c7"
      decimals="INF"
      id="F_7a323798-2d90-4b1d-967b-c97d970cff3f"
      unitRef="U_shares">34017</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_cf6044bc-91e6-4b8c-82c8-fab4740fed04"
      decimals="-3"
      id="F_57a7e6ae-95fd-4869-a7f2-2de49b5e599d"
      unitRef="U_USD">186000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="-3"
      id="F_9a827b54-c458-414c-990a-4fb129524ea5"
      unitRef="U_USD">186000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <mnmd:StockIssuedDuringPeriodSharesUponSettlementOfRestrictedStockUnitAwardsNetOfSharesWithheldForTax
      contextRef="C_cb6db0ce-574c-45c7-a69a-4330f84bb3c7"
      decimals="INF"
      id="F_6ad861fe-d154-4983-8900-4b6d657e6859"
      unitRef="U_shares">186708</mnmd:StockIssuedDuringPeriodSharesUponSettlementOfRestrictedStockUnitAwardsNetOfSharesWithheldForTax>
    <mnmd:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="C_2711bf7d-51fa-4c13-8e64-2c94219ab80a"
      decimals="INF"
      id="F_21414216-831e-4d02-8568-6df38fe8a3c1"
      unitRef="U_shares">136346</mnmd:StockIssuedDuringPeriodSharesWarrantsExercised>
    <mnmd:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="C_6feaeecd-fd52-496a-87c2-1985d67f38f0"
      decimals="-3"
      id="F_da69e159-9da8-47f9-bb7c-6ebd26acb336"
      unitRef="U_USD">874000</mnmd:StockIssuedDuringPeriodValueWarrantsExercised>
    <mnmd:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="C_b180f4c3-0072-43ff-9725-7c3a3e4ad1f1"
      decimals="-3"
      id="F_69519416-2fbb-48bb-ab1c-069490a05475"
      unitRef="U_USD">874000</mnmd:StockIssuedDuringPeriodValueWarrantsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_cf6044bc-91e6-4b8c-82c8-fab4740fed04"
      decimals="-3"
      id="F_1a905233-2840-423f-b534-76538864042f"
      unitRef="U_USD">3426000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="-3"
      id="F_555c6fb8-2017-44c1-aadd-c799a0fec8b2"
      unitRef="U_USD">3426000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_cb6db0ce-574c-45c7-a69a-4330f84bb3c7"
      decimals="INF"
      id="F_5ad89844-1047-437a-9759-1b59c66d1ead"
      unitRef="U_shares">53541</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_cf6044bc-91e6-4b8c-82c8-fab4740fed04"
      decimals="-3"
      id="F_4230cb0e-a4d7-4940-a358-5463ce2974ea"
      unitRef="U_USD">237000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="-3"
      id="F_c779ba4c-c3a7-4586-83f1-d9645c020072"
      unitRef="U_USD">237000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_4abdbb57-7e44-40e1-a361-dedbe9966b38"
      decimals="-3"
      id="F_dbc62f05-59a2-4171-acf1-14b51068bad5"
      unitRef="U_USD">-17000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_39a7f94d-b020-4c68-859b-28f61826d359"
      decimals="-3"
      id="F_b3dfc902-15e2-480b-b241-39fabb3fccea"
      unitRef="U_USD">-23348000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="-3"
      id="F_45f81ea0-6cc0-4ca4-841c-df94dab6b339"
      unitRef="U_USD">-23365000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="C_98c96557-3887-4999-b5e8-247c1ed96005"
      decimals="INF"
      id="F_70dc6267-c2aa-4050-adf7-f07b4ea7fca6"
      unitRef="U_shares">75511375</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_83fc4e0e-c83d-497b-af6e-c962abe5d2fd"
      decimals="-3"
      id="F_b56c4304-03f3-4866-a719-72724ac5a294"
      unitRef="U_USD">644231000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_cb762e0c-1384-4979-be76-95297f6af7c8"
      decimals="-3"
      id="F_5447cb05-dd39-49c4-b4ea-e04d5b272ab1"
      unitRef="U_USD">802000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_939e4af1-6bdb-4858-a841-8acd4d2a47f4"
      decimals="-3"
      id="F_a1090ea5-7851-460f-9c99-ad065c789b3a"
      unitRef="U_USD">-422227000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256"
      decimals="-3"
      id="F_79072a10-fecd-4155-a12e-a4116446fef4"
      unitRef="U_USD">222806000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_57494605-d58d-4ef0-b4ff-8e96f7bcf04c"
      decimals="INF"
      id="F_d3332014-cd2a-4dc0-af74-509bb3a69adb"
      unitRef="U_shares">41101303</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_54995453-beb7-498a-8683-7850a8191dba"
      decimals="-3"
      id="F_df3929db-867c-4f4f-89f0-59601617ee1d"
      unitRef="U_USD">367991000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_a39c400a-978e-47bc-a958-d2b3c57c3ab7"
      decimals="-3"
      id="F_ae6d0c66-aeaa-44db-bd60-1ad4044b5e5f"
      unitRef="U_USD">343000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_37fa8a98-03fc-4f71-9bce-63073a3d3907"
      decimals="-3"
      id="F_245c1c4d-3690-40cc-a044-8ea050f7a3ca"
      unitRef="U_USD">-290200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_ebfcf44a-8b21-4107-a576-08b906d78af5"
      decimals="-3"
      id="F_be5cb3dc-ecc9-4eb2-86f1-d856bebf65b0"
      unitRef="U_USD">78134000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_a76dd043-ee75-4b71-a525-e4107e5d3732"
      decimals="INF"
      id="F_8678f894-375a-422f-a71c-f5da2233db56"
      unitRef="U_shares">29338553</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_925b985b-901b-4479-a40b-d64febbd22cf"
      decimals="-3"
      id="F_17683d08-1404-4398-aad6-a86a22a38d85"
      unitRef="U_USD">164298000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb"
      decimals="-3"
      id="F_5d9294ce-c2d1-4cfa-a00c-c3b8bc0abbba"
      unitRef="U_USD">164298000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <mnmd:StockIssuedDuringPeriodSharesUponSettlementOfRestrictedStockUnitAwardsNetOfSharesWithheldForTax
      contextRef="C_a76dd043-ee75-4b71-a525-e4107e5d3732"
      decimals="INF"
      id="F_c7c69cd6-cbab-4d05-b347-2d7cc9478d37"
      unitRef="U_shares">204968</mnmd:StockIssuedDuringPeriodSharesUponSettlementOfRestrictedStockUnitAwardsNetOfSharesWithheldForTax>
    <mnmd:StockIssuedDuringPeriodValueUponSettlementOfRestrictedStockUnitAwardsNetOfSharesWithheldForTax
      contextRef="C_925b985b-901b-4479-a40b-d64febbd22cf"
      decimals="-3"
      id="F_92247aa7-f82b-4da8-8a73-823a987b114c"
      unitRef="U_USD">-54000</mnmd:StockIssuedDuringPeriodValueUponSettlementOfRestrictedStockUnitAwardsNetOfSharesWithheldForTax>
    <mnmd:StockIssuedDuringPeriodValueUponSettlementOfRestrictedStockUnitAwardsNetOfSharesWithheldForTax
      contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb"
      decimals="-3"
      id="F_7e49f9eb-f630-438f-9437-7fa4c5ee2468"
      unitRef="U_USD">-54000</mnmd:StockIssuedDuringPeriodValueUponSettlementOfRestrictedStockUnitAwardsNetOfSharesWithheldForTax>
    <mnmd:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="C_8e1a6127-7406-40c2-a294-e96d17a71e6c"
      decimals="INF"
      id="F_2b9b200f-a13f-4b4f-b591-a93232cd217f"
      unitRef="U_shares">400000</mnmd:StockIssuedDuringPeriodSharesWarrantsExercised>
    <mnmd:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="C_24991487-9f41-4eb3-b745-b05e5c54af14"
      decimals="-3"
      id="F_37dc5674-963c-4a9f-9b0f-e005d3668d72"
      unitRef="U_USD">3369000</mnmd:StockIssuedDuringPeriodValueWarrantsExercised>
    <mnmd:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="C_9e259264-1dab-4ca4-a6a1-b8eba8c5e07f"
      decimals="-3"
      id="F_73704735-4ed7-4bfd-be14-72c71b7b4bb6"
      unitRef="U_USD">3369000</mnmd:StockIssuedDuringPeriodValueWarrantsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_925b985b-901b-4479-a40b-d64febbd22cf"
      decimals="-3"
      id="F_6fa5c2de-5013-475c-a591-2f8fb95e657a"
      unitRef="U_USD">3689000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb"
      decimals="-3"
      id="F_c460ca0c-30f8-40e2-ae93-23c2ccf38ac1"
      unitRef="U_USD">3689000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_a76dd043-ee75-4b71-a525-e4107e5d3732"
      decimals="INF"
      id="F_3bfb4ae9-f030-4e92-81c5-1233abcf6c91"
      unitRef="U_shares">118896</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_925b985b-901b-4479-a40b-d64febbd22cf"
      decimals="-3"
      id="F_1f788144-715a-4c69-a7e8-87b61611d930"
      unitRef="U_USD">530000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb"
      decimals="-3"
      id="F_e2925748-10b5-4395-b4b1-bc25ec5a3890"
      unitRef="U_USD">530000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_75bc9303-a477-4604-852c-7370782dc59b"
      decimals="-3"
      id="F_b167cd98-8234-461d-ae22-fce9431c0292"
      unitRef="U_USD">493000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_01a2dc55-35b5-4300-97d4-8821ba88df11"
      decimals="-3"
      id="F_30930b7e-cc6b-4194-9ccf-17741fb14766"
      unitRef="U_USD">-54400000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb"
      decimals="-3"
      id="F_1fbd5933-e1f2-474d-8431-9a84bea3106b"
      unitRef="U_USD">-53907000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="C_095bf73d-2ada-4710-8b73-6c8b87d5dc15"
      decimals="INF"
      id="F_66963c86-bf8f-4621-9d49-2c9329476389"
      unitRef="U_shares">71163720</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_e6549b22-6f92-4409-ac7d-193000c6fe21"
      decimals="-3"
      id="F_7a0f254d-1aa7-436d-a548-fde333f4b752"
      unitRef="U_USD">539823000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_13b67830-d4f4-404f-a407-d676bfd7b796"
      decimals="-3"
      id="F_764070d0-2797-4255-b781-72aacdc94370"
      unitRef="U_USD">836000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_bd03d603-030d-4d7d-8bdb-3dd6759f747f"
      decimals="-3"
      id="F_6adbc681-e903-4ed7-818b-1aec56edf750"
      unitRef="U_USD">-344600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_06e3dec8-4efa-4049-969d-372ad64052f3"
      decimals="-3"
      id="F_30c98250-2f2a-4b73-aca6-0e69e693fa67"
      unitRef="U_USD">196059000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="-3"
      id="F_c8bad7b0-d86c-4e66-ae5c-7c557f9e242c"
      unitRef="U_USD">-23348000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb"
      decimals="-3"
      id="F_10a45c67-09ff-4d30-896a-d32cfc3d07b5"
      unitRef="U_USD">-54400000</us-gaap:ProfitLoss>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="-3"
      id="F_fe342b06-e385-400a-90f7-cafe2708aa1b"
      unitRef="U_USD">3426000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb"
      decimals="-3"
      id="F_62d766a5-2bab-4749-8f56-9d31cb1c0b03"
      unitRef="U_USD">3689000</us-gaap:AllocatedShareBasedCompensationExpense>
    <mnmd:ChangeInFairValueOnDirectorsDeferredShareUnits
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="-3"
      id="F_0e897274-6d06-45ca-bc09-e93b5c892cfe"
      unitRef="U_USD">18000</mnmd:ChangeInFairValueOnDirectorsDeferredShareUnits>
    <mnmd:ChangeInFairValueOnDirectorsDeferredShareUnits
      contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb"
      decimals="-3"
      id="F_9f67234e-c641-464d-a55b-c77d9d5466e0"
      unitRef="U_USD">-781000</mnmd:ChangeInFairValueOnDirectorsDeferredShareUnits>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="-3"
      id="F_ca1ab64e-b623-4be0-afb3-6870c497838c"
      unitRef="U_USD">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb"
      decimals="-3"
      id="F_b3efe1c0-a04e-4a6a-9e72-b12621f1311f"
      unitRef="U_USD">527000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="-3"
      id="F_cf898555-3ad8-44e3-8a10-41459dde0c1f"
      unitRef="U_USD">-6999000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb"
      decimals="-3"
      id="F_19e1b528-850a-4728-9c85-e33f4e530b08"
      unitRef="U_USD">32893000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="-3"
      id="F_2402945e-2653-47b3-a89b-e4d199ede957"
      unitRef="U_USD">-0</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb"
      decimals="-3"
      id="F_3ca463c5-0c0c-4801-bf52-d73b137473d5"
      unitRef="U_USD">-514000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <mnmd:OtherNonCashAdjustments
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="-3"
      id="F_326ee79f-0909-4a79-9c86-4a9122e2365e"
      unitRef="U_USD">-19000</mnmd:OtherNonCashAdjustments>
    <mnmd:OtherNonCashAdjustments
      contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb"
      decimals="-3"
      id="F_84272f74-58ff-45fb-948d-f22194dec162"
      unitRef="U_USD">75000</mnmd:OtherNonCashAdjustments>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="-3"
      id="F_e9ffc9d1-297b-4508-bc82-80882082d596"
      unitRef="U_USD">1380000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb"
      decimals="-3"
      id="F_93098d1c-f52e-4458-8f75-c6f884653286"
      unitRef="U_USD">-468000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="-3"
      id="F_0632fe4b-4d47-401c-8b62-f5ee1f2524a5"
      unitRef="U_USD">10000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb"
      decimals="-3"
      id="F_c744ddfb-6bb0-417d-89de-bebdc54d46b8"
      unitRef="U_USD">-66000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="-3"
      id="F_57ebd9c9-6196-4648-b259-0b2349cf057f"
      unitRef="U_USD">258000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb"
      decimals="-3"
      id="F_87158d5d-84de-4997-b510-de17f8bb4853"
      unitRef="U_USD">1509000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="-3"
      id="F_0e47e25d-ad9c-4bc0-ae75-590bc81c56b3"
      unitRef="U_USD">-1329000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb"
      decimals="-3"
      id="F_774ba73f-3789-4994-a74c-4af92a05c76f"
      unitRef="U_USD">-2703000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <mnmd:OtherLiabilitiesLongTerm
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="-3"
      id="F_87b86468-3cf6-44e4-825b-a6df240a6044"
      unitRef="U_USD">0</mnmd:OtherLiabilitiesLongTerm>
    <mnmd:OtherLiabilitiesLongTerm
      contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb"
      decimals="-3"
      id="F_082d6792-fecb-4452-b1eb-9f37510c05f6"
      unitRef="U_USD">17000</mnmd:OtherLiabilitiesLongTerm>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="-3"
      id="F_860687b8-092b-4634-ab27-98a9ae40da4e"
      unitRef="U_USD">-29419000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb"
      decimals="-3"
      id="F_bbe5c696-85c3-4b1f-a367-e0d3ec088817"
      unitRef="U_USD">-16598000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="-3"
      id="F_578e3791-d1ff-4487-9c61-1b27286190c2"
      unitRef="U_USD">162458000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb"
      decimals="-3"
      id="F_047900d2-eae1-4713-9e26-84fd8abb359f"
      unitRef="U_USD">0</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="-3"
      id="F_c3f3450d-d935-4b0f-99dd-49c8c51e651f"
      unitRef="U_USD">-162458000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb"
      decimals="-3"
      id="F_432ac63c-fa70-48ab-8056-6d466362d425"
      unitRef="U_USD">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <mnmd:ProceedsFromOfferingAndPrivatePlacement
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="-3"
      id="F_44ab149d-97c8-4047-a548-099e633e6f7f"
      unitRef="U_USD">0</mnmd:ProceedsFromOfferingAndPrivatePlacement>
    <mnmd:ProceedsFromOfferingAndPrivatePlacement
      contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb"
      decimals="-3"
      id="F_5cac1732-efea-4a8f-851e-f5971f2c88ca"
      unitRef="U_USD">175000000</mnmd:ProceedsFromOfferingAndPrivatePlacement>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="-3"
      id="F_ec37bf7a-8b5c-407d-8a74-74213d2cda03"
      unitRef="U_USD">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb"
      decimals="-3"
      id="F_38d14adb-2ac9-4200-b727-065c9faf09a2"
      unitRef="U_USD">8720000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="-3"
      id="F_597e4570-08d3-4024-a2df-309d72308d9d"
      unitRef="U_USD">0</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb"
      decimals="-3"
      id="F_57b4e01e-c0cc-4b4d-acfd-26a2aeaf5d2a"
      unitRef="U_USD">128000</us-gaap:PaymentsOfFinancingCosts>
    <mnmd:ProceedsFromAtTheMarketOfferingProgramNetOfIssuanceCosts
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="-3"
      id="F_4d887e9d-0058-491c-b4d8-158bfceaa47c"
      unitRef="U_USD">0</mnmd:ProceedsFromAtTheMarketOfferingProgramNetOfIssuanceCosts>
    <mnmd:ProceedsFromAtTheMarketOfferingProgramNetOfIssuanceCosts
      contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb"
      decimals="-3"
      id="F_7f3da661-3851-4476-8e3d-ffff156fd678"
      unitRef="U_USD">984000</mnmd:ProceedsFromAtTheMarketOfferingProgramNetOfIssuanceCosts>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="-3"
      id="F_476b7a77-c848-4ed8-a656-3dec3fd507eb"
      unitRef="U_USD">579000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb"
      decimals="-3"
      id="F_ce2f122b-ce7e-4d06-ac17-8c9614d657ae"
      unitRef="U_USD">1700000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="-3"
      id="F_6ddd3af6-0da8-4428-a601-078a0db9d8e6"
      unitRef="U_USD">237000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb"
      decimals="-3"
      id="F_349f0d70-bb21-4b8e-bcaa-7e88076d0938"
      unitRef="U_USD">465000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="-3"
      id="F_4999393a-846a-432e-9430-a8582e5a690b"
      unitRef="U_USD">186000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb"
      decimals="-3"
      id="F_723d9e9b-c03e-45d4-97d6-4dcc568e5d92"
      unitRef="U_USD">0</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="-3"
      id="F_f1920035-f711-4e71-bd18-5a0dfbe9d4a3"
      unitRef="U_USD">0</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb"
      decimals="-3"
      id="F_3f2ea04c-1157-4266-9da6-69d3576a50fb"
      unitRef="U_USD">54000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="-3"
      id="F_b72a2688-53a2-4264-9593-00cdfa90789b"
      unitRef="U_USD">1002000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb"
      decimals="-3"
      id="F_382a40f9-87f1-4275-b65e-a3eb01c7daba"
      unitRef="U_USD">169247000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="-3"
      id="F_b29808d8-c6fe-47a9-a1d4-e8b2afcba0b1"
      unitRef="U_USD">-12000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb"
      decimals="-3"
      id="F_761bc4ce-ed6f-4571-bf57-5ed2106ac4c6"
      unitRef="U_USD">-21000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="-3"
      id="F_6fa63cf5-0ddb-41b8-ae42-c8b2aa2bf46b"
      unitRef="U_USD">-190887000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb"
      decimals="-3"
      id="F_d5069f48-320e-442a-8a21-b2ab1f23e669"
      unitRef="U_USD">152628000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc"
      decimals="-3"
      id="F_35853e7b-aea9-49d3-933e-5f57968eeaa4"
      unitRef="U_USD">273741000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_ebfcf44a-8b21-4107-a576-08b906d78af5"
      decimals="-3"
      id="F_cd0c1698-86da-4e7e-bb50-2b0875fa58f3"
      unitRef="U_USD">99704000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256"
      decimals="-3"
      id="F_2868d349-319c-4b84-9b60-3f8eb7ba2f36"
      unitRef="U_USD">82854000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_06e3dec8-4efa-4049-969d-372ad64052f3"
      decimals="-3"
      id="F_e97942fd-0a04-4337-a9c1-375e5573aa44"
      unitRef="U_USD">252332000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:InterestPaidNet
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="-3"
      id="F_c98c0437-e364-4947-bfcd-cff6d826692d"
      unitRef="U_USD">602000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb"
      decimals="-3"
      id="F_873252c1-66e8-42df-b160-79ce5f8a08cb"
      unitRef="U_USD">434000</us-gaap:InterestPaidNet>
    <us-gaap:StockIssued1
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="-3"
      id="F_26a33404-82cc-4fac-a2a5-0eb135fabc15"
      unitRef="U_USD">295000</us-gaap:StockIssued1>
    <us-gaap:StockIssued1
      contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb"
      decimals="-3"
      id="F_6e388cca-cef7-4f3f-a76f-7ab2f2c9fcc9"
      unitRef="U_USD">1669000</us-gaap:StockIssued1>
    <mnmd:UnpaidIssuanceCostsForOfferingAndPrivatePlacement
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="-3"
      id="F_a5b54769-6c2d-4aff-9735-d1b22354e475"
      unitRef="U_USD">0</mnmd:UnpaidIssuanceCostsForOfferingAndPrivatePlacement>
    <mnmd:UnpaidIssuanceCostsForOfferingAndPrivatePlacement
      contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb"
      decimals="-3"
      id="F_bf45a1d2-0e61-4657-a79a-35c7a3272913"
      unitRef="U_USD">2340000</mnmd:UnpaidIssuanceCostsForOfferingAndPrivatePlacement>
    <mnmd:ProceedsFromExerciseOfOptionsInPrepaidAndOtherCurrentAssets
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="-3"
      id="F_521a9ddb-a807-4509-8a81-a139d9000eac"
      unitRef="U_USD">0</mnmd:ProceedsFromExerciseOfOptionsInPrepaidAndOtherCurrentAssets>
    <mnmd:ProceedsFromExerciseOfOptionsInPrepaidAndOtherCurrentAssets
      contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb"
      decimals="-3"
      id="F_18a945af-bbf3-4555-9be8-d4b237a95bc4"
      unitRef="U_USD">65000</mnmd:ProceedsFromExerciseOfOptionsInPrepaidAndOtherCurrentAssets>
    <mnmd:ReclassOfDeferredFinancingFeesToAdditionalPaidInCapital
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="-3"
      id="F_14641fa9-e1d3-4382-a203-788c8a13ecd5"
      unitRef="U_USD">0</mnmd:ReclassOfDeferredFinancingFeesToAdditionalPaidInCapital>
    <mnmd:ReclassOfDeferredFinancingFeesToAdditionalPaidInCapital
      contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb"
      decimals="-3"
      id="F_9dfccbd8-0015-48d9-bd26-04aacae529f1"
      unitRef="U_USD">332000</mnmd:ReclassOfDeferredFinancingFeesToAdditionalPaidInCapital>
    <us-gaap:NatureOfOperations
      contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb"
      id="F_c56a2f01-a753-48be-af3e-04598df8c1bf">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;1.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;DESCRIPTION OF THE BUSINESS&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Mind Medicine (MindMed) Inc. (the &#x201c;Company&#x201d; or &#x201c;MindMed&#x201d;) is incorporated under the laws of the Province of British Columbia. Its wholly owned subsidiaries, Mind Medicine, Inc. (&#x201c;MindMed US&#x201d;), HealthMode, Inc., MindMed Pty Ltd., and MindMed GmbH are incorporated in Delaware, Delaware, Australia and Switzerland respectively. MindMed US was incorporated on May 30, 2019.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;MindMed is a late-stage clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders. The Company&#x2019;s mission is to be the global leader in the development and delivery of treatments for brain health disorders that unlock new opportunities to improve patient outcomes. The Company is developing a pipeline of innovative product candidates targeting neurotransmitter pathways that play key roles in brain health. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, the Company&#x2019;s lead product candidates.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Liquidity&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of March 31, 2025, the Company had an accumulated deficit of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;422.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. Through March 31, 2025, the Company&#x2019;s financial support has primarily been provided by proceeds from the issuance of its common shares, no par value per share (&#x201c;Common Shares&#x201d;) and warrants to purchase Common Shares, and the Company&#x2019;s credit facility.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As the Company continues its expansion, it may seek additional financing and/or strategic investments; however, there can be no assurance that any additional financing or strategic investments will be available to the Company on acceptable terms, if at all. If events or circumstances occur such that the Company does not obtain additional funding, it will most likely be required to reduce its plans and/or certain discretionary spending, which could have a material adverse effect on the Company&#x2019;s ability to achieve its intended business objectives. The accompanying unaudited condensed consolidated financial statements do not include any adjustments that might be necessary if it were unable to continue as a going concern. Management believes that it has sufficient working capital on hand to fund operations through at least the next twelve months from the date of the issuance of these unaudited condensed consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Emerging Growth Company Status&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use the extended transition period for complying with new or revised accounting standards, and as a result of this election, the unaudited condensed consolidated financial statements may not be comparable to companies that comply with public company Financial Accounting Standards Board (&#x201c;FASB&#x201d;) standards&#x2019; effective dates. The Company may take advantage of these exemptions up until the last day of the fiscal year following the fifth anniversary of the first sale of its common equity securities under an effective Securities Act of 1933 (the "Securities Act") registration statement or such earlier time that it is no longer an emerging growth company.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In the opinion of management, these unaudited condensed consolidated financial statements reflect all adjustments necessary for a fair presentation of the Company's financial position and results of operations and cash flows for the periods presented.&lt;/span&gt;&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256"
      decimals="-5"
      id="F_35c02392-1070-4376-964a-756a1ec0cbef"
      unitRef="U_USD">-422200000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      id="F_806caf41-aa05-4d5f-9fef-ffa4e2408309">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;2.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;BASIS OF pRESENTATION AND Summary of Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#x201c;U.S. GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification and as amended by Accounting Standards Updates of FASB. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the related notes thereto for the year ended December 31, 2024, which are included in the Company&#x2019;s 2024 Annual Report on Form 10-K filed with the SEC on March 6, 2025 (the &#x201c;2024 Annual Report&#x201d;). The Company&#x2019;s significant accounting policies are disclosed in the audited consolidated financial statements for the periods ended December 31, 2024 and 2023, included in the 2024 Annual Report. Since the date of those financial statements, there have been no changes to the Company's significant accounting policies.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make a number of estimates and assumptions relating to the reporting of assets and liabilities and the disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates under different assumptions or conditions.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Intercompany balances and transactions, and any unrealized income and expenses arising from intercompany transactions, are eli&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;minated in preparing the unaudited condensed consolidated financial statements.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Foreign Currency&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Prior to April 1, 2024, the Company&#x2019;s functional currency was the Canadian dollar (&#x201c;CAD&#x201d;). Translation gains and losses from the application of the U.S. dollar (&#x201c;USD&#x201d;) as the reporting currency during the period that the Canadian dollar was the functional currency were included as part of cumulative currency translation adjustment, which is reported as a component of shareholders&#x2019; equity as accumulated other comprehensive income.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Following the Company&#x2019;s voluntary delisting from Cboe Canada in April 2024, the Company reassessed its functional currency and determined that, as of April 1, 2024, its functional currency had changed from the CAD to the USD.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For periods commencing April 1, 2024, monetary assets and liabilities denominated in currencies other than USD are remeasured at period-end using the period-end exchange rate. Opening balances related to non-monetary assets and liabilities are based on prior period translated amounts, and non-monetary assets acquired, and non-monetary liabilities incurred after April 1, 2024, are translated at the approximate exchange rate prevailing at the date of the transaction. Income and expense accounts are translated at the average rates in effect during the fiscal year. Foreign exchange gains and losses are included in the unaudited condensed cons&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;olidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.535%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.037%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company considers all investments with an original maturity date at the time of purchase of three months or less to be cash equivalents. As of March 31, 2025, the Company&#x2019;s cash equivalents consisted of U.S. government money market funds at a high-credit quality and federally insured financial institution. The Company&#x2019;s accounts may, at times, exceed federally insured limits. The &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Company had cash equivalents of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million as of March 31, 2025, and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;271.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million as of December 31, 2024.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Investments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.535%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.037%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;All investments have been classified as &#x201c;available-for-sale&#x201d; and are carried at fair value as determined based upon quoted market prices or pricing models for similar securities at period end. Investments with contractual maturities within 12 months at the balance sheet date are considered short-term investments. Those investments with contractual maturities greater than 12 months at the balance sheet date are considered long-term investments. Dividend and interest income are recognized when earned. Realized gains and losses are included in earnings and are derived using the specific identification method for determining the cost of securities sold. Unrealized gains and losses are reported as a component of accumulated other comprehensive income (loss). The Company reviews its portfolio of available-for-sale debt securities, using both quantitative and qualitative factors, to determine if declines in fair value below cost have resulted from a credit-related loss or other factors. If the decline in fair value is due to credit-related factors, a loss is recognized in statements of operations, whereas if the decline in fair value is not due to credit-related factors, the loss is recorded in other co&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;mprehensive income (loss).&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Net Loss per Share&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.535%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.037%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For the three-month period ended March 31, 2025, the Company determined that the 2022 USD Financing Warrants had a dilutive impact to the calculation of net loss per share. As a result, the Company calculated the diluted net loss per Common Share for the three months ended March 31, 2025.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table sets forth the computation of basic and diluted net loss per share attributable to common shareholders (in thousands, except sh&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;are and per share amounts). As the exercise price of the Company&#x2019;s pre-funded warrants is $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, it was determined to be non-substantive for accounting purposes and the pre-funded warrants were included in the denominator of both basic and diluted loss per share:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
         &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
          &lt;tr style="visibility:collapse;"&gt;
           &lt;td style="width:66.673%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:1.64%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:13.023%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:1.64%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:13.023%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss attributable to common shareholders, basic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,348&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;54,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in fair value of the 2022 USD Financing Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,999&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss attributable to common shareholders, diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,347&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;54,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average pre-funded warrants used in computing net loss&lt;br/&gt;per share attributable to common shareholders, basic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,753,775&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average shares used in computing net loss per share&lt;br/&gt;attributable to common shareholders, basic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75,314,080&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;47,860,757&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total weighted-average shares used in computing net loss per&lt;br/&gt;share attributable to common shareholders, basic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85,067,855&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;47,860,757&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Incremental shares from 2022 USD Financing Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,023,606&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total weighted-average shares used in computing net loss per&lt;br/&gt;share attributable to common shareholders, diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;87,091,461&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;47,860,757&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Net loss per share:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Basic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
         &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following potentially dilutive securities have been excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
         &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
          &lt;tr style="visibility:collapse;"&gt;
           &lt;td style="width:66.967%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2022 USD Financing Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,949,954&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,631,823&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,465,831&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,696,128&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;RSUs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,948,852&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,112,546&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Conversion Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;249,377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;997,506&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Estimated ESPP awards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,939&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,641,953&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,438,003&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
         &lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      id="F_3f60e965-3732-4faa-a4af-15b74ed14535">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#x201c;U.S. GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification and as amended by Accounting Standards Updates of FASB. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the related notes thereto for the year ended December 31, 2024, which are included in the Company&#x2019;s 2024 Annual Report on Form 10-K filed with the SEC on March 6, 2025 (the &#x201c;2024 Annual Report&#x201d;). The Company&#x2019;s significant accounting policies are disclosed in the audited consolidated financial statements for the periods ended December 31, 2024 and 2023, included in the 2024 Annual Report. Since the date of those financial statements, there have been no changes to the Company's significant accounting policies.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make a number of estimates and assumptions relating to the reporting of assets and liabilities and the disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates under different assumptions or conditions.&lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Intercompany balances and transactions, and any unrealized income and expenses arising from intercompany transactions, are eli&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;minated in preparing the unaudited condensed consolidated financial statements.&lt;/span&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      id="F_c577902d-2e4f-4113-ad2f-63c18af90ccb">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Foreign Currency&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Prior to April 1, 2024, the Company&#x2019;s functional currency was the Canadian dollar (&#x201c;CAD&#x201d;). Translation gains and losses from the application of the U.S. dollar (&#x201c;USD&#x201d;) as the reporting currency during the period that the Canadian dollar was the functional currency were included as part of cumulative currency translation adjustment, which is reported as a component of shareholders&#x2019; equity as accumulated other comprehensive income.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Following the Company&#x2019;s voluntary delisting from Cboe Canada in April 2024, the Company reassessed its functional currency and determined that, as of April 1, 2024, its functional currency had changed from the CAD to the USD.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For periods commencing April 1, 2024, monetary assets and liabilities denominated in currencies other than USD are remeasured at period-end using the period-end exchange rate. Opening balances related to non-monetary assets and liabilities are based on prior period translated amounts, and non-monetary assets acquired, and non-monetary liabilities incurred after April 1, 2024, are translated at the approximate exchange rate prevailing at the date of the transaction. Income and expense accounts are translated at the average rates in effect during the fiscal year. Foreign exchange gains and losses are included in the unaudited condensed cons&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;olidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      id="F_7038a90e-2d4b-4a99-a16c-f9231dc51695">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.535%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.037%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company considers all investments with an original maturity date at the time of purchase of three months or less to be cash equivalents. As of March 31, 2025, the Company&#x2019;s cash equivalents consisted of U.S. government money market funds at a high-credit quality and federally insured financial institution. The Company&#x2019;s accounts may, at times, exceed federally insured limits. The &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Company had cash equivalents of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million as of March 31, 2025, and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;271.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million as of December 31, 2024.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256"
      decimals="-5"
      id="F_a933acaf-b691-4d6a-b5fd-f046149c7387"
      unitRef="U_USD">80400000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc"
      decimals="-5"
      id="F_751ec4db-c570-4196-952f-e2422b86eaa1"
      unitRef="U_USD">271500000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesPurchasedOptionsPricePolicy
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      id="F_5a9700df-dbee-4b5b-958e-a400f202b714">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Investments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.535%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.037%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;All investments have been classified as &#x201c;available-for-sale&#x201d; and are carried at fair value as determined based upon quoted market prices or pricing models for similar securities at period end. Investments with contractual maturities within 12 months at the balance sheet date are considered short-term investments. Those investments with contractual maturities greater than 12 months at the balance sheet date are considered long-term investments. Dividend and interest income are recognized when earned. Realized gains and losses are included in earnings and are derived using the specific identification method for determining the cost of securities sold. Unrealized gains and losses are reported as a component of accumulated other comprehensive income (loss). The Company reviews its portfolio of available-for-sale debt securities, using both quantitative and qualitative factors, to determine if declines in fair value below cost have resulted from a credit-related loss or other factors. If the decline in fair value is due to credit-related factors, a loss is recognized in statements of operations, whereas if the decline in fair value is not due to credit-related factors, the loss is recorded in other co&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;mprehensive income (loss).&lt;/span&gt;&lt;/p&gt;</us-gaap:AvailableForSaleSecuritiesPurchasedOptionsPricePolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      id="F_9d9e2b06-4656-4e21-a722-268ac3bb676e">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Net Loss per Share&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.535%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.037%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For the three-month period ended March 31, 2025, the Company determined that the 2022 USD Financing Warrants had a dilutive impact to the calculation of net loss per share. As a result, the Company calculated the diluted net loss per Common Share for the three months ended March 31, 2025.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table sets forth the computation of basic and diluted net loss per share attributable to common shareholders (in thousands, except sh&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;are and per share amounts). As the exercise price of the Company&#x2019;s pre-funded warrants is $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, it was determined to be non-substantive for accounting purposes and the pre-funded warrants were included in the denominator of both basic and diluted loss per share:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
         &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
          &lt;tr style="visibility:collapse;"&gt;
           &lt;td style="width:66.673%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:1.64%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:13.023%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:1.64%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:13.023%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss attributable to common shareholders, basic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,348&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;54,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in fair value of the 2022 USD Financing Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,999&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss attributable to common shareholders, diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,347&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;54,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average pre-funded warrants used in computing net loss&lt;br/&gt;per share attributable to common shareholders, basic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,753,775&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average shares used in computing net loss per share&lt;br/&gt;attributable to common shareholders, basic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75,314,080&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;47,860,757&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total weighted-average shares used in computing net loss per&lt;br/&gt;share attributable to common shareholders, basic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85,067,855&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;47,860,757&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Incremental shares from 2022 USD Financing Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,023,606&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total weighted-average shares used in computing net loss per&lt;br/&gt;share attributable to common shareholders, diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;87,091,461&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;47,860,757&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Net loss per share:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Basic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
         &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following potentially dilutive securities have been excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
         &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
          &lt;tr style="visibility:collapse;"&gt;
           &lt;td style="width:66.967%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2022 USD Financing Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,949,954&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,631,823&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,465,831&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,696,128&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;RSUs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,948,852&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,112,546&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Conversion Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;249,377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;997,506&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Estimated ESPP awards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,939&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,641,953&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,438,003&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
         &lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      id="F_38310de2-f545-4825-88fb-ecd08a1a73fb">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table sets forth the computation of basic and diluted net loss per share attributable to common shareholders (in thousands, except sh&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;are and per share amounts). As the exercise price of the Company&#x2019;s pre-funded warrants is $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, it was determined to be non-substantive for accounting purposes and the pre-funded warrants were included in the denominator of both basic and diluted loss per share:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
         &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
          &lt;tr style="visibility:collapse;"&gt;
           &lt;td style="width:66.673%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:1.64%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:13.023%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:1.64%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:13.023%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss attributable to common shareholders, basic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,348&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;54,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in fair value of the 2022 USD Financing Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,999&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss attributable to common shareholders, diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,347&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;54,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average pre-funded warrants used in computing net loss&lt;br/&gt;per share attributable to common shareholders, basic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,753,775&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average shares used in computing net loss per share&lt;br/&gt;attributable to common shareholders, basic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75,314,080&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;47,860,757&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total weighted-average shares used in computing net loss per&lt;br/&gt;share attributable to common shareholders, basic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85,067,855&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;47,860,757&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Incremental shares from 2022 USD Financing Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,023,606&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total weighted-average shares used in computing net loss per&lt;br/&gt;share attributable to common shareholders, diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;87,091,461&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;47,860,757&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Net loss per share:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Basic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
         &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_aff55750-479b-4423-af77-60c8f43e209e"
      decimals="3"
      id="F_0ebc797c-63ed-480c-b6f7-6cb01f046151"
      unitRef="U_UsdShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="-3"
      id="F_b4db1957-0d10-41e3-9c75-d2c2f81c4910"
      unitRef="U_USD">-23348000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb"
      decimals="-3"
      id="F_388520b1-3212-4744-b1a0-af57e3099dd0"
      unitRef="U_USD">-54400000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="-3"
      id="F_c9551053-2dd8-466b-9913-b76f53685b8d"
      unitRef="U_USD">-6999000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="-3"
      id="F_9af5800b-1d0b-4575-a966-27d532904582"
      unitRef="U_USD">-30347000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb"
      decimals="-3"
      id="F_0f5ef660-b4fb-4726-87e2-05219a72d896"
      unitRef="U_USD">-54400000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <mnmd:WeightedAverageNumberOfPreFundedWarrantsOutstandingBasic
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="0"
      id="F_38eff021-6ccb-4dec-b16b-f7ca14230e70"
      unitRef="U_shares">9753775</mnmd:WeightedAverageNumberOfPreFundedWarrantsOutstandingBasic>
    <mnmd:WeightedAverageNumberOfCommonSharesOutstandingBasic
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="0"
      id="F_31eec6aa-2a84-4e50-8bfb-e982c0a5dcea"
      unitRef="U_shares">75314080</mnmd:WeightedAverageNumberOfCommonSharesOutstandingBasic>
    <mnmd:WeightedAverageNumberOfCommonSharesOutstandingBasic
      contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb"
      decimals="0"
      id="F_df5d9900-0da0-4e5b-b084-636b8ab3438c"
      unitRef="U_shares">47860757</mnmd:WeightedAverageNumberOfCommonSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="0"
      id="F_3fe522a7-11b4-45bf-8ac7-455a954fe3e2"
      unitRef="U_shares">85067855</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb"
      decimals="0"
      id="F_77f27da7-da1f-41e7-9393-95262baf480e"
      unitRef="U_shares">47860757</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="0"
      id="F_94a50a80-3f17-42d8-92eb-a4e13f17cf22"
      unitRef="U_shares">2023606</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="0"
      id="F_66c1f9a2-d3a9-4c84-a7e5-df824a62160c"
      unitRef="U_shares">87091461</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb"
      decimals="0"
      id="F_c5079fa6-8c21-467e-8b17-95743a68d195"
      unitRef="U_shares">47860757</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="2"
      id="F_18e74aca-ad74-4ca5-9faf-cfc09f1d9188"
      unitRef="U_UsdShare">-0.27</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb"
      decimals="2"
      id="F_22449ade-f464-48af-8a42-d2d1ff9da220"
      unitRef="U_UsdShare">-1.14</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="2"
      id="F_0dc2a204-cafc-44b6-9c8d-72d17fdf1ed0"
      unitRef="U_UsdShare">-0.35</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb"
      decimals="2"
      id="F_4a1347c7-247c-4e1f-8934-c79b10128ab5"
      unitRef="U_UsdShare">-1.14</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      id="F_9f73c574-481f-482f-93ee-da1babfb1670">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following potentially dilutive securities have been excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
         &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
          &lt;tr style="visibility:collapse;"&gt;
           &lt;td style="width:66.967%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2022 USD Financing Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,949,954&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,631,823&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,465,831&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,696,128&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;RSUs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,948,852&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,112,546&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Conversion Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;249,377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;997,506&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Estimated ESPP awards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,939&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
           &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,641,953&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,438,003&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
         &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_fd8b6f33-1ed4-4940-897a-df0a934092d1"
      decimals="0"
      id="F_700f9d7f-e338-485e-a711-64cc48855722"
      unitRef="U_shares">4949954</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_3eda8f94-de7e-4394-a39c-79afdb6058ce"
      decimals="0"
      id="F_63862701-f34b-48bb-914e-8abed8613e7b"
      unitRef="U_shares">6631823</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_6011eb25-af6f-4f60-b18a-f48be80a2b48"
      decimals="0"
      id="F_5bb634fa-e89e-45a2-b118-0b206ac55f44"
      unitRef="U_shares">4465831</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_d74b207d-4c84-4383-8d90-5ecc70a0eeb9"
      decimals="0"
      id="F_12cfb136-c3e9-47c8-801d-debbbb94755e"
      unitRef="U_shares">3696128</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_db671577-db0a-4a9e-b198-84650c9bc0dd"
      decimals="0"
      id="F_81928284-cbaf-428f-a605-dfb7a48f24ec"
      unitRef="U_shares">5948852</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_7cf3b999-3819-4049-8c52-90a0e922de85"
      decimals="0"
      id="F_2526006b-9d33-42a4-a2f0-529043bccece"
      unitRef="U_shares">2112546</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_093e9bfe-6581-4ff9-8a14-13447fd595d8"
      decimals="0"
      id="F_280a9f35-e7fe-44dd-a2af-35ef37f039bf"
      unitRef="U_shares">249377</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_4167881d-1e68-4b3c-b401-a89cc1d4f259"
      decimals="0"
      id="F_2d592266-b6e6-4771-8f3b-38a643f63052"
      unitRef="U_shares">997506</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_3c75786f-e793-48f9-af75-c6a4be9a5a7f"
      decimals="0"
      id="F_b2300244-379f-4aca-aed6-99c67dd6fbba"
      unitRef="U_shares">27939</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="0"
      id="F_25c3af2f-2fc1-4786-a46d-a0cdc69f41e6"
      unitRef="U_shares">15641953</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb"
      decimals="0"
      id="F_0560b09f-81c0-4c74-a60e-f6fe9a9f5c65"
      unitRef="U_shares">13438003</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      id="F_dad2b098-0ff5-463e-940c-54f8cbb4c91e">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;3.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;INVESTMENTS&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company's available-for-sale investments consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:50.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;March 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized Gain&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Estimated Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Short-term:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32,725&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32,722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. agency bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;96,868&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;96,865&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;129,593&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;129,587&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Long-term:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. agency bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,083&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,099&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,083&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,099&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has determined that there were no material declines in the fair value of its investments due to credit-related factors as of March 31, 2025. The Company held &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; available-for-sale investments as of December 31, 2024.&lt;/span&gt;&lt;/p&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      id="F_9dc64658-9a1f-4207-a84b-f3b11399661a">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company's available-for-sale investments consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:50.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;March 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized Gain&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Estimated Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Short-term:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32,725&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32,722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. agency bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;96,868&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;96,865&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;129,593&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;129,587&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Long-term:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. agency bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,083&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,099&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,083&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,099&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0229cf68-edf9-4c29-9a29-b011952417f5"
      decimals="-3"
      id="F_e8fcf2cc-2b25-4bc9-af9c-0506f72088af"
      unitRef="U_USD">32725000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0229cf68-edf9-4c29-9a29-b011952417f5"
      decimals="-3"
      id="F_ebb39847-d3ab-48a2-a1bb-0af3a02818e1"
      unitRef="U_USD">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0229cf68-edf9-4c29-9a29-b011952417f5"
      decimals="-3"
      id="F_e8ab12c2-b901-49f2-98f2-990f56d6c14b"
      unitRef="U_USD">32722000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_592df924-3dca-44fb-a185-3cc0e5436ffc"
      decimals="-3"
      id="F_e1aa825b-d3cf-4242-9811-4a88fd35f101"
      unitRef="U_USD">96868000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_592df924-3dca-44fb-a185-3cc0e5436ffc"
      decimals="-3"
      id="F_31ef0644-8775-447d-9933-df6eb46bd4ee"
      unitRef="U_USD">9000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_592df924-3dca-44fb-a185-3cc0e5436ffc"
      decimals="-3"
      id="F_ce614dd5-3ffc-4633-97bf-1f4f4b7a65ea"
      unitRef="U_USD">12000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_592df924-3dca-44fb-a185-3cc0e5436ffc"
      decimals="-3"
      id="F_1197bc3e-4756-42fd-b6f5-1b13b18608c8"
      unitRef="U_USD">96865000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_9530e32c-7cf2-41f3-bd67-a92ee6762331"
      decimals="-3"
      id="F_485f4d3b-fbf8-4b92-823d-9f59a2ba77d7"
      unitRef="U_USD">129593000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_9530e32c-7cf2-41f3-bd67-a92ee6762331"
      decimals="-3"
      id="F_0c1dbff7-fdee-4a58-8492-c15aa636558e"
      unitRef="U_USD">9000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_9530e32c-7cf2-41f3-bd67-a92ee6762331"
      decimals="-3"
      id="F_06150f8e-ce8b-41ea-a490-f7ed8ee8ee7d"
      unitRef="U_USD">15000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_9530e32c-7cf2-41f3-bd67-a92ee6762331"
      decimals="-3"
      id="F_66cac4d6-8897-47ea-a2f8-2e77a2d5f9ca"
      unitRef="U_USD">129587000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_afb02b48-cbcb-40bd-950a-da13b4f46b8a"
      decimals="-3"
      id="F_3bdd9bc9-34a6-460d-9b90-bbab1981e3a3"
      unitRef="U_USD">33083000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_afb02b48-cbcb-40bd-950a-da13b4f46b8a"
      decimals="-3"
      id="F_1d2a98be-744c-49d1-9a95-fdc2811b13d6"
      unitRef="U_USD">17000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_afb02b48-cbcb-40bd-950a-da13b4f46b8a"
      decimals="-3"
      id="F_6b5ca835-fdd9-4e58-bd10-c10a0adf39da"
      unitRef="U_USD">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_afb02b48-cbcb-40bd-950a-da13b4f46b8a"
      decimals="-3"
      id="F_fd8a0932-a7a0-438d-9156-6207bcc8ffc8"
      unitRef="U_USD">33099000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_e34dffa8-783f-47f9-b3eb-1d1ea40a50f2"
      decimals="-3"
      id="F_dca33761-6c90-4ed4-9c84-000584c02b86"
      unitRef="U_USD">33083000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_e34dffa8-783f-47f9-b3eb-1d1ea40a50f2"
      decimals="-3"
      id="F_ba954ef0-e464-4b4b-b506-58285ed17cd0"
      unitRef="U_USD">17000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_e34dffa8-783f-47f9-b3eb-1d1ea40a50f2"
      decimals="-3"
      id="F_61a19fa9-e1cd-4191-9be3-f89064a9f7da"
      unitRef="U_USD">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_e34dffa8-783f-47f9-b3eb-1d1ea40a50f2"
      decimals="-3"
      id="F_df9e87cb-687b-4e91-a31a-2b934a6da1f2"
      unitRef="U_USD">33099000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc"
      decimals="-3"
      id="F_27efdac6-da73-4957-84c8-43e5d791e134"
      unitRef="U_USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      id="F_4e43f441-4924-4015-99bc-f8299808d4de">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;4.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;FAIR VALUE OF FINANCIAL INSTRUMENTS&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents information about the Company&#x2019;s assets and liabilities measured at the fair value on a recurring basis as of March 31, 2025 and December 31, 2024 (in thousands), and the fair value hierarchy of the valuation techniques utilized.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The Company classifies its assets and liabilities as either short-term or long-term based on maturity and anticipated realization dates.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&#160;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:50.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;March 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financial assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80,444&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80,444&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32,722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32,722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. agency bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;129,964&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;129,964&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;113,166&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;129,964&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;243,130&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financial liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;DDSU Liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,129&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,129&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2022 USD Financing Warrant Liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,716&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,716&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,129&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,716&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,845&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financial assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;271,537&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;271,537&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;271,537&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;271,537&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financial liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;DDSU Liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,148&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,148&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2022 USD Financing Warrant Liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,010&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,010&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,148&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,010&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,158&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; transfers into or out of Level 1, Level 2, or Level 3 during the three months ended March 31, 2&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;25 and the year ended December 31, 2024.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company issued liability-classified warrants to purchase Common Shares in our underwritten public offering that closed on September 30, 2022 (the &#x201c;2022 USD Financing Warrants&#x201d;). The warrant liability is measured at fair value on a recurring basis and is classified as Level 3 in the fair value hierarchy. Its fair value is determined using the Black-Scholes option pricing model using the following assumptions:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:35.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.86%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:29.52%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.86%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:29.52%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of March 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Share price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.85&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.96&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;79.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;90.70&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk-free rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.85&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.18&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.5 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.75 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      id="F_a5f8a319-5a68-4a15-8582-8bc165c98c0b">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents information about the Company&#x2019;s assets and liabilities measured at the fair value on a recurring basis as of March 31, 2025 and December 31, 2024 (in thousands), and the fair value hierarchy of the valuation techniques utilized.&lt;/span&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:50.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;March 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financial assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80,444&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80,444&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32,722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32,722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. agency bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;129,964&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;129,964&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;113,166&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;129,964&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;243,130&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financial liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;DDSU Liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,129&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,129&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2022 USD Financing Warrant Liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,716&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,716&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,129&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,716&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,845&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financial assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;271,537&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;271,537&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;271,537&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;271,537&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financial liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;DDSU Liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,148&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,148&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2022 USD Financing Warrant Liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,010&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,010&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,148&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,010&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,158&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_8e014f8c-ec6c-4965-ad7a-4716062b7c4d"
      decimals="-3"
      id="F_72d65443-bbf8-4a8a-9d8a-47fed1c2890b"
      unitRef="U_USD">80444000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_36b4af29-5d76-4291-b73b-cd8c72915e01"
      decimals="-3"
      id="F_48e708e5-ad40-4df4-a9f9-957bfe4faba6"
      unitRef="U_USD">80444000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_634127f7-e2ca-4f43-b3c1-b5a15d394d01"
      decimals="-3"
      id="F_a715a5e3-bf9f-4e1c-a5af-a4b3ff260106"
      unitRef="U_USD">32722000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_4f9c94fe-d4da-4fdb-80c6-934c635c61cf"
      decimals="-3"
      id="F_20d96744-c359-4c0d-9b95-d059284d7187"
      unitRef="U_USD">32722000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_5e3a61c1-28b2-4c74-befa-0a83e0e3f355"
      decimals="-3"
      id="F_0a850b7e-21b4-4d42-adc7-d845b930b9da"
      unitRef="U_USD">129964000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_02d3e741-f89c-4731-a810-9c92f1a21ee4"
      decimals="-3"
      id="F_24150ff2-9482-4bfe-92a8-5acd2d6610e0"
      unitRef="U_USD">129964000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_8e014f8c-ec6c-4965-ad7a-4716062b7c4d"
      decimals="-3"
      id="F_adfeb40f-20dc-4709-8a9d-57f9b8c6c24a"
      unitRef="U_USD">113166000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_ade2e71f-765e-4fb6-86cf-647ae7dd133c"
      decimals="-3"
      id="F_39de1689-f511-4427-a33d-9f8d22c7658b"
      unitRef="U_USD">129964000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_36b4af29-5d76-4291-b73b-cd8c72915e01"
      decimals="-3"
      id="F_6388d9c0-091b-46cf-be10-4929244df589"
      unitRef="U_USD">243130000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_05d13ef9-8e4a-4163-9c2d-b90faeb5d396"
      decimals="-3"
      id="F_40d0fbb1-8554-4c35-9f96-ce878b8446c8"
      unitRef="U_USD">1129000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_26a40041-e25c-4e75-bf9d-fa804e8cd077"
      decimals="-3"
      id="F_47e33917-00f6-4459-b8f3-d95644c4e487"
      unitRef="U_USD">1129000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_910d296e-b905-4051-81fa-bd26919dc2be"
      decimals="-3"
      id="F_d331c7af-b70a-4c3d-83e2-196eb5121e6e"
      unitRef="U_USD">16716000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_dd654da2-3037-41d6-b072-b777c8f63fe4"
      decimals="-3"
      id="F_5394d51a-6958-43d9-9db6-3bd1aecba1f1"
      unitRef="U_USD">16716000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_8e014f8c-ec6c-4965-ad7a-4716062b7c4d"
      decimals="-3"
      id="F_4e9cb890-cf6e-48d9-aac1-9e46c63920fc"
      unitRef="U_USD">1129000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_73ffda6d-742d-40f9-a06d-603da3eab457"
      decimals="-3"
      id="F_1e43fb8f-0760-49d8-89f2-6818286fcf9d"
      unitRef="U_USD">16716000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_36b4af29-5d76-4291-b73b-cd8c72915e01"
      decimals="-3"
      id="F_546168a6-4b91-4b53-b305-e3ef1069fee2"
      unitRef="U_USD">17845000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_3719fe9d-d9b5-450f-af3d-bfac82d59821"
      decimals="-3"
      id="F_48551829-4186-4c9e-abd6-be866c9e7f43"
      unitRef="U_USD">271537000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_2e42dac1-0eaa-4f5d-b79b-b48d8486374e"
      decimals="-3"
      id="F_29dd9796-2d9a-4438-bb6a-b19ffb516741"
      unitRef="U_USD">271537000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_3719fe9d-d9b5-450f-af3d-bfac82d59821"
      decimals="-3"
      id="F_b3963f28-7184-4658-9b5f-5f4133b8198c"
      unitRef="U_USD">271537000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_2e42dac1-0eaa-4f5d-b79b-b48d8486374e"
      decimals="-3"
      id="F_a3097839-2bcf-4260-a856-02e62cb79aa4"
      unitRef="U_USD">271537000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_8eca3c03-2aed-492a-b29b-dd10aed0202f"
      decimals="-3"
      id="F_84557089-1249-431b-ac84-4274e679abcc"
      unitRef="U_USD">1148000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_d2978ec1-8cd7-4990-abd7-153da97219c6"
      decimals="-3"
      id="F_e7de39a7-bc69-4e2f-84dc-1ad549e2cc12"
      unitRef="U_USD">1148000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_b72d06dd-d6d5-41b9-91f8-bad834196904"
      decimals="-3"
      id="F_9fc852ed-0c65-402c-a938-ea8cda8da9ab"
      unitRef="U_USD">24010000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_4350eef0-c7b4-4a27-8d23-cb926ba2db8d"
      decimals="-3"
      id="F_7f158224-4c8d-454f-866f-10e199fc8ed7"
      unitRef="U_USD">24010000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_3719fe9d-d9b5-450f-af3d-bfac82d59821"
      decimals="-3"
      id="F_09d4623c-b6b3-4215-9239-a2f7795d16e0"
      unitRef="U_USD">1148000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_12ece47b-93f1-4de7-b519-aa935811a9f5"
      decimals="-3"
      id="F_e3818ad6-984b-4ad6-9130-6c8f21a49e4e"
      unitRef="U_USD">24010000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_2e42dac1-0eaa-4f5d-b79b-b48d8486374e"
      decimals="-3"
      id="F_67af5662-5f33-4d65-b9a4-275944e1b168"
      unitRef="U_USD">25158000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="INF"
      id="F_4d917a83-8c96-40b8-ad98-749b2ce8762a"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
      contextRef="C_62a1dfe7-53cc-4860-88cd-5195a323ecfb"
      decimals="INF"
      id="F_f51ec0b7-52c6-42fb-9c31-fd050057e214"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="INF"
      id="F_837b2834-dc76-4534-89c0-7d4f12716fd8"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
      contextRef="C_62a1dfe7-53cc-4860-88cd-5195a323ecfb"
      decimals="INF"
      id="F_f6223532-be0f-4478-a26d-7f183044cef3"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="INF"
      id="F_5c8abac6-a3f4-44a6-a89b-d392e4466657"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
      contextRef="C_62a1dfe7-53cc-4860-88cd-5195a323ecfb"
      decimals="INF"
      id="F_de936f17-57bd-47dc-ab11-0f380f161f9b"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="INF"
      id="F_12d9193c-b41d-49eb-9ad0-b0517dab7671"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
      contextRef="C_62a1dfe7-53cc-4860-88cd-5195a323ecfb"
      decimals="INF"
      id="F_d203d8f1-27ae-4b62-8979-4e6c71c883e3"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      id="F_a39ced36-31a7-4dc4-89a8-a9fe960f0d48">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company issued liability-classified warrants to purchase Common Shares in our underwritten public offering that closed on September 30, 2022 (the &#x201c;2022 USD Financing Warrants&#x201d;). The warrant liability is measured at fair value on a recurring basis and is classified as Level 3 in the fair value hierarchy. Its fair value is determined using the Black-Scholes option pricing model using the following assumptions:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:35.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.86%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:29.52%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.86%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:29.52%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of March 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Share price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.85&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.96&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;79.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;90.70&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk-free rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.85&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.18&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.5 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.75 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="C_97bfc649-2b8e-41f0-8976-f5330877ad56"
      decimals="2"
      id="F_2bf69522-2802-475c-a635-d4b2111ab9a7"
      unitRef="U_UsdShare">5.85</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="C_cf111989-4654-4f24-8b88-1ac2ede3bffd"
      decimals="2"
      id="F_84d2c804-6ac4-4f1d-b982-7499d74e0015"
      unitRef="U_UsdShare">6.96</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="C_a5257296-f7b1-43a0-9556-3801f55d61c2"
      decimals="3"
      id="F_69a26bb1-cfc7-4cc7-ac35-5792179e5a55"
      unitRef="U_pure">0.792</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="C_c9514733-173b-4015-8d17-721fcab04ad2"
      decimals="4"
      id="F_9d5f7baf-1781-402f-be22-162f88d757e4"
      unitRef="U_pure">0.907</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="C_5d84c0a3-45aa-4e65-83e3-9a191c580b57"
      decimals="4"
      id="F_10c37ae5-199f-4762-ac81-c9fb3cbbde6f"
      unitRef="U_pure">0.0385</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="C_71fe533e-e23e-4d50-b70c-175f681b0e12"
      decimals="4"
      id="F_c094441e-229e-44c8-954a-8cbcc61004b6"
      unitRef="U_pure">0.0418</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="C_30b95ea8-0cae-41e0-b81a-309b08ca75f2"
      id="F_c3877cfd-cc94-4fa4-ad1c-825b60db715d">P2Y6M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="C_bc56a365-8e98-4a9c-b1c1-8e03984015fd"
      id="F_abde0ef5-72f9-4663-baca-2a4e716103a8">P2Y9M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      id="F_16490e19-a99a-49e1-b881-b656fbb1440b">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;5.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;GOODWILL&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the three months ended March 31, 2025, the Company has made &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; additions to its outstanding goodwill. There were no triggering events identified, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; indication of impairment of the Company&#x2019;s goodwill, and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; impairment charges recorded during the three months ended March 31, 2025 and 2024, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="INF"
      id="F_17f3e916-1dc9-4c89-91b2-c6df3b23db04"
      unitRef="U_USD">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <mnmd:IndicationOfImpairmentOfGoodwillAndLongLivedAssets
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="INF"
      id="F_0c3759f5-4e62-49dd-8372-65913e9b0e6a"
      unitRef="U_USD">0</mnmd:IndicationOfImpairmentOfGoodwillAndLongLivedAssets>
    <mnmd:IndicationOfImpairmentOfGoodwillAndLongLivedAssets
      contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb"
      decimals="INF"
      id="F_aa8d9631-ecc0-40f1-91cc-1ef96ee8cc1b"
      unitRef="U_USD">0</mnmd:IndicationOfImpairmentOfGoodwillAndLongLivedAssets>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="INF"
      id="F_5bfd7d3a-f8c9-4542-9459-c6265a82f35c"
      unitRef="U_USD">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb"
      decimals="INF"
      id="F_28727d97-69f1-4ba9-88e4-50b8bc0c5d1c"
      unitRef="U_USD">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      id="F_d421ad91-4b95-440c-9a60-8c08c05855ee">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;6.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ACCRUED EXPENSES&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At March 31, 2025 and December 31, 2024, accrued expenses consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:64.167%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.76%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.157%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.76%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.157%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;March 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,361&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,405&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued clinical trial costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,537&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,332&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued other research and development costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;901&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;841&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Professional services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,437&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;973&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other accruals&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;261&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;278&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,497&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,829&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      id="F_e908c9bc-d6fc-45ab-8fe1-d82a1971803d">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At March 31, 2025 and December 31, 2024, accrued expenses consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:64.167%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.76%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.157%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.76%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.157%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;March 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,361&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,405&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued clinical trial costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,537&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,332&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued other research and development costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;901&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;841&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Professional services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,437&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;973&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other accruals&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;261&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;278&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,497&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,829&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:WorkersCompensationLiabilityCurrent
      contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256"
      decimals="-3"
      id="F_ee2a0774-fa3f-4adc-953c-1edb5fbede77"
      unitRef="U_USD">4361000</us-gaap:WorkersCompensationLiabilityCurrent>
    <us-gaap:WorkersCompensationLiabilityCurrent
      contextRef="C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc"
      decimals="-3"
      id="F_dc92f530-0b1e-4328-b410-bd30388d34b3"
      unitRef="U_USD">6405000</us-gaap:WorkersCompensationLiabilityCurrent>
    <mnmd:AccruedClinicalAndManufacturingCosts
      contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256"
      decimals="-3"
      id="F_c5947fdf-4b6f-48fc-9ab8-3297ec8d3a28"
      unitRef="U_USD">4537000</mnmd:AccruedClinicalAndManufacturingCosts>
    <mnmd:AccruedClinicalAndManufacturingCosts
      contextRef="C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc"
      decimals="-3"
      id="F_75323b55-91a3-4f77-b426-600997c28074"
      unitRef="U_USD">4332000</mnmd:AccruedClinicalAndManufacturingCosts>
    <mnmd:AccruedOtherResearchAndDevelopmentCostsCurrent
      contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256"
      decimals="-3"
      id="F_6f4b0c90-d7d7-4d47-bdae-3066c35d93bf"
      unitRef="U_USD">901000</mnmd:AccruedOtherResearchAndDevelopmentCostsCurrent>
    <mnmd:AccruedOtherResearchAndDevelopmentCostsCurrent
      contextRef="C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc"
      decimals="-3"
      id="F_dcb3c05a-1a62-49e9-b8d1-fb868be8cb39"
      unitRef="U_USD">841000</mnmd:AccruedOtherResearchAndDevelopmentCostsCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256"
      decimals="-3"
      id="F_26e02522-3174-4af1-b0de-03370cefca5d"
      unitRef="U_USD">1437000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc"
      decimals="-3"
      id="F_f20e7d1b-1dc2-4613-a072-04d0bbcdad6b"
      unitRef="U_USD">973000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256"
      decimals="-3"
      id="F_d230770f-242a-49c3-b25c-629350ef0803"
      unitRef="U_USD">261000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc"
      decimals="-3"
      id="F_6bf5ba19-74bb-40f3-a260-d002c9e2e76c"
      unitRef="U_USD">278000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256"
      decimals="-3"
      id="F_0619732c-de9d-431b-ad93-fac8cd10e793"
      unitRef="U_USD">11497000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc"
      decimals="-3"
      id="F_b8cc9eeb-913e-4e0e-bbb8-a80b43f2de0f"
      unitRef="U_USD">12829000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      id="F_5767ccfd-6237-43ca-b2a7-9341eff798e2">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;7.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;SHAREHOLDERS' EQUITY&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Common Shares&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is authorized to issue an unlimited number of Common Shares, which have &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; par value. As of March 31, 2025, the Company ha&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;d &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75,511,375&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Common Shares issued and outstanding.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;At-The-Market Facilities&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On May 4, 2022, the Company filed a shelf registration statement on Form S-3 (the &#x201c;2022 Registration Statement&#x201d;), as well as an accompanying prospectus supplement (the &#x201c;Prior ATM Prospectus&#x201d;). &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In connection with the filing of the 2022 Registration Statement and Prior ATM Prospectus, the Company also entered into a sales agreement (the &#x201c;Prior Sales Agreement&#x201d;) with Cantor Fitzgerald &amp;amp; Co. and Oppenheimer &amp;amp; Co. Inc. as sales agents (together, the &#x201c;Prior Sales Agents&#x201d;), pursuant to which the Company was able to issue and sell Common Shares for an aggregate offering price of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million under an at-the-market offering program (the &#x201c;Prior ATM&#x201d;). During the three months ended March 31, 2024, the Company sold &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;171,886&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Common Shares for net proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million under the Prior ATM. As of March 7, 2024, the Company had raised an aggregate of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million under the ATM and had the remaining availability of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;59.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. On March 7, 2024, the Company announced that it had delivered written notice to the Sales Agents that it was suspending and terminating the Prior ATM Prospectus. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On May 28, 2024, the Company delivered written notice to the Prior Sales Agents that it was terminating the Prior Sales Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On June 28, 2024, the Company filed a shelf registration statement on Form S-3 (the &#x201c;2024 Registration Statement&#x201d;), as well as an accompanying prospectus supplement (&#x201c;New ATM Prospectus&#x201d;). In connection with the filing of the 2024 Registration Statement and the New ATM Prospectus, the Company entered into a sales agreement (the "Sales Agreement") with Leerink Partners LLC (the &#x201c;Sales Agent&#x201d;) pursuant to which the Company may issue and sell from time to time Common Shares for an aggregate offering price of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;150.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in accordance with the New ATM Prospectus under an at-the-market offering program (the "2024 ATM"). Pursuant to the 2024 ATM, the Company will pay the Sales Agent a commission rate of up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the gross proceeds from the sale of any Common Shares. The Company is not obligated to make any sales of its Common Shares under the 2024 ATM. The Company has not sold any Common Shares under the 2024 ATM as of March 31, 2025.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;The March 2024 Offering and Private Placement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On March 7, 2024, the Company entered into an underwriting agreement with Leerink Partners LLC and Cantor Fitzgerald &amp;amp; Co., as representatives of the underwriters named therein, in connection with the issuance and sale by the Company in an underwritten offering (the &#x201c;March 2024 Offering&#x201d;) of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,666,667&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Common Shares, at an offering price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, less underwriting discounts and commissions.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The net proceeds to the Company from the March 2024 Offering were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;93.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Also on March 7, 2024, the Company entered into a securities purchase agreement with certain investors, pursuant to which the investors agreed to purchase, and the Company agreed to sell &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,500,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Common Shares (the &#x201c;Private Placement Shares&#x201d;), at a price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per Private Placement Share, in a private placement transaction (the &#x201c;March 2024 Private Placement&#x201d;).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The net proceeds to the Company from the March 2024 Private Placement were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;70.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, after deducting fees and expenses payable by the Company.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company intends to use the net proceeds from the March 2024 Offering and the March 2024 Private Placement for (i) the research and development of the Company&#x2019;s product candidates and (ii) working capital and general corporate purposes.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The March 2024 Offering and the March 2024 Private Placement closed on March 11, 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;The August 2024 Offering&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On August 9, 2024, the Company entered into an underwriting agreement with Leerink Partners LLC and Evercore Group L.L.C., as representatives of the several underwriters named therein, in connection with an underwritten public offering (the &#x201c;August 2024 Offering&#x201d;) of (i) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,285,511&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Common Shares (the &#x201c;Shares&#x201d;), and (ii) to certain investors, pre-funded warrants (the &#x201c;Pre-Funded Warrants&#x201d;) to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,428,775&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Common Shares (the "Pre-Funded Warrant Shares"). The offering price for the Shares was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, less underwriting discounts and commissions. The offering price for the Pre-Funded Warrants was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.999&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per Pre-Funded Warrant, which represents the per share public offering price for the Shares less a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share exercise price for each such Pre-Funded Warrant.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The net proceeds to the Company from the August 2024 Offering were approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;70.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, after deducting underwriting discounts and commissions and other offering expenses payable by the Company. The August 2024 Offering closed on August 12, 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company intends to use the net proceeds from the August 2024 Offering to fund the research and development of its product candidates and for working capital and general corporate purposes.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Pre-Funded Warrants are exercisable at any time after the date of issuance. The exercise price and the number of Pre-Funded Warrant Shares are subject to appropriate adjustment in the event of certain share dividends and distributions, share splits, share combinations, reclassifications or similar events affecting the Common Shares as well as upon any distribution of assets, including cash, securities or other property, to the Company&#x2019;s shareholders. The Pre-Funded Warrants will not expire and are exercisable in cash or by means of a cashless exercise. A holder of Pre-Funded Warrants may not exercise such Pre-Funded Warrants if the aggregate number of Common Shares beneficially owned by such holder, together with its affiliates, would exceed more than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.99&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% or &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.99&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% (at the initial election of the holder) of the number of Common Shares outstanding following such exercise, as such percentage ownership is determined in accordance with the terms of the Pre-Funded Warrants. A holder of Pre-Funded Warrants may increase or decrease this percentage not in excess of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19.99&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% by providing at least 61 days&#x2019; prior notice to the Company.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;October 2024 Exchange Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On October 17, 2024, the Company entered into exchange agreements (the &#x201c;Exchange Agreements&#x201d;) with Commodore Capital Master LP, Deep Track Biotechnology Master Fund, LTD and certain other investors (collectively, the &#x201c;Holders&#x201d;) pursuant to which the Holders exchanged an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,325,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Common Shares for pre-funded warrants to purchase an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,325,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Common Shares with an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share. Such Common Shares were retired upon exchange. The exchange transactions represented offsetting increases and decreases with additional paid-in capital that had no overall impact to the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockNoParValue
      contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256"
      decimals="INF"
      id="F_c3dd4293-4fa1-4599-9946-42716f946089"
      unitRef="U_UsdShare">0</us-gaap:CommonStockNoParValue>
    <mnmd:CommonStockSharesIssuedAndOutstanding
      contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256"
      decimals="INF"
      id="F_124fd2db-0d6f-4fb2-9e1e-d1ed95bcc451"
      unitRef="U_shares">75511375</mnmd:CommonStockSharesIssuedAndOutstanding>
    <mnmd:SaleOfEquityAggregatePublicOfferingAmount
      contextRef="C_e69e4c45-b9fa-4c14-a874-f74d991218c1"
      decimals="-5"
      id="F_56257f19-9a73-44db-9e33-aaf74b78d8a3"
      unitRef="U_USD">100000000</mnmd:SaleOfEquityAggregatePublicOfferingAmount>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_d6c40bae-8846-460f-9af3-802080fee535"
      decimals="INF"
      id="F_4441c8bf-c8b3-477f-92d1-a0ac73e1fa12"
      unitRef="U_shares">171886</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_d6c40bae-8846-460f-9af3-802080fee535"
      decimals="-5"
      id="F_7d5fd069-c6c3-4af3-9316-5752260ba78b"
      unitRef="U_USD">700000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <mnmd:SaleOfEquityAggregatePublicOfferingAmount
      contextRef="C_e36f91bd-0fb2-41fd-b1b0-74152cad4505"
      decimals="-5"
      id="F_495bc5df-7f84-44bc-8222-0b31401087c1"
      unitRef="U_USD">40900000</mnmd:SaleOfEquityAggregatePublicOfferingAmount>
    <mnmd:SaleOfEquityRemainingOfferingAmount
      contextRef="C_e36f91bd-0fb2-41fd-b1b0-74152cad4505"
      decimals="-5"
      id="F_9c2f009c-99c0-476d-8af2-0202e5d73fbe"
      unitRef="U_USD">59100000</mnmd:SaleOfEquityRemainingOfferingAmount>
    <mnmd:SaleOfEquityAggregatePublicOfferingAmount
      contextRef="C_90573d83-d120-4c4b-9277-fd2e39b59277"
      decimals="-5"
      id="F_a051f9a4-8e1b-4b8f-b1cd-dc8abf98a443"
      unitRef="U_USD">150000000</mnmd:SaleOfEquityAggregatePublicOfferingAmount>
    <mnmd:PercentageOfGrossProceedsSaleOfCommonSharesPayableAsSalesAgentsCommissionRate
      contextRef="C_90573d83-d120-4c4b-9277-fd2e39b59277"
      decimals="INF"
      id="F_1d17eb8f-f21b-4343-9a6f-e2b3b500bc35"
      unitRef="U_pure">0.03</mnmd:PercentageOfGrossProceedsSaleOfCommonSharesPayableAsSalesAgentsCommissionRate>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_81f4f1da-ef96-4aad-9e47-23f8b90a22b7"
      decimals="INF"
      id="F_ed4df974-6f78-4152-a286-34000de5c3a8"
      unitRef="U_shares">16666667</us-gaap:CommonStockSharesIssued>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_81f4f1da-ef96-4aad-9e47-23f8b90a22b7"
      decimals="INF"
      id="F_27a9565d-8b02-43c8-90fe-04309e222a72"
      unitRef="U_UsdShare">6</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_11c49272-f55d-49f3-b7a7-0fefff64a7f1"
      decimals="-5"
      id="F_853a0e05-e663-4f40-bee2-1cf535247d77"
      unitRef="U_USD">93500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_2e215081-711a-47c3-8879-d448652f7b35"
      decimals="INF"
      id="F_d45b2e7a-88c7-4833-b7e1-9e4e6f4fc9f1"
      unitRef="U_shares">12500000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_430d76fe-9c73-4a88-a973-58ab8a42cea6"
      decimals="INF"
      id="F_438d7c7e-ba1f-4d0b-96ac-ca9b76c98d9a"
      unitRef="U_UsdShare">6</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_2e215081-711a-47c3-8879-d448652f7b35"
      decimals="-5"
      id="F_a6b6af0f-80fc-4336-9486-5d9d8b1a75a0"
      unitRef="U_USD">70100000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_528dd0c0-1ac6-48fd-ba94-56b201899f5f"
      decimals="INF"
      id="F_80ccd0bf-1e36-4316-bdae-64618646e858"
      unitRef="U_shares">9285511</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_307c81b2-2ca0-4668-bba0-7a7b5291fc9f"
      decimals="INF"
      id="F_48116889-394d-4ce5-b9ef-fbabb3459da9"
      unitRef="U_shares">1428775</us-gaap:CommonStockSharesIssued>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_b2ef454a-9f53-4e0f-adeb-d446b560c825"
      decimals="2"
      id="F_601bdb64-2025-4913-8e62-80aac9ec7f97"
      unitRef="U_UsdShare">7</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_307c81b2-2ca0-4668-bba0-7a7b5291fc9f"
      decimals="3"
      id="F_6b6d46fd-6590-4750-a8e9-5c8d088dd6c5"
      unitRef="U_UsdShare">6.999</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_cf474416-20d3-4fb7-a080-b12775ae6c42"
      decimals="3"
      id="F_5c601759-08f4-4736-96d8-8f0450cc2c36"
      unitRef="U_UsdShare">0.001</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_d0dd088c-1d9e-451f-88b7-d6ec7c48a41b"
      decimals="-5"
      id="F_21ce7817-ebd6-45a5-9ba2-9099cf1cb601"
      unitRef="U_USD">70000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <mnmd:AggregateNumberOfCommonSharesOwnedByHolderPercentage
      contextRef="C_2bdf42cd-b1cd-4bff-9840-27592a404165"
      decimals="4"
      id="F_0ccbfbd9-2323-4035-abdc-c0bb5800357d"
      unitRef="U_pure">0.0499</mnmd:AggregateNumberOfCommonSharesOwnedByHolderPercentage>
    <mnmd:AggregateNumberOfCommonSharesOwnedByHolderPercentage
      contextRef="C_ec162c56-805d-451c-8646-927ea169440e"
      decimals="4"
      id="F_2206d91a-a30f-4ec5-ae62-db8d2c69383c"
      unitRef="U_pure">0.0999</mnmd:AggregateNumberOfCommonSharesOwnedByHolderPercentage>
    <mnmd:PercentageOfIncreaseOrDecreaseOfOwnershipByPreFundedWarrantsHolder
      contextRef="C_ec162c56-805d-451c-8646-927ea169440e"
      decimals="4"
      id="F_fbc41c8f-6260-48c0-aa61-850678374c75"
      unitRef="U_pure">0.1999</mnmd:PercentageOfIncreaseOrDecreaseOfOwnershipByPreFundedWarrantsHolder>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="C_795cce7f-e02c-4025-a046-7502e810b283"
      decimals="INF"
      id="F_b7362358-fb8f-471d-944c-2d36ebaadd7b"
      unitRef="U_shares">8325000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_4b6d6580-13c5-46e6-baba-77d54955725a"
      decimals="INF"
      id="F_fa7fd6dc-e03e-48f9-b0a2-0a3a3266c996"
      unitRef="U_shares">8325000</us-gaap:CommonStockSharesIssued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_4b6d6580-13c5-46e6-baba-77d54955725a"
      decimals="3"
      id="F_0cafbd4a-7812-4843-9221-197e8f6e1af4"
      unitRef="U_UsdShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <mnmd:WarrantsDisclosureTextBlock
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      id="F_c28bd0c3-3728-4305-bf11-1114a14a0d63">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;8.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;WARRANTS&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;2022 USD Financing Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On September 30, 2022, the Company closed an underwritten public offering of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,058,823&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Common Shares and accompanying 2022 USD Financing Warrants to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,058,823&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Common Shares. Each 2022 USD Financing Warrant is immediately exercis&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;able for one Common Share at an initial exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per Common Share, subject to certain adjustments, and will expire on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;September 30, 2027&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:'Calibri',sans-serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The table below represents the activity &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;associated with the Company's outstanding liability-classified 2022 USD Financing Warrants for the three months ended March 31, 2025.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.88%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:29.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022 USD Financing Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,086,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Issued&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;136,346&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at March 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,949,954&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The 2022 USD Financing Warrants are liability-classified. Accordingly, the 2022 USD Financing Warrants are recognized at fair value upon issuance and are adjusted to fair value at the end of each reporting period. Any change in fair value is recognized on the condensed consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The below table summarizes the activity of the outstanding liability for the 2022 USD Financing Warrants for the three months ended March 31, 2025 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:67.725%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:27.775000000000002%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of March 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,010&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Warrant exercise&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in fair value of the warrant liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,999&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at March 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,716&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;</mnmd:WarrantsDisclosureTextBlock>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_c223fe50-1eba-4855-9ab8-186a0c6e6c18"
      decimals="INF"
      id="F_c290faad-ad4f-4635-a260-5b4e4b233ea6"
      unitRef="U_shares">7058823</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_8105c1cf-df27-4598-b667-6e48ef3b3337"
      decimals="INF"
      id="F_0f227aae-5b88-446d-9ab5-f0843b1f0559"
      unitRef="U_shares">7058823</us-gaap:CommonStockSharesIssued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_2995588c-67ea-4d43-b4bf-a6059a698028"
      decimals="INF"
      id="F_9ef03d7f-5959-4919-aae2-d49e08c1d08f"
      unitRef="U_UsdShare">4.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <mnmd:CommonShareAndWarrantPublicOfferingExpireDate
      contextRef="C_fc88df44-67ae-47e8-a51a-83bbbe2805d6"
      id="F_68783136-3504-4389-ae36-d821d4f09bd6">2027-09-30</mnmd:CommonShareAndWarrantPublicOfferingExpireDate>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      id="F_781bd0a2-92bb-48ba-a65e-629c3165d3c8">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The table below represents the activity &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;associated with the Company's outstanding liability-classified 2022 USD Financing Warrants for the three months ended March 31, 2025.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.88%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:29.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022 USD Financing Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,086,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Issued&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;136,346&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at March 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,949,954&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_4ea41252-c084-4a13-8fad-6ff6f7cfeccf"
      decimals="INF"
      id="F_afa81824-2e72-4cb3-9e77-6adfd059fd4d"
      unitRef="U_shares">5086300</us-gaap:ClassOfWarrantOrRightOutstanding>
    <mnmd:WarrantsIssued
      contextRef="C_dff63d85-7ca9-411d-a4f5-a8cf59bcaded"
      decimals="INF"
      id="F_2d4a12f9-539c-45e0-b580-12b3ebf0e86e"
      unitRef="U_shares">0</mnmd:WarrantsIssued>
    <mnmd:WarrantsExercised
      contextRef="C_dff63d85-7ca9-411d-a4f5-a8cf59bcaded"
      decimals="INF"
      id="F_175789b4-c475-4b55-a7f0-6b1a2b7c2b74"
      unitRef="U_shares">136346</mnmd:WarrantsExercised>
    <mnmd:WarrantsExpired
      contextRef="C_dff63d85-7ca9-411d-a4f5-a8cf59bcaded"
      decimals="INF"
      id="F_e65f9179-050b-40cd-8eb8-c09880578fd5"
      unitRef="U_shares">0</mnmd:WarrantsExpired>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_71fc6e95-5099-42fb-ad90-d49887a3de3c"
      decimals="INF"
      id="F_074de9ed-ac23-44c2-aedc-0cf69450d9ef"
      unitRef="U_shares">4949954</us-gaap:ClassOfWarrantOrRightOutstanding>
    <mnmd:ScheduleOfWarrantLiabilityTableTextBlock
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      id="F_9b3674d2-14cd-4aee-8600-ba7b1f76370a">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The below table summarizes the activity of the outstanding liability for the 2022 USD Financing Warrants for the three months ended March 31, 2025 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:67.725%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:27.775000000000002%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of March 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,010&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Warrant exercise&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in fair value of the warrant liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,999&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at March 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,716&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</mnmd:ScheduleOfWarrantLiabilityTableTextBlock>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_b58805d9-68aa-4a81-99f4-2a397090939f"
      decimals="-3"
      id="F_f52d9ffb-a303-4f4b-8e05-73f97576718c"
      unitRef="U_USD">24010000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <mnmd:WarrantExercise
      contextRef="C_e3b59676-7289-49e6-94f9-2ea1da43b0c3"
      decimals="-3"
      id="F_6b92c3c8-904f-43d2-af44-4b4e685a03fe"
      unitRef="U_USD">-295000</mnmd:WarrantExercise>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_e3b59676-7289-49e6-94f9-2ea1da43b0c3"
      decimals="-3"
      id="F_114def8d-0f36-415d-a7d4-5140a85b05b0"
      unitRef="U_USD">-6999000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_122040ac-3410-4ee2-92d7-5ca02f09a42e"
      decimals="-3"
      id="F_c7bcd366-0104-4f7b-a58a-ae48b259b2e8"
      unitRef="U_USD">16716000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      id="F_a97ecfdd-f77b-43ed-aaca-9e0674133b69">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;9.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;STOCK-BASED COMPENSATION&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is authorized to issue such number of equity awards equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the Company&#x2019;s issued and outstanding Common Shares under the terms of the MindMed Stock Option Plan (the &#x201c;Stock Option Plan&#x201d;), together with Common Shares that are issuable pursuant to outstanding awards or grants under any other compensation or incentive mechanism involving the issuance or potential issuance of Common Shares, including the Performance and Restricted Share Unit Plan (the &#x201c;PRSU Plan&#x201d;) and ESPP. The Option Plan and the PRSU Plan were retired effective March 14, 2025, and no further grants will be made under the Option Plan or the PRSU Plan. With the retirement of the Option Plan and the PRSU Plan, the ESPP and any other compensation or incentive mechanism involving the issuance or potential issuance of Common Shares (including inducement grants made outside a plan) are no longer subject to the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% cap from the Option Plan and PRSU Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stock Options&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the Company&#x2019;s stock option activity for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three months ended March 31, 2025:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:37.305%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.695%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.399%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.235%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.695%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.399%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.275%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted Average Remaining Contractual Life (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate Intrinsic &lt;br/&gt;Value (USD$)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options outstanding at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,225,032&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,147,893&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;755,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.65&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53,541&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.42&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;385,629&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75,531&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17.39&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options outstanding at March 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,465,831&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.88&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.9&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,681,194&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options vested and exercisable at March 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,879,772&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18.52&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;805,673&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The expense recognized related to options during the three months ended March 31, 2025 and 2024 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Restricted Share Units&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the Company's restricted share activity for the three months ended March 31, 2025:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:63.593%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.943%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.463%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of RSUs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,371,266&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,024,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Vested and issued&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;186,708&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.76&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;260,206&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.74&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at March 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,948,852&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the three months ended March 31, 2025, RSUs granted include &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,696,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; performance share units that vest based on the achievement of certain clinical milestones and require service for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;36&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; months after grant. As of March 31, 2025, the Company has determined that all of these milestones are probable of achievement. The Company will recognize the related compensation expense for awards that are probable of vesting over the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;36&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; month requisite service period.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The expense recognized related to RSUs during the three months ended March 31, 2025 and 2024 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Employee Share Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In August 2024, the Company commenced the first offering under the ESPP. Subsequent to this offering, new offerings under the ESPP will commence every six months. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the three months ended March 31, 2025, the Company recognized a nominal amount of expense in relation to its ESPP and issued &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;34,017&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares under the ESPP.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stock-based Compensation Expense&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation expense for all equity arrangements for the three months ended March 31, 2025 and 2024 was as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:67.033%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.863000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.863000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,053&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,455&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,373&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,234&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,426&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,689&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of March&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; 31, 2025, there was approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of total unrecognized stock-based compensation expense, related to unvested options granted to employees under the Option Plan that is expected to be recognized over a weighted average period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;3.1&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years. As of March 31, 2025, there was approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of total unrecognized stock-based compensation expense, related to restricted share units granted to employees under the PRSU Plan that is expected to be recognized over a &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;weighted average period of&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Directors' Deferred Share Unit Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On April 16, 2021, the Company adopted the MindMed Director&#x2019;s Deferred Share Unit Plan (the &#x201c;DDSU Plan&#x201d;). The DDSU Plan sets out a framework to grant non-employee directors DDSUs, which are cash settled awards. The DDSUs generally vest ratably over twelve months after grant and are settled within 90 days of the date the director ceases service to the Company. For the three months ended March 31, 2025 and 2024, compensation expense of a nominal amount and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively, was recognized relating to the revaluation of the vested DDSUs, recorded in general and administrative expense in the accompanying condensed consolidated statements of operations and comprehensive loss. During the three months ended March 31, 2025, the Company did not issue any additional DDSUs. There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;178,697&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; DDSUs vested as of March 31, 2025. The liability associated with the outstanding vested DDSU&#x2019;s was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million as of March 31, 2025, and was recorded to accrued expenses in the accompanying condensed consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.535%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.037%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;To conform with the current year presentation, certain prior year amounts related to DDSUs expense have been reclassified and separately presented from stock-based compensation on the statement of cash flows.&lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_8951a923-02f7-4d9d-aa15-eece5d45babf"
      decimals="2"
      id="F_fb0f367f-cf54-4d1e-84e1-db45eff66174"
      unitRef="U_pure">0.15</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_8951a923-02f7-4d9d-aa15-eece5d45babf"
      decimals="2"
      id="F_299be47e-812b-4639-8b5c-d02feb32e318"
      unitRef="U_pure">0.15</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      id="F_b70cc795-916d-4eda-92c1-0845fcf91e32">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the Company&#x2019;s stock option activity for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three months ended March 31, 2025:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:37.305%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.695%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.399%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.235%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.695%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.399%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.275%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted Average Remaining Contractual Life (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate Intrinsic &lt;br/&gt;Value (USD$)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options outstanding at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,225,032&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,147,893&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;755,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.65&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53,541&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.42&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;385,629&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75,531&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17.39&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options outstanding at March 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,465,831&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.88&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.9&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,681,194&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options vested and exercisable at March 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,879,772&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18.52&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;805,673&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc"
      decimals="INF"
      id="F_dc82ce29-2c25-485c-b1d8-ec59e5c5a519"
      unitRef="U_shares">4225032</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc"
      decimals="2"
      id="F_999115c8-7c0c-404d-9728-2a462b727a94"
      unitRef="U_UsdShare">12.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_62a1dfe7-53cc-4860-88cd-5195a323ecfb"
      id="F_20dca849-27d6-431a-9f07-b86f61178355">P6Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc"
      decimals="-3"
      id="F_e956c060-2594-4d6e-a194-2822f6f712c6"
      unitRef="U_USD">4147893000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="0"
      id="F_2ac1ffc8-c15f-4b4c-8354-e5900f89857e"
      unitRef="U_shares">755500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="2"
      id="F_989ae172-4be8-4ad3-b208-2861c1bf8428"
      unitRef="U_UsdShare">6.65</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="0"
      id="F_ca7acf04-b27c-4527-9216-d57929880ece"
      unitRef="U_shares">53541</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="2"
      id="F_4706b9f9-5148-48d6-9767-803741e7682a"
      unitRef="U_UsdShare">4.42</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="0"
      id="F_d9fd97c5-d1bd-4fde-b9a4-895cc0d22d64"
      unitRef="U_shares">385629</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="2"
      id="F_7753a2da-e318-4587-8571-ad5e17f1d667"
      unitRef="U_UsdShare">6.75</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="0"
      id="F_cb3bb8ef-66ca-493d-9e44-9083446f066a"
      unitRef="U_shares">75531</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="2"
      id="F_4d64fe77-3eea-442b-814e-671b196e0bab"
      unitRef="U_UsdShare">17.39</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256"
      decimals="INF"
      id="F_887ee81e-1c61-4f6c-a1f0-bea3a25a489d"
      unitRef="U_shares">4465831</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256"
      decimals="2"
      id="F_94b399e6-ecc2-4a26-9ce2-a56fa28d1127"
      unitRef="U_UsdShare">11.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      id="F_4b7ad1f3-753c-4cdd-8714-193185b56c56">P6Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256"
      decimals="-3"
      id="F_f26bfaa4-fa61-4251-b633-8530d0e7d4da"
      unitRef="U_USD">1681194000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256"
      decimals="0"
      id="F_56c2c4b7-97f6-4ad0-9697-8df83f5985a0"
      unitRef="U_shares">1879772</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256"
      decimals="2"
      id="F_9b31f86f-bb8d-40fe-a434-02f2e06a1765"
      unitRef="U_UsdShare">18.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      id="F_f88a8184-65d6-43b1-a834-63a7b9aa0643">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256"
      decimals="-3"
      id="F_ea3007f1-505a-47db-9363-ab2b332f6062"
      unitRef="U_USD">805673000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_8951a923-02f7-4d9d-aa15-eece5d45babf"
      decimals="-5"
      id="F_8c070a78-221f-4e6a-b3da-da87ff4e8150"
      unitRef="U_USD">1600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_c2fa1d86-6d26-4f04-8543-c015b28e335a"
      decimals="-5"
      id="F_8e6ff065-91d2-4b16-b69a-5c99acc0f2c3"
      unitRef="U_USD">1600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      id="F_2a45eae2-413c-4c2f-a655-85badecc9cbe">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the Company's restricted share activity for the three months ended March 31, 2025:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:63.593%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.943%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.463%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of RSUs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,371,266&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,024,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Vested and issued&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;186,708&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.76&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;260,206&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.74&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at March 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,948,852&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_16552037-eed1-494f-9bc7-fe5f2b5e07a7"
      decimals="INF"
      id="F_dfdea9cf-e85b-4325-9e81-74272b5f4fd2"
      unitRef="U_shares">1371266</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_4fd9b7f3-bd3c-4f80-bb93-a8f9f1efc8fc"
      decimals="2"
      id="F_24c0dcc3-20d2-47cf-9b2a-44f88c4ae92f"
      unitRef="U_UsdShare">6.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_074eb5b5-3385-4cab-a533-970336354d46"
      decimals="0"
      id="F_af17ea4f-4eec-4af9-bbd8-97972c14db7e"
      unitRef="U_shares">5024500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_074eb5b5-3385-4cab-a533-970336354d46"
      decimals="2"
      id="F_b9410b7c-668f-493a-af2d-9f86e8367011"
      unitRef="U_UsdShare">6.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <mnmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriod
      contextRef="C_074eb5b5-3385-4cab-a533-970336354d46"
      decimals="0"
      id="F_d706285d-368c-4636-98e5-c70b2d66fae7"
      unitRef="U_shares">186708</mnmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriod>
    <mnmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_074eb5b5-3385-4cab-a533-970336354d46"
      decimals="2"
      id="F_13bf2ecd-3f48-445c-b8c4-09a826af576a"
      unitRef="U_UsdShare">10.76</mnmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndIssuedInPeriodWeightedAverageGrantDateFairValue>
    <mnmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod
      contextRef="C_074eb5b5-3385-4cab-a533-970336354d46"
      decimals="0"
      id="F_3cd256be-ff17-421b-a997-d466d765c600"
      unitRef="U_shares">260206</mnmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod>
    <mnmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_074eb5b5-3385-4cab-a533-970336354d46"
      decimals="2"
      id="F_8cae6a8e-a524-4056-8c16-6c6c5f814fac"
      unitRef="U_UsdShare">5.74</mnmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_0054b3c6-4d0e-43c8-b522-a912b7fc8728"
      decimals="INF"
      id="F_1e20ff5e-c2b5-4007-b3f2-a78141cee11f"
      unitRef="U_shares">5948852</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_0054b3c6-4d0e-43c8-b522-a912b7fc8728"
      decimals="2"
      id="F_c8ce68ac-0c6b-41b5-bd76-091f164b6c5b"
      unitRef="U_UsdShare">6.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_92619440-2ce2-4466-9498-1c8dd0f4bb1c"
      decimals="0"
      id="F_355d095f-5065-4645-8255-e7612b467119"
      unitRef="U_shares">3696000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_92619440-2ce2-4466-9498-1c8dd0f4bb1c"
      id="F_a8d50a92-f384-41c1-bed1-676d0d6d6826">P36M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="C_92619440-2ce2-4466-9498-1c8dd0f4bb1c"
      id="F_a0c45b2b-6219-46c0-a2cb-137bf2482d42">P36M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_074eb5b5-3385-4cab-a533-970336354d46"
      decimals="-5"
      id="F_881839cc-2793-4070-b200-d7a1b4d71335"
      unitRef="U_USD">1800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_9b3887ab-9632-4cdf-8108-dd0d06f5614f"
      decimals="-5"
      id="F_c887855d-1a77-4d98-8177-e643e7fe2f9b"
      unitRef="U_USD">2100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_214de9bb-0f67-49d7-91e6-f326f72e5fda"
      decimals="INF"
      id="F_eb7f80a0-b017-477e-a90c-2849a02a3d55"
      unitRef="U_shares">34017</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      id="F_30ba998a-427c-4d1f-9624-a3d136e9e62d">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation expense for all equity arrangements for the three months ended March 31, 2025 and 2024 was as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:67.033%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.863000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.863000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,053&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,455&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,373&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,234&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,426&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,689&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_7f0ccbf3-018b-4d47-8587-c44623598ad3"
      decimals="-3"
      id="F_4e4f9f5b-8989-4333-b20c-a950262f7edc"
      unitRef="U_USD">2053000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_47ed8762-d376-4fac-a861-d53fdd21f2ce"
      decimals="-3"
      id="F_7787ca5d-9931-4822-935d-abd8d9b8f2f2"
      unitRef="U_USD">1455000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_a897d154-518a-4ffc-a776-063ea244783d"
      decimals="-3"
      id="F_035ac182-222b-4e2d-9518-ffce838b26b9"
      unitRef="U_USD">1373000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_6a7256ae-8741-49e1-a84a-94da6e3a03ec"
      decimals="-3"
      id="F_3ed168c4-1ea7-497b-aa41-b73f2fc35a20"
      unitRef="U_USD">2234000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="-3"
      id="F_33592675-32fc-4461-beb0-12f2ff07a421"
      unitRef="U_USD">3426000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb"
      decimals="-3"
      id="F_66ed097f-b037-4f18-8fad-23a0cf7b201e"
      unitRef="U_USD">3689000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256"
      decimals="-5"
      id="F_29f9dec8-7157-454a-89cf-1ea871b9240c"
      unitRef="U_USD">12900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      id="F_1bfed3f0-2283-481a-8d60-5be21c3f5060">P3Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_0054b3c6-4d0e-43c8-b522-a912b7fc8728"
      decimals="-5"
      id="F_a083140b-79c6-436c-ad8f-8a8469a9e3e7"
      unitRef="U_USD">35900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_214de9bb-0f67-49d7-91e6-f326f72e5fda"
      id="F_421cb478-21af-4edf-bd9f-df2671078e47">P3Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_6f79a0fa-c5d0-4e2a-bc5d-e6aec1b53c1e"
      decimals="-5"
      id="F_7c677d2c-1c26-4652-80a8-71b50e0d296b"
      unitRef="U_USD">800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_74cedffa-5bb3-47b3-afc1-6024110f7963"
      decimals="-5"
      id="F_420b614b-ad9d-475a-84fb-c002888bea5c"
      unitRef="U_USD">800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_6f79a0fa-c5d0-4e2a-bc5d-e6aec1b53c1e"
      decimals="0"
      id="F_871d542c-050a-47d4-91df-93097ee9ad99"
      unitRef="U_shares">178697</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_8ddb2856-0c3b-4cce-9cc5-aab5dca27c39"
      decimals="-5"
      id="F_cef37743-77ee-4a44-b7a0-4ac5b8bbd361"
      unitRef="U_USD">1100000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      id="F_3969b4b0-608b-4722-b9e9-fa84d3c2611c">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;10.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of March 31, 2025, the Company had obligations to make future payments, representing significant research and development contracts and other commitments that are known and committed in the amount of approxima&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;tely $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;114.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; mi&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;llion. Most of these agreements are cancelable by the Company with notice. These commitments include agreements related to the conduct of the clinical trials, sponsored research, manufacturing and preclinical studies.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company enters into research, development and license agreements in the ordinary course of business where the Company receives research services and rights to proprietary technologies. Milestone and royalty payments that may become due under various agreements are dependent on, among other factors, clinical trials, regulatory approvals and ultimately the successful development of a new drug, the outcome and timing of which are uncertain.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company periodically enters into research and license agreements with third parties that include indemnification provisions customary in the industry. These guarantees generally require the Company to compensate the other party for certain damages and costs incurred as a result of claims arising from research and development activities undertaken by or on behalf of the Company. In some cases, the maximum potential amount of future payments that could be required under these indemnification provisions could be unlimited. These indemnification provisions generally survive termination of the underlying agreement. The nature of the indemnification obligations prevents the Company from making a reasonable estimate of the maximum potential amount it could be required to pay. Historically, the Company has not made any indemnification payments under such agreements and no amount has been accrued in the unaudited condensed consolidated financial statements with respect to these indemnification obligations.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:OtherCommitment
      contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256"
      decimals="-5"
      id="F_af1a97b0-1edd-4dfa-81c5-850e22bc3e1c"
      unitRef="U_USD">114700000</us-gaap:OtherCommitment>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      id="F_ce89e396-f264-4f28-bfea-0fa0f5493ffb">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;11.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;CREDIT FACILITY&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On August 11, 2023 (the &#x201c;Closing Date&#x201d;), the Company and certain of its subsidiaries party thereto, as co-borrowers (together wi&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;th the Company, the &#x201c;Borrowers&#x201d;) entered into a Loan and Security Agreement (the &#x201c;Loan Agreement&#x201d;) with K2 HealthVentures LLC (&#x201c;K2HV&#x201d;), as administrative agent and Canadian collateral agent for lenders thereunder (K2HV, together with any other lender from time to time, the "Lenders"), and Ankura Trust Company, LLC, as collateral trustee for the Lenders. The Loan Agreement provides for up to an aggregate principal amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in term loans (the &#x201c;Term Loan&#x201d;) consisting of a first tranche term loan of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million funded on the Closing Date, subsequent tranches of term loans totaling $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million to be funded upon the achievement of certain time-based, clinical and regulatory milestones, and an additional tranche term loan of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million upon the Company&#x2019;s request, subject to the Lenders' review of certain information from the Company and discretionary approval by the Lenders. On the Closing Date, the Company paid a facility fee of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million to K2HV. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The second milestone-based tranche of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million was funded in the second quarter of 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Term Loan matures on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;August 1, 2027&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, and the Company's obligations under the Loan Agreement are secured by substantially all of the assets of the Company, excluding intellectual property.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Term Loan bears a variable interest rate equal to the greater of (i) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.95&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% and (ii) the sum of (a) the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_878b4f9e-49e3-4bfc-bf0e-3f4c1e867bf8;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;prime rate&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; as reported in The Wall Street Journal plus (b) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.95&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The Company may prepay, at its option, all, but not less than all, of the outstanding principal balance and all accrued and unpaid interest with respect to the principal balance being prepaid of the Term Loan, subject to certain prepayment notice requirements; provided that such prepayment notice may be conditioned upon the effectiveness of a refinancing or any other transaction, in which case such prepayment notice may be revoked by the Company. Principal payments were postponed from March 2025 to March 2026 as the interest-only extension event per the Loan Agreement was met. Additionally, the Term Loan contains a final payment fee of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.95&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the original principal amount borrowed due upon the final maturity date or upon prepayment of the Term Loan. As of March 31, 2025, the Company has accrued $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in relation to this final payment fee.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Lenders may elect at any time following the Closing Date and prior to the full repayment of the Term Loan to convert any portion of the principal amount of the term loans then outstanding, up to an aggregate principal amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, into the Company&#x2019;s Common Shares (the &#x201c;Conversion Shares&#x201d;), at a conversion price equal to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.01&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per Conversion Share, subject to certain limitations. The embedded conversion option qualifies for a scope exception from derivative accounting because it is both indexed to the Company&#x2019;s shares and meets the conditions for equity classification. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On November 11, 2024, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of principal was converted into &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;748,129&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of the Company's Common Shares. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of March 31, 2025, the Company estimated the fair value of the Conversion Shares to be $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million using the Black-Scholes option pricing model.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Loan Agreement contains customary representations and warranties and affirmative and negative covenants, including covenants that limit or restrict the Company's ability to, among other things, dispose of assets; make changes to the Company's business, management, ownership, or business locations; merge or consolidate; incur additional indebtedness, encumbrances, or liens; pay dividends or other distributions or repurchase equity; make investments; and enter into certain transactions with affiliates, in each case subject to certain exceptions. The Company was in compliance with the Loan Agreement as of March 31, 2025. On April 18, 2025, the Company entered into an amendment to the Loan Agreement. See Note 13 for additional information.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recorded $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in interest expense for the three months ended March 31, 2025.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Future expected repayments of principal amount due on the credit facility as of March 31, 2025 were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:76.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:19.56%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Remainder of 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,999&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,001&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total principal repayments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unamortized debt issuance costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;567&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued final payment fee&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;603&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total credit facility, non-current, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,036&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of March 31, 2025, the Company estimated the fair value of the credit facility to be &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;21.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;million, assuming the full $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of principal is converted into Conversion Shares.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_6451cf6d-c95a-4e4b-8351-0fe9c5190c13"
      decimals="-5"
      id="F_446f688f-d890-4dcd-be1e-ab09e6f27045"
      unitRef="U_USD">50000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_fe5a097f-3c97-4699-94f4-51951985f607"
      decimals="-5"
      id="F_7f87b77d-db29-433a-b1d0-e958a4ac01c2"
      unitRef="U_USD">15000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_ea9d77da-eba9-4810-91d9-0f141316dc18"
      decimals="-5"
      id="F_fe75fb54-378a-42d7-805e-273998d001c6"
      unitRef="U_USD">20000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_eb1ae7bc-3517-4ce3-9504-2825a5456a78"
      decimals="-5"
      id="F_b952bb17-2cd1-4b32-9692-50e7a712ad36"
      unitRef="U_USD">15000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="C_0c871994-f7b4-4304-86d5-391aaec3c1e0"
      decimals="-5"
      id="F_e6ce557f-2986-460e-930e-6a575fc7ba58"
      unitRef="U_USD">300000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_21b8ddb5-b023-4fb7-95ad-c159194b8c6f"
      decimals="-5"
      id="F_367d900c-de9d-4cb5-bb54-d23e0f09817c"
      unitRef="U_USD">10000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="C_0c871994-f7b4-4304-86d5-391aaec3c1e0"
      id="F_ee6c2793-56bc-4b87-a234-2b0b0223bc69">2027-08-01</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentInterestRateTerms
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      id="F_98623321-316d-4077-9d55-401c6dfb77ca">The Term Loan bears a variable interest rate equal to the greater of (i) 10.95% and (ii) the sum of (a) the prime rate as reported in The Wall Street Journal plus (b) 2.95%.</us-gaap:DebtInstrumentInterestRateTerms>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="C_42ce987a-6c17-43ee-b6d2-679c22b90e37"
      decimals="4"
      id="F_f9c74a38-4a83-4ee9-9544-9a6526bdf7ef"
      unitRef="U_pure">0.1095</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="C_0c871994-f7b4-4304-86d5-391aaec3c1e0"
      decimals="4"
      id="F_7deaad58-6571-4bf1-b6b1-bf0145706c01"
      unitRef="U_pure">0.0295</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <mnmd:PercentageOfFinalPaymentFee
      contextRef="C_0c871994-f7b4-4304-86d5-391aaec3c1e0"
      decimals="4"
      id="F_e07b60bc-1588-4d12-8f4e-4e6c076d4fdd"
      unitRef="U_pure">0.0695</mnmd:PercentageOfFinalPaymentFee>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="C_6e0c796f-cafa-42be-9627-7b5c560ee658"
      decimals="-5"
      id="F_ed7d23c7-c4ef-434c-b968-1c7de989bc63"
      unitRef="U_USD">600000</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature
      contextRef="C_239ca22a-8f41-45e3-9088-34e3006f84b0"
      decimals="INF"
      id="F_c12b689c-715b-4996-ba48-ddf1b7eb538e"
      unitRef="U_USD">4000000</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="C_6451cf6d-c95a-4e4b-8351-0fe9c5190c13"
      decimals="2"
      id="F_5dff88a9-542c-420e-a536-3f7afedf0a71"
      unitRef="U_UsdShare">4.01</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal
      contextRef="C_e2246019-6180-4085-ac79-bbe6f51150c7"
      decimals="-5"
      id="F_41f6cb75-6bf1-4aaf-a246-3e1c438604ae"
      unitRef="U_USD">3000000</us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal>
    <mnmd:DebtInstrumentConvertibleConvertedIntoCommonShares
      contextRef="C_6f8c2f52-b2c4-47bf-b3a7-5478bee3c660"
      decimals="INF"
      id="F_a8429ac0-3cc5-4d78-9f0b-5b50d66e4be5"
      unitRef="U_shares">748129</mnmd:DebtInstrumentConvertibleConvertedIntoCommonShares>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="C_54d8dbd9-a485-4061-8471-60237a056875"
      decimals="-5"
      id="F_8c0a77de-30eb-4e88-84f4-c04cc85629bf"
      unitRef="U_USD">900000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:InterestExpenseDebt
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="-5"
      id="F_4b375418-86b2-449a-bf03-a41aa91a71c0"
      unitRef="U_USD">600000</us-gaap:InterestExpenseDebt>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      id="F_626217ba-7dc6-4ca0-9e49-990e03134e7a">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Future expected repayments of principal amount due on the credit facility as of March 31, 2025 were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:76.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:19.56%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Remainder of 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,999&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,001&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total principal repayments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unamortized debt issuance costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;567&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued final payment fee&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;603&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total credit facility, non-current, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,036&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <mnmd:DebtRepaymentsOfPrincipalInNextTwelveMonthsBeforeUnamortizedDebtIssuanceCost
      contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256"
      decimals="-3"
      id="F_4621b250-a1f6-41d1-9684-5b15b42002ab"
      unitRef="U_USD">12999000</mnmd:DebtRepaymentsOfPrincipalInNextTwelveMonthsBeforeUnamortizedDebtIssuanceCost>
    <mnmd:DebtRepaymentsOfPrincipalInYearTwoBeforeUnamortizedDebtIssuanceCost
      contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256"
      decimals="-3"
      id="F_e93ea6af-b35c-4053-82af-ee5b552b48ad"
      unitRef="U_USD">9001000</mnmd:DebtRepaymentsOfPrincipalInYearTwoBeforeUnamortizedDebtIssuanceCost>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256"
      decimals="-3"
      id="F_cb4b3026-d998-47c8-b619-1ea3ebfec6b0"
      unitRef="U_USD">22000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256"
      decimals="-3"
      id="F_81c9f98b-2776-42cc-a129-b51f1741848d"
      unitRef="U_USD">567000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256"
      decimals="-3"
      id="F_b1a83803-e2c8-4810-916e-13a9e8947a73"
      unitRef="U_USD">603000</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="C_fbd55b55-3ca4-42cd-ba02-af13b09e1256"
      decimals="-3"
      id="F_7cc766ee-f7b0-480e-9a81-25da4335ac13"
      unitRef="U_USD">22036000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding
      contextRef="C_6e0c796f-cafa-42be-9627-7b5c560ee658"
      decimals="-5"
      id="F_26cd60e0-8f7e-4d04-b4ff-3a70e48944a1"
      unitRef="U_USD">21900000</us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding>
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature
      contextRef="C_f83f983a-590e-4074-8513-66e59d9de42c"
      decimals="INF"
      id="F_28c64274-01a4-4035-910c-fd176f845049"
      unitRef="U_USD">1000000</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      id="F_beb52212-ed78-42a4-ace4-d477c723a3ef">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;12.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;SEGMENT REPORTING&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; reportable segment related to the research and development of the Company&#x2019;s product candidates.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s Chief Operating Decision Maker (the &#x201c;CODM&#x201d;), its Chief Executive Officer, reviews the Company&#x2019;s operations, including reviewing budgets and trial-related data, and decides how to allocate resources and assess performance. When evaluating the Company&#x2019;s financial performance, the CODM regularly reviews total expenses and total assets and the CODM makes decisions using this information on a consolidated basis. The CODM uses consolidated net income or loss as a measure of profit or loss in allocating resources &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;and assessing segment performance. &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In addition to the expense categories included within net income presented on the Company's Consolidated Statements of Operations and Comprehensive Loss, see below for additional expense details that are routinely reviewed by the CODM: &lt;/span&gt;&lt;/span&gt;&lt;span style=""&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:'Calibri',sans-serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:50.89%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:20.136%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:20.136%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Internal expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,846&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,452&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;External expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,511&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,253&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,357&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,705&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Internal expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,822&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,163&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;External expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,336&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,802&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,499&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Loss from operations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32,159&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,204&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total other income/(loss), net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,811&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32,196&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,348&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;54,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="INF"
      id="F_9cd7d630-f007-430b-9871-09cf4828e950"
      unitRef="U_Segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      id="F_2f4dcc0b-bd22-4a18-a219-41634c989c0e">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In addition to the expense categories included within net income presented on the Company's Consolidated Statements of Operations and Comprehensive Loss, see below for additional expense details that are routinely reviewed by the CODM: &lt;/span&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:50.89%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:20.136%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:20.136%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Internal expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,846&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,452&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;External expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,511&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,253&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,357&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,705&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Internal expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,822&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,163&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;External expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,336&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,802&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,499&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Loss from operations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32,159&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,204&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total other income/(loss), net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,811&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32,196&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,348&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;54,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <mnmd:ResearchAndDevelopmentInternalExpense
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="-3"
      id="F_ac74684a-decc-4d61-b23c-d58032ff77ef"
      unitRef="U_USD">7846000</mnmd:ResearchAndDevelopmentInternalExpense>
    <mnmd:ResearchAndDevelopmentInternalExpense
      contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb"
      decimals="-3"
      id="F_d8084499-8100-41f4-8494-bda7046ccf9b"
      unitRef="U_USD">5452000</mnmd:ResearchAndDevelopmentInternalExpense>
    <mnmd:ResearchAndDevelopmentExternalExpense
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="-3"
      id="F_ffddcee4-eee5-4eda-b122-cd724efce1ec"
      unitRef="U_USD">15511000</mnmd:ResearchAndDevelopmentExternalExpense>
    <mnmd:ResearchAndDevelopmentExternalExpense
      contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb"
      decimals="-3"
      id="F_ad5d404a-f045-40d2-a32c-ba3305577e63"
      unitRef="U_USD">6253000</mnmd:ResearchAndDevelopmentExternalExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="-3"
      id="F_2cb2f6b5-8a8e-4bda-a253-e82e7be65866"
      unitRef="U_USD">23357000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb"
      decimals="-3"
      id="F_cbbfb22a-fee3-433d-99f7-12ee0c262ee7"
      unitRef="U_USD">11705000</us-gaap:ResearchAndDevelopmentExpense>
    <mnmd:GeneralAndAdministrativeInternalExpense
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="-3"
      id="F_196613d6-7a90-4b29-9995-761b43a4a2f4"
      unitRef="U_USD">3822000</mnmd:GeneralAndAdministrativeInternalExpense>
    <mnmd:GeneralAndAdministrativeInternalExpense
      contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb"
      decimals="-3"
      id="F_ceb82065-0003-4922-9a3e-93b649b5bb54"
      unitRef="U_USD">5163000</mnmd:GeneralAndAdministrativeInternalExpense>
    <mnmd:GeneralAndAdministrativeExternalExpense
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="-3"
      id="F_b96f31c1-0bec-426f-b3b6-e220e816f5ce"
      unitRef="U_USD">4980000</mnmd:GeneralAndAdministrativeExternalExpense>
    <mnmd:GeneralAndAdministrativeExternalExpense
      contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb"
      decimals="-3"
      id="F_ea9d78e4-4553-4d26-aa86-a84f509e171d"
      unitRef="U_USD">5336000</mnmd:GeneralAndAdministrativeExternalExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="-3"
      id="F_6cf1ad67-917d-401b-9e32-285d38ef9b40"
      unitRef="U_USD">8802000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb"
      decimals="-3"
      id="F_33b1720b-f874-4d3c-9d53-19eceb7ba101"
      unitRef="U_USD">10499000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="-3"
      id="F_6a6194d4-c9f8-4cf3-8a7f-ddaf761b2f65"
      unitRef="U_USD">-32159000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb"
      decimals="-3"
      id="F_51e09576-a9ff-4dc6-8509-84db0be4aac8"
      unitRef="U_USD">-22204000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="-3"
      id="F_f6ebc799-0102-41ab-b09d-4570713d2f75"
      unitRef="U_USD">8811000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb"
      decimals="-3"
      id="F_4a27a766-8897-4cd9-bcbc-152c50a5f300"
      unitRef="U_USD">-32196000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      decimals="-3"
      id="F_a083bc25-6c90-4b0e-a2b4-733a44d7512a"
      unitRef="U_USD">-23348000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_53549879-ba1d-4877-b935-3c96fc46f9bb"
      decimals="-3"
      id="F_0c3707bf-17f5-49de-a96f-270855be2243"
      unitRef="U_USD">-54400000</us-gaap:NetIncomeLoss>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      id="F_b438a5f0-e3f6-462e-9c68-4b2b9eebb42f">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;13.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On April 18, 2025 (the &#x201c;Effective Date&#x201d;), the Borrowers, entered into the First Amendment to the Loan Agreement with K2HV (as amended by the First Amendment, the &#x201c;Amended Loan Agreement&#x201d;).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Amended Loan Agreement provide for, among other things: (i) an aggregate principal amount of term loans (the &#x201c;Amendment Term Loans&#x201d;) of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;120.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;consisting of (A) a new Restatement First Tranche Term Loan (as defined in the&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Amended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Loan Agreement) of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, which was funded on the Effective Date, a portion of the proceeds of which was used on the Effective Date to refinance in full all Term Loans outstanding under the Loan Agreement, and to pay fees and expenses in connection with the Amended Loan Agreement and the refinancing of the existing term loans, (B) subsequent tranches of Amendment Term Loans totaling up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, subject to the occurrence of certain time-based clinical and regulatory milestones and (C) an additional tranche of Amendment Term Loans of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million upon the Company&#x2019;s request, subject to review by the Lenders of certain information from the Company and discretionary approval by the Lenders, (ii) to the extent any Amendment Term Loans other than the Restatement First Tranche Term Loans are made during the term of the Amended Loan Agreement, a minimum liquidity covenant, beginning on the earlier to occur of (x) July 1, 2026 (which may be extended to July 1, 2027 to the extent the Company has achieved certain fundraising milestones) and (y) the date on which certain clinical and regulatory milestones are not achieved, which covenant shall be waived in any period where the Company&#x2019;s market capitalization exceeds $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;500.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, (iii) a decrease in the interest rate applicable to all Amendment Term Loans under the Amended Loan Agreement to the greater of (x) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% and (y) the sum of (a) the Prime Rate as reported in The Wall Street Journal plus (b) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.75&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% per annum, and (iv) a conversion right at the election of the Lenders at any time following the Effective Date and prior to the full repayment of the Amendment Term Loans to convert up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of the outstanding Amendment Term Loans into the Company&#x2019;s common shares (the &#x201c;Amendment Conversion Shares&#x201d;), at conversion prices ranging from $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.01&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per Amendment Conversion Share to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per Amendment Conversion Share. The Amendment Term Loans mature on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;April 1, 2029&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, provided that upon the occurrence of certain events the maturity date may be extended to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;October 1, 2029&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The obligations of the Borrowers under the Amended Loan Agreement are secured by substantially all of the assets of the Borrowers, excluding intellectual property. Other than as described above, the proceeds of borrowings under the Amended Loan Agreement are expected to be used for working capital and other general corporate purposes and/or to further support commercial activities and/or business development opportunities. Once repaid, the Amendment Term Loans may not be reborrowed.&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:LineOfCredit
      contextRef="C_21366178-d703-4ba8-b838-8bd6400186cc"
      decimals="-5"
      id="F_e53e70ad-d721-41a1-9e55-7f4e5c7b1ece"
      unitRef="U_USD">120000000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="C_d169998a-953e-4d00-b8cc-a69fa0e9660b"
      decimals="-5"
      id="F_0cdf5f78-981a-4afe-a89d-9856fdab4b3e"
      unitRef="U_USD">42000000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="C_c9d7271c-3855-4150-a286-178b67eef766"
      decimals="-5"
      id="F_0c9901b7-0625-4847-874f-1b9e0cb0022b"
      unitRef="U_USD">28000000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="C_4094340a-fb0c-443d-8f83-3a756fca8506"
      decimals="-5"
      id="F_dd21dd7c-d507-46ae-8e24-e4223fd745e7"
      unitRef="U_USD">50000000</us-gaap:LineOfCredit>
    <mnmd:CovenantShallBeWaivedDuringMarketCapitalizationExceeds
      contextRef="C_6ad17a66-7ef6-4b6b-947f-8a82218b53f9"
      decimals="-5"
      id="F_593764e2-30f7-4e7f-9666-e9da43824b93"
      unitRef="U_USD">500000000</mnmd:CovenantShallBeWaivedDuringMarketCapitalizationExceeds>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="C_d320d06d-9c2c-4fb0-9558-f2351f1dc8ad"
      decimals="4"
      id="F_b5b2c2db-2352-4a4a-a0ce-ca38fd24d0d6"
      unitRef="U_pure">0.1025</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="C_6ad17a66-7ef6-4b6b-947f-8a82218b53f9"
      decimals="4"
      id="F_a6d08c09-44e8-44e4-81b9-9e09b524d2c9"
      unitRef="U_pure">0.0275</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature
      contextRef="C_7141ebf5-28cf-4a53-aafe-4ebd1582b154"
      decimals="-5"
      id="F_109e40a6-4774-43a2-acb2-a43e55217359"
      unitRef="U_USD">7000000</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="C_d320d06d-9c2c-4fb0-9558-f2351f1dc8ad"
      decimals="2"
      id="F_22fae705-f83b-46a0-bda7-e2fa78b53bba"
      unitRef="U_UsdShare">4.01</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="C_21366178-d703-4ba8-b838-8bd6400186cc"
      decimals="2"
      id="F_80ca251d-ae7c-4a47-9756-3fa3401c1857"
      unitRef="U_UsdShare">9</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="C_6ad17a66-7ef6-4b6b-947f-8a82218b53f9"
      id="F_58f69050-d3d0-4946-9192-fa957d871a55">2029-04-01</us-gaap:DebtInstrumentMaturityDate>
    <mnmd:DebtInstrumentExtendedMaturityDate
      contextRef="C_6ad17a66-7ef6-4b6b-947f-8a82218b53f9"
      id="F_6496631b-51f5-4d22-9da6-a575d0b10987">2029-10-01</mnmd:DebtInstrumentExtendedMaturityDate>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      id="F_39b5d04b-fabb-4eaa-8fc1-88db62f0cf04">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      id="F_f1907158-8f89-4f10-9e4b-4a3a942e34bd">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      id="F_1f07950d-c32c-4a59-aa74-691aca48ae66">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="C_eb56ad75-806f-4117-8a10-7450fb345387"
      id="F_4961a9ce-3172-4bc4-8f64-d1084ecec3b4">false</ecd:NonRule10b51ArrTrmntdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
